NOTICE OF SPECIAL MEETINGS OF SHAREHOLDERS

to be held on December 23, 2026

and

JOINT MANAGEMENT INFORMATION CIRCULAR

with respect to a

PLAN OF ARRANGEMENT

involving

ORGANIGRAM GLOBAL INC.

and

AURORA CANNABIS INC.

Dated: November 20, 2026

This joint management information circular and the accompanying materials are important and require your immediate attention. Please carefully read this joint management information circular, including its accompanying materials and the documents incorporated by reference herein, as they contain detailed information related to, among other things, the proposed plan of arrangement that will be voted upon at the special meeting. If you are in doubt as to how to deal with these documents or the matters to which they refer, please consult a professional advisor.

THE BOARD OF DIRECTORS OF AURORA CANNABIS INC. UNANIMOUSLY RECOMMENDS THAT AURORA SHAREHOLDERS VOTE FOR THE ARRANGEMENT RESOLUTION, AND THE BOARD OF DIRECTORS OF ORGANIGRAM GLOBAL INC. (WITH THE REPRESENTATIVES OF BAT ABSTAINING IN RESPECT OF THE BAT PRIVATE PLACEMENT) UNANIMOUSLY RECOMMENDS THAT ORGANIGRAM SHAREHOLDERS VOTE FOR THE ORGANIGRAM SHARE ISSUANCE RESOLUTION, EACH AS SET FORTH IN THIS JOINT MANAGEMENT INFORMATION CIRCULAR

TABLE OF CONTENTS

Letter to Aurora Shareholders ..... **i**
Letter to Organigram Shareholders ..... **vii**
Notice of Special Meeting of Aurora Shareholders ..... **xii**
Notice of Special Meeting of Organigram Shareholders ..... **xv**
Aurora Shareholders – Questions and Answers ..... **xvii**
Organigram Shareholders – Questions and Answers ..... **xxxi**
Glossary of Terms **1**
Conventions **17**
Joint Information Circular **18**
Forward-Looking Statements and Information **21**
Information for Beneficial Holders **30**
Summary **33**
The Arrangement **56**
Effect of the Arrangement **82**
Procedure for the Arrangement to Become Effective **102**
Interests of Certain Persons or Companies in the Arrangement **114**
Legal Developments **121**
Dissent Rights **121**
Certain Canadian Federal Income Tax Considerations **124**
Certain United States Federal Income Tax Considerations **133**
Additional Tax Considerations **139**
Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement **140**
Timing **148**
Risk Factors **149**
The Hostile Bid **156**
Information Concerning Aurora Cannabis Inc. **156**
Information Concerning Organigram Global Inc. **156**
Comparison of Shareholder Rights **156**
Matters to be Considered at the Aurora Shareholders' Meeting **161**
Matters to be Considered at the Organigram Shareholders' Meeting **163**
General Proxy Matters – Aurora **164**
General Proxy Matters – Organigram **169**
Expenses of the Arrangement **173**
Depositary **173**
Legal Matters and Interests of Experts **173**
Additional Information **173**
Questions And Other Assistance **173**
Aurora Directors' Approval **174**
Organigram Directors' Approval **175**
Consents **176**

ADDENDA

Appendix “A”	Arrangement Resolution
Appendix “B”	Organigram Share Issuance Resolution
Appendix “C”	Plan of Arrangement
Appendix “D”	Interim Order
Appendix “E”	Petition and Notice of Hearing of Petition
Appendix “F”	Aurora Fairness Opinions
Appendix “G”	Organigram Fairness Opinion
Appendix “H”	Pro Forma Condensed Consolidated Financial Statements of Organigram Global Inc.
Appendix “I”	Information Concerning Aurora Cannabis Inc.
Appendix “J”	Information Concerning Organigram Global Inc.
Appendix “K”	Division 2 of Part 8 of the *Business Corporations Act* (British Columbia)

LETTER TO AURORA SHAREHOLDERS

November 20, 2026

Dear Aurora Shareholders:

You are invited to attend a special meeting (the "**Aurora Shareholders' Meeting**") of the holders (the "**Aurora Shareholders**") of common shares ("**Aurora Common Shares**") in the capital of Aurora Cannabis Inc. ("**Aurora**", "**we**", "**us**", or "**our**"), to be held on Wednesday, December 23, 2026 at 9:30 a.m. (Toronto time) in a virtual-only format that will be conducted via live webcast accessible at meetnow.global/MQAVTRW.

At the Aurora Shareholders' Meeting, the Aurora Shareholders will be asked to consider and vote on, among other matters, a special resolution approving the plan of arrangement (the "**Arrangement**") under section 288 of the *Business Corporations Act* (British Columbia), involving the acquisition by Organigram Global Inc. ("**Organigram**") of all of the issued and outstanding Aurora Common Shares, as more particularly described in the joint management information circular of Organigram and Aurora dated November 20, 2026 (the "**Joint Information Circular**").

Your vote is important. The proxy deadline is 9:30 a.m. (Toronto time) on December 21, 2026. See "*How to Vote Your Aurora Common Shares*" below.

The Arrangement

Aurora and Organigram entered into an arrangement agreement dated November 2, 2026 (as supplemented, modified or amended, the "**Arrangement Agreement**"), which was unanimously approved by the respective boards of directors of Aurora and Organigram. Pursuant to the Arrangement Agreement and the accompanying plan of arrangement, Organigram will acquire all of the issued and outstanding Aurora Common Shares. Aurora Shareholders will be entitled to receive, at the election of each Aurora Shareholder, for each Aurora Common Share: (a) $7.80 in cash (the "**Cash Alternative**"); (b) 5.8626 common shares of Organigram ("**Organigram Common Shares**") (the "**Share Alternative**"); or (c) a combination of $3.75 in cash and 3.0431 Organigram Common Shares (the "**Combination Alternative**"), subject, in the case of the Cash Alternative and the Share Alternative, to proration such that the aggregate cash payable and the aggregate number of Organigram Common Shares issuable under the Arrangement will not exceed $3.75 and 3.0431 Organigram Common Shares, respectively, multiplied by the number of Aurora Common Shares outstanding immediately prior to completion of the Arrangement (collectively, the "**Consideration**").

Current Aurora Shareholders are expected to hold approximately 37% of the economic interest and 41% of the voting rights in Organigram, on a fully diluted basis, immediately after the completion of the Arrangement and the BAT Private Placement (as defined herein), with the balance held by current holders (the "**Organigram Shareholders**") of Organigram Common Shares (including BT DE Investments Inc. ("**BAT**")).

The Arrangement is currently anticipated to be completed in January 2027, and in any event not before January 6, 2027, subject to the satisfaction or waiver of all conditions precedent in the Arrangement Agreement, including receipt of all court, shareholder and regulatory approvals.

Reasons for and Benefits of the Arrangement

Organigram and Aurora expect that the Arrangement will create a global cannabis leader with leading positions in Canada, Europe and Australia, supported by Organigram's strategic shareholder, BAT. The combined company is

expected to have a global platform with greater scale, broader capabilities, financial strength and international reach, bringing together Organigram's recreational cannabis leadership, production network, research and development platform and European medical commercial operations with Aurora's global medical cannabis leadership, established international presence and EU-GMP certified manufacturing capabilities. The anticipated benefits of the Arrangement include:

- *Creates a Global Cannabis Leader* with a scaled, Canadian-headquartered global cannabis platform with leading positions in five nationally legal cannabis markets – Canada, Germany, Poland, Australia and New Zealand – and meaningful operations in other key markets.

- *Significant Premium and Choice of Consideration*. Aurora Shareholders may elect the Cash Alternative, the Share Alternative or the Combination Alternative, subject, in the case of the Cash Alternative and the Share Alternative, to proration, with an implied value of $7.80 per Aurora Common Share, representing a premium of approximately 93% to the Unaffected Price (as defined in the Joint Information Circular) and approximately 21% to the implied value of the Hostile Bid (as defined in the Joint Information Circular) as of November 2, 2026.

- *Superior to the Hostile Bid*, which the board of directors of Aurora (the "**Aurora Board**") and the independent special committee of the Aurora Board (the "**Aurora Special Committee**") have twice unanimously determined to be financially inadequate, with the Arrangement offering a larger cash component at a fixed price.

- *Attractive Valuation.* Approximately 9.4x LTM Adjusted EBITDA and 1.4x LTM Net Revenue for the twelve months ended June 30, 2026.

- *Complementary Capabilities* across Organigram's Canadian adult-use leadership, diversified production and cultivation capabilities, research and development platform and European medical market presence, and Aurora's global medical cannabis leadership, genetics expertise and EU-GMP certified manufacturing capacity.

- *Meaningful Synergies* of more than $50 million annually, with Aurora Shareholders who retain Organigram Common Shares participating in the value of such synergies to the extent realized.

- *Accelerates Product Innovation and Commercial Growth*, through the combined company's scale and cross-border infrastructure, which are expected to create a platform for shared innovation and brand building, supported by BAT's demonstrated expertise in research and development, innovative product development and global supply chain management.

- *Attractive Organigram Common Shares*, listed on the Toronto Stock Exchange and Nasdaq, with a single class of voting shares, no controlling shareholder and a supportive strategic shareholder in BAT.

- *Preferred Outcome of a Robust Competitive Strategic Process* following the unsolicited offer by Curaleaf, as amended, which the Aurora Special Committee and the Aurora Board have determined remains inadequate and significantly undervalues Aurora.

- *Role of the Special Committee.* The Arrangement is the result of a strategic process undertaken with the supervision and involvement of the Aurora Special Committee, advised by experienced and qualified external legal and financial advisors. The Arrangement was unanimously recommended to the Aurora Board by the Aurora Special Committee on the basis described herein and on the basis of the legal and financial advice that was received by the Aurora Special Committee.

- *High Likelihood of Completion.* The Arrangement is subject to only a limited number of customary conditions, and is not subject to any financing or due diligence condition. The only Required Regulatory Approvals are approval under the *Competition Act* (Canada) and clearance under German foreign direct investment laws, and Aurora and Organigram believe that meaningful regulatory challenges are unlikely

given the complementary nature of their respective operations. Completion of the Arrangement is expected to occur in January 2027.

For additional information with respect to these and other anticipated benefits of the Arrangement, see "*The Arrangement – Reasons for and Benefits of the Arrangement*" and "*The Arrangement – Reasons for and Benefits of the Arrangement – Additional Reasons and Benefits for Aurora Shareholders*" in the Joint Information Circular.

How to Vote Your Aurora Common Shares

Proxy deadline: 9:30 a.m. (Toronto time) on December 21, 2026 or, if the Aurora Shareholders' Meeting is adjourned or postponed, 48 hours (excluding Saturdays, Sundays and statutory holidays in the Province of Ontario) prior to the time of the adjourned or postponed Aurora Shareholders' Meeting (the "**Aurora Proxy Deadline**").

Submit your form of proxy to Aurora's transfer agent and registrar, Computershare Investor Services Inc. ("**Computershare**"), as soon as possible.

Step 1: Find out what type of shareholder you are

If you…	**You are a…**
received a **form of proxy** from Computershare	**Registered** Aurora Shareholder
hold your Aurora Common Shares through a broker, investment dealer, bank, trust company, custodian, nominee or other intermediary, and received a **voting instruction form**	**Beneficial** Aurora Shareholder. You can appoint yourself or a proxyholder to participate in the virtual Aurora Shareholders' Meeting.

Step 2: Follow the steps that apply to you

Shareholder type	**Instructions**
Registered shareholder attending yourself	Sign in to the virtual meeting by clicking **"Shareholder"** and entering the 15-digit control number on your form of proxy or in your email notification.
Registered shareholder appointing a proxyholder	**(1)** Submit your form of proxy, naming your proxyholder, by the Aurora Proxy Deadline. **(2)** Then register your proxyholder's name and email address at https://www.computershare.com/Aurora.
Beneficial shareholder attending yourself, or appointing a proxyholder	**(1)** Insert your own name or your proxyholder's name on your voting instruction form and submit it. **(2)** Then register that name and email address at https://www.computershare.com/Aurora.

After the Aurora Proxy Deadline, Computershare will send, via email, an **invite code** to each registered person. The invite code is required to log into the Aurora Shareholders' Meeting by clicking **"Invitation"**.

Both steps are required. If you or your proxyholder do not complete both steps, you or your proxyholder will only be able to enter the meeting as a guest.

Elect Your Form of Consideration

Registered Aurora Shareholders

Election deadline: Elections must be received by the depositary before 5:00 p.m. (Toronto time) on the election deadline, which will be announced by Aurora by news release at least two business days in advance.

Complete and return the enclosed **Letter of Transmittal and Election Form** to the depositary, together with:

- the certificate(s) or DRS Advice(s) representing your Aurora Common Shares; and
- all other required documents.

When properly completed and returned, this will enable you to elect the form of consideration and obtain the consideration you are entitled to receive under the Arrangement.

Non-registered Aurora Shareholders

If you are a non-registered Aurora Shareholder, you should contact your broker or other intermediary regarding your Consideration election.

Aurora Shareholders who do not make a valid election by the election deadline will be deemed to have elected the Combination Alternative.

Shareholder Votes

The special resolution approving the Arrangement (the "**Arrangement Resolution**") must be approved by (a) not less than 66⅔% of the votes cast by the Aurora Shareholders present virtually or represented by proxy and entitled to vote at the Aurora Shareholders' Meeting, voting together as a single class; and (b) a simple majority of the votes cast by the Aurora Shareholders present virtually or represented by proxy and entitled to vote at the Aurora Shareholders' Meeting, excluding the votes attached to Aurora Common Shares held by persons described in items (a) through (d) of section 8.1(2) of Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions* ("**MI 61-101**"), being only Mr. Miguel Martin.

In addition to the approval by the Aurora Shareholders of the Arrangement Resolution, completion of the Arrangement is subject to and conditional upon, among other things: (a) the approval of the issuance of the Organigram Common Shares issuable pursuant to the Arrangement and the Organigram securities issuable pursuant to the concurrent private placement of Organigram securities to BAT (the "**BAT Private Placement**") (the "**Organigram Share Issuance Resolution**") by greater than (i) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at a special meeting (the "**Organigram Shareholders' Meeting**") of Organigram Shareholders to be held on Wednesday, December 23, 2026 at 9:00 a.m. (Toronto time), and (ii) 50% of such votes cast, excluding the votes required to be excluded under the TSX Company Manual and MI 61-101; (b) the approval of the Arrangement by the Supreme Court of British Columbia; (c) the conditional approval of the listing of the Organigram Common Shares to be issued pursuant to the Arrangement on the Toronto Stock Exchange and the notification to the Nasdaq Global Select Market of the listing of such Organigram Common Shares without objection; (d) the receipt of certain required regulatory approvals, being approval under the *Competition Act* (Canada) and clearance under German foreign direct investment laws; (e) dissent rights not having been validly exercised, and not withdrawn, with respect to more than 10% of the issued and outstanding Aurora Common Shares; and (f) there not having occurred a material adverse effect in respect of Aurora or Organigram, as applicable, that is continuing as of the effective date of the Arrangement. Organigram's obligations under the Arrangement Agreement are not subject to any financing condition, and completion of the Arrangement is not conditional on the completion of the BAT Private Placement.

If the Arrangement Resolution is not approved by the Aurora Shareholders at the Aurora Shareholders' Meeting, the Arrangement will not be completed. Similarly, if the Organigram Share Issuance Resolution is not approved by the Organigram Shareholders at the Organigram Shareholders' Meeting, the Arrangement will not be completed.

Aurora Support Agreements

All of the directors and executive officers of Aurora (the "**Supporting Aurora Shareholders**") have entered into agreements (the "**Aurora Support Agreements**") with Organigram to support the Arrangement. The Supporting Aurora Shareholders collectively hold approximately 0.62% of the issued and outstanding Aurora Common Shares and each Supporting Aurora Shareholder has agreed to, among other things, vote all of their Aurora Common Shares in favour of the Arrangement at the Aurora Shareholders' Meeting and not to sell, transfer or tender (or agree to sell, transfer or tender) their Aurora securities, including by tendering to the unsolicited take-over bid for the Aurora Common Shares made by affiliates of Curaleaf Holdings, Inc. (as amended) or to any other take-over bid made for the Aurora Common Shares, subject to limited exceptions.

Organigram Support Agreements

BAT and each of the directors and executive officers of Organigram who hold Organigram Common Shares (collectively, the "**Supporting Organigram Shareholders**") have entered into agreements (the "**Organigram Support Agreements**") with Aurora to support the Arrangement. The Supporting Organigram Shareholders collectively hold approximately 30.95% of the issued and outstanding Organigram Common Shares and each Supporting Organigram Shareholder has agreed to, among other things, vote all of their Organigram Common Shares in favour of the Organigram Share Issuance Resolution at the Organigram Shareholders' Meeting and to otherwise support the Arrangement. Organigram Common Shares held by BAT and its affiliates will be excluded from the votes cast for purposes of the disinterested shareholder approval required under the TSX Company Manual and the minority approval required under MI 61-101, and accordingly will not be counted towards those approvals.

Aurora Fairness Opinions

Fort Capital Partners

Fort Capital Partners ("**Fort Capital**") acted as financial advisor to Aurora and provided the Aurora Special Committee and the Aurora Board with its opinion (the "**Fort Capital Fairness Opinion**") to the effect that, as of November 2, 2026, based upon and subject to the assumptions, limitations and qualifications set forth therein, the Consideration to be received by Aurora Shareholders pursuant to the Arrangement is fair, from a financial point of view, to such Aurora Shareholders. The full text of the written opinion of Fort Capital setting out the assumptions made, matters considered and limitations and qualifications on the review undertaken in connection with the Fort Capital Fairness Opinion is contained in Appendix "F" to the Joint Information Circular. Fort Capital provided its opinion solely for the information and assistance of the Aurora Special Committee and the Aurora Board in connection with its consideration of the Arrangement. The Fort Capital Fairness Opinion is not a recommendation as to how any Aurora Shareholder should vote with respect to the Arrangement, or any other matter. The Fort Capital Fairness Opinion was one of a number of factors taken into consideration by the Aurora Special Committee in making its recommendation and the Aurora Board in making its unanimous determination that the Arrangement is fair to Aurora Shareholders, that the Arrangement and the entry into the Arrangement Agreement are in the best interests of Aurora and to unanimously recommend that the Aurora Shareholders vote in favour of the Arrangement Resolution.

Origin Merchant Partners

Origin Merchant Partners ("**Origin**") acted as financial advisor to the Aurora Special Committee and provided the Aurora Special Committee and the Aurora Board with its opinion (the "**Origin Fairness Opinion**") to the effect that, as of November 2, 2026, based upon and subject to the assumptions, limitations and qualifications set forth therein, the Consideration to be received by Aurora Shareholders pursuant to the Arrangement is fair, from a financial point of view, to the Aurora Shareholders. The full text of the written opinion of Origin setting out the assumptions made, matters considered and limitations and qualifications on the review undertaken in connection with the Origin Fairness Opinion is contained in Appendix "F" to the Joint Information Circular. Origin provided its opinion solely for the information and assistance of the Aurora Special Committee and the Aurora Board in connection with its consideration of the Arrangement. The Origin Fairness Opinion is not a recommendation as to how any Aurora Shareholder should vote with respect to the Arrangement, or any other matter. The Origin Fairness Opinion was one of a number of factors taken into consideration by the Aurora Special Committee in making its recommendation and the Aurora Board in making its unanimous determination that the Arrangement is fair to Aurora Shareholders, that the Arrangement and

the entry into the Arrangement Agreement are in the best interests of Aurora and to unanimously recommend that the Aurora Shareholders vote in favour of the Arrangement Resolution.

Recommendation

After consulting with Fort Capital and Origin, members of senior management and with Aurora's legal, tax and other advisors, and after considering, among other things, the Fort Capital Fairness Opinion and the Origin Fairness Opinion, and based upon the unanimous recommendation of the Aurora Special Committee, **the Aurora Board unanimously determined: (a) that the Arrangement is fair to the Aurora Shareholders; (b) that the Arrangement and the entry into the Arrangement Agreement are in the best interests of Aurora; and (c) to unanimously recommend that the Aurora Shareholders vote in favour of the Arrangement Resolution.**

The Joint Information Circular contains a detailed description of the Arrangement, as well as detailed information regarding Aurora and Organigram and certain pro forma and other information about Organigram after giving effect to the Arrangement. It also includes certain risk factors relating to Aurora, Organigram, the Arrangement and Organigram after giving effect to the Arrangement. Please give this material your careful consideration and, if you require assistance, consult your financial, legal, tax or other professional advisors.

The Aurora Shareholders' Meeting will be held in a virtual-only format conducted via live webcast online at meetnow.global/MQAVTRW. At this website, Aurora Shareholders and duly appointed proxyholders will be able to hear the meeting live, submit questions and vote their Aurora Common Shares on all items of business while the Aurora Shareholders' Meeting is being held. **While Aurora Shareholders and duly appointed proxyholders will not be able to attend the Aurora Shareholders' Meeting in person, regardless of geographic location and ownership, they will have an equal opportunity to participate in the Aurora Shareholders' Meeting and vote on, among other matters, the Arrangement Resolution. Detailed instructions about how to participate in the Aurora Shareholders' Meeting can be found in the Notice of Special Meeting of Aurora Shareholders and the Joint Information Circular.**

Your vote is important to Aurora and we strongly encourage you to participate in the Aurora Shareholders' Meeting or submit the applicable enclosed form of proxy or voting instruction form. If you have any questions about any of the information or require assistance in completing your form of proxy or voting instruction form for your Aurora Common Shares, as applicable, please contact your financial, legal, tax or other professional advisors, or Kingsdale Advisors, at the contact details below.

Aurora Shareholder Questions

If you are an Aurora Shareholder and have any questions or need assistance in voting your Aurora Common Shares, please contact your financial, legal or other professional advisors or Kingsdale Advisors for assistance. You can reach Kingsdale Advisors at 1-800-749-9052 (toll-free in North America) or 416-623-4172 (text and call enabled outside North America) or by e-mail at contactus@kingsdaleadvisors.com. For further information visit voteyesaurora.com.

On behalf of the Board of Directors of Aurora, we look forward to your participation at the Aurora Shareholders' Meeting.

Yours sincerely,

(signed) "*Miguel Martin*"

Miguel Martin
Executive Chairman and Chief Executive Officer
Aurora Cannabis Inc.

ORGANIGRAM
GLOBAL

LETTER TO ORGANIGRAM SHAREHOLDERS

November 20, 2026

Dear Organigram Shareholders:

Holders of common shares in the capital of Organigram Global Inc. have the opportunity to participate as Organigram acquires Aurora Cannabis Inc. and establishes a global leader in nationally legal cannabis markets, including Canada, Europe and Australia. There are multiple drivers expected to accelerate growth, unlock efficiencies, meet global medical demand and drive long-term shareholder value.

You are invited to attend a special meeting (the "**Organigram Shareholders' Meeting**") of the holders (the "**Organigram Shareholders**") of common shares ("**Organigram Common Shares**") in the capital of Organigram Global Inc. ("**Organigram**", "**we**", "**us**", or "**our**"), to be held on Wednesday, December 23, 2026 at 9:00 a.m. (Toronto time) in a virtual-only format that will be conducted via live audio webcast accessible at https://virtual-meetings.tsxtrust.com/2000 using the meeting password "ogi2026" (case sensitive).

Organigram and Aurora Cannabis Inc. ("**Aurora**") entered into an arrangement agreement dated November 2, 2026 (as supplemented, modified or amended, the "**Arrangement Agreement**"), which was unanimously approved by the respective boards of directors of Organigram and Aurora. Pursuant to the Arrangement Agreement and a plan of arrangement under section 288 of the *Business Corporations Act* (British Columbia) (the "**Arrangement**"), Organigram will acquire all of the issued and outstanding common shares in the capital of Aurora ("**Aurora Common Shares**"). Holders of Aurora Common Shares ("**Aurora Shareholders**") will be entitled to receive, at the election of each Aurora Shareholder, for each Aurora Common Share: (a) $7.80 in cash (the "**Cash Alternative**"); (b) 5.8626 Organigram Common Shares (the "**Share Alternative**"); or (c) a combination of $3.75 in cash and 3.0431 Organigram Common Shares (the "**Combination Alternative**"), subject, in the case of the Cash Alternative and the Share Alternative, to proration such that the aggregate cash payable and the aggregate number of Organigram Common Shares issuable under the Arrangement will not exceed $3.75 and 3.0431 Organigram Common Shares, respectively, multiplied by the number of Aurora Common Shares outstanding immediately prior to completion of the Arrangement (collectively, the "**Consideration**").

At the Organigram Shareholders' Meeting, Organigram Shareholders will be asked to consider and vote on an ordinary resolution (the "**Organigram Share Issuance Resolution**") approving the issuance of the Organigram Common Shares issuable pursuant to the Arrangement and Organigram securities issuable pursuant to the concurrent private placement of Organigram securities to BT DE Investments Inc. ("**BAT**") (the "**BAT Private Placement**"), the full text of which is set forth in Appendix "B" to the accompanying joint management information circular of Organigram and Aurora dated November 20, 2026 (the "**Joint Information Circular**").

Your vote is important. The proxy deadline is 9:00 a.m. (Toronto time) on December 21, 2026. See "*How to Vote For the Resolution Today*" below.

Reasons for and Benefits of the Arrangement

Organigram and Aurora expect that the Arrangement will create a global cannabis leader with leading positions in Canada, Europe and Australia, supported by Organigram's strategic shareholder, BAT. The combined company is expected to have a global platform with greater scale, broader capabilities, financial strength and international reach, bringing together Organigram's recreational cannabis leadership, production network, research and development platform and European medical commercial operations with Aurora's global medical cannabis leadership, established international presence and EU-GMP certified manufacturing capabilities. The combined company's scale and cross-

border infrastructure are expected to create a platform for shared innovation and brand building. BAT, as a significant shareholder, has demonstrated expertise across research and development, product development and global supply chain management. The anticipated benefits of the Arrangement include:

- *Creates a Global Cannabis Leader* with a scaled, Canadian-headquartered global cannabis platform with leading positions in five nationally legal cannabis markets – Canada, Germany, Poland, Australia and New Zealand – and meaningful operations in other key markets.

- *Meaningful Synergies* of more than $50 million annually, driven by cross-selling opportunities, procurement scale, consolidated distribution, public company expenses, and routing international demand to the lowest-cost production asset across the combined network.

- *Premium Medical Revenue Mix That Supports Sustainable Growth and Margins*. The majority of pro forma revenue is expected to be derived from higher-margin international medical channels, which command structurally better pricing than the Canadian recreational market, while Organigram's Canadian recreational cannabis leadership is expected to continue to provide a stable commercial base and a proving ground for product innovation.

- *Industry-Leading EU-GMP Platform with Significant Production Capacity*. The combined company is expected to have five EU-GMP production and distribution sites across Canada and Germany, providing certified supply capacity and a combined cultivation capacity of approximately 170,000 kg per annum across 14 production, research and distribution sites, which is expected to be expensive and time-consuming for competitors to replicate. The combined platform is also expected to support faster cash conversion, resulting in lower investment in inventory and improved working capital efficiency.

- *Committed Financing*, with the cash portion of the Consideration fully financed through a combination of cash on hand, the BAT Private Placement and the ATB Credit Facilities.

- *Enhanced Scale and Capital Markets Profile*, including improved trading liquidity and access to capital.

For additional information with respect to these and other anticipated benefits of the Arrangement, see "*The Arrangement – Reasons for and Benefits of the Arrangement*" and "*The Arrangement – Reasons for and Benefits of the Arrangement – Additional Reasons and Benefits for Organigram Shareholders*" in the Joint Information Circular.

Shareholder Votes

The Organigram Share Issuance Resolution must be approved by greater than (i) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, and (ii) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, excluding the 42,231,089 votes attached to Organigram Common Shares held by BAT and its affiliates (representing approximately 30% of the Organigram Common Shares outstanding as of November 19, 2026 on a non-diluted basis) and any other persons required to be excluded under the TSX Company Manual and MI 61-101.

In addition to the approval by the Organigram Shareholders of the Organigram Share Issuance Resolution, completion of the Arrangement is subject to and conditional upon, among other things: (a) the approval of the Arrangement (the "**Arrangement Resolution**") by not less than 66⅔% of the votes cast by the Aurora Shareholders present virtually or represented by proxy at a special meeting (the "**Aurora Shareholders' Meeting**") of Aurora Shareholders to be held on Wednesday, December 23, 2026 at 9:30 a.m. (Toronto time) and by a simple majority of such votes cast excluding the votes required to be excluded under Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions* ("**MI 61-101**"), in accordance with the interim order of the Supreme Court of British Columbia; (b) the approval of the Arrangement by the Supreme Court of British Columbia; (c) the conditional approval of the listing of the Organigram Common Shares to be issued pursuant to the Arrangement on the Toronto Stock Exchange and the notification to the Nasdaq Global Select Market of the listing of such Organigram Common Shares without objection; (d) the receipt of certain required regulatory approvals, being approval under the *Competition Act* (Canada)

and clearance under German foreign direct investment laws; (e) dissent rights not having been validly exercised, and not withdrawn, with respect to more than 10% of the issued and outstanding Aurora Common Shares; and (f) there not having occurred a material adverse effect in respect of Aurora or Organigram, as applicable, that is continuing as of the effective date of the Arrangement. Organigram's obligations under the Arrangement Agreement are not subject to any financing condition, and completion of the Arrangement is not conditional on the completion of the BAT Private Placement.

If the Arrangement Resolution is not approved by the Aurora Shareholders at the Aurora Shareholders' Meeting, the Arrangement will not be completed. Similarly, if the Organigram Share Issuance Resolution is not approved by the Organigram Shareholders at the Organigram Shareholders' Meeting, the Arrangement will not be completed.

Aurora Support Agreements

All of the directors and executive officers of Aurora (the "**Supporting Aurora Shareholders**") have entered into agreements with Organigram to support the Arrangement. The Supporting Aurora Shareholders collectively hold approximately 0.62% of the issued and outstanding Aurora Common Shares and each Supporting Aurora Shareholder has irrevocably agreed to, among other things, vote all of their Aurora Common Shares in favour of the Arrangement at the Aurora Shareholders' Meeting and not to sell, transfer or tender (or agree to sell, transfer or tender) their Aurora securities, including by tendering to the unsolicited take-over bid for the Aurora Common Shares made by affiliates of Curaleaf Holdings, Inc. (as amended) or to any other take-over bid made for the Aurora Common Shares, subject to limited exceptions.

Organigram Support Agreements

BAT and each of the directors and executive officers of Organigram who hold Organigram Common Shares (collectively, the "**Supporting Organigram Shareholders**") have entered into agreements (the "**Organigram Support Agreements**") with Aurora to support the Arrangement. The Supporting Organigram Shareholders collectively hold approximately 30.95% of the issued and outstanding Organigram Common Shares and each Supporting Organigram Shareholder has agreed to, among other things, vote all of their Organigram Common Shares in favour of the Organigram Share Issuance Resolution at the Organigram Shareholders' Meeting and to otherwise support the Arrangement. Organigram Common Shares held by BAT and its affiliates will be excluded from the votes cast for purposes of the disinterested shareholder approval required under the TSX Company Manual and the minority approval required under MI 61-101, and accordingly will not be counted towards those approvals.

Organigram Fairness Opinion

BMO Capital Markets acted as financial advisor to Organigram in connection with the Arrangement and has provided the board of directors of Organigram (the "**Organigram Board**") with its opinion (the "**Organigram Fairness Opinion**") to the effect that, as of November 2, 2026, and based upon and subject to the assumptions, limitations and qualifications set forth therein, the Consideration to be paid by Organigram pursuant to the Arrangement is fair, from a financial point of view, to Organigram. The full text of the written opinion of BMO Capital Markets, which sets forth, among other things, the assumptions made, procedures followed, information reviewed, matters considered and limitations and qualifications on the scope of review undertaken in connection with rendering the Organigram Fairness Opinion, is contained in Appendix "G" to the Joint Information Circular and should be read carefully and in its entirety.

BMO Capital Markets provided its opinion solely for the information and assistance of the Organigram Board in connection with its consideration of the Arrangement and the opinion is subject to the assumptions, limitations and qualifications contained therein. The Organigram Fairness Opinion is not a recommendation as to how any Organigram Shareholder should vote or act with respect to the Arrangement or its Organigram Common Shares. The Organigram Fairness Opinion was one of a number of factors taken into consideration by the Organigram Board in making its unanimous determination that the Arrangement is fair to the Organigram Shareholders and the holders of Organigram's Class A preferred shares, that the Arrangement and the entry into the Arrangement Agreement are in the best interests of Organigram and to unanimously recommend that the Organigram Shareholders vote in favour of the Organigram Share Issuance Resolution.

Organigram Board Recommendation to Organigram Shareholders: Vote in Favour of the Resolution

After consulting with Organigram's senior management and with its financial, legal, tax and other advisors, and after considering, among other things, the Organigram Fairness Opinion, **the Organigram Board (with the representatives of BAT abstaining in respect of the BAT Private Placement) unanimously determined: (a) that the Arrangement is fair to the Organigram Shareholders and the holders of Organigram's Class A preferred shares; (b) that the Arrangement and the entry into the Arrangement Agreement are in the best interests of Organigram; and (c) to unanimously recommend that the Organigram Shareholders vote in favour of the Organigram Share Issuance Resolution**.

The Joint Information Circular contains a detailed description of the Arrangement, as well as detailed information regarding Organigram and Aurora and certain pro forma and other information about Organigram after giving effect to the Arrangement. It also includes certain risk factors relating to Organigram, Aurora, the Arrangement and Organigram after giving effect to the Arrangement. Please give this material your careful consideration and, if you require assistance, consult your financial, legal, tax or other professional advisors.

The Organigram Shareholders' Meeting will be held in a virtual-only format conducted via live audio webcast online at https://virtual-meetings.tsxtrust.com/2000 using the meeting password "ogi2026" (case sensitive). **At this website, registered Organigram Shareholders and duly appointed proxyholders will be able to hear the meeting live, submit questions and vote their Organigram Common Shares while the Organigram Shareholders' Meeting is being held. Organigram Shareholders will not be able to attend the Organigram Shareholders' Meeting in person. Detailed instructions about how to participate in the Organigram Shareholders' Meeting can be found in the Notice of Special Meeting of Organigram Shareholders, the Joint Information Circular and the TSX Trust virtual meeting guide accompanying the Meeting Materials**.

How to Vote For the Resolution Today

Your vote is important to Organigram and we strongly encourage you to participate in the Organigram Shareholders' Meeting or submit the enclosed form of proxy or voting instruction form, as applicable. If you have any questions about any of the information or require assistance in completing your form of proxy or voting instruction form for your Organigram Common Shares, as applicable, please contact your financial, legal, tax or other professional advisors, or Sodali & Co, at the contact details below.

Proxy deadline: 9:00 a.m. (Toronto time) on December 21, 2026 or, if the Organigram Shareholders' Meeting is adjourned or postponed, 48 hours (excluding Saturdays, Sundays and statutory holidays in the Province of Ontario) prior to the time of the adjourned or postponed Organigram Shareholders' Meeting (the "**Organigram Proxy Deadline**").

To ensure that your vote is counted, submit your form of proxy to Organigram's transfer agent and registrar, TSX Trust Company ("**TSX Trust**"), as soon as possible.

Step 1: Find out what type of shareholder you are

If you…	**You are a…**
received a **form of proxy** from TSX Trust	**Registered** Organigram Shareholder
hold your Organigram Common Shares through a broker, investment dealer, bank, trust company, custodian, nominee or other intermediary, and received a **voting instruction form**	**Beneficial** Organigram Shareholder. You can appoint yourself or a proxyholder to participate in the virtual Organigram Shareholders' Meeting.

Step 2: Follow the steps that apply to you

Shareholder type	Instructions
Registered shareholder attending yourself	Log in to the virtual Organigram Shareholders' Meeting at https://virtual-meetings.tsxtrust.com/2000 using the control number on your form of proxy and the meeting password "ogi2026".
Registered shareholder appointing a proxyholder	**(1)** Insert your proxyholder's name in the space provided on the form of proxy and submit it by the Organigram Proxy Deadline. **(2)** Then register your proxyholder at tsxtrust.com/resource/en/75 resource/en/75 by the Organigram Proxy Deadline so that TSX Trust can email your proxyholder a Meeting Access Number required to log into the Organigram Shareholders' Meeting.
Beneficial shareholder attending yourself, or appointing a proxyholder	**(1)** Insert your own name or your proxyholder's name in the space provided on your voting instruction form and carefully follow the instructions and procedures of your intermediary well in advance of the Organigram Proxy Deadline. **(2)** Then register yourself or your proxyholder at tsxtrust.com/resource/en/75 by the Organigram Proxy Deadline so that TSX Trust can email a Meeting Access Number required to log into the Organigram Shareholders' Meeting.

Both steps are required. If you do not follow these steps, you or your proxyholder will only be able to attend the meeting as a guest and will not be able to vote or ask questions.

Organigram Shareholder Questions

If you are an Organigram Shareholder and have any questions or need assistance in voting your Organigram Common Shares, please contact your financial, legal or other professional advisors or Sodali & Co for assistance. You can reach Sodali & Co at 1-833-830-9806 (North America) (1-289-695-3075 for calls outside North America) or by e-mail at assistance@investor.sodali.com.

On behalf of the Board of Directors of Organigram, we are very excited about this opportunity to combine Organigram and Aurora and create a global cannabis leader in nationally legal markets, with vast potential to further benefit all of our collective stakeholders. I strongly encourage you to vote in favour of this opportunity. We firmly believe this transaction represents a defining step in Organigram's future and we look forward to delivering on our vision together with Aurora in the years ahead, and to your participation at the Organigram Shareholders' Meeting.

Yours sincerely,

(signed) *"James Yamanaka"*

James Yamanaka
Chief Executive Officer
Organigram Global Inc.

NOTICE OF SPECIAL MEETING OF AURORA SHAREHOLDERS

NOTICE IS HEREBY GIVEN that a special meeting (the "**Aurora Shareholders' Meeting**") of the holders ("**Aurora Shareholders**") of common shares ("**Aurora Common Shares**") of Aurora Cannabis Inc. ("**Aurora**") will be held at 9:30 a.m. (Toronto time) on Wednesday, December 23, 2026 in a virtual-only format that will be conducted via live webcast accessible online at meetnow.global/MQAVTRW for the following purposes:

1. to consider, pursuant to an interim order (the "**Interim Order**") of the Supreme Court of British Columbia (the "**Court**") dated November 20, 2026, and, if deemed advisable, to approve, with or without variation, a special resolution of the Aurora Shareholders (the "**Arrangement Resolution**"), the full text of which is set forth in Appendix "A" to the accompanying joint management information circular dated November 20, 2026 (the "**Joint Information Circular**"), to approve a plan of arrangement (the "**Arrangement**") under section 288 of the *Business Corporations Act* (British Columbia) (the "**BCBCA**") involving Aurora, Aurora Shareholders and Organigram Global Inc. ("**Organigram**"), whereby, among other things, Organigram will acquire all of the issued and outstanding Aurora Common Shares in exchange for, at the election of each Aurora Shareholder, $7.80 in cash, 5.8626 common shares of Organigram ("**Organigram Common Shares**") or a combination of $3.75 in cash and 3.0431 Organigram Common Shares for each Aurora Common Share, subject to proration, as more particularly described in the Joint Information Circular; and

2. to transact such further and other business as may properly be brought before the Aurora Shareholders' Meeting or any adjournment(s) or postponement(s) thereof.

Specific details of the matters to be put before the Aurora Shareholders' Meeting are set forth in the Joint Information Circular.

The Board of Directors of Aurora unanimously recommends that Aurora Shareholders vote <u>FOR</u> the Arrangement Resolution. It is a condition to the completion of the Arrangement that the Arrangement Resolution be approved at the Aurora Shareholders' Meeting. If the Arrangement Resolution is not approved by the Aurora Shareholders, the Arrangement cannot be completed.

The full text of the plan of arrangement (the "**Plan of Arrangement**") implementing the Arrangement is attached as Appendix "C" to the Joint Information Circular. The Interim Order is attached as Appendix "D" to the Joint Information Circular.

Each Aurora Common Share entitled to be voted in respect of the Arrangement Resolution will entitle the holder to one vote at the Aurora Shareholders' Meeting with respect to such resolution. The Arrangement Resolution must be approved by not less than 66⅔% of the votes cast by the Aurora Shareholders present virtually or represented by proxy and entitled to vote at the Aurora Shareholders' Meeting, voting together as a single class, and by a simple majority of such votes cast, excluding the votes attached to Aurora Common Shares held by persons described in items (a) through (d) of section 8.1(2) of Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions*, being only Mr. Miguel Martin.

The record date (the "**Aurora Record Date**") for determining the Aurora Shareholders entitled to receive notice of and to vote at the Aurora Shareholders' Meeting is the close of business on November 18, 2026. Aurora Shareholders whose names have been entered in the register of holders of Aurora Common Shares at the close of business on the Aurora Record Date will be entitled to receive notice of and to vote at the Aurora Shareholders' Meeting.

Registered Aurora Shareholders may attend the Aurora Shareholders' Meeting virtually or may be represented by proxy. Aurora Shareholders who are unable to attend the Aurora Shareholders' Meeting or any adjournments or postponements thereof virtually are requested to date, sign and return the accompanying form of proxy for use at the Aurora Shareholders' Meeting or any adjournment or postponement thereof. To be effective, the applicable enclosed form of proxy must be dated, signed and deposited with Aurora's transfer agent and registrar, Computershare Investor Services Inc. ("**Computershare**"): (a) by mail, using the enclosed return envelope or one addressed to Computershare, Attention: Proxy Department, 320 Bay Street, 14th Floor, Toronto, Ontario M5H 4A6; (b) by facsimile at 1-866-249-7775; or (c) through the internet at www.investorvote.com, no later than: 9:30 a.m. (Toronto time) on December 21,

2026 or, if the Aurora Shareholders' Meeting is adjourned or postponed, no later than 48 hours before the beginning of any adjourned or postponed Aurora Shareholders' Meeting (excluding Saturdays, Sundays and statutory holidays in Ontario). The time limit for the deposit of proxies may be waived or extended by the Chair of the Aurora Shareholders' Meeting at his or her discretion without notice. To vote through the internet you will require your 15-digit control number found on your proxy form.

If an Aurora Shareholder receives more than one form of proxy because such holder owns Aurora Common Shares registered in different names or addresses, each form of proxy should be completed and returned.

A proxyholder has discretion under the accompanying form of proxy in respect of amendments or variations to matters identified in this Notice and with respect to other matters which may properly come before the Aurora Shareholders' Meeting, or any adjournment or postponement thereof. As of the date hereof, management of Aurora knows of no amendments, variations or other matters to come before the Aurora Shareholders' Meeting other than the matters set forth in this Notice. Aurora Shareholders who are planning to return the form of proxy are encouraged to review the Joint Information Circular carefully before submitting the proxy form.

Directors, officers and employees of, or advisors to, Aurora may solicit proxies by personal interviews, telephone or other means of communication. In addition, Aurora has engaged Kingsdale Advisors as its strategic shareholder advisor and proxy solicitation agent to assist management of Aurora with, among other things, the solicitation of proxies from Aurora Shareholders.

It is the intention of the persons named in the applicable enclosed form of proxy, if not expressly directed to the contrary in such form of proxy, to vote in favour of the Arrangement Resolution and each of the other matters to be brought before the Aurora Shareholders' Meeting.

Pursuant to the Interim Order, registered holders of Aurora Common Shares as of the Aurora Record Date have been granted the right to dissent with respect to the Arrangement Resolution and, if the Arrangement becomes effective, to be paid the fair value of their Aurora Common Shares in accordance with Division 2 of Part 8 of the BCBCA, as modified by the Interim Order, the Plan of Arrangement and any other order of the Court. The right of an Aurora Shareholder to dissent is more particularly described in the Joint Information Circular and in the Interim Order and the text of Division 2 of Part 8 of the BCBCA, which are set forth in Appendices "D" and "K", respectively, to the accompanying Joint Information Circular. To exercise such right to dissent, a registered Aurora Shareholder who holds Aurora Common Shares as of the Aurora Record Date must deliver to Aurora, c/o Torys LLP, Suite 2800, 79 Wellington St. W., Toronto, Ontario M5K 1N2, Attention: Andrew Gray and Colette Koopman, a written notice of dissent that strictly complies with section 242 of the BCBCA (a "**Notice of Dissent**"), which Notice of Dissent must be received by 9:30 a.m. (Toronto time) on December 21, 2026 or, if the Aurora Shareholders' Meeting is adjourned or postponed, by 9:30 a.m. (Toronto time) on the date that is two Business Days (as defined in the Plan of Arrangement) immediately preceding the date of the adjourned or postponed Aurora Shareholders' Meeting. A registered Aurora Shareholder may only dissent in respect of all, and not less than all, of its Aurora Common Shares.

Failure to strictly comply with the requirements set forth in sections 237 to 247 of the BCBCA, as modified by the Interim Order and the Plan of Arrangement, may result in the loss of any right of dissent. Persons who are beneficial owners of Aurora Common Shares registered in the name of a broker, investment dealer, bank, trust company, custodian, nominee or other intermediary who wish to dissent should be aware that only the registered holders of such Aurora Common Shares are entitled to dissent. Accordingly, a beneficial owner of Aurora Common Shares desiring to exercise the right of dissent must make arrangements for the Aurora Common Shares beneficially owned by such holder to be registered in the holder's name prior to the time the Notice of Dissent is required to be received by Aurora or, alternatively, make arrangements for the registered holder of such Aurora Common Shares to dissent on behalf of the beneficial holder. It is strongly recommended that any Aurora Shareholders wishing to dissent seek independent legal advice.

Dated at Toronto, Ontario, this 20th day of November, 2026.

BY ORDER OF THE BOARD OF DIRECTORS OF AURORA CANNABIS INC.

(signed) "*Miguel Martin*"

Miguel Martin
Executive Chairman and Chief Executive Officer
Aurora Cannabis Inc.

NOTICE OF SPECIAL MEETING OF ORGANIGRAM SHAREHOLDERS

NOTICE IS HEREBY GIVEN that a special meeting (the "**Organigram Shareholders' Meeting**") of the holders ("**Organigram Shareholders**") of common shares ("**Organigram Common Shares**") of Organigram Global Inc. ("**Organigram**") will be held at 9:00 a.m. (Toronto time) on Wednesday, December 23, 2026 in a virtual-only format that will be conducted via live audio webcast at https://virtual-meetings.tsxtrust.com/2000 using the meeting password "ogi2026" (case sensitive) for the following purposes:

1. to consider and, if deemed advisable, to approve, with or without variation, an ordinary resolution (the "**Organigram Share Issuance Resolution**"), the full text of which is set forth in Appendix "B" to the accompanying joint management information circular dated November 20, 2026 (the "**Joint Information Circular**"), to approve and authorize the issuance of such number of Organigram Common Shares to allow Organigram to meet its obligations under the Arrangement Agreement (as defined below) pursuant to a plan of arrangement under section 288 of the *Business Corporations Act* (British Columbia) (the "**Arrangement**") involving Aurora Cannabis Inc. ("**Aurora**"), the holders of the common shares of Aurora, and Organigram, pursuant to the terms of an arrangement agreement dated November 2, 2026 (as supplemented, modified or amended, the "**Arrangement Agreement**") between Organigram and Aurora, and the issuance of Organigram securities to BT DE Investments Inc. ("**BAT**") pursuant to the concurrent private placement (the "**BAT Private Placement**"), all as more particularly described in the Joint Information Circular; and

2. to transact such further and other business as may properly be brought before the Organigram Shareholders' Meeting or any adjournment(s) or postponement(s) thereof.

Specific details of the matters to be put before the Organigram Shareholders' Meeting are set forth in the Joint Information Circular.

The Board of Directors of Organigram (with the representatives of BAT abstaining in respect of the BAT Private Placement) unanimously recommends that Organigram Shareholders vote FOR the Organigram Share Issuance Resolution. It is a condition to the completion of the Arrangement that the Organigram Share Issuance Resolution be approved at the Organigram Shareholders' Meeting. If the Organigram Share Issuance Resolution is not approved by the Organigram Shareholders, the Arrangement cannot be completed.

Each Organigram Common Share entitled to be voted in respect of the Organigram Share Issuance Resolution will entitle the holder to one vote at the Organigram Shareholders' Meeting. The Organigram Share Issuance Resolution must be approved by greater than (i) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, and (ii) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, excluding the votes attached to Organigram Common Shares held by BAT and its affiliates and any other persons required to be excluded under the TSX Company Manual and Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions*.

The record date (the "**Organigram Record Date**") for determining the Organigram Shareholders entitled to receive notice of and to vote at the Organigram Shareholders' Meeting is the close of business on November 18, 2026. Organigram Shareholders whose names have been entered in the register of holders of Organigram Common Shares at the close of business on the Organigram Record Date will be entitled to receive notice of and to vote at the Organigram Shareholders' Meeting.

Registered Organigram Shareholders may attend the Organigram Shareholders' Meeting virtually or may be represented by proxy. Organigram Shareholders who are unable to attend the Organigram Shareholders' Meeting or any adjournments or postponements thereof virtually are requested to date, sign and return the accompanying form of proxy for use at the Organigram Shareholders' Meeting or any adjournment or postponement thereof. To be effective, the enclosed form of proxy must be dated, signed and deposited with Organigram's registrar and transfer agent, TSX Trust Company ("**TSX Trust**"): (a) by mail, using the enclosed return envelope or one addressed to TSX Trust Company, 100 Adelaide Street West, Suite 301, Toronto, Ontario M5H 4H1; (b) by facsimile at 416-595-9593; or (c) through the internet at www.voteproxyonline.com, no later than 9:00 a.m. (Toronto time) on December 21, 2026 or, if the Organigram Shareholders' Meeting is adjourned or postponed, no later than 48 hours (excluding Saturdays,

Sundays and statutory holidays in Ontario) before the beginning of any adjourned or postponed Organigram Shareholders' Meeting (the "**Organigram Proxy Deadline**"). The time limit for the deposit of proxies may be waived or extended by the Chair of the Organigram Shareholders' Meeting at his or her discretion without notice. To vote through the internet you will require your 12-digit control number found on your proxy form. Organigram Shareholders who wish to appoint a proxyholder other than the management nominees named in the form of proxy (including non-registered Organigram Shareholders who wish to appoint themselves) must also register such proxyholder at tsxtrust.com/resource/en/75 by the Organigram Proxy Deadline so that TSX Trust can provide the proxyholder with a Meeting Access Number required to vote at the Organigram Shareholders' Meeting.

If an Organigram Shareholder receives more than one form of proxy because such holder owns Organigram Common Shares registered in different names or addresses, each form of proxy should be completed and returned.

A proxyholder has discretion under the accompanying form of proxy in respect of amendments or variations to matters identified in this Notice and with respect to other matters which may properly come before the Organigram Shareholders' Meeting, or any adjournment or postponement thereof. As of the date hereof, management of Organigram knows of no amendments, variations or other matters to come before the Organigram Shareholders' Meeting other than the matters set forth in this Notice. Organigram Shareholders who are planning to return the form of proxy are encouraged to review the Joint Information Circular carefully before submitting the proxy form.

Directors, officers and employees of, or advisors to, Organigram may solicit proxies by personal interviews, telephone or other means of communication. In addition, Organigram has engaged Sodali & Co as its proxy solicitation and information agent to assist management of Organigram with, among other things, the solicitation of proxies from Organigram Shareholders.

It is the intention of the persons named in the enclosed form of proxy, if not expressly directed to the contrary in such form of proxy, to vote in favour of the Organigram Share Issuance Resolution.

Dated at Toronto, Ontario, this 20th day of November, 2026.

BY ORDER OF THE BOARD OF DIRECTORS OF ORGANIGRAM GLOBAL INC.

(signed) "*James Yamanaka*"

James Yamanaka
Chief Executive Officer
Organigram Global Inc.

AURORA SHAREHOLDERS – QUESTIONS AND ANSWERS

The following is intended to address certain key questions concerning the Arrangement and the Aurora Shareholders' Meeting. The information contained below is of a summary nature and therefore is not complete and is qualified in its entirety by the more detailed information contained elsewhere in or incorporated by reference in this Joint Information Circular, including the Appendices hereto, all of which are important and should be reviewed carefully. Capitalized terms used but not otherwise defined in this "*Aurora Shareholders – Questions and Answers*" have the meanings set forth under the heading "*Glossary of Terms*".

Q: Why did I receive this Joint Information Circular?

A: You received this Joint Information Circular because you are an Aurora Shareholder who will be asked at the Aurora Shareholders' Meeting to approve, among other things, the Arrangement involving Aurora and Organigram.

Q: What is the Arrangement?

A: On November 2, 2026, Aurora and Organigram agreed to the terms and conditions of the Arrangement Agreement. Pursuant to the Arrangement Agreement, Organigram has agreed to acquire all of the issued and outstanding Aurora Common Shares under a court-approved Plan of Arrangement in accordance with the provisions of the BCBCA. If completed, the Arrangement will result in Organigram acquiring all of the Aurora Common Shares. Pursuant to the Arrangement, each Aurora Shareholder will be entitled to receive, at its election, for each Aurora Common Share held: (a) the Cash Alternative of $7.80 in cash; (b) the Share Alternative of 5.8626 Organigram Common Shares; or (c) the Combination Alternative of $3.75 in cash and 3.0431 Organigram Common Shares, subject, in the case of the Cash Alternative and the Share Alternative, to proration as described under "*Effect of the Arrangement – Elections and Proration*". Current Aurora Shareholders are expected to hold approximately 37% of the economic interest and 41% of the voting rights in Organigram, on a fully diluted basis, immediately after completion of the Arrangement and the BAT Private Placement.

Q: What am I entitled to receive under the Arrangement?

A: Aurora Shareholders will have the option to elect to receive: (i) the Cash Alternative of $7.80 per Aurora Common Share in cash; (ii) the Share Alternative of 5.8626 Organigram Common Shares per Aurora Common Share; or (iii) the Combination Alternative of $3.75 in cash plus 3.0431 Organigram Common Shares per Aurora Common Share held, subject, in the case of the Cash Alternative and the Share Alternative, to proration as described under "*Effect of the Arrangement – Elections and Proration*".

Q: Does the Aurora Board support the Arrangement?

A: Yes. After consulting with Aurora's Financial Advisors, members of senior management and with Aurora's legal, tax and other advisors, and after considering, among other things, the Fort Capital Fairness Opinion and the Origin Fairness Opinion, and based upon the unanimous recommendation of the Aurora Special Committee, the Aurora Board unanimously determined: (a) that the Arrangement is fair to the Aurora Shareholders; (b) that the Arrangement and the entry into the Arrangement Agreement are in the best interests of Aurora; and (c) to unanimously recommend that the Aurora Shareholders vote in favour of the Arrangement Resolution.

THE AURORA BOARD UNANIMOUSLY RECOMMENDS THAT AURORA SHAREHOLDERS VOTE FOR THE ARRANGEMENT RESOLUTION.

See "*The Arrangement – Recommendation of the Aurora Board*", "*The Arrangement – Reasons for and Benefits of the Arrangement*" and "*The Arrangement – Reasons for and Benefits of the Arrangement – Additional Reasons and Benefits for Aurora Shareholders*". The full text of the Arrangement Resolution is set forth in Appendix "A" to this Joint Information Circular.

Q: Why is the Arrangement superior to the Hostile Bid or other alternatives?

A: Organigram and Aurora expect that the Arrangement will create a global cannabis leader with leading positions in Canada, Europe and Australia, supported by Organigram's strategic shareholder, BAT. The combined company is expected to have a global platform with greater scale, broader capabilities, financial strength and international reach, bringing together Organigram's recreational cannabis leadership, production network, research and development platform and European medical commercial operations with Aurora's global medical cannabis leadership, established international presence and EU-GMP certified manufacturing capabilities. The following are some, but not all, of the expected benefits of the Arrangement to Aurora Shareholders:

- *Significant Premium*. The Consideration has an implied value of $7.80 per Aurora Common Share, representing a premium of approximately 93% to the Unaffected Price and approximately 21% to the implied value of the Hostile Bid as of November 2, 2026.

- *Choice of Consideration*. Aurora Shareholders may elect the Cash Alternative, the Share Alternative or the Combination Alternative, subject to proration, providing both certainty of value and the opportunity for continued participation in the combined company.

- *Continued Participation*. Aurora Shareholders are expected to hold approximately 37% of the economic interest and 41% of the voting rights in Organigram, on a fully diluted basis, following completion of the Arrangement and the BAT Private Placement and, to the extent they retain Organigram Common Shares, will participate in the expected synergies and growth of the combined company.

- *Inadequacy of the Hostile Bid*. With the benefit of the Fort Capital Inadequacy Opinion and the Updated Inadequacy Opinion, the Aurora Board and the Aurora Special Committee have twice unanimously determined that Curaleaf's bid is financially inadequate. Approximately 48% of the value of the Consideration is payable in cash, compared to approximately 20% under the Hostile Bid.

- *Attractive Organigram Common Shares and Balance Sheet Strength*. Aurora Shareholders who receive Organigram Common Shares will hold a TSX- and Nasdaq-listed security of a company with a single class of voting shares, no controlling shareholder and a strong balance sheet, rather than assuming exposure to Curaleaf's leverage and tax liabilities.

- *Complementary Platform and Strategic Partner*. The combined company is expected to bring together complementary capabilities in Canada, Europe, Australia and other international markets with the continued support of BAT.

- *Governance and Voting Influence*. Curaleaf is a controlled company: its Chairman and Chief Executive Officer holds multiple voting shares carrying approximately 69% of the votes on an economic interest of approximately 18%, and Aurora Shareholders would receive subordinate voting shares under the Hostile Bid, becoming a minority in a company controlled by a single individual. Under the Arrangement, Aurora Shareholders are expected to become the largest voting constituency in Organigram, which has a single class of voting shares and a strategic shareholder whose voting interest is contractually capped at 30%.

See "*The Arrangement – Reasons for and Benefits of the Arrangement*" and "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement*".

Q: Would Aurora Shareholders own part of the combined company?

A: Aurora Shareholders who elect to receive Organigram Common Shares either through the Share Alternative or the Combination Alternative (or proration of the Cash Alternative) would participate in the combined

company. Current Aurora Shareholders are expected to hold approximately 37% of the economic interest and 41% of the voting rights in Organigram, on a fully diluted basis, immediately after completion of the Arrangement and the BAT Private Placement.

Q: Are there support agreements in place with any Aurora Shareholders?

A: Yes. All of the directors and executive officers of Aurora have entered into agreements with Organigram to support the Arrangement. The Supporting Aurora Shareholders collectively hold approximately 0.62% of the issued and outstanding Aurora Common Shares and each Supporting Aurora Shareholder has irrevocably agreed to, among other things, vote all of their Aurora Common Shares in favour of the Arrangement at the Aurora Shareholders' Meeting and not to sell, transfer or tender (or agree to sell, transfer or tender) their Aurora securities, including by tendering to the Hostile Bid or to any other take-over bid made for the Aurora Common Shares, subject to limited exceptions.

See "*Effect of the Arrangement – Aurora Support Agreements*".

Q: Are there support agreements in place with any Organigram Shareholders?

A: Yes. BAT and each of the directors and executive officers of Organigram who hold Organigram Common Shares have entered into agreements with Aurora to support the Arrangement. The Supporting Organigram Shareholders collectively hold approximately 30.95% of the issued and outstanding Organigram Common Shares and each Supporting Organigram Shareholder has agreed to, among other things, vote all of their Organigram Common Shares in favour of the Organigram Share Issuance Resolution at the Organigram Shareholders' Meeting and to otherwise support the Arrangement. Organigram Common Shares held by BAT and its affiliates will be excluded for purposes of the disinterested shareholder approval required under the TSX Company Manual and the minority approval required under MI 61-101.

See "*Effect of the Arrangement – Organigram Support Agreements*".

Q: Is there a fairness opinion regarding the Consideration to be received by Aurora Shareholders?

A: Yes.

Fort Capital has provided the Aurora Special Committee and the Aurora Board with the Fort Capital Fairness Opinion to the effect that, as of November 2, 2026 and subject to the assumptions, limitations and qualifications set forth therein, in the opinion of Fort Capital, the Consideration to be received by Aurora Shareholders pursuant to the Arrangement is fair, from a financial point of view, to such Aurora Shareholders.

Origin has also provided the Aurora Special Committee and the Aurora Board with the Origin Fairness Opinion to the effect that, as of November 2, 2026 and subject to the assumptions, limitations and qualifications set forth therein, in the opinion of Origin, the Consideration to be received by the Aurora Shareholders pursuant to the Arrangement is fair, from a financial point of view, to the Aurora Shareholders.

See "*The Arrangement – Aurora Fairness Opinions*", "*The Arrangement – Reasons for and Benefits of the Arrangement*" and "*The Arrangement – Reasons for and Benefits of the Arrangement – Additional Reasons and Benefits for Aurora Shareholders*".

Q: What is the recommendation of the Aurora Board with regards to the Hostile Bid?

A: The Aurora Board continues to reiterate that the Hostile Bid from Curaleaf is not in the best interests of Aurora or the Aurora Shareholders and unanimously recommends that Aurora Shareholders **REJECT** the Hostile Bid by taking no action and **DO NOT TENDER** their Aurora Common Shares to the Hostile Bid.

Q: How do I reject the Hostile Bid?

A: To reject the Hostile Bid, simply do nothing. **DO NOT TENDER** your Aurora Common Shares to the Hostile Bid. If you are contacted by Curaleaf or any of its representatives, do not complete any documents they may provide (letter of transmittal, notice of guaranteed delivery, etc.).

Q: Can I withdraw my Aurora Common Shares if I have already tendered?

A: **YES**. If you have already tendered your Aurora Common Shares to the Hostile Bid, you can withdraw them at any time before your Aurora Common Shares have been taken up and paid for by Curaleaf pursuant to the Hostile Bid. If you have already tendered your Aurora Common Shares to the Hostile Bid, we recommend you withdraw your Aurora Common Shares from the Hostile Bid. We recommend you contact your broker or dealer, or Kingsdale Advisors, Aurora's strategic shareholder advisor and information agent, for assistance with withdrawing your Aurora Common Shares from the Hostile Bid.

Q: What should I do if I am contacted by Curaleaf or its representatives?

A: You may be contacted by Curaleaf or its representatives and encouraged to tender your Aurora Common Shares. The Aurora Board recommends that Aurora Shareholders **TAKE NO ACTION** with respect to the Hostile Bid. Do not sign or return any documents relating to the Hostile Bid unless and until you have carefully considered all available information and alternatives.

Q: Why is the Aurora Shareholders' Meeting being held?

A: The Aurora Shareholders' Meeting is being held for the purposes of obtaining the Aurora Shareholder approval contemplated by the Arrangement Agreement and the Interim Order. Pursuant to the Interim Order, the Arrangement Resolution must be approved by not less than 66⅔% of the votes cast by Aurora Shareholders present virtually or represented by proxy and entitled to vote at the Aurora Shareholders' Meeting, voting together as a single class, and by a simple majority of such votes cast, excluding the votes attached to Aurora Common Shares held by persons described in items (a) through (d) of section 8.1(2) of MI 61-101, being only Mr. Miguel Martin. The full text of the Arrangement Resolution is set forth in Appendix "A" to this Joint Information Circular.

Q: When and where is the Aurora Shareholders' Meeting being held?

A: There is no physical location for the Aurora Shareholders' Meeting. The Aurora Shareholders' Meeting will be held on December 23, 2026 at 9:30 a.m. (Toronto time) in a virtual-only format that will be conducted via live webcast accessible at meetnow.global/MQAVTRW. Aurora Shareholders will not be able to attend the Aurora Shareholders' Meeting in person.

Q: How do I access the virtual Aurora Shareholders' Meeting?

A: Registered Aurora Shareholders and duly appointed proxyholders can access and vote at the Aurora Shareholders' Meeting as follows:

- Go to meetnow.global/MQAVTRW in a web browser on a smartphone, tablet, or computer prior to the start of the Aurora Shareholders' Meeting. The virtual meeting platform is fully supported across most commonly used web browsers (note: Internet Explorer is not a supported browser). You should allow ample time to check in to the virtual Aurora Shareholders' Meeting to check compatibility and complete the related procedures.

- Click "Shareholder" and enter your 15-digit control number (your control number is located on your form of proxy or in the email notification you received). Duly appointed proxyholders: click "Invitation" and enter the invite code provided by Computershare by email after the Aurora Proxy Deadline has passed.

Guests, including non-registered Aurora Shareholders who have not duly appointed themselves as proxyholders, can log in to the Aurora Shareholders' Meeting as set out below. Guests can listen to the Aurora Shareholders' Meeting but are not able to vote or submit questions.

- Go to meetnow.global/MQAVTRW in a web browser on a smartphone, tablet, or computer prior to the start of the Aurora Shareholders' Meeting. The virtual meeting platform is fully supported across most commonly used web browsers (note: Internet Explorer is not a supported browser). You should allow ample time to check in to the virtual Aurora Shareholders' Meeting to check compatibility and complete the related procedures.

- Click "Guest" and then complete the online form.

See "*General Proxy Matters – Aurora – How to Participate at the Aurora Shareholders' Meeting*". For information on how a non-registered (beneficial) Aurora Shareholder can participate in the Aurora Shareholders' Meeting and vote its Aurora Common Shares, see the question below "*How can a non-registered Aurora Shareholder vote during the Aurora Shareholders' Meeting?* "

Q: Who can ask questions at the Aurora Shareholders' Meeting?

A: Only registered Aurora Shareholders and duly appointed proxyholders may attend and participate in the Aurora Shareholders' Meeting virtually via live webcast, including by asking questions, provided they follow the instructions in this Joint Information Circular. Any Aurora Shareholder who wishes to pose questions in advance of the Aurora Shareholders' Meeting is invited to send them by email to ir@auroramj.com.

- Registered Aurora Shareholders and duly appointed proxyholders who participate by attending online will be able to listen to the proceedings of the Aurora Shareholders' Meeting and ask questions on the applicable resolution during the specified times, provided they remain connected to the internet.

- Non-registered (beneficial) Aurora Shareholders who wish to participate during the Aurora Shareholders' Meeting must follow the instructions under the heading "*Information for Beneficial Holders*" and appoint themselves as proxyholder. Non-registered (beneficial) Aurora Shareholders who have not duly appointed themselves as proxyholders may still attend the Aurora Shareholders' Meeting as guests, but will not be able to ask questions.

- Guests, including non-registered (beneficial) Aurora Shareholders who have not duly appointed themselves as proxyholder, will be able to log in and listen to the proceedings of the Aurora Shareholders' Meeting but will not be able to submit questions.

Aurora believes that the ability to participate in the Aurora Shareholders' Meeting in a meaningful way remains important despite the decision to hold the Aurora Shareholders' Meeting virtually. It is anticipated that registered Aurora Shareholders and duly appointed proxyholders will have substantially the same opportunity to ask questions on matters of business before the Aurora Shareholders' Meeting as if the Aurora Shareholders' Meeting was being held in person. Aurora Shareholders will have the opportunity to submit questions at the Aurora Shareholders' Meeting by submitting them in writing through the virtual meeting platform. Questions received from Aurora Shareholders which relate to the business of the Aurora Shareholders' Meeting are expected to be addressed at specified times during the course of the Aurora Shareholders' Meeting. Such questions will be read by the Chair of the Aurora Shareholders' Meeting or a designee of the Chair of the Aurora Shareholders' Meeting and responded to by a representative of Aurora. To ensure fairness for all attendees, the Chair of the Aurora Shareholders' Meeting will decide on the amount of time allocated to each question and will have the right to limit or consolidate questions and to reject questions that do not relate to the business of the Aurora Shareholders' Meeting or which are determined to be inappropriate or otherwise out of order.

Further instructions on how to submit a question during the Aurora Shareholders' Meeting can be found in the Virtual Meeting User Guide, which is available on Aurora's website at www.auroramj.com/investors, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

Q: Who is entitled to vote at the Aurora Shareholders' Meeting?

A: Only Aurora Shareholders of record at the close of business on November 18, 2026, being the Aurora Record Date, will be entitled to receive notice of and vote on the applicable resolutions at the Aurora Shareholders' Meeting, or any adjournment or postponement thereof. Aurora Shareholders will be entitled to one vote at the Aurora Shareholders' Meeting for each Aurora Common Share held.

Q: How do I vote?

A: If your Aurora Common Shares are registered in your name, there are two ways you may vote. You may vote at the Aurora Shareholders' Meeting virtually, or you may complete, sign and return the applicable enclosed form of proxy appointing the named persons or some other person you choose, who need not be an Aurora Shareholder, to represent you as proxyholder and vote your securities at the Aurora Shareholders' Meeting. Registered Aurora Shareholders may vote at the Aurora Shareholders' Meeting by completing a ballot online during the Aurora Shareholders' Meeting, as further described below under "*How can a registered Aurora Shareholder vote during the Aurora Shareholders' Meeting?*"

If your Aurora Common Shares are not registered in your name, but are held in the name of a nominee (usually a broker, investment dealer, bank, trust company, custodian, or other financial institution), you should have received a Voting Instruction Form from your nominee. Please note that Aurora has limited access to the names of its non-registered shareholders. If you attend the Aurora Shareholders' Meeting, Aurora may have no record of your shareholdings or of your entitlement to vote unless your nominee has appointed you as proxyholder. Therefore, if you wish to vote at the Aurora Shareholders' Meeting, insert your own name in the space provided on the Voting Instruction Form and return the same by following the instructions provided therein. Do not otherwise complete the Voting Instruction Form as your vote will be taken at the Aurora Shareholders' Meeting. If you do not intend to attend the Aurora Shareholders' Meeting, follow the instructions on the Voting Instruction Form to vote by telephone or internet or complete, sign and mail the Voting Instruction Form in the postage-prepaid envelope provided. Your completed Voting Instruction Form must be submitted on or before the deadline specified on the form.

Any Aurora Shareholders that have any questions or need assistance in voting should contact their financial, legal or other professional advisors or Kingsdale Advisors for assistance. You can reach Kingsdale Advisors at 1-800-749-9052 (toll-free in North America) or 416-623-4172 (text and call enabled outside North America) or by e-mail at contactus@kingsdaleadvisors.com. For further information visit voteyesaurora.com.

Q: How can a registered Aurora Shareholder vote during the Aurora Shareholders' Meeting?

A: Registered Aurora Shareholders can vote in one of the following ways:

During the Virtual Aurora Shareholders' Meeting	If you are a registered Aurora Shareholder, you can attend the Aurora Shareholders' Meeting by going to meetnow.global/MQAVTRW in a web browser on a smartphone, tablet, or computer, clicking "Shareholder" and entering your 15-digit control number (your control number is located on your form of proxy or in the email notification you received). Follow the instructions to access the Aurora Shareholders' Meeting and vote when prompted. See "*General Proxy Matters – Aurora – How to Participate at the Aurora Shareholders' Meeting*".

REGISTERED AURORA SHAREHOLDERS (YOU HOLD A SHARE CERTIFICATE OR DIRECT REGISTRATION STATEMENT REGISTERED IN YOUR NAME)		
Voting by Internet	**Voting by Phone**	**Voting by Mail**
Visit **www.investorvote.com** (**French: www.voteendirect.com**) and follow the instructions on your Form of Proxy. You will need the control number located on your Form of Proxy. Carefully follow the prompts to vote, then confirm that your voting instructions have been properly recorded.	Use a touchtone phone to transmit voting choices by toll-free number in North America to **+1-866-732-VOTE (8683)** or to **+1-312-588-4290** outside North America.	Complete, sign, and date your Form of Proxy and mail it in the postage-paid envelope included in your package to: **Computershare Trust Company of Canada Attention: Proxy Department to 320 Bay Street, 14th Floor, Toronto, Ontario M5H 4A6**

If you are an Aurora Shareholder and have any questions or need assistance in voting your Aurora Common Shares, please contact your financial, legal or other professional advisors or Kingsdale Advisors for assistance. You can reach Kingsdale Advisors at 1-800-749-9052 (toll-free in North America) or 416-623-4172 (text and call enabled outside North America) or by e-mail at contactus@kingsdaleadvisors.com. For Further information visit voteyesaurora.com.

Q: How can a non-registered Aurora Shareholder vote during the Aurora Shareholders' Meeting?

A: Non-registered (beneficial) holders of Aurora Common Shares can vote in one of the following ways:

During the Virtual Aurora Shareholders' Meeting

If you are a non-registered Aurora Shareholder, you can attend and vote at the Aurora Shareholders' Meeting by filling in your name in the blank space provided on the Voting Instruction Form and appointing yourself as proxy and sending in the completed Voting Instruction Form to the address specified on the Voting Instruction Form in advance of the Aurora Shareholders' Meeting.

After submitting your Voting Instruction Form, you must also visit https://www.computershare.com/Aurora to register your name and email address so that after the Aurora Proxy Deadline, Computershare can send you, via email, an invite code that will be required to log into the Aurora Shareholders' Meeting. United States beneficial Aurora Shareholders must first obtain a valid legal proxy from their broker, bank or other agent and register in advance with Computershare.

You can then attend the Aurora Shareholders' Meeting by going to meetnow.global/MQAVTRW in a web browser, on a smartphone, tablet or computer, clicking "Invitation", entering the invite code that you received in an email from Computershare, and then following the instructions to access the Aurora Shareholders' Meeting and vote when prompted.

Non-registered Aurora Shareholders who have not duly appointed themselves as proxy will not be able to vote online at the virtual Aurora Shareholders' Meeting or submit questions. You will be able to join a live webcast of the Aurora Shareholders' Meeting by going to meetnow.global/MQAVTRW, clicking on "Guest" and filling in the online form.

See "*General Proxy Matters – Aurora – How to Participate at the Aurora Shareholders' Meeting*".

BROADRIDGE CANADIAN BENEFICIAL AURORA SHAREHOLDERS (YOU HOLD SHARES THROUGH A CANADIAN BANK, BROKER OR OTHER INTERMEDIARY)		
Voting by Internet	**Voting by Phone**	**Voting by Mail**
Go to **www.proxyvote.com** specified on your **VIF** and then follow the voting instructions on the screen. You will require a **16-digit control number** (located on the front of your **VIF**) to identify yourself to the system.	Shareholders who wish to vote by phone should call **1-800-474-7493** (English) or **1-800-474-7501** (French). You will require a **16-digit control number** (located on the front of your **VIF**) to identify yourself to the system.	Complete, sign and date your **VIF** and return it in the postage prepaid envelope provided to the address set out on the envelope.

BROADRIDGE U.S. BENEFICIAL AURORA SHAREHOLDERS (YOU HOLD SHARES THROUGH A U.S. BANK, BROKER OR OTHER INTERMEDIARY)		
Voting by Internet	**Voting by Phone**	**Voting by Mail**
Go to **www.proxyvote.com** specified on your **VIF** and then follow the voting instructions on the screen. You will require a **16-digit control number** (located on the front of your **VIF**) to identify yourself to the system.	Shareholders who wish to vote by phone should call **1-800-454-8683**. You will require a **16-digit control number** (located on the front of your **VIF**) to identify yourself to the system.	Complete, sign, and date your **VIF** and return it in the postage prepaid envelope provided to the address set out on the envelope.

MEDIANT (BetaNXT, Inc.) U.S. BENEFICIAL AURORA SHAREHOLDERS (YOU HOLD SHARES THROUGH A U.S. BANK, BROKER OR OTHER INTERMEDIARY)		
Voting by Internet	**Voting by Phone**	**Voting by Mail**
Go to www.proxypush.com specified on your **VIF** and then follow the voting instructions on the screen. You will require a **12-digit control number** (located on the front of your **VIF**) to identify yourself to the system.	Shareholders who wish to vote by phone should call **1-866-586-3109**. You will require a **12-digit control number** (located on the front of your **VIF**) to identify yourself to the system. Use any touch-tone telephone, 24 hours a day, 7 days a week and follow the recorded instructions.	Complete, sign, and date your **VIF**. Fold and return it in the postage-paid envelope provided to the address set out on the envelope.

Q: Who is soliciting my proxy?

A: Management of Aurora is soliciting your proxy. In addition, Aurora has engaged Kingsdale Advisors as its strategic shareholder advisor and proxy solicitation agent to assist management of Aurora with, among other things, the solicitation of proxies from Aurora Shareholders. Solicitation of proxies is done primarily by mail and electronic means. The costs of preparing and distributing the Joint Information Circular and the other Meeting Materials will be borne by Aurora and Organigram, as applicable.

Q: When do I have to vote my Aurora Common Shares by?

A: Proxies must be received in each case no later than the Aurora Proxy Deadline, being 9:30 a.m. (Toronto time) on December 21, 2026, or, if the Aurora Shareholders' Meeting is adjourned or postponed, 48 hours before the beginning of any adjourned or postponed Aurora Shareholders' Meeting (excluding Saturdays, Sundays and statutory holidays in the Province of Ontario). The time limit for deposit of proxies may be waived or extended by the Chair of the Aurora Shareholders' Meeting at his or her discretion, without notice.

Q: Can I appoint someone other than the individuals named in the enclosed proxy to vote my Aurora Common Shares?

A: Yes, you have the right to appoint another person of your choice, who need not be an Aurora Shareholder, to attend and vote on your behalf at the Aurora Shareholders' Meeting. If you wish to appoint a person other than those named in the enclosed proxy or Voting Instruction Form, insert the name of your chosen proxyholder in the space provided.

NOTE: It is important for you to ensure that any other person you appoint will attend the Aurora Shareholders' Meeting and is aware that his or her appointment has been made to vote your securities.

The following applies to securityholders who wish to appoint as their proxyholders individuals other than those named in the proxy or Voting Instruction Form. This includes non-registered Aurora Shareholders who wish to appoint themselves as proxyholders to attend, participate in or vote at the Aurora Shareholders' Meeting.

Aurora Shareholders who wish to appoint as their proxyholders individuals other than those named in the proxy or Voting Instruction Form to attend and participate in the Aurora Shareholders' Meeting and vote their securities MUST submit their proxies or Voting Instruction Forms, as applicable, appointing such individuals as proxyholders AND register such proxyholders online, as described below. Registering your proxyholder is an additional step to be completed AFTER you have submitted your proxy or Voting Instruction Form. Failure to register the proxyholder will result in the proxyholder not receiving an invite code that is required to vote at the Aurora Shareholders' Meeting.

Step 1: Submit your proxy or Voting Instruction Form: To appoint someone other than the individuals named in the proxy or Voting Instruction Form as proxyholder, insert that person's name in the blank space provided in the proxy or Voting Instruction Form (if permitted) and follow the instructions for submitting such proxy or Voting Instruction Form. This must be completed before registering such proxyholder, which is an additional step to be completed once you have submitted your proxy or Voting Instruction Form.

If you are a non-registered Aurora Shareholder and wish to vote at the Aurora Shareholders' Meeting, you must insert your own name in the space provided on the Voting Instruction Form sent to you by your intermediary, follow all of the applicable instructions provided by your intermediary AND register yourself as your proxyholder, as described below in Step 2. By doing so, you are instructing your intermediary to appoint you as proxyholder. It is important that you comply with the signature and other instructions provided by your intermediary. Please also see further instructions above under "*How can a non-registered Aurora Shareholder vote during the Aurora Shareholders' Meeting?*"

If you are a non-registered Aurora Shareholder located in the United States and wish to vote at the Aurora Shareholders' Meeting or, if permitted, appoint a third party as your proxyholder, in addition to the steps described above under "*How can a non-registered Aurora Shareholder vote during the Aurora Shareholders' Meeting?*", you must obtain a valid legal proxy from your intermediary. Follow the instructions from your intermediary included with the legal proxy form or contact your intermediary to request a legal proxy form if you have not received one. After obtaining a valid legal proxy from your intermediary, you must then submit such legal proxy to Computershare. Requests for registration from non-registered Aurora Shareholders located in the United States that wish to vote at the Aurora Shareholders' Meeting or, if permitted, appoint third parties as their proxyholders must be directed to Computershare, 320

Bay Street, 14th Floor, Toronto, Ontario M5H 4A6, e-mail (USlegalproxy@computershare.com), and in both cases, must be labelled "Legal Proxy" and received no later than the Aurora Proxy Deadline.

Step 2: Register your proxyholder: To register a third-party proxyholder, you must visit https://www.computershare.com/Aurora by the Aurora Proxy Deadline and provide Computershare with the required proxyholder contact information so that Computershare may provide the proxyholder with an invite code via email. **Without an invite code, proxyholders will not be able to vote at the Aurora Shareholders' Meeting but will be able to participate as guests.**

Q: Will my securities intermediary vote my Aurora Common Shares for me?

A: A broker or other securities intermediary will vote your Aurora Common Shares only if you provide instructions to such intermediary on how to vote. If you fail to provide proper instructions, the Aurora Common Shares will not be voted on your behalf at the Aurora Shareholders' Meeting. If you do not wish to appoint yourself as proxy, as a non-registered (beneficial) Aurora Shareholder, you should instruct your intermediary to vote your Aurora Common Shares on your behalf by following the directions on the Voting Instruction Form provided by such intermediary. Unless your intermediary gives you its proxy to vote at the Aurora Shareholders' Meeting, you cannot vote the Aurora Common Shares owned by you at the Aurora Shareholders' Meeting.

Q: Should I send my form of proxy or Voting Instruction Form now?

A: Yes. Once you have carefully read and considered the information in this Joint Information Circular, you need to complete and submit the applicable enclosed form of proxy or Voting Instruction Form, as applicable. You are encouraged to vote well in advance of the Aurora Proxy Deadline to ensure that your Aurora Common Shares are voted at the Aurora Shareholders' Meeting.

Q: Can I revoke my vote after I have voted by proxy?

A: Yes. In addition to revocation in any other manner permitted by law, an Aurora Shareholder may revoke or change a previously made proxy vote: (a) by accessing the Aurora Shareholders' Meeting by following the instructions under "*General Proxy Matters – Aurora – How to Participate at the Aurora Shareholders' Meeting*" in this Joint Information Circular and voting their Aurora Common Shares during the designated time; (b) by an instrument in writing executed by the Aurora Shareholder or such Aurora Shareholder's attorney authorized in writing or if the Aurora Shareholder is a corporation, under its corporate seal or by an officer or attorney thereof, duly authorized, indicating the capacity under which such officer or attorney is signing and deposited with Computershare, the transfer agent of Aurora, at the office designated in the Notice of Special Meeting of Aurora Shareholders no later than the Aurora Proxy Deadline; or (c) by a duly executed and deposited proxy as provided herein bearing a later date or time than the date or time of the proxy being revoked.

Q: Which form of proxy should I complete, sign and return?

A: Accompanying this Joint Information Circular is a form of proxy or Voting Instruction Form for use by Aurora Shareholders. If you hold Aurora Common Shares, please complete, sign and return the form of proxy or Voting Instruction Form for Aurora Shareholders.

Q: What other conditions are required for the Arrangement to be completed?

A: In addition to the approval by the Aurora Shareholders of the Arrangement Resolution, in order for the Arrangement to be completed: (a) the Organigram Share Issuance Resolution must be approved by greater than (i) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, and (ii) 50% of such votes cast, excluding the votes required to be excluded under the TSX Company Manual and MI 61-101; (b) the Final Order must be obtained from the Supreme Court of British Columbia; (c) the TSX must conditionally approve the listing of the Organigram

Common Shares to be issued to Aurora Shareholders pursuant to the Arrangement, and Organigram must notify the Nasdaq of the listing of such Organigram Common Shares without objection; (d) the Required Regulatory Approvals, being the Competition Act Approval and the German FDI Approval, must be obtained; (e) Dissent Rights must not have been validly exercised, and not withdrawn, with respect to more than 10% of the issued and outstanding Aurora Common Shares; and (f) there must not have occurred a Material Adverse Effect in respect of Aurora or Organigram, as applicable, that is continuing as of the Effective Date. Organigram's obligations under the Arrangement Agreement are not subject to any financing condition, and completion of the Arrangement is not conditional on the completion of the BAT Private Placement.

Under the Arrangement Agreement, Organigram and Aurora have agreed to make the filings required to obtain the Required Regulatory Approvals, being the Competition Act Approval and the German FDI Approval, within five business days after the date of the Arrangement Agreement, to cooperate with one another in obtaining the Regulatory Approvals and not to take any action that would reasonably be expected to make obtaining the Regulatory Approvals materially more difficult or to materially delay them. Organigram will pay all filing fees in respect of the Regulatory Approvals. In addition, a Party may not extend the Outside Date if the failure to obtain the Regulatory Approvals is primarily the result of that Party's failure to comply with its covenants in the Arrangement Agreement. Aurora and Organigram believe that meaningful challenges are unlikely due to the complementary nature of Aurora and Organigram's operations.

See "*Procedure for the Arrangement to Become Effective*"

Q: When will the Arrangement become effective?

A: The Arrangement will become effective on the date and at the time specified in the Plan of Arrangement following the filing with the Registrar of the records and information required under section 292 of the BCBCA, which is expected to occur in January 2027, provided that all required approvals are obtained. Under the Arrangement Agreement, the Effective Date may not occur prior to January 6, 2027. However, completion of the Arrangement is subject to a number of conditions and it is possible that factors outside the control of Aurora and/or Organigram could result in the Arrangement being completed at a later time, or not at all. Subject to certain limitations, each Party may terminate the Arrangement Agreement if it is not consummated by the Outside Date, being May 2, 2027; however, either Party may, by giving written notice to the other Party, extend the Outside Date on no more than two occasions by 90 days each (not exceeding 180 days in the aggregate) if the Effective Date has not occurred as a result of the failure to obtain one or more Regulatory Approvals, provided that the failure is not primarily the result of such Party's failure to comply with its covenants in the Arrangement Agreement.

Q: How will I know when all required approvals have been obtained?

A: Aurora and Organigram will issue a press release once all the necessary approvals have been received and conditions to the completion of the Arrangement have been satisfied or waived, other than conditions that, by their terms, cannot be satisfied until the Effective Time.

Q: If I own shares of both Aurora and Organigram am I required to vote at both meetings?

A: No. You are not required to vote at both meetings, and your vote at one meeting does not depend on your vote at the other, although we highly encourage you to do so. However, if you wish to have all of your securities voted, you must complete and return both the proxy or Voting Instruction Form for Aurora and the proxy or Voting Instruction Form for Organigram, depending on whether you are a registered or a Beneficial Holder. If you only submit one proxy or Voting Instruction Form, only the shares covered by that specific form will be voted.

If you are an Aurora Shareholder and have any questions, you can reach Kingsdale Advisors at 1-800-749-9052 (toll-free in North America) or 416-623-4172 (text and call enabled outside North America) or by e-mail at contactus@kingsdaleadvisors.com. For further information visit voteyesaurora.com.

See "*Timing*".

Q: How do I receive the Organigram Common Shares that I am entitled to under the Arrangement?

A: Registered Aurora Shareholders must complete and return the enclosed Letter of Transmittal and Election Form which, when properly completed and returned together with the certificate(s) or DRS Advice(s) representing Aurora Common Shares and all other required documents, will enable each Aurora Shareholder to elect the Cash Alternative, the Share Alternative or the Combination Alternative and to obtain the Consideration that the Aurora Shareholder is entitled to receive under the Arrangement. Aurora Shareholders who do not make a valid election by the Election Deadline will be deemed to have elected the Combination Alternative. See "*Procedure for the Arrangement to Become Effective – Procedure for Exchange of Aurora Common Share Certificates or DRS Advices*".

Aurora Shareholders whose Aurora Common Shares are registered in the name of a broker, investment dealer, bank, trust company, custodian, nominee or other intermediary must contact their intermediary to deposit their Aurora Common Shares.

Q: How and when do I make an election as to the form of Consideration I will receive?

A: Registered Aurora Shareholders may elect the Cash Alternative, the Share Alternative or the Combination Alternative by completing the Letter of Transmittal and Election Form and depositing it, together with the certificate(s) or DRS Advice(s) representing their Aurora Common Shares and all other required documents, with the Depositary before 5:00 p.m. (Toronto time) on the date agreed by Aurora and Organigram and announced by Aurora by news release at least two Business Days before such date (the "**Election Deadline**"). Aurora Shareholders whose Aurora Common Shares are registered in the name of a broker, investment dealer, bank, trust company, custodian, nominee or other intermediary must contact their intermediary to make an election and should be aware that their intermediary may set a deadline earlier than the Election Deadline. A Letter of Transmittal and Election Form, once deposited with the Depositary, is irrevocable and may not be withdrawn except as expressly provided in the Letter of Transmittal and Election Form. See "*Effect of the Arrangement – Elections and Proration*".

If you are a non-registered Aurora Shareholder, you should contact your broker or other intermediary regarding your Consideration election.

Q: What happens if I do not make a valid election?

A: Aurora Shareholders (other than Dissenting Aurora Shareholders) who do not deposit a duly completed Letter of Transmittal and Election Form making a valid election with the Depositary before the Election Deadline, or who otherwise fail to comply with the election requirements, will be deemed to have elected the Combination Alternative in respect of all of their Aurora Common Shares, which is not subject to proration. Registered Aurora Shareholders who do not make an election will still be required to deposit a duly completed Letter of Transmittal and Election Form, together with the certificate(s) or DRS Advice(s) representing their Aurora Common Shares, in order to receive the Consideration to which they are entitled. See "*Effect of the Arrangement – Elections and Proration*".

Q: How does proration work?

A: The aggregate cash payable and the aggregate number of Organigram Common Shares issuable under the Arrangement are limited to the Maximum Cash Consideration and the Maximum Share Consideration, respectively. The Combination Alternative is not subject to proration. If the Organigram Common Shares that would be issuable to holders electing the Share Alternative exceed the Organigram Common Shares

remaining available after the Combination Alternative (and an allowance for Dissenting Aurora Shareholders), those holders will receive their pro rata share of the remaining Organigram Common Shares and the balance in cash. Similarly, if the cash that would be payable to holders electing the Cash Alternative exceeds the cash remaining available, those holders will receive their pro rata share of the remaining cash and the balance in Organigram Common Shares, provided that no holder electing the Cash Alternative will receive less cash than it would have received under the Combination Alternative. As a result, Aurora Shareholders who elect the Cash Alternative or the Share Alternative may receive a combination of cash and Organigram Common Shares that differs from their election. No fractional Organigram Common Shares will be issued, fractional entitlements will be rounded down to the nearest whole Organigram Common Share without compensation, and cash amounts will be rounded down to the nearest cent (subject to a minimum of $0.01). See "*Effect of the Arrangement – Elections and Proration*".

Q: What will happen if the Arrangement Resolution is not approved or the Arrangement is not completed for any reason?

A: If the Arrangement Resolution is not approved, the Arrangement Agreement may be terminated by either Aurora or Organigram. Pursuant to the terms of the Arrangement Agreement, each of Aurora and Organigram has agreed not to solicit, initiate, encourage or otherwise facilitate any Acquisition Proposal. The Aurora Board may respond to unsolicited Superior Proposals subject to certain requirements and notification to Organigram, which has the right to match any Superior Proposal within a five-business day period. The Arrangement Agreement provides for an Aurora Termination Fee of $25.2 million payable by Aurora, and an Organigram Termination Fee of $38.4 million payable by Organigram, if the Arrangement Agreement is terminated in certain circumstances.

See "*Effect of the Arrangement – The Arrangement Agreement – Termination*".

Q: What are the Canadian federal income tax consequences of the Arrangement?

A: For a summary of certain of the material Canadian federal income tax consequences of the Arrangement applicable to Aurora Shareholders, see "*Certain Canadian Federal Income Tax Considerations*". Such summary is not intended to be legal or tax advice. Aurora Shareholders should consult their own tax advisors as to the Canadian and other tax consequences of the Arrangement to them with respect to their particular circumstances.

Q: What are the U.S. federal income tax consequences of the Arrangement?

A: For a summary of certain of the material U.S. federal income tax consequences of the Arrangement applicable to a U.S. Holder, see "*Certain United States Federal Income Tax Considerations*". Such summary is not intended to be legal or tax advice. Aurora Shareholders should consult their own tax advisors as to the U.S. and other tax consequences of the Arrangement to them with respect to their particular circumstances.

Q: Are Aurora Shareholders entitled to Dissent Rights?

A: Registered Aurora Shareholders who hold Aurora Common Shares as of the Aurora Record Date may, upon compliance with certain conditions and in certain circumstances, exercise Dissent Rights. However, failure to strictly comply with the requirements set forth in sections 237 to 247 of the BCBCA, as modified by the Interim Order and the Plan of Arrangement, may result in the loss of the right of dissent. It is strongly recommended that any Aurora Shareholders wishing to dissent seek independent legal advice.

See "*Dissent Rights*".

Q: Who should I contact if I have questions?

A: Any Aurora Shareholders that have any questions about the Arrangement or the matters described in this Joint Information Circular, or need assistance in voting, should contact their financial, legal or other

professional advisors or Kingsdale Advisors for assistance. You can reach Kingsdale Advisors at 1-800-749-9052 (toll-free in North America) or 416-623-4172 (text and call enabled outside North America) or by e-mail at contactus@kingsdaleadvisors.com. For further information visit voteyesaurora.com.

ORGANIGRAM SHAREHOLDERS – QUESTIONS AND ANSWERS

The following is intended to address certain key questions concerning the Arrangement and the Organigram Shareholders' Meeting. The information contained below is of a summary nature and therefore is not complete and is qualified in its entirety by the more detailed information contained elsewhere in or incorporated by reference in this Joint Information Circular, including the Appendices hereto, all of which are important and should be reviewed carefully. Capitalized terms used but not otherwise defined in this "*Organigram Shareholders – Questions and Answers*" have the meanings set forth under the heading "*Glossary of Terms*".

Q: Why did I receive this Joint Information Circular?

A: You received this Joint Information Circular because you are an Organigram Shareholder and Organigram Shareholders will be asked at the Organigram Shareholders' Meeting to approve the Organigram Share Issuance Resolution.

Q: What is the Arrangement?

A: On November 2, 2026, Organigram and Aurora agreed to the terms and conditions of the Arrangement Agreement. Pursuant to the Arrangement Agreement, Organigram has agreed to acquire all of the issued and outstanding Aurora Common Shares under a court-approved Plan of Arrangement in accordance with the provisions of the BCBCA. If completed, the Arrangement will result in Organigram acquiring all of the Aurora Common Shares. Pursuant to the Arrangement, each Aurora Shareholder will be entitled to receive, at its election, for each Aurora Common Share held: (a) the Cash Alternative of $7.80 in cash; (b) the Share Alternative of 5.8626 Organigram Common Shares; or (c) the Combination Alternative of $3.75 in cash and 3.0431 Organigram Common Shares, subject, in the case of the Cash Alternative and the Share Alternative, to proration such that the aggregate cash payable and the aggregate number of Organigram Common Shares issuable under the Arrangement will not exceed the Maximum Cash Consideration and the Maximum Share Consideration, respectively.

Current Aurora Shareholders are expected to hold approximately 37% of the economic interest and 41% of the voting rights in Organigram, on a fully diluted basis, immediately after completion of the Arrangement and the BAT Private Placement.

Q: Does the Organigram Board support the Arrangement?

A: Yes. After consulting with Organigram's senior management and with its financial, legal, tax and other advisors, and after considering, among other things, the Organigram Fairness Opinion, the Organigram Board (with the representatives of BAT abstaining in respect of the BAT Private Placement) unanimously determined: (a) that the Arrangement is fair to the Organigram Shareholders and the holders of Organigram Preferred Shares; (b) that the Arrangement and entry into the Arrangement Agreement are in the best interests of Organigram; and (c) to unanimously recommend that the Organigram Shareholders vote in favour of the Organigram Share Issuance Resolution.

THE ORGANIGRAM BOARD (WITH THE REPRESENTATIVES OF BAT ABSTAINING IN RESPECT OF THE BAT PRIVATE PLACEMENT) UNANIMOUSLY RECOMMENDS THAT ORGANIGRAM SHAREHOLDERS VOTE FOR THE ORGANIGRAM SHARE ISSUANCE RESOLUTION.

See "*The Arrangement – Recommendation of the Organigram Board*", "*The Arrangement – Reasons for and Benefits of the Arrangement*" and "*The Arrangement – Reasons for and Benefits of the Arrangement – Additional Reasons and Benefits for Organigram Shareholders*". The full text of the Organigram Share Issuance Resolution is set forth in Appendix "B" to this Joint Information Circular.

Q: What are the benefits of the Arrangement?

A: Organigram and Aurora expect that the Arrangement will create a global cannabis leader with leading positions in Canada, Europe and Australia, supported by Organigram's strategic shareholder, BAT. The following are some, but not all, of the expected benefits of the Arrangement to Organigram Shareholders:

- *Creates a Global Cannabis Leader* with a scaled, Canadian-headquartered global cannabis platform with leading positions in five nationally legal cannabis markets – Canada, Germany, Poland, Australia and New Zealand – and meaningful operations in other key markets.
- *Meaningful Synergies* of more than $50 million annually, driven by shared manufacturing and distribution infrastructure, cost efficiencies and cross-selling opportunities.
- *Committed Financing*, with the cash portion of the Consideration fully financed through a combination of cash on hand, the BAT Private Placement and the ATB Credit Facilities.
- *Enhanced Scale and Capital Markets Profile*, including improved trading liquidity and access to capital.

See "*The Arrangement – Reasons for and Benefits of the Arrangement*" and "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement*".

Q: Are there support agreements in place with any Aurora Shareholders?

A: Yes. All of the directors and executive officers of Aurora have entered into agreements with Organigram to support the Arrangement. The Supporting Aurora Shareholders collectively hold approximately 0.62% of the issued and outstanding Aurora Common Shares and each Supporting Aurora Shareholder has irrevocably agreed to, among other things, vote all of their Aurora Common Shares in favour of the Arrangement at the Aurora Shareholders' Meeting and not to sell, transfer or tender (or agree to sell, transfer or tender) their Aurora securities, including by tendering to the Hostile Bid or to any other take-over bid made for the Aurora Common Shares, subject to limited exceptions.

See "*Effect of the Arrangement – Aurora Support Agreements*".

Q: Are there support agreements in place with any Organigram Shareholders?

A: Yes. BAT and each of the directors and executive officers of Organigram who hold Organigram Common Shares have entered into agreements with Aurora to support the Arrangement. The Supporting Organigram Shareholders collectively hold approximately 30.95% of the issued and outstanding Organigram Common Shares and each Supporting Organigram Shareholder has agreed to, among other things, vote all of their Organigram Common Shares in favour of the Organigram Share Issuance Resolution at the Organigram Shareholders' Meeting and to otherwise support the Arrangement. Organigram Common Shares held by BAT and its affiliates will be excluded for purposes of the disinterested shareholder approval required under the TSX Company Manual and the minority approval required under MI 61-101.

See "*Effect of the Arrangement – Organigram Support Agreements*".

Q: Has Organigram received a fairness opinion regarding the Consideration to be issued under the Arrangement?

A: Yes. BMO Capital Markets has provided the Organigram Board with the Organigram Fairness Opinion to the effect that, as of November 2, 2026, and based upon and subject to the assumptions, limitations and qualifications set forth therein, the Consideration to be paid by Organigram pursuant to the Arrangement is fair, from a financial point of view, to Organigram.

The full text of the written opinion of BMO Capital Markets, which sets forth, among other things, the assumptions made, procedures followed, information reviewed, matters considered and limitations and qualifications on the scope of review undertaken in connection with the Organigram Fairness Opinion, is contained in Appendix "G" to the Joint Information Circular. BMO Capital Markets provided its opinion solely for the information and assistance of the Organigram Board in connection with its consideration of the Arrangement. The Organigram Fairness Opinion is not a recommendation as to how any Organigram Shareholder should vote or act with respect to the Arrangement or its Organigram Common Shares.

See "*The Arrangement – Organigram Fairness Opinion*", "*The Arrangement – Reasons for and Benefits of the Arrangement*" and "*The Arrangement – Reasons for and Benefits of the Arrangement – Additional Reasons and Benefits for Organigram Shareholders*".

Q: Why is the Organigram Shareholders' Meeting being held?

A: The Organigram Common Shares to be issued to Aurora Shareholders under the Arrangement and to BAT in connection with the BAT Private Placement, together with the Organigram Common Shares that will be issuable upon the exercise of Replacement Options, will constitute greater than 25% of the issued and outstanding Organigram Common Shares (on a non-diluted basis) immediately prior to the Arrangement. Pursuant to the applicable rules of the TSX, the issuance of such Organigram Common Shares requires the approval of greater than 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting.

In addition, the BAT Private Placement requires the approval of greater than 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, excluding the votes attached to Organigram Common Shares beneficially owned, or over which control or direction is exercised, by BAT and its affiliates, under sections 604(a)(ii), 607(g)(ii) and 611(b) of the TSX Company Manual and MI 61-101. This is required because, among other things, BAT is an insider of Organigram under the TSX rules and a related party of Organigram under MI 61-101.

Q: What are Organigram Shareholders being asked to vote on?

A: Organigram Shareholders will be asked to vote on the Organigram Share Issuance Resolution, the full text of which is set forth in Appendix "B" to this Joint Information Circular.

If approved, the Organigram Share Issuance Resolution will authorize the issuance of the number of Organigram Common Shares that would allow Organigram to meet its obligations under (i) the Arrangement Agreement, which provides for the issuance of Organigram Common Shares to Aurora Shareholders who elect (or are deemed to elect) the Share Alternative or the Combination Alternative, subject to proration, and (ii) the BAT Equity Commitment.

Pursuant to the BAT Equity Commitment, 140,986,255 Organigram Common Shares and/or Organigram Preferred Shares are issuable to BAT. To the extent that the issuance of Organigram Common Shares to BAT would result in BAT, together with its affiliates, associates, related parties and joint actors, holding more than 30% of the issued and outstanding Organigram Common Shares on a post-issuance basis, BAT will be issued Organigram Preferred Shares in lieu of such excess Organigram Common Shares.

Pursuant to the Arrangement, up to 3.0431 Organigram Common Shares are issuable for each Aurora Common Share outstanding immediately prior to completion of the Arrangement, being the Maximum Share Consideration. Based on the 65,748,913 Aurora Common Shares outstanding as of November 19, 2026, up to 200,080,517 Organigram Common Shares will be issuable to Aurora Shareholders in consideration for their Aurora Common Shares. In addition, each Aurora Option will be exchanged for a Replacement Option to acquire Organigram Common Shares based on the Option Exchange Ratio, being $7.80 divided by $1.33. Based on the 2,214,519 Aurora Options outstanding as of November 19, 2026, up to approximately 12,987,407 Organigram Common Shares would be issuable upon the exercise of Replacement Options. The Organigram Share Issuance Resolution will also approve the issuance of an additional 9,991,849 Organigram

Common Shares to account for clerical and administrative matters or changes in the number of Aurora Common Shares outstanding between the date hereof and the closing of the Arrangement.

Q: When and where is the Organigram Shareholders' Meeting being held?

A: There is no physical location for the Organigram Shareholders' Meeting. The Organigram Shareholders' Meeting will be held on December 23, 2026 at 9:00 a.m. (Toronto time) in a virtual-only format that will be conducted via live audio webcast at https://virtual-meetings.tsxtrust.com/2000 using the meeting password "ogi2026" (case sensitive). Organigram Shareholders will not be able to attend the Organigram Shareholders' Meeting in person.

Q: How do I access the virtual Organigram Shareholders' Meeting?

A: Registered Organigram Shareholders and duly appointed proxyholders can access and vote at the Organigram Shareholders' Meeting by logging in online at https://virtual-meetings.tsxtrust.com/2000, selecting "I have a Control Number / Meeting Access Number" and entering their 12-digit control number (located on the form of proxy or in the email notification received from TSX Trust) or, in the case of duly appointed proxyholders, the Meeting Access Number provided by TSX Trust, together with the meeting password "ogi2026" (case sensitive). You should allow ample time to log in and check compatibility; Organigram recommends that you log in at least fifteen (15) minutes before the start of the Organigram Shareholders' Meeting.

Guests, including non-registered Organigram Shareholders who have not duly appointed themselves as proxyholders, can log in to the Organigram Shareholders' Meeting by selecting "I am a Guest" on the login screen and filling in the required information. Guests can listen to the Organigram Shareholders' Meeting but are not able to vote or ask questions. If you experience technical difficulties, please contact TSX Trust, the provider of the virtual meeting interface, at 1-866-600-5869 or tsxtis@tmx.com.

See "*General Proxy Matters – Organigram – How to Participate at the Organigram Shareholders' Meeting*".

Q: Who can ask questions at the Organigram Shareholders' Meeting?

A: Only registered Organigram Shareholders and duly appointed proxyholders may participate in the Organigram Shareholders' Meeting virtually via live audio webcast, including by asking questions, provided they follow the instructions in this Joint Information Circular.

- Registered Organigram Shareholders and duly appointed proxyholders who participate by attending online will be able to listen to the proceedings of the Organigram Shareholders' Meeting and ask questions during the specified times, provided they remain connected to the internet.

- Non-registered (beneficial) Organigram Shareholders who wish to participate in the Organigram Shareholders' Meeting must follow the instructions under the heading "*Information for Beneficial Holders*" and appoint themselves as proxyholder. Non-registered (beneficial) Organigram Shareholders who have not duly appointed themselves as proxyholders may still attend the Organigram Shareholders' Meeting as guests, but will not be able to vote or ask questions.

- Guests, including non-registered (beneficial) Organigram Shareholders who have not duly appointed themselves as proxyholder, will be able to log in and listen to the proceedings of the Organigram Shareholders' Meeting but will not be able to submit questions.

Any questions pertinent to the Organigram Shareholders' Meeting that cannot be answered during the Organigram Shareholders' Meeting due to time constraints will be posted online and answered at https://investors.organigram.ca/. The questions and answers will be available on Organigram's investor page as soon as practicable after the Organigram Shareholders' Meeting and will remain available until one week after posting. The Chair of the Organigram Shareholders' Meeting has broad authority in all matters pertaining to the Organigram Shareholders' Meeting. To ensure that the Organigram Shareholders' Meeting

is conducted in a timely manner, the Chair may exercise broad discretion with respect to, for example and without limitation, the questions and topics that will be addressed at the Organigram Shareholders' Meeting and the amount of time devoted to any question or topic. If there are any matters of individual concern to an Organigram Shareholder and not of general concern to all Organigram Shareholders, or if a question posed was not otherwise answered, such matters may be raised separately after the Organigram Shareholders' Meeting by contacting Organigram's Director of Investor Relations by email at investors@organigram.ca.

Q: Who is entitled to vote at the Organigram Shareholders' Meeting?

A: Only Organigram Shareholders of record at the close of business on November 18, 2026, being the Organigram Record Date, will be entitled to receive notice of and vote at the Organigram Shareholders' Meeting, or any adjournment or postponement thereof. Organigram Shareholders will be entitled to one vote at the Organigram Shareholders' Meeting for each Organigram Common Share held.

Q: How can a registered Organigram Shareholder vote?

A: Registered Organigram Shareholders can vote in one of the following ways:

During the Virtual Organigram Shareholders' Meeting	If you are a registered Organigram Shareholder, you can attend the Organigram Shareholders' Meeting virtually by logging in at https://virtual-meetings.tsxtrust.com/2000 using the meeting password "ogi2026" (case sensitive) and entering your 12-digit control number, and cast your vote on the Organigram Share Issuance Resolution online. You do not need to complete or return your form of proxy. See "*General Proxy Matters – Organigram – How to Participate at the Organigram Shareholders' Meeting*".
Internet	Go to www.voteproxyonline.com. Enter the 12-digit control number printed on the form of proxy and follow the instructions on screen.
Fax	416-595-9593.
Mail	Enter voting instructions, sign the form of proxy and send your completed form of proxy to Organigram's registrar and transfer agent in the envelope provided, or to TSX Trust Company, 100 Adelaide Street West, Suite 301, Toronto, Ontario M5H 4H1. If you are an Organigram Shareholder and have any questions or need assistance in voting your Organigram Common Shares, please contact your financial, legal or other professional advisors or Sodali & Co for assistance. You can reach Sodali & Co at 1-833-830-9806 (North America) (1-289-695-3075 for calls outside North America) or by e-mail at assistance@investor.sodali.com.

Q: How can a non-registered Organigram Shareholder vote?

A: Non-registered (beneficial) holders of Organigram Common Shares can vote in one of the following ways:

During the Virtual Organigram Shareholders' Meeting	If you are a non-registered Organigram Shareholder, you can attend and vote at the virtual Organigram Shareholders' Meeting by filling in your name in the blank space provided on the Voting Instruction Form, appointing yourself as proxy and sending in your completed Voting Instruction Form to the address specified on the Voting Instruction Form in advance of the Organigram Shareholders' Meeting, and registering yourself as proxyholder at tsxtrust.com/resource/en/75 by the Organigram Proxy Deadline. You must contact your intermediary well in advance of the Organigram Shareholders' Meeting and carefully follow its instructions and procedures. TSX Trust will then provide you with a Meeting Access Number by email, which you can use to log in to the Organigram Shareholders' Meeting at https://virtual-meetings.tsxtrust.com/2000 by selecting "I have a Control Number / Meeting Access Number" and using the meeting password "ogi2026" (case sensitive) and vote online. Non-registered Organigram Shareholders who have not duly appointed themselves as proxy will not be able to vote or ask questions at the Organigram Shareholders' Meeting, but may attend as guests by going to https://virtual-meetings.tsxtrust.com/2000, selecting "I am a Guest" and filling in the required information. See "*General Proxy Matters – Organigram – How to Participate at the Organigram Shareholders' Meeting*".
Canadian Beneficial Holders (Broadridge)	If you hold your Organigram Common Shares through a Canadian bank, broker or other intermediary, you may vote by Internet at www.proxyvote.com, using the 16-digit control number on the front of your Voting Instruction Form. You may also vote by telephone by calling 1-800-474-7493 (English) or 1-800-474-7501 (French), or by mail by completing, signing and dating your Voting Instruction Form and returning it in the postage prepaid envelope provided.
U.S. Beneficial Holders (Broadridge)	If you hold your Organigram Common Shares through a U.S. bank, broker or other intermediary served by Broadridge, you may vote by Internet at www.proxyvote.com, using the 16-digit control number on the front of your Voting Instruction Form. You may also vote by telephone by calling 1-800-454-8683, or by mail by completing, signing and dating your Voting Instruction Form and returning it in the postage prepaid envelope provided.
U.S. Beneficial Holders (Mediant)	If your U.S. bank, broker or other intermediary uses Mediant (BetaNXT, Inc.), you may vote by Internet at www.proxypush.com, using the 12-digit control number on the front of your Voting Instruction Form. You may also vote by telephone by calling 1-866-586-3109 from any touch-tone telephone, 24 hours a day, 7 days a week, and following the recorded instructions, or by mail by completing, signing and dating your Voting Instruction Form and returning it in the postage-paid envelope provided.
U.S. Beneficial Holders (Robinhood)	Clients of Robinhood Securities, LLC who are eligible to vote will receive a voting notice from noreply@robinhood.com, with voting hosted by Say Technologies.

Voting Instruction Form If your intermediary does not use one of the platforms above, follow the instructions on the Voting Instruction Form provided by your intermediary.

If you are an Organigram Shareholder and have any questions or need assistance in voting your Organigram Common Shares, please contact your financial, legal or other professional advisors or Sodali & Co for assistance. You can reach Sodali & Co at 1-833-830-9806 (North America) (1-289-695-3075 for calls outside North America) or by e-mail at assistance@investor.sodali.com.

Q: Who is soliciting my proxy?

A: Management of Organigram is soliciting your proxy. In addition, Organigram has engaged Sodali & Co as its proxy solicitation and information agent to assist management of Organigram with, among other things, the solicitation of proxies from Organigram Shareholders. Solicitation of proxies is done primarily by mail and electronic means. The costs of preparing and distributing the Joint Information Circular and the other Meeting Materials will be borne by Organigram and Aurora, as applicable.

Q: When do I have to vote my Organigram Common Shares by?

A: Proxies must be received no later than the Organigram Proxy Deadline, being 9:00 a.m. (Toronto time) on December 21, 2026, or, if the Organigram Shareholders' Meeting is adjourned or postponed, 48 hours (excluding Saturdays, Sundays and statutory holidays in the Province of Ontario) before the beginning of any adjourned or postponed Organigram Shareholders' Meeting. The time limit for deposit of proxies may be waived or extended by the Chair of the Organigram Shareholders' Meeting at his or her discretion, without notice.

Q: Can I appoint someone other than the individuals named in the enclosed proxy to vote my Organigram Common Shares?

A: Yes, you have the right to appoint another person of your choice, who need not be an Organigram Shareholder, to attend and vote on your behalf at the Organigram Shareholders' Meeting. If you wish to appoint a person other than those named in the enclosed proxy or Voting Instruction Form, insert the name of your chosen proxyholder in the space provided.

NOTE: It is important for you to ensure that any other person you appoint will attend the virtual Organigram Shareholders' Meeting, is aware that his or her appointment has been made to vote your securities and has been registered with TSX Trust to receive a Meeting Access Number.

See "*General Proxy Matters – Organigram – How to Participate at the Organigram Shareholders' Meeting*".

Q: Will my securities intermediary vote my Organigram Common Shares for me?

A: A broker or other securities intermediary will vote your Organigram Common Shares only if you provide instructions to such intermediary on how to vote. If you fail to provide proper instructions, your Organigram Common Shares will not be voted on your behalf at the Organigram Shareholders' Meeting. If you do not wish to appoint yourself as proxy, as a non-registered (beneficial) Organigram Shareholder, you should instruct your intermediary to vote your Organigram Common Shares on your behalf by following the directions on the Voting Instruction Form provided by such intermediary. Unless your intermediary gives you its proxy to vote at the Organigram Shareholders' Meeting, you cannot vote the Organigram Common Shares owned by you at the Organigram Shareholders' Meeting.

Q: Should I send my form of proxy or Voting Instruction Form now?

A: Yes. Once you have carefully read and considered the information in this Joint Information Circular, you will need to complete and submit the enclosed form of proxy or Voting Instruction Form, as applicable. You are

encouraged to vote well in advance of the Organigram Proxy Deadline to ensure that your Organigram Common Shares are voted at the Organigram Shareholders' Meeting.

Q: Can I revoke my vote after I have voted by proxy?

A: Yes. In addition to revocation in any other manner permitted by law, an Organigram Shareholder may revoke or change a previously made proxy vote: (a) by accessing the Organigram Shareholders' Meeting via the live audio webcast and voting their Organigram Common Shares during the designated time, which will revoke any previously submitted proxy; (b) by an instrument in writing executed by the Organigram Shareholder or such Organigram Shareholder's attorney authorized in writing or if the Organigram Shareholder is a corporation, under its corporate seal or by an officer or attorney thereof, duly authorized, indicating the capacity under which such officer or attorney is signing and deposited with TSX Trust Company, the transfer agent of Organigram, at the office designated in the Notice of Special Meeting of Organigram Shareholders no later than the Organigram Proxy Deadline; or (c) by a duly executed and deposited proxy as provided herein bearing a later date or time than the date or time of the proxy being revoked.

Q: Which form of proxy should I complete, sign and return?

A: Accompanying this Joint Information Circular is a form of proxy or Voting Instruction Form for use by Organigram Shareholders. If you hold Organigram Common Shares, please complete, sign and return the form of proxy or Voting Instruction Form, as applicable.

Q: What other conditions are required for the Arrangement to be completed?

A: In addition to the approval by the Organigram Shareholders of the Organigram Share Issuance Resolution, in order for the Arrangement to be completed: (a) the Arrangement Resolution must be approved by not less than 66⅔% of the votes cast by the Aurora Shareholders present virtually or represented by proxy at the Aurora Shareholders' Meeting and by a simple majority of such votes cast excluding the votes required to be excluded under MI 61-101, in the manner required by the Interim Order; (b) the Final Order must be obtained from the Supreme Court of British Columbia; (c) the TSX must conditionally approve the listing of the Organigram Common Shares to be issued to Aurora Shareholders pursuant to the Arrangement, and Organigram must notify the Nasdaq of the listing of such Organigram Common Shares without objection; (d) the Required Regulatory Approvals, being the Competition Act Approval and the German FDI Approval, must be obtained; (e) Dissent Rights must not have been validly exercised, and not withdrawn, with respect to more than 10% of the issued and outstanding Aurora Common Shares; and (f) there must not have occurred a Material Adverse Effect in respect of Aurora or Organigram, as applicable, that is continuing as of the Effective Date. Organigram's obligations under the Arrangement Agreement are not subject to any financing condition, and completion of the Arrangement is not conditional on the completion of the BAT Private Placement.

Under the Arrangement Agreement, Organigram and Aurora have agreed to make the filings required to obtain the Required Regulatory Approvals, being the Competition Act Approval and the German FDI Approval, within five business days after the date of the Arrangement Agreement, to cooperate with one another in obtaining the Regulatory Approvals and not to take any action that would reasonably be expected to make obtaining the Regulatory Approvals materially more difficult or to materially delay them. Organigram will pay all filing fees in respect of the Regulatory Approvals. In addition, a Party may not extend the Outside Date if the failure to obtain the Regulatory Approvals is primarily the result of that Party's failure to comply with its covenants in the Arrangement Agreement. Aurora and Organigram believe that meaningful challenges are unlikely due to the complementary nature of Aurora and Organigram's operations.

See "*Procedure for the Arrangement to Become Effective*".

Q: When will the Arrangement become effective?

A: The Arrangement will become effective on the date and at the time specified in the Plan of Arrangement following the filing with the Registrar of the records and information required under section 292 of the BCBCA, which is expected to occur in January 2027, provided that all required approvals are obtained. Under the Arrangement Agreement, the Effective Date may not occur prior to January 6, 2027. However, completion of the Arrangement is subject to a number of conditions and it is possible that factors outside the control of Aurora and/or Organigram could result in the Arrangement being completed at a later time, or not at all. Subject to certain limitations, each Party may terminate the Arrangement Agreement if it is not consummated by the Outside Date, being May 2, 2027; however, either Party may, by giving written notice to the other Party, extend the Outside Date on no more than two occasions by 90 days each (not exceeding 180 days in the aggregate) if the Effective Date has not occurred as a result of the failure to obtain one or more Regulatory Approvals, provided that the failure is not primarily the result of such Party's failure to comply with its covenants in the Arrangement Agreement.

See "*Timing*".

Q: What will happen if the Organigram Share Issuance Resolution is not approved or the Arrangement is not completed for any reason?

A: If the Organigram Share Issuance Resolution is not approved, the Arrangement Agreement may be terminated by either Aurora or Organigram. Pursuant to the terms of the Arrangement Agreement, each of Aurora and Organigram has agreed not to solicit, initiate, encourage or otherwise facilitate any Acquisition Proposal. The Aurora Board may respond to unsolicited Superior Proposals subject to certain requirements and notification to Organigram, which has the right to match any Superior Proposal within a five-business day period. The Arrangement Agreement provides for an Aurora Termination Fee of $25.2 million payable by Aurora, and an Organigram Termination Fee of $38.4 million payable by Organigram, if the Arrangement Agreement is terminated in certain circumstances. The Organigram Termination Fee is payable if the Arrangement Agreement is terminated by Aurora following an Organigram Change in Recommendation, or if the Arrangement Agreement is terminated because the Organigram Share Issuance Resolution is not approved (or by Aurora for Organigram's breach) and (a) prior to the Organigram Shareholders' Meeting, a *bona fide* Acquisition Proposal in respect of Organigram was made or publicly announced and was not withdrawn at least five business days before the Organigram Shareholders' Meeting, and (b) within 12 months following termination, an Acquisition Proposal in respect of Organigram is consummated or Organigram enters into a definitive agreement in respect of an Acquisition Proposal that is later consummated. In addition, if the Arrangement Agreement is terminated because the Organigram Share Issuance Resolution is not approved, Organigram will be required to pay Aurora the Expense Fee of $5.6 million.

See "*Effect of the Arrangement – The Arrangement Agreement – Termination*" and "*Effect of the Arrangement – The Arrangement Agreement – Termination Fees*".

Q: Are Organigram Shareholders entitled to dissent rights?

A: No. Organigram Shareholders are not entitled to dissent rights in connection with the Organigram Share Issuance Resolution or the Arrangement.

Q: Who should I contact if I have questions?

A: Any Organigram Shareholders that have any questions about the Arrangement or the matters described in this Joint Information Circular, should contact their financial, legal or other professional advisors or Sodali & Co for assistance. You can reach Sodali & Co at 1-833-830-9806 (North America) (1-289-695-3075 for calls outside North America) or by e-mail at assistance@investor.sodali.com.

GLOSSARY OF TERMS

The following is a glossary of certain terms used in this Joint Information Circular including the Summary and Appendices "H", "I" and "J". Terms and abbreviations used in the Appendices to this Joint Information Circular other than Appendices "H", "I" and "J" are defined separately and the terms and abbreviations defined below are not used therein, except where otherwise indicated.

"**Acquisition Proposal**" means, with respect to a Party, other than the transactions contemplated by the Arrangement Agreement and other than any transaction involving only that Party and/or one or more of its wholly-owned Subsidiaries, any offer, proposal or inquiry (written or oral) from any Person or group of Persons other than the other Party (or any of its affiliates or joint actors) (but including, for clarity, in the case of an Acquisition Proposal with respect to Aurora, Curaleaf or any Person or group of Persons acting jointly or in concert with Curaleaf) after the date of the Arrangement Agreement relating to (whether in one transaction or a series of transactions):

(a) any sale, disposition, alliance or joint venture (or any lease, long-term supply agreement or other arrangement having the same economic effect as a sale), direct or indirect, in a single transaction or a series of related transactions, of assets representing 20% or more of the consolidated assets or contributing 20% or more of the consolidated revenue of that Party and its Subsidiaries or of 20% or more of the voting or equity securities of that Party and its Subsidiaries (or rights or interests therein or thereto), taken as a whole;

(b) any direct or indirect take-over bid, tender offer, exchange offer, treasury issuance or other transaction that, if consummated, would result in a Person or group of Persons beneficially owning 20% or more of any class of voting or equity securities (including through securities convertible into or exercisable or exchangeable for voting or equity securities) of that Party or any of its Subsidiaries;

(c) any plan of arrangement, merger, amalgamation, consolidation, share exchange, business combination, reorganization, recapitalization, liquidation, dissolution, winding up or other similar transaction involving that Party pursuant to which any Person or group of Persons would acquire, directly or indirectly, 20% or more of the voting or equity securities of that Party or the surviving or resulting entity or the resulting direct or indirect parent of that Party or the surviving or resulting entity, or assets of that Party representing 20% or more of the consolidated assets or contributing 20% or more of the consolidated revenue or earnings of that Party and its Subsidiaries, taken as a whole; or

(d) any other transaction, the consummation of which would reasonably be expected to impede, interfere with, prevent or delay the transactions contemplated by the Arrangement Agreement or the Arrangement,

and for greater certainty, the Parties acknowledge and agree that the Hostile Bid is an Acquisition Proposal with respect to Aurora (notwithstanding that it was made prior to the date of the Arrangement Agreement), and any and each Amended Bid shall be deemed to be a new and distinct Acquisition Proposal for the purposes of the Arrangement Agreement;

"**acting jointly or in concert**" has the meaning set forth in NI 62-104;

"**adjusted EBITDA**" means adjusted net income before total interest less capitalized interest, income taxes, depreciation and amortization;

"**affiliate**" has the meaning ascribed thereto in National Instrument 45-106 – *Prospectus Exemptions*;

"**allowable capital loss**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Taxation of Capital Gains and Losses*";

"**Alternative Financing**" means alternative debt or equity financing obtained by Organigram in accordance with the Arrangement Agreement if all or any portion of the Organigram Financing becomes unavailable on the terms of the Financing Commitments;

"**Amended and Restated IRA**" means the second amended and restated investor rights agreement between Organigram and BAT entered into on April 15, 2026 in connection with the completion of Organigram's acquisition of Sanity Group;

"**Amended Bid**" means any extension, change or variation of the Hostile Bid that changes the amount or form of consideration offered thereunder (including the type of consideration and/or the respective proportion of each type of consideration offered), each of which shall constitute a new and distinct Amended Bid and an Acquisition Proposal;

"**ARC**" has the meaning ascribed thereto under the heading "*Procedure for the Arrangement to Become Effective – Regulatory Approvals – Competition Act Approval*";

"**Arrangement**" means the arrangement under Section 288 of the BCBCA, on the terms and subject to the conditions set out in the Plan of Arrangement, subject to any amendments or variations thereto made in accordance with the terms of the Arrangement Agreement and the Plan of Arrangement or made at the direction of the Court in the Final Order with the prior written consent of the Parties, each acting reasonably;

"**Arrangement Agreement**" means the arrangement agreement between Aurora and Organigram dated November 2, 2026 (including the schedules thereto) as supplemented, modified or amended, and not to any particular article, section, schedule or other portion thereof;

"**Arrangement Filings**" means the records and information required under section 292 of the BCBCA to be filed with the Registrar to give effect to the Arrangement after the Final Order is made, together with a copy of the entered Final Order, in a form and content satisfactory to the Parties, each acting reasonably;

"**Arrangement Resolution**" means a special resolution of the Aurora Shareholders in respect of the Arrangement to be considered at the Aurora Shareholders' Meeting, the full text of which is set forth in Appendix "A" to this Joint Information Circular;

"**ASC**" means the Alberta Securities Commission;

"**associate**" has the meaning set forth in the *Securities Act* (Ontario);

"**ATB Commitment Letter**" means the executed commitment letter dated November 2, 2026 between Organigram and ATB Financial, (including all exhibits, schedules and annexes thereto and any related fee letter), as such commitment letter may be amended, restated, replaced or supplemented in accordance with the Arrangement Agreement, as more particularly described under the heading "*Effect of the Arrangement – BAT Equity Commitment – ATB Debt Financing*";

"**ATB Credit Facilities**" means the senior secured credit facilities of up to $210,000,000 to be provided to Organigram pursuant to the ATB Commitment Letter;

"**ATB Financial**" means ATB Financial, lender to Organigram;

"**ATM Program**" means the at-the-market equity program established by Aurora on February 4, 2026, under which Aurora may issue from treasury, through TD Securities (USA) LLC as agent, up to US$100 million of Aurora Common Shares;

"**Aurora**" means Aurora Cannabis Inc., a corporation existing under the BCBCA;

"**Aurora AGM Circular**" means the management information circular of Aurora dated June 24, 2026 relating to the annual general meeting of Aurora Shareholders held on August 7, 2026;

"**Aurora AIF**" means the annual information form of Aurora for the year ended March 31, 2026 dated June 10, 2026;

"**Aurora Annual Financial Statements**" means the audited consolidated financial statements of Aurora as at and for the years ended March 31, 2026 and 2025 together with the notes thereto and the auditors' report thereon;

"**Aurora Annual MD&A**" means management's discussion and analysis of the financial and operating results of Aurora for the years ended March 31, 2026 and 2025;

"**Aurora Board**" means the board of directors of Aurora;

"**Aurora Cash DSUs**" means the outstanding Aurora DSUs issued under the Aurora DSU Cash Plan;

"**Aurora Cash PSUs**" means the outstanding Aurora PSUs issued under the Aurora PRSU Cash Plan;

"**Aurora Cash RSUs**" means the outstanding Aurora RSUs issued under the Aurora PRSU Cash Plan;

"**Aurora Change in Recommendation**" has the meaning ascribed thereto under the heading "*Effect of the Arrangement – The Arrangement Agreement – Termination*";

"**Aurora Common Shares**" means the common shares in the capital of Aurora;

"**Aurora Data Room**" means the electronic data room established by Aurora in connection with the transactions contemplated by the Arrangement Agreement, as such data room existed as of 11:59 p.m. (Eastern time) on November 1, 2026;

"**Aurora Disclosure Letter**" means the disclosure letter delivered by Aurora to Organigram and dated November 2, 2026;

"**Aurora DSU Cash Plan**" means the non-employee directors deferred share unit cash plan of Aurora effective June 8, 2023, as amended effective August 9, 2024;

"**Aurora DSU Plans**" means, collectively, the Aurora DSU Cash Plan and the Aurora DSU Share Plan;

"**Aurora DSU Share Plan**" means the non-employee directors deferred share unit plan of Aurora effective October 5, 2018, as amended, including as amended by the Aurora Shareholders on November 12, 2020, November 14, 2022 and August 9, 2024;

"**Aurora DSUs**" means the outstanding deferred share units issued under the Aurora DSU Plans;

"**Aurora Fairness Opinions**" means, collectively, the Fort Capital Fairness Opinion and the Origin Fairness Opinion;

"**Aurora Financial Advisors**" means Fort Capital and Origin, financial advisors to Aurora and the Aurora Special Committee, respectively;

"**Aurora Incentive Awards**" means, collectively, the Aurora Options, the Aurora DSUs, the Aurora RSUs and the Aurora PSUs;

"**Aurora Interim Financial Statements**" means the unaudited condensed interim consolidated financial statements of Aurora as at and for the three and six months ended September 30, 2026 and 2025;

"**Aurora Interim MD&A**" means management's discussion and analysis of the financial and operating results of Aurora for the three and six months ended September 30, 2026 and 2025;

"**Aurora Options**" means the outstanding options to purchase Aurora Common Shares granted under the Aurora Stock Option Plan;

"**Aurora PRSU Cash Plan**" means the performance share unit and restricted share unit long-term cash settled plan of Aurora effective June 8, 2023, as amended effective August 8, 2025;

"**Aurora PSU Plan**" means, collectively, the Aurora PSU Share Plan and the Aurora PRSU Cash Plan, in each case as it relates to performance share units;

"**Aurora PSU Share Plan**" means the performance share unit plan of Aurora instituted effective as of August 8, 2025;

"**Aurora Proxy Deadline**" means 9:30 a.m. (Toronto time) on December 21, 2026, or 48 hours prior to the time of any adjournment or postponement of the Aurora Shareholders' Meeting (excluding Saturdays, Sundays and statutory holidays in the Province of Ontario);

"**Aurora PSUs**" means the outstanding performance share units issued under the Aurora PSU Plan;

"**Aurora Record Date**" means November 18, 2026;

"**Aurora Right**" means a right issued under the Aurora Shareholder Rights Plan attached to each outstanding Aurora Common Share;

"**Aurora RSU Plan**" means, collectively, the Aurora RSU Share Plan and the Aurora PRSU Cash Plan, in each case as it relates to restricted share units;

"**Aurora RSU Share Plan**" means the restricted share unit plan of Aurora last approved by the Aurora Shareholders on August 8, 2025, as amended by the Aurora Board on June 10, 2026;

"**Aurora RSUs**" means the outstanding restricted share units issued under the Aurora RSU Plan;

"**Aurora Share DSUs**" means the outstanding Aurora DSUs issued under the Aurora DSU Share Plan;

"**Aurora Share RSUs**" means the outstanding Aurora RSUs issued under the Aurora RSU Share Plan;

"**Aurora Shareholder Rights Plan**" means the amended and restated shareholder rights plan agreement dated as of October 4, 2018 between Aurora and the Rights Agent, originally approved by Aurora Shareholders on November 30, 2018 and most recently reconfirmed by Aurora Shareholders on August 9, 2024, as amended, amended and restated, replaced or supplemented from time to time;

"**Aurora Shareholders**" means the holders of Aurora Common Shares;

"**Aurora Shareholders' Meeting**" means such meeting or meetings of the Aurora Shareholders, including any adjournment or postponement thereof in accordance with the Arrangement Agreement, that is or are to be convened as provided by the Interim Order to consider, and if deemed advisable approve, the Arrangement Resolution;

"**Aurora Special Committee**" means the independent committee of the Aurora Board comprised of independent directors (within the meaning of applicable Canadian Securities Laws);

"**Aurora Stock Option Plan**" means the share option plan of Aurora dated August 8, 2025;

"**Aurora Support Agreements**" means the support agreements between Organigram and each of the Supporting Aurora Shareholders pursuant to which the Supporting Aurora Shareholders agreed, among other things, to vote the Aurora Common Shares held by them in favour of the Arrangement Resolution and to otherwise support the Arrangement;

"**Aurora Termination Fee**" has the meaning ascribed thereto under the heading "*Effect of the Arrangement – The Arrangement Agreement – Termination Fees*";

"**Aurora Termination Fee Event**" has the meaning ascribed thereto under the heading "*Effect of the Arrangement – The Arrangement Agreement – Termination Fees*";

"**BAT**" means BT DE Investments Inc., a wholly-owned indirect subsidiary of British American Tobacco p.l.c., or any permitted assignee of BT DE Investments Inc. under the BAT Equity Commitment;

"**BAT Equity Commitment**" means the executed subscription agreement dated November 2, 2026 between Organigram and BAT providing for the subscription by BAT for 140,986,255 Organigram Common Shares and/or Organigram Preferred Shares at a price of £0.709289 (approximately $1.33 based on the GBP/CAD exchange rate on November 2, 2026) per share for aggregate proceeds of £99,999,999.82 (approximately $187.5 million based on the GBP/CAD exchange rate on November 2, 2026), as such subscription agreement may be amended, replaced or supplemented in accordance with the Arrangement Agreement;

"**BAT Private Placement**" means the subscription by BAT for Organigram Common Shares and/or Organigram Preferred Shares pursuant to the BAT Equity Commitment, as more particularly described under the heading "*Effect of the Arrangement – BAT Equity Commitment*";

"**BCBCA**" means the *Business Corporations Act*, S.B.C. 2002, c. 57, as amended, including the regulations promulgated thereunder;

"**Beneficial Holder**" means a Shareholder who does not hold their Shares in their own name;

"**BMO Capital Markets**" means BMO Nesbitt Burns Inc., financial advisor to Organigram;

"**business day**" or "**Business Day**" means any day, other than a Saturday, a Sunday or a statutory or civic holiday in Toronto, Ontario, Calgary, Alberta, London, United Kingdom or New York City, New York, provided that, when used in connection with any deadline or period under the Plan of Arrangement (including the deadline for delivering a Notice of Dissent, the Election Deadline and the computation of time under the Plan of Arrangement), "**Business Day**" has the meaning given to it in the Plan of Arrangement, being any day, other than a Saturday, a Sunday or a statutory or civic holiday in Toronto, Ontario or Calgary, Alberta;

"**Canadian Securities Administrators**" means the securities commission or other securities regulatory authority of each province and territory of Canada;

"**Canadian Securities Laws**" means the securities legislation or ordinance and regulations thereunder of each province and territory of Canada and the rules, instruments, policies and orders of each Canadian Securities Administrator made thereunder;

"**Cash Alternative**" means $7.80 in cash per Aurora Common Share, subject to proration;

"**CBCA**" means the *Canada Business Corporations Act*, R.S.C. 1985, c. C-44, as amended, including the regulations promulgated thereunder;

"**CDS**" means CDS Clearing and Depository Services Inc. or its nominee, CDS & Co.;

"**Code**" has the meaning ascribed thereto under the heading "*Certain United States Federal Income Tax Considerations*";

"**Combination Alternative**" means $3.75 in cash and 3.0431 Organigram Common Shares per Aurora Common Share;

"**Commissioner**" means the Commissioner of Competition appointed under subsection 7(1) of the Competition Act, or the Commissioner's designee;

"**Competition Act**" means the *Competition Act*, R.S.C. 1985, c. C-34, as amended;

"**Competition Act Approval**" means that:

(a) the Commissioner shall have issued an ARC; or

(b) (i) the applicable waiting period under section 123 of the Competition Act shall have expired or been terminated by the Commissioner, or (ii) the obligation to submit a notification shall have been waived by the Commissioner under paragraph 113(c) of the Competition Act, and, unless such requirement is waived by Organigram in its sole discretion, in either case (i) or (ii), the Commissioner shall have issued a No Action Letter in writing;

"**Computershare**" means Computershare Investor Services Inc., the registrar and transfer agent for the Aurora Common Shares;

"**Consideration**" means, for each Aurora Common Share, at the election of the holder thereof, the Cash Alternative, the Share Alternative or the Combination Alternative, subject, in the case of the Cash Alternative and the Share Alternative, to proration such that the aggregate cash payable and the aggregate number of Organigram Common Shares issuable under the Arrangement will not exceed the Maximum Cash Consideration and the Maximum Share Consideration, respectively;

"**Control Shares**" has the meaning ascribed thereto under the heading "*Joint Information Circular – Information for United States Securityholders*";

"**Controlling Individual**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Eligibility for Investment*";

"**Convention**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations - Holders Not Resident in Canada – Holding and Disposing of Organigram Common Shares – Dividends Received on Organigram Common Shares*";

"**Court**" means the Supreme Court of British Columbia;

"**CRA**" means the Canada Revenue Agency;

"**Curaleaf**" means Curaleaf Holdings, Inc., a corporation existing under the laws of the Province of British Columbia, and unless the context otherwise requires, includes its subsidiaries and affiliates;

"**Curaleaf Notice of Variation**" means the notice of variation, change and extension of Curaleaf dated October 6, 2026, amending the terms of the Original Curaleaf Bid;

"**Curaleaf Shares**" means the subordinate voting shares in the capital of Curaleaf;

"**Depositary**" means Computershare, or such other Person that may be appointed by the Parties in connection with the Arrangement for the purpose of receiving deposits of certificates or DRS Advices formerly representing Aurora Common Shares;

"**Directors' Circular**" means the directors' circular of the Aurora Board dated September 1, 2026 in respect of the Original Curaleaf Bid;

"**Directors' Notice of Change**" means the notice of change to the Directors' Circular dated October 14, 2026 in respect of the Hostile Bid;

"**Dissent Rights**" means the rights of dissent in respect of the Arrangement granted to registered Aurora Shareholders pursuant to Division 2 of Part 8 of the BCBCA, as modified by Section 4.1 of the Plan of Arrangement, the Interim Order and any other order of the Court;

"**Dissenting Aurora Shareholders**" means the registered Aurora Shareholders who held Aurora Common Shares as of the Aurora Record Date and who validly exercise their Dissent Rights, which exercise of Dissent Rights has not been withdrawn, or is not deemed to have been withdrawn, before the Effective Time;

"**Dissenting Non-Resident Holder**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Not Resident in Canada – Dissenting Non-Resident Holders of Aurora Common Shares*";

"**Dissenting Resident Holder**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Dissenting Resident Holders of Aurora Common Shares*";

"**DRS Advice**" means a Direct Registration System (DRS) advice;

"**DTC**" means The Depository Trust Company or its nominee, Cede & Co.;

"**Effective Date**" means the date upon which the Arrangement becomes effective, as set out in Section 2.10(b) of the Arrangement Agreement;

"**Effective Time**" means 12:01 a.m. (Toronto time) on the Effective Date, or such other time as Organigram and Aurora may agree in writing before the Effective Date;

"**Elected Amount**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Participation in the Arrangement – With a Section 85 Election*";

"**Election Deadline**" has the meaning ascribed thereto under the heading "*Effect of the Arrangement – Elections and Proration*";

"**Eligible Holder**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Participation in the Arrangement – With a Section 85 Election*";

"**Entitlement Date**" means, in respect of an Aurora PSU, the "Entitlement Date" as defined in the applicable Aurora PSU Plan;

"**Exchanges**" means the TSX and the Nasdaq;

"**Expense Fee**" means $5.6 million, payable by Organigram to Aurora in the circumstances described under the heading "*Effect of the Arrangement – The Arrangement Agreement – Termination Fees*";

"**FHSAs**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Eligibility for Investment*";

"**Final Order**" means the final order of the Court pursuant to section 291 of the BCBCA, in a form acceptable to the Parties, each acting reasonably, approving the Arrangement, as such order may be amended by the Court (with the consent of both the Parties, each acting reasonably) at any time prior to the Effective Date or, if appealed, then, unless such appeal is withdrawn or denied, as affirmed or as amended (provided that any such amendment is acceptable to both the Parties, each acting reasonably) on appeal;

"**Financing Commitments**" means, collectively, the ATB Commitment Letter and the BAT Equity Commitment, in each case as may be amended, restated, replaced or supplemented in accordance with the Arrangement Agreement;

"**Fort Capital**" means Fort Capital Partners, financial advisor to Aurora;

"**Fort Capital Fairness Opinion**" means the written opinion of Fort Capital to the Aurora Special Committee and the Aurora Board dated November 2, 2026, a copy of which is attached as Appendix "F" to this Joint Information Circular;

"**Fort Capital Inadequacy Opinion**" has the meaning ascribed thereto under the heading "*The Arrangement – Background to the Arrangement*";

"**forward-looking statements**" has the meaning ascribed thereto under the heading "*Forward-Looking Statements and Information*";

"**German FDI Approval**" means that the German Federal Ministry for Economic Affairs and Energy (*Bundesministerium für Wirtschaft und Energie*) (the "**BMWE**") has issued (a) a clearance decision (*Freigabebescheid*), (b) a certificate of non-objection (*Unbedenklichkeitsbescheinigung*), or (c) any other written confirmation that the Arrangement and the Organigram Financing are not subject to a mandatory foreign direct investment filing obligation pursuant to Section 55a(4) or Section 60(3) of the German Foreign Trade and Payments Ordinance (*Außenwirtschaftsverordnung*), provided that, in the case of (a), any terms or conditions attached thereto (including conditions or obligations imposed by the BMWE (*Auflagen*), a partial clearance (*Teilfreigabe*) or the conclusion of a public law agreement (*öffentlich-rechtlicher Vertrag*)) are acceptable to Organigram and do not impose any obligation, condition or requirement on BAT or its affiliates, or that clearance is deemed to have been granted by operation of law pursuant to Section 14a of the German Foreign Trade and Payments Act (*Außenwirtschaftsgesetz*) (*Freigabefiktion*);

"**Good Reason**" has the meaning ascribed thereto in the applicable employment agreement between Aurora and the relevant executive officer;

"**Goodmans**" means Goodmans LLP, legal counsel to Organigram;

"**Governmental Entity**" means any applicable: (a) multinational, national, federal, provincial, state, regional, municipal, local or other government, governmental or public department, minister, central bank, court, tribunal, arbitral body, commission, board, bureau or agency, domestic or foreign; (b) subdivision, agent, commission, commissioner, board or authority of any of the foregoing; (c) quasi-governmental or private body, including any tribunal, commission, regulatory agency or self-regulatory organization, exercising any regulatory, expropriation or taxing authority under or for the account of any of the foregoing; or (d) the Exchanges;

"**Holder**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations*";

"**Hostile Bid**" means the Original Curaleaf Bid as varied, changed and extended, as applicable, by the Curaleaf Notice of Variation;

"**IFRS**" means International Financial Reporting Standards as incorporated in the Chartered Professional Accountants of Canada Handbook, at the relevant time applied on a consistent basis;

"**Indication**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Participation in the Arrangement – With a Section 85 Election*";

"**Inside Date**" means January 6, 2027, being the date prior to which the Effective Date may not occur under the Arrangement Agreement;

"**Interim Order**" means the interim order of the Court pursuant to section 291 of the BCBCA, in a form acceptable to the Parties, each acting reasonably, made in connection with the Arrangement and providing for, among other things, the calling and holding of the Aurora Shareholders' Meeting, as the same may be amended, supplemented or varied by the Court (with the consent of the Parties, each acting reasonably), a copy of which is attached as Appendix "D" to this Joint Information Circular;

"**IRS**" has the meaning ascribed thereto under the heading "*Certain United States Federal Income Tax Considerations*";

"**Joint Information Circular**" means the notice of the Organigram Shareholders' Meeting and the notice of the Aurora Shareholders' Meeting to be sent to Organigram Shareholders and Aurora Shareholders, respectively, and the management information circular prepared in connection with the Organigram Shareholders' Meeting and the Aurora Shareholders' Meeting, together with any amendments thereto or supplements thereof, and any other registration statement, information circular or proxy statement which may be prepared in connection with the Organigram Shareholders' Meeting and/or the Aurora Shareholders' Meeting;

"**Kingsdale Advisors**" means Kingsdale Advisors, strategic shareholder advisor and proxy solicitation agent to Aurora;

"**Laws**" means all laws (including common law), by-laws, statutes, rules, regulations, principles of law and equity, orders, rulings, ordinances, judgements, injunctions, determinations, awards, decrees or other requirements of any Governmental Entity having the force of law (including the rules of any stock exchange), whether domestic or foreign, and the terms and conditions of any grant of approval, permission, authority or license of any Governmental Entity, including any Cannabis Laws (as defined in the Arrangement Agreement), and the term "**applicable**" with respect to such Laws and in a context that refers to one or more Persons, means such Laws as are applicable to such Person or its business, undertaking, assets, property or securities and emanate from a Person having jurisdiction over the Person or Persons or its or their business, undertaking, assets, property or securities; and "**Laws**" includes Canadian Securities Laws and U.S. Securities Laws;

"**Letter of Transmittal and Election Form**" means the letter of transmittal and election form sent to registered Aurora Shareholders pursuant to which registered Aurora Shareholders are required to deliver certificates or DRS Advices representing the Aurora Common Shares to the Depositary and may elect the Cash Alternative, the Share Alternative or the Combination Alternative in order to receive the Consideration on the Arrangement becoming effective;

"**Matching Period**" has the meaning ascribed thereto under the heading "*Effect of the Arrangement – The Arrangement Agreement – Covenants Regarding Non-Solicitation*";

"**Material Adverse Effect**" means, with respect to Organigram or Aurora, as applicable, any fact or state of facts, circumstance, change, effect, occurrence or event which, either individually is or in the aggregate are, or individually or in the aggregate would reasonably be expected to be, material and adverse to the business, operations, results of operations, properties, assets, liabilities (whether absolute, accrued, contingent or otherwise) or financial condition of such Party and its Subsidiaries, on a consolidated basis, except for and excluding any fact or state of facts, circumstance, change, effect, occurrence or event to the extent resulting from or arising in connection with:

(a) any change in applicable generally accepted accounting principles, including IFRS (or authoritative interpretation thereof);

(b) any adoption, proposal, implementation or change in Law or in any interpretation, application or non-application of any Laws by any Governmental Entity;

(c) any change, development or condition in or relating to global, national or regional political conditions (including the outbreak or escalation of war, acts of terrorism, strikes, lockouts, riots, outbreaks of illness or facility takeover for emergency purposes) or in general economic, business, regulatory, financial, credit, currency exchange, interest rate, rates of inflation or market conditions or in national or global financial or capital markets, including credit markets or securities markets, including, without limitation, the imposition or adjustment of tariffs, other limitations on trade or the threat thereof;

(d) any change, development or condition resulting from any act of sabotage, espionage, hacking or cyberattack or any escalation or worsening of such acts of sabotage, espionage, hacking or cyberattack;

(e) any change, development, condition or event generally affecting the industries, businesses or segments thereof in which such Party and its Subsidiaries operate (the "**Relevant Business**");

(f) climatic or other natural events or conditions (including drought, any other weather conditions and any natural disaster);

(g) the failure of such Party to meet any internal, published or public projections, forecasts, guidance, estimates or predictions in respect of, without limitation, revenues, earnings or other financial or operating metrics before, on or after the date of the Arrangement Agreement, or changes in the market price, credit rating or trading volume of such Party's securities after the date of the Arrangement Agreement (it being understood that the underlying facts giving rise or contributing to such failure or change may, if not otherwise excluded from the definition of Material Adverse Effect, be deemed either alone or in combination to constitute, or be taken into account in determining whether there has been, a Material Adverse Effect);

(h) the execution, announcement, pendency or performance of the Arrangement Agreement or the consummation of the transactions contemplated thereby, including any lawsuit in respect of the Arrangement Agreement or the transactions contemplated thereby or any loss or threatened loss of, or adverse change or threatened adverse change in, the relationship of such Party or any of its affiliates with any Governmental Entity or their respective current or prospective customers, clients, suppliers, officers, employees, partners, lessors, licensors, regulators, rating agencies, creditors, shareholders, contractors and other Persons with which such Party or any of its affiliates has business relations;

(i) any matters disclosed in or pursuant to the Arrangement Agreement, in the Aurora Data Room or the Organigram Data Room;

(j) any actions taken (or omitted to be taken) at the written request, or with the prior written consent, of the other Party;

(k) any action taken by such Party or any of its Subsidiaries that is expressly required by Law or pursuant to the Arrangement Agreement; or

(l) any change in the market price or trading volume of the equity securities of such Party (it being understood that the causes underlying such change in market price or trading volume may be taken into account in determining whether a Material Adverse Effect has occurred),

provided, however, that with respect to paragraphs (a) through (f) above, such matters will be considered to the extent that they have a materially disproportionate effect on such Party and its Subsidiaries, taken as a whole, relative to comparable entities operating in such Party's industries, markets, businesses or segments thereof; and references in certain sections of the Arrangement Agreement to dollar amounts are not intended to be, and shall not be deemed to be, illustrative or interpretative for purposes of determining whether a Material Adverse Effect has occurred;

"**Maximum Cash Consideration**" means $3.75 multiplied by the number of Aurora Common Shares outstanding immediately prior to the Effective Time, being the maximum aggregate cash payable under the Arrangement;

"**Maximum Share Consideration**" means 3.0431 Organigram Common Shares multiplied by the number of Aurora Common Shares outstanding immediately prior to the Effective Time, being the maximum aggregate number of Organigram Common Shares issuable under the Arrangement;

"**Meetings**" means collectively, the Aurora Shareholders' Meeting and the Organigram Shareholders' Meeting, and "**Meeting**" means either of them;

"**Meeting Materials**" means, collectively, this Joint Information Circular, the notices of the Meetings, the forms of proxy and voting instruction forms for the Meetings and the Letter of Transmittal and Election Form;

"**MI 61-101**" means Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions*;

"**Nasdaq**" means the Nasdaq Global Select Market or, in respect of Aurora's current listing, the Nasdaq Capital Market;

"**NI 62-104**" means National Instrument 62-104 – *Take-Over Bids and Issuer Bids*;

"**No Action Letter**" has the meaning ascribed thereto under the heading "*Procedure for the Arrangement to Become Effective – Regulatory Approvals – Competition Act Approval*";

"**Non-IFRS Measures**" has the meaning ascribed thereto under the heading "*Supplemental Disclosure – Non-IFRS Measures*";

"**Non-Resident Holder**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Not Resident in Canada*";

"**Notice of Dissent**" means a written notice of dissent delivered by a registered Aurora Shareholder in strict compliance with section 242 of the BCBCA, as modified by the Interim Order and the Plan of Arrangement;

"**Notice Shares**" has the meaning ascribed thereto under the heading "*Dissent Rights*";

"**Option Exchange Ratio**" means the quotient obtained by dividing $7.80 by $1.33, being the deemed price per Organigram Common Share, subject to adjustment (if any) pursuant to Section 2.14 of the Arrangement Agreement;

"**Organigram**" means Organigram Global Inc.;

"**Organigram AGM Circular**" means the management information circular of Organigram dated February 23, 2026 relating to the annual general and special meeting of Organigram Shareholders held on March 30, 2026;

"**Organigram AIF**" means the annual information form of Organigram for the year ended September 30, 2025 dated December 16, 2025;

"**Organigram Annual Financial Statements**" means the audited consolidated financial statements of Organigram as at and for the years ended September 30, 2025 and 2024 together with the notes thereto and the auditors' report thereon;

"**Organigram Annual MD&A**" means management's discussion and analysis of the financial and operating results of Organigram for the years ended September 30, 2025 and 2024;

"**Organigram Board**" means the board of directors of Organigram;

"**Organigram Change in Recommendation**" has the meaning ascribed thereto under the heading "*Effect of the Arrangement – The Arrangement Agreement – Termination*";

"**Organigram Common Shares**" means the common shares in the capital of Organigram;

"**Organigram Credit Facilities**" means the existing credit facilities of Organigram under its credit agreement with ATB Financial dated April 14, 2026, which will be amended and restated in accordance with the ATB Commitment Letter to provide the ATB Credit Facilities;

"**Organigram Data Room**" means the electronic data room established by Organigram in connection with the transactions contemplated by the Arrangement Agreement, hosted by Datasite, as such data room existed as of 11:59 p.m. (Eastern time) on November 1, 2026;

"**Organigram DSUs**" means the outstanding deferred share units granted under the Organigram Equity Incentive Plan;

"**Organigram Equity Incentive Plan**" means, collectively, the long-term omnibus equity incentive plan of Organigram approved by the Organigram Board on January 23, 2020, as re-approved from time to time (including the re-approval of unallocated awards by the Organigram Shareholders on March 30, 2026), together with Organigram's 2017 equity incentive plan and 2011 stock option plan, each of which remains in effect only in respect of outstanding awards and under which no further awards may be granted;

"**Organigram Fairness Opinion**" means the written opinion of BMO Capital Markets to the Organigram Board dated November 2, 2026, a copy of which is attached as Appendix "G" to this Joint Information Circular;

"**Organigram Financing**" means the debt and equity financing contemplated by the Financing Commitments, including the BAT Private Placement, and any Alternative Financing obtained in accordance with the Arrangement Agreement;

"**Organigram Interim Financial Statements**" means the unaudited condensed interim consolidated financial statements of Organigram as at and for the three and nine months ended June 30, 2026 and 2025;

"**Organigram Interim MD&A**" means management's discussion and analysis of the financial and operating results of Organigram for the three and nine months ended June 30, 2026 and 2025;

"**Organigram Options**" means the outstanding options to purchase Organigram Common Shares granted under or otherwise subject to the Organigram Equity Incentive Plan;

"**Organigram Preferred Shares**" means the non-voting Class A preferred shares in the capital of Organigram;

"**Organigram Pro Forma Financial Statements**" has the meaning ascribed thereto under the heading "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement – Selected Unaudited Pro Forma Consolidated Financial Information*";

"**Organigram Proxy Deadline**" means 9:00 a.m. (Toronto time) on December 21, 2026, or 48 hours (excluding Saturdays, Sundays and statutory holidays in the Province of Ontario) prior to the time of any adjournment or postponement of the Organigram Shareholders' Meeting;

"**Organigram PSUs**" means the outstanding performance share units granted under the Organigram Equity Incentive Plan;

"**Organigram Record Date**" means November 18**,** 2026;

"**Organigram RSUs**" means the outstanding restricted share units granted under the Organigram Equity Incentive Plan;

"**Organigram Share Issuance Resolution**" means the ordinary resolution of the Organigram Shareholders to authorize and approve the issuance by Organigram of the Organigram Common Shares to the Aurora Shareholders pursuant to the Arrangement and to BAT pursuant to the BAT Private Placement, and to authorize and approve the BAT Private Placement, the full text of which is set forth in Appendix "B" to this Joint Information Circular;

"**Organigram Shareholders**" means the holders of Organigram Common Shares;

"**Organigram Shareholders' Meeting**" means such meeting or meetings of the Organigram Shareholders, including any adjournment or postponement thereof in accordance with the Arrangement Agreement, that is to be convened to consider, and if deemed advisable, approve the Organigram Share Issuance Resolution;

"**Organigram Support Agreements**" means the support agreements between Aurora and each of the Supporting Organigram Shareholders pursuant to which the Supporting Organigram Shareholders agreed, among other things, to vote the Organigram Common Shares held by them in favour of the Organigram Share Issuance Resolution and to otherwise support the Arrangement;

"**Organigram Termination Fee**" has the meaning ascribed thereto under the heading "*Effect of the Arrangement – The Arrangement Agreement – Termination Fees*";

"**Organigram Termination Fee Event**" has the meaning ascribed thereto under the heading "*Effect of the Arrangement –The Arrangement Agreement – Termination Fees*";

"**Origin**" means Origin Merchant Partners, financial advisor to the Aurora Special Committee;

"**Origin Fairness Opinion**" means the written opinion of Origin to the Aurora Special Committee and the Aurora Board dated November 2, 2026, a copy of which is attached as Appendix "F" to this Joint Information Circular;

"**Original Curaleaf Bid**" means the offer by Curaleaf dated August 18, 2026 to purchase all of the issued and outstanding Aurora Common Shares, together with the associated Aurora Rights issued under the Aurora Shareholder Rights Plan, for consideration per Aurora Common Share of US$0.75 in cash and 0.3463 of a subordinate voting share of Curaleaf, subject to a maximum value of US$5.00 per Aurora Common Share and to adjustment as provided therein, as set out in the offer to purchase and take-over bid circular of Curaleaf dated August 18, 2026;

"**Outside Date**" means May 2, 2027, or such later date as may be agreed to in writing by the Parties, provided that if the Effective Date has not occurred by May 2, 2027 as a result of the failure to obtain one or more of the Regulatory Approvals, either Party may elect, by notice in writing to the other Party, to extend the Outside Date on no more than two occasions by a period of 90 days each, provided that such extensions shall not exceed 180 days in the aggregate from May 2, 2027, and provided further that a Party shall not be permitted to extend the Outside Date if the failure to obtain the Regulatory Approvals is primarily the result of such Party's failure to comply with its covenants in the Arrangement Agreement;

"**Parties**" means Organigram and Aurora, and "**Party**" means either one of them;

"**Person**" includes an individual, partnership, association, company, corporation, body corporate, limited liability company, unincorporated association, unincorporated syndicate, unincorporated organization, trust, trustee, executor, administrator, legal representative, government (including any Governmental Entity) or any other entity, whether or not having legal status;

"**PFIC**" has the meaning ascribed thereto under the heading "*Certain United States Federal Income Tax Considerations – U.S. Federal Income Tax Considerations of the Arrangement*";

"**Plan of Arrangement**" means the plan of arrangement substantially in the form and on the terms set forth in Schedule A of the Arrangement Agreement, subject to any amendments or variations to such plan made in accordance with Section 9.1 of the Arrangement Agreement and the Plan of Arrangement or made at the direction of the Court in the Final Order with the consent of Organigram and Aurora, each acting reasonably;

"**Pre-Acquisition Reorganization**" has the meaning ascribed thereto in Section 5.8 of the Arrangement Agreement;

"**Proposed Amendments**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations*";

"**RDSPs**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Eligibility for Investment*";

"**Registered Plans**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Eligibility for Investment*";

"**Registrar**" means the Registrar of Companies appointed pursuant to Section 400 of the BCBCA;

"**Regulatory Approvals**" means any consent, waiver, permit, exemption, review, order, decision or approval of, or any registration and filing with, any Governmental Entity, or the expiry, waiver or termination of any waiting period imposed by applicable Law or a Governmental Entity, in each case in connection with the Arrangement and the Organigram Financing, and, for greater certainty, includes the Required Regulatory Approvals and all notifications, filings and approvals required from, or required to be provided to, Health Canada or any other Governmental Entity under applicable Laws relating to cannabis in connection with the Arrangement;

"**Relevant Business**" has the meaning set forth in the definition of "**Material Adverse Effect**";

"**Replacement Option**" means an option to purchase Organigram Common Shares granted by Organigram in exchange for an Aurora Option pursuant to the Plan of Arrangement;

"**Representatives**" means, collectively, in respect of a Person, (a) its directors, officers, employees, agents, representatives and any financial advisor, law firm, accounting firm or other professional firm retained to assist the Person in connection with the transactions contemplated by the Arrangement Agreement, and (b) the Person's Subsidiaries and the directors, officers, employees, agents and representatives and advisors thereof;

"**Required Regulatory Approvals**" means the Competition Act Approval and the German FDI Approval;

"**Resident Holder**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada*";

"**RESPs**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Eligibility for Investment*";

"**Rights Agent**" means Computershare Trust Company of Canada, rights agent under the Aurora Shareholder Rights Plan;

"**RRIFs**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Eligibility for Investment*";

"**RRSPs**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Eligibility for Investment*";

"**Sanity Group**" means Sanity Group GmbH;

"**SEC**" means the United States Securities and Exchange Commission;

"**Section 85 Election**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Participation in the Arrangement – With a Section 85 Election*";

"**SEDAR+**" means the System for Electronic Document Analysis and Retrieval maintained on behalf of the Canadian Securities Administrators;

"**Share Alternative**" means 5.8626 Organigram Common Shares per Aurora Common Share, subject to proration;

"**Shareholders**" means collectively, the Aurora Shareholders and/or the Organigram Shareholders, as the context requires;

"**Shares**" means collectively, the Aurora Common Shares and/or the Organigram Common Shares, as the context requires;

"**Sodali & Co**" means Sodali & Co, proxy solicitation and information agent to Organigram;

"**Specified Adverse Amendment**" has the meaning ascribed thereto under the heading "*Effect of the Arrangement – BAT Equity Commitment – Closing and Conditions*";

"**Specified Termination Event**" has the meaning ascribed thereto under the heading "*Effect of the Arrangement – Organigram Support Agreements*";

"**Stikeman**" means Stikeman Elliott LLP, legal counsel to Aurora;

"**Subsidiary**" means, with respect to a Person, any entity, whether incorporated or unincorporated: (i) of which such Person or any other subsidiary of such Person is a general partner; or (ii) at least a majority of the securities or other interests of which having by their terms ordinary voting power to elect a majority of the board of directors or other Persons performing similar functions with respect to such corporation or other organization is directly or indirectly owned or controlled by such Person and/or by any one or more of its subsidiaries; and shall include any body corporate, partnership, joint venture or other entity over which it exercises direction or control. For purposes of this definition, "control" when used with respect to any Person means the power to direct the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise;

"**Superior Proposal**" means a bona fide unsolicited written Acquisition Proposal in respect of a Party made after the date of the Arrangement Agreement that:

(a) complies with applicable Laws in all material respects and did not result from or otherwise involve a breach of Section 7.1, Section 7.2, Section 7.3, Section 7.4 or Section 7.5 of the Arrangement Agreement by such Party or its Representatives;

(b) relates to the acquisition of all of the shares in the capital of such Party (other than any such shares held by the Persons or group of Persons making such Acquisition Proposal) or all or substantially all of the consolidated assets of such Party and its Subsidiaries;

(c) in respect of which the board of directors of the Party determines, in its good faith judgment, after consultation with its financial advisor(s) and outside legal counsel, that it is reasonably capable of being completed at the time and on the terms proposed, without undue delay, taking into account the financial, legal, regulatory (including with respect to the Required Regulatory Approvals) and other aspects of such Acquisition Proposal and the Person or group of Persons making such Acquisition Proposal;

(d) that is not subject to a financing condition and in respect of which it has been demonstrated to the satisfaction of the board of directors of such Party, acting in good faith (and after receipt of advice from its financial advisor(s) and its outside legal counsel), that adequate arrangements have been made in respect of any financing required to complete such Acquisition Proposal at the time and on the basis set out therein;

(e) that is not subject to any due diligence and/or access condition; and

(f) in respect of which the board of directors of such Party determines, in its good faith judgment, after consultation with outside legal counsel and after receiving advice from its financial advisor(s) that having regard to all of its terms and conditions, such Acquisition Proposal would, if consummated in accordance with its terms (but not assuming away any risk of non-completion), result in a transaction more favourable, from a financial point of view, to, in the case of Aurora, the Aurora Shareholders, and in the case of Organigram, the Organigram Shareholders and the holders of Organigram Preferred Shares, than the Arrangement (in the case of Aurora, after taking into account any change to the Arrangement proposed by Organigram pursuant to Section 7.4(b) and/or Section 7.4(f) of the Arrangement Agreement);

provided, however, that the Hostile Bid shall be deemed not to be, and may not constitute, a Superior Proposal for any purpose of the Arrangement Agreement (recognizing that any and each Amended Bid may constitute a Superior Proposal provided such Amended Bid complies with this definition);

"**Superior Proposal Notice**" has the meaning ascribed thereto under the heading "*Effect of the Arrangement – The Arrangement Agreement – Covenants Regarding Non-Solicitation*";

"**Supplementary Information Request**" has the meaning ascribed thereto under the heading "*Procedure for the Arrangement to Become Effective – Regulatory Approvals – Competition Act Approval*";

"**Supporting Aurora Shareholders**" means all of the directors and executive officers of Aurora;

"**Supporting Organigram Shareholders**" means BAT and each of the directors and executive officers of Organigram who hold Organigram Common Shares;

"**Tax**" or "**Taxes**" means all taxes, duties, fees, premiums, assessments, imposts, levies and other charges of any kind whatsoever, however denominated, together with any interest, penalties or other additions that may become payable in respect thereof, imposed by any Governmental Entity, which taxes shall include, without limiting the generality of the foregoing, all income or profits taxes (including federal, provincial and state income taxes), capital taxes, payroll and employee withholding taxes, gasoline and fuel taxes, employment insurance, social insurance taxes (including Canada Pension Plan payments), sales and use taxes (including goods and services, harmonized sales, provincial or territorial sales tax), ad valorem taxes, value-added taxes, excise taxes, franchise taxes, gross receipts taxes, business license taxes, occupation taxes, real and personal property taxes, stamp taxes, withholding, environmental taxes, carbon taxes, transfer taxes, workers' compensation premiums or charges, pension assessment and other governmental charges, customs duties and import and export taxes, and other obligations of the same or of a similar nature to any of the foregoing, which one of the Parties or any of its Subsidiaries is required to pay, withhold or collect;

"**Tax Act**" means the *Income Tax Act* (Canada), R.S.C. 1985, c. 1 (5th Supp.), as amended, including the regulations promulgated thereunder, as amended from time to time;

"**taxable capital gain**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Taxation of Capital Gains and Losses*";

"**TCP Proposals**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Not Resident in Canada – Aurora Common Shares – Taxable Canadian Property*";

"**TFSAs**" has the meaning ascribed thereto under the heading "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Eligibility for Investment*";

"**Torys**" means Torys LLP, independent legal counsel to the Aurora Special Committee;

"**Tribunal**" has the meaning ascribed thereto under the heading "*Procedure for the Arrangement to Become Effective – Regulatory Approvals – Competition Act Approval*";

"**TSX**" means The Toronto Stock Exchange;

"**TSX Company Manual**" means the TSX Company Manual, as amended;

"**TSX Trust**" means TSX Trust Company, the registrar and transfer agent for the Organigram Common Shares;

"**U.S. Exchange Act**" means the United States *Securities Exchange Act of 1934*, as amended;

"**U.S. Holder**" has the meaning ascribed thereto under the heading "*Certain United States Federal Income Tax Considerations*";

"**U.S. Securities Act**" means the United States *Securities Act of 1933*, as amended;

"**U.S. Securities Laws**" means federal and state securities legislation of the United States and all rules, regulations and orders promulgated thereunder;

"**Unaffected Date**" means August 10, 2026, being the last trading day prior to the announcement by Curaleaf of its intention to make the Original Curaleaf Bid;

"**Unaffected Price**" means $4.03, being the closing price of the Aurora Common Shares on the TSX on the Unaffected Date;

"**Unvested Aurora PSU**" means an Aurora PSU outstanding immediately prior to the Effective Time that is not a Vested Aurora PSU;

"**Updated Inadequacy Opinion**" has the meaning ascribed thereto under the heading "*The Arrangement – Background to the Arrangement*";

"**Vested Aurora PSU**" means an Aurora PSU outstanding immediately prior to the Effective Time that is vested, including any Aurora PSU that vests in accordance with its terms as a result of the Arrangement; and

"**Voting Instruction Form**" means the voting instruction form provided by an intermediary to a Beneficial Holder in lieu of a form of proxy.

Words importing the singular include the plural and vice versa and words importing any gender include all genders.

CONVENTIONS

Certain terms used herein are defined in the "*Glossary of Terms*". Unless otherwise indicated, references herein to "$" or "dollars" are to Canadian dollars and references herein to "US$" or "U.S. dollars" are to United States dollars. All financial information in Appendices "H", "I" and "J" to this Joint Information Circular has been presented in Canadian dollars in accordance with IFRS.

JOINT INFORMATION CIRCULAR

Introduction

This Joint Information Circular is furnished in connection with the solicitation of proxies by the management of Aurora and Organigram for use at the Aurora Shareholders' Meeting and the Organigram Shareholders' Meeting, respectively, and at any adjournment(s) or postponement(s) thereof. No person has been authorized to give any information or make any representation in connection with the Arrangement and the issuance of Organigram Common Shares in connection with the Arrangement, or any other matters to be considered at the Aurora Shareholders' Meeting and Organigram Shareholders' Meeting other than those contained in this Joint Information Circular, and if given or made, any such information or representation must not be relied upon as having been authorized.

The information concerning Aurora contained and incorporated by reference in this Joint Information Circular, including, but not limited to, the information in Appendix "I" to this Joint Information Circular, has been provided by Aurora. Although Organigram has no knowledge that would indicate that any of such information is untrue or incomplete, Organigram does not assume any responsibility for the accuracy or completeness of such information or the failure by Aurora to disclose events which may have occurred or may affect the completeness or accuracy of such information but which are unknown to Organigram.

The information concerning Organigram contained and incorporated by reference in this Joint Information Circular, including, but not limited to, the information in Appendix "J" to this Joint Information Circular, has been provided by Organigram. Although Aurora has no knowledge that would indicate that any of such information is untrue or incomplete, Aurora does not assume any responsibility for the accuracy or completeness of such information or the failure by Organigram to disclose events which may have occurred or may affect the completeness or accuracy of such information but which are unknown to Aurora.

This Joint Information Circular does not constitute an offer to sell or a solicitation of an offer to purchase any securities or the solicitation of a proxy by any person in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such an offer or solicitation of an offer or a proxy solicitation. Neither the delivery of this Joint Information Circular nor any distribution of the securities referred to in this Joint Information Circular will, under any circumstances, create an implication that there has been no change in the information set forth herein since the date as of which such information is given in this Joint Information Circular.

Information contained in or otherwise accessed through Aurora's website or Organigram's website, or any other website, other than those documents incorporated by reference herein and filed on SEDAR+ and EDGAR, does not constitute part of this Joint Information Circular.

All summaries of, and references to, the Arrangement Agreement, the Arrangement and the Plan of Arrangement in this Joint Information Circular are qualified in their entirety by reference to the complete text of the Arrangement Agreement, which is incorporated by reference in this Joint Information Circular, and may be viewed on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. A copy of the Plan of Arrangement is attached as Appendix "C" to this Joint Information Circular. **You are urged to carefully read the full text of the Arrangement Agreement and the Plan of Arrangement.**

All capitalized terms used in this Joint Information Circular (including Appendices "H", "I" and "J" hereto) but not otherwise defined herein have the meanings set forth herein under "*Glossary of Terms*". The terms and abbreviations used in the Appendices to this Joint Information Circular, other than in Appendices "H", "I" and "J", are defined separately therein. Details of the Arrangement are set forth under the headings "*The Arrangement*" and "*Effect of the Arrangement*". For details of the matters to be considered by the Aurora Shareholders at the Aurora Shareholders' Meeting and the Organigram Shareholders at the Organigram Shareholders' Meeting, see "*Matters to be Considered at the Aurora Shareholders' Meeting*" and "*Matters to be Considered at the Organigram Shareholders' Meeting*", respectively.

Notice of Potential Amendments, Revisions, Updates and Supplements to Meeting Materials

Information contained in this Joint Information Circular is given as of November 19, 2026, unless otherwise specifically stated. Aurora Shareholders and Organigram Shareholders are advised that, pursuant to the Interim Order, Aurora and Organigram may give notice of any amendments, revisions, updates or supplements to any of the information contained in the Meeting Materials by disseminating a press release in accordance with applicable Laws. Following the dissemination of any such press release, the Meeting Materials to which such press release relates shall be deemed to have been so amended, revised, updated or supplemented without any further act or formality. As such, Aurora and Organigram may amend the Meeting Materials without delivering to Aurora Shareholders or Organigram Shareholders, as applicable, an amendment to such Meeting Materials. Aurora Shareholders and Organigram Shareholders are advised that any such amendment, revision, update or supplement may be material. Accordingly, Aurora Shareholders and Organigram Shareholders are encouraged to regularly monitor Aurora's and Organigram's respective websites and SEDAR+ profiles at www.sedarplus.ca and www.sec.gov, where any such press release will be posted and filed, respectively.

Supplemental Disclosure – Non-IFRS Measures

Certain financial measures in this Joint Information Circular, including under the headings "*Summary – Reasons for and Benefits of the Arrangement*" (including under the subheadings "*Additional Reasons and Benefits for Aurora Shareholders*" and "*Additional Reasons and Benefits for Organigram Shareholders*"), in Appendix "I" – "*Information Concerning Aurora Cannabis Inc.*" and in certain documents incorporated by reference herein, including adjusted EBITDA, adjusted gross margin, free cash flow and net debt (collectively, the "**Non-IFRS Measures**"), are not measures recognized by IFRS.

These non-IFRS measures do not have standardized meanings prescribed by IFRS and therefore may not be comparable to similar measures presented by other entities. Readers are cautioned that these non-IFRS measures should not be construed as alternatives to other measures calculated in accordance with IFRS. These measures have been described and presented in order to provide Shareholders, potential investors and analysts with additional information for assessing the Arrangement, including the reasons for and benefits thereof. Aurora and Organigram consider these non-IFRS measures to be important indicators in evaluating the performance of Aurora, Organigram and their respective businesses, as applicable. As non-IFRS measures do not have a standardized meaning, applicable securities Laws require that non-IFRS measures be clearly defined, qualified and reconciled to their most directly comparable IFRS measure. See the "*Non-GAAP Financial Measures*" section in the Aurora Annual MD&A and the "*Non-GAAP Measures*" section in the Organigram Annual MD&A for further information on the definition, calculation and reconciliation of the Non-IFRS Measures used by Aurora and Organigram, respectively.

Information for United States Securityholders

The Organigram Common Shares and the Replacement Options under the Arrangement have not been and will not be registered under the U.S. Securities Act or any U.S. state securities laws, and such securities are intended to be issued in reliance upon the exemption from the registration requirements of the U.S. Securities Act provided by section 3(a)(10) thereof.

Section 3(a)(10) of the U.S. Securities Act exempts the issuance of any security issued in exchange for one or more bona fide outstanding securities, claims or property interests, or partly in such exchange and partly for cash, from the registration requirements of the U.S. Securities Act where the terms and conditions of the issuance and exchange have, after a hearing upon their fairness to the persons to whom the securities are proposed to be issued, been approved by a court authorized to hold such hearing and grant such approval, provided that all such persons have the right to appear at the hearing, and receive timely notice thereof. The Court is authorized to conduct a hearing at which the substantive and procedural fairness of the terms and conditions of the Arrangement will be considered and to grant approval thereof. The Court issued the Interim Order on November 20, 2026. Subject to receipt of the requisite shareholder approvals, a hearing for the Final Order approving the Arrangement is expected to be held on December 30, 2026 (or as soon thereafter as legal counsel can be heard). All persons to whom securities are proposed to be issued in reliance on section 3(a)(10), including Aurora Shareholders and holders of Aurora Options receiving Replacement Options, are entitled to appear and be heard at that hearing, subject to the applicable procedural requirements of the Interim Order and the notice of hearing. See "*Procedure for the Arrangement to Become Effective – Court Approval*". The

Final Order, if granted, will constitute the basis for the Section 3(a)(10) exemption with respect to the Organigram Common Shares and Replacement Options issuable pursuant to the Arrangement.

Organigram Common Shares to be received by Aurora Shareholders pursuant to the Arrangement generally may be resold without registration in the United States, except in respect of resales by persons who are "affiliates" of Organigram within the meaning of Rule 144 under the U.S. Securities Act at the time of such resale or who have been affiliates of Organigram within 90 days before such resale (such shares, "Control Shares"). Further, Organigram Common Shares issuable upon exercise of Replacement Options after the Effective Time will not be issued in reliance upon Section 3(a)(10) of the U.S. Securities Act and may be issued only pursuant to an effective registration statement under the U.S. Securities Act or an available exemption from registration, and in compliance with applicable U.S. state securities laws. Shares issued upon such exercise in reliance on an exemption may be "restricted securities" within the meaning of Rule 144 and may be subject to transfer restrictions, depending on the exemption relied upon. See "*Procedure for the Arrangement to Become Effective – Securities Law Matters – United States*". This discussion does not apply to securities issued pursuant to the BAT Private Placement.

Each of Aurora and Organigram is a "foreign private issuer" within the meaning of Rule 3b-4 under the U.S. Exchange Act, and the solicitation of proxies for the Aurora Shareholders' Meeting and the Organigram Shareholders' Meeting is exempt from the requirements of Section 14(a) of the U.S. Exchange Act pursuant to Rule 3a12-3(b) thereunder. Accordingly, this Joint Information Circular has been prepared solely in accordance with disclosure requirements applicable in Canada. Securityholders in the United States should be aware that such requirements are different from those of the United States applicable to registration statements under the U.S. Securities Act and proxy statements under the U.S. Exchange Act.

Information concerning the assets and operations of Aurora and Organigram contained or incorporated by reference in this Joint Information Circular has been prepared in accordance with the requirements of Canadian securities laws, which differ from the requirements of United States securities laws. The financial statements and other financial information of Aurora and Organigram included or incorporated by reference in this Joint Information Circular have been prepared in accordance with IFRS, as issued by the International Accounting Standards Board, which differs from United States generally accepted accounting principles in certain material respects, and thus may not be directly comparable to financial statements of United States companies prepared in accordance with United States generally accepted accounting principles.

Aurora Shareholders subject to United States federal income taxation should be aware that the description of tax consequences to them of the Arrangement under certain United States federal income tax laws provided in this Joint Information Circular is a summary only. They are advised to consult their tax advisors to determine the particular tax consequences to them of participating in the Arrangement and the ownership and disposition of Organigram Common Shares acquired pursuant to the Arrangement.

The enforcement by Aurora Shareholders and Organigram Shareholders of civil liabilities under United States federal and state securities laws may be affected adversely by the fact that: (a) Aurora is organized under the laws of British Columbia, Canada and Organigram is organized under the federal laws of Canada; (b) some or all of their officers and directors are residents of countries other than the United States; (c) some of the experts named in this Joint Information Circular are residents of countries other than the United States; and (d) a substantial portion of the assets of Organigram, Aurora and such persons are located outside the United States. As a result, it may be difficult or impossible for Aurora Shareholders and Organigram Shareholders in the United States to effect service of process within the United States upon Organigram and Aurora, as applicable, and their respective directors or officers, or to realize against them upon judgments of courts of the United States predicated upon civil liabilities under the federal securities laws of the United States or the securities laws of any state within the United States. In addition, Aurora Shareholders and Organigram Shareholders in the United States should not assume that the courts of Canada: (a) would enforce judgments of United States courts obtained in actions against such persons predicated upon civil liabilities under the federal securities laws of the United States or the securities laws of any state within the United States; or (b) would enforce, in original actions, liabilities against such persons predicated upon civil liabilities under the federal securities laws of the United States or the securities laws of any state within the United States.

No broker, dealer, salesperson or other person has been authorized to give any information or make any representation other than those contained in this Joint Information Circular and, if given or made, such information or representation must not be relied upon as having been authorized by Organigram or Aurora.

ORGANIGRAM COMMON SHARES AND REPLACEMENT OPTIONS ISSUABLE PURSUANT TO THE ARRANGEMENT HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR THE SECURITIES REGULATORY AUTHORITY OF ANY STATE OF THE UNITED STATES, NOR HAS THE SEC OR ANY SUCH STATE SECURITIES REGULATORY AUTHORITY PASSED UPON THE ACCURACY OR ADEQUACY OF THIS JOINT INFORMATION CIRCULAR. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENCE.

Important Notice to Aurora Shareholders in the European Union

This Joint Information Circular and the accompanying Letter of Transmittal and Election Form have not been prepared under Regulation (EU) 2017/1129 (the "EU Prospectus Regulation") or any measure implementing it in an EU Member State. They are not a prospectus or, in particular, an exemption document within the meaning of Article 1(4)(f) or (g) of the EU Prospectus Regulation. No competent authority in any EU Member State has reviewed or approved this Joint Information Circular or the Letter of Transmittal and Election Form.

Exchange Rate Information

The following table sets forth, for each period indicated: (a) the rate of exchange for one U.S. dollar, expressed in Canadian dollars, in effect at the end of the period; and (b) the average, high and low exchange rates during the period, in each case based on the daily average exchange rate published on the Bank of Canada's website as being in effect on each trading day.

	Nine Months Ended June 30	Year ended September 30	
	2026	**2025**	**2024**
Rate at End of Period	$1.4210	$1.3921	$1.3499
Average Rate During Period	$1.3836	$1.3986	$1.3609
High	$1.4234	$1.4603	$1.3875
Low	$1.3515	$1.3491	$1.3205

On November 19, 2026, the Bank of Canada daily average exchange rate for US$1.00 was C$1.4317.

FORWARD-LOOKING STATEMENTS AND INFORMATION

Certain statements contained in this Joint Information Circular (including in Appendices "H", "I" and "J" to this Joint Information Circular) and in the documents incorporated by reference herein constitute forward-looking statements and forward-looking information (collectively referred to as "**forward-looking statements**") within the meaning of applicable Canadian Securities Laws and applicable U.S. Securities Laws, including the U.S. *Private Securities Litigation Reform Act of 1995*, that are based on Organigram's and Aurora's current expectations, estimates, projections and assumptions about the future in light of their experiences and perceptions of historical trends. Although Organigram and Aurora believe that the expectations represented by such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "continue", "estimate", "expect", "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "would", "believe", "develop", "create", "budget", "scheduled", "forecast", "pro forma", and similar expressions suggesting future events, performance or outcomes, or the negative thereof or other variations thereof (including "does not expect" and "does not anticipate").

In particular, this Joint Information Circular (including Appendices "H", "I" and "J" to this Joint Information Circular) contains forward-looking statements pertaining to, without limitation, the following:

- the expected structure, procedural steps, timing and effect of the Arrangement;
- the anticipated benefits and value of the Arrangement to Organigram's and Aurora's respective securityholders, customers and stakeholders, both generally and, in the case of Aurora Shareholders, in comparison to the Hostile Bid;
- the anticipated synergies and cost savings associated with the Arrangement (including strategic integration and diversification opportunities) and the expected size, sources, timing, sustainability and effects thereof, as well as the plans and strategies to achieve such synergies;
- the respective aggregate shareholdings of former Aurora Shareholders and current Organigram Shareholders in Organigram following the completion of the Arrangement;
- pro forma information, including pro forma financial and operational information pertaining to Organigram after giving effect to the Arrangement;
- the characteristics of Organigram following the completion of the Arrangement, including its expected size, scale, valuation, capacity, cash flows, profitability, share capital, asset base, funding capabilities, product development capabilities, growth opportunities, market access, market position, competitiveness and ability to service customers;
- the attributes of the Organigram Common Shares, including the liquidity thereof;
- the composition of the Organigram Board and management of Organigram following the completion of the Arrangement;
- Organigram's auditors, registrar and transfer agent following the completion of the Arrangement;
- the impact of the Arrangement on the financial position and earnings profile of Organigram following the completion of the Arrangement;
- Organigram's capacity and opportunities to pursue growth opportunities in Canada and internationally following the completion of the Arrangement, as well as the anticipated nature, size, timing, risk profile and impact thereof;
- the ongoing utilization and expansion of, and additions to, Organigram's business and asset base, growth and growth potential following the completion of the Arrangement;
- financial results related to growth and expansion opportunities associated with the assets of Organigram following the completion of the Arrangement;
- the BAT Private Placement, including the expected size, timing, pricing and effect thereof, and BAT's expected economic and voting interest in Organigram following completion of the Arrangement;
- the expected impacts of past and future investments by Organigram and Aurora;
- the Curaleaf subordinate voting shares that Aurora Shareholders would receive under the Hostile Bid, including the characteristics thereof and tax consequences associated therewith;

- the Canadian and U.S. federal income tax consequences of the Arrangement applicable to Aurora Shareholders, both generally and in comparison to the expected tax consequences associated with the Hostile Bid;
- the anticipated treatment of the Arrangement, Organigram Shareholders and Aurora Shareholders under securities Laws, including the approvals required under the TSX Company Manual and MI 61-101 and the exclusion of votes for purposes thereof;
- the listing of the Organigram Common Shares issuable pursuant to the Arrangement on the TSX and the Nasdaq, and the timing thereof;
- the delisting of the Aurora Common Shares from the TSX and the Nasdaq, Aurora ceasing to be a reporting issuer, and the timing thereof;
- the elections by Aurora Shareholders among the Cash Alternative, the Share Alternative and the Combination Alternative, the application of proration and the form and amount of Consideration ultimately received by Aurora Shareholders;
- the Organigram Financing, including the ATB Credit Facilities and the BAT Private Placement, and the use of proceeds thereof;
- expectations regarding the receipt of third-party approvals required in connection with the Arrangement, including Shareholder approvals, stock exchange approvals, Court approval and Regulatory Approvals (including the Required Regulatory Approvals), and the timing thereof;
- the likelihood of meaningful regulatory challenges to the Arrangement and the expected impact of certain provisions of the Arrangement Agreement in relation to the prospects of any such challenge;
- the effect of the Arrangement on the vesting, settlement and payout of Aurora Incentive Awards;
- the expected costs associated with the treatment of outstanding Aurora Incentive Awards and any change of control, severance or similar payments to directors, officers and employees of Aurora in connection with the Arrangement;
- the anticipated application for the Final Order and the filing with the Registrar of the records and information required under section 292 of the BCBCA, including the content and timing of such application, the considerations of the Court in granting the Final Order, and the effect of the Final Order;
- the timing, administration, format and conduct of the Meetings and the means by which Organigram Shareholders and Aurora Shareholders may vote and participate at the Organigram Shareholders' Meeting and the Aurora Shareholders' Meeting, respectively;
- the expected effect of the Aurora Termination Fee and other deal protection provisions of the Arrangement Agreement, including whether such provisions would preclude a third party from making a Superior Proposal;
- the availability of the exemption from the registration requirements of the U.S. Securities Act provided by Section 3(a)(10) thereof in respect of the Organigram Common Shares and Replacement Options issuable pursuant to the Arrangement, and the absence of resale restrictions on such Organigram Common Shares under applicable Canadian Securities Laws (subject to certain limitations);
- the anticipated Effective Date and Outside Date, and the timing of the expiry of any applicable waiting periods under the Competition Act and other Regulatory Approvals;

- the solicitation of proxies by or on behalf of management of Aurora and Organigram, including by any proxy solicitation agent;
- the payment of future dividends on, and the market price of, the Organigram Common Shares;
- the plans, priorities and focus of Organigram following the completion of the Arrangement and the anticipated benefits thereof;
- the anticipated announcement by Organigram of its financial results for the fiscal year and fourth quarter ended September 30, 2026, and the timing thereof;
- the Aurora Shareholder Rights Plan and its treatment under the Arrangement; and
- the ability to enforce civil liabilities under U.S. Securities Laws against Organigram, Aurora and their respective officers and directors and the ability to effect service of process or realize judgments against Organigram and Aurora.

The respective reports of PKF O'Connor Davies, LLP, Organigram's former auditors, and Ernst & Young LLP, Aurora's auditors, incorporated by reference in this Joint Information Circular refer exclusively to the historical financial statements described therein and do not extend to the prospective financial information included in this Joint Information Circular and should not be read to do so.

Developing forward-looking statements involves reliance on a number of expectations and assumptions, as well as the consideration of certain risks and uncertainties, some of which are specific to each of Organigram (both before and after giving effect to the Arrangement) and Aurora, while others apply to the Relevant Business more generally. In particular, the forward-looking statements included in this Joint Information Circular (including Appendices "H", "I" and "J" to this Joint Information Circular) are based on expectations and assumptions regarding, among other things:

- the perceived benefits of the Arrangement and the expected attributes of Organigram after giving effect to the Arrangement;
- the ability of Organigram and Aurora to satisfy the conditions to closing of the Arrangement in a timely manner and substantially on the terms described in this Joint Information Circular;
- the adherence to the terms of the Arrangement Agreement and agreements related to the Arrangement Agreement, including the Aurora Support Agreements, the Organigram Support Agreements and the Financing Commitments;
- that the results of operations of Organigram following the completion of the Arrangement will be consistent with past performance and management expectations in relation thereto;
- that the expected synergies associated with the Arrangement will materialize in the manner described in this Joint Information Circular;
- Organigram's ability to successfully integrate the business of Aurora with its own;
- the achievement of further cost reductions and the sustainability thereof;
- the ability of Organigram to realize the anticipated innovation, scale and capital markets benefits of the Arrangement;

- that favourable circumstances continue to exist in respect of current operations and current and future growth initiatives, including demand for and pricing of medical and adult-use cannabis products in Canada, Germany and other international markets;
- the maintenance and renewal of all licences, permits and authorizations required to cultivate, process, import, export and sell cannabis products, including under the *Cannabis Act* (Canada) and applicable German and other foreign Laws;
- prevailing regulatory and tax Laws and regulations, including Laws relating to cannabis;
- that there will be no unanticipated changes to prevailing legal and regulatory regimes that could or would be expected to have a material adverse effect on Organigram, Aurora or Organigram after giving effect to the Arrangement, or any of their respective assets and operations;
- that the Organigram Financing, including the BAT Private Placement and the ATB Credit Facilities, will be completed on the terms and within the timing currently anticipated, including receipt of all required approvals;
- projected capital investment levels (both generally and as may be required to achieve the synergies associated with the Arrangement discussed in this Joint Information Circular), the flexibility of capital spending plans and associated sources and availability of funding;
- future cash flows, cash balances on hand and access to credit and demand facilities being sufficient to fund capital investments;
- Organigram's ability to finance its operations through the issuance of debt and equity securities on favourable terms following the completion of the Arrangement;
- prevailing interest rates, tax rates and exchange rates (including the exchange rate between the Canadian dollar, the U.S. dollar, the pound sterling and the euro);
- inflation and other assumptions inherent in the current guidance of Organigram and Aurora;
- future operating costs;
- that any required commercial agreements can be reached;
- that all required regulatory approvals (including the Required Regulatory Approvals) can be obtained on the necessary terms and in a timely manner;
- that all of the requirements of the TSX and the Nasdaq, as applicable, in regards to the listing of the Organigram Common Shares issuable pursuant to the Arrangement on the TSX and the Nasdaq and the delisting of the Aurora Common Shares from the TSX will be satisfied on the necessary terms and in a timely manner;
- that the minimum listing requirements of the Nasdaq in respect of the Organigram Common Shares will continue to be met;
- that counterparties will comply with contracts in a timely manner;
- that the information currently available to each of Organigram and Aurora regarding the other Party and regarding Curaleaf is accurate and complete;

- that the Hostile Bid, any Amended Bid or any other competing proposal will not materially impact the Arrangement, the required approvals or the respective businesses of Organigram and Aurora or their key stakeholder relationships;
- that no litigation relating to the Arrangement will be instituted against Organigram or Aurora;
- the absence of adverse reactions or changes to the business relationships of Organigram or Aurora, including with employees, suppliers, customers and competitors, resulting from the completion of the Arrangement;
- certain steps in, and the timing of, the Arrangement and the Effective Date, which are based upon the terms of the Arrangement Agreement and advice received from external counsel relating to timing expectations;
- that there will be no material change to, or material adverse change in, the business or operations of Organigram or Aurora prior to the completion of the Arrangement;
- the number of Aurora Incentive Awards to be exercised or settled prior to the Effective Time;
- that there are no unforeseen events preventing the performance of contracts or the operation of the relevant facilities;
- that there are no unforeseen material costs relating to the relevant facilities or operations;
- maintenance of operating margins;
- the amount of future liabilities relating to lawsuits, product liability claims, product recalls or other regulatory obligations that may, from time to time, arise;
- the availability of coverage under Organigram's insurance policies (including in respect of Organigram's business interruption insurance policy); and
- accounting estimates and judgments.

In addition, the forward-looking statements concerning the treatment of Aurora Shareholders under tax Laws are based on, and subject to, the expectations, assumptions and qualifications discussed under the headings "*Certain Canadian Federal Income Tax Considerations*" and "*Certain United States Federal Income Tax Considerations*".

Although Organigram and Aurora believe that the expectations and material factors and assumptions reflected in these forward-looking statements are reasonable as of the date hereof, there can be no assurance that these expectations, factors and assumptions will prove to be correct. These forward-looking statements are not guarantees of future performance and are subject to a number of known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements, including, but not limited to:

- Organigram and Aurora may not receive, or obtain waivers in respect of, in a timely manner or at all, the necessary third-party approvals and other conditions required in connection with the Arrangement, including Shareholder approvals, stock exchange approvals, Court approval and Required Regulatory Approvals (including the Competition Act Approval), and, as a result, the Arrangement may not be completed within the anticipated time, on the terms currently proposed and disclosed in this Joint Information Circular or at all;
- the timing of the Meetings, the Final Order and the Effective Date may be changed or delayed or may not occur at all;
- potential actions by Aurora Shareholders or Organigram Shareholders in opposition to the Arrangement, including the exercise of Dissent Rights by Aurora Shareholders;

- there may be unforeseen or unexpected tax and other consequences of the Arrangement that could have a material adverse effect on Organigram following the completion of the Arrangement;
- potential adverse reactions or changes to the business relationships of Organigram or Aurora, including with employees, suppliers, customers, competitors and shareholders, resulting from the announcement or completion of the Arrangement, and the ability to maintain relationships with partners and to successfully manage and operate the combined business;
- forward-looking statements and future-oriented financial information contained in this Joint Information Circular may prove to be inaccurate;
- health epidemics, pandemics and other outbreaks of communicable diseases, which may delay or prevent the completion of the Arrangement or adversely affect the business of Organigram and Aurora;
- the failure to realize, or the failure to realize within the expected timeframes, the anticipated benefits and synergies associated with the Arrangement due to integration issues or otherwise;
- the failure to access or implement some or all of the technology necessary to efficiently and effectively operate the assets of Organigram following the completion of the Arrangement and achieve expected future results related thereto;
- lower than anticipated results of operations from Organigram's and Aurora's respective business initiatives;
- the estimates, assumptions, limitations, analysis, conclusions and materials (including the Aurora Fairness Opinions and the Organigram Fairness Opinion) that informed the reasons for, and benefits of, the Arrangement discussed in this Joint Information Circular may be incorrect or may have been given an improper weight;
- the pro forma financial and operational information of Organigram after giving effect to the Arrangement may prove to be inaccurate;
- litigation relating to the Arrangement may prevent, delay or give rise to significant costs or liabilities on the part of Organigram (either before or after giving effect to the Arrangement) or Aurora;
- dilution and share price volatility, including a material decrease in the trading price or liquidity of the Organigram Common Shares;
- increased costs, delays, suspensions and technical challenges associated with capital projects and facility operations;
- adverse changes to the Laws applicable to the Relevant Business, including the *Cannabis Act* (Canada) and applicable German and other foreign cannabis Laws, and the suspension, revocation, non-renewal or adverse modification of any licence required to carry on the business of Organigram or Aurora;
- interloper risk, including actions taken by Governmental Entities or others (including Curaleaf) seeking to prevent or alter the terms of the Arrangement, or claim monetary damages as a result of the Arrangement, or competing offers for Aurora that arise as a result of, or in connection with, the Arrangement, including the Hostile Bid and any variations, changes or amendments thereto;
- the Arrangement Agreement could be terminated by either Party under certain circumstances and, as a result, the Arrangement may not be completed;

- if the Arrangement is not completed, either Party may be required to pay a termination fee to the other Party in certain circumstances, and Organigram may be required to pay the Expense Fee to Aurora if the Organigram Share Issuance Resolution is not approved;
- BAT or ATB Financial may fail to fund all or a portion of the Organigram Financing, in which case Organigram would remain obligated to complete the Arrangement and pay the aggregate cash Consideration;
- as a result of proration, Aurora Shareholders who elect the Cash Alternative or the Share Alternative may receive a combination of cash and Organigram Common Shares that differs from their election;
- if the Arrangement is not completed, neither Organigram Shareholders nor Aurora Shareholders will realize the anticipated benefits of the Arrangement and Organigram's and Aurora's respective future businesses and operations could be adversely affected;
- Organigram and Aurora will incur significant costs relating to the Arrangement, regardless of whether the Arrangement is completed, which may have a negative impact on their respective financial positions;
- the focus of management's time and attention on the Arrangement may detract from other aspects of the respective businesses of Organigram and Aurora;
- actions by Governmental Entities, including changes in tax Laws and treatment, changes in excise duties, product restrictions or other cannabis regulation, as well as costs associated with compliance therewith;
- Organigram, either before or following the completion of the Arrangement, may be unable to secure, on favourable terms, the necessary sources and amounts of debt and equity capital to finance its growth projects and other capital expenditures;
- Organigram may be unable to utilize and apply, or carry forward, as applicable, tax losses and other tax attributes in the future;
- the Parties may discover previously undisclosed liabilities following the Effective Date;
- adverse general economic and market conditions in Canada, Germany, North America and worldwide (both generally and in relation to the cannabis industry in particular), including changes, or prolonged weaknesses, as applicable, in interest rates, foreign currency exchange rates, inflation, tariffs, product pricing, supply/demand trends and overall industry activity levels;
- the political environment in North America, Europe and elsewhere, and public opinion;
- the potential exposure to political, economic, or social instability in certain jurisdictions in which Organigram will operate following the completion of the Arrangement;
- Organigram's and Aurora's operations, either before or following the completion of the Arrangement, as applicable, near communities may cause such communities to regard their operations as being detrimental to them;
- labour shortages and shortages of the materials required to operate Organigram's and Aurora's respective businesses;
- the unavailability of, and constraints on, adequate cultivation, processing and distribution capacity;
- non-performance or default by counterparties to agreements which Organigram, Aurora or one or more of their respective affiliates has entered into in respect of its business;

- customer demand for the products and services of Organigram following the completion of the Arrangement;
- competition, and the effects of competition and pricing pressures;
- reliance on key relationships and agreements;
- reliance on key employees, including the risk that Organigram may not be able to retain key employees following completion of the Arrangement in a timely manner, on favourable terms, or at all;
- reliance on third parties to successfully operate and maintain certain assets;
- fluctuations in operating results;
- counterparty credit risk;
- technology and cybersecurity risks;
- risk of loss and increased cost due to natural catastrophes, acts of war, terrorism, sabotage, civil disturbances, fires, equipment failures, crop failures or contamination, extreme weather events, technological changes and resource shortages or similar events, including those related to climate change; and
- certain other risks detailed from time to time in Organigram's public disclosure documents available at www.sedarplus.ca, www.sec.gov and through Organigram's website at www.organigram.ca, and in Aurora's public disclosure documents available at www.sedarplus.ca, www.sec.gov and through Aurora's website at www.auroramj.com.

With regard to the forward-looking statements in Aurora's and Organigram's documents incorporated by reference herein and unless otherwise stated therein, please refer to the forward-looking statements advisories in such documents in respect of the forward-looking statements contained therein, the assumptions upon which they are based and the risk factors in respect of such forward-looking statements.

Certain information in this Joint Information Circular, including the estimates of adjusted EBITDA margin and free cash flow, may be considered to be future oriented financial information or financial outlook for the purposes of applicable Canadian Securities Laws. Any future oriented financial information or financial outlook contained in this Joint Information Circular about prospective financial performance, financial position or cash flows is based on assumptions about future events, including economic conditions and proposed courses of action, based on the assessment by management of each of Organigram and Aurora of the relevant information currently available, and to become available in the future. These projections constitute forward-looking statements and are based on a number of material assumptions and factors set out above. Actual results may differ significantly from the projections presented herein. See above for a discussion of the risks that could cause actual results to vary. The future-oriented financial information or financial outlook contained in this Joint Information Circular have been approved by management as of the date of this Joint Information Circular. Readers are cautioned that any such future oriented financial information or financial outlook contained herein should not be used for purposes other than those for which it is disclosed herein. Organigram, Aurora and their respective management groups believe that the prospective financial information has been prepared on a reasonable basis, reflecting management's best estimates and judgments, and represents, to the best of management's knowledge and opinion, Organigram's expected course of action. However, because this information is highly subjective, it should not be relied on as necessarily indicative of future results. Unless otherwise stated herein, all such information was made as of the date of this Joint Information Circular.

Readers are cautioned that the foregoing lists of factors should not be construed as exhaustive. Events or circumstances could cause actual results to differ materially from those estimated, predicted, forecasted or projected and expressed in, or implied by, such forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this Joint Information Circular and in the documents incorporated by reference herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained in this Joint Information Circular and in the documents incorporated by

reference speak only as of the date of the document in which they are contained. Except as required by Law, neither Aurora nor Organigram undertakes any obligation to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Forward-looking statements regarding the percentage of Organigram Common Shares expected to be held by former Aurora Shareholders, current Organigram Shareholders and BAT immediately following the completion of the Arrangement have been calculated based on the number of Aurora Common Shares and Organigram Common Shares outstanding as of November 19, 2026.

Certain of the forward-looking statements and other information contained herein concerning the cannabis industry and Organigram's and Aurora's general expectations concerning the cannabis industry, Organigram and Aurora are based on estimates prepared by Organigram or Aurora using data from publicly available industry sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which both Organigram and Aurora believe to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, this data is inherently imprecise. While Organigram and Aurora are not aware of any misstatement regarding any industry data presented herein, the cannabis industry involves risk and uncertainties that are subject to change based on various factors.

Readers should also carefully consider the matters discussed under the headings "*Risk Factors*", "*Certain Canadian Federal Income Tax Considerations*", "*Certain United States Federal Income Tax Considerations*" and other risks described elsewhere in this Joint Information Circular and in the documents incorporated by reference herein, as they may cause actual results to differ materially from those contemplated by such forward-looking statements. In particular, readers are encouraged to carefully review and consider the matters discussed in Appendices "H", "I" and "J", the Aurora AIF, the Organigram AIF, the Aurora Annual MD&A, the Aurora Interim MD&A, the Organigram Annual MD&A and the Organigram Interim MD&A, each of which is incorporated by reference herein. Additional information on these and other factors that could affect the operations or financial results of Aurora or Organigram (both before and after giving effect to the Arrangement) is included in documents on file with applicable Canadian Securities Administrators and may be accessed on Aurora's and Organigram's respective issuer profiles through the SEDAR+ website (www.sedarplus.ca) and EDGAR website (www.sec.gov). Such documents, unless expressly incorporated by reference herein, do not form part of this Joint Information Circular.

INFORMATION FOR BENEFICIAL HOLDERS

The information set forth in this section is of significant importance to many Shareholders, as a substantial number of such Shareholders do not hold Aurora Common Shares or Organigram Common Shares in their own name. Beneficial Holders should note that only proxies deposited by Shareholders whose names appear on the records of the registrar and transfer agent for Aurora or Organigram, as applicable, as the registered holders of Shares can be recognized and acted upon at the Meetings, as applicable. If Shares are listed in an account statement provided to a Shareholder by a broker, then, in almost all cases, those Shares will not be registered in a holder's name on the records of Aurora or Organigram. Such Shares will most likely be registered in the name of either (a) the holder's broker, investment dealer, bank, trust company, custodian, nominee or other intermediary that the Beneficial Holder deals with in respect of the Shares; or (b) a clearing agency of which the intermediary is a participant. In Canada, the vast majority of such shares are registered under the name of CDS & Co. (the registration name for CDS, which acts as nominee for many Canadian brokerage firms). Shares held by brokers or their nominees can only be voted (for or against resolutions) upon instructions of the Beneficial Holder. Without specific instructions, brokers/nominees are prohibited from voting Shares for their clients. **Beneficial Holders should therefore ensure that instructions regarding the voting of their Shares are properly communicated to their intermediary or that the Shares are duly registered in their name well in advance of the applicable Meeting.**

Applicable regulatory policies require intermediaries/brokers to seek voting instructions from Beneficial Holders in advance of shareholder meetings. Every intermediary/broker has its own mailing procedures and provides its own return instructions which should be carefully followed by Beneficial Holders in order to ensure that their Shares are voted at the applicable Meeting. Often, the form of proxy supplied to a Beneficial Holder by its broker is identical to that provided to a registered shareholder. However, its purpose is limited to instructing the registered shareholder on how to vote on behalf of the Beneficial Holder. Many brokers delegate responsibility for obtaining instructions from clients to a third-party service provider, which typically mails a Voting Instruction Form in lieu of the applicable form

of proxy. The Beneficial Holder is requested to complete and return the Voting Instruction Form in accordance with the instructions set out in it, which may include voting by mail, telephone or internet. A Beneficial Holder receiving a form of proxy or Voting Instruction Form from its broker or other intermediary (or an agent or nominee of such broker or other intermediary) cannot use that form to vote Shares directly at the applicable Meeting. Voting instructions must be communicated to the broker, intermediary, agent or nominee (in accordance with the instructions provided by it or on its behalf) well in advance of the applicable Meeting in order to have the Shares to which such instructions relate voted at the applicable Meeting. Beneficial Holders sending their completed Voting Instruction Form by mail should take into account the possibility of any mail delivery interruptions or delays. It is the responsibility of the Beneficial Holder to ensure that its voting instructions are received prior to the applicable deadline, and late voting instructions may not be accepted.

A Beneficial Holder who wishes to change or revoke its voting instructions must contact its intermediary for instructions on whether this is possible and the procedures to be followed. The change or revocation of voting instructions by a Beneficial Holder can take several days or longer to complete and, accordingly, any such action should be completed well in advance of the deadline set out in the Voting Instruction Form provided by the intermediary or its service company to ensure that it is effective.

If you are a Beneficial Holder and wish to vote at the applicable Meeting, you must insert your own name in the space provided on the Voting Instruction Form sent to you by your intermediary, follow all of the applicable instructions provided by your intermediary and register yourself as your proxyholder, as described below in Step 2. By doing so, you are instructing your intermediary to appoint you as proxyholder. It is important that you comply with the signature and return instructions provided by your intermediary. Please also see further instructions on attending and voting at the applicable Meeting under the headings "*General Proxy Matters – Aurora – How to Participate at the Aurora Shareholders' Meeting*" and "*General Proxy Matters – Organigram – How to Participate at the Organigram Shareholders' Meeting*".

For each Meeting, registering your proxyholder, or yourself as proxyholder, is an additional step to be completed after you have submitted the Voting Instruction Form, and failure to do so will result in the proxyholder, or yourself, not receiving an invite code that is required to vote at the applicable Meeting.

Step 1: Submit the Voting Instruction Form: To appoint someone other than the individuals named in the Voting Instruction Form as proxyholder, insert that person's name in the blank space provided in the Voting Instruction Form (if permitted) and follow the instructions for submitting such Voting Instruction Form. This must be completed before registering such proxyholder, which is an additional step to be completed once you have submitted the Voting Instruction Form.

If you are a Beneficial Holder located in the United States and wish to vote at the applicable Meeting or, if permitted, appoint a third party as your proxyholder, you must additionally obtain a valid legal proxy from your intermediary. Follow the instructions from your intermediary included with the legal proxy form or contact your intermediary to request a legal proxy form if you have not received one. After obtaining a valid legal proxy from your intermediary, you must then submit such legal proxy to, in the case of an Aurora Shareholder, 320 Bay Street, 14th Floor, Toronto, Ontario M5H 4A6, or, in the case of an Organigram Shareholder, 301-100 Adelaide Street West, Toronto, Ontario M5H 4H1. Requests for registration from non-registered Aurora Shareholders or non-registered Organigram Shareholders located in the United States that wish to vote at the applicable Meeting or, if permitted, appoint third parties as their proxyholders must be sent by e-mail or by courier to:

- in the case of a beneficial Aurora Shareholder: USlegalproxy@computershare.com (if by e-mail); or Computershare, 320 Bay Street, 14th Floor, Toronto, Ontario M5H 4A6 (if by courier), and in both cases, must be labelled "Legal Proxy" and received no later than the Aurora Proxy Deadline; or

- in the case of a beneficial Organigram Shareholder: 416-595-9593 (if by fax); or TSX Trust Company, 301 - 100 Adelaide Street West, Toronto ON M5H 4H1 (if by courier), and in both cases, must be labelled "Legal Proxy" and received no later than the Organigram Proxy Deadline.

Step 2: Register your proxyholder: To register a third-party proxyholder, you must:

- in the case of a beneficial Aurora Shareholder: visit https://www.computershare.com/Aurora by the Aurora Proxy Deadline and provide Computershare with the required proxyholder contact information so that Computershare may provide the proxyholder with an invite code via email; or

- in the case of a beneficial Organigram Shareholder: visit tsxtrust.com/resource/en/75 by the Organigram Proxy Deadline and provide TSX Trust with the required proxyholder contact information so that TSX Trust may provide the proxyholder with a Meeting Access Number via email.

WITHOUT AN INVITE CODE FROM COMPUTERSHARE, PROXYHOLDERS WILL NOT BE ABLE TO VOTE AT THE AURORA SHAREHOLDERS' MEETING BUT WILL BE ABLE TO PARTICIPATE AS GUESTS.

WITHOUT A MEETING ACCESS NUMBER FROM TSX TRUST, PROXYHOLDERS WILL NOT BE ABLE TO VOTE OR ASK QUESTIONS AT THE ORGANIGRAM SHAREHOLDERS' MEETING BUT WILL BE ABLE TO PARTICIPATE AS GUESTS.

Aurora Shareholders whose Aurora Common Shares are registered in the name of a broker, investment dealer, bank, trust company, custodian, nominee or other intermediary must contact their intermediary to deposit their Aurora Common Shares.

The Letter of Transmittal and Election Form is for use by registered Aurora Shareholders only. Beneficial Holders of Aurora Common Shares who wish to elect the Cash Alternative, the Share Alternative or the Combination Alternative must instruct their intermediary to make such election on their behalf and should carefully follow any instructions provided by such intermediary. Intermediaries may establish cut-off times that are earlier than the Election Deadline, and Beneficial Holders are urged to contact their intermediary and provide election instructions well in advance of such deadline. Beneficial Holders who do not provide election instructions in a timely manner will be deemed to have elected the Combination Alternative, which is not subject to proration. Beneficial Holders will receive the Consideration to which they are entitled through their account with their intermediary as soon as practicable after the Effective Date.

SUMMARY

This summary is qualified in its entirety by the more detailed information appearing elsewhere in this Joint Information Circular, including the Appendices hereto. Terms with initial capital letters in this summary are defined in the "**Glossary of Terms**" set out elsewhere in this Joint Information Circular.

The Arrangement

On November 2, 2026, Aurora and Organigram agreed to the terms and conditions of the Arrangement Agreement. Pursuant to the Arrangement Agreement, Organigram has agreed to acquire all of the issued and outstanding Aurora Common Shares under a court-approved Plan of Arrangement in accordance with the provisions of the BCBCA. If completed, the Arrangement will result in Organigram acquiring all of the Aurora Common Shares. Pursuant to the Arrangement, each Aurora Shareholder (excluding Dissenting Aurora Shareholders) will be entitled to receive the Consideration, being, at its election, the Cash Alternative, the Share Alternative or the Combination Alternative for each Aurora Common Share held, subject to proration. The Cash Alternative is $7.80 in cash, the Share Alternative is 5.8626 Organigram Common Shares and the Combination Alternative is $3.75 in cash and 3.0431 Organigram Common Shares, in each case per Aurora Common Share. The aggregate cash payable and the aggregate number of Organigram Common Shares issuable under the Arrangement are capped at the Maximum Cash Consideration and the Maximum Share Consideration, respectively, and elections of the Cash Alternative or the Share Alternative will be prorated to the extent either cap would otherwise be exceeded (provided that no holder electing the Cash Alternative will receive less cash than it would have received under the Combination Alternative). The Combination Alternative is not subject to proration.

Current Aurora Shareholders are expected to hold approximately 37% of the economic interest and 41% of the voting rights in Organigram, on a fully diluted basis, immediately after completion of the Arrangement and the BAT Private Placement.

Aurora Shareholders who wish to make an election must deposit a duly completed Letter of Transmittal and Election Form with the Depositary prior to the Election Deadline. Aurora Shareholders who do not make a valid election prior to the Election Deadline will be deemed to have elected the Combination Alternative, which is not subject to proration. See "*Effect of the Arrangement – Elections and Proration*" and "*Procedure for the Arrangement to Become Effective – Procedure for Exchange of Aurora Common Share Certificates or DRS Advices*".

See "*Effect of the Arrangement*".

Aurora Cannabis Inc.

Aurora is a corporation existing under the BCBCA. Aurora was incorporated under the BCBCA on December 21, 2006 under the name "Milk Capital Corp." and changed its name to "Aurora Cannabis Inc." effective October 2, 2014. Aurora's principal strategic business lines are focused on the production, distribution and sale of cannabis products in Canada and internationally. Aurora currently conducts the following key business activities: (a) production, distribution and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; (b) production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and (c) distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Aurora's current principal medical markets are Canada, Germany, the United Kingdom, Poland and Australia.

Aurora is a reporting issuer (or the equivalent) under the securities laws of each of the provinces of Canada. The Aurora Common Shares trade on the TSX and Nasdaq under the symbol "ACB" and are quoted on the open market of the Frankfurt Stock Exchange under the symbol "21P".

Pursuant to the Arrangement, all of the Aurora Common Shares will be acquired by Organigram. Following completion of the Arrangement, it is anticipated that the Aurora Common Shares will be delisted from the TSX and Nasdaq as promptly as practicable following the Effective Date. Under the Arrangement Agreement, Aurora has agreed to cooperate with Organigram in taking all steps required to delist the Aurora Common Shares from the TSX

and Nasdaq and to cause Aurora to cease to be a reporting issuer as promptly as practicable following the Effective Time, and Organigram intends to cause Aurora to terminate the registration of the Aurora Common Shares and its reporting obligations under the U.S. Exchange Act.

Aurora's head office and principal address is located at 2207-90B Street SW, Edmonton, Alberta T6X 0J9 and its registered office is located at Suite 1700, 666 Burrard Street, Vancouver, British Columbia V6C 2X8. See Appendix "I" – "*Information Concerning Aurora Cannabis Inc.*".

Organigram Global Inc.

Organigram is a corporation existing under the *Canada Business Corporations Act*. Organigram was incorporated under the BCBCA on July 5, 2010 as "Inform Resources Corp.", was continued under the *Canada Business Corporations Act* on April 6, 2016 and changed its name from "Organigram Holdings Inc." to "Organigram Global Inc." on March 24, 2025. Organigram Inc., a subsidiary of Organigram Global Inc., is a leading Canadian licensed producer of high quality cannabis and cannabis-derived products for consumers in Canada, and has various international business relationships that it continuously seeks to develop in order to expand its global footprint. Organigram Inc.'s core operations are based in Moncton, New Brunswick, with four additional cannabis facilities in Winnipeg, Manitoba, Lac-Supérieur, Québec, London, Ontario and Aylmer, Ontario. Through its recent acquisition of Sanity Group GmbH, Organigram also participates in the German medical cannabis market and other emerging markets within Europe.

Organigram is a reporting issuer (or the equivalent) under the securities laws of each of the provinces of Canada. The Organigram Common Shares are listed and posted for trading on the TSX and Nasdaq under the symbol "OGI".

Organigram's head office is located at 1400-145 King Street West, Toronto, Ontario M5H 1J8 and its registered office is located at 35 English Drive, Moncton, New Brunswick E1E 3X3. See Appendix "J" – "*Information Concerning Organigram Global Inc.*".

The Aurora Shareholders' Meeting

The Aurora Shareholders' Meeting will be held at 9:30 a.m. (Toronto time) on December 23, 2026, in a virtual-only format that will be conducted via live webcast accessible at meetnow.global/MQAVTRW, for the purposes set forth in the accompanying notice of special meeting. The business of the Aurora Shareholders' Meeting will be for Aurora Shareholders to consider and vote on the Arrangement Resolution. See "*The Arrangement*", "*Effect of the Arrangement*" and also see "*Matters to be Considered at the Aurora Shareholders' Meeting*".

The Aurora Record Date for determining Aurora Shareholders entitled to receive notice of, and to vote at, the Aurora Shareholders' Meeting is the close of business on November 18, 2026. Only Aurora Shareholders of record as of the Aurora Record Date are entitled to receive notice of, and to vote at, the Aurora Shareholders' Meeting.

See "*General Proxy Matters – Aurora*".

The Organigram Shareholders' Meeting

The Organigram Shareholders' Meeting will be held at 9:00 a.m. (Toronto time) on December 23, 2026, in a virtual-only format that will be conducted via live audio webcast at https://virtual-meetings.tsxtrust.com/2000 using the meeting password "ogi2026" (case sensitive), for the purposes set forth in the accompanying notice of special meeting. The business of the Organigram Shareholders' Meeting will be for Organigram Shareholders to consider and vote on the Organigram Share Issuance Resolution, approving the issuance of Organigram Common Shares pursuant to the Arrangement and to BAT pursuant to the BAT Private Placement. See "*Matters to be Considered at the Organigram Shareholders' Meeting*".

The Organigram Record Date for determining Organigram Shareholders entitled to receive notice of, and to vote at, the Organigram Shareholders' Meeting is the close of business on November 18, 2026. Only Organigram Shareholders of record as of the Organigram Record Date are entitled to receive notice of, and to vote at, the Organigram

Shareholders' Meeting. Organigram Shareholders of record will be entitled to vote those Organigram Common Shares included in the list of Organigram Shareholders prepared as at the Organigram Record Date. See "*General Proxy Matters – Organigram*".

Background to the Arrangement

The terms of the Arrangement are the result of arm's length negotiations between representatives of Aurora, including the Aurora Special Committee, and Organigram and their respective financial and legal advisors. This Joint Information Circular contains a summary of the events leading up to the negotiation of the Arrangement Agreement and the meetings, negotiations, discussions and actions by the Parties, their respective boards of directors and senior management teams that preceded the execution and public announcement of the Arrangement Agreement.

See "*The Arrangement – Background to the Arrangement – Aurora*" and "*The Arrangement – Background to the Arrangement – Organigram*".

Arrangement Agreement

The obligations of Organigram and Aurora to complete the Arrangement are subject to the satisfaction or waiver, to the extent they may be capable of waiver in accordance with the Arrangement Agreement, of certain conditions set out in the Arrangement Agreement. These conditions include, among others, approval of the Arrangement Resolution by not less than 66⅔% of the votes cast by the Aurora Shareholders at the Aurora Shareholders' Meeting and by a simple majority of such votes cast excluding the votes required to be excluded under MI 61-101; approval of the Organigram Share Issuance Resolution by greater than 50% of the votes cast by Organigram Shareholders at the Organigram Shareholders' Meeting and by greater than 50% of such votes cast excluding the votes required to be excluded under the TSX Company Manual and MI 61-101; the Interim Order and the Final Order; the conditional approval of the listing of the Organigram Common Shares issuable pursuant to the Arrangement on the TSX and the notification to the Nasdaq of the listing of such Organigram Common Shares without objection; receipt of the Required Regulatory Approvals; and no Law being in effect that makes the Arrangement illegal or otherwise prevents or prohibits its consummation. See "*Effect of the Arrangement – The Arrangement Agreement – Mutual Conditions*". It is also a condition in favour of Organigram that Dissent Rights shall not have been validly exercised, and not withdrawn, with respect to more than 10% of the issued and outstanding Aurora Common Shares, a condition in favour of Aurora that Organigram shall have deposited with the Depositary sufficient funds and Organigram Common Shares to satisfy the aggregate Consideration, and a condition in favour of each Party that no Material Adverse Effect has occurred in respect of the other Party that is continuing as of the Effective Date. See "*Effect of the Arrangement – The Arrangement Agreement – Conditions to the Obligations of Organigram*" and "*Effect of the Arrangement – The Arrangement Agreement – Conditions to the Obligations of Aurora*". Organigram's obligations under the Arrangement Agreement are not subject to any financing condition, and completion of the Arrangement is not conditional on the completion of the BAT Private Placement. Upon all such conditions being satisfied or waived in accordance with the Arrangement Agreement, Aurora is required to file with the Registrar the records and information required under section 292 of the BCBCA in order to give effect to the Arrangement.

In addition to certain covenants, representations and warranties made by each of Organigram and Aurora in the Arrangement Agreement, each of Aurora and Organigram is bound by certain reciprocal non-solicitation covenants in favour of the other Party. However, such covenants are subject to the right of the Aurora Board or the Organigram Board, as applicable, to, prior to the approval of the Arrangement Resolution or the Organigram Share Issuance Resolution, as applicable, respond to and take certain actions in furtherance of an unsolicited *bona fide* written Acquisition Proposal that constitutes or could (in the case of Aurora) or would (in the case of Organigram) reasonably be expected to lead to a Superior Proposal. The Hostile Bid is deemed not to be, and may not constitute, a Superior Proposal, although any Amended Bid may constitute a Superior Proposal. If Aurora receives a Superior Proposal, Organigram has the right to match such Superior Proposal within a period of five business days, and a new three business day matching period applies to each successive amendment to such Superior Proposal (including any Amended Bid). See "*Effect of the Arrangement – The Arrangement Agreement – Covenants Regarding Non-Solicitation*".

The Arrangement Agreement provides for the payment by Aurora to Organigram of the $25.2 million Aurora Termination Fee if the Arrangement Agreement is terminated in certain specified circumstances, including, among

other things, in the event that: (a) the Aurora Board makes an Aurora Change in Recommendation or Aurora breaches its non-solicitation covenants; (b) Aurora terminates the Arrangement Agreement to enter into a definitive agreement with respect to a Superior Proposal; or (c) the Arrangement Resolution is not approved or Aurora breaches the Arrangement Agreement, a bona fide Acquisition Proposal in respect of Aurora was made or publicly announced prior to the Aurora Shareholders' Meeting and had not expired or been publicly withdrawn at least five business days prior to the Aurora Shareholders' Meeting and, within 12 months following termination, an Acquisition Proposal in respect of Aurora (with references to 20% in the definition of Acquisition Proposal read as 50% and for purposes of (c) only, excluding the Hostile Bid unless it is changed or varied to change the amount or form of consideration offered) is consummated, or Aurora enters into a definitive agreement in respect of an Acquisition Proposal that is later consummated. The Arrangement Agreement also provides for the payment by Organigram to Aurora of the $38.4 million Organigram Termination Fee if the Arrangement Agreement is terminated in certain specified circumstances, including if the Organigram Board makes an Organigram Change in Recommendation or Organigram breaches its non-solicitation covenants, or if the Organigram Share Issuance Resolution is not approved or Organigram breaches the Arrangement Agreement, a bona fide Acquisition Proposal in respect of Organigram was made or publicly announced prior to the Organigram Shareholders' Meeting and had not expired or been publicly withdrawn at least five business days prior to the Organigram Shareholders' Meeting and, within 12 months following termination, an Acquisition Proposal in respect of Organigram (with references to 20% read as 50%) is consummated, or Organigram enters into a definitive agreement in respect of an Acquisition Proposal that is later consummated. In addition, Organigram will be required to pay Aurora the $5.6 million Expense Fee if the Arrangement Agreement is terminated because the Organigram Share Issuance Resolution is not approved. See "*Effect of the Arrangement – The Arrangement Agreement – Termination Fees*".

The Arrangement Agreement may be terminated by mutual written consent of Organigram and Aurora and by either Party in certain circumstances, including, subject to certain limitations, if the Arrangement is not consummated by the Outside Date of May 2, 2027 (which may be extended by up to two 90-day periods, not exceeding 180 days in aggregate, in certain circumstances). Organigram may also terminate the Arrangement Agreement upon an Aurora Change in Recommendation or if the Hostile Bid is consummated, and Aurora may also terminate the Arrangement Agreement upon an Organigram Change in Recommendation or, subject to Organigram's right to match and concurrent payment of the Aurora Termination Fee, to enter into a definitive agreement with respect to a Superior Proposal. See "*Effect of the Arrangement – The Arrangement Agreement – Termination*".

The above is a summary of certain terms of the Arrangement Agreement and is qualified in its entirety by the full text of the Arrangement Agreement, which is incorporated by reference in this Joint Information Circular and may be viewed on SEDAR+ at www.sedarplus.ca or EDGAR at www.sec.gov, and by the more detailed summary provided under the heading "*Effect of the Arrangement – The Arrangement Agreement*" in this Joint Information Circular.

Reasons for and Benefits of the Arrangement

Organigram and Aurora expect that the Arrangement will create a global cannabis leader with leading positions in Canada, Europe and Australia, supported by Organigram's strategic shareholder, BAT. The combined company is expected to have a global platform with greater scale, broader capabilities, financial strength and international reach, bringing together Organigram's recreational cannabis leadership, production network, research and development platform and European medical commercial operations with Aurora's global medical cannabis leadership, established international presence and EU-GMP certified manufacturing capabilities. The anticipated benefits of the Arrangement include, among others:

- *Creates a Global Cannabis Leader* with a scaled, Canadian-headquartered global cannabis platform with leading positions in five nationally legal cannabis markets – Canada, Germany, Poland, Australia and New Zealand – and meaningful operations in other key markets.

- *Complementary Capabilities* across the Canadian adult-use, research and development, European medical, genetics and EU-GMP production platforms of the two companies.

- *Broader Geographic Reach and More Diversified Revenue Base* across medical and adult-use channels.

- *Premium Medical Revenue Mix*, with the majority of pro forma revenue expected to be derived from higher-margin international medical channels.

- *Industry-Leading EU-GMP Platform*, with five EU-GMP production and distribution sites across Canada and Germany, which is also expected to support faster cash conversion through lower investment in inventory.

- *Meaningful Synergies* of more than $50 million annually, driven by shared infrastructure, cost efficiencies and cross-selling opportunities.

- *Positioned for Stronger Financial Performance* with respect to revenue, gross margin, adjusted EBITDA margin, operating cash flow and free cash flow in future periods.

- *Accelerates Product Innovation and Commercial Growth*, supported by BAT's research and development, innovative product development and global supply chain expertise.

- *Continued Support of a Strategic Partner* in BAT, including through the BAT Private Placement.

- *Committed Financing*, with the cash portion of the Consideration fully financed through a combination of cash on hand, the BAT Private Placement and the ATB Credit Facilities.

- *Enhanced Scale and Capital Markets Profile,* with a larger market capitalization and improved trading liquidity on the TSX and Nasdaq.

- *Experienced Leadership Team* with deep industry knowledge and complementary expertise.

- *Comprehensive Negotiated Process* supported by the Aurora Fairness Opinions and the Organigram Fairness Opinion.

- *Shareholder and Court Approval* provide assurance of the fairness and reasonableness of the Arrangement.

See "*The Arrangement – Reasons for and Benefits of the Arrangement*" and "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement*".

Aurora

In determining, based on the unanimous recommendation of the Aurora Special Committee, that the Arrangement is fair to the Aurora Shareholders, that the Arrangement and entry into the Arrangement Agreement are in the best interests of Aurora and to unanimously recommend that the Aurora Shareholders vote in favour of the Arrangement Resolution, the Aurora Board considered and relied upon a number of factors, including, among others, the following:

- *Greater Value than the Hostile Bid*. The Consideration has an implied value of $7.80 per Aurora Common Share, representing a premium of approximately 93% to the Unaffected Price and approximately 21% to the implied value of the Hostile Bid as of November 2, 2026.

- *Choice of Consideration and Continued Participation*. Aurora Shareholders may elect the Cash Alternative, the Share Alternative or the Combination Alternative, subject to proration, providing certainty of value together with the opportunity to participate in the future growth and synergies of the combined company.

- *Certainty of Funding*. The cash portion of the Consideration is fully financed, and Organigram's obligations under the Arrangement Agreement are not subject to any financing condition.

- *Special Committee Process*. The Arrangement was reviewed, considered and negotiated under the oversight of the Aurora Special Committee, comprised entirely of independent directors, with the advice of independent financial and legal advisors.

- *Fairness Opinions*. The Aurora Special Committee and the Aurora Board received the Fort Capital Fairness Opinion and the Origin Fairness Opinion, each to the effect that, as of the date thereof and subject to the assumptions, limitations and qualifications set forth therein, the Consideration to be received by Aurora Shareholders is fair, from a financial point of view, to such Aurora Shareholders.

- *Ability to Respond to Superior Proposals*. Subject to the terms of the Arrangement Agreement, including Organigram's right to match, the Aurora Board retains the ability to respond to unsolicited Superior Proposals and Aurora may terminate the Arrangement Agreement to enter into a definitive agreement with respect to a Superior Proposal upon concurrent payment of the Aurora Termination Fee, which is, in the view of the Aurora Board, reasonable in the circumstances.

- *Shareholder and Court Approvals and Dissent Rights*. The Arrangement must be approved by Aurora Shareholders and the Court, and registered Aurora Shareholders who do not support the Arrangement may exercise Dissent Rights.

- *Tax-Deferred Exchange.* The Arrangement has been structured with the objective of permitting eligible Canadian resident Aurora Shareholders to exchange their Aurora Common Shares for Organigram Common Shares on a tax-deferred basis for Canadian federal income tax purposes.

- *Support of Directors and Executive Officers*. All of the directors and executive officers of Aurora have entered into Aurora Support Agreements to vote in favour of the Arrangement.

The information and factors described above and considered by the Aurora Special Committee and the Aurora Board in reaching their determinations and making their approvals are not intended to be exhaustive but include material factors considered by the Aurora Special Committee and the Aurora Board. In view of the wide variety of factors considered in connection with their evaluation of the Arrangement and the complexity of these matters, the Aurora Special Committee and the Aurora Board did not find it useful, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In addition, individual members of the Aurora Special Committee and the Aurora Board may have given different weight to different factors.

See "*The Arrangement – Reasons for and Benefits of the Arrangement*", "*The Arrangement – Reasons for and Benefits of the Arrangement – Additional Reasons and Benefits for Aurora Shareholders*" and "*The Arrangement – Recommendation of the Aurora Board*".

Organigram

In determining that the Arrangement is fair to the Organigram Shareholders and the holders of Organigram Preferred Shares, that the Arrangement and the entry into the Arrangement Agreement are in the best interests of Organigram and to unanimously recommend that the Organigram Shareholders vote in favour of the Organigram Share Issuance Resolution, the Organigram Board considered and relied upon a number of factors, including, among others (including those described under "*Reasons for and Benefits of the Arrangement*" above), the following:

- *Strategic and Financial Benefits*. The strategic and financial benefits described under "*Reasons for and Benefits of the Arrangement*" above, including expected annual run-rate synergies of more than $50 million.

- *Organigram Fairness Opinion*. The Organigram Board received the Organigram Fairness Opinion to the effect that, as of the date thereof and subject to the assumptions, limitations and qualifications set forth therein, the Consideration to be paid by Organigram pursuant to the Arrangement is fair, from a financial point of view, to Organigram. The fee payable to BMO Capital Markets for delivering the Organigram Fairness Opinion is not contingent on the completion of the Arrangement.

- *Committed Financing and BAT Support*. The cash portion of the Consideration is fully financed through cash on hand, the BAT Private Placement and the ATB Credit Facilities, and BAT has entered into an Organigram Support Agreement.

- *Arm's Length Negotiations and Terms of the Arrangement Agreement*. The Arrangement Agreement is the result of arm's length negotiations with the Aurora Special Committee, supervised by the Organigram Board, and includes, among other things, Aurora's non-solicitation covenants, Organigram's right to match any Superior Proposal and the Aurora Termination Fee payable to Organigram in certain circumstances.

- *Shareholder Approval*. The Organigram Share Issuance Resolution must be approved by greater than 50% of the votes cast by Organigram Shareholders and by greater than 50% of such votes cast, excluding the votes required to be excluded under the TSX Company Manual and MI 61-101.

- *Aurora Support Agreements*. All of the directors and executive officers of Aurora have irrevocably agreed to vote their Aurora Common Shares in favour of the Arrangement and to otherwise support the Arrangement.

- *BAT Private Placement Pricing Aligned with Aurora Shareholders*. The subscription price under the BAT Private Placement of £0.709289 (approximately $1.33 based on the GBP/CAD exchange rate on November 2, 2026) per share is equal to the deemed price per Organigram Common Share used to determine the Share Alternative, being the 20-day volume-weighted average trading price of the Organigram Common Shares on the TSX as of November 2, 2026, the last trading day prior to the announcement of the Arrangement, and accordingly represents no discount to Organigram's unaffected share price. As a result, the pricing of the BAT Private Placement does not transfer value from, or otherwise disadvantage Organigram Minority Shareholders.

- *Continued Control, Strong BAT Support and Protection of Minority Shareholders*. Organigram will continue as the parent company of the combined business, led by its current management team, and existing Organigram Shareholders (including BAT) are expected to hold approximately 63% of the economic interest and 59% of the voting rights in Organigram following completion of the Arrangement and the BAT Private Placement. BAT's significant investment in the BAT Private Placement demonstrates its support for the combined company, while BAT's voting interest will remain capped at 30%, the BAT representatives on the Organigram Board abstained from voting on the BAT Private Placement, and the Arrangement cannot proceed unless the Organigram Share Issuance Resolution is approved by a majority of the votes cast by Organigram Shareholders at the Organigram Shareholders' Meeting other than BAT and its affiliates.

The information and factors described above and considered by the Organigram Board in reaching its determinations and making its approvals are not intended to be exhaustive, but include material factors considered by the Organigram Board. In view of the wide variety of factors considered in connection with its evaluation of the Arrangement and the complexity of these matters, the Organigram Board did not find it useful, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In addition, individual members of the Organigram Board may have given different weight to different factors.

See "*The Arrangement – Reasons for and Benefits of the Arrangement*", "*The Arrangement – Reasons for and Benefits of the Arrangement – Additional Reasons and Benefits for Organigram Shareholders*" and "*The Arrangement – Recommendation of the Organigram Board*".

Aurora Fairness Opinions

Fort Capital Fairness Opinion

Aurora retained Fort Capital pursuant to an engagement letter dated July 7, 2026 to act as financial advisor in connection with, among other things, the Arrangement and the Hostile Bid. The Fort Capital Fairness Opinion provides an opinion by Fort Capital to the Aurora Special Committee and the Aurora Board to the effect that, as of November 2, 2026 and subject to the assumptions, limitations and qualifications set forth therein, the Consideration to be received by Aurora Shareholders is fair, from a financial point of view, to such Aurora Shareholders.

The full text of the Fort Capital Fairness Opinion, setting out the assumptions made, matters considered and limitations and qualifications on the review undertaken in connection with the Fort Capital Fairness Opinion, is attached as Appendix "F" to this Joint Information Circular.

Any summary of the Fort Capital Fairness Opinion herein is qualified in its entirety by reference to the full text of the Fort Capital Fairness Opinion attached as Appendix "F" to this Joint Information Circular. The Fort Capital Fairness Opinion was provided solely for the use of the Aurora Special Committee and the Aurora Board (solely in their capacity as such) in connection with the Aurora Special Committee's and the Aurora Board's evaluation of the Arrangement and may not be relied upon by any Aurora Shareholders or any other person. The Fort Capital Fairness Opinion is not intended to and does not constitute a recommendation as to how the Aurora Shareholders should vote in respect of the Arrangement Resolution.

See "*The Arrangement – Aurora Fairness Opinions - Fort Capital Fairness Opinion*". For the full text of the Fort Capital Fairness Opinion, see Appendix "F" – "*Aurora Fairness Opinions*".

Origin Fairness Opinion

Aurora retained Origin pursuant to an engagement letter effective October 24, 2026 to act as the financial advisor to the Aurora Special Committee. The Origin Fairness Opinion provides an opinion by Origin to the Aurora Special Committee and the Aurora Board to the effect that, as of November 2, 2026 and subject to the assumptions, limitations, and qualifications set forth therein, the Consideration to be received by the Aurora Shareholders pursuant to the Arrangement is fair, from a financial point of view, to the Aurora Shareholders.

The full text of the Origin Fairness Opinion, setting out the assumptions made, matters considered and limitations and qualifications on the review undertaken in connection with the Origin Fairness Opinion, is attached as Appendix "F" to this Joint Information Circular.

This summary of the Origin Fairness Opinion herein is qualified in its entirety by reference to the full text of the Origin Fairness Opinion attached as Appendix "F" to this Joint Information Circular. The Origin Fairness Opinion was provided solely for the use of the Aurora Special Committee and the Aurora Board (solely in their capacity as such) in connection with the Aurora Special Committee's and the Aurora Board's evaluation of the Arrangement and may not be relied upon by any Aurora Shareholders or any other person. The Origin Fairness Opinion is not intended to and does not constitute a recommendation as to how the Aurora Shareholders should vote in respect of the Arrangement Resolution.

See "*The Arrangement – Aurora Fairness Opinions – Origin Fairness Opinion*". For the full text of the Origin Fairness Opinion, see *Appendix "F" – "Aurora Fairness* Opinions".

Organigram Fairness Opinion

Organigram retained BMO Capital Markets as financial advisor to Organigram in connection with the Arrangement. As part of this mandate, BMO Capital Markets was requested to provide the Organigram Board with its opinion as to the fairness to Organigram, from a financial point of view, of the Consideration to be paid by Organigram pursuant to the Arrangement. In connection with this mandate, BMO Capital Markets has prepared and delivered the Organigram Fairness Opinion. The Organigram Fairness Opinion states that, as of November 2, 2026, and based upon and subject to the assumptions, limitations and qualifications set forth therein, the Consideration to be paid by Organigram pursuant to the Arrangement is fair, from a financial point of view, to Organigram.

The full text of the written opinion of BMO Capital Markets dated November 2, 2026, which sets forth, among other things, the assumptions made, procedures followed, information reviewed, matters considered and limitations and qualifications on the scope of review undertaken in connection with rendering the Organigram Fairness Opinion, is attached as Appendix "G" to this Joint Information Circular and should be read carefully and in its entirety. The Organigram Fairness Opinion was provided solely for the information and assistance of the Organigram Board in connection with its consideration of the Arrangement and may not be used or relied upon by any Organigram Shareholders or any other person for any other purpose. The Organigram

Fairness Opinion is not a recommendation as to how any Organigram Shareholder should vote or act with respect to the Arrangement or its Organigram Common Shares.

This summary of the Organigram Fairness Opinion is qualified in its entirety by reference to the full text of the Organigram Fairness Opinion attached as Appendix "G" to this Joint Information Circular.

See "*The Arrangement – Organigram Fairness Opinion*". For the full text of the Organigram Fairness Opinion, see Appendix "G" – *"Organigram Fairness Opinion*".

Recommendation of the Aurora Board

After consulting with the Aurora Financial Advisors, members of senior management and with Aurora's legal, tax, and other advisors, and after considering, among other things, the Fort Capital Fairness Opinion and the Origin Fairness Opinion, and based upon the unanimous recommendation of the Aurora Special Committee, the Aurora Board unanimously determined: (a) that the Arrangement is fair to the Aurora Shareholders; (b) that the Arrangement and the entry into the Arrangement Agreement are in the best interests of Aurora; and (c) to unanimously recommend that the Aurora Shareholders vote in favour of the Arrangement Resolution.

See "*The Arrangement – Recommendation of the Aurora Board".*

Recommendation of the Organigram Board

After consulting with Organigram's senior management and with its financial, legal, tax and other advisors, and after considering, among other things, the Organigram Fairness Opinion, the Organigram Board (with the representatives of BAT abstaining in respect of the BAT Private Placement) unanimously determined: (a) that the Arrangement is fair to the Organigram Shareholders and the holders of Organigram Preferred Shares; (b) that the Arrangement and entry into the Arrangement Agreement are in the best interests of Organigram; and (c) to unanimously recommend that the Organigram Shareholders vote in favour of the Organigram Share Issuance Resolution.

See "*The Arrangement – Recommendation of the Organigram Board".*

Aurora Support Agreements

On November 2, 2026, each of the Supporting Aurora Shareholders, who collectively hold approximately 0.62% of the issued and outstanding Aurora Common Shares, entered into an Aurora Support Agreement with Organigram pursuant to which each Supporting Aurora Shareholder has agreed, among other things, solely in its capacity as a securityholder of Aurora, to vote all of the Aurora Common Shares directly or indirectly beneficially owned, controlled or directed or subsequently acquired by such Supporting Aurora Shareholder: (a) in favour of the Arrangement Resolution, the Arrangement and the other transactions contemplated by the Arrangement Agreement; and (b) against any Acquisition Proposal in respect of Aurora and any matter that would reasonably be expected to prevent, materially delay or interfere with the Arrangement. Each Supporting Aurora Shareholder has also agreed not to transfer (including by tendering to the Hostile Bid or any other take-over bid) its Aurora securities, subject to limited exceptions. The Aurora Support Agreements terminate automatically in limited circumstances, including on an Aurora Change in Recommendation, an Organigram Change in Recommendation or termination of the Arrangement Agreement.

See "*Effect of the Arrangement – Aurora Support Agreements".*

Organigram Support Agreements

On November 2, 2026, each of the Supporting Organigram Shareholders, being BAT and each of the directors and executive officers of Organigram who hold Organigram Common Shares, who collectively hold approximately 30.95% of the issued and outstanding Organigram Common Shares, entered into an Organigram Support Agreement

with Aurora pursuant to which each Supporting Organigram Shareholder has agreed, among other things, to vote all of the Organigram Common Shares directly or indirectly beneficially owned, controlled or directed or subsequently acquired by such Supporting Organigram Shareholder: (a) in favour of the Organigram Share Issuance Resolution; and (b) against any Acquisition Proposal in respect of Organigram and any matter that would reasonably be expected to prevent, materially delay or interfere with the Arrangement. Organigram Common Shares held by BAT and its affiliates will be excluded for purposes of the disinterested shareholder approval required under the TSX Company Manual and the minority approval required under MI 61-101. The Organigram Support Agreements with the directors and executive officers of Organigram who hold Organigram Common Shares terminate automatically in limited circumstances, including on an Aurora Change in Recommendation, an Organigram Change in Recommendation or termination of the Arrangement Agreement. The Organigram Support Agreement with BAT does not terminate until the six-month anniversary of termination of the Arrangement Agreement in certain circumstances and does not automatically terminate on an Aurora Change in Recommendation or an Organigram Change in Recommendation.

See "*Effect of the Arrangement – Organigram Support Agreements*".

Sources of Funds for the Arrangement

Organigram intends to fund the aggregate cash Consideration and related transaction expenses through cash on hand and the Organigram Financing, being: (a) the ATB Credit Facilities, which provide for up to $210,000,000 of senior secured credit facilities, including a $115,000,000 term tranche to be drawn on closing and up to $35,000,000 under the revolving facility, in each case to fund a portion of the cash Consideration; and (b) the BAT Private Placement, pursuant to which BAT has agreed to subscribe for 140,986,255 Organigram Common Shares and/or Organigram Preferred Shares at a price of £0.709289 (approximately $1.33 based on the GBP/CAD exchange rate on November 2, 2026) per share for aggregate proceeds of £99,999,999.82 (approximately $187.5 million based on the GBP/CAD exchange rate on November 2, 2026). Following completion of the BAT Private Placement, BAT's economic interest in Organigram is expected to be approximately 44%, with its voting interest capped at 30%. Organigram's obligations under the Arrangement Agreement are not subject to any financing condition, and completion of the Arrangement is not conditional on the completion of the BAT Private Placement. See "*Effect of the Arrangement – BAT Equity Commitment*".

MI 61-101

BAT is a "related party" of Organigram and the BAT Private Placement is a "related party transaction" of Organigram under MI 61-101. The BAT Private Placement is exempt from the formal valuation requirement of MI 61-101 but is subject to minority approval, and accordingly the votes attached to Organigram Common Shares held by BAT, its affiliates and certain other persons will be excluded from the vote on the Organigram Share Issuance Resolution. As certain related parties of Aurora are entitled to receive a "collateral benefit" in connection with the Arrangement, the Arrangement is a "business combination" in respect of Aurora under MI 61-101 and the Arrangement Resolution also requires minority approval, excluding the votes attached to Aurora Common Shares held by such related parties. See "*Procedure for the Arrangement to Become Effective – Securities Law Matters – Canada – MI 61-101*".

Interests of Certain Persons or Companies in the Arrangement

In considering the recommendations of the Aurora Board and the Organigram Board, Shareholders should be aware that certain directors and executive officers of Aurora and Organigram, and BAT, have interests in the Arrangement or the BAT Private Placement that are, or may be, different from, or in addition to, the interests of Shareholders generally.

See "*Interests of Certain Persons or Companies in the Arrangement*" and "*Interests of Certain Persons or Companies in the Arrangement – Aurora – Summary of Interests of Directors and Executive Officers of Aurora in the Arrangement*".

Treatment of Aurora Incentive Awards

Pursuant to the Plan of Arrangement, Aurora DSUs, Aurora RSUs and Vested Aurora PSUs will be cancelled in exchange for cash payments from Aurora of $7.80 per underlying Aurora Common Share (multiplied by a performance ratio of 100% in the case of Vested Aurora PSUs), Unvested Aurora PSUs will remain outstanding and be settled in cash at $7.80 per underlying share (multiplied by a performance ratio of 100%) on their Entitlement Date, subject to vesting and otherwise on the same terms and conditions, including under any applicable employment agreement, as applied before the Effective Time, and Aurora Options will be exchanged for Replacement Options to acquire Organigram Common Shares.

There were 2,214,519 Aurora Options, 28,555 Aurora DSUs, 1,537,786 Aurora RSUs and 494,897 Aurora PSUs outstanding as of November 19, 2026.

See "*Effect of the Arrangement – Aurora Incentive Awards*".

Procedure for the Arrangement to Become Effective

Procedural Steps

The Arrangement is proposed to be carried out pursuant to section 288 of the BCBCA. The following procedural steps must be taken in order for the Arrangement to become effective:

(a) the Arrangement Resolution must be approved by not less than 66⅔% of the votes cast by the Aurora Shareholders present virtually or represented by proxy at the Aurora Shareholders' Meeting and by a simple majority of such votes cast excluding the votes required to be excluded under MI 61-101, in the manner set forth in the Interim Order;

(b) the Organigram Share Issuance Resolution must be approved by greater than (i) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, and (ii) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, excluding the votes attached to Organigram Common Shares held by BAT and its affiliates (and, for purposes of MI 61-101, their respective directors and officers and other persons required to be excluded);

(c) the Court must grant the Final Order approving the Arrangement;

(d) all conditions precedent to the Arrangement, as set forth in the Arrangement Agreement, including receipt of the Required Regulatory Approvals, must be satisfied or waived by the appropriate Party; and

(e) the Final Order and the records and information required under section 292 of the BCBCA must be filed with the Registrar.

There is no assurance that the conditions set out in the Arrangement Agreement will be satisfied or waived on a timely basis or at all.

Upon the conditions precedent set forth in the Arrangement Agreement being satisfied or waived, Aurora is required to file with the Registrar the records and information required under section 292 of the BCBCA, including a copy of the entered Final Order, in order to give effect to the Arrangement.

See "*Procedure for the Arrangement to Become Effective – Procedural Steps".*

Shareholder Approvals

Arrangement Resolution

Pursuant to the Interim Order, the Arrangement Resolution must, subject to further order of the Court, be approved by not less than 66⅔% of the votes cast by Aurora Shareholders, present virtually or represented by proxy and entitled to vote at the Aurora Shareholders' Meeting, voting together as a single class, and by a simple majority of such votes cast, excluding the votes attached to Aurora Common Shares held by persons described in items (a) through (d) of section 8.1(2) of MI 61-101, being only Mr. Miguel Martin. It is a condition to the completion of the Arrangement that the Arrangement Resolution be approved at the Aurora Shareholders' Meeting. Accordingly, if the Arrangement Resolution is not approved by Aurora Shareholders, the Arrangement will not be completed. However, the Arrangement Resolution authorizes the Aurora Board, without further notice to or approval of Aurora Shareholders: (a) to amend the Arrangement Agreement or the Plan of Arrangement, to the extent permitted by the Arrangement Agreement and the Plan of Arrangement; and (b) subject to the terms of the Arrangement Agreement, to disregard the Aurora Shareholders' approval and not proceed with the Arrangement. See Appendix "A" to this Joint Information Circular for the full text of the Arrangement Resolution.

It is the intention of the persons named in the enclosed form of proxy, if not expressly directed to the contrary in such form of proxy, to vote such proxy in favour of the Arrangement Resolution set forth in Appendix "A" to this Joint Information Circular.

See "*Procedure for the Arrangement to Become Effective – Shareholder Approvals – Arrangement Resolution*".

Organigram Share Issuance Resolution

At the Organigram Shareholders' Meeting, Organigram Shareholders will be asked to approve the issuance of up to 223,071,951 Organigram Common Shares pursuant to the Arrangement and 140,986,255 Organigram Common Shares and/or Organigram Preferred Shares pursuant to the BAT Private Placement.

The Organigram Common Shares issuable pursuant to the Arrangement will consist of: (a) Organigram Common Shares issuable in consideration for Aurora Common Shares; (b) Organigram Common Shares issuable upon the exercise of Replacement Options; and (c) a 5% buffer of Organigram Common Shares to account for clerical and administrative matters or changes in the number of Aurora Common Shares outstanding between the date hereof and the closing of the Arrangement. Based on the 65,748,913 Aurora Common Shares and 2,214,519 Aurora Options outstanding as of November 19, 2026, 200,080,517 Organigram Common Shares would be issued in consideration for Aurora Common Shares, 12,987,407 Organigram Common Shares would be issuable upon the exercise of Replacement Options and the issuance of an additional 9,991,849 Organigram Common Shares would be approved to account for clerical and administrative matters or changes in the number of Aurora Common Shares outstanding between the date hereof and the closing of the Arrangement.

In accordance with the applicable rules of the TSX and MI 61-101, the Organigram Share Issuance Resolution must be approved by greater than (i) 50% of the votes cast by Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, and (ii) 50% of the votes cast by Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, excluding the votes attached to Organigram Common Shares held by BAT and its affiliates (and, for purposes of MI 61-101, their respective directors and officers and other persons required to be excluded).

It is a condition to the completion of the Arrangement that the Organigram Share Issuance Resolution be approved at the Organigram Shareholders' Meeting. Accordingly, if the Organigram Share Issuance Resolution is not approved by Organigram Shareholders, the Arrangement will not be completed. However, the Organigram Share Issuance Resolution authorizes the Organigram Board, without further notice to or approval of Organigram Shareholders: (i) to amend the Arrangement Agreement or the Plan of Arrangement, to the extent permitted by the Arrangement Agreement and the Plan of Arrangement; and (ii) subject to the terms of the Arrangement Agreement, to not proceed with the Arrangement. See Appendix "B" to this Joint Information Circular for the full text of the Organigram Share Issuance Resolution.

It is the intention of the persons named in the enclosed form of proxy, if not expressly directed to the contrary in such form of proxy, to vote such proxy in favour of the Organigram Share Issuance Resolution set forth in Appendix "B" to this Joint Information Circular.

See "*Procedure for the Arrangement to Become Effective – Shareholder Approvals – Organigram Share Issuance Resolution".*

Court Approval

Interim Order

On November 20, 2026, Aurora obtained the Interim Order providing for the calling and holding of the Aurora Shareholders' Meeting and other procedural matters relating to the Meetings. The Interim Order is attached as Appendix "D" to this Joint Information Circular.

Final Order

The Arrangement requires approval by the Court under section 291 of the BCBCA. Subject to the terms of the Arrangement Agreement, if the Arrangement Resolution is approved at the Aurora Shareholders' Meeting in the manner required by the Interim Order and the Organigram Share Issuance Resolution is approved at the Organigram Shareholders' Meeting, Aurora will make an application to the Court for the Final Order. The hearing in respect of the Final Order is expected to take place on December 30, 2026 at 9:45 a.m. (Vancouver time) at the Vancouver Law Courts, 800 Smithe Street, Vancouver, British Columbia, or via video conference if so directed by the Court, or as soon thereafter as counsel may be heard. Copies of the Interim Order and the Petition and Notice of Hearing of Petition for the Final Order are attached as Appendix "D" and Appendix "E", respectively, to this Joint Information Circular. At the hearing, the Court will consider, among other things, the fairness and reasonableness of the Arrangement.

Under the terms of the Interim Order, any Aurora Shareholder or other interested party who wishes to appear or be represented and to present evidence or arguments at the hearing of the application for the Final Order must file with the Court and serve upon Aurora a Response to Petition in the form required by the Supreme Court Civil Rules (British Columbia), together with any affidavits or other materials on which such person intends to rely and such person's address for service, by no later than 4:00 p.m. (Vancouver time) on December 23, 2026. Service on Aurora is to be effected by service upon the solicitors for Aurora: Torys LLP, Suite 2800, 79 Wellington St. W., Toronto, Ontario M5K 1N2, Attention: Andrew Gray and Colette Koopman, with a copy to the solicitors for Organigram: Goodmans LLP, Bay Adelaide Centre – West Tower, 333 Bay Street, Suite 3400, Toronto, Ontario M5H 2S7, Attention: Tom Friedland. If the hearing is postponed, adjourned or rescheduled then, subject to further direction of the Court, only those persons having previously filed and served a Response to Petition in compliance with the Interim Order will be given notice of the new date.

See "*Procedure for the Arrangement to Become Effective – Court Approval".*

Regulatory Approvals

The Arrangement Agreement provides that receipt (or, where applicable, waiver) of all Required Regulatory Approvals is a condition precedent to the Arrangement becoming effective.

The Required Regulatory Approvals consist of the Competition Act Approval and the German FDI Approval. See "*Procedure for the Arrangement to Become Effective – Regulatory Approvals*".

It is also a condition to the completion of the Arrangement that the TSX shall have conditionally approved the listing of the Organigram Common Shares to be issued to Aurora Shareholders pursuant to the Arrangement and that Organigram shall have notified the Nasdaq of the listing of such Organigram Common Shares and the Nasdaq shall not have objected thereto. Organigram's obligations under the Arrangement Agreement are not subject to any

financing condition, and completion of the Arrangement is not conditional on the completion of the BAT Private Placement.

See "*Procedure for the Arrangement to Become Effective – Regulatory Approvals".*

Dissent Rights

Subject to the Interim Order and the satisfaction of certain conditions described therein and summarized under the heading "*Dissent Rights*" in this Joint Information Circular, each registered Aurora Shareholder that held Aurora Common Shares as of the Aurora Record Date is entitled, in addition to any other right such Aurora Shareholder may have, to dissent in respect of the Arrangement and to be paid by Organigram the fair value of the Aurora Common Shares held by such Aurora Shareholder, which value, notwithstanding anything to the contrary in the BCBCA, will be determined as of the close of business on the last business day before the Arrangement Resolution was adopted.

Dissenting Aurora Shareholders must deliver a Notice of Dissent, in strict compliance with section 242 of the BCBCA, that is received by Aurora c/o Torys LLP, Suite 2800, 79 Wellington St. W., Toronto, Ontario M5K 1N2, Attention: Andrew Gray and Colette Koopman, by not later than 9:30 a.m. (Toronto time) on December 21, 2026 (or, in the case of any adjournment or postponement of the Aurora Shareholders' Meeting, by not later than 9:30 a.m. (Toronto time) on the day that is two Business Days immediately preceding the day on which the adjourned meeting is reconvened or the postponed meeting is convened, as applicable). Failure to properly exercise Dissent Rights may result in the loss or unavailability of the right to dissent in respect of the Arrangement.

Pursuant to sections 237 to 247 of the BCBCA and the Interim Order, a registered Aurora Shareholder may not exercise Dissent Rights in respect of only a portion of such Aurora Shareholder's Aurora Common Shares, but may exercise Dissent Rights only with respect to all of the Aurora Common Shares held by such Aurora Shareholder or on behalf of any one Beneficial Holder and registered in the Dissenting Aurora Shareholder's name.

Only registered Aurora Shareholders may exercise Dissent Rights. In many cases, Aurora Common Shares beneficially owned by a Beneficial Holder are registered either: (a) in the name of a broker, investment dealer, bank, trust company, custodian, nominee or other intermediary; or (b) in the name of a clearing agency (such as CDS) of which the intermediary is a participant. Accordingly, a Beneficial Holder will not be entitled to exercise its Dissent Rights directly (unless the Aurora Common Shares are re-registered in the Beneficial Holder's name). A Beneficial Holder who wishes to exercise Dissent Rights should immediately contact the intermediary with whom the Beneficial Holder deals in respect of its Aurora Common Shares and either: (a) instruct the intermediary to exercise Dissent Rights on the Beneficial Holder's behalf (which, if the Aurora Common Shares are registered in the name of CDS or another clearing agency, may require that such Aurora Common Shares first be re-registered in the name of the intermediary); or (b) instruct the intermediary to re-register such Aurora Common Shares in the name of the Beneficial Holder, in which case the Beneficial Holder would be able to exercise Dissent Rights directly.

Unless otherwise waived in accordance with the Arrangement Agreement, it is a condition to the completion of the Arrangement in favour of Organigram that Dissent Rights shall not have been validly exercised, and not withdrawn, with respect to more than 10% of the issued and outstanding Aurora Common Shares.

See "*Dissent Rights*".

Summary of Canadian Federal Income Tax Considerations

This Joint Information Circular contains a summary of certain Canadian federal income tax considerations generally applicable under the Tax Act to certain Aurora Shareholders in respect of the disposition of Aurora Common Shares pursuant to the Arrangement, and the receipt, holding and disposition of Organigram Common Shares received pursuant to the Arrangement. See the discussion under the heading "*Certain Canadian Federal Income Tax Considerations*".

Aurora Shareholders should consult their own tax advisors for advice with respect to the Canadian federal income tax consequences to them in respect of the Arrangement.

Summary of Certain United States Federal Income Tax Considerations

This Joint Information Circular contains a summary of certain U.S. federal income tax considerations generally applicable to certain U.S. Holders that transfer Aurora Common Shares pursuant to the Arrangement. See the discussion under the heading "*Certain United States Federal Income Tax Considerations*".

Aurora Shareholders should consult their own tax advisors for advice with respect to the U.S. federal income tax consequences to them in respect of the Arrangement.

Additional Tax Considerations

This Joint Information Circular discusses certain Canadian and United States federal income tax considerations applicable to certain Aurora Shareholders. Tax consequences applicable to Aurora Shareholders who are resident in jurisdictions other than Canada or the United States are not discussed herein and such Aurora Shareholders should consult their tax advisors with respect to the tax implications of the Arrangement, including any associated filing requirements, in such jurisdictions and with respect to the tax implications in such jurisdictions of owning Organigram Common Shares after the Arrangement. All Aurora Shareholders should consult their own tax advisors regarding the provincial, state, local and territorial tax consequences of the Arrangement and of holding Organigram Common Shares.

This Joint Information Circular does not discuss any tax considerations applicable to holders of Aurora Incentive Awards. Such holders should consult their own tax advisors regarding the consequences of the Arrangement to them in their particular circumstances.

Timing

If the Meetings are held as scheduled and are not adjourned or postponed, and the necessary conditions for completion of the Arrangement are otherwise satisfied or waived, Aurora is expected to apply for the Final Order approving the Arrangement on or about December 30, 2026. If the Final Order is obtained in form and substance satisfactory to Aurora and Organigram and all other conditions set forth in the Arrangement Agreement are otherwise satisfied or waived, including with respect to Required Regulatory Approvals, Aurora and Organigram expect the Effective Date will occur in January 2027. Pursuant to the Arrangement Agreement, the Effective Date shall not occur prior to the Inside Date, and if the conditions to closing are satisfied earlier, the Arrangement Filings will be made on the Inside Date. It is not possible, however, to state with certainty when the Effective Date will occur and it is possible that factors outside the control of Aurora and/or Organigram could result in the Arrangement being completed at a later date, or not at all.

The Arrangement will become effective at the Effective Time specified in the Plan of Arrangement following the filing with the Registrar of the records and information required under section 292 of the BCBCA, including a copy of the entered Final Order.

The Effective Date could be delayed for a number of reasons, including an objection before the Court at the hearing of the application for the Final Order or the failure to receive any Required Regulatory Approvals in a timely manner.

See "*Timing*".

Selected Unaudited Pro Forma Consolidated Financial Information for Organigram After Giving Effect to the Arrangement

The following is a summary of selected unaudited pro forma consolidated financial information of Organigram, both before and after giving effect to the completion of the Arrangement, the BAT Private Placement and the Organigram Financing, as at and for the nine-month period ended June 30, 2026 and for the year ended September 30, 2025. The

pro forma adjustments are based upon available information and certain assumptions that Organigram believes are reasonable under the circumstances. The unaudited pro forma consolidated financial information set forth below and the unaudited pro forma consolidated financial statements of Organigram attached to this Joint Information Circular as Appendix "H" – "*Pro Forma Condensed Consolidated Financial Statements of Organigram Global* Inc." are presented for illustrative purposes only and are not necessarily indicative of either (a) the financial position or the results of operations that would have occurred as at such dates or for such periods had the Arrangement been effective as of June 30, 2026 (in the case of the pro forma statement of financial position) or October 1, 2025 and October 1, 2024 (in the case of the pro forma statements of operations for the nine months ended June 30, 2026 and the year ended September 30, 2025, respectively), as applicable, or (b) the financial position or results of operations for Organigram in future years if the Arrangement is completed. The actual adjustments will differ from those reflected in such unaudited pro forma consolidated financial statements and such differences may be material.

The following is a summary only and must be read in conjunction with the Organigram Pro Forma Financial Statements, including the notes thereto, attached as Appendix "H" to this Joint Information Circular. Reference should also be made to the Organigram Interim Financial Statements, Organigram Annual Financial Statements, Aurora Interim Financial Statements and Aurora Annual Financial Statements, each of which is incorporated by reference herein. See Appendix "H" – "*Pro Forma Condensed Consolidated Financial Statements of Organigram Global* Inc.".

Unaudited Pro Forma Condensed Consolidated Financial Information as at and for the Nine Months Ended June 30, 2026

	Organigram Global Inc. as at June 30, 2026	Aurora Cannabis Inc. as at June 30, 2026	Pro forma adjustments	Pro forma combined	Note
ASSETS					
Current assets					
Cash and cash equivalents	$ 10,851	$ 69,307	$ 131,609	$ 127,084	3 (a)
			186,912		3 (b)
			(259,773)		3 (c)
			(11,822)		3 (c)
Restricted cash	-	49,086	-	49,086	
Short-term investments	816	30,722	-	31,538	
Accounts and other receivables	88,605	41,091	-	129,696	
Biological assets	17,292	24,000	-	41,292	
Inventories	147,764	163,543	-	311,307	
Prepaid expenses, deposits and other current assets	14,758	12,564	-	27,322	
Assets held for sale	-	3,136	-	3,136	
Total current assets	**$ 280,086**	**$ 393,449**	**$ 46,926**	**$ 720,461**	
Non-current assets					
Property, plant and equipment	$ 121,148	$ 146,752	$ -	$ 267,900	
Intangible assets	203,506	32,731	(32,731)	203,506	3 (c)
Goodwill	194,717	27,342	(27,342)	287,433	3 (c)
			92,716		3 (c)
Long-term investments and other financial assets	19,831	12,533	-	32,364	
Deferred charges, deposits and other long-term assets	974	2,267	-	3,241	
Lease receivable	-	3,246	-	3,246	
Deferred tax assets	-	2,557	-	2,557	
Total non-current assets	**$ 540,176**	**$ 227,428**	**$ 32,643**	**$ 800,247**	
TOTAL ASSETS	**$ 820,262**	**$ 620,877**	**$ 79,569**	**$ 1,520,708**	
LIABILITIES					
Current liabilities					
Accounts payable and accrued liabilities	$ 99,933	$ 56,830	$ 26,038	$ 182,801	3 (c)
Income taxes payable	-	7,439	-	7,439	
Deferred revenue	-	799	(799)	-	3 (e)
Current portion of loans and borrowings	3,365	-	27,000	30,365	3 (a)
Lease liabilities – current portion	-	5,875	(5,875)	-	3 (e)
Derivative liabilities – current	1,637	-	-	1,637	
Provisions and other current liabilities	2,346	2,486	799	11,506	3 (e)
			5,875		3 (e)
Total current liabilities	**$ 107,281**	**$ 73,429**	**$ 53,038**	**$ 233,748**	
Non-current liabilities					
Loans and borrowings	17,608	-	$ 104,609	$ 122,217	3 (a)
Lease liabilities	-	16,809	(16,809)	-	3 (e)
Derivative liabilities	198	2,892	(1,300)	1,790	3 (c)
Preferred shares	71,057	-	73,276	144,333	3 (b), 3 (f)
Deferred income taxes	49,619	47	-	49,666	
Other long-term liabilities	89,037	569	16,809	106,415	3 (e)
Total non-current liabilities	**$ 227,519**	**$ 20,317**	**$ 176,585**	**$ 424,421**	
TOTAL LIABILITIES	**$ 334,800**	**$ 93,746**	**$ 229,623**	**$ 658,169**	
SHAREHOLDERS' EQUITY					
Share capital	$ 933,648	$ 7,027,979	$ (7,027,979)	$ 1,313,625	3 (c)
			266,107		3 (c)
			113,870		3 (b)
Equity reserves / contributed surplus	37,451	158,807	(158,807)	46,607	3 (c)
			9,156		3 (c)
Accumulated other comprehensive income (loss)	(1,496)	(213,714)	213,714	(1,496)	3 (c)
Accumulated deficit	(484,141)	(6,445,941)	6,445,941	(496,197)	3 (c)
			(234)		3 (b)
			(11,822)		3 (c)
Total shareholders' equity	**$ 485,462**	**$ 527,131**	**$ (150,054)**	**$ 862,539**	
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	**$ 820,262**	**$ 620,877**	**$ 79,569**	**$ 1,520,708**	

	Organigram Global Inc. for the nine months ended June 30, 2026	Aurora Cannabis Inc. for the nine months ended June 30, 2026	Pro forma adjustments	Pro forma combined	Note
REVENUE					
Gross revenue	$ 335,619	$ 247,939	$ -	$ 583,558	
Excise taxes	(106,505)	(12,677)	-	(119,182)	
Net revenue	**$ 229,114**	**$ 235,262**	**$ -**	**$ 464,376**	
Cost of sales	151,801	122,744	-	274,545	
Gross margin before fair value adjustments	**$ 77,313**	**$ 112,518**	**$ -**	**$ 189,831**	
Realized fair value on inventories and biological assets sold	(53,155)	(100,480)	-	(153,635)	
Unrealized gain on changes in fair value of biological assets	56,986	95,562	-	152,548	
Gross margin	**$ 81,144**	**$ 107,600**	**$ -**	**$ 188,744**	
OPERATING EXPENSES					
General and administrative	$ 50,488	$ 78,003	$ 2,605	$ 131,096	*3 (e)*
Sales and marketing	29,785	46,473	-	76,258	
Business development costs	-	2,882	-	2,882	
Research and development	6,324	3,230	-	9,554	
Depreciation and amortization	-	2,605	(2,605)	-	*3 (e)*
Share-based compensation	2,428	831	(500)	10,766	*3 (c)*
			8,007		*3 (c)*
Impairment of property, plant and equipment	-	-	2,250	2,250	*3 (e)*
Impairment of intangible assets and goodwill	5,800	-	-	5,800	
Total operating expenses	**$ 94,825**	**$ 134,024**	**$ 9,757**	**$ 238,606**	
Loss from operations	**$ (13,681)**	**$ (26,424)**	**$ (9,757)**	**$ (49,862)**	
OTHER (INCOME) EXPENSE					
Interest and investment (income) loss, net	$ (889)	$ (3,172)	$ -	$ (4,061)	
Finance and other costs	1,025	1,368	6,417	8,810	*3 (a)*
Acquisition and transaction costs	11,129	-	234	23,185	*3 (b)*
			11,822		*3 (c)*
Change in fair value of contingent consideration	(8,924)	-	-	(8,924)	
Change in fair value of derivative liabilities, preferred shares and other financial assets	(139,838)	-	-	(139,838)	
Foreign exchange gain	-	(553)	-	(553)	
Other non-operating (income) expense, net	820	(997)	-	(177)	
Impairment of property, plant and equipment	-	2,250	(2,250)	-	*3 (e)*
Impairment of intangible assets and goodwill	-	-	-	-	
Total other (income) expense	**$ (136,677)**	**$ (1,104)**	**$ 16,223**	**$ (121,558)**	
Income (loss) before income taxes	**$ 122,996**	**$ (25,320)**	**$ (25,980)**	**$ 71,696**	
INCOME TAX (RECOVERY) EXPENSE					
Current	$ (34)	$ 2,309	$ -	$ 2,275	*3 (d)*
Deferred, net	(1,556)	(2,345)	-	(3,901)	*3 (d)*
Total income tax (recovery) expense	**$ (1,590)**	**$ (36)**	**$ -**	**$ (1,626)**	
Net income (loss) from continuing operations	**$ 124,586**	**$ (25,284)**	**$ (25,980)**	**$ 73,322**	
Net loss from discontinued operations, net of tax	-	(41,799)	-	(41,799)	
NET INCOME (LOSS)	**$ 124,586**	**$ (67,083)**	**$ (25,980)**	**$ 31,523**	

	Organigram Global Inc. for the nine months ended June 30, 2026	Aurora Cannabis Inc. for the nine months ended June 30, 2026	Pro forma adjustments	Pro forma combined	Note
OTHER COMPREHENSIVE INCOME (LOSS)					
Change in fair value of investments at fair value through other comprehensive income (loss)	$ (1,238)	$ -	$ -	$ (1,238)	
Foreign currency transaction (loss) gain	(663)	2,273	-	1,610	
Cash flow hedge reserve	(198)	-	-	(198)	
Total other comprehensive income (loss)	**$ (2,099)**	**$ 2,273**	**$ -**	**$ 174**	
Comprehensive loss from continuing operations	$ 122,487	$ (23,011)	$ (25,980)	$ 73,496	
Comprehensive loss from discontinued operations	-	(41,799)	-	(41,799)	
COMPREHENSIVE INCOME (LOSS)	**$ 122,487**	**$ (64,810)**	**$ (25,980)**	**$ 31,697**	
Net income (loss) from continuing operations attributable to:					
Common shareholders	$ 124,586	$ (25,284)	$ (25,980)	$ 73,322	
Non-controlling interests	-	-	-	-	
	$ 124,586	**$ (25,284)**	**$ (25,980)**	**$ 73,322**	
Net income (loss) from discontinued operations attributable to:					
Common shareholders	$ -	$ (33,826)	$ -	$ (33,826)	
Non-controlling interests	-	(7,973)	-	(7,973)	
	$ -	**$ (41,799)**	**$ -**	**$ (41,799)**	
Comprehensive income (loss) attributable to:					
Common shareholders	$ 122,487	$ (56,837)	$ (25,980)	$ 39,670	
Non-controlling interests	-	(7,973)	-	(7,973)	
	$ 122,487	**$ (64,810)**	**$ (25,980)**	**$ 31,697**	
Net income (loss) per common share, basic					
Continuing operations				$ 0.17	
Discontinued operations				$ (0.08)	
Total operations				**$ 0.09**	
Net income (loss) per common share, diluted					
Continuing operations				$ 0.15	
Discontinued operations				$ (0.07)	
Total operations				**$ 0.08**	

Unaudited Pro Forma Condensed Consolidated Financial Information for the Year Ended September 30, 2025

	Organigram Global Inc. for the year ended September 30, 2025	Aurora Cannabis Inc. for the twelve months ended September 30, 2025	Pro forma adjustments	Pro forma combined	Note
REVENUE					
Gross revenue	$ 403,024	$ 335,845	$ -	$ 738,869	
Excise taxes	(143,841)	(26,891)	-	(170,732)	
Net revenue	**$ 259,183**	**$ 308,954**	**$ -**	**$ 568,137**	
Cost of sales	$ 174,850	$ 151,932	$ -	$ 326,782	
Gross margin before fair value adjustments	**$ 84,333**	**$ 157,022**	**$ -**	**$ 241,355**	
Realized fair value on inventories and biological assets sold and other inventory charges	$ (67,125)	$ (137,851)	$ -	$ (204,976)	
Unrealized gain on changes in fair value of biological assets	73,008	142,464	-	215,472	
Gross margin	**$ 90,216**	**$ 161,635**	**$ -**	**$ 251,851**	
OPERATING EXPENSES					
General and administrative	$ 59,499	$ 101,348	$ 3,165	$ 164,012	*3 (e)*
Sales and marketing	31,097	57,226	-	88,323	
Business development costs	-	2,125	-	2,125	
Research and development	10,945	3,447	-	14,392	
Depreciation and amortization	-	3,165	(3,165)	-	*3 (e)*
Share-based compensation	3,975	12,598	(5,900)	18,680	*3 (c)*
			8,007		*3 (c)*
Impairment of property, plant and equipment	-	-	1,092	1,092	*3 (e)*
Impairment of intangible assets and goodwill	-	-	13,186	13,186	*3 (e)*
Total operating expenses	**$ 105,516**	**$ 179,909**	**$ 16,385**	**$ 301,810**	
Loss from operations	**$ (15,300)**	**$ (18,274)**	**$ (16,385)**	**$ (49,959)**	
OTHER (INCOME) EXPENSE					
Interest and investment (income) loss, net	$ (1,747)	$ (8,454)	$ -	$ (10,201)	
Finance and other costs	597	2,661	8,356	11,614	*3 (a)*
Acquisition, transaction and business development costs	6,580	-	234	18,636	*3 (b)*
			11,822		*3 (c)*
Loss (gain) on disposal of property, plant and equipment and intangible assets	9	-	-	9	
Change in fair value of contingent consideration	(9,743)	-	-	(9,743)	
Change in fair value of derivative liabilities, preferred shares and other financial assets	27,505	-	-	27,505	
Foreign exchange gain	-	(11,178)	-	(11,178)	
Share issuance costs allocated to derivative liabilities and preferred shares	170	-	-	170	
Other non-operating (income) expense	(142)	302	-	160	
Impairment of property, plant and equipment	-	1,092	(1,092)	-	*3 (e)*
Impairment of intangible assets and goodwill	-	13,186	(13,186)	-	*3 (e)*
Total other (income) expense	**$ 23,229**	**$ (2,391)**	**$ 6,134**	**$ 26,972**	
Loss before income taxes	**$ (38,529)**	**$ (15,883)**	**$ (22,519)**	**$ (76,931)**	
INCOME TAX (RECOVERY) EXPENSE					
Current	$ -	$ 5,810	$ -	$ 5,810	*3 (d)*
Deferred, net	(13,770)	(370)	-	(14,140)	*3 (d)*
Total income tax (recovery) expense	**$ (13,770)**	**$ 5,440**	**$ -**	**$ (8,330)**	
Net loss from continuing operations	**$ (24,759)**	**$ (21,323)**	**$ (22,519)**	**$ (68,601)**	
Net loss from discontinued operations, net of tax	-	(41,059)	-	(41,059)	
Net loss	**$ (24,759)**	**$ (62,382)**	**$ (22,519)**	**$ (109,660)**	

	Organigram Global Inc. for the year ended September 30, 2025	Aurora Cannabis Inc. for the twelve months ended September 30, 2025	Pro forma adjustments	Pro forma combined	Note
OTHER COMPREHENSIVE INCOME (LOSS)					
Change in fair value of investments at fair value through other comprehensive income (loss)	$ 666	$ -	$ -	$ 666	
Foreign currency transaction (loss)	-	(1,701)	-	(1,701)	
Cash flow hedge reserve	-	-	-	-	
Total other comprehensive income (loss)	**$ 666**	**$ (1,701)**	**$ -**	**$ (1,035)**	
Comprehensive loss from continuing operations	$ (24,093)	$ (23,024)	$ (22,519)	$ (69,636)	
Comprehensive loss from discontinued operations	-	(41,059)	-	(41,059)	
COMPREHENSIVE LOSS	**$ (24,093)**	**$ (64,083)**	**$ (22,519)**	**$ (110,695)**	
Net loss from continuing operations attributable to:					
Common shareholders	$ (24,759)	$ (21,323)	$ (22,519)	$ (68,601)	
Non-controlling interests	-	-	-	-	
	$ (24,759)	**$ (21,323)**	**$ (22,519)**	**$ (68,601)**	
Net loss from discontinued operations attributable to:					
Common shareholders	$ -	$ (36,447)	$ -	$ (36,447)	
Non-controlling interests	-	(4,612)	-	(4,612)	
	$ -	**$ (41,059)**	**$ -**	**$ (41,059)**	
Comprehensive loss attributable to:					
Common shareholders	$ (24,093)	$ (59,471)	$ (22,519)	$ (106,083)	
Non-controlling interests	-	(4,612)	-	(4,612)	
	$ (24,093)	**$ (64,083)**	**$ (22,519)**	**$ (110,695)**	
Net loss per common share, basic					
Continuing operations				$ (0.17)	
Discontinued operations				$ (0.08)	
Total operations				**$ (0.25)**	
Net loss per common share, diluted					
Continuing operations				$ (0.17)	
Discontinued operations				$ (0.08)	
Total operations				**$ (0.25)**	

See "*The Arrangement – Reasons for and Benefits of the Arrangement*" and "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement*".

Risk Factors

Aurora Shareholders voting in favour of the Arrangement Resolution and Organigram Shareholders voting in favour of the Organigram Share Issuance Resolution, as applicable, will be choosing to combine the businesses of Aurora and Organigram and, in the case of Aurora Shareholders, to invest in Organigram Common Shares, as applicable. The completion of the Arrangement and investment in Organigram Common Shares involves risks.

An investment in Organigram Common Shares is subject to certain risks, which are generally associated with an investment in shares of a cannabis company. **The following is a list of certain additional risk factors associated with the Arrangement and the investment in Organigram Common Shares which Aurora Shareholders and Organigram Shareholders should carefully consider before approving the Arrangement Resolution and the Organigram Share Issuance Resolution, as applicable:**

- Organigram, after giving effect to the Arrangement, may fail to realize the anticipated benefits of the Arrangement;
- the conditions precedent to completion of the Arrangement, including receipt of all Required Regulatory Approvals, Court approval, conditional approval of the TSX and the notification to the Nasdaq, may not be satisfied or waived by the Outside Date, which may result in the Arrangement not being completed;
- risks related to the integration of Aurora's business into Organigram's business;
- risks that Shareholders may be exposed to additional business risks not previously applicable to their investment, as the business mix of Organigram following completion of the Arrangement will be different than that of Aurora and Organigram as separate entities;
- the market price of the Aurora Common Shares and/or the Organigram Common Shares may be subject to material fluctuations if the Arrangement is delayed or is not completed;

- the Arrangement Agreement could be terminated by either Party under certain circumstances;
- Aurora and Organigram will incur significant costs relating to the Arrangement, regardless of whether the Arrangement is completed;
- if the Arrangement is not completed, Aurora Shareholders and Organigram Shareholders will not realize the benefits of the Arrangement and Aurora's and Organigram's future business and operations could be adversely affected;
- Aurora and Organigram are restricted from taking certain actions while the Arrangement is pending;
- Aurora's and Organigram's business relationships may be adversely impacted while the Arrangement is pending;
- the pending Arrangement may divert the attention of Aurora's and Organigram's management;
- the number of Organigram Common Shares comprising the Share Alternative and the Combination Alternative is fixed and will not be adjusted in the event of any change in either Aurora's or Organigram's respective share prices;
- because of proration, Aurora Shareholders may not receive the form of Consideration they elect;
- a substantial delay in obtaining satisfactory approvals or the imposition of unfavourable terms or conditions in Regulatory Approvals, including the Required Regulatory Approvals, could adversely affect the business, financial condition or results of operations of Organigram, Aurora or Organigram following completion of the Arrangement;
- Aurora Shareholders have the right to exercise Dissent Rights and, if there are a significant number of Dissenting Aurora Shareholders, a substantial cash payment may be required to be made to such Dissenting Aurora Shareholders that could have an adverse effect on Organigram's financial condition and cash resources if the Arrangement is completed;
- there may be undisclosed liabilities that Organigram or Aurora failed to discover or was unable to quantify in their respective due diligence of the other Party;
- BAT or ATB Financial may fail to fund all or a portion of the Organigram Financing, in which case Organigram would remain obligated to complete the Arrangement and pay the aggregate cash Consideration;
- the ATB Credit Facilities are conditional on receipt of the BAT Private Placement proceeds and BAT's funding obligation is conditional on the debt financing being funded, and Organigram may be required to prepay a portion of the $115,000,000 acquisition term tranche after closing if the required appraisals of Aurora's assets are not delivered or do not support the required value;
- Organigram will have increased secured indebtedness following the Arrangement and will be subject to financial covenants, scheduled amortization and interest rate risk;
- BAT will have a significant economic interest in Organigram following the BAT Private Placement and has consent rights under the BAT Equity Commitment over certain amendments to the Arrangement Agreement, including any Specified Adverse Amendment, which may limit Organigram's flexibility in responding to an Amended Bid;
- the Hostile Bid, any Amended Bid or another competing proposal for Aurora may interfere with or prevent completion of the Arrangement;

- Aurora may terminate the Arrangement Agreement to accept a Superior Proposal;
- the Aurora Termination Fee may discourage other parties from making an Acquisition Proposal;
- Organigram Shareholders will experience dilution following the issuance of the Organigram Common Shares pursuant to the Arrangement;
- there is no assurance that listing of the Organigram Common Shares issuable pursuant to and in connection with the Arrangement on the TSX and on the Nasdaq will occur in a timely manner or at all;
- the pro forma financial information provided may not be an accurate depiction of the financial condition or results of operations of Organigram after giving effect to the Arrangement, as it relies on a number of adjustments and assumptions that may not be accurate;
- changes in income or other tax laws or actions taken by taxing authorities could have adverse implications on Organigram, Aurora or their respective securityholders;
- risks relating to the income tax consequences of the Arrangement and the taxation of Organigram;
- future dividends on the Organigram Common Shares may not be approved by the Organigram Board;
- Organigram and Aurora directors and officers, who were involved with negotiating the terms of the Arrangement Agreement, may have interests in the Arrangement that differ from those of Organigram Shareholders and Aurora Shareholders;
- as a result of the Arrangement, Organigram and Aurora may become the targets of litigation or other legal claims including securities class actions or derivative lawsuits; and
- the timing of the Meetings, the Final Order and the anticipated Effective Date may be changed or delayed.

The risk factors listed above are an abbreviated list of risk factors summarized elsewhere in this Joint Information Circular, the Aurora AIF, the Aurora Annual MD&A, the Aurora Interim MD&A, the Organigram AIF, the Organigram Annual MD&A and the Organigram Interim MD&A, each of which is incorporated by reference herein. See "*Risk Factors*". Aurora Shareholders and Organigram Shareholders should carefully consider all such risk factors.

THE ARRANGEMENT

General

Organigram and Aurora entered into the Arrangement Agreement on November 2, 2026. The Arrangement Agreement is incorporated by reference in this Joint Information Circular and can be viewed on SEDAR+ at www.sedarplus.ca or EDGAR at www.sec.gov. The Arrangement Agreement provides for the implementation of the Plan of Arrangement (a copy of which is attached as Appendix "C" to this Joint Information Circular) pursuant to which, among other things, all of the issued and outstanding Aurora Common Shares will be exchanged for the Consideration, being, at the election of each holder, the Cash Alternative, the Share Alternative or the Combination Alternative for each Aurora Common Share held, subject to proration.

Current Aurora Shareholders are expected to hold approximately 37% of the economic interest and 41% of the voting rights in Organigram, on a fully diluted basis, immediately after completion of the Arrangement and the BAT Private Placement.

Background to the Arrangement

The terms of the Arrangement are the result of arm's length negotiations between representatives of Aurora, including the Aurora Special Committee, and Organigram and their respective financial and legal advisors. The following is a summary of the events leading up to the negotiation of the Arrangement Agreement and the key meetings, negotiations, discussions and actions by and between the Parties that preceded the execution and public announcement of the Arrangement Agreement.

Aurora

The Aurora Board and Aurora's management are executing a long-term international strategy to focus on prioritizing global medical cannabis growth. Through years of operating large-scale EU-GMP-certified facilities, Aurora has developed the scientific, cultivation, regulatory and operational capabilities that support its global medical cannabis strategy. Aurora has also completed acquisitions of businesses and significant investments in international assets to further support this strategic plan and facilitate market access. In particular, Aurora's recently completed acquisition of the Safari Flower Company builds on Aurora's global medical cannabis platform and leverages its diversified and scaled network and strong balance sheet to build sustainable, long-term shareholder value. As part of this strategic plan, Aurora has historically and continues to evaluate additional opportunities, including potential acquisitions, joint ventures, business combinations and other similar transactions, to expand this capacity and add shareholder value.

On June 22, 2026, Miguel Martin, Aurora's Executive Chairman and CEO, and Boris Jordan, Curaleaf's Chief Executive Officer, had a virtual meeting where Mr. Jordan indicated Curaleaf would provide a letter outlining its interest in a transaction with Aurora.

On June 23, 2026, Mr. Jordan delivered to Mr. Martin and Michael Singer, Aurora's Lead Independent Director, an unsolicited indication of interest regarding a potential acquisition of Aurora (the "**June 23 Curaleaf Proposal**") and requesting a 30-day exclusivity period. The June 23 Curaleaf Proposal did not include any proposed financial terms or reference to the consideration mix, which is customary in the circumstances, particularly when exclusivity is requested as part of the proposal. After discussion, Messrs. Martin and Singer informed the other Aurora Board members of the June 23 Curaleaf Proposal and discussed with them their intention to reject Curaleaf's request for exclusivity and request more information on the basis that the June 23 Curaleaf Proposal did not include any substantive proposed terms, including no indication of price or value of the potential acquisition to Aurora Shareholders.

On July 6, 2026, Aurora, through Mr. Martin, responded to Mr. Jordan by phone, declining exclusivity on the basis described above, and noting that Aurora's management remained available to discuss should a more definitive proposal be made. On July 7, 2026, Curaleaf sent a subsequent unsolicited non-binding acquisition proposal to Mr. Martin proposing a price of approximately US$4.00 per Aurora Common Share (the "**July 7 Curaleaf Proposal**"), comprised of Curaleaf Shares plus a cash portion and demanding a substantive response within five business days.

The July 7 Curaleaf Proposal did not include any detail regarding the mix of cash and share consideration and did not mention any cap on the amount of consideration. Mr. Martin informed the Aurora Board of the July 7 Curaleaf Proposal upon receipt.

On July 10, 2026, the Aurora Board met with its external financial advisor, Fort Capital, and its external legal advisor, Stikeman, to consider and discuss the July 7 Curaleaf Proposal. Following receipt of advice from its legal and financial advisors and after considering the July 7 Curaleaf Proposal in detail, the Aurora Board unanimously determined that the July 7 Curaleaf Proposal was not in the best interests of Aurora or the Aurora Shareholders and unanimously rejected it, but indicated that it would be open to further communication with Curaleaf, including to consider improved offer terms. The Aurora Board authorized Mr. Singer to advise Curaleaf of the Aurora Board's response, which response was delivered to Mr. Jordan on July 14, 2026.

There was further correspondence between Mr. Jordan and Mr. Singer regarding the July 7 Curaleaf Proposal in July 2026. As part of this correspondence, Mr. Singer noted that Aurora was focused on continuing to execute its business plan over the short to medium term but that Aurora remained open to continuing dialogue between the parties going forward.

On August 11, 2026, Curaleaf issued a press release announcing an intention to launch an unsolicited take-over bid for all of the issued and outstanding Aurora Common Shares at a stated implied consideration of US$4.00 per Aurora Common Share, consisting of 0.3463 Curaleaf Shares plus US$0.75 in cash per Aurora Common Share. This proposal added a cap on the value of the consideration of US$5.00 per Aurora Common Share, which was not contained in the July 7 Curaleaf Proposal, and which is a lower price than Aurora Common Shares have traded at as recently as December 18, 2025.

In response to Curaleaf's announcement, Aurora issued a press release on the same day, advising Aurora Shareholders that the Aurora Board intended to form a special committee of independent directors to consider the potential take-over bid for all of the issued and outstanding Aurora Common Shares by Curaleaf.

The Aurora Board met later that day with members of senior management, together with Aurora's external financial advisor and external legal advisor. The Aurora Board formed the Aurora Special Committee of independent directors, comprised of Michael Singer (Chair), Chitwant Kohli, Norma Beauchamp and Rajesh Uttamchandani. The mandate of the Aurora Special Committee is to, among other things, oversee and direct matters relating to the potential take-over bid, including retaining and instructing advisors, reviewing and evaluating the terms of the potential take-over bid, considering alternatives to the potential take-over bid and making recommendations to the Aurora Board with respect thereto.

On August 12, 2026, Mr. Singer contacted Torys about representing the Aurora Special Committee as independent legal advisor.

On August 12, 2026, Mr. Martin and Mr. Jordan had a telephone discussion regarding the potential take-over bid, during which Mr. Jordan indicated that a formal take-over bid could be delivered as early as the following week.

On August 18, 2026, Curaleaf filed a take-over bid circular (the "**Curaleaf Circular**") and related documents, including a copy of the advertisement on Aurora's SEDAR+ profile and EDGAR profile, commencing the Original Curaleaf Bid, being an unsolicited take-over bid to acquire all of the Aurora Common Shares for stated implied consideration of US$4.00 per Aurora Common Share, consisting of 0.3463 Curaleaf Shares plus US$0.75 in cash per Aurora Common Share, subject to a maximum combined value per Aurora Common Share of US$5.00.

The Aurora Special Committee formally retained Torys as independent legal counsel effective August 18, 2026.

Since the commencement of the Original Curaleaf Bid, the Aurora Special Committee met on multiple occasions with its legal advisor, Torys, as well as Stikeman, Fort Capital, Origin (since their engagement on October 24, 2026) and members of senior management. At these meetings, the Aurora Special Committee reviewed, with assistance from legal and financial advisors, the material terms and conditions of the Original Curaleaf Bid (including its later revisions pursuant to the Hostile Bid), the contents of disclosure made by Curaleaf (including the Curaleaf Circular and the

Curaleaf Notice of Variation) and received advice from their legal advisors as to Aurora's directors' fiduciary duties and legal obligations in the circumstances. The Aurora Special Committee received presentations from management and financial advisors, including their respective analyses of the Curaleaf Shares, the strength of Aurora's long-term strategy, strategic alternatives and the reactions in the marketplace to the Original Curaleaf Bid and the Hostile Bid in connection with its consideration and evaluation of, and potential responses to, the Original Curaleaf Bid and the Hostile Bid. Each Aurora Special Committee meeting included an in-camera portion, during which the Aurora Special Committee met separately with Torys and without the presence of management or Aurora's legal and financial advisors. The members of the Aurora Special Committee also had numerous informal discussions and updates with the legal and financial advisors, and members of senior management.

The Aurora Special Committee held its initial formal meeting on August 18, 2026, at which its independent legal advisor, Aurora's legal and financial advisors and members of management also attended. The Aurora Special Committee discussed the events leading up to the Original Curaleaf Bid and received advice from its and Aurora's legal and financial advisors. Following discussion, the Aurora Special Committee recommended that Aurora issue a press release recommending that Aurora Shareholders take no action with respect to the Original Curaleaf Bid until the Aurora Board makes a formal recommendation. That press release was issued by Aurora on August 19, 2026.

On August 23, 2026, Mr. James Yamanaka, Organigram's Chief Executive Officer, unsolicitedly contacted Mr. Martin by e-mail inviting a discussion to explore potential business opportunities. On August 24, 2026, Mr. Yamanaka called Mr. Martin to express that Organigram would potentially be interested in exploring a negotiated business combination with, or acquisition of, Aurora, and subsequently delivered a letter to Mr. Martin and Mr. Singer reinforcing that interest. The letter did not include any indication of price or other terms, but expressed that Organigram viewed a transaction with Aurora as a compelling strategic alternative capable of delivering a significant premium to Aurora Shareholders. The letter also noted that any proposal would be dependent on customary due diligence and indicated Organigram's willingness to enter into a customary non-disclosure and standstill agreement to facilitate that work.

On August 24, 2026, following consultation with the Aurora Special Committee and the Aurora Board, Aurora issued a press release outlining several factual claims made by Curaleaf in the Curaleaf Circular and press releases regarding Aurora's operational and market performance that do not accurately or fully reflect Aurora's business model or actual financial results, and again recommending that Aurora Shareholders take no action with respect to the Original Curaleaf Bid until the Aurora Board made a formal recommendation.

During an in-camera portion of an Aurora Special Committee meeting held on August 27, 2026, during which Torys was also in attendance, Fort Capital provided a detailed presentation regarding its preliminary financial analysis of the Original Curaleaf Bid and responded to questions from the Aurora Special Committee. Following a lengthy discussion, it was determined that Fort Capital would refine its analysis based on feedback provided by the Aurora Special Committee, which updated analysis would be taken into account in Fort Capital's opinion with respect to the consideration being offered to Aurora Shareholders pursuant to the Original Curaleaf Bid.

On August 31, 2026, the Aurora Special Committee met with management, Torys, Stikeman and Fort Capital to discuss the draft directors' circular in response to the Curaleaf Circular, which had been circulated in advance of the meeting. The Aurora Special Committee discussed in detail the draft disclosure and their rationale for potentially recommending rejection of the Original Curaleaf Bid and provided comments to be reflected in a revised draft of the circular prior to the Aurora Special Committee's final determination and approval of its contents.

At a September 1, 2026 meeting of the Aurora Special Committee, at which management, Torys, Stikeman and Fort Capital also attended, Fort Capital provided a detailed presentation regarding its financial analysis of the Original Curaleaf Bid, refined from feedback previously provided by the Aurora Special Committee, and responded to various inquiries from members of the Aurora Special Committee and the Aurora Board. Following discussion and an in-camera session during which only the Aurora Special Committee, Torys and Fort Capital were in attendance, Fort Capital rendered an oral opinion to both the Aurora Special Committee and the Aurora Board, confirmed by delivery of a written opinion dated September 1, 2026, to the effect that, as of September 1, 2026 and based on and subject to various assumptions made, procedures followed, matters considered and limitations and qualifications on the review undertaken described in such opinion, the consideration offered to Aurora Shareholders pursuant to the Original Curaleaf Bid was inadequate, from a financial point of view, to such holders (the "**Fort Capital Inadequacy Opinion**"). After a thorough and careful review and consideration of the best interests of Aurora and the impact on,

and consideration of, the Aurora Shareholders and Aurora's other stakeholders, and following an in-camera discussion, the Aurora Special Committee concluded that the Original Curaleaf Bid was not in the best interests of Aurora for, among other reasons, the factors set out in the Directors' Circular, including that it did not recognize the full and fair value of Aurora and its business and was an attempt by Curaleaf to acquire Aurora without offering adequate consideration to Aurora Shareholders. The Aurora Special Committee then unanimously recommended to the Aurora Board that it recommend to Aurora Shareholders that they reject the Original Curaleaf Bid and not tender their Aurora Common Shares to the Original Curaleaf Bid.

Based on the Aurora Special Committee's unanimous recommendation and receipt of legal and financial advice, including the Fort Capital Inadequacy Opinion, the Aurora Board unanimously recommended to the Aurora Shareholders that they reject the Original Curaleaf Bid and approved the contents and delivery of the Directors' Circular.

The Directors' Circular was filed on Aurora's SEDAR+ profile and EDGAR profile on September 2, 2026.

Immediately following filing of the Directors' Circular, on September 2, 2026, Torys sent a letter to the ASC, which letter was shared with Curaleaf, highlighting several significant deficiencies in the Original Curaleaf Bid that were contrary to the Canadian take-over bid rules and would deprive Aurora Shareholders of sufficient information and time needed to fully evaluate the Original Curaleaf Bid. Those deficiencies are described in the Directors' Circular.

During an in-camera portion of an Aurora Special Committee meeting held on September 8, 2026, at which Fort Capital, Aurora's financial advisor, and Torys, the Aurora Special Committee's independent legal advisor, were also in attendance, the Aurora Special Committee discussed its process to consider strategic alternatives to the Original Curaleaf Bid that may offer Aurora Shareholders greater value than the Original Curaleaf Bid. At the meeting, Fort Capital provided its advice with respect to a potential process to solicit alternative proposals to acquire Aurora from third parties, including Organigram pursuant to its earlier expression of interest in exploring a potential transaction. That process would be commenced by Fort Capital reaching out to parties on a preliminary basis to assess potential interest, followed by negotiation and entry into a confidentiality agreement with Aurora on customary terms in order to access confidential information in respect of Aurora's business. Each confidentiality agreement Aurora entered into in connection with the process included a standstill provision, which is customary in the circumstances, to protect Aurora from the potential abuse of its confidential information by limiting its use to the assessment, negotiation and consummation of a transaction supported by the Aurora Board (i.e., by prohibiting the applicable third party from using such information to attempt to take control of Aurora without the support of the Aurora Board). Torys also provided advice to the Aurora Special Committee on its legal duties in the context of the Original Curaleaf Bid and its consideration of other strategic alternatives, including the solicitation of alternative acquisition proposals. The Aurora Special Committee endorsed the process recommended by Fort Capital and directed Fort Capital to commence its reach out to third parties potentially interested in participating in the process.

Following the September 8 Aurora Special Committee meeting, Aurora, through its financial advisor, Fort Capital, contacted parties that the Aurora Special Committee considered to be prospective acquirors of Aurora based on the advice of Fort Capital. In addition, given the ongoing public Original Curaleaf Bid and Aurora's response to date, other parties had the opportunity to contact Aurora or Fort Capital if they had an interest in pursuing a transaction with Aurora. Multiple parties, including Organigram, entered into non-disclosure and standstill agreements with Aurora and were granted access to an electronic data room containing certain non-public financial and operational information of Aurora and engaged in discussions with Aurora and Fort Capital with respect to potential value-maximizing transactions.

On September 14, 2026, Curaleaf filed an application with the ASC seeking to halt further sales under Aurora's ATM Program while the Original Curaleaf Bid remained outstanding, and issued a related press release. Aurora responded to the application and issued a press release that noted the application appeared to be an attempt by Curaleaf to distract Aurora Shareholders from Curaleaf's inadequate offer and that the ATM Program was publicly announced in February 2026, over six months before Curaleaf launched the Original Curaleaf Bid. The ATM Program was established to provide Aurora with flexibility to pursue strategic and accretive opportunities that support long-term shareholder value, including increased cultivation capacity and M&A.

Also on September 14, 2026, Torys received a response to its September 2 letter from counsel to Curaleaf, stating that Curaleaf did not agree with the list of deficiencies identified in that letter. The letter was clear that Curaleaf did not at that time intend to amend its Original Curaleaf Bid to comply with those Canadian securities law requirements.

On September 16, 2026, Aurora issued a press release providing a business update to Aurora Shareholders, re-affirming its fiscal year 2027 Q2 guidance for sequential growth in quarterly net revenue and adjusted EBITDA, and noting Aurora's plan to continue to invest over the next several quarters in its international business to support growth in key markets and position Aurora to create greater shareholder value.

On September 22, 2026, the Aurora Special Committee met with management, Fort Capital, Stikeman and Torys. At the meeting, management and Fort Capital provided an update with respect to the process to solicit alternative acquisition proposals, noting that the parties that had entered into non-disclosure and standstill agreements with Aurora, including Organigram, had been granted access to certain confidential information concerning Aurora.

On September 23, 2026, management representatives from Aurora and Organigram met, together with their respective financial and legal advisors, for Aurora management to present on various aspects of Aurora's business.

On September 23, 2026, Aurora filed its application with the ASC for an order requiring Curaleaf to amend the Original Curaleaf Bid to comply with Canadian securities laws. Aurora took this step in order to protect Aurora Shareholders' ability to make a fully-informed decision regarding the Original Curaleaf Bid by having the required disclosure provided to Aurora Shareholders, and giving them the amount of time prescribed under Canadian securities laws to consider the Original Curaleaf Bid.

At an Aurora Special Committee meeting held on September 29, 2026, at which Stikeman and Torys also attended, management and Fort Capital provided a further update on the process to solicit alternative acquisition proposals, noting that parties who had entered into non-disclosure and standstill agreements with Aurora continued to perform due diligence and providing an update from the management diligence session held with Organigram on September 23, 2026.

On October 5, 2026, Curaleaf announced its intention to revise the Original Curaleaf Bid to offer revised implied consideration of US$5.00 per Aurora Common Share, consisting of 0.4013 Curaleaf Shares plus US$1.00 in cash per Aurora Common Share, and to increase the maximum value of the consideration from US$5.00 to US$6.00 per Aurora Common Share. Curaleaf's press release also noted that it would now be amending the Original Curaleaf Bid to address certain of the deficiencies raised in Aurora's application to the ASC, namely by providing the required pro forma financial statements and extending the expiry time to 11:59 p.m. (Mountain Time) on December 4, 2026. Aurora responded by issuing a press release the same day, urging shareholders to take no action until a formal notice of variation and change had been filed by Curaleaf and until the Aurora Board and Aurora Special Committee fully considered the revised offer and made a formal recommendation to Aurora Shareholders.

On October 6, 2026, Curaleaf filed the Curaleaf Notice of Variation, formally making the changes to the Original Curaleaf Bid described in its press release the day before. On the same day, Aurora issued a press release reinforcing that Aurora Shareholders should not take any action until the Aurora Board and Aurora Special Committee fully considered the revised offer and made a formal recommendation to Aurora Shareholders.

On October 6, 2026, the Aurora Special Committee met with management, Fort Capital, Stikeman and Torys. At the meeting, management and Fort Capital provided an update with respect to the process to solicit alternative acquisition proposals, providing an overview of diligence conducted with each party that had entered into non-disclosure and standstill agreements with Aurora and discussions with each, as well as the anticipated timing of receipt of expressions of interest. The Aurora Special Committee also discussed the process to review the Curaleaf Notice of Variation, including requesting that Fort Capital update its financial analysis. In addition, because the Curaleaf Notice of Variation had now sufficiently remedied the deficiencies in the Original Curaleaf Bid identified by Aurora, it was determined by the Aurora Special Committee that the ASC application requesting an order to address those deficiencies had been successful in meeting its objectives and was no longer necessary and would be withdrawn.

On October 9, 2026, Organigram delivered a non-binding letter of intent to Aurora (the "**First Organigram Proposal**") subject to due diligence and proposing an acquisition of all of the Aurora Common Shares for consideration, comprised of $3.10 in cash and 3.1633 Organigram Common Shares per Aurora Common Share on a fully prorated basis, representing a stated value of $7.75 per Aurora Common Share[1], and including the ability of Aurora Shareholders to elect the form of consideration they wished to receive subject to proration, maximum amounts and adjustments. Such price represented a 92% premium to the Unaffected Price and a 13% premium relative to the implied value of the Hostile Bid of $6.84 as of October 8, 2026[2]. The First Organigram Proposal contemplated a 21-day exclusivity period in order for Organigram to conduct final confirmatory due diligence and for definitive transaction agreements to be negotiated, and described that those agreements would contemplate customary deal protection provisions, subject to a fiduciary out in favour of Aurora and a termination fee of 4.5% of the purchase price. On the same day, Business of Cannabis reported that Organigram and Aurora were in discussions regarding a potential transaction.

Between October 10 and 13, 2026, Fort Capital engaged in a number of discussions with BMO Capital Markets, Organigram's financial advisor, with respect to the price, exclusivity and other terms contemplated in the First Organigram Proposal. On the morning of October 14, 2026, BMO Capital Markets communicated to Fort Capital Organigram's proposal to increase the price offered to $3.10 in cash and 3.2789 Organigram Common Shares per Aurora Common Share on a fully prorated basis, representing a stated value of $7.92 per Aurora Common Share[3], subject to all of the same terms contained in the First Organigram Proposal (the "**Second Organigram Proposal**") and reiterating Organigram's requirement that it would only continue discussions and work towards a potential transaction on an exclusive basis.

At an October 14, 2026 meeting of the Aurora Special Committee, at which management, Torys, Stikeman and Fort Capital also attended, Fort Capital provided a detailed presentation regarding its financial analysis of the Hostile Bid as well as its preliminary analysis of the Second Organigram Proposal. Fort Capital also noted that while multiple other parties had performed due diligence regarding Aurora and expressed different levels of interest in pursuing a potential transaction with Aurora, none of those parties had delivered an expression of interest in a particular transaction. Following discussion and an in-camera session during which only the Aurora Special Committee, Torys and Fort Capital were in attendance, it was determined that the price contemplated by the Second Organigram Proposal remained inadequate. In addition, the Aurora Special Committee objected to the duration and other terms of the exclusivity period, and the quantum of the proposed termination fee. The Aurora Special Committee therefore directed management and Fort Capital to undertake negotiations with Organigram and its representatives on each of those points. With respect to the Hostile Bid, Fort Capital rendered an oral opinion to both the Aurora Special Committee and the Aurora Board, confirmed by delivery of a written opinion dated October 14, 2026, to the effect that, as of October 14, 2026 and based on and subject to various assumptions made, procedures followed, matters considered and limitations and qualifications on the review undertaken described in such opinion, the consideration offered to Aurora Shareholders pursuant to the Hostile Bid remained inadequate, from a financial point of view, to such holders (the "**Updated Inadequacy Opinion**"). After a thorough and careful review and consideration of the best interests of Aurora and the impact on, and consideration of, the Aurora Shareholders and Aurora's other stakeholders, the Aurora Special Committee concluded that the Hostile Bid was not in the best interests of Aurora for, among other reasons, the factors described under the heading "*Reasons for Rejection of the Hostile Bid*" in the Directors' Notice of Change, including that it did not recognize the full and fair value of Aurora and its business and was thus an attempt by Curaleaf to acquire Aurora without offering adequate consideration to Aurora Shareholders. The Aurora Special Committee unanimously recommended to the Aurora Board that it should recommend to Aurora Shareholders that they reject the Hostile Bid and not tender their Aurora Common Shares to the Hostile Bid.

[1] Based on the 20-day volume-weighted average trading price of the Organigram Common Shares on the TSX of approximately $1.47 as of October 8, 2026.

[2] Based on the closing price of Curaleaf Shares on the TSX on October 8, 2026, and assuming a USD/CAD exchange rate of 1.4229.

[3] Based on the 20-day volume-weighted average trading price of the Organigram Common Shares on the TSX of approximately $1.47 as of October 8, 2026.

Based on the Aurora Special Committee's unanimous recommendation and receipt of legal and financial advice, including the Updated Inadequacy Opinion, the Aurora Board unanimously recommended to the Aurora Shareholders that they reject the Hostile Bid and approved the contents and delivery of the Directors' Notice of Change.

The Directors' Notice of Change was filed on Aurora's SEDAR+ profile and EDGAR profile on October 15, 2026.

As directed by the Aurora Special Committee, on October 15, 2026, Fort Capital delivered a counter-proposal to BMO Capital Markets contemplating an increase in the price to represent a stated value of $8.34, comprised of $3.10 in cash and 3.6162 Organigram Common Shares per Aurora Common Share, a shortened exclusivity period expiring on the earlier of November 2, 2026 or Curaleaf announcing an amendment to the Hostile Bid to change the amount or form of consideration offered, and a reduced termination fee of 3.25%. The counter-proposal also expressly permitted Aurora, the Aurora Board and the Aurora Special Committee to comply with applicable securities laws in respect of the Hostile Bid or any other take-over bid.

On October 16, 2026, Organigram responded by delivering a revised non-binding letter of intent to Aurora contemplating a consideration comprised of $3.45 in cash and 3.2501 Organigram Common Shares per Aurora Common Share on a fully prorated basis, representing a stated value of $8.16 per Aurora Common Share[4] (the "**Third Organigram Proposal**"), representing a 103% premium to the Unaffected Price and a 32% premium relative to the implied value of the Hostile Bid of $6.19 as of October 15, 2026[5]. In addition, the Third Organigram Proposal contemplated a shorter exclusivity period through November 2, 2026, subject to extension to November 9, 2026 if Organigram continued to diligently pursue the proposed transaction, but rejected the earlier termination trigger of the exclusivity period linked to Curaleaf announcing an amendment to the Hostile Bid to change the amount or form of consideration offered. The Third Organigram Proposal also contemplated a termination fee of 3.99% and accepted the ability of Aurora, the Aurora Board and the Aurora Special Committee to comply with applicable securities laws in respect of the Hostile Bid or any take-over bid.

Between October 16 and 17, 2026, representatives of Torys, Stikeman and Goodmans, counsel to Organigram, engaged in several discussions with respect to the terms of the exclusivity period. During those discussions, the Torys representatives communicated the Aurora Special Committee's view that an exclusivity period would only be acceptable if it permitted Aurora to engage with Curaleaf in the event it amended the Hostile Bid to a price higher than that contemplated in Organigram's proposal. Meanwhile, Fort Capital and BMO Capital Markets also met to discuss the price of Organigram's proposal and the quantum of the termination fee, with BMO Capital Markets stating that Organigram was not willing to increase its price above the amount offered in the Third Organigram Proposal.

Following those discussions and exchange of several revised drafts, on October 18, 2026, the non-binding letter of intent was settled (the "**LOI**"), contemplating the same consideration as the Third Organigram Proposal (and a stated value of $8.16 per Aurora Common Share). The LOI continued to contemplate an exclusivity period expiring on November 2, 2026, subject to extension to November 9, 2026 if Organigram continued to diligently pursue the proposed transaction, but contained an early termination of that period if (i) Curaleaf amended the Hostile Bid to increase the amount of consideration offered, (ii) the Aurora Board determined that the Hostile Bid, as amended, would if consummated reasonably be expected to lead to a transaction more favourable from a financial point of view to Aurora Shareholders than the transaction with Organigram contemplated by the LOI and (iii) Organigram did not increase the price contemplated under the LOI such that (ii) is no longer true within two business days. The LOI also contemplated a reduced termination fee of 3.99%. The LOI was signed by Aurora and Organigram on October 18, 2026. Despite the exclusivity provisions of the LOI, Curaleaf did not contact Aurora or propose an increased price to the Hostile Bid prior to announcement of the Arrangement.

[4] Based on the 20-day volume-weighted average trading price of the Organigram Common Shares on the TSX of approximately $1.45 as of October 15, 2026.

[5] Based on the closing price of Curaleaf Shares on the TSX on October 15, 2026, and assuming a USD/CAD exchange rate of 1.4196.

On October 18, 2026, Stikeman and Torys shared an initial draft of the Arrangement Agreement with Goodmans. Shortly thereafter, representatives of Aurora were granted access to an electronic data room containing Organigram confidential information so that Aurora could complete its due diligence on Organigram's business.

On October 20, 2026, the Aurora Special Committee met to receive an update on the process from management, Fort Capital, Torys and Stikeman. In addition to receiving updates on negotiations and due diligence being conducted on Organigram, the Aurora Special Committee discussed the financial advice and opinion from Fort Capital that would be received in connection with announcing a transaction with Organigram and decided to retain an additional and independent fairness opinion provider on a fixed fee basis.

Between October 20 and 23, 2026 the Aurora Special Committee reached out to, and received proposals from, several potential fairness opinion providers. On October 24, 2026, the Aurora Special Committee retained Origin as its independent financial advisor based on its qualifications and experience in the industry and with similar mandates. Origin's mandate included providing the Aurora Special Committee with financial analysis and advice in respect of the Arrangement (or any alternative transaction) and, if requested, providing a fairness opinion in connection therewith. Pursuant to the terms of the engagement letter with Origin, Aurora would be obligated to pay a flat fee to Origin and no portion of the fees payable to Origin for its services would be contingent upon the value of any transaction, its completion or the conclusions reached in Origin's fairness opinion.

During the period between October 18 and November 2, 2026, the parties, with the assistance of their respective legal and financial advisors, negotiated the definitive terms of the Arrangement Agreement, the Aurora Support Agreements and the Organigram Support Agreements while due diligence continued (including reverse due diligence by Aurora which involved meetings between Aurora and Organigram management, attended by each party's legal and financial advisors, that occurred on October 21 and 23 and a site visit by representatives of Aurora at Organigram's main Moncton facility that week). The Aurora Special Committee also met several times over that period to receive updates on and oversee that process. At such meetings, representatives of management, Torys and Stikeman provided updates to the Aurora Special Committee with respect to their discussions with Organigram's and BAT's respective counsel and reported to the Aurora Special Committee as to open issues with respect to the draft transaction agreements. The Aurora Special Committee then instructed Torys and Stikeman as to the terms and conditions of such agreements that would be acceptable to it, including provisions relating to deal certainty and closing risk allocation (such as regulatory approvals and other closing conditions, and the scope of Aurora's representations, warranties and interim operating covenants), the nature of the non-solicitation provisions, the circumstances in which each party would be permitted to terminate the Arrangement Agreement, and the voting support agreement to be entered into with BAT, the consequences of termination (including the remedies available to Aurora) and the instances in which a termination fee would be payable by Aurora and a reverse termination fee would be payable by Organigram. Those Aurora Special Committee meetings also included updates from Fort Capital and Origin on their respective financial analyses. The Aurora Special Committee also met separately with only Torys and Origin.

In particular, it was of critical importance to the Aurora Special Committee that the Aurora Board maintain the ability to change its recommendation to Aurora Shareholders or terminate the Arrangement Agreement in the event a Superior Proposal surfaced (including an Amended Bid by Curaleaf), subject to Organigram's right to match. This was in contrast to Organigram's desire to maximize deal certainty. Ultimately, following lengthy negotiations and discussions amongst the parties, the Aurora Special Committee agreed to an increased termination fee of 4.5% of the purchase price in exchange for maintaining Aurora's right to terminate the Arrangement Agreement in the event of a Superior Proposal that Organigram elects not to match.

On November 1, 2026, Organigram proposed to increase the amount of cash that would be available to Aurora Shareholders under the Arrangement and correspondingly reduce the number of Organigram Common Shares. Based on updated trading data as of November 2, 2026, the revised proposal represented a price of $7.80[6], comprised of $3.75 in cash and 3.0431 Organigram Common Shares per Aurora Common Share on a fully prorated basis. Aurora Shareholders would be able to elect to receive (i) $7.80 in cash, (ii) 5.8626 Organigram Common Shares or (iii) a combination of $3.75 in cash and 3.0431 Organigram Common Shares, in each case per Aurora Common Share and

[6] Based on the 20-day volume-weighted average trading price of the Organigram Common Shares on the TSX of approximately $1.33 as of November 2, 2026.

subject to proration. The change to the stated value was a result of updated Organigram trading data to November 2, 2026, rather than representing a decrease in the proposed purchase price. The Aurora Special Committee, with the advice of its and Aurora's financial and legal advisors, decided to accept the revised proposal as the increased amount of cash being offered provided Aurora Shareholders with greater certainty in value and greater liquidity.

On the afternoon of November 2, 2026, the Aurora Special Committee met with Origin and Torys to review Origin's financial analysis of the Arrangement. Later that evening, the Aurora Special Committee reconvened. Following a briefing of the finalized key terms of the definitive transaction agreements, including the Arrangement Agreement, from Torys and Stikeman, Origin and Fort Capital rendered the oral Origin Fairness Opinion and oral Fort Capital Fairness Opinion, respectively, to the Aurora Special Committee and the Aurora Board. Based upon the Aurora Special Committee's consideration of, among other things, the Aurora Fairness Opinions and the advice of external legal and financial advisors, the Aurora Special Committee unanimously recommended to the Aurora Board, among other things, that the Aurora Board (i) determine that the Arrangement is in the best interests of Aurora; (ii) determine that the Arrangement is fair to the Aurora Shareholders; (iii) approve the entering into, execution, delivery and performance of Aurora's obligations under the definitive transaction agreements to which Aurora is a party, including the Arrangement Agreement; (iv) recommend that Aurora Shareholders vote in favour of the Arrangement Resolution; and (v) continue to reject the Hostile Bid and recommend that Aurora Shareholders not tender their Aurora Common Shares to the Hostile Bid. Based on the recommendation of the Aurora Special Committee and the Aurora Board's consideration of, among other things, the Aurora Fairness Opinions and the advice of external legal and financial advisors, the Aurora Board, among other things, unanimously (i) determined that the Arrangement is in the best interests of Aurora; (ii) determined that the Arrangement is fair to the Aurora Shareholders; (iii) approved the entering into, execution, delivery and performance of Aurora's obligations under the definitive transaction agreements to which Aurora is a party, including the Arrangement Agreement; (iv) recommended that Aurora Shareholders vote in favour of the Arrangement Resolution; and (v) determined to continue to reject the Hostile Bid and recommend that Aurora Shareholders not tender their Aurora Common Shares to the Hostile Bid.

The Arrangement Agreement and other transaction documents were finalized and executed on the evening of November 2, 2026, and a press release announcing the transaction was issued, and a second notice of change to the Directors' Circular containing the Aurora Board's recommendation to continue to reject the Hostile Bid was filed, on November 3, 2026, prior to the opening of trading of Aurora Common Shares on the TSX or Nasdaq.

Organigram

The Organigram Board and senior management of Organigram regularly review and consider opportunities to better realize the potential of Organigram's business, as well as Organigram's overall position in the industry, in each case with a view to enhancing value for Organigram Shareholders. In that regard, Organigram regularly evaluates and considers the possibility of participating in strategic transactions with various industry participants. Consistent with its strategic priority of international expansion, Organigram completed its acquisition of Sanity Group on April 15, 2026, providing Organigram with a presence in the German medical cannabis market and other European markets, and on August 20, 2026 announced the accelerated integration of Sanity Group under a unified global operating structure.

Throughout Organigram's consideration of the Arrangement, the representatives of BAT on the Organigram Board and on the investment committee of the Organigram Board (the "**Investment Committee**") declared their respective interests in the BAT Private Placement and abstained from voting in connection therewith. In addition, at meetings of the Organigram Board or the Investment Committee at which matters relating to Organigram's negotiations with BAT were considered, the remaining members held a separate session excluding the representatives of BAT.

On August 18, 2026, Curaleaf commenced the Original Curaleaf Bid, an unsolicited take-over bid to acquire all of the outstanding Aurora Common Shares (including the associated rights under the Aurora Shareholder Rights Plan) for consideration of US$0.75 in cash plus 0.3463 of a Curaleaf Share per Aurora Common Share (representing, as stated by Curaleaf, implied consideration of US$4.00 per Aurora Common Share), subject to a maximum value of US$5.00 per Aurora Common Share. August 10, 2026 was the last trading day prior to Curaleaf's announcement of its intention to make the Original Curaleaf Bid.

On August 20, 2026, members of Organigram's executive team met with BMO Capital Markets to discuss a potential acquisition of Aurora as an alternative to the Original Curaleaf Bid. Organigram discussed the potential opportunity with BAT, which confirmed that it was supportive of Organigram's evaluation of the opportunity with a view to a potential proposal.

On August 23, 2026, James Yamanaka, Chief Executive Officer of Organigram, contacted Miguel Martin, Executive Chairman and Chief Executive Officer of Aurora, by e-mail to invite a discussion regarding potential business opportunities. On August 24, 2026, Mr. Yamanaka called Mr. Martin to discuss a potential business combination of Organigram and Aurora, registering Organigram's interest in, and intention to submit, a written proposal.

On August 25, 2026, Organigram sent a written non-binding expression of interest to Michael Singer, the Chair of the Aurora Special Committee, and Mr. Martin. The expression of interest did not include any indication of price or other terms, but requested access to certain confidential information, noted that any proposal would be subject to customary due diligence and indicated Organigram's willingness to enter into a customary non-disclosure and standstill agreement with a view to providing an indicative proposal.

In September 2026, Organigram engaged BMO Capital Markets as its financial advisor, Goodmans as its legal counsel and Deloitte LLP as its financial due diligence and tax structuring advisor in connection with the Arrangement. BAT engaged Osler, Hoskin & Harcourt LLP as its legal counsel and ATB Financial engaged Gowling WLG (Canada) LLP as its legal counsel.

Subsequently, Organigram commenced work and analysis with its financial and legal advisors and began discussions with BAT and ATB Financial regarding financing options. Update meetings were held with the Investment Committee throughout, with the representatives of BAT abstaining from any discussion related to the BAT Private Placement. Organigram also continued to assemble a due diligence team.

On September 8, 2026, following a meeting of the Aurora Special Committee, Mr. Martin advised Mr. Yamanaka that the Aurora Special Committee had determined, as part of its process to consider strategic alternatives to the Original Curaleaf Bid, to engage with Organigram regarding a potential transaction. Organigram and Aurora subsequently entered into a mutual non-disclosure agreement containing customary standstill provisions to facilitate the exchange of confidential information in connection with a potential transaction, to which BAT became party by way of joinder.

In September 2026, Organigram engaged BMO Capital Markets as its financial advisor, Goodmans as its legal counsel and Deloitte LLP as its financial due diligence and tax structuring advisor in connection with the Arrangement. BAT engaged Osler, Hoskin & Harcourt LLP as its legal counsel and ATB Financial engaged Gowling WLG (Canada) LLP as its legal counsel.

On September 17, 2026, Organigram discussed acquisition financing and the due diligence process with ATB Financial. On the same day, Peter Amirault, Chair of the Organigram Board, Mr. Yamanaka and Finn Age Hänsel, President, Rest of World of Organigram, met with Mr. Singer and Mr. Martin to discuss a potential transaction. On September 22, 2026, members of the Organigram and Aurora executive teams and their financial advisors met again.

On September 23, 2026, members of the Organigram and Aurora executive teams and their legal and financial advisors met at the offices of counsel to the Aurora Special Committee to receive management presentations regarding Aurora's business and to engage in due diligence discussions. Separate legal and financial due diligence sessions were held during the week of September 28, 2026.

During this period, Organigram met with representatives of BAT and ATB Financial on several occasions to discuss potential financing structures, and met with its financial advisors and such financing sources to review and settle an initial proposed price. Organigram also negotiated a financing term sheet with ATB Financial. Additionally, the Investment Committee met to discuss the proposed offer and bid range.

On October 6, 2026, Curaleaf filed the Curaleaf Notice of Variation, varying, changing and extending the Original Curaleaf Bid. On the same day, Mr. Martin and Mr. Yamanaka discussed Organigram's potential proposal, including its pricing, in light of the Hostile Bid. On October 8, 2026, the Investment Committee met with Organigram's financial

and legal advisors and, on October 9, 2026, the Organigram Board met. On October 9, 2026, Organigram also held a legal due diligence session with members of Aurora, and Organigram representatives met with BAT to discuss the proposed indicative offer to Aurora. Organigram continued to work with its financial advisors to assess the consideration to be offered, the mix of cash and Organigram Common Shares and BAT's relative ownership in the combined company.

On October 9, 2026, Organigram delivered the First Organigram Proposal, being a non-binding letter of intent, subject to due diligence, proposing to acquire all of the Aurora Common Shares for consideration comprised of $3.10 in cash and 3.1633 Organigram Common Shares per Aurora Common Share on a fully prorated basis, representing a stated value of $7.75 per Aurora Common Share, with Aurora Shareholders having the ability to elect cash, Organigram Common Shares or a combination thereof, subject to proration, maximum amounts and adjustments. The First Organigram Proposal contemplated a 21-day exclusivity period to permit Organigram to conduct confirmatory due diligence and for definitive agreements to be negotiated, as well as customary deal protection provisions, subject to a fiduciary out in favour of Aurora and a termination fee of 4.5% of the purchase price.

On October 10, 2026, Mr. Yamanaka and Mr. Martin discussed the First Organigram Proposal. Aurora indicated that it was seeking an improved proposal to present to the Aurora Special Committee, noted that some form of exclusivity may be possible if the other terms were acceptable and suggested a termination fee lower than the 4.5% proposed.

On October 11, 2026, Fort Capital and BMO Capital Markets discussed the First Organigram Proposal, with a focus on price, terms and overall value. On October 12, 2026, Fort Capital delivered a revised draft of the letter of intent to BMO Capital Markets to advance the negotiation of the purchase price, exclusivity period and the termination fee.

On October 14, 2026, BMO Capital Markets communicated to Fort Capital the Second Organigram Proposal to increase the price offered to $3.10 in cash and 3.2789 Organigram Common Shares per Aurora Common Share on a fully prorated basis, representing a stated value of $7.92 per Aurora Common Share, subject to the same terms contained in the First Organigram Proposal, and reiterated Organigram's requirement that it would only continue discussions on an exclusive basis. Organigram continued to progress its due diligence, including with its financing partners with a view to obtaining committed financing, which included sharing due diligence findings. Organigram also worked on its quality of earnings analysis and merger model with the assistance of its advisors.

On October 15, 2026, Fort Capital delivered a counter-proposal to BMO Capital Markets contemplating an increase in the price to a stated value of $8.34 per Aurora Common Share, comprised of $3.10 in cash and 3.6162 Organigram Common Shares per Aurora Common Share, an exclusivity period expiring on the earlier of November 2, 2026 and Curaleaf announcing an amendment to the Hostile Bid to change the amount or form of consideration offered, a reduced termination fee of 3.25% and express permission for Aurora, the Aurora Board and the Aurora Special Committee to comply with applicable securities laws in respect of the Hostile Bid or any other take-over bid.

After receipt of the counter proposal on October 15, 2026, Organigram met with its advisors, and with BAT, to carefully assess the proposed terms. On October 16, 2026, the Investment Committee met and approved the terms of the Third Organigram Proposal, which included a stated value of $8.16 (US$5.75) per Aurora Common Share, $3.45 in cash and 3.2501 Organigram Common Shares per Aurora Common Share, a termination fee of 3.99% and an exclusivity period through November 2, 2026, subject to extension to November 9, 2026 in certain circumstances.

On October 16, 2026, Organigram delivered the Third Organigram Proposal to Aurora. The Third Organigram Proposal contemplated that the cash component would be funded through cash on hand, an increase to Organigram's credit facility with ATB Financial and a concurrent private placement with BAT, which had provided its approval in principle for the proposed transaction.

On October 16, 2026, Mr. Martin and Mr. Yamanaka discussed the Third Organigram Proposal and Aurora provided a revised draft of the letter of intent. Between October 16 and 17, 2026, the Parties, with the assistance of their respective legal and financial advisors, negotiated the exclusivity provisions and the termination fee, and BMO Capital Markets advised Fort Capital that Organigram was not willing to increase its price above that offered in the Third Organigram Proposal. On October 18, 2026, Aurora and Organigram signed the LOI, which contemplated the same consideration as the Third Organigram Proposal, a reduced termination fee of 3.99% and an exclusivity period expiring on November 2, 2026, subject to extension to November 9, 2026, and subject to early termination if Curaleaf amended

the Hostile Bid to increase the consideration offered, the Aurora Board determined that the amended Hostile Bid would reasonably be expected to lead to a transaction more favourable, from a financial point of view, to Aurora Shareholders and Organigram did not increase its price within two business days.

Between October 18, 2026 and November 2, 2026, Organigram and its advisors participated in confirmatory due diligence and, commencing on October 21, 2026, reciprocal due diligence, including reverse due diligence management sessions on October 21 and 23, 2026 and a site visit by representatives of Aurora to Organigram's Moncton facility, and negotiated the Arrangement Agreement, the Aurora Support Agreements, the Organigram Support Agreements and the Financing Commitments. During this period, the Investment Committee met on a number of occasions with members of senior management and their respective advisors in attendance to receive updates on the status of negotiations and due diligence and to provide instructions, as necessary. Following negotiations, the Parties agreed to a termination fee of 4.5% of the purchase price, together with Aurora's right to terminate the Arrangement Agreement in the event of a Superior Proposal that Organigram elects not to match.

On November 1, 2026, Organigram proposed to increase the cash component of the Consideration and correspondingly reduce the share component. Following negotiations, the terms proposed in the LOI, having an implied value of $8.16 per Aurora Common Share, were revised to the final Consideration, having an implied value of $7.80 per Aurora Common Share based on the 20-day volume-weighted average trading price of the Organigram Common Shares on the TSX as of November 2, 2026, with the cash component increased to $3.75 per Aurora Common Share and the share component reduced to 3.0431 Organigram Common Shares per Aurora Common Share.

On November 2, 2026, the Organigram Board met with BMO Capital Markets and Goodmans in attendance to review and consider the terms of the Arrangement Agreement and the BAT Private Placement, and BMO Capital Markets provided its oral opinion that, as of such date and subject to the assumptions, limitations and qualifications to be set out in its written opinion, the Consideration to be paid by Organigram pursuant to the Arrangement is fair, from a financial point of view, to Organigram. The Organigram Board (with the representatives of BAT abstaining in respect of the BAT Private Placement) unanimously approved the Arrangement and the BAT Private Placement. See "*The Arrangement – Recommendation of the Organigram Board*".

On the evening of November 2, 2026, Organigram and Aurora entered into the Arrangement Agreement, the applicable parties entered into the Aurora Support Agreements and the Organigram Support Agreements, Organigram and BAT entered into the BAT Equity Commitment and Organigram accepted the ATB Commitment Letter. Prior to the opening of markets on November 3, 2026, Organigram and Aurora issued a joint press release announcing the Arrangement.

Reasons for and Benefits of the Arrangement

Organigram and Aurora expect that the Arrangement will create a global cannabis leader with leading positions in Canada, Europe and Australia, supported by Organigram's strategic shareholder, BAT. The combined company is expected to have a global platform with greater scale, broader capabilities, financial strength and international reach, bringing together Organigram's recreational cannabis leadership, production network, research and development platform and European medical commercial operations with Aurora's global medical cannabis leadership, established international presence and EU-GMP certified manufacturing capabilities. The following are some, but not all, of the anticipated benefits of the Arrangement:

- *Creates a Global Cannabis Leader*. The combination of Organigram and Aurora is expected to create a scaled, Canadian-headquartered global cannabis platform with strong positions in five nationally legal cannabis markets – Canada, Germany, Poland, Australia and New Zealand – and meaningful operations in other key markets.

- *Complementary Capabilities*. Organigram's leadership in the Canadian adult-use market, diversified production and cultivation capabilities, sophisticated research and development platform and European medical market presence are expected to complement Aurora's global medical cannabis leadership, established European operations, scientific leadership in breeding and genetics and EU-GMP certified production capabilities. In particular, supplying Sanity Group's German sales with EU-GMP certified flower

produced within the combined company's network, in place of flower purchased from third parties, is expected to generate cost savings in Germany.

- *Broader Geographic Reach and More Diversified Revenue Base*. The combined company is expected to have a broader geographic footprint, a deeper portfolio of brands and products across medical and adult-use channels, and a more diversified revenue base, reducing its reliance on any single market, channel or product category.

- *Premium Medical Revenue Mix That Supports Sustainable Growth and Margins*. The majority of pro forma revenue is expected to be derived from higher-margin international medical channels, which command structurally better pricing than the Canadian recreational market, while Organigram's Canadian recreational cannabis leadership is expected to continue to provide a stable commercial base and a proving ground for product innovation.

- *Industry-Leading EU-GMP Platform with Significant Production Capacity*. The combined company is expected to have five EU-GMP production and distribution sites across Canada and Germany, providing certified supply capacity and a combined cultivation capacity of approximately 170,000 kg per annum across 14 production, research and distribution sites, which is expected to be expensive and time-consuming for competitors to replicate. The combined platform is also expected to support faster cash conversion, resulting in lower investment in inventory and improved working capital efficiency.

- *Meaningful Synergies*. The Arrangement is expected to result in more than $50 million in synergies annually, including from shared manufacturing and distribution infrastructure, lower public company costs, lower general, administrative and operating costs, procurement and supply chain optimization, and revenue opportunities from cross-selling across the Canadian and international footprints of Organigram and Aurora.

- *Positioned for Stronger Financial Performance*. The Arrangement is expected to position Organigram for stronger revenue, enhanced margin, and cash flow generation in future periods.

- *Accelerates Product Innovation and Commercial Growth*. The combined company's scale and cross-border infrastructure are expected to create a platform for shared innovation and brand building, supported by BAT's demonstrated expertise in research and development, innovative product development and global supply chain management. The combined company is expected to bring together Aurora's breeding and genetics centre at Aurora Coast with Organigram's product development capabilities in non-flower formats, including the Centre of Excellence established with BAT and its dedicated edibles and extraction facilities, providing innovation capabilities across both flower and derivative products.

- *Continued Support of a Strategic Partner*. BAT, Organigram's largest shareholder, is a global consumer goods company with demonstrable innovation, marketing and product development capabilities around the world. BAT has demonstrated its support for the Arrangement through the BAT Private Placement on the same pricing basis as the Share Alternative and is expected to hold an economic interest of approximately 44% in the combined company following completion of the Arrangement, with its voting interest remaining capped at 30%.

- *Committed Financing*. The cash portion of the Consideration is fully financed through a combination of cash on hand, the BAT Private Placement and the ATB Credit Facilities, a structure designed to preserve financial flexibility and support continued investment in the combined company's growth priorities.

- *Enhanced Scale and Capital Markets Profile*. The combined company is expected to have greater scale, a larger market capitalization and improved trading liquidity on the TSX and Nasdaq, which is expected to enhance its profile with institutional investors and its access to capital, and to position it for a potential valuation re-rating.

- *Experienced Leadership Team*. The combined company is expected to be led by an experienced management team, with deep industry knowledge and complementary expertise across cultivation, production, regulatory compliance and international commercialization.

- *Comprehensive Negotiated Process and Fairness Opinions*. The terms of the Arrangement Agreement are the result of a comprehensive arm's length negotiation process undertaken with the participation of each Party's financial and legal advisors and, in the case of Aurora, the Aurora Special Committee and its financial and legal advisors. The Aurora Board and Aurora Special Committee received the Fort Capital Fairness Opinion and the Origin Fairness Opinion, and the Organigram Board received the Organigram Fairness Opinion.

- *Shareholder and Court Approvals*. The Arrangement must be approved by not less than 66⅔% of the votes cast by Aurora Shareholders and by a simple majority of such votes cast excluding the votes required to be excluded under MI 61-101, and the Organigram Share Issuance Resolution must be approved by greater than 50% of the votes cast by Organigram Shareholders and by greater than 50% of such votes cast, excluding the votes required to be excluded under the TSX Company Manual and MI 61-101. The Arrangement must also be approved by the Court, which will consider, among other things, the fairness and reasonableness of the Arrangement.

See "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement*".

Additional Reasons and Benefits for Aurora Shareholders

On November 3, 2026, Aurora and Organigram announced that they entered into the Arrangement Agreement. Under the Arrangement, holders of Aurora Common Shares (other than Dissenting Aurora Shareholders) will be entitled to receive, at their election, $7.80 in cash, 5.8626 Organigram Common Shares or a combination of $3.75 in cash and 3.0431 Organigram Common Shares for each Aurora Common Share held, subject to proration. See "*The Arrangement*" and "*Effect of the Arrangement*" in this Joint Information Circular.

The Aurora Board and Aurora Special Committee are of the view that, compared to the Hostile Bid, the Arrangement provides greater value to Aurora Shareholders, underpinned by a significant cash component at a fixed price, a substantial premium, and the expected synergies, growth prospects and future opportunities of the combined business. Moreover, the Arrangement offers Aurora Shareholders the opportunity to continue to benefit from the future value of Aurora's existing business, with Aurora Shareholders expected to hold approximately 37% of the economic interest and 41% of the voting rights in Organigram, on a fully diluted basis, immediately after giving effect to the Arrangement and the BAT Private Placement.

After thorough consideration of all aspects of the Arrangement and the Hostile Bid, and advice from their financial and legal advisors, the Aurora Board and Aurora Special Committee have **UNANIMOUSLY** determined that the benefits of the Arrangement to Aurora and the Aurora Shareholders outweigh, and are superior to, the Hostile Bid. The Aurora Board recommends Aurora Shareholders **APPROVE** the Arrangement and **REJECT** the Hostile Bid. The benefits of the Arrangement include, without limitation, the following:

- **The Consideration Delivers Compelling and Immediate Value to Aurora Shareholders**

    - ***Significant Premium***

      The implied value of the Consideration of $7.80 per Aurora Common Share represents a premium of approximately 93% to the Unaffected Price, and a premium of approximately 101% to the 30-day volume weighted average price of the Aurora Common Shares on the TSX of $3.88 as at the Unaffected Date. The implied value of the Consideration is also approximately 40% above the average analyst target price for the Aurora Common Shares of $5.56 as at the Unaffected Date.

- ***Attractive Implied Valuation***

  The Consideration values Aurora significantly in excess of the multiples at which Aurora's Canadian licensed producer peers trade, even after applying a control premium, and within the range of multiples paid in precedent Canadian cannabis transactions. The implied value of the Consideration is also within the range of values for the Aurora Common Shares implied by a discounted cash flow analysis of management's forecast.

- ***Certainty of Value and Flexibility of Consideration***

  Aurora Shareholders who elect the Cash Alternative will receive a fixed price of $7.80 per Aurora Common Share, subject to proration, providing certainty of value that the Hostile Bid, which consists of approximately 80% Curaleaf Shares with no floor or collar, does not. Aurora Shareholders may alternatively elect to receive the Share Alternative or the Combination Alternative, allowing each Aurora Shareholder to tailor the form of consideration to its own objectives, liquidity needs and tax position, subject to proration. In aggregate, approximately 48% of the value of the Consideration is payable in cash, more than double the approximately 20% cash component of the Hostile Bid.

- **The Arrangement is Superior to the Hostile Bid**

The Aurora Board and the Aurora Special Committee have twice unanimously determined, with the benefit of the Fort Capital Inadequacy Opinion and the Updated Inadequacy Opinion, that the Original Curaleaf Bid and the Hostile Bid, respectively, are financially inadequate and significantly undervalue Aurora. The reasons set out in the Directors' Circular and the Directors' Notice of Change continue to apply.

- ***Higher Implied Value than the Hostile Bid***

  The Hostile Bid, as varied on October 6, 2026, offers US$1.00 in cash and 0.4013 of a Curaleaf Share per Aurora Common Share, subject to a maximum of US$6.00 per Aurora Common Share, with approximately 80% of the consideration consisting of Curaleaf Shares. As at November 2, 2026, the Hostile Bid had an implied value of approximately $6.41 per Aurora Common Share, and the implied value of the Consideration under the Arrangement is $7.80 per Aurora Common Share, representing a premium of approximately 21% to the implied value of the Hostile Bid. The cash component of the Combination Alternative alone ($3.75) is approximately 2.7 times the cash component of the Hostile Bid (US$1.00, or approximately $1.41).

- ***Independent Equity Research Analysts View the Arrangement as Superior to the Hostile Bid***

  Following announcement of the Arrangement, each of TD Cowen, ATB Capital Markets and Roth Capital Partners set its target price for the Aurora Common Shares at $7.80, the implied value of the Consideration. Notably, TD Cowen, which maintained its buy rating throughout the pendency of the Original Curaleaf Bid and the Hostile Bid and did not recommend that Aurora Shareholders tender, now recommends that Aurora Shareholders support the Arrangement, stating that "Organigram offers a potentially cleaner path to value realization than Curaleaf…despite a similar headline price: cash up front, less balance-sheet risk on the equity portion, and a combination linking Aurora's EU-GMP supply with Sanity's German commercial platform", and citing greater monetization certainty, less balance sheet risk, and a complementary fit, especially in Germany. No independent equity research analyst covering Aurora has recommended that Aurora Shareholders accept the Hostile Bid in preference to the Arrangement.

  Under the Hostile Bid, Aurora Shareholders would receive subordinate voting shares and become a minority in a company controlled by a single individual through a multiple voting share structure, under which Curaleaf's Chairman and Chief Executive Officer holds approximately 69% of the votes on an economic interest of approximately 18%. Under the Arrangement, Aurora Shareholders

would receive shares of a company with a single class of voting shares carrying one vote per share and no controlling shareholder, and are expected to hold approximately 41% of the voting rights in the combined company, at least commensurate with their approximately 37% economic interest.

- **Opportunity to Participate in a Larger, Stronger and More Diversified Combined Company**

  - ***Meaningful Continued Ownership and Influence***

    On completion of the Arrangement and the BAT Private Placement, Aurora Shareholders are expected to hold approximately 37% of the economic interest and 41% of the voting rights in Organigram, on a fully diluted basis. The Arrangement provides Aurora Shareholders who receive Organigram Common Shares with continued participation in the future growth and value of Aurora's international medical platform, while gaining exposure to Organigram's leading Canadian recreational position, its low-cost cultivation base and its German and other international operations, and a meaningful voice in the combined company. Under the Hostile Bid, by contrast, Aurora Shareholders would hold only approximately 9% of the economic interest in Curaleaf and a smaller share of the votes, such that substantially all of the value created by a combination would accrue to Curaleaf's existing shareholders.

  - ***Aurora's Assets are Expected to be More Valuable in a Combination***

    The Aurora Board and Aurora Special Committee believe that Aurora's principal assets have the potential to generate greater value within the combined company than on a standalone basis. Aurora's EU-GMP certified production is expected to supply Sanity Group's commercial platform in Germany, Europe's largest cannabis market, where the combined company is expected to hold a strong market position. Further, Aurora's breeding and genetics program is expected to be paired with Organigram's product development capabilities in non-flower formats. As holders of Organigram Common Shares following the completion of the Arrangement, Aurora Shareholders who retain Organigram Common Shares will participate in the value of these opportunities to the extent realized.

  - ***Opportunity to Participate in Potential Synergies***

    Organigram has publicly disclosed the potential for meaningful near and longer-term synergies from the Arrangement. As holders of Organigram Common Shares following the completion of the Arrangement, Aurora Shareholders who retain Organigram Common Shares will participate in the value of such synergies to the extent realized. See "*The Arrangement – Reasons for and Benefits of the Arrangement – Additional Reasons and Benefits for Organigram Shareholders*" in this Joint Information Circular.

    For example, some of the opportunities for synergy upside include:

    - Opportunities for cross-selling across Organigram's and Aurora's Canadian and international footprints;

    - Procurement scale across the combined company;

    - Consolidated distribution;

    - Reduced public company expenses, including by eliminating duplicate costs such as insurance, audit, stock exchange listing and legal fees;

    - Routing international demand to the lowest-cost certified production asset across the combined network, and greater efficiency in the international supply chain from increased vertical integration;

- Consolidating information technology systems and related infrastructure;
- Operational and process improvements across the combined cultivation, processing and distribution network; and
- Savings in general and administrative costs from consolidating overlapping functions and third-party contracts.

- ***Balance Sheet Strength and Liquidity***

  Both companies bring strong balance sheets to the combination, and the Arrangement is financed to preserve them. As at September 30, 2026, Aurora had no funded debt and held approximately $133 million of cash, and Organigram carried minimal net debt as at June 30, 2026. The cash component of the Consideration is fully financed, with no financing condition, through cash on hand, the concurrent BAT Private Placement and an increase in Organigram's existing credit facilities. A majority of the cash component of the Consideration is funded by new equity rather than debt, and the debt carries an interest rate of approximately half of what Curaleaf pays on its senior secured notes. The combined company will retain flexibility to fund integration, growth and further international expansion.

  By comparison, as at September 30, 2026, Curaleaf carried approximately US$1.1 billion of debt, leases and financing obligations, including US$500 million of 11.5% senior secured notes due February 2029, and a US$476 million uncertain tax liability relating to its position under Section 280E of the U.S. Internal Revenue Code, with its taxation years 2020 through 2024 under audit by the IRS. Under the Hostile Bid, Aurora Shareholders would contribute Aurora's debt-free balance sheet and cash to Curaleaf and assume a proportionate exposure to Curaleaf's leverage, cost of debt and tax exposure. Under the Arrangement, Aurora's balance sheet is preserved and Aurora Shareholders have the opportunity to participate in a stronger combined company.

- **Organigram Common Shares Have Highly Attractive Characteristics**

  - ***Organigram Common Shares Received at an Attractive Valuation***

    As at November 2, 2026, the last trading day before announcement of the Arrangement, the Organigram Common Shares traded at approximately 7.5x consensus calendar 2026 Adjusted EBITDA and 5.2x consensus calendar 2027 Adjusted EBITDA, below the multiples at which Aurora's Canadian licensed producer peers trade, and research analysts covering Organigram had an average target price of $3.12 per Organigram Common Share, with four of five analysts rating the Organigram Common Shares a buy. The Aurora Board and Aurora Special Committee believe that Aurora Shareholders who receive Organigram Common Shares are receiving shares at an attractive valuation with meaningful upside potential.

  - ***Governance – Single Class of Shares, Well-Capitalized and Supportive Strategic Shareholder***

    Organigram has a single class of voting shares, carrying one vote per share, and no controlling shareholder. Its cornerstone shareholder, BAT, a global consumer goods company, has been Organigram's strategic partner since 2021, has funded its growth on successive occasions, and has now committed to fund a substantial portion of the cash component of the Consideration. BAT is expected to hold approximately 44% of the economic ownership of the combined company, with its ownership of voting shares contractually capped at 30%, and Aurora Shareholders are expected to hold approximately 41% of the voting shares.

    Curaleaf, by contrast, is a controlled company: its Chairman and Chief Executive Officer holds multiple voting shares carrying approximately 69% of the votes on an economic interest of approximately 18%. Under the Hostile Bid, Aurora Shareholders would become a minority in a

company controlled by a single individual; under the Arrangement, they become the largest voting constituency in a company backed by a well-capitalized, long-term strategic shareholder whose influence is capped below control.

- ***Trading Liquidity***

  The Organigram Common Shares are listed on the TSX and Nasdaq, so Aurora Shareholders who receive Organigram Common Shares will continue to hold a security listed on a senior U.S. exchange. Organigram intends to maintain its Nasdaq listing in the long-term notwithstanding Nasdaq's recent notification to Organigram that it is not in compliance with its minimum bid price requirement. Following completion of the Arrangement, the combined company is expected to attract broader institutional ownership, research coverage, index eligibility and trading liquidity over time.

- ***Tax-Deferred Exchange***

  The Arrangement has been structured with the objective of permitting eligible Canadian resident Aurora Shareholders to exchange their Aurora Common Shares for Organigram Common Shares on a tax-deferred basis for Canadian federal income tax purposes. See "*Certain Canadian Federal Income Tax Considerations*". For U.S. tax purposes, the Arrangement is expected to be a taxable transaction for Aurora Shareholders who are U.S. Holders. See "*Certain United States Federal Income Tax Considerations*" in this Joint Information Circular. **Aurora Shareholders should consult their own tax advisors for advice with respect to the Canadian and U.S. federal income tax consequences to them in respect of the Arrangement.**

- **The Arrangement was the Result of a Full and Fair Process and is Supported by All of Aurora's Directors**

  - ***Preferred Outcome of a Robust Strategic Alternatives Process***

    The Arrangement was determined to be the preferred strategic alternative available to Aurora and the Aurora Shareholders following the conclusion of a robust strategic review process conducted under the oversight and supervision of the Aurora Special Committee. The Aurora Special Committee was mandated to, among other things, review and evaluate the Original Curaleaf Bid (including as subsequently varied by the Hostile Bid), identify and consider strategic alternatives available to Aurora, including pursuing Aurora's existing strategy as a standalone entity, supervise the negotiation of any alternative transaction, and make recommendations to the Aurora Board. With the assistance of its advisors, the Aurora Special Committee oversaw an extensive market canvass of a broad range of potential alternatives to maximizing value for Aurora Shareholders, including outreach to multiple parties in respect of possible change of control transactions. See "*Background to the Arrangement*".

  - ***Arm's-Length Negotiations and Reciprocal Due Diligence***

    The Arrangement Agreement is the result of arm's-length negotiations between the Aurora Special Committee, with the assistance of its financial and legal advisors, and Organigram, following reciprocal due diligence by each of Aurora and Organigram on the other, including Aurora's due diligence on the value of the Organigram Common Shares to be received by Aurora Shareholders. Over the course of the negotiations, the Aurora Special Committee obtained successive improvements in Organigram's terms. The First Organigram Proposal on October 9, 2026 offered a stated value of $7.75, comprised of $3.10 in cash plus 3.1633 Organigram Common Shares per Aurora Common Share. The LOI executed on October 18, 2026 increased both components, to a stated value of $8.16, comprised of $3.45 in cash plus 3.2501 Organigram Common Shares. The definitive terms agreed on November 2, 2026 increased the cash component to $3.75 per Aurora Common Share, approximately 21% above the amount initially proposed, by converting a portion

of the share component into cash, giving Aurora Shareholders greater certainty of value and liquidity than under any prior proposal.

- ***All of the directors and executive officers of Aurora have entered into Aurora Support Agreements with Organigram pursuant to which such directors and executive officers have agreed, among other things, to vote in favour of the Arrangement, subject to the terms and conditions contained therein***

  The Aurora Support Agreements may only be terminated under limited circumstances, including in the event of termination of the Arrangement Agreement. A copy of the form of Aurora Support Agreement is available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. See "*Effect of the Arrangement – Aurora Support Agreements*" in this Joint Information Circular.

- **Fort Capital and Origin have each provided a fairness opinion in respect of the Arrangement**

  The Aurora Board and Aurora Special Committee have received an opinion from each of Fort Capital and Origin (which acted as financial advisor to the Aurora Special Committee) to the effect that, as of the date thereof, and based on and subject to the assumptions made, procedures followed, matters considered and limitations and qualifications set forth therein, the Consideration to be received by the Aurora Shareholders pursuant to the Arrangement is fair, from a financial point of view, to the Aurora Shareholders.

  Copies of the written opinions of Fort Capital and Origin, which describe, among other things, the assumptions made, procedures followed, matters considered and limitations and qualifications on the review undertaken in connection with each such opinion, are appended to this Joint Information Circular in Appendix "F" – "*Aurora Fairness Opinions*".

- **The Arrangement Agreement Provides Deal Certainty and Protections to Aurora Shareholders**

  - ***The Arrangement Agreement Includes Limited Conditions Precedent***

    Organigram's obligation to complete the Arrangement is subject to a limited number of conditions, which the Aurora Board believes are reasonable under the circumstances.

    The Aurora Board believes that the Arrangement is likely to be completed in accordance with its terms and within a reasonable time. The Arrangement is currently expected to close in January 2027.

  - ***The Arrangement is Not Subject to a Financing Condition***

    Organigram intends to fund the aggregate cash Consideration and related transaction expenses through cash on hand, the BAT Private Placement and the ATB Credit Facilities. Organigram has made certain covenants under the Arrangement Agreement in connection with its financing commitments, but Organigram's obligation to close the Arrangement is not conditioned on its ability to obtain financing.

  - ***The Arrangement is Subject to Procedural Safeguards***

    - The Arrangement Resolution must be approved by not less than 66⅔% of the votes cast by the Aurora Shareholders present virtually or represented by proxy and entitled to vote at the Aurora Shareholders' Meeting, voting together as a single class, and by a simple majority of such votes cast, excluding the votes required to be excluded under MI 61-101.

    - The Arrangement will be subject to a judicial determination of the Court that the Arrangement is fair and reasonable, both procedurally and substantively, to Aurora Shareholders.

- Aurora Shareholders who do not vote in favour of the Arrangement will have the right to require a judicial appraisal of their Aurora Common Shares and obtain "fair value" pursuant to the proper exercise of the Dissent Rights.

- ***The Arrangement Agreement Does Not Preclude a Superior Proposal***

  Pursuant to the Arrangement Agreement, the Aurora Board, in certain circumstances, will still be able to consider, accept and enter into a definitive agreement with respect to a Superior Proposal, provided that Aurora pays to Organigram the Aurora Termination Fee. The Aurora Board and Aurora Special Committee are of the view that the Aurora Termination Fee would not preclude a third party from making a potential unsolicited Superior Proposal in respect of Aurora.

- ***BAT has Entered into an Agreement to Vote in Favour of, and Otherwise Support, the Arrangement***

  Pursuant to the terms of the Organigram Support Agreement signed by BAT, BAT has agreed to vote in favour of the Organigram Share Issuance Resolution and otherwise support the Arrangement. If the Arrangement Agreement is terminated in certain circumstances, BAT's Organigram Support Agreement will not terminate until six-months following such termination, enhancing deal certainty for Aurora Shareholders. See "*The Arrangement – Organigram Support Agreements*".

In the course of their deliberations, the Aurora Special Committee and the Aurora Board also considered a variety of risks (as described in greater detail under the heading "*Risk Factors*" in this Joint Information Circular) and potentially negative factors in connection with the Arrangement, including, but not limited to:

- the limitations contained in the Arrangement Agreement on Aurora's ability to solicit alternative transactions from third parties, as well as the fact that if the Arrangement Agreement is terminated in certain circumstances, Aurora may also be required to pay the Aurora Termination Fee, which may adversely affect Aurora's financial condition;

- the conditions to Organigram's obligation to complete the Arrangement and the rights of Organigram to terminate the Arrangement Agreement in certain circumstances;

- the restrictions imposed pursuant to the Arrangement Agreement on the conduct of Aurora's business during the period between the entering into of the Arrangement Agreement and the consummation of the Arrangement;

- the fact that certain of Aurora's directors and executive officers have interests in the Arrangement that differ from, or are in addition to, the Consideration to be received by Aurora Shareholders pursuant to the Arrangement, which interests are described under the heading "*Interests of Certain Persons or Companies in the Arrangement – Aurora*";

- if the Arrangement is successfully completed, Aurora will no longer exist as an independently publicly traded company and the Aurora Shareholders will be unable to fully participate in the long-term potential benefits of the business of Aurora;

- if the Arrangement Agreement is terminated and the Aurora Board decides to seek another transaction or business combination, there is no assurance that Aurora will be able to find a transaction that delivers greater or equivalent value to Aurora Shareholders compared to the value of the Consideration available to Aurora Shareholders under the Arrangement; and

- if the Arrangement Agreement is terminated, Aurora's business may be negatively impacted as a result of pursuing the Arrangement, including as a result of costs to Aurora in pursuing the Arrangement, the diversion of management attention away from the conduct of Aurora's business in the ordinary course and the potential loss of key employees.

The recommendations of the Aurora Special Committee and the Aurora Board were made after giving consideration to a number of factors including, without limitation, those set forth above and in light of the Aurora Special Committee's and the Aurora Board's knowledge of the business, financial condition and prospects of Aurora and Organigram, and in consultation with and taking into account the advice of financial and legal advisors. The information and factors described above and considered by the Aurora Special Committee and the Aurora Board in reaching their determinations and making their approvals are not intended to be exhaustive, but include material factors considered by the Aurora Board and the Aurora Special Committee. In view of the wide variety of factors considered in connection with their evaluation of the Arrangement and the complexity of these matters, the Aurora Special Committee and the Aurora Board did not find it useful, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In addition, individual members of the Aurora Special Committee and the Aurora Board may have given different weight to different factors.

See "*The Arrangement – Recommendation of the Aurora Board*".

The foregoing reasons for recommending the Arrangement include certain assumptions relating to forward-looking information, and such information and assumptions are subject to various risks. See "*Forward-Looking Statements and Information*" and "*Risk Factors*".

Additional Reasons and Benefits for Organigram Shareholders

In determining that the Arrangement is fair to the Organigram Shareholders and the holders of Organigram Preferred Shares, that the Arrangement and the entry into the Arrangement Agreement are in the best interests of Organigram and to unanimously recommend that the Organigram Shareholders vote in favour of the Organigram Share Issuance Resolution, the Organigram Board considered and relied upon a number of factors, including, among others (including those described under "*Reasons for and Benefits of the Arrangement*" above), the following:

- *Expected Synergies*. On a run-rate basis, the combined company has identified more than $50 million in annual synergies, which are expected to be realized within 18 to 24 months following completion of the Arrangement.

- *Accelerates international Medical Strategy*. The Arrangement significantly accelerates Organigram's international growth strategy by adding Aurora's established medical cannabis platform, commercial infrastructure and customer relationships across key international markets, providing Organigram with immediate scale and capabilities that would otherwise take significant time and investment to develop organically. The Arrangement further diversifies Organigram beyond its leading Canadian recreational cannabis position by materially increasing its exposure to international medical cannabis markets, following its prior acquisition of Sanity Group, which generally benefit from higher pricing and margins, while reducing Organigram's reliance on any single market or channel.

- *Enhanced Ability to Grow*. The combined company is expected to have enhanced access to capital, a broader portfolio of brands and products, and greater operational and financial capacity to pursue growth opportunities in Canada and internationally.

- *Adds Scarce EU-GMP Infrastructure and Production Capacity*. The Arrangement provides Organigram with access to Aurora's established EU-GMP certified manufacturing capabilities and, together with Organigram's existing assets, creates a platform with five EU-GMP production and distribution sites across Canada and Germany and approximately 170,000 kg of annual cultivation capacity, capabilities that would be costly and time-consuming to replicate independently

- *Attractive Financing and Strategic Validation from BAT*. BAT's participation in the financing of the Arrangement demonstrates continued support from Organigram's largest shareholder and enables Organigram to finance the cash portion of the Consideration while preserving balance sheet flexibility to continue investing in the combined company's growth priorities.

- *Organigram Fairness Opinion*. BMO Capital Markets provided the Organigram Fairness Opinion, the full text of which is attached as Appendix "G" to this Joint Information Circular, to the Organigram Board to the effect that, as of November 2, 2026, and based upon and subject to the assumptions, limitations and qualifications set forth therein, the Consideration to be paid by Organigram pursuant to the Arrangement is fair, from a financial point of view, to Organigram.

- *Organigram Shareholder Approval*. Greater than (i) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting and (ii) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, excluding the votes required to be excluded under the TSX Company Manual and MI 61-101, is required to approve the Organigram Share Issuance Resolution.

- *Arm's Length Negotiation*. The Arrangement Agreement is the result of arm's length negotiations with the Aurora Special Committee, and the Organigram Board supervised the negotiation of the key economic and other material terms of the Arrangement Agreement and the Plan of Arrangement.

- *Aurora Support Agreements*. Organigram has entered into the Aurora Support Agreements with the Supporting Aurora Shareholders, being all of the directors and executive officers of Aurora, each of which has agreed to, among other things, vote all of their Aurora Common Shares in favour of the Arrangement at the Aurora Shareholders' Meeting and to otherwise support the Arrangement.

See "*The Arrangement – Recommendation of the Organigram Board*".

The information and factors described above and considered by the Organigram Board in reaching its determinations and making its approvals are not intended to be exhaustive, but include material factors considered by the Organigram Board. In view of the wide variety of factors considered in connection with its evaluation of the Arrangement and the complexity of these matters, the Organigram Board did not find it useful, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In addition, individual members of the Organigram Board may have given different weight to different factors.

Aurora Fairness Opinions

Fort Capital Fairness Opinion

Following the initial approach by Curaleaf in June 2026, Aurora retained Fort Capital to consider Curaleaf's proposal, including the Hostile Bid, and potential transactions that might be pursued by Aurora as an alternative to the Hostile Bid. Fort Capital was retained pursuant to an engagement letter dated July 7, 2026. Pursuant to the engagement letter, Fort Capital provided financial advice to Aurora, the Aurora Special Committee and the Aurora Board and was requested to deliver a fairness opinion to the Aurora Special Committee and the Aurora Board in connection with the Arrangement. The Fort Capital Fairness Opinion provides an opinion by Fort Capital to the Aurora Special Committee and the Aurora Board to the effect that, as of November 2, 2026 and subject to the assumptions, limitations, and qualifications set forth therein, the Consideration to be received by Aurora Shareholders is fair, from a financial point of view, to such Aurora Shareholders.

The full text of the Fort Capital Fairness Opinion, setting out the assumptions made, matters considered and limitations and qualifications on the review undertaken in connection with the Fort Capital Fairness Opinion, is attached as Appendix "F" to this Joint Information Circular.

The Fort Capital Fairness Opinion is not a recommendation as to how the Aurora Shareholders should vote with respect to the Arrangement or any other matter. The Fort Capital Fairness Opinion was one of a number of factors taken into consideration by the Aurora Special Committee in making its recommendations and the Aurora Board in making its unanimous determinations that the Arrangement is fair to the Aurora Shareholders, that the Arrangement and the entry into the Arrangement Agreement are in the best interests of Aurora and to unanimously recommend that the Aurora Shareholders vote in favour of the Arrangement Resolution.

Pursuant to the terms of its engagement letter with Aurora, Fort Capital will receive a fee for rendering the Fort Capital Fairness Opinion. Fort Capital will also receive a fee for its advisory services, a substantial portion of which is contingent upon a change of control of Aurora or certain other events, including the completion of the Arrangement. Aurora has also agreed to reimburse Fort Capital for its reasonable expenses and to indemnify Fort Capital against certain liabilities that may arise out of its engagement with Aurora. Neither Fort Capital nor any of its affiliated entities is an insider, associate or affiliate (as such terms are defined in the Securities Act (Ontario)) of Organigram or Aurora.

During the 24 months preceding the date on which Fort Capital was first contacted with respect to the engagement regarding Curaleaf's proposal, the Hostile Bid and the Arrangement, Fort Capital was engaged by Aurora from time to time to provide financial advisory services in the ordinary course and received customary fees in connection with such engagements. During the same period, Fort Capital has not provided any financial advisory services to Organigram.

Any summary of the Fort Capital Fairness Opinion herein is qualified in its entirety by reference to the full text of the Fort Capital Fairness Opinion as set out in Appendix "F" to this Joint Information Circular. The Fort Capital Fairness Opinion was provided solely for the use of the Aurora Special Committee and the Aurora Board (solely in their capacities as such) in connection with the Aurora Special Committee's and the Aurora Board's evaluation of the Arrangement and may not be relied upon by any Aurora Shareholders or any other person. The Fort Capital Fairness Opinion is not intended to and does not constitute a recommendation as to how the Aurora Shareholders should vote in respect of the Arrangement Resolution. The Fort Capital Fairness Opinion was one of a number of factors taken into consideration by the Aurora Special Committee in making its recommendations and the Aurora Board in making its unanimous determinations that the Arrangement is fair to the Aurora Shareholders, that the Arrangement and the entry into the Arrangement Agreement are in the best interests of Aurora and to unanimously recommend that the Aurora Shareholders vote in favour of the Arrangement Resolution. Fort Capital expresses no view as to, and the Fort Capital Fairness Opinion does not address, the relative merits of the Arrangement as compared to other transactions or business strategies that might be available to Aurora, the underlying business decision to implement the Arrangement or any other term or aspect of the Arrangement or any other agreements entered into or amended in connection with the Arrangement.

Origin Fairness Opinion

Aurora retained Origin pursuant to an engagement letter effective October 24, 2026 to act as the independent financial advisor to the Aurora Special Committee in connection with the Arrangement or any alternative transaction. Pursuant to the engagement letter, Origin provided financial advice to the Aurora Special Committee and was requested to deliver a fairness opinion to the Aurora Special Committee and the Aurora Board in connection with the Arrangement. The Origin Fairness Opinion provides an opinion by Origin to the Aurora Special Committee and the Aurora Board to the effect that, as of November 2, 2026 and subject to the assumptions, limitations, and qualifications set forth therein, the Consideration to be received by the Aurora Shareholders pursuant to the Arrangement is fair, from a financial point of view, to the Aurora Shareholders.

The full text of the Origin Fairness Opinion, setting out the assumptions made, matters considered and limitations and qualifications on the review undertaken in connection with the Origin Fairness Opinion, is attached as Appendix "F" to this Joint Information Circular.

The Origin Fairness Opinion is not a recommendation as to how the Aurora Shareholders should vote with respect to the Arrangement or any other matter. The Origin Fairness Opinion was one of a number of factors taken into consideration by the Aurora Special Committee in making its recommendations and the Aurora Board in making its unanimous determinations that the Arrangement is fair to the Aurora Shareholders, that the Arrangement and the entry into the Arrangement Agreement are in the best interests of Aurora and to unanimously recommend that the Aurora Shareholders vote in favour of the Arrangement Resolution.

Pursuant to the terms of its engagement letter with Aurora, Origin will receive a fixed fee for rendering the Origin Fairness Opinion and no portion of the fees payable to Origin for its services are contingent upon the value of any transaction, its completion or the conclusions reached in any fairness opinion. Aurora has also agreed to reimburse Origin for its reasonable costs and expenses and to indemnify Origin against certain liabilities arising out of its

engagement. Neither Origin nor any of its affiliated entities is an insider, associate or affiliate (as such terms are defined in the Securities Act (Ontario)) of Organigram or Aurora.

During the 24 months preceding the date on which Origin was first contacted with respect to the engagement of Origin by Aurora, Origin and its affiliates have not had any material financial advisory or other material commercial or investment banking relationships with either of Aurora or Organigram.

Any summary of the Origin Fairness Opinion herein is qualified in its entirety by reference to the full text of the Origin Fairness Opinion as set out in Appendix "F" to this Joint Information Circular. The Origin Fairness Opinion was provided solely for the use of the Aurora Special Committee and the Aurora Board (solely in their capacities as such) in connection with the Aurora Special Committee's and the Aurora Board's evaluation of the Arrangement and may not be relied upon by any Aurora Shareholders or any other person. The Origin Fairness Opinion is not intended to and does not constitute a recommendation as to how the Aurora Shareholders should vote in respect of the Arrangement Resolution. The Origin Fairness Opinion was one of a number of factors taken into consideration by the Aurora Special Committee in making its recommendations and the Aurora Board in making its unanimous determinations that the Arrangement is fair to the Aurora Shareholders, that the Arrangement and the entry into the Arrangement Agreement are in the best interests of Aurora and to unanimously recommend that the Aurora Shareholders vote in favour of the Arrangement Resolution. Origin expresses no view as to, and the Origin Fairness Opinion does not address, any other aspect or implication of the Arrangement, the underlying business decision of the Aurora Board to effect the Arrangement, or the relative merits of the Arrangement as compared to any alternative business strategies that might be available for Aurora.

Organigram Fairness Opinion

Pursuant to an engagement letter dated September 16, 2026, Organigram retained BMO Capital Markets as financial advisor to Organigram in connection with the Arrangement. As part of this mandate, BMO Capital Markets was requested to provide the Organigram Board with its opinion as to the fairness to Organigram, from a financial point of view, of the Consideration to be paid by Organigram pursuant to the Arrangement. In connection with this mandate, BMO Capital Markets has prepared and delivered the Organigram Fairness Opinion. The Organigram Fairness Opinion states that, as of November 2, 2026, and based upon and subject to the assumptions, limitations and qualifications set forth therein, the Consideration to be paid by Organigram pursuant to the Arrangement is fair, from a financial point of view, to Organigram.

The full text of the written opinion of BMO Capital Markets dated November 2, 2026, which sets forth, among other things, the assumptions made, procedures followed, information reviewed, matters considered and limitations and qualifications on the scope of review undertaken in connection with rendering the Organigram Fairness Opinion, is attached as Appendix "G" to this Joint Information Circular and should be read carefully and in its entirety.

BMO Capital Markets provided its opinion solely for the information and assistance of the Organigram Board in connection with its consideration of the Arrangement and the opinion is subject to the assumptions, limitations and qualifications contained therein. The Organigram Fairness Opinion is not a recommendation as to how any Organigram Shareholder should vote or act with respect to the Arrangement or its Organigram Common Shares. The Organigram Fairness Opinion was one of a number of factors taken into consideration by the Organigram Board in making its unanimous determination that the Arrangement is fair to the Organigram Shareholders and the holders of Organigram Preferred Shares, that the Arrangement and the entry into the Arrangement Agreement are in the best interests of Organigram and to unanimously recommend that the Organigram Shareholders vote in favour of the Organigram Share Issuance Resolution.

Pursuant to the terms of its engagement with Organigram, Organigram has agreed to pay BMO Capital Markets a fee for its services as financial advisor, including a fixed fee for rendering the Organigram Fairness Opinion. A portion of the fees that BMO Capital Markets will receive for its advisory services is contingent upon the completion of the Arrangement. The fees payable for delivery of the Organigram Fairness Opinion are not contingent on the completion of the Arrangement. In addition, Organigram has agreed to reimburse BMO Capital Markets for its reasonable out-of-pocket expenses and to indemnify BMO Capital Markets in certain circumstances.

Neither BMO Capital Markets nor any of its affiliates is an insider or affiliate (as those terms are defined in the *Securities Act* (Ontario) or the rules made thereunder) of Organigram, Aurora or any of their respective affiliates. During the 24 months preceding the date on which the Organigram Fairness Opinion was rendered, neither BMO Capital Markets nor any of its affiliates had been engaged to provide any financial advisory services, nor had BMO Capital Markets or any of its affiliates participated in any financing, involving Organigram or Aurora, or any of their respective associates or affiliates, other than (i) as financial advisor to Organigram in connection with the Arrangement; (ii) as financial advisor to Organigram and the investment committee of the Organigram Board in connection with providing an opinion with respect to the acquisition of Sanity Group; and (iii) as financial advisor to Organigram in connection with the acquisition of Motif Labs Ltd. in 2024. In addition, BMO Capital Markets may provide currency hedging arrangements in connection with the Arrangement.

Any summary of the Organigram Fairness Opinion herein is qualified in its entirety by reference to the full text of the Organigram Fairness Opinion attached as Appendix "G" to this Joint Information Circular. The Organigram Fairness Opinion was provided solely for the information and assistance of the Organigram Board in connection with its consideration of the Arrangement and may not be used or relied upon by any Organigram Shareholders or any other person for any other purpose. The Organigram Fairness Opinion is not a recommendation as to how any Organigram Shareholder should vote or act with respect to the Arrangement or its Organigram Common Shares. The Organigram Fairness Opinion does not address the relative merits of the Arrangement as compared to any strategic alternatives that may be available to Organigram.

Recommendation of the Aurora Board

Based upon the Aurora Special Committee's consideration of, among other things, the Aurora Fairness Opinions and the advice of external legal and financial advisors, the Aurora Special Committee unanimously recommended to the Aurora Board, among other things, that the Aurora Board (i) determine that the Arrangement is in the best interests of Aurora; (ii) determine that the Arrangement is fair to the Aurora Shareholders; (iii) approve the entering into, execution, delivery and performance of Aurora's obligations under the definitive transaction agreements to which Aurora is a party, including the Arrangement Agreement; (iv) recommend that Aurora Shareholders vote in favour of the Arrangement Resolution; and (v) continue to reject the Hostile Bid and recommend that Aurora Shareholders not tender their Aurora Common Shares to the Hostile Bid. Based on the recommendation of the Aurora Special Committee and the Aurora Board's consideration of, among other things, the Aurora Fairness Opinions and the advice of external legal and financial advisors, the Aurora Board, among other things, unanimously (i) determined that the Arrangement is in the best interests of Aurora; (ii) determined that the Arrangement is fair to the Aurora Shareholders; (iii) approved the entering into, execution, delivery and performance of Aurora's obligations under the definitive transaction agreements to which Aurora is a party, including the Arrangement Agreement; (iv) recommended that Aurora Shareholders vote in favour of the Arrangement Resolution; and (v) determined to continue to reject the Hostile Bid and recommend that Aurora Shareholders not tender their Aurora Common Shares to the Hostile Bid.

See "*The Arrangement – Background to the Arrangement*".

The Aurora Board unanimously recommends that the Aurora Shareholders vote <u>FOR</u> the Arrangement Resolution.

In coming to its conclusion and recommendations, the Aurora Special Committee and the Aurora Board considered, among others, the following factors:

(a) the purpose and anticipated benefits of the Arrangement as outlined elsewhere in this Joint Information Circular including under the headings "*Reasons for and Benefits of the Arrangement*" and "*Additional Reasons and Benefits for Aurora Shareholders*" above;

(b) information concerning the financial condition, results of operations, business plans and prospects of Aurora, and the resulting potential for the enhancement of the business efficiency, management effectiveness and financial results of Organigram after giving effect to the Arrangement;

(c) the Arrangement, on the terms and conditions provided for in the Arrangement Agreement;

(d) the alternatives available to Aurora;

(e) the advice and assistance of external legal counsel; and

(f) the advice and assistance of the Aurora Financial Advisors in evaluating the Arrangement, the Fort Capital Fairness Opinion and the Origin Fairness Opinion. See "*Aurora Fairness* Opinions" at Appendix "F" to this Joint Information Circular.

In addition, under the Arrangement Agreement, until the time that the Arrangement Resolution is approved by the Aurora Shareholders, the Aurora Board has retained the ability to consider and respond to Acquisition Proposals on the specific terms and conditions set forth in the Arrangement Agreement, and to accept a Superior Proposal in certain circumstances.

The foregoing discussion of the information and factors considered and given weight by the Aurora Board is not intended to be exhaustive. In addition, in reaching the determination to approve and recommend the Arrangement, the Aurora Board did not assign any relative or specific weights to the foregoing factors which were considered, and individual directors may have given differing weights to different factors.

The Aurora Board realizes that there are risks associated with the Arrangement, including that some of the potential benefits set forth above may not be realized or that there may be significant costs associated with realizing such benefits. The Aurora Board believes that the factors in favour of the Arrangement outweigh the risks and potential disadvantages, although there can be no assurance in this regard. See "*Risk Factors*".

Notwithstanding the unanimous recommendation of the Aurora Board that Aurora Shareholders vote in favour of the Arrangement Resolution, Aurora Shareholders should make their own decisions whether to vote their Aurora Common Shares in favour of the Arrangement Resolution and, if appropriate, should consult their own legal, tax, financial or other professional advisors in making that decision.

Recommendation of the Organigram Board

At a meeting of the Organigram Board held on November 2, 2026 prior to Organigram entering into the Arrangement Agreement, the Organigram Board reviewed and considered the specific transaction terms that had been negotiated by Organigram and Aurora and the proposed terms of the Arrangement Agreement and Plan of Arrangement, and received the oral opinion of BMO Capital Markets to the effect that, as of November 2, 2026, and based upon and subject to the assumptions, limitations and qualifications on the review undertaken, the Consideration to be paid by Organigram pursuant to the Arrangement is fair, from a financial point of view, to Organigram.

After consulting with Organigram's senior management and with its financial, legal, tax, and other advisors, and after considering, among other things, the Organigram Fairness Opinion, the Organigram Board (with the representatives of BAT abstaining in respect of the BAT Private Placement) unanimously determined: (a) that the Arrangement is fair to the Organigram Shareholders and the holders of Organigram Preferred Shares; (b) that the Arrangement and entry into the Arrangement Agreement are in the best interests of Organigram; and (c) to unanimously recommend that the Organigram Shareholders vote in favour of the Organigram Share Issuance Resolution.

The Organigram Board (with the representatives of BAT abstaining in respect of the BAT Private Placement) unanimously recommends that the Organigram Shareholders vote <u>FOR</u> the Organigram Share Issuance Resolution.

In coming to its conclusion and recommendations, the Organigram Board consulted with and received advice from legal counsel and considered, among others, the following factors:

(a) the purpose and anticipated benefits of, and the inherent risks of proceeding, or not, with the Arrangement as outlined elsewhere in this Joint Information Circular including under the headings

"*Reasons for and Benefits of the Arrangement*" and "*Additional Reasons and Benefits for Organigram Shareholders*" above;

(b) information concerning the financial condition, results of operations, business plans and prospects of Organigram, and the resulting potential for the enhancement of the business efficiency, management effectiveness and financial results of Organigram following completion of the Arrangement;

(c) the alternatives reasonably available to Organigram; and

(d) the advice and assistance of BMO Capital Markets in evaluating the Arrangement. See *Appendix "G" – "Organigram Fairness Opinion*" to this Joint Information Circular.

The foregoing discussion of the information and factors considered and given weight by the Organigram Board is not intended to be exhaustive. In addition, in reaching the determination to approve and recommend the Arrangement, the Organigram Board did not assign any relative or specific weights to the foregoing factors which were considered, and individual directors may have given differing weights to different factors.

The Organigram Board realizes that there are risks associated with the Arrangement, including that some of the potential benefits set forth above may not be realized or that there may be significant costs associated with realizing such benefits. The Organigram Board believes that the factors in favour of the Arrangement outweigh the risks and potential disadvantages, although there can be no assurance in this regard. See "*Risk Factors*".

Notwithstanding the recommendation of the Organigram Board that Organigram Shareholders vote in favour of the Organigram Share Issuance Resolution, Organigram Shareholders should make their own decision whether to vote their Organigram Common Shares in favour of the Organigram Share Issuance Resolution and, if appropriate, should consult their own legal, tax, financial or other professional advisors in making that decision.

EFFECT OF THE ARRANGEMENT

General

The Arrangement will result in each Aurora Shareholder (other than Dissenting Aurora Shareholders) receiving, for each Aurora Common Share held immediately prior to the Effective Time, at its election, the Cash Alternative ($7.80 in cash), the Share Alternative (5.8626 Organigram Common Shares) or the Combination Alternative ($3.75 in cash and 3.0431 Organigram Common Shares), subject, in the case of the Cash Alternative and the Share Alternative, to proration such that the aggregate cash payable and the aggregate number of Organigram Common Shares issuable under the Arrangement will not exceed the Maximum Cash Consideration and the Maximum Share Consideration, respectively. See "*Effect of the Arrangement – Elections and Proration*" and "*Procedure for the Arrangement to Become Effective – Procedure for Exchange of Aurora Common Share Certificates or DRS Advices*".

As at November 19, 2026, there were 65,748,913 Aurora Common Shares and 141,114,081 Organigram Common Shares outstanding (in each case, on a non-diluted basis). Upon completion of the Arrangement and the BAT Private Placement, assuming there are no Dissenting Aurora Shareholders and that no Aurora Common Shares or Organigram Common Shares are issued between the date of the Arrangement Agreement and the Effective Date (other than pursuant to the BAT Private Placement), there will be approximately 427,085,757 Organigram Common Shares issued and outstanding, of which existing holders of Aurora Common Shares and Organigram Common Shares will collectively own approximately 37% and 63%, respectively (in each case, assuming the conversion of the Organigram Preferred Shares).

No fractional Organigram Common Shares will be issued under the Arrangement. Where an Aurora Shareholder would otherwise be entitled to a fractional Organigram Common Share, the number of Organigram Common Shares to be issued will be rounded down to the nearest whole Organigram Common Share and no consideration will be paid in lieu of the fractional share. Any aggregate cash amount payable to a former securityholder that is less than $0.01 will be rounded up to $0.01, and any other cash amount that

includes a fraction of $0.01 will be rounded down to the nearest whole $0.01. In calculating such fractional interests, all Aurora Common Shares registered in the name of or beneficially held by such Aurora Shareholders or their nominee shall be aggregated.

Elections and Proration

Making an Election. Each holder of Aurora Common Shares (other than in respect of Aurora Common Shares for which Dissent Rights have been validly exercised) may elect to receive the Cash Alternative, the Share Alternative or the Combination Alternative in respect of any and all of its Aurora Common Shares.

Registered Holders. Aurora Shareholders whose Aurora Common Shares are registered in their name may make an election by depositing (or having the registered holder deposit on its behalf) with the Depositary a duly completed Letter of Transmittal and Election Form, together with any certificate(s) or DRS Advice(s) representing such Aurora Common Shares, before the Election Deadline, being 5:00 p.m. (Toronto time) on the date agreed by Aurora and Organigram, each acting reasonably, and announced by Aurora by news release at least two Business Days before such date. An election will be valid only if the Letter of Transmittal and Election Form is properly completed, duly executed and actually received by the Depositary before the Election Deadline. A Letter of Transmittal and Election Form, once deposited, is irrevocable and may not be withdrawn except as expressly provided in the Letter of Transmittal and Election Form.

Non-Registered Holders. Aurora Shareholders whose Aurora Common Shares are registered in the name of a broker, investment dealer, bank, trust company, custodian, nominee or other intermediary must instruct their intermediary to make an election on their behalf. Intermediaries are likely to set deadlines that are earlier than the Election Deadline, and non-registered Aurora Shareholders should contact their intermediary promptly. Elections by non-registered holders will be made through the facilities of CDS or DTC, as applicable.

Default Alternative. Any Aurora Shareholder (other than a Dissenting Aurora Shareholder) who does not deposit a duly completed Letter of Transmittal and Election Form making a valid election with the Depositary before the Election Deadline, or who otherwise fails to comply with the election requirements, will be deemed to have elected the Combination Alternative in respect of all of its Aurora Common Shares. Any such registered Aurora Shareholders will still be required to deposit a duly completed Letter of Transmittal and Election Form, together with the certificate(s) or DRS Advice(s) representing their Aurora Common Shares, in order to receive the Consideration to which they are entitled. Any Aurora Shareholder who exercises Dissent Rights but is ultimately not entitled to be paid fair value, or who withdraws its dissent, will be deemed to have participated in the Arrangement and will receive the Combination Alternative.

Proration. Organigram is not obligated to pay more than the Maximum Cash Consideration or issue more than the Maximum Share Consideration under the Arrangement. The Combination Alternative is not subject to proration. The cash available to Aurora Shareholders electing the Cash Alternative and the Organigram Common Shares available to Aurora Shareholders electing the Share Alternative are first reduced by the amounts payable to holders electing (or deemed to elect) the Combination Alternative and the amounts that would be payable to Dissenting Aurora Shareholders if they were Combination Alternative holders. Depending on the elections made, (a) if the Organigram Common Shares that would be issuable to holders electing the Share Alternative exceed the remaining available Organigram Common Shares, each such holder will receive its pro rata share (based on its Share Alternative entitlement) of the available Organigram Common Shares and of the cash remaining after payment to holders electing the Cash Alternative; or (b) if the cash that would be payable to holders electing the Cash Alternative exceeds the remaining available cash, each such holder will receive its pro rata share (based on its Cash Alternative entitlement) of the available cash and of the Organigram Common Shares remaining after issuance to holders electing the Share Alternative, provided that any holder electing the Cash Alternative who would, as a result, receive less cash than it would have received under the Combination Alternative will instead be deemed to have elected the Combination Alternative. As a result, Aurora Shareholders who elect the Cash Alternative or the Share Alternative may receive a combination of cash and Organigram Common Shares that differs from their election.

Determination of Elections. Pursuant to the Plan of Arrangement, a Letter of Transmittal and Election Form, once deposited with the Depositary, is irrevocable and may not be withdrawn except as expressly provided in the Letter of Transmittal and Election Form, and any Aurora Shareholder (other than a Dissenting Aurora Shareholder) who does

not deposit a duly and properly completed Letter of Transmittal and Election Form prior to the Election Deadline, or who otherwise fails to comply with the requirements of the Plan of Arrangement and the Letter of Transmittal and Election Form, will be deemed to have elected the Combination Alternative. All questions as to the validity, form and timeliness of any election will be determined by Organigram, acting reasonably, in consultation with the Depositary, and such determination will be final and binding. None of Organigram, Aurora or the Depositary will be under any duty to give notice of any defect in an election. The Depositary will calculate the Consideration payable to each Aurora Shareholder, after giving effect to proration, as soon as practicable after the Election Deadline, and Organigram will announce the results of the elections and any proration by press release on or about the Effective Date.

The Plan of Arrangement provides that, until surrendered to the Depositary with a duly completed Letter of Transmittal and Election Form and such other documents as the Depositary may reasonably require, each certificate or DRS Advice that immediately prior to the Effective Time represented Aurora Common Shares (other than Aurora Common Shares held by Dissenting Aurora Shareholders) shall be deemed after the Effective Time to represent only the right to receive, upon such surrender, the applicable Consideration (without interest and subject to rounding and withholding), together with any dividends or distributions on the Organigram Common Shares with a record date after the Effective Time. To the extent a former Aurora Shareholder has not complied with these requirements on or before the third anniversary of the Effective Date, the Consideration to which such holder was entitled shall be deemed to have been surrendered to Organigram for cancellation for no consideration, and any unclaimed payment or right to payment shall terminate and be forfeited to Organigram. For more information regarding the effect of the Arrangement on Dissenting Aurora Shareholders see "*Dissent Rights*".

Aurora Incentive Awards

Pursuant to the Plan of Arrangement: (a) each Aurora DSU and Aurora RSU (vested or unvested) will be cancelled in exchange for a cash payment from Aurora of $7.80 per underlying Aurora Common Share (in the case of Aurora DSUs, immediately after the holder ceases to be a director of Aurora); (b) each Vested Aurora PSU will be cancelled in exchange for a cash payment from Aurora of $7.80 per underlying Aurora Common Share, multiplied by a performance ratio of 100%; (c) each Unvested Aurora PSU will remain outstanding and entitle the holder to a cash payment of $7.80 per underlying Aurora Common Share, multiplied by a performance ratio of 100%, on its Entitlement Date, subject to the applicable vesting conditions and otherwise on the same terms and conditions, including under any applicable employment agreement, as applied before the Effective Time; and (d) each Aurora Option will be exchanged for a Replacement Option to acquire Organigram Common Shares based on the Option Exchange Ratio, being $7.80 divided by $1.33, on the same terms, including as to expiry and vesting, as the exchanged Aurora Option. Cash payments will be made, less applicable withholdings, through Aurora's payroll or equity plan administration systems. Holders of Aurora Incentive Awards are not entitled to Dissent Rights in respect of those awards. See "*Effect of the Arrangement – Details of the Arrangement*".

There were 2,214,519 Aurora Options, 28,555 Aurora DSUs, 1,537,786 Aurora RSUs and 494,897 Aurora PSUs outstanding as of November 19, 2026, in each case settled in Aurora Common Shares, as well as 330,312 cash-settled deferred share units, 14,359 cash-settled restricted share units and 1,782,775 cash-settled performance share units of Aurora.

See "*Interests of Certain Persons or Companies in the Arrangement – Aurora – Aurora Incentive Awards*" and "*Interests of Certain Persons or Companies in the Arrangement – Aurora – Summary of Interests of Directors and Executive Officers of Aurora in the Arrangement*".

Aurora Employment Agreements

Aurora is party to employment agreements with each of its executive officers. The particulars of these agreements, and the estimated severance and other benefits to which the executive officers of Aurora would be entitled if their employment were terminated by Aurora without cause, or they resigned for Good Reason, within 12 months following completion of the Arrangement, are set out under "*Interests of Certain Persons or Companies in the Arrangement – Aurora – Aurora Employment Agreements*" and "*Interests of Certain Persons or Companies in the Arrangement – Aurora – Summary of Interests of Directors and Executive Officers of Aurora in the Arrangement*".

Details of the Arrangement

The following is a summary only of the Plan of Arrangement and reference should be made to the full text of the Plan of Arrangement, which is set forth in Appendix "C" to this Joint Information Circular.

Pursuant to the Plan of Arrangement, commencing at the Effective Time, each of the events set out below shall occur and shall be deemed to occur consecutively in the following order, at one-minute intervals, without any further act or formality:

- **Aurora Shareholder Rights Plan**. The Aurora Shareholder Rights Plan shall be terminated, all Aurora Rights shall be cancelled without any payment in respect thereof, and the Aurora Shareholder Rights Plan shall be of no further force or effect.

- **Aurora DSUs and Aurora RSUs**. Each Aurora DSU and Aurora RSU (whether vested or unvested) outstanding immediately prior to the Effective Time shall (in the case of an Aurora DSU, immediately following the holder ceasing to hold office as a director of Aurora) be cancelled in exchange for a cash payment from Aurora equal to $7.80 multiplied by the number of Aurora Common Shares subject to such award, less applicable withholdings.

- **Vested Aurora PSUs**. Each Vested Aurora PSU shall be cancelled in exchange for a cash payment from Aurora equal to $7.80 multiplied by the number of Aurora Common Shares underlying such PSU, multiplied by a performance ratio of 100%, less applicable withholdings.

- **Unvested Aurora PSUs**. Each Unvested Aurora PSU shall remain outstanding and, for each underlying Aurora Common Share, entitle the holder to receive from Aurora, on the applicable Entitlement Date and subject to satisfaction of the applicable vesting conditions, a cash payment equal to $7.80 multiplied by a performance ratio of 100%, less applicable withholdings, on the same terms and conditions, including those set out in any applicable employment agreement, as applied before the Effective Time. Holders of Unvested Aurora PSUs will have no right to receive Aurora Common Shares or Organigram Common Shares or any dividends in respect of such PSUs.

- **Dissenting Aurora Shareholders**. Simultaneously with the step below, the Aurora Common Shares held by Dissenting Aurora Shareholders shall be deemed to have been transferred to Organigram (free and clear of all liens) in consideration for a debt claim against Organigram for their fair value, such Dissenting Aurora Shareholders shall cease to have any rights as Aurora Shareholders, other than the right to be paid the fair value of their Aurora Common Shares by Organigram, their names shall be removed from the register of Aurora Common Shares and Organigram shall be recorded as the holder of such shares. A Dissenting Aurora Shareholder who is ultimately not entitled to be paid fair value will be deemed to have participated in the Arrangement and will receive the Combination Alternative. See "*Dissent Rights*".

- **Acquisition of Aurora Common Shares by Organigram**. Each issued and outstanding Aurora Common Share (other than those held by Dissenting Aurora Shareholders) shall be transferred by the holder thereof without any further act or formality on its part (free and clear of all liens) to Organigram in exchange for, as applicable, the Combination Alternative (for Aurora Shareholders who elect or are deemed to elect it), or, subject to proration, the Cash Alternative or the Share Alternative, subject to the rounding, fractional share and withholding provisions of the Plan of Arrangement, and upon such transfer: (a) the holders of such Aurora Common Shares shall cease to have any rights as Aurora Shareholders, other than the right to receive the Consideration in accordance with the Plan of Arrangement, and their names shall be removed from the register of Aurora Common Shares; and (b) Organigram shall be recorded as the holder of the Aurora Common Shares so transferred. An Aurora Shareholder who receives both cash and Organigram Common Shares will be deemed to have exchanged a proportionate number of its Aurora Common Shares (based on a deemed price of $1.33 per Organigram Common Share) solely for Organigram Common Shares and the balance solely for cash, unless it indicates in its Letter of Transmittal and Election Form that it intends to make a Section 85 Election, in which case it will be deemed to have transferred all of its Aurora Common Shares as a single transaction.

- **Aurora Options**. Each Aurora Option (whether vested or unvested) outstanding immediately prior to the Effective Time shall be exchanged for a Replacement Option to purchase from Organigram the number of Organigram Common Shares (rounded down to the nearest whole share) equal to the number of Aurora Common Shares subject to such Aurora Option multiplied by the Option Exchange Ratio (being $7.80 divided by the deemed Organigram share price of $1.33), at an exercise price per Organigram Common Share (rounded up to the nearest whole cent) equal to the exercise price of the Aurora Option divided by the Option Exchange Ratio, subject to any increase required so that the in-the-money value of the Replacement Option does not exceed that of the Aurora Option. All other terms of each Replacement Option, including term to expiry and vesting, will be the same as the exchanged Aurora Option and will be governed by the Aurora Stock Option Plan and any agreement or instrument relating to the exchanged Aurora Option, including any applicable employment agreement, which Organigram will assume.

The Arrangement Agreement

General

The Arrangement will be effected pursuant to the Arrangement Agreement, which provides for the implementation of the Plan of Arrangement. The Arrangement Agreement contains covenants, representations and warranties of and from each of Aurora and Organigram and various conditions precedent, both mutual, for the benefit of each Party, and individual, for the exclusive benefit of Aurora or Organigram, as applicable. Unless all such conditions are satisfied or waived by the Party for whose benefit such conditions exist, to the extent they may be capable of waiver in accordance with the Arrangement Agreement, the Arrangement will not proceed. There is no assurance that such conditions will be satisfied or waived on a timely basis, or at all.

The following is a summary of certain provisions of the Arrangement Agreement and is qualified in its entirety by the full text of the Arrangement Agreement, which is incorporated by reference in this Joint Information Circular and can be viewed on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Aurora Shareholders and Organigram Shareholders are urged to read the Arrangement Agreement in its entirety.

Representations and Warranties

The Arrangement Agreement contains certain customary representations and warranties of each of Aurora and Organigram relating to, among other things, their respective organizations, qualification, capitalization, compliance with laws and regulations and other matters, including their authority to enter into the Arrangement Agreement and to consummate the Arrangement. In addition, Aurora has made certain representations and warranties in the Arrangement Agreement with respect to its business, operations, assets and employees. The representations and warranties of each Party are qualified by the disclosure in its disclosure letter and in its publicly filed disclosure record (excluding risk factor, forward-looking statement and other forward-looking disclosure). For the complete text of the applicable provisions, see Article 3, Article 4, Schedule "C" and Schedule "D" of the Arrangement Agreement, which is incorporated by reference in this Joint Information Circular and may be viewed on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

Covenants Relating to the Conduct of Business of the Parties

Pursuant to the Arrangement Agreement, each of the Parties has covenanted and agreed, until the earlier of the Effective Time and the time that the Arrangement Agreement is terminated in accordance with its terms, subject to certain exceptions, to, among other things, conduct its business, and cause its subsidiaries to conduct their businesses, in the ordinary course, and to use commercially reasonable efforts to maintain and preserve their business organization, assets, permits, goodwill and business relationships and to keep available the services of their officers and employees as a group. Aurora is subject to specified restrictions, including on dispositions, acquisitions, indebtedness, capital expenditures and settlements above $1 million, settlement of material litigation and on hiring or terminating employees with an annual base salary or fees above $250,000. Organigram is subject to more limited restrictions, including on issuing securities (other than under its equity incentive plans, the BAT Equity Commitment and other issuances not exceeding $10 million), repurchasing securities above $10 million, amending its outstanding indebtedness (other than in connection with the Financing Commitments or non-adverse amendments) and materially

amending its equity incentive plans. For the complete text of the provisions relating to the Parties' interim covenants, see Article 5 of the Arrangement Agreement.

Organigram Financing

Organigram intends to fund the cash consideration payable under the Arrangement through cash on hand and the Organigram Financing, being the debt financing contemplated by the commitment letter with ATB Financial (which will take the form of an amendment and restatement of Organigram's existing credit agreement) and the BAT Private Placement contemplated by the BAT Equity Commitment. Organigram has represented that the net proceeds of the Organigram Financing, together with its cash on hand, will be sufficient to pay the aggregate cash consideration and all other amounts payable by it under the Arrangement Agreement and the Plan of Arrangement. Organigram has agreed to use its reasonable best efforts to obtain the Organigram Financing on the terms of the Financing Commitments, including to maintain the Financing Commitments in full force and effect, satisfy the funding conditions within its control, complete the Organigram Financing at or prior to the Effective Time and enforce its rights under the Financing Commitments in the event of any breach, default or repudiation by a financing source. Organigram may not, without Aurora's prior written consent (not to be unreasonably withheld, conditioned or delayed), amend, replace, waive or terminate the Financing Commitments in a manner that would reduce the available proceeds, together with its cash on hand, below the amount required to pay the aggregate cash consideration and other amounts payable under the Arrangement Agreement, add to or expand the conditions to funding, prevent, materially delay or impair the Organigram Financing or the Arrangement, adversely affect its ability to enforce its rights against the financing sources or cause any Financing Commitment to expire before the Outside Date. Organigram must promptly notify Aurora of certain adverse developments relating to the Organigram Financing and, if any portion becomes unavailable, use its reasonable best efforts to obtain Alternative Financing prior to the Outside Date on terms with funding conditions no more onerous than those in the Financing Commitments. Any proceeds funded before the Effective Date must be held in cash or cash equivalents and used only to pay amounts due under the Arrangement Agreement and the Plan of Arrangement. Aurora has agreed to use its reasonable best efforts to provide customary cooperation in connection with the debt financing (with Organigram responsible for preparing any pro forma financial statements and marketing materials), Organigram may use Aurora's logos and share Aurora's confidential information with debt financing sources on a confidential basis, and Organigram has agreed to reimburse Aurora's related costs and indemnify Aurora in connection with such cooperation and any information provided at Organigram's request (except to the extent arising from the negligence, wilful misconduct or fraud of Aurora, its subsidiaries or their representatives). No Person other than Organigram may enforce the BAT Equity Commitment, and Organigram may not enforce, and no Person may cause Organigram to enforce, BAT's funding obligation unless the conditions in favour of Organigram and the mutual conditions have been satisfied or waived, the debt financing has been or will be funded at closing and Aurora has irrevocably confirmed that it is ready, willing and able to complete the Arrangement. Aurora has agreed that it has no rights or claims against ATB Financial, BAT or any other financing source in connection with the Arrangement Agreement or the Organigram Financing, without limiting Aurora's rights against BAT under its Organigram Support Agreement or Aurora's right to seek specific performance to compel Organigram to comply with its obligations under the Arrangement Agreement. Organigram's obligations under the Arrangement Agreement, including its obligation to complete the Arrangement and pay the aggregate cash consideration, are not conditional on obtaining or completing the Organigram Financing or any other financing, and a failure to obtain the Organigram Financing does not limit Aurora's rights and remedies under the Arrangement Agreement.

Dividends

Pursuant to the Arrangement Agreement, each of Aurora and Organigram has agreed not to split, consolidate or reclassify its shares or declare, set aside or pay any dividend or other distribution prior to the earlier of the Effective Time and the termination of the Arrangement Agreement without the prior written consent of the other Party (not to be unreasonably withheld, conditioned or delayed).

Mutual Conditions

The respective obligations of Organigram and Aurora to complete the transactions contemplated by the Arrangement Agreement are subject to the fulfillment, on or before the Effective Time, of the following conditions, each of which may only be waived with the mutual consent of Organigram and Aurora:

(a) the Arrangement Resolution shall have been passed by the Aurora Shareholders at the Aurora Shareholders' Meeting in accordance with the Interim Order;

(b) the Organigram Share Issuance Resolution shall have been approved at the Organigram Shareholders' Meeting by a majority of the votes cast by Organigram Shareholders, as required by section 611 of the TSX Company Manual, and, if required, by a majority of such votes cast excluding the votes attached to Organigram Common Shares held by persons described in items (a) through (d) of section 8.1(2) of MI 61-101 (which, as described under "*Procedure for the Arrangement to Become Effective – Stock Exchange Listings*", will in each case exclude the votes attached to Organigram Common Shares held by BAT and its affiliates);

(c) the Interim Order and the Final Order shall each have been obtained on terms consistent with the Arrangement Agreement and in form and substance satisfactory to each Party, acting reasonably, and shall not have been set aside or modified in a manner unacceptable to either Party, acting reasonably, on appeal or otherwise;

(d) no Governmental Entity shall have enacted, issued, promulgated, enforced or entered any Law which is then in effect and has the effect of making the Arrangement illegal or otherwise preventing or prohibiting the consummation of the Arrangement;

(e) the Required Regulatory Approvals shall have been obtained; and

(f) the TSX shall have conditionally approved the listing of the Organigram Common Shares to be issued under the Arrangement, subject only to customary listing conditions, and the Nasdaq shall have been notified of the listing of such Organigram Common Shares and shall not have objected thereto.

Conditions to the Obligations of Organigram

The obligation of Organigram to complete the transactions contemplated by the Arrangement Agreement is subject to the fulfillment of the following conditions at or before the Effective Time:

(a) the representations and warranties made by Aurora:

(i) set out in paragraphs (a) *[Organization and Qualification]*, (b) *[Corporate Authorization]*, (c) *[Directors' Approvals]*, (e) *[Execution and Binding Obligation]*, (i)(i) *[Authorized and Issued Capital]* and (ll) *[Brokers]* of Schedule C of the Arrangement Agreement shall be true and correct in all respects (other than *de minimis* inaccuracies) as of the Effective Time as though made on and as of the Effective Time (except for representations and warranties made as of a specified date, the accuracy of which shall be determined as of that specified date); and

(ii) in the remainder of Schedule C of the Arrangement Agreement shall be true and correct as of the Effective Time as though made on and as of the Effective Time (except for representations and warranties made as of a specified date, the accuracy of which shall be determined as of that specified date), except where any failure or failures of such representations and warranties to be so true and correct would not, individually or in the aggregate, have a Material Adverse Effect in respect of Aurora (and, for this purpose, any reference to "material", "Material Adverse Effect" or any other concept of materiality in such representations and warranties shall be ignored);

and Aurora shall have provided to Organigram a certificate of a senior executive officer of Aurora (on Aurora's behalf and without personal liability) confirming the foregoing as at the Effective Time;

(b) Aurora shall have duly performed, fulfilled or complied with, in all material respects, all covenants under the Arrangement Agreement to be performed, fulfilled or complied with by it on or before the Effective Date, and Aurora shall have provided to Organigram a certificate of a senior executive officer of Aurora (on Aurora's behalf and without personal liability) confirming the same as at the Effective Time;

(c) since the date of the Arrangement Agreement, there shall not have occurred any Material Adverse Effect in respect of Aurora which is continuing as of the Effective Date; and

(d) Dissent Rights shall not have been validly exercised, and not withdrawn, with respect to more than 10% of the issued and outstanding Aurora Common Shares.

The foregoing conditions are for the exclusive benefit of Organigram and may be asserted by Organigram regardless of the circumstances or may be waived in writing by Organigram in its sole discretion, in whole or in part, at any time and from time to time without prejudice to any other rights which Organigram may have.

Conditions to the Obligations of Aurora

The obligation of Aurora to complete the transactions contemplated by the Arrangement Agreement is subject to the fulfillment of the following conditions at or before the Effective Time:

(a) the representations and warranties made by Organigram:

(i) set out in paragraphs (a) *[Organization and Qualification]*, (b) *[Corporate Authorization]*, (c) *[Directors' Approvals]*, (i) *[Execution and Binding Obligation]* and (j)(i) and (j)(ii) *[Authorized and Issued Capital]* of Schedule D of the Arrangement Agreement shall be true and correct in all respects (other than *de minimis* inaccuracies) as of the Effective Time as though made on and as of the Effective Time (except for representations and warranties made as of a specified date, the accuracy of which shall be determined as of that specified date); and

(ii) in the remainder of Schedule D of the Arrangement Agreement shall be true and correct as of the Effective Time as though made on and as of the Effective Time (except for representations and warranties made as of a specified date, the accuracy of which shall be determined as of that specified date), except where any failure or failures of such representations and warranties to be so true and correct would not, individually or in the aggregate, have a Material Adverse Effect in respect of Organigram (and, for this purpose, any reference to "material", "Material Adverse Effect" or any other concept of materiality in such representations and warranties shall be ignored);

and Organigram shall have provided to Aurora a certificate of a senior executive officer of Organigram (on Organigram's behalf and without personal liability) confirming the foregoing as at the Effective Time;

(b) Organigram shall have duly performed, fulfilled or complied with, in all material respects, all covenants under the Arrangement Agreement to be performed, fulfilled or complied with by it on or before the Effective Date, and Organigram shall have provided to Aurora a certificate of a senior executive officer of Organigram (on Organigram's behalf and without personal liability) confirming the same as at the Effective Time;

(c) since the date of the Arrangement Agreement, there shall not have occurred any Material Adverse Effect in respect of Organigram which is continuing as of the Effective Date; and

(d) Organigram shall have delivered to the Depositary, in escrow pending the Effective Time, sufficient funds to satisfy the aggregate cash consideration and sufficient Organigram Common Shares to satisfy the aggregate share consideration payable under the Arrangement.

The foregoing conditions are for the exclusive benefit of Aurora and may be asserted by Aurora regardless of the circumstances or may be waived in writing by Aurora in its sole discretion, in whole or in part, at any time and from time to time without prejudice to any other rights which Aurora may have.

Covenants Regarding Non-Solicitation

Under the Arrangement Agreement, each of Aurora and Organigram has agreed to reciprocal non-solicitation covenants, subject to exceptions permitting its board to respond to an unsolicited *bona fide* written Acquisition Proposal that constitutes or could (in the case of Aurora) or would (in the case of Organigram) reasonably be expected to lead to a Superior Proposal. Organigram has a five business day right to match any Superior Proposal in respect of Aurora, and a three business day right to match each successive amendment. Subject to Organigram's right to match, Aurora may terminate the Arrangement Agreement to enter into a definitive agreement with respect to a Superior Proposal, provided that it concurrently pays the Aurora Termination Fee. The Hostile Bid is deemed not to be, and may not constitute, a Superior Proposal, although any Amended Bid may constitute a Superior Proposal. The non-solicitation covenants are summarized below.

(a) *Non-Solicitation.* Except as expressly permitted by the Arrangement Agreement, neither Party shall, directly or indirectly, through any of its Representatives or subsidiaries: (i) solicit, assist, initiate, encourage or otherwise knowingly facilitate any inquiry, proposal or offer that constitutes or may reasonably be expected to lead to an Acquisition Proposal; (ii) engage, continue or participate in any discussions or negotiations with any Person (other than the other Party) regarding any such inquiry, proposal or offer, provided that either Party may advise any Person of the restrictions of the Arrangement Agreement and advise any Person making an unsolicited Acquisition Proposal that it does not constitute, and could not reasonably be expected to constitute, a Superior Proposal; (iii) in the case of Aurora, make an Aurora Change in Recommendation, and in the case of Organigram, make an Organigram Change in Recommendation; or (iv) accept or enter into, or publicly propose to accept or enter into, any agreement in respect of an Acquisition Proposal (other than a permitted confidentiality agreement). Each Party has also agreed to immediately cease any existing solicitations, discussions or negotiations with any Person (other than the other Party) with respect to any potential Acquisition Proposal and, within two business days of the date of the Arrangement Agreement, to discontinue access to its confidential information (including any data room) and to request the return or destruction of confidential information provided to any such Person.

(b) *Notification of Acquisition Proposals.* If a Party (or any of its subsidiaries or Representatives) receives any inquiry, proposal or offer that constitutes or may reasonably be expected to lead to an Acquisition Proposal, or any related request for confidential information, such Party shall, as soon as practicable and in any event within 24 hours, notify the other Party orally and then in writing, including a description of its material terms, the identity of the Persons involved and copies of all written documents, material correspondence and other material received, and shall keep the other Party fully informed on a current basis of the status of material or substantive developments and any permitted discussions or negotiations.

(c) *Responding to Acquisition Proposals.* Notwithstanding the foregoing, if, prior to the approval of the Arrangement Resolution (in the case of Aurora) or the Organigram Share Issuance Resolution (in the case of Organigram), a Party receives a *bona fide* written Acquisition Proposal from a third party that is not in breach of any confidentiality or standstill agreement and that did not result from any breach (in the case of Aurora) or any material breach (in the case of Organigram) of its non-solicitation covenants, such Party may contact the Person making it to clarify its terms and, if its board of directors first determines in good faith, after consultation with its financial advisors and outside legal counsel, that the Acquisition Proposal constitutes or could (in the case of Aurora) or would (in the case of Organigram) reasonably be expected to constitute or lead to a Superior Proposal, may engage in discussions or negotiations with, and provide information to, such Person.

Before providing information, the Party must give the other Party written notice and a copy of an executed confidentiality and standstill agreement no less favourable to it than the Confidentiality Agreement (except that any such agreement with Curaleaf is not required to contain a standstill restriction prohibiting the Hostile Bid in its current form), and may not provide any material information that is more extensive than, or earlier than, that provided to the other Party.

Nothing in the Arrangement Agreement prohibits the board of directors of either Party from taking action ordered by a Governmental Entity or making disclosure required by applicable Law in response to an Acquisition Proposal (including a directors' circular), provided that the other Party is given a reasonable opportunity to review and comment on such disclosure where practicable and that its comments are considered in good faith. This does not permit an Aurora Change in Recommendation or an Organigram Change in Recommendation other than in accordance with the Arrangement Agreement, and does not limit Organigram's right to terminate the Arrangement Agreement and receive the Aurora Termination Fee following an Aurora Change in Recommendation.

(d) *Organigram Right to Match.* If Aurora receives a Superior Proposal prior to the approval of the Arrangement Resolution, Aurora may make an Aurora Change in Recommendation or enter into a definitive agreement with respect to such Superior Proposal only if, among other things: (i) Aurora has complied in all material respects with its non-solicitation covenants; (ii) the Aurora Board (based on, among other things, the recommendation of the Aurora Special Committee) has determined, after consultation with its outside legal and financial advisors, that the Acquisition Proposal is a Superior Proposal and that failing to act would be inconsistent with its fiduciary duties; (iii) Aurora has delivered to Organigram a written notice of the determination of the Aurora Board that such Acquisition Proposal constitutes a Superior Proposal and of its intention to make an Aurora Change in Recommendation or to enter into a definitive agreement with respect to such Superior Proposal (a "**Superior Proposal Notice**"), together with a copy of the proposed definitive agreement (if any) and all supporting materials; (iv) at least five business days (the "**Matching Period**") have elapsed from the later of Organigram's receipt of the Superior Proposal Notice and of all such materials; (v) after the Matching Period, the Aurora Board has determined in good faith that the Acquisition Proposal continues to be a Superior Proposal compared to any amendments proposed by Organigram; and (vi) if Aurora is entering into a definitive agreement with respect to the Superior Proposal, Aurora, prior to or concurrently with entering into such agreement, terminates the Arrangement Agreement and pays the Aurora Termination Fee. During the Matching Period, the Aurora Board must review in good faith any offer by Organigram to amend the Arrangement and negotiate in good faith with Organigram and, if the Aurora Board determines that the Acquisition Proposal would cease to be a Superior Proposal, the Parties shall amend the Arrangement Agreement accordingly. Each successive amendment to an Acquisition Proposal (including any Amended Bid) that changes the consideration or other material terms constitutes a new Acquisition Proposal and gives rise to a new three business day Matching Period.

(e) *Reaffirmation and Adjournment.* The Aurora Board shall promptly, and in any event within two business days, reaffirm its recommendation by press release (on which Organigram may comment) after any publicly announced Acquisition Proposal is determined not to be a Superior Proposal, or after the Aurora Board determines that a proposed amendment by Organigram would result in an Acquisition Proposal no longer being a Superior Proposal. If Aurora delivers a Superior Proposal Notice less than 10 business days before the Aurora Shareholders' Meeting, Organigram may adjourn or postpone the Organigram Shareholders' Meeting and require Aurora to adjourn or postpone the Aurora Shareholders' Meeting to a date specified by Organigram that is not less than five and not more than 10 business days after the scheduled date (but not less than five business days before the Outside Date, and provided that the Organigram Shareholders' Meeting must always be held before the Aurora Shareholders' Meeting), and, if a Matching Period would not end before the Aurora Shareholders' Meeting, Organigram may require that meeting to be adjourned or postponed to a date at least five business days after the end of the Matching Period.

(f) *Amended Bid.* In addition, in the event of any Amended Bid, whether or not such Amended Bid constitutes a Superior Proposal, Aurora shall, if requested by Organigram, cause one of its financial advisors and its external legal counsel to negotiate in good faith with Organigram to allow Organigram to increase or otherwise adjust the consideration or amend the terms of the Arrangement Agreement and the Arrangement (on terms no less favourable to Aurora or the Aurora Shareholders). If Curaleaf (or any affiliate thereof) amends the amount or form of the consideration offered under the Hostile Bid, or announces its intention to do so, less than five business days before the Aurora Shareholders' Meeting, Organigram may adjourn or postpone the Organigram Shareholders' Meeting and require Aurora to adjourn or postpone the Aurora Shareholders' Meeting to a date not less than five and not more than 10 business days after the scheduled date (but not less than five business days before the Outside Date, and provided that the Organigram Shareholders' Meeting must always be held before the Aurora Shareholders' Meeting).

(g) *Organigram Superior Proposal.* If Organigram receives a Superior Proposal prior to the approval of the Organigram Share Issuance Resolution, Organigram may make an Organigram Change in Recommendation or enter into a definitive agreement with respect to such Superior Proposal only if Organigram has complied in all material respects with its non-solicitation covenants, the Organigram Board has determined, after consultation with its outside legal and financial advisors, that the Acquisition Proposal is a Superior Proposal and that failing to act would be inconsistent with its fiduciary duties, and the definitive agreement is conditional on the Organigram Share Issuance Resolution not being approved and the Arrangement Agreement having been terminated in accordance with its terms. Aurora does not have a right to match a Superior Proposal in respect of Organigram.

Additional Covenants

Additional Covenants of Aurora. Aurora has agreed, among other things, to: (a) not adopt, implement or amend any new shareholder rights plan, or waive the application of any shareholder rights plan in favour of any Person other than Organigram; (b) subject to its non-solicitation covenants, continue to recommend that Aurora Shareholders reject the Hostile Bid and any Amended Bid that does not constitute a Superior Proposal, and file and mail any required notices of change to its directors' circular in consultation with Organigram; (c) cooperate with Organigram to delist the Aurora Common Shares from the TSX and Nasdaq and cause Aurora to cease to be a reporting issuer as promptly as practicable following the Effective Time; (d) use commercially reasonable efforts to obtain any third-party consents required under its material contracts and real property leases in connection with the Arrangement, without paying any consideration or incurring any liability without Organigram's consent; and (e) keep Organigram reasonably informed as to material decisions or actions with respect to the operation of its business, subject to confidentiality obligations and applicable Law.

Additional Covenants of Organigram. Organigram has agreed, among other things, to use commercially reasonable efforts to: (a) obtain any third-party consents required under its material contracts in connection with the Arrangement; (b) obtain the conditional approval of the TSX for the listing of, and notify Nasdaq of the listing of, the Organigram Common Shares issuable under the Arrangement and pursuant to the BAT Equity Commitment; and (c) at or prior to the Effective Time, allot and reserve a sufficient number of Organigram Common Shares to meet its obligations under the Plan of Arrangement. Organigram has also agreed to promptly notify Aurora of any Material Adverse Effect in respect of Organigram and of certain third-party consent requirements, material relationship changes and material proceedings. In addition, Organigram has agreed to publicly announce its revenue, net revenue, adjusted EBITDA, free cash flow and adjusted gross margin for the fiscal year and fourth quarter ended September 30, 2026 on or before the opening of trading on the TSX on December 15, 2026.

Meetings. Each of Aurora and Organigram has agreed to set the record date for its Meeting no later than November 19, 2026 and to use commercially reasonable efforts to hold its Meeting on or before December 23, 2026, and in any event to hold its Meeting on or before December 31, 2026. The Meetings are to be held on the same day, with the Organigram Shareholders' Meeting held before, and the Aurora Shareholders' Meeting later in the day than, the other, and the Aurora Shareholders' Meeting must be adjourned or postponed if necessary to preserve that order. Aurora has also agreed to apply for the Interim Order no later than November 27, 2026. Each Party may adjourn its Meeting for up to 10 business days in the aggregate to solicit proxies. Each Party may use, or at the other Party's request and

expense will use, proxy solicitation firms, but neither Party is required to continue soliciting proxies following a permitted change in its board's recommendation.

Pre-Acquisition Reorganizations. At Organigram's request, Aurora has agreed to use its commercially reasonable efforts to effect such reorganizations of its corporate structure, capital structure, business, operations, subsidiaries and assets as Organigram may reasonably request prior to the Effective Time (each, a "Pre-Acquisition Reorganization"), and the Plan of Arrangement will be modified if required, provided that no Pre-Acquisition Reorganization may require Aurora Shareholder approval (other than the Arrangement Resolution), impair, prevent or materially delay the Arrangement, be prejudicial to Aurora or the Aurora Shareholders, as a whole, in any material respect, be incapable of being unwound without adversely affecting Aurora if the Arrangement is not completed, contravene applicable Laws or Aurora's constating documents, breach a material contract or permit or materially breach an employee plan, or result in more than de minimis adverse tax or other consequences to Aurora, its subsidiaries or any Aurora Shareholder. Organigram must give at least 15 business days' notice before the Effective Date of any Pre-Acquisition Reorganization, and no Pre-Acquisition Reorganization will become effective until Organigram has confirmed in writing that the conditions in its favour have been satisfied or waived and that it is prepared to proceed with the Arrangement. If the Arrangement Agreement is terminated (other than by Organigram for Aurora's wilful breach or in circumstances in which the Aurora Termination Fee is payable), Organigram will reimburse Aurora's reasonable out-of-pocket costs and indemnify Aurora for liabilities arising from any Pre-Acquisition Reorganization or its reversal (including any taxes).

Employee Matters. Following the Effective Time, Organigram has agreed to cause Aurora and any successor to Aurora to continue to honour and comply with the obligations to employees of Aurora and its subsidiaries under all written employment agreements and benefit plans, including those disclosed in the Aurora Disclosure Letter, including by paying any amounts owing thereunder, and to ensure that any successor to, or acquirer of all or substantially all of the assets of, Aurora assumes those obligations. This covenant does not give any employee a right to continued employment or any third-party beneficiary rights.

Regulatory Approvals. Organigram and Aurora have agreed, within five business days after the date of the Arrangement Agreement (or such other date as they may agree), to jointly request an ARC or, alternatively, a No Action Letter, and to file their notifications under the Competition Act, and to make the filing required to obtain the German FDI Approval (if not already made). The Parties have agreed to cooperate in obtaining the Regulatory Approvals and not to enter into any transaction or take any other action that would reasonably be expected to make obtaining the Regulatory Approvals materially more difficult or to materially delay them. Organigram will pay all filing fees in respect of the Regulatory Approvals.

Insurance and Indemnification. Prior to the Effective Date, Aurora shall purchase customary "tail" directors' and officers' liability insurance providing coverage no less favourable in the aggregate than its existing policies for claims arising from facts or events occurring on or before the Effective Date, at a cost not exceeding 300% of Aurora's current annual premium (failing which Aurora shall obtain the maximum coverage available for that amount), and Organigram will cause such policies to be maintained for six years. Organigram will also cause Aurora to maintain the indemnification provisions in its articles and by-laws, and to honour existing indemnification and exculpation rights in favour of present and former directors, officers and employees of Aurora and its subsidiaries, for at least six years following the Effective Date, and will ensure that any successor to Aurora assumes these obligations.

Expenses and Specific Performance. Except as otherwise provided in the Arrangement Agreement (including with respect to the Expense Fee), each Party will pay its own fees, costs and expenses in connection with the Arrangement, except that Organigram will pay all regulatory filing fees (including any applicable taxes). The Parties are entitled to injunctive relief and specific performance to prevent breaches of the Arrangement Agreement and, if a Party brings an action to enforce specific performance, the Outside Date will be automatically extended to the 20th business day following resolution of the action (or such other period as the court may establish).

Termination

The Arrangement Agreement may be terminated at any time prior to the Effective Time:

(a) by mutual written agreement of Organigram and Aurora;

(b) by either Organigram or Aurora if:

(i) the Arrangement Resolution shall have failed to receive the requisite vote of the Aurora Shareholders to approve such resolution at the Aurora Shareholders' Meeting (including any adjournment or postponement thereof) in accordance with the Interim Order;

(ii) the Organigram Share Issuance Resolution shall have failed to receive the requisite vote of the Organigram Shareholders to approve such resolution at the Organigram Shareholders' Meeting (including any adjournment or postponement thereof) in accordance with applicable Law;

(iii) the Effective Time shall not have occurred on or prior to the Outside Date, except that the right to terminate the Arrangement Agreement in such a case shall not be available to any Party if the failure of the Effective Time to so occur has been caused by, or is a result of, a breach by such Party of any of its representations or warranties or the failure of such Party to perform any of its covenants or agreements under the Arrangement Agreement; or

(iv) after the date of the Arrangement Agreement, any Law is enacted, made, enforced or amended that makes the consummation of the Arrangement illegal or otherwise prohibits or enjoins Aurora or Organigram from consummating the Arrangement, and such Law has, if applicable, become final and non-appealable, provided that the Party seeking to terminate has used commercially reasonable efforts to appeal or overturn such Law or otherwise have it lifted or rendered non-applicable in respect of the Arrangement;

(c) by Organigram if:

(i) a breach of any representation or warranty or failure to perform any covenant or agreement on the part of Aurora set forth in the Arrangement Agreement (other than its non-solicitation, notification, response and right to match covenants) occurs that would cause the condition described in paragraphs (a) *[Aurora Reps and Warranties Condition]* or (b) *[Aurora Covenants Condition]* under the heading "*Conditions to the Obligations of Organigram*" above not to be satisfied, and such breach or failure is incapable of being cured or is not cured in accordance with the applicable "notice and cure" provisions of the Arrangement Agreement (which generally provide for a cure period ending on the earlier of 10 business days after notice and the Outside Date); provided that (A) any wilful breach shall be deemed to be incapable of being cured, and (B) Organigram is not then in breach of the Arrangement Agreement so as to cause any condition described above in paragraphs (a) *[Organigram Reps and Warranties Condition]* or (b) *[Organigram Covenants Condition]* under the heading "*Conditions to the Obligations of Aurora*" not to be satisfied;

(ii) prior to the approval of the Arrangement Resolution, (A) the Aurora Board (or the Aurora Special Committee) fails to recommend or withdraws, amends, modifies or qualifies (or publicly proposes to do so), in a manner adverse to Organigram, its recommendation, (B) the Aurora Board (or the Aurora Special Committee) accepts, approves, endorses or recommends, or publicly proposes to do so, an Acquisition Proposal (including the Hostile Bid or any other Acquisition Proposal by or involving Curaleaf or any Person acting jointly or in concert with Curaleaf), or takes no position or remains neutral with respect to a publicly announced Acquisition Proposal for more than five business days (or, if earlier, beyond the third business day before the Aurora Shareholders' Meeting) or without having rejected such Acquisition Proposal and reaffirmed its recommendation within that period (each of (A) and (B), an "**Aurora Change in Recommendation**"), (C) the Aurora Board or Aurora authorizes, accepts, approves, endorses or enters into (other than a permitted confidentiality and standstill agreement), or publicly proposes to do so, any agreement in respect of an Acquisition Proposal, or (D) Aurora is in breach in any material respect of its non-solicitation, notification, response or right to match covenants;

(iii) the Hostile Bid is consummated or effected; or

(iv) any condition described above under the headings "*Mutual Conditions*" or "*Conditions to the Obligations of Organigram*" is incapable of being satisfied by the Outside Date, provided that Organigram is not then in breach of the Arrangement Agreement so as to cause any such condition not to be satisfied.

(d) by Aurora if:

(i) a breach of any representation or warranty or failure to perform any covenant or agreement on the part of Organigram set forth in the Arrangement Agreement (other than its non-solicitation and notification covenants) occurs that would cause the condition described in paragraphs (a) *[Organigram Reps and Warranties Condition]* or (b) *[Organigram Covenants Condition]* under the heading "*Conditions to the Obligations of Aurora*" above not to be satisfied, and such breach or failure is incapable of being cured or is not cured in accordance with applicable "notice and cure" provisions of the Arrangement Agreement; provided that (A) any wilful breach shall be deemed to be incapable of being cured, and (B) Aurora is not then in breach of the Arrangement Agreement so as to cause any condition described above in paragraphs (a) *[Aurora Reps and Warranties Condition]* or (b) *[Aurora Covenants Condition]* under the heading "*Conditions to the Obligations of Organigram*" not to be satisfied;

(ii) prior to the approval of the Organigram Share Issuance Resolution, (A) the Organigram Board fails to recommend or withdraws, amends, modifies or qualifies (or publicly proposes to do so), in a manner adverse to Aurora, its recommendation, (B) the Organigram Board accepts, approves, endorses or recommends, or publicly proposes to do so, an Acquisition Proposal in respect of Organigram, or takes no position or remains neutral with respect to a publicly announced Acquisition Proposal in respect of Organigram for more than five business days (or, if earlier, beyond the third business day before the Organigram Shareholders' Meeting) or without having rejected such Acquisition Proposal and reaffirmed its recommendation within that period (each of (A) and (B), an "**Organigram Change in Recommendation**"), (C) the Organigram Board or Organigram enters into (other than a permitted confidentiality and standstill agreement) or publicly proposes to enter into any agreement in respect of an Acquisition Proposal in respect of Organigram, or (D) Organigram is in breach in any material respect of its non-solicitation or notification covenants;

(iii) prior to the approval of the Arrangement Resolution, subject to Aurora having complied with its non-solicitation, notification, response and right to match covenants, the Aurora Board authorizes Aurora to enter into an agreement (other than a permitted confidentiality agreement) with respect to a Superior Proposal, provided that Aurora concurrently pays the Aurora Termination Fee; or

(iv) any condition described above under the headings "*Mutual Conditions*" or "*Conditions to the Obligations of Aurora*" is incapable of being satisfied by the Outside Date, provided that Aurora is not then in breach of the Arrangement Agreement so as to cause any such condition not to be satisfied.

A Party wishing to terminate the Arrangement Agreement (other than by mutual agreement) must give notice of termination to the other Party. If the Arrangement Agreement is terminated, it will become void and of no further effect, except that certain provisions (including those relating to termination fees, the Expense Fee, expenses, the financing sources and confidentiality) will survive. Termination will not relieve a Party of liability arising before termination or for any wilful breach, and liabilities and damages are not limited to reimbursement of expenses or out-of-pocket costs.

Termination Fees

Organigram and Aurora have agreed that, in certain circumstances, a termination fee may be payable by a Party to the other Party on the termination of the Arrangement Agreement:

(a) If an Aurora Termination Fee Event occurs, Aurora shall pay Organigram the Aurora Termination Fee, and if an Organigram Termination Fee Event occurs, Organigram shall pay Aurora the Organigram Termination Fee, in each case as described below. In no event shall either Party be required to pay a termination fee more than once. Each termination fee is consideration for the disposition of the recipient Party's rights under the Arrangement Agreement.

(b) For the purposes of the Arrangement Agreement, "**Aurora Termination Fee**" means $25.2 million, and "**Aurora Termination Fee Event**" means the termination of the Arrangement Agreement:

(i) by Organigram, in the circumstances described above in paragraph (c)(ii) *[Aurora Change in Recommendation]* under the heading "*Termination*";

(ii) by Aurora, in the circumstances described above in paragraph (d)(iii) *[Aurora Superior Proposal]* under the heading "*Termination*"; or

(iii) by either Party in the circumstances described above in paragraph (b)(i) *[Failure of Aurora Shareholders to Approve]*, or by Organigram in the circumstances described above in paragraph (c)(i) *[Breach of Aurora Reps and Warranties/Covenants]*, under the heading "*Termination*", but only if: (A) following the date of the Arrangement Agreement and prior to the Aurora Shareholders' Meeting, a *bona fide* Acquisition Proposal in respect of Aurora shall have been made to Aurora or publicly announced, or any Person shall have publicly announced an intention to make such an Acquisition Proposal (in each case, other than Organigram), and such Acquisition Proposal has not expired or been publicly withdrawn at least five business days prior to the Aurora Shareholders' Meeting; and (B) within 12 months following such termination, an Acquisition Proposal in respect of Aurora (whether or not the same Acquisition Proposal) is consummated, or Aurora enters into a definitive agreement in respect of an Acquisition Proposal that is later consummated (for these purposes, references to 20% in the definition of Acquisition Proposal are read as 50%, and the Hostile Bid in its current form is excluded but any Amended Bid is included).

(c) The Aurora Termination Fee shall be paid on the second business day following termination in the circumstances described in paragraph (b)(i) above, concurrently with termination in the circumstances described in paragraph (b)(ii) above, and within two business days following the closing of the applicable transaction in the circumstances described in paragraph (b)(iii) above, in each case by wire transfer of immediately available funds.

(d) For the purposes of the Arrangement Agreement, "**Organigram Termination Fee**" means $38.4 million, and "**Organigram Termination Fee Event**" means the termination of the Arrangement Agreement:

(i) by Aurora, in the circumstances described above in paragraph (d)(ii) *[Organigram Change in Recommendation]* under the heading "*Termination*"; or

(ii) by either Party in the circumstances described above in paragraph (b)(ii) *[Failure of Organigram Shareholders to Approve]*, or by Aurora in the circumstances described above in paragraph (d)(i) *[Breach of Organigram Reps and Warranties/Covenants]*, under the heading "*Termination*", but only if: (A) following the date of the Arrangement Agreement and prior to the Organigram Shareholders' Meeting, a *bona fide* Acquisition Proposal in respect of Organigram shall have been made to Organigram or publicly announced, or any Person shall have publicly announced an intention to make such an Acquisition Proposal

(in each case, other than Aurora), and such Acquisition Proposal has not expired or been publicly withdrawn at least five business days prior to the Organigram Shareholders' Meeting; and (B) within 12 months following such termination, an Acquisition Proposal in respect of Organigram (whether or not the same Acquisition Proposal) is consummated, or Organigram enters into a definitive agreement in respect of an Acquisition Proposal that is later consummated (for these purposes, references to 20% in the definition of Acquisition Proposal are read as 50%).

(e) The Organigram Termination Fee shall be paid on the second business day following termination in the circumstances described in paragraph (d)(i) above, and within two business days following the closing of the applicable transaction in the circumstances described in paragraph (d)(ii) above, in each case by wire transfer of immediately available funds.

(f) In addition, if the Arrangement Agreement is terminated by either Party in the circumstances described above in paragraph (b)(ii) *[Failure of Organigram Shareholders to Approve]* under the heading "*Termination*", Organigram shall pay Aurora the Expense Fee of $5.6 million within two business days of such termination, in addition to any Organigram Termination Fee that may become payable.

(g) Each termination fee is a payment of liquidated damages representing a genuine pre-estimate of the damages the receiving Party will suffer and is not a penalty. If a termination fee is paid in full, the Party receiving it will be precluded from any other remedy against the paying Party, except in the case of a wilful breach by the paying Party, in which case the fee will not limit any damages or other remedies (including specific performance or injunctive relief) available to the receiving Party. Nothing in these provisions precludes a Party from seeking injunctive relief or specific performance prior to termination.

Aurora Support Agreements

The following is a summary of certain provisions of the Aurora Support Agreements and is qualified in its entirety by the full text of the form of such agreement, which has been filed on Aurora's SEDAR+ profile at www.sedarplus.ca and on Aurora's EDGAR profile at www.sec.gov. Aurora Shareholders and Organigram Shareholders are urged to read the form of the Aurora Support Agreements in its entirety.

On November 2, 2026, each of the Supporting Aurora Shareholders, being the directors and executive officers of Aurora, who collectively hold approximately 0.62% of the issued and outstanding Aurora Common Shares, entered into an Aurora Support Agreement with Organigram. The Aurora Support Agreements and the Organigram Support Agreements with the directors and executive officers of Organigram who hold Organigram Common Shares are in substantially the same form. Pursuant to the Aurora Support Agreements, each Supporting Aurora Shareholder has agreed, among other things, solely in its capacity as a securityholder of Aurora and not in any capacity as a director or officer of Aurora, to cause its Aurora Common Shares directly or indirectly beneficially owned, controlled or directed or subsequently acquired by such Supporting Aurora Shareholder (including on the exercise of Aurora Options or the settlement in Aurora Common Shares of Aurora RSUs, Aurora PSUs or Aurora DSUs) to be counted as present for purposes of quorum and to vote such Aurora Common Shares: (a) in favour of the Arrangement Resolution, the Arrangement and any other transactions contemplated by the Arrangement Agreement, any permitted adjournment or postponement of the Aurora Shareholders' Meeting and any other matter that could reasonably be expected to facilitate the Arrangement; and (b) against any Acquisition Proposal in respect of Aurora and any matter that would reasonably be expected to adversely affect, reduce the likelihood of, prevent, materially delay or interfere with the Arrangement. Each Supporting Aurora Shareholder has also agreed not to sell, transfer, tender, pledge or otherwise dispose of its Aurora securities (including by tendering to the Hostile Bid or any other take-over bid), grant any proxy or voting right in respect of them, or requisition a meeting or give any consent in respect of an Acquisition Proposal, subject to exceptions permitting the exercise or settlement of incentive awards and transfers to controlled entities that agree to be bound. Each Supporting Aurora Shareholder has also agreed to waive any dissent or appraisal rights and to notify Organigram of any newly acquired Aurora securities, which become subject to the Aurora Support Agreement. Nothing in the Aurora Support Agreements restricts a Supporting Aurora Shareholder who is a director

or officer of Aurora from discharging his or her fiduciary duties in that capacity in compliance with the Arrangement Agreement.

Each Aurora Support Agreement may be terminated by mutual written agreement and will terminate automatically on the earliest of: (a) the Effective Time; (b) an Organigram Change in Recommendation; (c) an Aurora Change in Recommendation; and (d) the termination of the Arrangement Agreement in accordance with its terms. No termination relieves a party from liability for a prior breach. Each Supporting Aurora Shareholder has also agreed to deliver a proxy or voting instruction form voting in favour of the Arrangement Resolution as soon as practicable after the mailing of this Joint Information Circular and in any event no later than ten Business Days before the Aurora Shareholders' Meeting (or as far in advance as practicable of any adjournment or postponement), and not to revoke it without Organigram's consent.

Organigram Support Agreements

The following is a summary of certain provisions of the Organigram Support Agreements and is qualified in its entirety by the full text of the form of such agreement, which has been filed on Organigram's SEDAR+ profile at www.sedarplus.ca and on Organigram's EDGAR profile at www.sec.gov. Aurora Shareholders and Organigram Shareholders are urged to read the form of the Organigram Support Agreements in its entirety.

On November 2, 2026, each of the Supporting Organigram Shareholders, being BAT and each of the directors and executive officers of Organigram who hold Organigram Common Shares, who collectively hold approximately 30.95% of the issued and outstanding Organigram Common Shares, entered into an Organigram Support Agreement with Aurora. BAT entered into a separate form of Organigram Support Agreement in respect of 42,231,089 Organigram Common Shares and 49,204,021 Organigram Preferred Shares. Pursuant to the Organigram Support Agreements, each Supporting Organigram Shareholder has agreed, among other things, solely in its capacity as a securityholder of Organigram and not in any capacity as a director or officer of Organigram, to cause its Organigram Common Shares directly or indirectly beneficially owned, controlled or directed or subsequently acquired by such Supporting Organigram Shareholder (including on the exercise or settlement of any convertible securities) to be counted as present for purposes of quorum and to vote such Organigram Common Shares: (a) in favour of the Organigram Share Issuance Resolution, the transactions contemplated by the Arrangement Agreement and any permitted adjournment or postponement of the Organigram Shareholders' Meeting; and (b) against any Acquisition Proposal in respect of Organigram and any matter that would reasonably be expected to prevent, materially delay or interfere with the Arrangement or any of the other transactions contemplated by the Arrangement Agreement. Organigram Common Shares held by BAT and its affiliates will be excluded for purposes of the disinterested shareholder approval required under the TSX Company Manual and the minority approval required under MI 61-101.

Each Supporting Organigram Shareholder has also agreed to deliver a proxy or voting instruction form voting in favour of the Organigram Share Issuance Resolution no later than ten Business Days (or, in the case of BAT, five Business Days) before the Organigram Shareholders' Meeting (or as far in advance as practicable of any adjournment or postponement), not to revoke it without Aurora's consent, to waive any dissent or appraisal rights, and to notify Aurora of any newly acquired Organigram securities, which become subject to the applicable Organigram Support Agreement. Subject to limited exceptions, including the exercise or settlement of incentive awards, transfers to controlled entities that agree to be bound and, in the case of BAT, transfers after the Final Order is granted, the Supporting Organigram Shareholders have agreed not to transfer their Organigram securities, grant any proxy or other voting right in respect of them, or requisition a meeting or give any consent in respect of an Acquisition Proposal. BAT has also agreed not to solicit, encourage or participate in discussions regarding any Acquisition Proposal in respect of Organigram, not to act jointly or in concert with others to oppose the Arrangement, and not to commence or join any action challenging the Organigram Support Agreement or alleging a breach of fiduciary duty in connection with the Arrangement Agreement (other than claims relating to its rights under the BAT Equity Commitment or its express third-party beneficiary rights under the Arrangement Agreement). Nothing in the Organigram Support Agreements restricts a Supporting Organigram Shareholder who is a director or officer of Organigram from discharging his or her fiduciary duties in that capacity in compliance with the Arrangement Agreement.

The Organigram Support Agreements with the directors and executive officers of Organigram who hold Organigram Common Shares may be terminated by mutual written agreement and will terminate automatically on the earliest of: (a) the Effective Time; (b) an Organigram Change in Recommendation; (c) an Aurora Change in Recommendation;

and (d) the termination of the Arrangement Agreement in accordance with its terms. The Organigram Support Agreement with BAT may be terminated by mutual written agreement, or by either party if the other party has breached its representations, warranties or covenants in any material respect and has not cured the breach within five business days after notice, and will terminate automatically on the earliest of: (a) the Effective Time; (b) the six-month anniversary of the termination of the Arrangement Agreement by Organigram; (c) the six-month anniversary of the termination of the Arrangement Agreement by Aurora because the Organigram Share Issuance Resolution is not approved, because of an Organigram Change in Recommendation or a material breach by Organigram of its non-solicitation covenants, or because of a breach by Organigram of its representations, warranties or covenants that is not cured, or in any other circumstance in which Aurora was entitled at the time of termination to terminate the Arrangement Agreement on any of those grounds (each, a "**Specified Termination Event**"); (d) the termination of the Arrangement Agreement by Aurora other than in a Specified Termination Event; and (e) the termination of the BAT Equity Commitment by BAT following a Specified Adverse Amendment or other materially adverse amendment to the Arrangement Agreement made without its consent.

BAT Equity Commitment

The following is a summary of certain provisions of the BAT Equity Commitment and is qualified in its entirety by the full text of the BAT Equity Commitment, which has been filed on Organigram's SEDAR+ profile at www.sedarplus.ca and on Organigram's EDGAR profile at www.sec.gov. Organigram Shareholders are urged to read the BAT Equity Commitment in its entirety.

Subscription and Pricing

Concurrently with the execution of the Arrangement Agreement, Organigram and BAT entered into the BAT Equity Commitment, pursuant to which BAT has agreed to subscribe for 140,986,255 Organigram Common Shares and/or Organigram Preferred Shares at a price of £0.709289 (approximately $1.33 based on the GBP/CAD exchange rate on November 2, 2026) per share for aggregate proceeds of £99,999,999.82 (approximately $187.5 million based on the GBP/CAD exchange rate on November 2, 2026). To the extent that the issuance of Organigram Common Shares to BAT would result in BAT and its affiliates, associates, related parties and joint actors holding more than 30% of the outstanding Organigram Common Shares, BAT will instead receive Organigram Preferred Shares for the excess. Following completion of the Arrangement and the BAT Private Placement, BAT is expected to hold an economic interest of approximately 44% in Organigram, with its voting interest remaining capped at 30%.

The subscription price under the BAT Equity Commitment is equal to the deemed value of the Organigram Common Shares under the Arrangement (being the 20-day volume-weighted average trading price of the Organigram Common Shares on the TSX as of November 2, 2026), and, for greater certainty, represents no discount to the "market price (as defined in the TSX Company Manual) as of November 2, 2026. The market price, being the volume-weighted average trading price of the Organigram Common Shares on the TSX for the five trading days immediately preceding November 2, 2026, was $1.328. The price for the BAT Equity Commitment was determined when Organigram and BAT were aware of material undisclosed information, being the proposed Arrangement, and the Arrangement would not occur but for the BAT Equity Commitment. In approving the BAT Private Placement, the Organigram Board also considered that raising a comparable amount of equity through a public offering or a private placement with third-party investors would likely have required pricing at a discount to market price and the payment of underwriting commissions or placement fees.

Use of Proceeds

Unless BAT consents, the proceeds of the BAT Private Placement may only be used to fund a portion of the aggregate cash Consideration and other amounts payable by Organigram under the Arrangement Agreement, and to pay transaction expenses in connection with the Arrangement and the BAT Private Placement, and may not be used to pay dividends or other distributions, repurchase, redeem or retract securities, pay bonuses or similar amounts outside the ordinary course or for any "specified unlawful activity" under 18 USC § 1956(c)(7).

Closing and Conditions

The BAT Private Placement is expected to close concurrently with the Arrangement, but not earlier than January 6, 2027 or later than October 29, 2027 unless the parties otherwise agree. If requested by Organigram, BAT will fund the subscription proceeds in advance of closing to permit Organigram to satisfy its funding obligations under the Arrangement Agreement, and Organigram will ensure the proceeds are promptly returned to BAT if the Arrangement does not close within two business days. The obligations of the parties are subject to, among other things: receipt of the approval of the TSX and notification to the Nasdaq; no law in effect making the BAT Private Placement illegal or otherwise preventing or prohibiting it; no material claim pending in connection with it; and the conditions to Organigram's obligation to complete the Arrangement having been satisfied or waived. BAT's obligation is also subject to Organigram having complied in all material respects with its covenants and the Arrangement Agreement not having been amended, or any provision waived or consent given, without BAT's consent (acting reasonably) in a manner that would change the Consideration (including the mix of cash and shares) such that BAT would hold less than 40% or 50% or more of the economic interests in Organigram on a pro forma basis, after giving effect to the maximum remaining earnout shares issuable in respect of Sanity Group (a "**Specified Adverse Amendment**"). If a condition cannot be satisfied at closing, the parties must use their best efforts to satisfy it within a further 30-day period before either party may terminate.

Covenants

Under the BAT Equity Commitment, BAT has agreed to vote its Organigram Common Shares in favour of the Arrangement and the BAT Private Placement, to deliver its proxy no later than five business days prior to the proxy deadline for the Organigram Shareholders' Meeting and not to transfer its Organigram Common Shares until the record date for the Organigram Shareholders' Meeting has passed. These covenants are in addition to BAT's separate obligations under its Organigram Support Agreement. See "*Effect of the Arrangement – Organigram Support Agreements*". Organigram has agreed to consult in good faith with BAT on strategic matters relating to the Arrangement and before exercising any right, including any consent right, under the Arrangement Agreement, and not to make a Specified Adverse Amendment without BAT's consent. Organigram has also agreed not to issue securities until six months after closing, subject to exceptions including issuances with BAT's consent, under its equity incentive plans or the Arrangement Agreement, pursuant to BAT's top-up and pre-emptive rights, under the earnouts in respect of Sanity Group and Collective Arts, or at or above the subscription price. Each party is entitled to injunctive relief and specific performance to enforce the BAT Equity Commitment.

Representations, Warranties and Indemnification

Organigram has given customary representations and warranties to BAT, and BAT has given customary representations and warranties to Organigram. Organigram has agreed to indemnify BAT and its affiliates for breaches of its representations, warranties and covenants for 18 months after closing (with fundamental representations surviving indefinitely and tax representations surviving until 60 days after the expiry of the applicable limitation period), subject to a cap equal to the subscription proceeds, except in the case of fraud, intentional misrepresentation or wilful breach.

Investor Rights Agreement

In connection with the BAT Private Placement, Organigram and BAT will amend the Amended and Restated IRA to provide that BAT's pre-emptive and top-up rights are not subject to a 19.9% limit or otherwise. Under the BAT Equity Commitment, BAT has irrevocably: (a) consented to the amendment and restatement of Organigram's credit agreement with ATB Financial, including additional borrowings of up to $140,000,000 if the Arrangement closes (or up to $10,000,000 if it does not); (b) confirmed that its top-up rights will not apply to the BAT Private Placement or to any Organigram Common Shares issued under the Arrangement Agreement; and (c) agreed that neither the Arrangement, the BAT Private Placement nor their announcement will cause the standstill restrictions in that agreement to lapse, such that they will continue in effect following completion of the Arrangement.

Termination

The BAT Equity Commitment may be terminated by mutual agreement, by either party if the Arrangement Agreement is validly terminated, by either party if the applicable closing conditions cannot be satisfied following a further 30-day period of best efforts (other than as a result of its own material breach), or by BAT if a Specified Adverse Amendment or other amendment to the Arrangement Agreement that is materially adverse to BAT is made without its consent and is not cured within five business days. The BAT Equity Commitment will terminate automatically on closing or on the day following the Outside Date, whichever is earlier.

Board Approval

In respect of the BAT Private Placement, the Organigram Board, together with its financial and legal advisors, considered the terms of the financing relative to alternative funding structures and market conditions, considering factors such as pricing, dilution, cost of capital and the strategic alignment between Organigram and BAT. After careful consideration, the Organigram Board unanimously (with the representatives of BAT abstaining) determined that the terms of the BAT Private Placement are fair, reasonable and in the best interests of Organigram.

ATB Debt Financing

In connection with the Arrangement, on November 2, 2026, Organigram entered into a commitment letter with ATB Financial (the "**ATB Commitment Letter**"), pursuant to which ATB Financial has committed, subject solely to the conditions described below, to amend and restate Organigram's existing credit agreement dated April 14, 2026 to provide senior secured credit facilities of up to $210,000,000 (the "ATB Credit Facilities"), consisting of: (a) a $10,000,000 revolving operating facility; (b) a $65,000,000 revolving credit facility, which may be used for general corporate purposes, including to partially finance the Arrangement, provided that no more than $35,000,000 may be drawn to finance the Arrangement and only once the acquisition term tranche has been drawn in full; and (c) a $135,000,000 non-revolving term facility, comprised of a $20,000,000 tranche that was drawn in connection with the acquisition of Sanity Group and a $115,000,000 tranche to be drawn on closing to fund a portion of the cash Consideration (any portion of which not drawn on closing will be cancelled). ATB Financial will act as sole lead arranger, bookrunner and administrative agent, may syndicate a portion of the ATB Credit Facilities and intends to retain the leading position in the aggregate commitments; the commitment is not conditional on syndication. The ATB Credit Facilities will mature three years after closing. The term facility will amortize in equal quarterly instalments based on a five-year straight-line amortization (initially $6,750,000 per quarter, subject to adjustment for any undrawn amounts cancelled on closing), with the balance due at maturity. The ATB Credit Facilities will be guaranteed by Organigram's material subsidiaries and, following completion of the Arrangement, by Aurora and its material subsidiaries, and secured by a first-priority security interest over substantially all of their assets, with certain security permitted to be delivered within 90 days after closing.

ATB Financial's obligation to fund on closing is subject only to a limited set of conditions, including: execution of the amended and restated credit agreement and delivery of the required security, in some cases in escrow pending completion of the Arrangement; receipt of the Final Order; evidence that cash proceeds of not less than the Canadian dollar equivalent of £100,000,000 under the BAT Equity Commitment have been or will be received substantially concurrently with the initial advance; completion of the Arrangement substantially simultaneously with the borrowing in all material respects in accordance with the Arrangement Agreement, without any amendment, waiver or consent that is materially adverse to the lenders unless ATB Financial consents; accuracy of certain specified representations; and payment of fees and other customary deliveries. Amendments or waivers that change the definition of "Material Adverse Effect" or waive a Material Adverse Effect in respect of Aurora, lower the Aurora voting threshold, increase the aggregate Consideration (other than increases that can be fully funded by the availability under the ATB Credit Facilities for the Arrangement or that are funded solely with equity proceeds), change the Outside Date, or waive a required regulatory approval are deemed materially adverse to the lenders. The commitment is not conditional on syndication or on any due diligence, and will terminate if the Arrangement is not completed by the Outside Date (as it may be extended), if the Arrangement Agreement is terminated or if the Arrangement is completed without using the ATB Credit Facilities.

Organigram has agreed to use commercially reasonable efforts to deliver third-party appraisals of the owned real property (other than certain properties held for sale), cultivation facilities and manufacturing equipment of Aurora and its subsidiaries by December 7, 2026 (or such later date as ATB Financial may agree). Delivery of the appraisals is not a condition to funding. However, if the appraisals are not delivered by that date, Organigram will be required, following closing, to prepay $80,000,000 of the $115,000,000 acquisition term tranche, and if the appraised orderly liquidation value is less than $50,000,000, Organigram will be required to prepay that tranche by 1.5 times the amount of the shortfall, in each case with a corresponding permanent reduction of the commitments. In addition, if any portion of the revolving facility is drawn to finance the Arrangement, Organigram will be required to repay that amount upon the release of certain restricted cash of Organigram, and no revolver draw for the Arrangement will be permitted if that cash is released before closing.

PROCEDURE FOR THE ARRANGEMENT TO BECOME EFFECTIVE

Procedural Steps

The Arrangement is proposed to be carried out pursuant to section 288 of the BCBCA. The following procedural steps must be taken in order for the Arrangement to become effective:

(a) the Arrangement Resolution must be approved by not less than 66⅔% of the votes cast by the Aurora Shareholders present virtually or represented by proxy at the Aurora Shareholders' Meeting and by a simple majority of such votes cast excluding the votes required to be excluded under MI 61-101, in the manner set forth in the Interim Order;

(b) the Organigram Share Issuance Resolution must be approved by greater than (i) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting and (ii) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, excluding the votes attached to Organigram Common Shares held by BAT and its affiliates (and, for purposes of MI 61-101, their respective directors and officers and other persons required to be excluded);

(c) the Court must grant the Final Order approving the Arrangement;

(d) all conditions precedent to the Arrangement, as set forth in the Arrangement Agreement, including receipt of the Required Regulatory Approvals, must be satisfied or waived by the appropriate Party; and

(e) the Final Order and the records and information required under section 292 of the BCBCA must be filed with the Registrar.

There is no assurance that the conditions set out in the Arrangement Agreement will be satisfied or waived on a timely basis or at all.

Upon the conditions precedent set forth in the Arrangement Agreement being satisfied or waived (excluding conditions that, by their terms, cannot be satisfied until the Effective Date), Aurora is required, unless another time or date is agreed to in writing by the Parties, to file the records and information required under section 292 of the BCBCA with the Registrar no later than the third Business Day thereafter, and the Arrangement will become effective at the Effective Time on the Effective Date in accordance with the Plan of Arrangement. Notwithstanding the foregoing, pursuant to the Arrangement Agreement, the Effective Date shall not occur prior to January 6, 2027.

Shareholder Approvals

Arrangement Resolution

Pursuant to the Interim Order, the Arrangement Resolution must, subject to further order of the Court, be approved by not less than 66⅔% of the votes cast by the Aurora Shareholders present virtually or represented by proxy and

entitled to vote at the Aurora Shareholders' Meeting, voting together as a single class, and by a simple majority of such votes cast, excluding the votes attached to Aurora Common Shares held by persons described in items (a) through (d) of section 8.1(2) of MI 61-101, being only Mr. Miguel Martin. If the Arrangement Resolution is not approved by the Aurora Shareholders, the Arrangement cannot be completed.

It is the intention of the persons named in the enclosed form of proxy, if not expressly directed to the contrary in such form of proxy, to vote such proxy in favour of the Arrangement Resolution set forth in Appendix "A" to this Joint Information Circular.

Notwithstanding the foregoing, the Arrangement Resolution proposed for consideration by the Aurora Shareholders authorizes the Aurora Board, without further notice to or approval of the Aurora Shareholders, subject to the terms of the Arrangement Agreement and the Interim Order, to amend the Arrangement Agreement or the Plan of Arrangement and to not proceed with the Arrangement. See Appendix "A" to this Joint Information Circular for the full text of the Arrangement Resolution.

Organigram Share Issuance Resolution

In accordance with the applicable rules of the TSX and MI 61-101, the Organigram Share Issuance Resolution must be approved by greater than (i) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, and (ii) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, excluding the votes attached to Organigram Common Shares held by BAT and its affiliates (and, for purposes of MI 61-101, their respective directors and officers and other persons required to be excluded). If the Organigram Share Issuance Resolution is not approved by the Organigram Shareholders, the Arrangement cannot be completed.

The Organigram Share Issuance Resolution requires the approval of greater than 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting pursuant to sections 607(g)(i) and 611(c) of the TSX Company Manual because the Organigram Common Shares to be issued to Aurora Shareholders under the Arrangement and to BAT in connection with the BAT Private Placement, together with the Organigram Common Shares that will be issuable upon the exercise of Replacement Options, will constitute greater than 25% of the issued and outstanding Organigram Common Shares (on a non-diluted basis) immediately prior to the Arrangement.

The Organigram Share Issuance Resolution requires the approval of greater than 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, excluding the votes attached to Organigram Common Shares beneficially owned, or over which control or direction is exercised, by BAT and its affiliates, pursuant to sections 604(a)(ii), 607(g)(ii) and 611(b) of the TSX Company Manual because the resolution authorizes and approves the BAT Private Placement and (i) the BAT Private Placement provides consideration to BAT that is greater than 10% of Organigram's market capitalization and (ii) the number of Organigram Common Shares issuable pursuant to the BAT Private Placement is greater than 10% of the number of Organigram Common Shares, on a non-diluted basis, that will be outstanding at the closing of the BAT Private Placement.

Additionally, the Organigram Share Issuance Resolution requires the approval of greater than 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, excluding the votes attached to Organigram Common Shares held by BAT and its affiliates and their respective directors and officers and other persons required to be excluded by MI 61-101 because BAT is a "related party" and the BAT Private Placement is a "related party transaction". See "*Procedure for the Arrangement to Become Effective – Securities Law Matters – Canada – MI 61-101*".

If the Organigram Share Issuance Resolution is approved, the TSX will generally not require further Organigram Shareholder approval for the issuance of up to an additional 55,767,987 Organigram Common Shares, being 25% of the number of Organigram Common Shares approved for issuance pursuant to the Arrangement (including upon the exercise of Replacement Options) by the Organigram Shareholders.

It is the intention of the persons named in the enclosed form of proxy, if not expressly directed to the contrary in such form of proxy, to vote such proxy in favour of the Organigram Share Issuance Resolution set forth in Appendix "B" to this Joint Information Circular.

Notwithstanding the foregoing, the Organigram Share Issuance Resolution proposed for consideration by the Organigram Shareholders authorizes the Organigram Board, without further notice to or approval of the Organigram Shareholders, subject to the terms of the Arrangement Agreement and the Plan of Arrangement, to amend the Arrangement Agreement or the Plan of Arrangement and to not proceed with the Arrangement.

Court Approval

Interim Order

On November 20, 2026, Aurora obtained the Interim Order providing for the calling and holding of the Aurora Shareholders' Meeting and other procedural matters relating to the Meetings. A copy of the Interim Order is attached as Appendix "D" to this Joint Information Circular.

Final Order

The Arrangement requires approval by the Court under section 291 of the BCBCA. Subject to the terms of the Arrangement Agreement, if the Arrangement Resolution is approved at the Aurora Shareholders' Meeting in the manner required by the Interim Order and the Organigram Share Issuance Resolution is approved at the Organigram Shareholders' Meeting, Aurora will, within five Business Days thereafter, make an application to the Court for the Final Order. The hearing in respect of the Final Order is expected to take place on December 30, 2026 at 9:45 a.m. (Vancouver time) at the Vancouver Law Courts, 800 Smithe Street, Vancouver, British Columbia, or via video conference if so directed by the Court, or as soon thereafter as counsel may be heard. Copies of the Interim Order and the Petition and Notice of Hearing of Petition for the Final Order are attached as Appendix "D" and Appendix "E", respectively, to this Joint Information Circular. At the hearing, the Court will consider, among other things, the fairness and reasonableness of the Arrangement.

Under the terms of the Interim Order, any Aurora Shareholder or other interested party who wishes to appear or be represented and to present evidence or arguments at the hearing of the application for the Final Order must file with the Court and serve upon Aurora a Response to Petition in the form required by the Supreme Court Civil Rules (British Columbia), together with any affidavits or other materials on which such person intends to rely and such person's address for service, by no later than 4:00 p.m. (Vancouver time) on December 23, 2026. Service on Aurora is to be effected by service upon the solicitors for Aurora: Torys LLP, Suite 2800, 79 Wellington St. W., Toronto, Ontario M5K 1N2, Attention: Andrew Gray and Colette Koopman, with a copy to the solicitors for Organigram: Goodmans LLP, Bay Adelaide Centre – West Tower, 333 Bay Street, Suite 3400, Toronto, Ontario M5H 2S7, Attention: Tom Friedland. If the hearing is postponed, adjourned or rescheduled then, subject to further direction of the Court, only those persons having previously filed and served a Response to Petition in compliance with the Interim Order will be given notice of the new date.

The Organigram Common Shares and the Replacement Options issuable to Aurora Shareholders and Aurora Optionholders, as applicable in exchange for their Aurora Common Shares pursuant to the Arrangement have not been and will not be registered under the U.S. Securities Act or any securities laws of any state within the United States, and will be issued in reliance upon the exemption from the registration requirements of the U.S. Securities Act provided by Section 3(a)(10) thereof. The Court has been advised that the Final Order, if granted, will constitute the basis for an exemption from the registration requirements of the U.S. Securities Act, pursuant to Section 3(a)(10) thereof, with respect to the issuance of the Organigram Common Shares issuable to Aurora Shareholders and the issuance of the Replacement Options to Aurora Optionholders pursuant to the Arrangement.

Aurora has been advised by its counsel, Stikeman, that the Court has broad discretion under the BCBCA when making orders with respect to plans of arrangement and that the Court, in hearing the application for the Final Order, will consider, among other things, the fairness and reasonableness of the Arrangement, both from a substantive and a procedural perspective, to the Aurora Shareholders and any other interested party as the Court determines appropriate.

The Court may approve the Arrangement either as proposed or as amended in any manner the Court may direct, subject to compliance with such terms and conditions, if any, as the Court may determine appropriate. Either Organigram or Aurora may, subject to the terms of the Arrangement Agreement, determine not to proceed with the Arrangement in the event that any amendment ordered by the Court is not satisfactory to such Party.

Regulatory Approvals

The Arrangement Agreement provides that receipt (or, where applicable, waiver) of all Required Regulatory Approvals and receipt of conditional approval to the listing of the Organigram Common Shares issuable pursuant to the Arrangement on the TSX, and the notification to the Nasdaq of the listing of the Organigram Common Shares issuable pursuant to the Arrangement without objection from the Nasdaq, is a condition precedent to the Arrangement becoming effective. See "*Effect of the Arrangement – The Arrangement Agreement – Mutual Conditions*".

Competition Act Approval

The Arrangement is a "notifiable transaction" for the purposes of Part IX of the Competition Act. When a transaction is a notifiable transaction under the Competition Act, certain prescribed information must be provided to the Commissioner under Part IX of the Competition Act and the transaction may not be completed until the expiry, waiver or termination of the applicable waiting period. Where a notification is made, the waiting period is 30 calendar days after the day on which the parties to the transaction submit the prescribed information, provided that, before the expiry of this period, the Commissioner has not notified the parties that the Commissioner requires additional information that is relevant to the Commissioner's assessment of the transaction (a "**Supplementary Information Request**"). If the Commissioner provides the Parties with a Supplementary Information Request, the Parties cannot complete their transaction until 30 calendar days after both Parties have complied with such Supplementary Information Request, provided that there is no order in effect prohibiting completion at the relevant time. Aurora and Organigram each filed their respective notifications under subsection 114(1) of the Competition Act on November 9, 2026.

The Commissioner may, upon application by the parties to a proposed transaction, issue an advance ruling certificate ("**ARC**") under Section 102 of the Competition Act where the Commissioner is satisfied that there would not be sufficient grounds on which to apply to the Competition Tribunal (the "**Tribunal**") for an order under Section 92 of the Competition Act. Further, if the transaction to which the ARC relates is substantially completed within one year after the ARC is issued, the Commissioner cannot seek an order of the Tribunal under Section 92 of the Competition Act in respect of the transaction solely on the basis of information that is the same or substantially the same as the information on the basis of which the ARC was issued. Where the Commissioner is of the view that there are not sufficient grounds on which to issue an ARC, but nonetheless does not, at that time, intend to apply to the Tribunal for an order under Section 92 of the Competition Act in respect of the proposed transaction, the Commissioner may issue a letter to the parties confirming same (a "**No Action Letter**"). If an ARC or a No Action Letter is issued in respect of a notifiable transaction, the parties may complete the transaction even if the 30-day waiting period described above has not expired. On November 9, 2026, concurrent with filing of the parties' respective notifications, Aurora and Organigram jointly requested that the Commissioner issue an ARC under Section 102 of the Competition Act or, alternatively, a No Action Letter in respect of the Arrangement.

The Commissioner may challenge the transaction under Section 92 of the Competition Act if the Commissioner is of the view that the transaction prevents or lessens, or is likely to prevent or lessen, competition substantially, and may also apply to the Tribunal for an interim order to prevent its closing pending the Tribunal's determination of the challenge. Such a challenge may be brought before completion or, where the transaction was notified, within one year after it is substantially completed, unless an ARC has been issued as described above. The issuance of a No Action Letter does not preclude such a challenge, but in practice a No Action Letter is significant comfort that an application under Section 92 is unlikely to be made.

It is a mutual condition to completion of the Arrangement that the Competition Act Approval shall have been obtained, being that: (a) an ARC shall have been issued by the Commissioner pursuant to subsection 102(1) of the Competition Act with respect to the transactions contemplated by the Arrangement Agreement; or (b)(i) the applicable waiting period under section 123 of the Competition Act shall have expired or shall have been terminated by the Commissioner, or (ii) the obligation to submit a notification under Part IX of the Competition Act shall have been waived by the Commissioner pursuant to paragraph 113(c) of the Competition Act, and, in either case, unless such

requirement is waived by Organigram in its sole discretion, the Commissioner shall have issued a written No Action Letter.

German FDI Approval

The Arrangement is subject to Germany's foreign direct investment screening regime, which is established by the German Foreign Trade and Payments Act (*Außenwirtschaftsgesetz*) (the "**AWG**") and the German Foreign Trade and Payments Ordinance (*Außenwirtschaftsverordnung*) (the "**AWV**") and administered by the BMWE. Under the cross-sector review mechanism of the AWV, a direct or indirect acquisition by an investor from outside the European Union or the European Free Trade Association of voting rights in a German company that is active in one of the sectors specified in the AWV, which include the development, manufacture or distribution of medicinal products and active pharmaceutical ingredients that are essential for the provision of healthcare in Germany, must be notified to the BMWE if the applicable voting rights threshold is met. Organigram is a corporation with its registered office and place of management in Canada and, on completion of the Arrangement, will indirectly acquire all of the issued shares of Aurora's German subsidiaries, Aurora Europe GmbH, Aurora Deutschland GmbH and Aurora Produktions GmbH, which produce and distribute medical cannabis products in Germany. The Arrangement is therefore subject to a notification obligation under the AWV. A notification in respect of the Arrangement was submitted to the BMWE on November 6, 2026.

Following the BMWE obtaining knowledge of an acquisition (e.g., by receipt of a notification), it has two months to clear the acquisition or to open an in-depth review. If the BMWE opens an in-depth review, it has a further four months from receipt of the complete documents requested from the parties to clear the acquisition, clear it subject to conditions or the conclusion of a public law agreement, or prohibit it. The BMWE may only refrain from clearing the acquisition unconditionally where the acquisition is likely to affect public order or security in Germany or in another Member State of the European Union. An acquisition that is subject to a notification obligation may not be completed before it has been cleared or clearance is deemed to have been granted.

It is a mutual condition to completion of the Arrangement that the German FDI Approval shall have been obtained, meaning that the BMWE has issued (a) a clearance decision (*Freigabebescheid*), (b) a certificate of non-objection (*Unbedenklichkeitsbescheinigung*), or (c) any other written confirmation that the Arrangement and the Organigram Financing are not subject to a mandatory foreign direct investment filing obligation pursuant to Section 55a(4) or Section 60(3) of the AWV, provided that, in the case of (a), any terms or conditions attached thereto (including conditions or obligations imposed by the BMWE (*Auflagen*), a partial clearance (*Teilfreigabe*) or the conclusion of a public law agreement (*öffentlich-rechtlicher Vertrag*)) are acceptable to Organigram and do not impose any obligation, condition or requirement on BAT or its affiliates, or that clearance is deemed to have been granted by operation of law pursuant to Section 14a of the AWG. See "Effect of the Arrangement – The Arrangement Agreement – Mutual Conditions".

As of the date of this Joint Information Circular, the BMWE has confirmed receipt of the notification but has not completed its review and the German FDI Approval has not yet been obtained.

Covenants to Obtain Regulatory Approvals

Under the Arrangement Agreement, Organigram and Aurora agreed, within five business days after the date of the Arrangement Agreement or such other date as the Parties may reasonably agree, to: (a) jointly prepare and file with the Commissioner a request for an ARC under section 102 of the Competition Act or, in the alternative, a No Action Letter; (b) prepare and file with the Commissioner their respective notifications under section 114 of the Competition Act; and (c) unless submitted prior to the date of the Arrangement Agreement, make the filing required to obtain the German FDI Approval. Organigram is responsible for all filing fees (including any Taxes thereon) in respect of any filing made to any Governmental Entity in respect of the Regulatory Approvals.

The Parties also agreed to cooperate with one another and provide such assistance as the other Party may reasonably request in obtaining the Regulatory Approvals as soon as reasonably practicable. In particular, each Party agreed: (a) not to extend or consent to any extension of any applicable waiting or review period, or enter into any agreement with a Governmental Entity not to complete the Arrangement, without the prior written consent of the other Party (not to be unreasonably withheld, conditioned or delayed); (b) to exchange drafts of all submissions, material correspondence,

filings and other materials to be submitted to any Governmental Entity, consider in good faith the other Party's comments and provide final copies (with competitively sensitive information provided on an external counsel-only basis); (c) to keep the other Party reasonably apprised of all substantive communications and meetings with any Governmental Entity and, unless prohibited, give the other Party the opportunity to participate in material communications and meetings; and (d) not to enter into any transaction or take any other action that would reasonably be expected to make obtaining the Regulatory Approvals materially more difficult or to materially delay them.

Stock Exchange Listings

Aurora is a reporting issuer (or the equivalent) under the securities laws of each of the provinces of Canada. The Aurora Common Shares are listed and posted for trading on the TSX and Nasdaq under the symbol "ACB" and are quoted on the open market of the Frankfurt Stock Exchange under the symbol "21P".

On November 2, 2026, the last trading day on which the Aurora Common Shares traded on the TSX prior to the announcement of the Arrangement, the closing price of the Aurora Common Shares on the TSX and Nasdaq was $5.89 and US$4.22, respectively. On November 19, 2026, the last trading day prior to the date of this Joint Information Circular, the closing price of the Aurora Common Shares on the TSX and Nasdaq was $6.14 and US$4.26, respectively.

Organigram is a reporting issuer (or the equivalent) under the securities laws of each of the provinces of Canada. The Organigram Common Shares are listed and posted for trading on the TSX and Nasdaq under the symbol "OGI".

On November 2, 2026, the last trading day on which the Organigram Common Shares traded on the TSX prior to the announcement of the Arrangement, the closing price of the Organigram Common Shares on the TSX and Nasdaq was $1.36 and US$0.965, respectively. On November 3, 2026, the first trading day following the announcement of the Arrangement, the closing price of the Organigram Common Shares on the TSX and Nasdaq was $1.28 and US$0.92, respectively, representing a change of approximately 5.9% from the closing price on November 2, 2026. Organigram believes that the limited share price reaction following announcement, notwithstanding the number of Organigram Common Shares to be issued under the Arrangement and the BAT Private Placement, reflects market recognition of the strategic and financial merits of the Arrangement. On November 19, 2026, the last trading day prior to the date of this Joint Information Circular, the closing price of the Organigram Common Shares on the TSX and Nasdaq was $0.90 and US$0.6296, respectively.

Following completion of the Arrangement, it is anticipated that the Aurora Common Shares will be delisted from the TSX and Nasdaq as promptly as practicable following the Effective Date, and Aurora has agreed to cooperate with Organigram in taking all steps required to delist the Aurora Common Shares from the TSX and Nasdaq and to cause Aurora to cease to be a reporting issuer as promptly as practicable following the Effective Time. Following the delisting, Organigram intends to cause Aurora to apply to cease to be a reporting issuer in each of the provinces of Canada and to terminate the registration of the Aurora Common Shares and its reporting obligations under the U.S. Exchange Act.

For information with respect to the trading history of the Organigram Common Shares and the Aurora Common Shares, see "*Information Concerning Organigram Global Inc. – Price Range and Trading Volumes" and "Information Concerning Aurora Cannabis Inc. – Price Range and Trading Volumes*" in Appendix "J" and Appendix "I" to this Joint Information Circular, respectively.

It is a condition to the completion of the Arrangement that the TSX shall have conditionally approved the listing of the Organigram Common Shares to be issued to Aurora Shareholders pursuant to the Arrangement, subject only to the customary listing conditions of the TSX, and that the Nasdaq shall have been notified of the listing of such Organigram Common Shares and shall not have objected thereto. Under the Arrangement Agreement, Organigram has agreed to use commercially reasonable efforts to obtain, prior to completion of the Arrangement, conditional approval of the listing on the TSX, and to notify the Nasdaq of the listing, of the Organigram Common Shares issuable pursuant to the Arrangement and the BAT Private Placement, subject only to the customary listing conditions of the TSX. The TSX has conditionally approved the listing of up to 364,058,206 Organigram Common Shares, consisting of the Organigram Common Shares to be issued to Aurora Shareholders pursuant to the Arrangement (including a buffer for any increase in the number of outstanding Aurora Common Shares prior to closing), the Organigram

Common Shares issuable upon the exercise of Replacement Options and the Organigram Common Shares issued and issuable to BAT pursuant to the BAT Private Placement (including upon conversion of Organigram Preferred Shares). Listing is subject to Organigram fulfilling all of the listing requirements of the TSX, including obtaining the requisite approvals of the Organigram Shareholders. Organigram will file a Notification Form: Listing of Additional Shares with the Nasdaq in respect of the Organigram Common Shares to be issued pursuant to the Arrangement, the Organigram Common Shares issuable upon exercise of Replacement Options and the Organigram Common Shares issuable pursuant to the BAT Private Placement (including upon conversion of Organigram Preferred Shares), as applicable, within the notice periods required by Nasdaq.

Securities Law Matters

Canada

General

The Organigram Common Shares to be issued to Aurora Shareholders pursuant to the Arrangement will be issued in reliance on exemptions from the prospectus requirements of applicable Canadian Securities Laws, will generally be "freely tradable" and the resale of such Organigram Common Shares will be exempt from the prospectus requirements (and not subject to any "restricted period" or "hold period") under applicable Canadian Securities Laws, if the following conditions are met: (a) the trade is not a control distribution (as defined in applicable Canadian Securities Laws); (b) no unusual effort is made to prepare the market or to create a demand for the securities that are the subject of the trade; (c) no extraordinary commission or consideration is paid to a person or company in respect of the trade; and (d) if the selling shareholder is an insider or an officer of Organigram, the selling shareholder has no reasonable grounds to believe that Organigram is in default of securities legislation. **Aurora Shareholders are urged to consult their legal advisors to determine the applicability to them of the resale restrictions prescribed by applicable Canadian Securities Laws.**

MI 61-101

Each of Aurora and Organigram is subject to the provisions of MI 61-101. MI 61-101 governs transactions that raise the potential for conflicts of interest, including insider bids, issuer bids, business combinations and related party transactions, to ensure equality of treatment among securityholders, generally by requiring enhanced disclosure, minority securityholder approval and, in certain instances, independent valuations and approval and oversight of certain transactions by a special committee of independent directors.

As described in this Joint Information Circular, all Aurora Common Shares (other than those held by Dissenting Aurora Shareholders) will be acquired by Organigram in exchange for the Consideration under the terms of the Plan of Arrangement. Unless certain exceptions apply, the Arrangement would be considered a "business combination" in respect of Aurora pursuant to MI 61-101, since the interest of a holder of an Aurora Common Share (being an "equity security" of Aurora within the meaning of MI 61-101) may be terminated without the holder's consent. Accordingly, unless no related party of Aurora is entitled to receive a "collateral benefit" (as defined in MI 61-101) in connection with the Arrangement, the transaction would be considered a "business combination" and subject to minority approval requirements at the Aurora Shareholders' Meeting.

As "minority approval" is required, in addition to the approval of the Arrangement Resolution by not less than 66⅔% of the votes cast by the Aurora Shareholders, present virtually or represented by proxy at the Aurora Shareholders' Meeting, the Arrangement also requires the approval of a simple majority of the votes cast by the Aurora Shareholders, excluding the votes attached to Aurora Common Shares held by persons described in items (a) through (d) of section 8.1(2) of MI 61-101, including any "related party" of Aurora who receives a "collateral benefit" (as such terms are defined in MI 61-101) as a consequence of the Arrangement, being only Mr. Miguel Martin.

However, under MI 61-101, a benefit received by a related party of the issuer is not a "collateral benefit" if it is received solely in connection with the related party's services as an employee, director or consultant of the issuer or an affiliate and: (a) the benefit is not conferred for the purpose, in whole or in part, of increasing the value of the consideration paid to the related party for its securities; (b) the conferring of the benefit is not, by its terms, conditional

on the related party supporting the transaction in any manner; (c) full particulars of the benefit are disclosed in the disclosure document for the transaction; and (d) either (i) at the time the transaction was agreed to, the related party and its associated entities beneficially owned or exercised control or direction over less than 1% of the outstanding equity securities of the issuer, or (ii) an independent committee of directors has determined, acting in good faith, that the value of the benefit, net of any offsetting costs to the related party, is less than 5% of the value the related party expects to receive pursuant to the terms of the transaction for its equity securities, and the independent committee's determination is disclosed in the disclosure document for the transaction.

In connection with the Arrangement, the outstanding Aurora Incentive Awards will be treated as set forth under "*Effect of the Arrangement – Aurora Incentive* Awards". As disclosed in this Joint Information Circular, certain current executive officers and directors of Aurora will receive payments in respect of their Aurora Incentive Awards upon completion of the Arrangement, and certain executive officers of Aurora may become entitled to severance payments and accelerated vesting of certain Aurora Incentive Awards if, following completion of the Arrangement, their employment is terminated without cause or they resign for Good Reason within 12 months following the Effective Time. Such severance payments are not triggered solely by completion of the Arrangement. For details regarding such executive officers and directors and a description of the compensation they will or may receive, see "*Interests of Certain Persons or Companies in the Arrangement – Aurora – Summary of Interests of Directors and Executive Officers of Aurora in the Arrangement*", "*Interests of Certain Persons or Companies in the Arrangement – Aurora – Aurora Incentive Awards*", and "*Interests of Certain Persons or Companies in the Arrangement – Aurora – Aurora Employment Agreements*".

Aurora has considered whether any of these payments or other benefits to be received by the executive officers and directors of Aurora would constitute a "collateral benefit" for purposes of MI 61-101 such that the Arrangement would therefore constitute a "business combination" under MI 61-101.

As of November 2, 2026, the date that the Arrangement was agreed to, other than Mr. Martin, each of the executive officers and directors of Aurora receiving such benefits as a result of the Arrangement beneficially owned, or exercised control or direction over, less than 1% of the outstanding Aurora Common Shares (taking into account Aurora Common Shares underlying Aurora Incentive Awards that are vested or will vest in connection with the Arrangement and beneficial ownership determined in accordance with MI 61-101). Therefore, the exception from the definition of "collateral benefit" described above is available for each of such related parties. On the same basis, Mr. Martin beneficially owned, or exercised control or direction over, 1,459,153 Aurora Common Shares (being 334,852 Aurora Common Shares and 1,124,301 Aurora Incentive Awards that are vested or will vest in connection with the Arrangement), representing approximately 2.1% of the outstanding Aurora Common Shares (on a fully diluted basis). Therefore, the benefit to be received by Mr. Martin constitutes a "collateral benefit" for purposes of MI 61-101, and his Aurora Common Shares will be excluded from the minority approval vote.

Accordingly, the Arrangement constitutes a "business combination" in respect of Aurora for the purposes of MI 61-101 and the Arrangement Resolution requires "minority approval", excluding the votes attached to the Aurora Common Shares held by Mr. Martin. To the knowledge of Aurora, after reasonable inquiry, 334,852 Aurora Common Shares held by Mr. Martin, representing approximately 0.51% of the outstanding Aurora Common Shares, will be excluded from such vote. See "*Interests of Certain Persons or Companies in the Arrangement – Aurora*".

Formal Valuation. Aurora is not required to obtain a formal valuation under MI 61-101 in connection with the Arrangement, as no "interested party" (as defined in MI 61-101) would, as a consequence of the Arrangement, directly or indirectly acquire Aurora or its business, or combine with Aurora, whether alone or with joint actors, and there is no "connected transaction" that would qualify as a "related party transaction" for which Aurora would be required to obtain a formal valuation.

Prior Valuations. To the knowledge of the directors and senior officers of Aurora, after reasonable inquiry, there have been no "prior valuations" (as defined in MI 61-101) in respect of Aurora within the 24 months preceding the date of this Joint Information Circular.

Prior Offers. Except as described under "*The Arrangement – Background to the Arrangement*" and "*The Hostile Bid*", Aurora has not received any bona fide prior offer (as contemplated in MI 61-101) that relates to the subject matter of, or is otherwise relevant to, the Arrangement during the 24 months preceding the date of the Arrangement Agreement.

BAT is a "related party" of Organigram within the meaning of MI 61-101, as it beneficially owns or exercises control or direction over more than 10% of the voting rights attached to the outstanding Organigram Common Shares and, accordingly, the BAT Private Placement constitutes a "related party transaction" of Organigram under MI 61-101. The acquisition of Aurora pursuant to the Arrangement is not a related party transaction of Organigram under MI 61-101.

The BAT Private Placement is exempt from the formal valuation requirement of section 5.4 of MI 61-101 pursuant to section 5.5(c) of MI 61-101, as the BAT Private Placement involves a distribution of securities to a related party for cash consideration and neither Organigram nor, to the knowledge of Organigram after reasonable inquiry, BAT has knowledge of any material information concerning Organigram or its securities that has not been generally disclosed.

The BAT Private Placement is subject to "minority approval" (as defined in MI 61-101) under section 5.6 of MI 61-101. Accordingly, the Organigram Share Issuance Resolution must be approved by greater than 50% of the votes cast by Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, excluding the votes attached to Organigram Common Shares beneficially owned, or over which control or direction is exercised, by BAT, its affiliates and their respective directors and officers, and any other "related parties" and "joint actors" (each as defined in MI 61-101) of BAT, in each case as of the Organigram Record Date. To the knowledge of Organigram, after reasonable inquiry, 42,231,089 Organigram Common Shares, representing approximately 30% of the outstanding Organigram Common Shares, will be excluded from such vote, all of which are held by BAT.

To the knowledge of Organigram and its directors and senior officers, after reasonable inquiry, there have been no "prior valuations" (as defined in MI 61-101) in respect of Organigram in the 24 months preceding the date of this Joint Information Circular, and no bona fide prior offer (as contemplated in MI 61-101) that relates to the BAT Private Placement has been received by Organigram during the 24 months preceding the execution of the agreement governing the BAT Private Placement.

To the knowledge of Organigram, after reasonable inquiry, no director of Organigram expressed a materially contrary view or abstained from voting on the BAT Private Placement, other than the representatives of BAT, who declared their interest and abstained. The Organigram Board approved the BAT Private Placement following the review described under "*Effect of the Arrangement – BAT Equity Commitment – Board Approval*".

United States

The following discussion is a general overview of certain requirements of United States federal securities laws that may be applicable to Aurora Shareholders and holders of Aurora Options. All holders are urged to consult their own legal counsel to ensure that any subsequent resale of securities issued or distributed to them pursuant to the Arrangement complies with applicable United States securities laws. Further information for securityholders resident in the United States is disclosed under "*Joint Information Circular – Information for United States Securityholders*".

The issuance of Organigram Common Shares and Replacement Options pursuant to the Arrangement, and the subsequent resale of such securities (including Organigram Common Shares issuable upon exercise of Replacement Options after the Effective Time), will be subject to applicable United States securities laws. The following discussion does not address Canadian securities laws that apply to the issuance or resale of securities in Canada. Holders' resident in the United States who resell their securities in Canada must also comply with Canadian securities laws. See "*Procedure for the Arrangement to Become Effective – Securities Law Matters – Canada*".

Exemption Relied Upon from the Registration Requirements of the U.S. Securities Act

The Organigram Common Shares and Replacement Options to be issued pursuant to the Arrangement have not been and will not be registered under the U.S. Securities Act or the securities laws of any state within the United States, and are intended to be issued in reliance upon the exemption from the registration requirements of the U.S. Securities Act provided by Section 3(a)(10) thereof and in compliance with applicable U.S. state securities laws, including available exemptions from registration or qualification requirements. Section 3(a)(10) of the U.S. Securities Act exempts the issuance of securities issued in exchange for one or more bona fide outstanding securities, claims or property interests, or partly in such exchange and partly for cash, from the general requirement of registration where

the terms and conditions of such issuance and exchange have been approved by a court of competent jurisdiction that is expressly authorized by law to grant such approval, after a hearing upon the substantive and procedural fairness of the terms and conditions of such issuance and exchange at which all persons to whom it is proposed to issue the securities have the right to appear and receive timely notice thereof. The Court has authority to conduct a hearing at which the substantive and procedural fairness of the terms and conditions of the Arrangement will be considered. The Court granted the Interim Order on November 20, 2026 and, subject to the approval of the Arrangement Resolution by the Aurora Shareholders and the Organigram Share Issuance Resolution by the Organigram Shareholders and satisfaction or waiver of certain other conditions, including receipt of Required Regulatory Approvals, a final hearing on the Arrangement is expected to be held on December 30, 2026 by the Court. All persons to whom securities are proposed to be issued in reliance on Section 3(a)(10), including Aurora Shareholders and holders of Aurora Options receiving Replacement Options, are entitled to timely notice of, and to appear and be heard at, this hearing, subject to the applicable procedural requirements of in the Interim Order and the notice of hearing. See "*Procedure for the Arrangement to Become Effective – Court Approval*". The Final Order of the Court will, if granted, constitute the basis for the exemption from the registration requirements of the U.S. Securities Act provided by section 3(a)(10) thereof with respect to the Organigram Common Shares and Replacement Options issuable in connection with the Arrangement.

Resales of Organigram Common Shares within the United States after the Effective Time

Organigram Common Shares received by Aurora Shareholders pursuant to the Arrangement will not be "restricted securities" within the meaning of Rule 144 under the U.S. Securities Act and will not be subject to resale restrictions in the United States under United States federal securities laws, except by persons who are affiliates of Organigram at the time of their proposed transfer or who have been affiliates of Organigram within 90 days before their proposed transfer. An "affiliate" of an issuer is a person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, the issuer. Typically, persons who are executive officers or directors of an issuer, and any person who beneficially owns or controls 10% or more of the voting securities of an issuer, are considered to be its "affiliates". Affiliate status depends on the facts and circumstances and is not determined solely by a specified percentage of share ownership.

Shareholders who are affiliates of Organigram at the time of their proposed resale of Organigram Common Shares or were affiliates of Organigram within 90 days of their proposed resale of Organigram Common Shares, will be subject to restrictions on resale of such Organigram Common Shares imposed by the U.S. Securities Act. These affiliates or former affiliates may not resell their Organigram Common Shares unless such securities are registered under the U.S. Securities Act or an exemption from registration (such as the resale safe harbor provided for in Rule 144 under the U.S. Securities Act) is available.

The foregoing discussion does not apply to Organigram Common Shares issuable upon exercise of Replacement Options or to securities issued pursuant to the BAT Private Placement.

Exercise of Replacement Options

Replacement Options are intended to be issued in exchange for Aurora Options pursuant to the Arrangement in reliance on section 3(a)(10) of the U.S. Securities Act and available exemptions under applicable U.S. state securities laws, subject to Court approval of that exchange and satisfaction of the requirements of the exemptions. Replacement Options may not be exercised for Organigram Common Shares unless the issuance of those shares is registered under the U.S. Securities Act or an exemption from registration is available. Section 3(a)(10) does not exempt that subsequent issuance upon exercise. Organigram Common Shares issued upon exercise in reliance on an exemption from registration may be subject to restrictions on offer, resale and transfer, depending on the exemption relied upon, and may not be offered or resold except pursuant to an effective registration statement or an available exemption from registration. Any such exercise and resale must also comply with applicable state securities laws. Holders should consult their own legal advisors concerning the registration or exemption requirements and any applicable resale restrictions.

Stock Exchange Listings

For information concerning the current listings of the Organigram Common Shares and the Aurora Common Shares, the proposed listing and notification arrangements for Organigram Common Shares issuable pursuant to the Arrangement and upon exercise of Replacement Options, and the delisting of Aurora Common Shares, see "*Procedure for the Arrangement to Become Effective – Court Approval – Stock Exchange Listings*".

Procedure for Exchange of Aurora Common Share Certificates or DRS Advices

Registered Aurora Shareholders (other than Dissenting Aurora Shareholders) must duly complete and return a Letter of Transmittal and Election Form, together with the certificate(s) or DRS Advice(s), as applicable, representing their Aurora Common Shares and all other required documents to the Depositary at one of the offices specified in the Letter of Transmittal and Election Form. Registered Aurora Shareholders who wish to make an election as to the form of Consideration must deposit their Letter of Transmittal and Election Form before the Election Deadline. See "*Effect of the Arrangement – Elections and Proration*". In the event that the Arrangement is not completed, such certificates or DRS Advices will be promptly returned to Aurora Shareholders who provided such certificates or DRS Advices to the Depositary.

Enclosed with this Joint Information Circular is a Letter of Transmittal and Election Form which, when properly completed and returned together with the certificate(s) or DRS Advice(s) representing Aurora Common Shares and all other required documents, will enable each Aurora Shareholder to make an election and to obtain the Consideration that the Aurora Shareholder is entitled to receive under the Arrangement.

The Letter of Transmittal and Election Form contains complete instructions on how to exchange your Aurora Common Shares.

From and after the Effective Time, certificates or DRS Advices formerly representing Aurora Common Shares shall represent only the right to receive the Consideration to which the former Aurora Shareholders are entitled under the Arrangement, or as to those held by Dissenting Aurora Shareholders, other than those Dissenting Aurora Shareholders deemed to have participated in the Arrangement pursuant to the Plan of Arrangement, to receive the fair value of the Aurora Common Shares represented by such certificates or DRS Advices. As soon as practicable following the later of the Effective Date and the date of deposit by a former holder of Aurora Common Shares acquired by Organigram under the Arrangement of a duly completed Letter of Transmittal and Election Form, and the certificate(s) or DRS Advice(s) representing such Aurora Common Shares and all other required documents, the Depositary shall either: (a) forward by first class mail to such former holder at the address specified in the Letter of Transmittal and Election Form; or (b) if requested by such Aurora Shareholder in the Letter of Transmittal and Election Form, make available or cause to be made available at the Depositary for pickup by such Aurora Shareholder, a cheque (or other form of immediately available funds) representing the cash payable and DRS Advices representing the number of Organigram Common Shares issued to such Aurora Shareholder under the Arrangement, together with any dividends or distributions with a record date after the Effective Time to which such holder is entitled, in each case without interest and less any amounts withheld. Registered Aurora Shareholders may instead request in the Letter of Transmittal and Election Form that cash be paid by wire transfer, subject to a banking fee.

No fractional Organigram Common Shares will be issued under the Arrangement. See "*Effect of the Arrangement – General*" for the treatment of fractional entitlements.

Subject to any applicable Laws relating to unclaimed personal property, if a former Aurora Shareholder has not deposited its certificate(s) or DRS Advice(s), together with all other documents required under the Plan of Arrangement, on or before the third anniversary of the Effective Date, the Consideration to which such holder was entitled (and any dividends or distributions thereon) shall be deemed to have been surrendered and forfeited to Organigram for no consideration, any unclaimed cheque or other right to payment shall cease to represent a claim of any kind, and the certificates formerly representing Aurora Common Shares shall cease to represent a right or claim of any kind or nature.

If any certificate which immediately prior to the Effective Time represented an interest in one or more outstanding Aurora Common Shares has been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming such certificate to be lost, stolen or destroyed and satisfying such requirements as may be imposed by Organigram and the Depositary in relation to the issuance of replacement share certificates, the Depositary will issue and deliver in exchange for such lost, stolen or destroyed certificate the Consideration and other property to which the holder is entitled pursuant to the Arrangement, deliverable in accordance with such holder's Letter of Transmittal and Election Form. The Person who is entitled to receive such Consideration shall, as a condition precedent to the delivery thereof, give a bond satisfactory to each of Organigram, Aurora and the Depositary in such form as is satisfactory to Organigram, and the Depositary (each acting reasonably) in such sum as Organigram may direct, or otherwise indemnify Organigram, Aurora and their respective transfer agents, to the reasonable satisfaction of such parties (acting reasonably), against any claim that may be made against any of them with respect to the certificate alleged to have been lost, stolen or destroyed. Alternatively, Aurora Shareholders whose certificate(s) representing Aurora Common Shares have been lost, stolen or destroyed may participate in the Depositary's blanket bond program by following the instructions in the Letter of Transmittal and Election Form.

The use of mail to transmit certificates representing Aurora Common Shares or the Letter of Transmittal and Election Form is at each registered Aurora Shareholder's risk. Aurora recommends that such certificates and documents be delivered by hand to the Depositary and a receipt therefor be obtained or that registered mail be used and appropriate insurance be obtained.

If a Letter of Transmittal and Election Form is executed by a person other than the registered holder of the Aurora Common Shares being exchanged or if the cheque(s) or DRS Advice(s) to be issued in exchange therefor are to be issued to a person other than the registered owner(s) or sent to an address other than the address of the registered holder(s) as shown on the register of Aurora Shareholders maintained by Aurora's registrar and transfer agent, the signature on the Letter of Transmittal and Election Form must be medallion guaranteed by an Eligible Institution (as defined in the Letter of Transmittal and Election Form). If the Letter of Transmittal and Election Form is executed by a person other than the registered owner(s) of the Aurora Common Shares and in certain other circumstances as set forth in the Letter of Transmittal and Election Form, the certificate(s) or DRS Advice(s) representing the Aurora Common Shares must be endorsed or be accompanied by an appropriate transfer power of attorney duly and properly completed by the registered owner(s). The signature(s) on the endorsement panel or the transfer power of attorney must correspond exactly to the name(s) of the registered owner(s) as registered or as appearing on the certificate(s) or DRS Advice(s) and must be medallion guaranteed by an Eligible Institution.

All questions as to validity, form, eligibility (including timely receipt), and acceptance of any Aurora Common Shares exchanged pursuant to the Arrangement and any election will be determined by Organigram, acting reasonably, in consultation with the Depositary. Depositing Aurora Shareholders agree that such determination shall be final and binding. Organigram reserves the absolute right to reject any and all deposits which it determines not to be in proper form or which may be unlawful for it to accept under the laws of any jurisdiction. Organigram reserves the absolute right to waive any defect or irregularity in the exchange of Aurora Common Shares. There shall be no duty or obligation on Organigram, Aurora, the Depositary or any other person to give notice of any defect or irregularity in any deposit of Aurora Common Shares and no liability shall be incurred by any of them for failure to give such notice.

Notwithstanding the provisions of this Joint Information Circular or the Letter of Transmittal and Election Form, DRS Advices representing Organigram Common Shares representing the Consideration to be received pursuant to the Arrangement will not be mailed if Organigram determines that delivery thereof by mail may be delayed. Persons entitled to DRS Advices which are not mailed for such reason may take delivery thereof at the office of the Depositary in which the deposited certificates or DRS Advices representing Aurora Common Shares were originally deposited until such time that it is determined that the delivery by mail will no longer be delayed.

Organigram, Aurora, the Depositary and any other Person that makes a payment under the Plan of Arrangement, as applicable, will be entitled to deduct and withhold from any amount payable or otherwise deliverable to any Person under the Plan of Arrangement such amounts (whether in cash or Organigram Common Shares) as are required to be deducted and withheld under the Tax Act or any other applicable Law, and any amounts so deducted, withheld and remitted will be treated for all purposes as having been paid to the Person in respect of which such deduction and withholding was made. Organigram, Aurora and the Depositary will cooperate, acting reasonably, to minimize any such deduction or withholding. To the extent the cash payable to a Person is insufficient to satisfy the amount required

to be withheld, the applicable payor will be entitled to sell or otherwise dispose of such portion of the Organigram Common Shares otherwise deliverable to such Person as is necessary to fund the withholding obligation, and will notify such Person and remit to such Person any unapplied balance of the net proceeds of such sale. No payor will be liable to any Person for any deficiency in respect of any proceeds received on such sale, including as a result of the manner or timing of such sale or the price at which such Organigram Common Shares are sold. No interest will be paid or accrued on any cash payable under the Arrangement.

Registered Aurora Shareholders are encouraged to deliver a validly completed and duly executed Letter of Transmittal and Election Form together with the relevant certificate(s) or DRS Advice(s), as applicable, to the Depositary as soon as possible. **Aurora Shareholders whose Aurora Common Shares are registered in the name of a broker, investment dealer, bank, trust company, custodian, nominee or other intermediary must contact their nominee to deposit their Aurora Common Shares.**

None of Aurora, Organigram or the Depositary are liable for failure to notify Aurora Shareholders, nor do they have any obligation to notify Aurora Shareholders, who make a deficient deposit with the Depositary.

INTERESTS OF CERTAIN PERSONS OR COMPANIES IN THE ARRANGEMENT

Except as described below, management of Aurora and Organigram are not aware of any material interest, direct or indirect, by way of beneficial ownership of securities or otherwise, in the Arrangement, the BAT Private Placement or any other matter to be acted upon at the Meetings of: (a) any director or executive officer of Aurora or Organigram, respectively, or anyone who has held office as such since the beginning of Aurora's and Organigram's last financial year, as applicable; (b) any person who beneficially owns, directly or indirectly, or exercises control or direction over, more than 10% of the voting rights attached to the Aurora Common Shares or the Organigram Common Shares; or (c) any associate or affiliate of any of the foregoing persons.

Aurora

Aurora Common Shares

As at November 19, 2026, the directors and executive officers of Aurora and their respective associates beneficially owned, controlled or directed, directly or indirectly, an aggregate of 409,246 Aurora Common Shares, representing approximately 0.62% of the outstanding Aurora Common Shares. All of the directors and executive officers of Aurora are Supporting Aurora Shareholders and have agreed under the Aurora Support Agreements to, among other things, vote their Aurora Common Shares in favour of the Arrangement Resolution. See "*Effect of the Arrangement – Aurora Support Agreements*".

All of the Aurora Common Shares held by such directors and executive officers of Aurora and their associates will be treated in the same fashion under the Arrangement as Aurora Common Shares held by the other Aurora Shareholders, including with respect to the Cash Alternative, the Share Alternative or the Combination Alternative, subject to proration. If the Arrangement is completed, the directors and executive officers of Aurora and their associates will receive, in exchange for such Aurora Common Shares, Consideration having an aggregate value of approximately $3,192,119 (based on the Cash Alternative of $7.80 per Aurora Common Share and without giving effect to proration) or, if each of them elected or was deemed to have elected the Combination Alternative, an aggregate of approximately $1,534,673 in cash and 1,245,376 Organigram Common Shares. See "*Summary of Interests of Directors and Executive Officers of Aurora in the Arrangement*".

Aurora Incentive Awards

As at November 19, 2026, the directors and executive officers of Aurora held an aggregate of: (a) 1,818,450 Aurora Options, representing approximately 82.1% of the outstanding Aurora Options; (b) 663,182 Aurora RSUs (648,823 Aurora Share RSUs and 14,359 Aurora Cash RSUs), representing approximately 42.7% of the outstanding Aurora RSUs; (c) 1,603,568 Aurora PSUs (all of which are Aurora Cash PSUs), representing approximately 70.4% of the outstanding Aurora PSUs; and (d) 358,867 Aurora DSUs, (28,555 Aurora Share DSUs and 330,312 Aurora Cash DSUs), representing all of the outstanding Aurora DSUs. Pursuant to the Aurora Support Agreements, the Supporting

Aurora Shareholders have also agreed, in their capacities as holders of Aurora Incentive Awards, not to sell, transfer or otherwise dispose of their Aurora Incentive Awards, subject to limited exceptions, and to otherwise support the Arrangement.

The Aurora Incentive Awards held by the directors and executive officers of Aurora will be treated in the same manner as all other Aurora Incentive Awards under the Plan of Arrangement. Based on the foregoing holdings, if the Arrangement is completed, the directors and executive officers of Aurora (a) would receive aggregate cash payments of approximately $7,971,842 in respect of their Aurora RSUs and Aurora DSUs (in the case of Aurora DSUs, immediately after the holder ceases to be a director of Aurora); (b) would be entitled to aggregate cash payments of approximately $12,507,830 in respect of their Aurora PSUs, payable at the Effective Time in the case of Vested Aurora PSUs and on the applicable Entitlement Dates, subject to the applicable vesting conditions, in the case of Unvested Aurora PSUs (which vesting conditions will be satisfied in full, under the employment agreements described below, if the holder's employment is terminated without cause or the holder resigns for Good Reason within 12 months following the Effective Time); and (c) would receive Replacement Options to acquire approximately 10,664,579 Organigram Common Shares in exchange for their Aurora Options.

See "*Effect of the Arrangement – Details of the Arrangement*" and "*Effect of the Arrangement – Aurora Incentive* Awards" and "*Summary of Interests of Directors and Executive Officers of Aurora in the Arrangement*".

Organigram Common Shares

As at November 19, 2026, Aurora did not beneficially own, control or direct, directly or indirectly, any Organigram Common Shares. As at November 19, 2026, the directors and executive officers of Aurora, as a group, beneficially owned, controlled or directed, directly or indirectly, less than 1% of the issued and outstanding Organigram Common Shares.

Aurora Employment Agreements

Except as set forth below, no agreement, commitment or understanding (including pursuant to which any payment or other benefit is to be made or given by way of compensation for loss of office or remaining in or retiring from office upon completion of the Arrangement) has been made or is proposed to be made between Aurora and any of its directors or executive officers. In the case of each agreement, commitment or understanding discussed below, where the term "change of control" is used, the completion of the Arrangement would constitute a change of control.

Aurora has employment agreements with each of Miguel Martin, Simona King, Alex Miller, Nathalie Clark, Lori Schick and Faris El Refaie that include change of control and termination provisions as described below.

Other than as noted below, the definition of "Good Reason" in each of the employment agreements is as follows: the occurrence within twelve (12) months after any change of control of any of the following without the executive's consent: (i) the relocation of the executive's principal workplace to a location that is more than 50 kilometers from the executive's then current principal workplace; (ii) a material reduction in the executive's overall compensation; (iii) a material, detrimental change to the executive's position, job duties, responsibilities and/or authority; or (iv) a material breach by Aurora of the employment agreement. Notwithstanding the foregoing, Good Reason shall not be deemed to exist unless (i) the executive gives Aurora written notice within four (4) weeks after the occurrence of the event that constitutes the basis for Good Reason, specifying the particular act or failure to act which they believe constitutes the basis for Good Reason; (ii) Aurora fails to cure such act or failure to act, if curable, within four (4) weeks after receipt of such notice; and (iii) the executive terminates their employment for Good Reason within four (4) weeks following the expiration of the four (4) week cure period. In respect of the employment agreements with Mr. Miguel Martin and Ms. Simona King, prong (i) of the definition is the relocation of the Executive's principal workplace to a location that is more than 35 miles from the Executive's then current principal workplace, and prong (ii) of the definition is a material reduction in the Executive's base compensation or bonus/incentive opportunity.

Mr. Miguel Martin, Executive Chairman and Chief Executive Officer

Mr. Martin's employment agreement provides that, in the event of a termination without cause not within 12 months following a change-of-control, Mr. Martin will be entitled to a payment of 24 months of his base salary, any awarded but not yet paid bonus for the previous fiscal year, a pro-rated bonus for the year of termination payable when and if any such bonus is declared, a payment equal to 24 months bonus' entitlement at target, and any and all unvested equity awards granted to him shall vest on a pro rata basis up to the termination date, and any unvested equity grants that have not vested on a pro rata basis as of the termination date shall be forfeited.

In the event of a termination without cause or a resignation for Good Reason within 12 months following a change of control, Mr. Martin will be entitled to a payment of 24 months of his base salary, any awarded but not yet paid bonus for the previous year, a pro-rated bonus for the year of termination calculated at target, a payment equal to 24 months bonus' entitlement at target, and all unvested equity grants will vest at 100% immediately. In the event of termination for cause or a resignation without Good Reason, Mr. Martin shall be entitled to any unpaid base salary and accrued but unpaid vacation, and all unvested equity awards shall be forfeited.

Ms. Simona King, Chief Financial Officer

Ms. King's employment agreement provides that, in the event of a termination without cause not within 12 months following a change-of-control, Ms. King will be entitled to a payment of 12 months of her base salary, any awarded but not yet paid bonus for the previous fiscal year, a pro-rated bonus payment for time worked to the date of termination payable when and if any such bonus is declared, a payment equal to 12 months bonus' entitlement at target, and any and all unvested equity awards granted to her shall vest immediately on a pro rata basis up to the effective date of termination.

In the event of a termination without cause or a resignation for Good Reason within 12 months following a change of control, Ms. King will be entitled to a payment equal to 18 months base salary, any bonus awarded but not yet paid for the previous fiscal year, a pro-rated bonus payment at target for time worked to the date of termination, a lump sum equal to the annual bonus entitlement calculated at target prorated to 18 months, and all unvested equity grants will vest at 100% immediately. In the event of termination for cause or a resignation without Good Reason, Ms. King shall be entitled to any unpaid base salary and accrued but unpaid vacation, and all unvested equity awards shall be forfeited.

Mr. Alex Miller, Executive Vice-President, Operations and Supply Chain

Mr. Miller's employment agreement provides that, in the event of a termination without cause not within 12 months following a change of control, Mr. Miller will be entitled to a payment of the greater of the sum of pay in lieu of notice and statutory severance pay (ESA termination payments) or 12 months' base salary, any awarded but not yet paid bonus for the previous fiscal year, a pro-rated bonus payment for time worked to the date of termination payable when and if any such bonus is declared, a payment equal to 12 months bonus' entitlement at target, and any and all unvested equity awards granted to him shall vest immediately on a pro rata basis up to the effective date of termination. All remaining unvested equity awards shall be forfeited.

In the event of a termination without cause or a resignation for Good Reason within 12 months following a change of control, Mr. Miller will be entitled to a payment of the greater of the sum of ESA termination payments or 18 months' base salary, any awarded but not yet paid bonus for the previous fiscal year, a pro-rated at-target bonus payment for time worked to the date of termination, a payment equal to 18 months bonus' entitlement at target, and all unvested equity awards shall vest at 100% immediately. In the event of termination with cause or resignation without Good Reason, Mr. Miller will receive any base salary owing, any accrued but unpaid vacation, and all unvested equity awards shall be forfeited.

Ms. Nathalie Clark, Executive Vice-President, General Counsel and Corporate Secretary

Ms. Clark's employment agreement provides that, in the event of a termination without cause not within 12 months following a change of control, Ms. Clark will be entitled to a payment of the greater of the sum of ESA termination

payments or 12 months' base salary, any awarded but not yet paid bonus for the previous fiscal year, a pro-rated bonus payment for time worked to the date of termination payable when and if any such bonus is declared, a payment equal to 12 months bonus' entitlement at target, and any and all unvested equity awards granted to her shall vest immediately on a pro rata basis up to the effective date of termination. All remaining unvested equity awards shall be forfeited.

In the event of a termination without cause or a resignation for Good Reason within 12 months following a change of control, Ms. Clark will be entitled to a payment of the greater of the sum of ESA termination payments or 18 months' base salary, any bonus awarded but not yet paid for the previous fiscal year, a pro-rated at-target bonus payment for time worked to the date of termination, a payment equal to 18 months bonus' entitlement at target, and all unvested equity awards shall vest at 100% immediately. In the event of termination with cause or resignation without Good Reason, Ms. Clark will receive any base salary owing, any accrued but unpaid vacation, and all unvested equity awards shall be forfeited.

Ms. Lori Schick, Executive Vice-President, Human Resources

Ms. Schick's employment agreement provides that, in the event of a termination without cause not within 12 months following a change of control, Ms. Schick will be entitled to a payment of the greater of the sum of ESA termination payments or 12 months' base salary, any bonus awarded but not yet paid for the previous fiscal year, a pro-rated bonus payment for time worked to the date of termination payable when and if any such bonus is declared, a payment equal to 12 months bonus' entitlement at target, and any and all unvested equity awards granted to her shall vest immediately on a pro rata basis up to the effective date of termination. All remaining unvested equity awards shall be forfeited.

In the event of a termination without cause or a resignation for Good Reason within 12 months following a change of control, Ms. Schick will be entitled to a payment of the greater of the sum of ESA termination payments or 18 months' base salary, any bonus awarded but not yet paid for the previous fiscal year, a pro-rated at-target bonus payment for time worked to the date of termination, a payment equal to 18 months bonus' entitlement at target, and all unvested equity awards shall vest at 100% immediately. In the event of termination with cause or a resignation without Good Reason, Ms. Schick will receive any base salary owing, any accrued but unpaid vacation, and all unvested equity awards shall be forfeited.

Faris El Refaie, Executive Vice-President, Global Commercial

Mr. El Refaie's employment agreement, which became effective on September 28, 2026, provides that, in the event of a termination without cause not within 12 months following a change of control, Mr. El Refaie will be entitled to a payment of the greater of the sum of ESA termination payments or 12 months' base salary, any bonus awarded but not yet paid for the previous fiscal year, a pro-rated bonus payment for time worked to the date of termination payable when and if any such bonus is declared, a payment equal to 12 months bonus' entitlement at target, and any and all unvested equity awards granted to him shall vest immediately on a pro rata basis up to the effective date of termination. All remaining unvested equity awards shall be forfeited.

In the event of a termination without cause or a resignation for Good Reason within 12 months following a change of control, Mr. El Refaie will be entitled to a payment of the greater of the sum of ESA termination payments or 18 months' base salary, any bonus awarded but not yet paid for the previous fiscal year, a pro-rated at-target bonus payment for time worked to the date of termination, a payment equal to 18 months bonus' entitlement at target, and all unvested equity awards shall vest at 100% immediately. In the event of termination with cause or a resignation without Good Reason, Mr. El Refaie will receive any base salary owing, any accrued but unpaid vacation, and all unvested equity awards shall be forfeited.

Under the Arrangement Agreement, Organigram has agreed that, following the Effective Time, it will cause Aurora and any successor to Aurora to continue to honour and comply with all of the obligations to the employees of Aurora and its subsidiaries under all written employment agreements and benefit plans, including those disclosed to Organigram, including by paying any amounts owing thereunder, without conferring on any employee any right to continued employment. As at the date of this Joint Information Circular, no agreement, commitment or understanding

has been entered into between Organigram and any director or executive officer of Aurora regarding employment, board service or other compensation following the Effective Time.

See "*Summary of Interests of Directors and Executive Officers of Aurora in the Arrangement*".

Continuing Insurance Coverage and Indemnification for Directors and Officers of Aurora

Pursuant to the Arrangement Agreement, prior to the Effective Date, Aurora will purchase customary "tail" or "run off" policies of directors' and officers' liability insurance providing protection no less favourable in the aggregate than the protection provided by the policies maintained by Aurora and its subsidiaries which are in effect immediately prior to the Effective Date, in respect of claims arising from facts or events that occurred on or prior to the Effective Date, and Organigram will, or will cause Aurora and its subsidiaries to, maintain such policies in effect without any reduction in scope or coverage for six years from the Effective Date, provided that the cost of such policies shall not exceed 300% of Aurora's current annual aggregate premium for directors' and officers' liability insurance (and, if the cost would exceed such amount, Aurora will obtain the maximum coverage available for such amount). Organigram has also agreed to cause Aurora to ensure that the articles and by-laws of Aurora and its subsidiaries (or their respective successors) contain the indemnification provisions set out in their current articles and by-laws and that such provisions are not, except to the extent required by applicable Laws, amended, repealed or otherwise modified for a period of six years from the Effective Date in any manner that would adversely affect the rights of indemnification of individuals who, immediately prior to the Effective Date, were directors or officers of Aurora or any of its subsidiaries. Organigram has further agreed to cause Aurora to honour all rights to indemnification or exculpation now existing in favour of present and former employees, officers and directors of Aurora and its subsidiaries, which rights will survive the completion of the Arrangement and continue in full force and effect in accordance with their terms and, in any event, for a period of not less than six years following the Effective Date. If Aurora or any of its subsidiaries, or any of their respective successors or assigns, consolidates with or merges into any other person and is not the continuing or surviving entity, or transfers all or substantially all of its properties and assets to any person, Organigram is required to ensure that such successor or assign assumes these obligations. These provisions of the Arrangement Agreement are intended for the benefit of, and are enforceable by, each insured or indemnified person and his or her heirs and legal representatives, and Aurora has confirmed that it is acting as agent and trustee on their behalf. See "*The Arrangement Agreement – Additional Covenants – Insurance and Indemnification*".

Summary of Interests of Directors and Executive Officers of Aurora in the Arrangement

To the knowledge of Aurora, after reasonable inquiry, the following table sets out, as at the Aurora Record Date, for each director and executive officer of Aurora: (i) the number of Aurora Common Shares, Aurora Options, Aurora DSUs, Aurora RSUs and Aurora PSUs beneficially owned, or over which control or direction is exercised, by such person and his or her associates; (ii) the Consideration receivable for such Aurora Common Shares (assuming the Cash Alternative is elected and without giving effect to proration); (iii) the number of Organigram Common Shares issuable on exercise of the Replacement Options to be received in exchange for such Aurora Options; (iv) the cash payments to which such person is or will become entitled in respect of such Aurora DSUs, Aurora RSUs and Aurora PSUs under the Plan of Arrangement; (v) the estimated severance and other benefits to which such person would become entitled under his or her employment agreement and any retention award on a termination of employment described under "Aurora Employment Agreements"; and (vi) the total of the amounts in (ii), (iv) and (v). Amounts are rounded to the nearest dollar and are before applicable withholdings. The Aurora Board and the Aurora Special Committee were aware of these interests and considered them, among other matters, in evaluating the Arrangement and in recommending that Aurora Shareholders vote in favour of the Arrangement Resolution.

Name and Position	Aurora Common Shares (#)[1][2]	Aurora Options (#)[3]	Aurora DSUs (#) (Share / Cash)[4][10]	Aurora RSUs (#) (Share / Cash)[5]	Aurora PSUs (#) (Cash)[6]	Consideration for Aurora Common Shares at $7.80 ($)[7]	Organigram Common Shares under Replacement Options (#)[3]	Cash payable for Aurora DSUs and Aurora RSUs ($)[4][5]	Cash payable for Aurora PSUs ($)[6]	Estimated Severance and Other Benefits ($)[8]	Total ($)[9]
Miguel Martin – Executive Chairman and Chief Executive Officer	334,852	800,061	—	300,786 / Nil	750,477	2,611,846	4,692,084	2,346,131	5,853,721	4,240,410	15,052,107
Simona King – Chief Financial Officer	21,248	282,176	—	129,895 / 4,359	320,254	165,734	1,654,865	1,047,181	2,497,981	1,823,133	5,534,029
Nathalie Clark – Executive Vice-President, General Counsel and Corporate Secretary	270	222,560	—	71,596 / 10,000	174,880	2,106	1,305,237	636,449	1,364,064	1,059,953	3,062,572
Alex Miller – Executive Vice-President, Operations and Supply Chain	9,740	256,723	—	76,070 / Nil	185,810	75,972	1,505,592	593,346	1,449,318	1,187,260	3,305,896
Lori Schick – Executive Vice-President, Human Resources	29,782	239,081	—	70,476 / Nil	172,147	232,300	1,402,126	549,713	1,342,747	1,043,391	3,168,150
Faris El Refaie – Executive Vice-President, Global Commercial	Nil	Nil	—	Nil	Nil	—	Nil	Nil	Nil	976,515	976,515
Michael Singer – Lead Independent Director	7,354	6,139	13,453 / 120,494	—	—	57,361	36,002	1,044,732	—	—	1,102,093
Chitwant Kohli – Independent Director	6,000	5,571	7,020 / 80,063	—	—	46,800	32,671	679,232	—	—	726,032
Norma Beauchamp – Independent Director	—	6,139	8,081 / 80,063	—	—	—	36,002	687,476	—	—	687,476
Rajesh Uttamchandani – Independent Director	—	—	Nil / 49,690	—	—	—	—	387,582	—	—	387,582
Total	**409,246**	**1,818,450**	**28,554 / 330,310**	**648,823 / 14,359**	**1,603,568**	**3,192,119**	**10,664,579**	**7,971,842**	**12,507,830**	**10,330,663**	**34,002,454**

Notes:

(1) As at the Aurora Record Date.

(2) As at November 2, 2026, there were 65,745,102 Aurora Common Shares outstanding. Each director and executive officer, together with his or her associates, beneficially owned, controlled or directed less than 1% of the outstanding Aurora Common Shares. The directors and executive officers as a group held approximately 0.62%. Michael Singer beneficially owns 7,354 Aurora Common Shares, 333 of which are held by 8115966 Canada Inc.

(3) Each Aurora Option is exercisable for one Aurora Common Share. Under the Plan of Arrangement, each Aurora Option will be exchanged for a Replacement Option to purchase the number of Organigram Common Shares (rounded down) equal to the number of Aurora Common Shares subject to the Aurora Option multiplied by the Option Exchange Ratio ($7.80 divided by $1.33, or approximately 5.8647), at an exercise price equal to the exercise price of the exchanged Aurora Option divided by the Option Exchange Ratio. The numbers shown are approximate because rounding applies to each Aurora Option grant separately. See "Effect of the Arrangement – Aurora Incentive Awards".

(4) Each Aurora DSU will be cancelled, immediately after the holder ceases to be a director of Aurora, in exchange for a cash payment of $7.80 per Aurora DSU.

(5) Each Aurora RSU, whether vested or unvested, will be cancelled at the Effective Time in exchange for a cash payment of $7.80 per Aurora RSU.

(6) All Aurora PSUs held by the executive officers of Aurora are Aurora Cash PSUs. Each Vested Aurora PSU will be cancelled at the Effective Time in exchange for a cash payment of $7.80 per Aurora PSU, multiplied by 100%. Each Unvested Aurora PSU will remain outstanding and will entitle the holder to a cash payment of $7.80 per Aurora PSU, multiplied by 100%, on its Entitlement Date, subject to the applicable vesting conditions and otherwise on the same terms and conditions, including under the holder's employment agreement, as applied before the Effective Time. Under the employment agreements described under "Aurora Employment Agreements", all Unvested Aurora PSUs held by an executive officer vest in full immediately if the holder's employment is terminated by Aurora without cause or the holder resigns for Good Reason within 12 months following the Effective Time. All of the Aurora PSUs held by the executive officers are expected to be Unvested Aurora PSUs at the Effective Time; the amounts shown assume all such Aurora PSUs vest.

(7) Assumes the Cash Alternative is elected and that no proration applies. An Aurora Shareholder electing (or deemed to have elected) the Combination Alternative would receive $3.75 in cash and 3.0431 Organigram Common Shares per Aurora Common Share, and an Aurora Shareholder electing the Share Alternative would receive 5.8626 Organigram Common Shares per Aurora Common Share, subject to proration. See "Effect of the Arrangement – Elections and Proration".

(8) (8) Reflects the estimated severance and other benefits payable under the employment agreements described under "Aurora Employment Agreements" and the retention awards for Mr. Martin and Mr. Miller, assuming the executive officer's employment is terminated by Aurora without cause, or the executive officer resigns for Good Reason, within 12 months following completion of the Arrangement. The amounts assume a termination date of January 6, 2027, include the lump-sum allowances payable to Mr. Martin and Ms. King in lieu of benefits continuation, and include the retention awards for Mr. Martin and Mr. Miller on a pro-rated basis to that date at an assumed performance factor of 100%. The actual amounts payable in respect of the retention awards will depend on the date of termination and on the actual level of achievement of the applicable performance measures. Amounts denominated in U.S. dollars have been converted to Canadian dollars using an exchange rate of US$1.00 = $1.4037. The amounts do not include any accrued but unpaid vacation pay that may be owing to an executive officer at the date of termination, or any value for the continuation of benefits to which Ms. Clark, Mr. Miller, Ms. Schick and Mr. El Refaie would be entitled under their employment agreements during the applicable severance period.

(9) Total of the Consideration for Aurora Common Shares, the cash payable for Aurora DSUs, Aurora RSUs and Aurora PSUs and the estimated severance and other benefits shown in the preceding columns. The total does not include any value for the Replacement Options, which are shown as the number of Organigram Common Shares issuable on exercise, and includes amounts in respect of Unvested Aurora PSUs that are payable only on the applicable Entitlement Dates, subject to the applicable vesting conditions.

(10) Each non-executive director of Aurora is entitled to two quarterly grants of Aurora DSUs, valued at $37,500 each, in respect of the August 2026 and November 2026 quarterly retainer payments, having an aggregate value of $300,000. These Aurora DSUs have not yet been granted and will be granted once the current trading blackout has been lifted. Such amounts are not reflected.

Organigram

Organigram Incentive Awards

The Arrangement will not result in any acceleration of vesting or payment in respect of such awards or any change of control or severance payment to Organigram's directors or executive officers.

BAT

BAT, who owns more than 10% of the voting rights attached to the Organigram Common Shares and is a Supporting Organigram Shareholder, "related party" of Organigram under MI 61-101 and an "insider" of Organigram under the TSX Company Manual, has an interest in the Arrangement that differs from that of Organigram Shareholders generally as a result of the BAT Private Placement, pursuant to which BAT will subscribe for 140,986,255 Organigram Common Shares and/or Organigram Preferred Shares (representing approximately 74.1% of the Organigram Common Shares and Organigram Preferred Shares issued and outstanding as of November 19, 2026 on a non-diluted basis) for aggregate gross proceeds of £99,999,999.82 (approximately $187.5 million) concurrently with completion of the Arrangement.

As of November 19, 2026, BAT owned 42,231,089 Organigram Common Shares (representing approximately 30% of the outstanding Organigram Common Shares on a non-diluted basis) and 49,204,021 Organigram Preferred Shares (representing 100% of the outstanding Organigram Preferred Shares on a non-diluted basis). Following the closing of the BAT Private Placement and the Arrangement, BAT is expected to own an aggregate of 232,421,365 Organigram Common Shares and Organigram Preferred Shares (representing approximately 122.1% of the Organigram Common Shares and Organigram Preferred Shares issued and outstanding on a non-diluted basis).

Following completion of the Arrangement and the BAT Private Placement, BAT's economic interest in Organigram is expected to be approximately 44%, with its voting interest capped at 30%. The representatives of BAT on the Organigram Board declared their interest and abstained from voting on the BAT Private Placement. BAT's investor rights agreement with Organigram will be amended in connection with the BAT Private Placement so that BAT's pre-emptive and top-up rights are not subject to a 19.9% limit or otherwise. The 42,231,089 votes attached to Organigram

Common Shares held by BAT and its affiliates, being approximately 30% of the Organigram Common Shares outstanding as of November 19, 2026, will be excluded from the minority approval vote on the Organigram Share Issuance Resolution. See "*Summary – Sources of Funds for the Arrangement*" and "*Procedure for the Arrangement to Become Effective – Securities Law Matters – Canada – MI 61-101*".

Aurora Common Shares

As at November 19, 2026, Organigram did not beneficially own, control or direct, directly or indirectly, any Aurora Common Shares. As at November 19, 2026, the directors and executive officers of Organigram, as a group, beneficially owned, controlled or directed, directly or indirectly, less than 1% of the issued and outstanding Aurora Common Shares.

LEGAL DEVELOPMENTS

Section 288 of the BCBCA provides that a company may propose an arrangement with shareholders, creditors or other persons, and section 291 of the BCBCA provides for the Court to approve such arrangement. Pursuant to these sections of the BCBCA, such an application will be made by Aurora for approval of the Arrangement. Aurora has been advised by its counsel, Stikeman, that the Court has broad discretion under the BCBCA when making orders with respect to plans of arrangement and that the Court will consider, among other things, the fairness and reasonableness of the Arrangement, both from a substantive and a procedural perspective. If the Arrangement has been approved by the Aurora Shareholders, the Court may make an order approving the Arrangement on the terms presented or substantially on those terms or may refuse to approve the Arrangement. Depending upon the nature of any required amendments, Aurora may determine not to proceed with the Arrangement.

There have been a number of judicial decisions considering section 288 of the BCBCA and applications to various arrangements. **Aurora Shareholders should consult their legal advisors with respect to the legal rights available to them in relation to the Arrangement.**

DISSENT RIGHTS

The following description of the Dissent Rights to which registered Aurora Shareholders are entitled is not a comprehensive statement of the procedures to be followed by a Dissenting Aurora Shareholder who seeks payment of the fair value of such Dissenting Aurora Shareholder's Aurora Common Shares and is qualified in its entirety by reference to the full text of the Plan of Arrangement, the Interim Order and the text of sections 237 to 247 of the BCBCA, which are attached to this Joint Information Circular as Appendix "C", Appendix "D" and Appendix "K", respectively. A Dissenting Aurora Shareholder who intends to exercise Dissent Rights should carefully consider and comply with the provisions of the BCBCA, as modified by the Plan of Arrangement and the Interim Order. Failure to comply with the provisions of the BCBCA, as so modified, and to adhere to the procedures established therein may result in the loss of all rights thereunder. Accordingly, each Dissenting Aurora Shareholder who is considering exercising Dissent Rights should consult his or her own legal advisor.

The Court hearing the application for the Final Order has the discretion to alter the Dissent Rights described herein based on the evidence presented at such hearing.

Subject to the Interim Order and the satisfaction of certain conditions described therein and summarized below, each registered Aurora Shareholder who holds Aurora Common Shares as of the Aurora Record Date is entitled, in addition to any other right such Aurora Shareholder may have, to dissent in respect of the Arrangement and, pursuant to the Plan of Arrangement, to be paid by Organigram the fair value of the Aurora Common Shares held by such Aurora Shareholder, which value, notwithstanding anything to the contrary in the BCBCA, will be determined as of the close of business on the last business day before the Arrangement Resolution was adopted.

Dissenting Aurora Shareholders must deliver a written notice of dissent, in strict compliance with section 242 of the BCBCA (a "Notice of Dissent"), that is received by Aurora c/o Torys LLP, Suite 2800, 79 Wellington St. W., Toronto, Ontario M5K 1N2, Attention: Andrew Gray and Colette Koopman, by not later than 9:30 a.m.

(Toronto time) on December 21, 2026 (or, in the case of any adjournment or postponement of the Aurora Shareholders' Meeting, by not later than 9:30 a.m. (Toronto time) on the day that is two Business Days immediately preceding the day on which the adjourned meeting is reconvened or the postponed meeting is convened, as applicable). Failure to properly exercise Dissent Rights may result in the loss or unavailability of the right to dissent in respect of the Arrangement.

The delivery of a Notice of Dissent does not deprive a registered Aurora Shareholder of the right to vote at the Aurora Shareholders' Meeting. A vote against the Arrangement Resolution, an abstention from voting or a proxy submitted instructing a proxyholder to vote against the Arrangement Resolution does not constitute a Notice of Dissent. **However, pursuant to the Interim Order, any Aurora Shareholder who has voted in favour of the Arrangement Resolution is not entitled to exercise Dissent Rights.**

Pursuant to sections 237 to 247 of the BCBCA and the Interim Order, a registered Aurora Shareholder may not exercise Dissent Rights in respect of only a portion of such Aurora Shareholder's Aurora Common Shares, but may exercise Dissent Rights only with respect to all of the Aurora Common Shares held by such Aurora Shareholder or on behalf of any one Beneficial Holder and registered in the Dissenting Aurora Shareholder's name.

Only registered Aurora Shareholders may exercise Dissent Rights. In many cases, Aurora Common Shares beneficially owned by a Beneficial Holder are registered either: (a) in the name of a broker, investment dealer, bank, trust company, custodian, nominee or other intermediary; or (b) in the name of a clearing agency (such as CDS) of which the intermediary is a participant. Accordingly, a Beneficial Holder will not be entitled to exercise its Dissent Rights directly (unless the Aurora Common Shares are re-registered in the Beneficial Holder's name). A Beneficial Holder who wishes to exercise Dissent Rights should immediately contact the intermediary with whom the Beneficial Holder deals in respect of its Aurora Common Shares and either: (a) instruct the intermediary to exercise Dissent Rights on the Beneficial Holder's behalf (which, if the Aurora Common Shares are registered in the name of CDS or another clearing agency, may require that such Aurora Common Shares first be re-registered in the name of the intermediary); or (b) instruct the intermediary to re-register such Aurora Common Shares in the name of the Beneficial Holder, in which case the Beneficial Holder would be able to exercise Dissent Rights directly.

A registered Aurora Shareholder who wishes to exercise Dissent Rights must prepare a separate Notice of Dissent for itself, if dissenting on its own behalf, and for each other person who beneficially owns Aurora Common Shares registered in its name and on whose behalf it is dissenting. The Notice of Dissent must set out the number of Aurora Common Shares in respect of which it is sent (the "**Notice Shares**") and: (a) if such Notice Shares constitute all of the Aurora Common Shares of which the holder is both the registered and beneficial owner and the holder owns no other Aurora Common Shares beneficially, a statement to that effect; (b) if such Notice Shares constitute all of the Aurora Common Shares of which the holder is both the registered and beneficial owner but the holder owns additional Aurora Common Shares beneficially, a statement to that effect and the names of the registered holders of such other Aurora Common Shares, the number of such Aurora Common Shares held by each such registered holder and a statement that Notices of Dissent are being or have been sent with respect to such other Aurora Common Shares; or (c) if Dissent Rights are being exercised by a registered holder on behalf of a beneficial owner who is not the Dissenting Aurora Shareholder, a statement to that effect, the name and address of the beneficial owner and a statement that the registered holder is dissenting with respect to all Aurora Common Shares of the beneficial owner registered in the registered holder's name.

If the Arrangement Resolution is approved and Aurora notifies a Dissenting Aurora Shareholder of its intention to act on the Arrangement Resolution under section 243 of the BCBCA, the Dissenting Aurora Shareholder, if it wishes to proceed with its dissent, must, within one month after the date of such notice, send to Aurora or its transfer agent the certificates (if any) representing the Notice Shares and a written statement that it requires Aurora to purchase all of the Notice Shares (including, if Dissent Rights are being exercised on behalf of a beneficial owner, a written statement signed by such beneficial owner that complies with section 244(2) of the BCBCA). Upon delivery of these documents, the Dissenting Aurora Shareholder is deemed to have sold the Notice Shares to Aurora and Aurora is deemed to have purchased them, and the Dissenting Aurora Shareholder may not vote, or exercise or assert any rights of an Aurora Shareholder, in respect of the Notice Shares, other than under Division 2 of Part 8 of the BCBCA, as modified by the Interim Order and the Plan of Arrangement.

Aurora and a Dissenting Aurora Shareholder who has complied with section 244(1) of the BCBCA may agree on the amount of the payout value of the Notice Shares, in which case Aurora must promptly pay that amount to the Dissenting Aurora Shareholder. Otherwise, either Aurora or the Dissenting Aurora Shareholder may apply to the Court, and the Court may determine the payout value of the Notice Shares (or order that it be established by arbitration or by reference to the registrar, or a referee, of the Court), join in the application each Dissenting Aurora Shareholder who has complied with section 244(1) of the BCBCA and has not entered into such an agreement, and make consequential orders and give directions it considers appropriate. There is no obligation on Aurora or Organigram to make an application to the Court. Promptly after a determination of the payout value, Aurora must pay that amount to each applicable Dissenting Aurora Shareholder.

Pursuant to the Plan of Arrangement and the Interim Order, at the Effective Time, without any further act or formality:

(a) the Aurora Common Shares held by Dissenting Aurora Shareholders shall be deemed to have been transferred to Organigram, free and clear of any liens, charges, encumbrances, claims and other interests of any kind, in consideration for a debt claim against Organigram for the fair value of such shares, and Organigram shall be recorded as the holder of such shares;

(b) each Dissenting Aurora Shareholder shall cease to have any rights as an Aurora Shareholder, other than the right to be paid the fair value of the Dissenting Aurora Shareholder's Aurora Common Shares by Organigram (determined as of the close of business on the last Business Day before the Arrangement Resolution was adopted); and

(c) the name of each Dissenting Aurora Shareholder shall be removed from the central securities register of Aurora.

Pursuant to the Plan of Arrangement and the Interim Order, following the Effective Time, none of Aurora, Organigram or any other person shall be required to recognize any Dissenting Aurora Shareholder as an Aurora Shareholder.

A Dissenting Aurora Shareholder will lose its Dissent Rights if, before full payment is made for the Notice Shares, among other things: (a) the Arrangement is abandoned or by its terms will not proceed; (b) the Arrangement Resolution is not passed, or is revoked before the Arrangement is effected; (c) a court permanently enjoins or sets aside the Arrangement; (d) the Dissenting Aurora Shareholder consents to, or votes in favour of, the Arrangement Resolution; (e) the Notice of Dissent is withdrawn with the written consent of Aurora; or (f) the Court determines that the Dissenting Aurora Shareholder is not entitled to dissent, in each case as provided in section 246 of the BCBCA. In such event, Aurora will return to the Dissenting Aurora Shareholder any certificates delivered in respect of the Notice Shares and the Dissenting Aurora Shareholder will regain the ability to vote and exercise shareholder rights.

Pursuant to the Plan of Arrangement and the Interim Order, notwithstanding the provisions of sections 237 to 247 of the BCBCA, a Dissenting Aurora Shareholder who, for any reason, is not ultimately entitled to be paid the fair value of such Dissenting Aurora Shareholder's Aurora Common Shares shall be deemed to have participated in the Arrangement on the same basis as a non-dissenting Aurora Shareholder.

Unless otherwise waived in accordance with the Arrangement Agreement, it is a condition to the completion of the Arrangement in favour of Organigram that Dissent Rights shall not have been validly exercised, and not withdrawn, with respect to more than 10% of the issued and outstanding Aurora Common Shares. Under the Arrangement Agreement, Aurora has agreed to promptly advise Organigram of any written notice of dissent, purported exercise or withdrawal of Dissent Rights and any written communications sent to Aurora Shareholders exercising Dissent Rights, and not to make any payment or settlement offer, or agree to any payment or settlement, with respect to Dissent Rights without the prior written consent of Organigram. See "*Certain Canadian Federal Income Tax Considerations*" for a discussion of the tax consequences to Dissenting Aurora Shareholders.

For greater certainty, in addition to any other restrictions in the Interim Order and under the BCBCA, none of the following shall be entitled to exercise Dissent Rights: (a) holders of Aurora Incentive Awards (in their capacity as such); (b) Aurora Shareholders who vote or instruct a proxyholder to vote their Aurora Common Shares in favour of

the Arrangement Resolution; and (c) any person who is not a registered holder of Aurora Common Shares as of the Aurora Record Date.

Aurora must not make a payment to a Dissenting Aurora Shareholder under section 245 of the BCBCA if there are reasonable grounds for believing that Aurora is insolvent or that the payment would render Aurora insolvent. In such event, Aurora must promptly send a notice to the Dissenting Aurora Shareholder that it is unable lawfully to pay for the Notice Shares, in which case the Dissenting Aurora Shareholder may, within 30 days after receipt of such notice, withdraw its Notice of Dissent, in which case Aurora is deemed to consent to the withdrawal and the Dissenting Aurora Shareholder shall be deemed to have participated in the Arrangement as an Aurora Shareholder. If the Dissenting Aurora Shareholder does not withdraw its Notice of Dissent, it retains a status as a claimant against Aurora to be paid as soon as Aurora is lawfully able to do so or, in a liquidation, to be ranked subordinate to the rights of creditors of Aurora but in priority to its shareholders.

Aurora Shareholders who are considering exercising Dissent Rights should be aware that there can be no assurance that the fair value of their Aurora Common Shares, as determined under the applicable provisions of the BCBCA (as modified by the Interim Order and the Plan of Arrangement or any other order of the Court), will be more than or equal to the consideration payable under the Arrangement. In addition, any judicial determination of fair value will result in delay of receipt by a Dissenting Aurora Shareholder of consideration for such Dissenting Aurora Shareholder's Aurora Common Shares. Furthermore, Aurora Shareholders who are considering exercising Dissent Rights should be aware of the consequences under applicable tax laws of exercising Dissent Rights in respect of the Arrangement. See "*Certain Canadian Federal Income Tax Considerations – Holders Resident in Canada – Dissenting Resident Holders of Aurora Common Shares*", "*Certain Canadian Federal Income Tax Considerations – Holders Not Resident in Canada – Dissenting Non-Resident Holders of Aurora Common Shares*" and "*Certain United States Federal Income Tax Considerations – U.S. Federal Income Tax Considerations of the Arrangement – U.S. Holders Exercising Dissent Rights*".

The above summary does not purport to provide a comprehensive statement of the procedures to be followed by Dissenting Aurora Shareholders who seek payment of the fair value of their Aurora Common Shares. Sections 237 to 247 of the BCBCA, as modified by the Interim Order and the Plan of Arrangement, require adherence to the procedures established therein and failure to do so may result in the loss of all rights thereunder. **Accordingly, Dissenting Aurora Shareholders who are considering exercising Dissent Rights should, in addition to consulting their own legal advisor, carefully consider and comply with the Plan of Arrangement, the Interim Order and the text of sections 237 to 247 of the BCBCA, the full text of which are attached to this Joint Information Circular as Appendix "C", Appendix "D" and Appendix "K", respectively.**

Unless otherwise waived in accordance with the Arrangement Agreement, it is a condition to the completion of the Arrangement in favour of Organigram that Dissent Rights shall not have been validly exercised, and not withdrawn, with respect to more than 10% of the issued and outstanding Aurora Common Shares.

CERTAIN CANADIAN FEDERAL INCOME TAX CONSIDERATIONS

The following is a summary of the principal Canadian federal income tax considerations generally applicable under the Tax Act to the disposition of Aurora Common Shares pursuant to the Arrangement, and the receipt, holding and disposition of Organigram Common Shares received pursuant to the Arrangement, that generally apply to a beneficial owner of Aurora Common Shares who, for purposes of the Tax Act and at all relevant times: (a) deals at arm's length with each of Aurora and Organigram; (b) is not affiliated with Aurora or Organigram; and (c) holds the Aurora Common Shares, and will hold any Organigram Common Shares received pursuant to the Arrangement, as capital property (each, a "**Holder**"). Generally, the Aurora Common Shares and the Organigram Common Shares will be considered to be capital property to a Holder provided the Holder does not use or hold such securities in the course of carrying on a business and has not acquired such securities in one or more transactions considered to be an adventure or concern in the nature of trade.

This summary is based on the facts set out in this document, the current provisions of the Tax Act in force on the date hereof, and an understanding of the current administrative policies and assessing practices of the CRA published in writing prior to the date hereof. This summary takes into account all specific proposals to amend the Tax Act publicly announced and published in writing by or on behalf of the Minister of Finance (Canada) prior to the date hereof (the

"**Proposed Amendments**") and assumes that all Proposed Amendments will be enacted in the form proposed. However, no assurance can be given that the Proposed Amendments will be enacted as proposed, or at all. This summary does not otherwise take into account or anticipate any changes in law or administrative policy or assessing practice, whether by legislative, regulatory, administrative or judicial action, nor does it take into account tax legislation or considerations of any province, territory or foreign jurisdiction, which may differ from those discussed herein. Holders should consult their own tax advisors in respect of the provincial, territorial or foreign income tax consequences of the Arrangement.

This summary is not applicable to: (a) a Holder that is a "specified financial institution"; (b) a Holder an interest in which is a "tax shelter investment"; (c) a Holder that is a "financial institution" for the purposes of the mark-to-market rules in the Tax Act; (d) a Holder that reports its "Canadian tax results" in a currency other than Canadian currency; (e) a Holder that has entered into, or will enter into, with respect to its Aurora Common Shares or Organigram Common Shares, as applicable, a "derivative forward agreement", "synthetic disposition arrangement", "synthetic equity arrangement" or "dividend rental arrangement"; (f) a Holder that is exempt from tax under Part I of the Tax Act; (g) a Holder who acquired their Aurora Common Shares pursuant to employee equity compensation plans of Aurora or otherwise in connection with employment; or (h) a Holder that is a "foreign affiliate" of a taxpayer resident in Canada for purposes of the Tax Act, in each case as defined in the Tax Act. Such Holders should consult their own tax advisors. This summary does not address the tax considerations applicable to holders of Aurora Incentive Awards. Holders of Aurora Incentive Awards should consult their own tax advisors regarding their particular circumstances.

Additional considerations, not discussed herein, may be applicable to a Holder that is a corporation resident in Canada and is, or becomes, controlled by a non-resident person or a group of non-resident persons not dealing with each other at arm's length for the purposes of the "foreign affiliate dumping" rules in section 212.3 of the Tax Act. Such Holders should consult their own tax advisors.

This summary is of a general nature only and is not, and is not intended to be, nor should it be construed to be, legal or tax advice to any particular Holder. This summary is not exhaustive of all Canadian federal income tax considerations applicable to a Holder in respect of the transactions described herein. The income or other tax consequences will vary depending on the particular circumstances of the Holder. This summary does not discuss any non-Canadian income or other tax consequences of the Arrangement. Holders resident or subject to taxation in a jurisdiction other than Canada should be aware that the Arrangement may have tax consequences both in Canada and in such other jurisdiction. Such consequences are not described in this summary. Holders should consult their own legal and tax advisors for advice with respect to the tax consequences of the transactions described herein based on their particular circumstances.

Holders Resident in Canada

This portion of the summary is generally applicable to a Holder who, at all relevant times, for purposes of the Tax Act and any applicable income tax convention, is, or is deemed to be, resident in Canada (a "**Resident Holder**"). Certain Resident Holders may be entitled to make or may have already made the irrevocable election permitted by subsection 39(4) of the Tax Act, the effect of which may be to deem any Aurora Common Shares or Organigram Common Shares (and all other "Canadian securities" (as defined in the Tax Act)) owned by such Resident Holder in the taxation year in which the election is made and in all subsequent taxation years to be capital property. Notwithstanding the foregoing, where a Resident Holder makes a Section 85 Election with respect to the disposition of the Aurora Common Shares under the Arrangement, the Organigram Common Shares received will not be "Canadian securities" to such holder and will not be deemed to be capital property under subsection 39(4) of the Tax Act. Resident Holders contemplating such an election should first consult their own tax advisors for advice as to whether the election is available or advisable in their particular circumstances.

Participation in the Arrangement – No Section 85 Election

Resident Holders who receive Cash only

In the event that a Resident Holder (other than a Dissenting Resident Holder) receives only cash in exchange for its Aurora Common Shares (and is not subject to proration resulting in the receipt of a combination of cash and Organigram Common Shares), the Resident Holder will realize a capital gain (or capital loss) to the extent that the

amount of cash received, net of any reasonable costs of disposition, exceeds (or is less than) the adjusted cost base of such Aurora Common Shares to the Resident Holder. See "*Taxation of Capital Gains and Losses*" below for a general discussion of the treatment of capital gains and capital losses under the Tax Act.

Resident Holders who receive Organigram Common Shares only

A Resident Holder (other than a Dissenting Resident Holder) that disposes of Aurora Common Shares solely for Organigram Common Shares (and is not subject to proration resulting in the receipt of a combination of cash and Organigram Common Shares) and does not make a Section 85 Election will be deemed to have disposed of such Aurora Common Shares under a tax-deferred share-for-share exchange pursuant to section 85.1 of the Tax Act, unless the Resident Holder chooses to recognize a capital gain (or capital loss) as described in paragraph (b) below, such that:

(a) Where a Resident Holder does not choose to recognize a capital gain (or capital loss) on the exchange, the Resident Holder will be deemed to have disposed of such Aurora Common Shares for proceeds of disposition equal to its aggregate adjusted cost base of those Aurora Common Shares, determined immediately before the exchange, and the Resident Holder will be deemed to have acquired the Organigram Common Shares at an aggregate cost equal to such adjusted cost base. This cost will be averaged with the adjusted cost base of any other Organigram Common Shares held by the Resident Holder as capital property immediately before the exchange for the purpose of determining the adjusted cost base of each Organigram Common Share held by the Resident Holder as capital property.

(b) A Resident Holder may choose to recognize a capital gain (or capital loss) in respect of the exchange of Aurora Common Shares for Organigram Common Shares by including the capital gain (or capital loss) in computing the Resident Holder's income for the taxation year in which the Arrangement takes place. In such circumstances, the Resident Holder will recognize a capital gain (or capital loss) equal to the amount, if any, by which the fair market value of the Organigram Common Shares received, net of any reasonable costs associated with the exchange, exceeds (or is less than) the aggregate of the adjusted cost base of such Aurora Common Shares to the Resident Holder, determined immediately before the exchange. For a description of the tax treatment of capital gains and capital losses, see "*Taxation of Capital Gains and Losses*" below. The cost of the Organigram Common Shares acquired on the exchange will be equal to the fair market value thereof at the time of the exchange. This cost will be averaged with the adjusted cost base of all other Organigram Common Shares held by the Resident Holder as capital property immediately before the exchange for the purpose of determining the adjusted cost base of each Organigram Common Share held by the Resident Holder as capital property.

Resident Holders who receive Organigram Common Shares and Cash

A Resident Holder who receives Organigram Common Shares and cash for their Aurora Common Shares, including as a result of proration, and who does not make an Indication (as defined below) (and who does not make a Section 85 Election) will be deemed to receive only Organigram Common Shares for that number of its Aurora Common Shares (including any fraction thereof) equal to the number of Aurora Common Shares then held by it multiplied by the proportion that the value of the Organigram Common Shares received (calculated based on the deemed price of $1.33 per Organigram Common Share under the Plan of Arrangement) is of the aggregate consideration received (being the value of the Organigram Common Shares at such deemed price and the amount of cash received), and only cash for the remaining number of Aurora Common Shares (including any fraction thereof). Under such circumstances, the tax considerations in respect of the portion of Aurora Common Shares disposed of for Organigram Common Shares will be the same as those described above under "*Participation in the Arrangement – No Section 85 Election – Resident Holders who receive Organigram Common Shares only*". Further, the tax considerations in respect of the portion of Aurora Common Shares disposed of for cash will be the same as those described above under "*Participation in the Arrangement – No Section 85 Election – Resident Holders who receive Cash only*".

A Resident Holder who receives Organigram Common Shares and cash for their Aurora Common Shares, including as a result of proration, and who makes an Indication but does not make a Section 85 Election will not be entitled to

the tax-deferred share-for-share exchange under section 85.1 of the Tax Act in respect of any of its Aurora Common Shares and will recognize a capital gain (or capital loss) equal to the amount, if any, by which the amount of cash and the fair market value of the Organigram Common Shares received, net of any reasonable costs associated with the exchange, exceeds (or is less than) the aggregate of the adjusted cost base of such Aurora Common Shares to the Resident Holder, determined immediately before the exchange. For a description of the tax treatment of capital gains and capital losses, see "*Taxation of Capital Gains and Losses*" below. The cost of the Organigram Common Shares acquired on the exchange will be equal to the fair market value thereof at the time of the exchange. This cost will be averaged with the adjusted cost base of any other Organigram Common Shares held by the Resident Holder as capital property immediately before the exchange for the purpose of determining the adjusted cost base of each Organigram Common Share held by the Resident Holder as capital property.

A Resident Holder who receives both cash and Organigram Common Shares and who makes an Indication will not be entitled to any tax deferral in respect of the exchange unless a valid Section 85 Election is made. The Canadian federal income tax consequences of the receipt of cash and Organigram Common Shares for the Aurora Common Shares to a Resident Holder that does not make a Section 85 Election may differ depending on whether or not the Resident Holder makes an Indication. Resident Holders are urged to consult their own tax advisors, having regard to their particular circumstances.

Participation in the Arrangement – With a Section 85 Election

A Resident Holder that is an Eligible Holder is entitled to make a joint election with Organigram pursuant to section 85 of the Tax Act (a "**Section 85 Election**"), and may thereby defer all or a portion of the capital gain that would otherwise be recognized for purposes of the Tax Act in respect of the exchange of Aurora Common Shares for consideration that includes Organigram Common Shares under the Arrangement, depending on the Elected Amount (as defined below), the Resident Holder's adjusted cost base of the Aurora Common Shares at the time of the exchange, and subject to the Section 85 Election requirements being met under the Tax Act. For purposes hereof, "**Eligible Holder**" means a beneficial owner of Aurora Common Shares that is (a) a resident of Canada for purposes of the Tax Act (other than a partnership) and not exempt from tax under Part I of the Tax Act, or (b) a partnership any member of which is a resident of Canada for purposes of the Tax Act (other than a partnership all members of which that are residents of Canada are exempt from tax under Part I of the Tax Act).

Each Resident Holder is urged to consult the Resident Holder's own advisors as soon as possible with respect to whether making a Section 85 Election is available or desirable having regard to the Resident Holder's particular circumstances. The comments herein with respect to such elections are provided for general assistance only. The law in this area is complex and contains numerous technical requirements not addressed in this summary.

A Resident Holder is only entitled to make a Section 85 Election with respect to the disposition of Aurora Common Shares for consideration that includes Organigram Common Shares. In this regard, where a Resident Holder who receives both cash and Organigram Common Shares indicates in its Letter of Transmittal and Election Form (and provided it is deposited with the Depositary by the Election Deadline) that it intends to make a Section 85 Election (an "**Indication**"), all of such Resident Holder's Aurora Common Shares will be deemed to be exchanged for consideration that includes Organigram Common Shares. If, however, a Resident Holder does not make an Indication, such Resident Holder will be deemed to receive only Organigram Common Shares for that number of its Aurora Common Shares (including any fraction thereof) equal to the number of Aurora Common Shares then held by it multiplied by the proportion that the value of the Organigram Common Shares received (calculated based on the deemed price of $1.33 per Organigram Common Share under the Plan of Arrangement) is of the aggregate consideration received (being the value of the Organigram Common Shares at such deemed price and the amount of cash received), and only cash for the remaining number of Aurora Common Shares (including any fraction thereof). The Indication cannot be made or changed after the Election Deadline, and a holder that is not an Eligible Holder should not make an Indication. As proration will not be determined until after the Election Deadline, a Resident Holder who elects the Cash Alternative or the Share Alternative will not know at the time of its election whether it will receive a combination of cash and Organigram Common Shares. A Resident Holder whose Aurora Common Shares are held through a broker or other intermediary must instruct the intermediary to make the Indication on its behalf. A Section 85 Election will not be available with respect to the Aurora Common Shares (including any fraction thereof) for which a Resident Holder is deemed to only receive cash. The tax considerations in respect of the portion of Aurora Common

Shares disposed of only for cash will be the same as those described above under "*Participation in the Arrangement – No Section 85 Election – Resident Holders who receive Cash only*". **The Canadian federal income tax consequences of the receipt of cash and Organigram Common Shares for the Aurora Common Shares to a Resident Holder that makes a Section 85 Election may differ depending on whether or not the Resident Holder makes an Indication. Resident Holders are urged to consult their own tax advisors as soon as possible in this regard, having regard to their particular circumstances.**

A Resident Holder making a Section 85 Election will be required to designate an amount (the "**Elected Amount**") in the election form that will be deemed to be the proceeds of disposition of the Resident Holder's Aurora Common Shares that are disposed of for consideration that includes Organigram Common Shares. In general, the Elected Amount may not be:

- less than the amount of cash received by the Resident Holder for such Aurora Common Shares;
- less than the lesser of (i) the Resident Holder's adjusted cost base of such Aurora Common Shares, and (ii) the fair market value of such Aurora Common Shares, in each case determined at the time of the exchange; or
- greater than the fair market value of such Aurora Common Shares at the time of the exchange.

An Elected Amount specified by a Resident Holder that does not comply with these limitations will automatically be adjusted under the Tax Act so that it is in compliance, and the amount so adjusted will be deemed to be the Elected Amount for purposes of such Section 85 Election.

The Canadian federal income tax treatment to a Resident Holder who properly makes a valid Section 85 Election jointly with Organigram in respect of Aurora Common Shares that are disposed of for consideration that includes Organigram Common Shares generally will be as follows:

- the Resident Holder will be deemed to have disposed of such Aurora Common Shares for proceeds of disposition equal to the Elected Amount;
- if the Elected Amount exceeds the Resident Holder's adjusted cost base of such Aurora Common Shares, then the Resident Holder will realize a capital gain equal to such excess less any reasonable costs of disposition (see "*Taxation of Capital Gains and Losses*" below);
- if the Resident Holder's adjusted cost base of such Aurora Common Shares exceeds the Elected Amount, then the Resident Holder will realize a capital loss equal to such excess plus any reasonable costs of disposition (see "*Taxation of Capital Gains and Losses*" below); and
- the aggregate cost to the Resident Holder of the Organigram Common Shares acquired on the exchange will equal the Elected Amount less the amount of any cash received by the Resident Holder for such Aurora Common Shares, and for the purpose of determining the Resident Holder's adjusted cost base of those Organigram Common Shares, such cost will be averaged with the Resident Holder's adjusted cost base of all other Organigram Common Shares, if any, held as capital property immediately before exchange.

A Resident Holder who intends to make a Section 85 Election must provide two duly completed and signed copies of the necessary election forms to Organigram within 90 days following the Effective Date. The relevant federal tax election form is CRA form T2057 (or, if the Resident Holder is a partnership, CRA form T2058). A tax instruction letter and CRA forms T2057 and T2058 will be made available on Organigram's website promptly following the Effective Date. Provincial election forms will not be included with the tax instruction letter or made available on Organigram's website. Resident Holders should consult their own tax advisors to determine whether they must file separate election forms with any provincial taxing jurisdiction. It is the responsibility of each Resident Holder who wishes to make an election for provincial income tax purposes to obtain any necessary provincial election forms. Resident Holders should consult their own tax advisors to determine all relevant filing requirements and procedures (including under provincial legislation) applicable in their particular circumstances.

The election form or forms will be signed by Organigram and returned to such Resident Holder within 60 days after the receipt thereof by Organigram for filing with the CRA (or the applicable provincial or territorial taxing authority). None of Aurora, Organigram or any successor corporation will be responsible for the proper completion or filing of any election form or for the payment of any late filing penalty, nor will any of them be responsible for any taxes, interest or penalties or any other costs or damages resulting from the failure by a Resident Holder to properly complete or file the election forms in the form and manner and within the time prescribed by the Tax Act (or any applicable provincial or territorial legislation). With the exception of the execution and delivery of completed Section 85 Election forms by Organigram within 60 days of receiving the duly completed and executed election forms from a Resident Holder, compliance with the requirements for making a valid Section 85 Election will be the sole responsibility of the Resident Holder making the election. **Resident Holders may be required to forward their tax election forms to Organigram earlier than 90 days after the Effective Date in order to avoid late filing penalties. Each Resident Holder is urged to consult the Resident Holder's own advisors as soon as possible with respect to any deadlines applicable to the Resident Holder having regard to their particular circumstances. All Resident Holders who wish to make a Section 85 Election should give immediate attention to this matter and in particular should consult their own tax advisors without delay.**

Dissenting Resident Holders of Aurora Common Shares

A Resident Holder who exercises Dissent Rights in respect of the Arrangement (a "**Dissenting Resident Holder**") and who disposes of Aurora Common Shares and receives from Organigram the fair value of such Dissenting Resident Holder's Aurora Common Shares will realize a capital gain (or capital loss) to the extent that the proceeds of disposition (excluding any interest awarded by a court), net of any reasonable costs of disposition, exceed (or are less than) the adjusted cost base of the Dissenting Resident Holder's Aurora Common Shares. See "*Taxation of Capital Gains and Losses*" below.

Any interest awarded by the Court to a Dissenting Resident Holder will be included in such Dissenting Resident Holder's income for the purposes of the Tax Act.

Dissenting Resident Holders should consult their own tax advisors having regard to their own particular circumstances.

Holding and Disposing of Organigram Common Shares

Dividends Received on Organigram Common Shares

A Resident Holder will be required to include in computing its income for a taxation year any dividends received (or deemed to be received) on the Organigram Common Shares. In the case of a Resident Holder that is an individual (other than certain trusts), such dividends will be subject to the gross-up and dividend tax credit rules applicable to taxable dividends received from taxable Canadian corporations, including the enhanced gross-up and dividend tax credit applicable to any dividends designated by Organigram as eligible dividends in accordance with the provisions of the Tax Act. There may be limitations on Organigram's ability to designate dividends as "eligible dividends".

Taxable dividends received by a Resident Holder that is an individual or a trust (other than certain trusts) may increase such Resident Holder's liability for alternative minimum tax. Resident Holders should consult their own tax advisors with respect to the potential application of alternative minimum tax.

A dividend received (or deemed to be received) by a Resident Holder that is a corporation will generally be deductible in computing the corporation's taxable income. In certain circumstances, however, a taxable dividend received (or deemed to be received) by a Resident Holder that is a corporation may be deemed to be a gain from the disposition of capital property or proceeds of disposition potentially giving rise to a capital gain. Resident Holders that are corporations should consult their own tax advisors having regard to their own particular circumstances.

A Resident Holder that is a "private corporation" or "subject corporation" (each as defined in the Tax Act) may be liable to pay a refundable tax under Part IV of the Tax Act on dividends received (or deemed to be received) on the Organigram Common Shares to the extent such dividends are deductible in computing the Resident Holder's taxable income for the taxation year.

Disposition of Organigram Common Shares

Generally, on a disposition or deemed disposition of an Organigram Common Share, a Resident Holder will realize a capital gain (or capital loss) equal to the amount, if any, by which the proceeds of disposition, net of any reasonable costs of disposition, exceed (or are less than) the adjusted cost base to the Resident Holder of the Organigram Common Share immediately before the disposition or deemed disposition. See "*Taxation of Capital Gains and Losses*" below for a general discussion of the treatment of capital gains and capital losses under the Tax Act.

Taxation of Capital Gains and Losses

Generally, a Resident Holder is required to include in computing its income for a taxation year one-half of the amount of any capital gain (a "**taxable capital gain**") realized in the year. Subject to and in accordance with the provisions of the Tax Act, a Resident Holder is required to deduct one-half of the amount of any capital loss (an "**allowable capital loss**") realized in a taxation year from taxable capital gains realized by the Resident Holder in the year, and allowable capital losses in excess of taxable capital gains for the year may be carried back and deducted in any of the three preceding taxation years or carried forward and deducted in any subsequent taxation year against net taxable capital gains realized in such years, to the extent and under the circumstances specified in the Tax Act.

The amount of any capital loss realized by a Resident Holder that is a corporation on the disposition or deemed disposition of an Aurora Common Share or an Organigram Common Share may be reduced by the amount of any dividends received (or deemed to be received) by the Resident Holder on such share (or on a share for which such share was exchanged) to the extent and under the circumstances specified in the Tax Act. Similar rules may apply where Aurora Common Shares or Organigram Common Shares are owned by a partnership or trust of which a corporation, trust or partnership is a member or beneficiary. Such Resident Holders should consult their own advisors.

Capital gains realized by a Resident Holder that is an individual (other than certain trusts) may increase such Resident Holder's liability for alternative minimum tax. Resident Holders should consult their own tax advisors with respect to the potential application of alternative minimum tax.

Additional Refundable Tax

A Resident Holder that is throughout the relevant taxation year a "Canadian-controlled private corporation", or that is (or is deemed to be) at any time in the relevant taxation year a "substantive CCPC" (each as defined in the Tax Act), may be liable to pay an additional tax (refundable in certain circumstances) on its "aggregate investment income" (as defined in the Tax Act) for the year, including taxable capital gains and interest.

Eligibility for Investment

Provided that the Organigram Common Shares are listed on a "designated stock exchange" (as defined in the Tax Act) (which currently includes the TSX and the Nasdaq) on the Effective Date, the Organigram Common Shares received by Aurora Shareholders pursuant to the Arrangement will be qualified investments under the Tax Act on such date for trusts governed by registered retirement savings plans ("**RRSPs**"), registered retirement income funds ("**RRIFs**"), registered education savings plans ("**RESPs**"), registered disability savings plans ("**RDSPs**"), first home savings accounts ("**FHSAs**"), tax-free savings accounts ("**TFSAs**" and, collectively with RRSPs, RRIFs, RESPs, RDSPs, and FHSAs, "**Registered Plans**"), and deferred profit sharing plans.

Notwithstanding that Organigram Common Shares may be qualified investments for a Registered Plan, the holder, subscriber or annuitant (the "**Controlling Individual**"), as applicable, of the Registered Plan will be subject to a penalty tax as set out in the Tax Act, if such Organigram Common Shares are a "prohibited investment" for the Registered Plan for purposes of the Tax Act. The Organigram Common Shares will generally not be a "prohibited investment" for a Registered Plan provided that the Controlling Individual (i) deals at arm's length with Organigram for the purposes of the Tax Act, and (ii) does not have a "significant interest" (as defined in subsection 207.01(4) of the Tax Act) in Organigram. In addition, the Organigram Common Shares will generally not be a prohibited investment if such shares are "excluded property" (as defined in subsection 207.01(1) of the Tax Act for purposes of the prohibited investment rules).

Resident Holders who will hold Organigram Common Shares in a Registered Plan should consult their own tax advisors regarding their particular circumstances.

Holders Not Resident in Canada

This portion of the summary is generally applicable to a Holder who for purposes of the Tax Act and at all relevant times, is not, and is not deemed to be, resident in Canada and does not use or hold, and is not deemed to use or hold, the Aurora Common Shares or Organigram Common Shares in a business carried on in Canada (a "**Non-Resident Holder**"). Special rules, which are not discussed in this summary, may apply to certain holders that are insurers carrying on an insurance business in Canada and elsewhere or to a holder that is an "authorized foreign bank" (as defined in the Tax Act). Such Non-Resident Holders should consult their own tax advisors with respect to the Arrangement.

Disposition of Aurora Common Shares under the Arrangement

A Non-Resident Holder will not be subject to tax under the Tax Act on any capital gain realized on a disposition of Aurora Common Shares pursuant to the Arrangement unless the Aurora Common Shares are "taxable Canadian property" (as defined in the Tax Act) to the Non-Resident Holder at the time of disposition and are not "treaty-protected property" (as defined in the Tax Act) of the Non-Resident Holder at that time. See "*Aurora Common Shares – Taxable Canadian Property*" below.

A Non-Resident Holder whose Aurora Common Shares are "taxable Canadian property" and are not "treaty-protected property" will generally have the same tax considerations (including the entitlement to the automatic tax-deferral provisions of section 85.1 of the Tax Act in respect of any Aurora Common Shares exchanged solely for Organigram Common Shares) as those described above under the headings "*Holders Resident in Canada – Participation in the Arrangement – No Section 85 Election*" and "*Holders Resident in Canada – Taxation of Capital Gains and Losses*". A Non-Resident Holder is not entitled to make a Section 85 Election and should not make an Indication.

Aurora Common Shares – Taxable Canadian Property

Generally, the Aurora Common Shares will not constitute "taxable Canadian property" to a Non-Resident Holder at a particular time provided that the Aurora Common Shares are listed at that time on a designated stock exchange (which currently includes the TSX and the Nasdaq), unless at any particular time during the 60-month period that ends at that time:

(a) one or any combination of: (i) the Non-Resident Holder, (ii) persons with whom the Non-Resident Holder does not deal at arm's length and (iii) partnerships in which the Non-Resident Holder or a person described in (ii) holds a membership interest directly or indirectly through one or more partnerships, has owned 25% or more of the issued shares of any class or series of the capital stock of Aurora; and

(b) more than 50% of the fair market value of Aurora Common Shares was derived directly or indirectly from one or any combination of: (i) real or immovable properties situated in Canada, (ii) "Canadian resource properties" (as defined in the Tax Act), (iii) "timber resource properties" (as defined in the Tax Act), and (iv) options in respect of, or interests in, or for civil law rights in, property in any of the foregoing whether or not the property exists.

Pursuant to Proposed Amendments released by the Department of Finance (Canada) on July 23, 2026 (the "**TCP Proposals**"), shares that are listed on a designated stock exchange would be deemed to include an option, an interest or a right in such shares, whether or not such shares exist, such that any such options, interests or rights held by a Non-Resident Holder (or by persons with whom the Non-Resident Holder does not deal at arm's length, or partnerships described in (a)(iii) above) would be included in determining whether the 25% threshold described in (a) above is met. The TCP Proposals are proposed to come into force on Royal Assent.

Notwithstanding the foregoing, in certain circumstances set out in the Tax Act, Aurora Common Shares could be deemed to be taxable Canadian property. Non-Resident Holders whose Aurora Common Shares may constitute taxable Canadian property should consult their own tax advisors.

Even if the Aurora Common Shares are taxable Canadian property to a Non-Resident Holder, a taxable capital gain resulting from the disposition of such shares will not be included in computing the Non-Resident Holder's income for the purposes of the Tax Act if the Aurora Common Shares constitute "treaty-protected property". Aurora Common Shares owned by a Non-Resident Holder generally will be treaty-protected property if the gain from the disposition of such shares would, because of an applicable income tax treaty or convention between Canada and the country in which the Non-Resident Holder is resident for purposes of such treaty or convention and in respect of which the Non-Resident Holder is entitled to receive benefits thereunder, be exempt from tax under the Tax Act.

A Non-Resident Holder who disposes of taxable Canadian property that is not treaty-protected property may be required to file a Canadian income tax return for the year in which the disposition occurs. Non-Resident Holders should consult their own tax advisors in this regard.

Dissenting Non-Resident Holders of Aurora Common Shares

A Non-Resident Holder who exercises Dissent Rights (a "**Dissenting Non-Resident Holder**") and who disposes of Aurora Common Shares and receives from Organigram the fair value of such Non-Resident Holder's Aurora Common Shares will realize a capital gain (or capital loss) to the extent that the proceeds of disposition (excluding any interest awarded by the Court), net of any reasonable costs of disposition, exceed (or are less than) the adjusted cost base of the Non-Resident Holder's Aurora Common Shares. As discussed above under "*Disposition of Aurora Common Shares under the Arrangement*", any resulting capital gain would only be subject to tax under the Tax Act if the Aurora Common Shares constitute taxable Canadian property to the Dissenting Non-Resident Holder at the time of the disposition and are not treaty-protected property of the Dissenting Non-Resident Holder at that time.

Generally, any interest awarded by the Court to a Non-Resident Holder that exercises Dissent Rights will not be subject to Canadian withholding tax under the Tax Act provided that such interest is not "participating debt interest" (as defined in the Tax Act). Non-Resident Holders exercising Dissent Rights should consult their own tax advisors having regard to their own particular circumstances.

Holding and Disposing of Organigram Common Shares

Dividends Received on Organigram Common Shares

Dividends paid or credited (or deemed to be paid or credited) on the Organigram Common Shares to a Non-Resident Holder will be subject to Canadian withholding tax at the rate of 25%, subject to any reduction in the rate of withholding to which the Non-Resident Holder is entitled under any applicable income tax convention. For example, under the Canada-U.S. Income Tax Convention (1980) (the "**Convention**"), where dividends on the Organigram Common Shares are considered to be paid to or derived by a Non-Resident Holder that is the beneficial owner of the dividends and is a U.S. resident for the purposes of, and is fully entitled to benefits in accordance with, the provisions of the Convention, the applicable rate of Canadian withholding tax is generally reduced to 15%.

Disposition of Organigram Common Shares

A Non-Resident Holder will not be subject to tax under the Tax Act on any capital gain realized on a disposition or deemed disposition of Organigram Common Shares, unless the Organigram Common Shares constitute "taxable Canadian property" to the Non-Resident Holder and do not constitute "treaty-protected property". For a description of "taxable Canadian property" and "treaty-protected property", see "*Aurora **Common Shares – Taxable** Canadian Property*" above, as the same tests, with the necessary modifications, will apply in respect of the Organigram Common Shares.

Pursuant to the provisions of the Tax Act, where Aurora Common Shares constitute "taxable Canadian property" to a Non-Resident Holder, any Organigram Common Shares received by the Non-Resident Holder on the exchange of

such Aurora Common Shares utilizing the rollover available under section 85.1 of the Tax Act will be deemed to constitute "taxable Canadian property" to the Non-Resident Holder for a period of 60 months. The result is that such Non-Resident Holder may be subject to tax under the Tax Act on future gains realized on a disposition of those Organigram Common Shares so long as such shares are deemed to constitute "taxable Canadian property" to the Non-Resident Holder.

A Non-Resident Holder who disposes of taxable Canadian property that is not treaty-protected property may be required to file a Canadian income tax return for the year in which the disposition occurs. Non-Resident Holders should consult their own tax advisors in this regard.

Non-Resident Holders whose Organigram Common Shares may constitute taxable Canadian property should consult their own tax advisors.

CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS

The following discussion is a summary of certain material U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) who exchanges Aurora Common Shares for Organigram Common Shares (and/or, cash) pursuant to the Arrangement. This discussion applies only to Aurora Common Shares and Organigram Common Shares that are held as "capital assets" within the meaning of Section 1221 of the U.S. Internal Revenue Code of 1986, as amended (the "**Code**") (generally, property held for investment).

The following does not purport to be a complete analysis of all potential tax considerations arising in connection with the closing of the Arrangement or the ownership and disposal of Organigram Common Shares. The effects and considerations of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or non-U.S. tax laws, are not discussed. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the "**IRS**"), in each case in effect as of the date hereof. These authorities may change or be subject to alternative interpretations by the IRS or the courts, including retroactively, in a manner which could result in a different tax treatment than discussed below. Neither Organigram nor Aurora has sought nor will seek any rulings from the IRS regarding the matters discussed below. This discussion is not binding on the IRS or any court, and there can be no assurance that the IRS will not take a contrary position or that such a position would not be sustained by a court. No U.S. legal or tax opinion is being given with respect to the U.S. tax consequences of the Arrangement to a U.S. Holder of Aurora Common Shares or the acquisition, ownership or disposition of Organigram Common Shares.

This discussion does not address the U.S. federal net investment income, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, or disposition of Aurora Common Shares and Organigram Common Shares. In addition, except as specifically set forth below, this discussion does not discuss applicable tax reporting requirements. Each U.S. Holder should consult its own tax advisor regarding the U.S. federal, U.S. federal net investment income, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Aurora Common Shares and Organigram Common Shares. The discussion does not constitute tax advice and does not address all of the U.S. federal income tax considerations that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special treatment under U.S. federal income tax law including, without limitation:

- banks, insurance companies, and certain other financial institutions;
- regulated investment companies and real estate investment trusts;
- brokers, dealers or traders in securities or foreign currency;
- traders in securities that elect to mark to market;
- tax-exempt organizations or governmental organizations;

- U.S. expatriates and former citizens or long-term residents of the United States;
- persons holding Aurora Common Shares or, after the Arrangement, Organigram Common Shares, as part of a hedge, straddle, constructive sale, or other risk reduction strategy or as part of a conversion transaction or other integrated investment;
- persons subject to special tax accounting rules as a result of any item of gross income with respect to Aurora Common Shares or Organigram Common Shares, as the case may be, being taken into account in an applicable financial statement;
- persons that actually or constructively own 5% or more (by vote or value) of the outstanding Aurora Common Shares or, after the Arrangement, the outstanding Organigram Common Shares;
- "controlled foreign corporations", "passive foreign investment companies" and corporations that accumulate earnings to avoid U.S. federal income tax;
- S corporations, partnerships or other entities or arrangements treated as partnerships or other flow-through entities for U.S. federal income tax purposes (and investors therein);
- U.S. Holders (as defined below) having a functional currency other than the U.S. dollar;
- persons who hold or received Aurora Common Shares or Organigram Common Shares, as the case may be, pursuant to the exercise of any employee stock option or otherwise as compensation; and
- tax-qualified retirement plans.

For purposes of this discussion, a "**U.S. Holder**" is any beneficial owner of Aurora Common Shares or Organigram Common Shares, as the case may be, that is for U.S. federal income tax purposes:

- an individual who is a citizen or resident of the United States;
- a corporation (or other entity taxable as a corporation) created or organized under the laws of the United States, any state thereof, or the District of Columbia;
- an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
- a trust that (a) is subject to the primary supervision of a U.S. court and the control of one or more "United States persons" (within the meaning of Section 7701(a)(30) of the Code), or (b) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes.

If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds Aurora Common Shares or Organigram Common Shares, the tax treatment of an owner of such entity will depend on the status of the partner and the activities of the entity or arrangement and certain determinations made at the owner level. Accordingly, entities or arrangements treated as partnerships for U.S. federal income tax purposes and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.

HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE U.S. FEDERAL, STATE, LOCAL, AND NON-U.S. INCOME AND OTHER TAX CONSEQUENCES OF THE ARRANGEMENT IN LIGHT OF A HOLDER'S PARTICULAR INVESTMENT OR TAX CIRCUMSTANCES.

U.S. Federal Income Tax Considerations of the Arrangement

Tax Consequences of the Receipt of the Consideration Pursuant to the Arrangement

The Arrangement has not been structured to qualify a U.S. Holder of Aurora Common Shares for U.S. tax deferral on the exchange of Aurora Common Shares pursuant to the Arrangement. Subject to the tax consequences described below in "*Tax Consequences of the Arrangement if Aurora is Classified as a PFIC*", a U.S. Holder of Aurora Common Shares will generally recognize gain or loss in an amount equal to the difference, if any, between (i) the sum of the cash and fair market value as of the closing date of the Arrangement of Organigram Common Shares received by such holder in the Arrangement and (ii) such U.S. Holder's adjusted tax basis in the Aurora Common Shares surrendered by such U.S. Holder in the Arrangement. Subject to the rules relating to the receipt of foreign currency and the Passive Foreign Investment Company ("**PFIC**") rules discussed below, any gain or loss so recognized would generally be long-term capital gain or loss if the U.S. Holder had held the Aurora Common Shares for more than one year (or short-term capital gain or loss otherwise). A U.S. Holder's tax basis in any Organigram Common Shares received in the Arrangement will equal the fair market value of such Organigram Common Shares as of the date of the Arrangement. A U.S. Holder's holding period in the Organigram Common Shares received in the Arrangement, if any, will begin on the day after the exchange.

Long-term capital gains of non-corporate U.S. Holders (including individuals) currently are eligible for preferential U.S. federal income tax rates. However, the deductibility of capital losses is subject to limitations.

Tax Consequences of the Arrangement if Aurora is Classified as a PFIC

A U.S. Holder of Aurora Common Shares could be subject to special U.S. federal income tax rules in respect of the Arrangement if Aurora were classified as a PFIC for any taxable year during which such U.S. Holder has held Aurora Common Shares. In general, a non-U.S. corporation (as determined for U.S. federal income tax purposes) is properly classified as a PFIC in a taxable year in which (a) seventy-five percent (75%) or more of its gross income is passive income (as defined for U.S. federal income tax purposes) or (b) fifty percent (50%) or more of the value of its assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value, of such assets. For purposes of the PFIC rules, "gross income" generally includes all sales revenues less cost of goods sold, plus income from investments and from incidental or outside operations or sources, and "passive income" generally includes dividends, interest, certain royalties and rents, certain gains from the sale of stock and securities, and certain gains from commodities transactions. In determining whether or not it is a PFIC, a non-U.S. corporation will be treated as owning its proportionate share of the assets and earning its proportionate share of the income of each corporation in which it owns, directly or indirectly, at least a twenty-five percent (25%) interest (by value).

Aurora believes that it was not a PFIC during its taxable year ended March 31, 2026 and, based on its current operations and financial expectations, Aurora expects it would not be a PFIC for its current taxable year if such taxable year were to end on the closing date of the Arrangement. However, the determination of whether Aurora is or was a PFIC during any taxable year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. Accordingly, there can be no assurance that the IRS will not challenge any determination made by Aurora concerning its PFIC status or that Aurora was not, or will not be, a PFIC for any taxable year. U.S. Holders should consult their own tax advisors regarding the PFIC status of Aurora.

Subject to certain elections described below, if Aurora were a PFIC at any time during a U.S. Holder's holding period for Aurora Common Shares, any gain on the exchange of Aurora Common Shares recognized by a U.S. Holder pursuant to the Arrangement, as well as the amount of any "excess distribution" (defined below) received by the U.S. Holder, would be allocated ratably over the U.S. Holder's holding period for Aurora Common Shares. The amounts allocated to the taxable year of the sale or other disposition (or the taxable year of receipt, in the case of an excess distribution) and to any year prior to the year in which Aurora became a PFIC would be taxed as ordinary income. The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for individuals or corporations, as appropriate, for that taxable year, and an interest charge would be imposed. For the purposes of these rules, an excess distribution is the amount by which any distribution received by a U.S. Holder on Aurora Common

Shares exceeds 125% of the average of the annual distributions on Aurora Common Shares received during the preceding three years or the U.S. Holder's holding period, whichever is shorter.

The tax consequences described above relating to gain on the disposition of shares in a PFIC generally would not apply if a "qualified electing fund" election (a "**QEF election**") were available and a U.S. Holder had validly made such an election as of the beginning of such U.S. Holder's holding period for the Aurora Common Shares. In such event, such U.S. Holder generally would have been required to include in income on a current basis such U.S. Holder's pro rata share of Aurora's ordinary income and net capital gains in each taxable year in which Aurora was a PFIC. A QEF election would only have been available to a U.S. Holder, however, if Aurora provided such U.S. Holder with certain information.

The tax consequences relating to excess distributions of a PFIC described above generally will not apply if a "mark-to-market" election was available and a U.S. Holder validly made such an election as of the beginning of such U.S. Holder's holding period for a Share. If such election was made, gain on the disposition of a Share pursuant to the Arrangement will not be treated as an excess distribution to such U.S. Holder. Instead, such U.S. Holder generally would have been required to take into account the difference, if any, between the fair market value of, and its adjusted tax basis in, such Share at the end of each taxable year in which Aurora was a PFIC as ordinary income or, to the extent of any net mark-to-market gains previously included in income, ordinary loss, and to make corresponding adjustments to the tax basis in such Share. A mark-to-market election was available to a U.S. Holder with respect to a Share only if such share was considered to be "marketable stock". Generally, stock is considered to be marketable stock if it is "regularly traded" on a "qualified exchange" within the meaning of applicable Treasury Regulations. A class of stock generally is regularly traded during any calendar year during which such class of stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. A non-U.S. securities exchange constitutes a qualified exchange if it is regulated or supervised by a governmental authority of the country in which the securities exchange is located and meets certain trading, listing, financial disclosure and other requirements set forth in Treasury Regulations. The Aurora Common Shares are listed on the TSX and the Nasdaq (symbol: ACB). Each U.S. Holder is urged to consult its own tax advisor with respect to whether a mark-to-market election was validly made with respect to the Aurora Common Shares.

In addition, if Aurora were a PFIC, a U.S. Holder would generally be treated as owning a proportionate share of any PFIC in which Aurora directly or indirectly owns an interest (a "lower-tier PFIC") and could be subject to the PFIC rules with respect to certain distributions from, and dispositions of, such lower-tier PFIC. A mark-to-market election generally would not be available with respect to a lower-tier PFIC.

Each U.S. Holder should consult its own tax advisor regarding the application of the PFIC rules to Aurora, the possible effect of the PFIC rules to such U.S. Holder in connection with the Arrangement and the exchange of the U.S. Holder's Aurora Common Shares, as well as the availability of any election or exception that may be available to such U.S. Holder to mitigate adverse U.S. federal income tax consequences of holding shares in a PFIC. The remainder of this discussion assumes that Aurora has not been a PFIC at any time during a U.S. Holder's holding period for Aurora Common Shares and is not a PFIC during its current taxable year.

U.S. Holders Exercising Dissent Rights

A U.S. Holder that exercises Dissent Rights with respect to its Aurora Common Shares and is paid cash in exchange for all of such U.S. Holder's Aurora Common Shares generally would recognize gain or loss in an amount equal to the difference, if any, between (a) the U.S. dollar value of the Canadian currency received by such U.S. Holder in exchange for such U.S. Holder's Aurora Common Shares (other than amounts, if any, that are or are deemed to be interest for U.S. federal income tax purposes, which amounts would be taxed as ordinary income) and (b) the adjusted tax basis of such U.S. Holder in such Aurora Common Shares surrendered. Subject to the discussion of the PFIC rules under "*Tax Consequences of the Arrangement if Aurora is Classified as a PFIC*", above, such gain or loss generally would be capital gain or loss, which would be long-term capital gain or loss if the holding period with respect to such Aurora Common Shares is more than one year as of the date of the exchange. Certain non-corporate U.S. Holders are entitled to preferential tax rates with respect to net long-term capital gains. The ability of a U.S. Holder to offset capital losses against ordinary income is limited.

Information Reporting and Backup Withholding

A U.S. Holder may be subject to information reporting and backup withholding (currently at a rate of 24%) in respect of any cash received in exchange for Aurora Common Shares in the Arrangement. Backup withholding will not apply to a U.S. Holder if such U.S. Holder furnishes a properly completed and executed IRS Form W-9, or otherwise establishes an exemption.

Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against the taxpayer's U.S. federal income tax liability, and a taxpayer may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for a refund with the IRS and furnishing any required information.

U.S. Federal Income Tax Considerations of the Ownership and Disposition of Organigram Common Shares

Dividends and Other Distributions on Organigram Common Shares

Subject to the PFIC rules discussed below, the gross amount of distributions that may be made by Organigram with respect to Organigram Common Shares (including the amount of non-U.S. taxes withheld therefrom, if any) generally would be includible as dividend income in a U.S. Holder's gross income in the year received, to the extent such distributions are paid out of Organigram's current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent the amount of the distribution exceeds Organigram's current and accumulated earnings and profits, as determined under U.S. federal income tax principles, such excess amount would be treated first as a tax-free return of a U.S. Holder's tax basis in Organigram Common Shares, and then, to the extent such excess amount exceeds the U.S. Holder's tax basis in such Organigram Common Shares, as capital gain. Because Organigram does not maintain calculations of its earnings and profits under U.S. federal income tax principles, a U.S. Holder should expect that all-cash distributions would be reported as dividends for U.S. federal income tax purposes. Such dividends would not be eligible for the dividends-received deduction allowed to U.S. corporations with respect to dividends received from other U.S. corporations. Subject to applicable limitations, dividend distributions paid by Organigram to non-corporate U.S. Holders, including individuals, generally would be eligible for qualified dividend treatment and the preferential tax rates applicable to long-term capital gains, provided certain holding period and other conditions are satisfied, including that Organigram is not classified as a PFIC in the taxable year of distribution, the immediately preceding taxable year, or in any preceding taxable year in the U.S. Holder's holding period. The rules concerning corporate distributions of cash and property are complex, and each U.S. Holder should consult its own tax advisor regarding the application of such rules.

The amount of any distribution paid in foreign currency that will be included in the gross income of a U.S. Holder would be equal to the U.S. dollar value of such currency, translated at the spot rate of exchange on the date such distribution is actually or constructively received by the U.S. Holder, regardless of whether the payment is in fact converted into U.S. dollars at that time. A U.S. Holder generally should not recognize any foreign currency gain or loss in respect of such distribution if such foreign currency is converted into U.S. dollars on the date received by the U.S. Holder. Any further gain or loss on a subsequent conversion or other disposition of the currency for a different U.S. dollar amount would be U.S. source ordinary income or loss. The amount of any distribution of property other than cash would be the U.S. dollar fair market value of such property on the date of distribution.

Dividends on Organigram Common Shares generally would constitute foreign source income for foreign tax credit limitation purposes. Subject to certain complex conditions and limitations, non-U.S. taxes withheld, if any, on any distributions on Organigram Common Shares may be eligible for credit against a U.S. Holder's U.S. federal income tax liability. The U.S. federal income tax rules relating to foreign tax credits are complex, and U.S. Holders should consult their tax advisors regarding the availability of a foreign tax credit in their particular circumstances and the possibility of claiming an itemized deduction (in lieu of the foreign tax credit) for any foreign taxes paid or withheld.

Sale or Other Taxable Disposition of Organigram Common Shares

Subject to the PFIC rules discussed below, upon a sale or other taxable disposition of Organigram Common Shares, a U.S. Holder would recognize capital gain or loss for U.S. federal income tax purposes in an amount equal to the

difference between the amount realized and the U.S. Holder's adjusted tax basis in such Organigram Common Shares. Any such gain or loss generally would be treated as long-term capital gain or loss if the U.S. Holder's holding period in the Organigram Common Shares exceeds one year. Non-corporate U.S. Holders (including individuals) generally would be subject to U.S. federal income tax on long-term capital gain at preferential rates. The deductibility of capital losses is subject to significant limitations. Gain or loss, if any, recognized by a U.S. Holder on the sale or other taxable disposition of Organigram Common Shares generally would be treated as U.S. source gain or loss for U.S. foreign tax credit limitation purposes.

If Organigram Common Shares are treated as traded on an established securities market, and the consideration received upon the sale or other taxable disposition of Organigram Common Shares is paid in foreign currency, the amount realized by a cash basis U.S. Holder generally would be the U.S. dollar value of the payment received, translated at the spot rate of exchange on the settlement date of the sale or other taxable disposition. An accrual basis U.S. Holder who has made a special election (which must be applied consistently from year to year and cannot be changed without the consent of the IRS) would determine the U.S. dollar value of the amount realized in foreign currency by translating the amount received at the spot rate of exchange on the settlement date of the sale or other taxable disposition. If Organigram Common Shares are not treated as traded on an established securities market, or the relevant U.S. Holder is an accrual basis taxpayer that does not make the special election, such U.S. Holder would recognize foreign currency gain or loss to the extent attributable to any difference between the U.S. dollar amount realized on the date of sale or other taxable disposition (as determined above) and the U.S. dollar value of the currency received translated at the spot rate on the settlement date, and such gain or loss generally would constitute U.S. source ordinary income or loss.

A U.S. Holder's initial U.S. federal income tax basis in Organigram Common Shares received pursuant to the Arrangement generally would be the fair market value of such Organigram Common Shares as of the date of the Arrangement.

Passive Foreign Investment Company Considerations

Under the PFIC rules, if Organigram were considered a PFIC at any time that a U.S. Holder holds Organigram Common Shares, Organigram generally would continue to be treated as a PFIC with respect to such U.S. Holder.

Organigram has not made any determination of its PFIC status for the current year. Organigram also has not made a PFIC determination for any prior taxable year. Therefore, there is no assurance that Organigram has not been a PFIC in prior taxable years, nor that Organigram will not be a PFIC in its current taxable year or become a PFIC in any future taxable year. No opinion is expressed with respect to Organigram's PFIC status for prior, current or future taxable years.

If Organigram were considered a PFIC at any time that a U.S. Holder holds Organigram Common Shares, any gain recognized by a U.S. Holder on a sale or other disposition of Organigram Common Shares, as well as the amount of any "excess distribution" (defined below) received by the U.S. Holder, would be allocated ratably over the U.S. Holder's holding period for Organigram Common Shares. The amounts allocated to the taxable year of the sale or other disposition (or the taxable year of receipt, in the case of an excess distribution) and to any year prior to the year in which Organigram became a PFIC would be taxed as ordinary income. The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for individuals or corporations, as appropriate, for that taxable year, and an interest charge would be imposed. For the purposes of these rules, an excess distribution is the amount by which any distribution received by a U.S. Holder on Organigram Common Shares exceeds 125% of the average of the annual distributions on Organigram Common Shares received during the preceding three years or the U.S. Holder's holding period, whichever is shorter.

The tax consequences described above relating to gain on the disposition of shares in a PFIC generally would not apply if a QEF election is available and a U.S. Holder validly makes such an election as of the beginning of such U.S. Holder's holding period for the Organigram Common Shares. In such event, such U.S. Holder generally would be required to include in income on a current basis such U.S. Holder's pro rata share of Organigram's ordinary income and net capital gains in each taxable year in which Organigram is a PFIC. A QEF election would only be available to a U.S. Holder, however, if Organigram provided such U.S. Holder with certain information.

The tax consequences relating to excess distributions of a PFIC described above generally will not apply if a "mark-to-market" election is available and a U.S. Holder validly makes such an election as of the beginning of such U.S. Holder's holding period for an Organigram Common Share. If such election is made, gain on the disposition of an Organigram Common Share will not be treated as an excess distribution to such U.S. Holder. Instead, such U.S. Holder generally would be required to take into account the difference, if any, between the fair market value of, and its adjusted tax basis in, such Organigram Common Share at the end of each taxable year in which Organigram is a PFIC as ordinary income or, to the extent of any net mark-to-market gains previously included in income, ordinary loss, and to make corresponding adjustments to the tax basis in such Organigram Common Share. A mark-to-market election is available to a U.S. Holder with respect to a Organigram Common Share only if such share was considered to be "marketable stock". Generally, stock is considered to be marketable stock if it is "regularly traded" on a "qualified exchange" within the meaning of applicable Treasury Regulations. A class of stock generally is regularly traded during any calendar year during which such class of stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. A non-U.S. securities exchange constitutes a qualified exchange if it is regulated or supervised by a governmental authority of the country in which the securities exchange is located and meets certain trading, listing, financial disclosure and other requirements set forth in Treasury Regulations. The Organigram Common Shares are listed on the TSX and the Nasdaq (symbol: OGI). Each U.S. Holder is urged to consult its own tax advisor with respect to whether a mark-to-market election may be validly made with respect to the Organigram Common Shares.

In addition, if Organigram were a PFIC, a U.S. Holder would generally be treated as owning a proportionate share of any lower-tier PFIC and could be subject to the PFIC rules with respect to certain distributions from, and dispositions of, such lower-tier PFIC. A mark-to-market election generally would not be available with respect to a lower-tier PFIC.

U.S. Holders should consult their tax advisors about the potential application of the PFIC rules to the ownership of Organigram Common Shares.

Information Reporting and Backup Withholding

Information reporting requirements may apply to dividends received by U.S. Holders of Organigram Common Shares and the proceeds received on the disposition of Organigram Common Shares effected within the United States (and, in certain cases, outside the United States), in each case other than U.S. Holders that are exempt recipients (such as corporations). Backup withholding (currently at a rate of 24%) may apply to such amounts if the U.S. Holder fails to provide an accurate taxpayer identification number (generally on an IRS Form W-9 provided to the paying agent of the U.S. Holder's broker) or is otherwise subject to backup withholding. Any proceeds from the sale, exchange, redemption or other disposition of Organigram Common Shares may be subject to information reporting to the IRS and possible U.S. backup withholding. U.S. Holders should consult their tax advisors regarding the application of the U.S. information reporting and backup withholding rules.

Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against the taxpayer's U.S. federal income tax liability, and a taxpayer may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for a refund with the IRS and furnishing any required information.

ADDITIONAL TAX CONSIDERATIONS

This Joint Information Circular discusses certain Canadian and United States federal income tax considerations applicable to certain Aurora Shareholders. Tax considerations applicable to Aurora Shareholders who are resident in jurisdictions other than Canada or the United States are not discussed and such Aurora Shareholders should consult their own tax advisors with respect to the tax implications of the Arrangement, including any associated filing requirements, in such jurisdictions and with respect to the tax implications in such jurisdictions of owning Organigram Common Shares after the Arrangement. All Aurora Shareholders should consult their own tax advisors regarding the provincial, state, local and territorial tax considerations relating to the Arrangement and of holding Organigram Common Shares.

This Joint Information Circular does not discuss any tax considerations applicable to holders of Aurora Incentive Awards. Such persons should consult their own tax advisors regarding the consequences of the Arrangement to them in their particular circumstances.

PRO FORMA INFORMATION CONCERNING ORGANIGRAM AFTER GIVING EFFECT TO THE ARRANGEMENT

Notice to Reader

The following pro forma information about Organigram following completion of the Arrangement should be read in conjunction with the documents incorporated by reference in this Joint Information Circular and the information concerning Organigram and Aurora, as applicable, appearing elsewhere in this Joint Information Circular. See Appendix "J" – "*Information Concerning Organigram Global Inc.*" and Appendix "I" – "*Information Concerning Aurora Cannabis Inc.*".

Information included in this section under the headings "*Selected Unaudited Pro Forma Consolidated Financial Information*" and "*Pro Forma Consolidated Capitalization of Organigram*" pertaining to Organigram and Aurora, as applicable, has been furnished by Organigram and Aurora, respectively. With respect to such information, the Organigram Board has relied exclusively upon Aurora, without independent verification by Organigram, and the Aurora Board has relied exclusively upon Organigram, without independent verification by Aurora. For further information regarding Organigram or Aurora, please refer to their respective filings available under their respective profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

See "*Forward-Looking Statements and Information*", "*Conventions*" and Appendix "H" – "*Pro Forma Condensed Consolidated Financial* Statements of Organigram Global Inc.".

General

The Arrangement will result in the acquisition by Organigram of all of the issued and outstanding Aurora Common Shares, following which Aurora will become a wholly-owned subsidiary of Organigram. Pursuant to the Arrangement, Aurora Shareholders will receive, at their election and subject to proration, the Cash Alternative, the Share Alternative or the Combination Alternative for each Aurora Common Share held. Current Aurora Shareholders are expected to hold approximately 37% of the economic interest and 41% of the voting rights in Organigram, on a fully diluted basis, immediately after completion of the Arrangement and the BAT Private Placement.

Description of Business

Following the Arrangement, Organigram will carry on the business and operations of Organigram and, through Aurora as its subsidiary, Aurora on a combined basis. For a detailed description of the businesses and operations of Organigram and Aurora, including the historical development of their respective businesses and operations, see the Organigram AIF and the Aurora AIF, respectively, each of which is incorporated by reference in this Joint Information Circular.

Organigram and Aurora expect that the Arrangement will create a global cannabis leader with leading positions in Canada, Europe and Australia, supported by Organigram's strategic shareholder, BAT. See "*The Arrangement – Reasons for and Benefits of the Arrangement*".

Following completion of the Arrangement, Organigram's head office will continue to be located at 1400-145 King Street West, Toronto, Ontario M5H 1J8 and its registered office will continue to be located at 35 English Drive, Moncton, New Brunswick.

Directors and Executive Officers of Organigram

Directors

As at the date of this Joint Information Circular, the Organigram Board consists of 11 directors, including three nominees of BAT. Pursuant to the Amended and Restated IRA, BAT has the right to designate up to 30% of the nominees to the Organigram Board for so long as it maintains certain share ownership thresholds. As at the date of this Joint Information Circular, no determination has been made as to whether any changes will be made to the composition of the Organigram Board in connection with the Arrangement. If it is determined prior to the Effective Date that any such changes will be made, Organigram will announce them by news release. For additional information about the current members of the Organigram Board, see the Organigram AIF and Organigram AGM Circular, each of which is incorporated by reference in this Joint Information Circular. The members of the Organigram Board will hold office until the next annual meeting of Organigram Shareholders, or until their respective successors have been duly elected or appointed.

Executive Officers

The current executive officers of Organigram are James Yamanaka, Chief Executive Officer; Greg Guyatt, Chief Financial Officer; Finn Age Hänsel, President, Rest of World & Chief Strategy Officer; Adrian Frenzel, Global Chief Operating Officer; Timothy Emberg, President of Organigram Canada; Helen Martin, Chief Legal Officer and Corporate Secretary; Valerie Rother, Chief People Officer. As at the date of this Joint Information Circular, no determination has been made as to whether any changes will be made to Organigram's executive officer team in connection with the Arrangement, including whether any executive officers of Aurora will join the management team of Organigram. If it is determined prior to the Effective Date that any such changes will be made, Organigram will announce them by news release. For additional information about the current executive officer team of Organigram, see the Organigram AIF and Organigram AGM Circular, each of which is incorporated by reference in this Joint Information Circular.

Selected Unaudited Pro Forma Consolidated Financial Information

The following is a summary of selected unaudited pro forma consolidated financial information of Organigram, both before and after giving effect to the completion of the Arrangement, the BAT Private Placement and the Organigram Financing, as at and for the nine-month period ended June 30, 2026 and for the year ended September 30, 2025. The pro forma adjustments are based upon available information and certain assumptions that Organigram believes are reasonable under the circumstances. The unaudited pro forma consolidated financial information set forth below and the unaudited pro forma consolidated financial statements of Organigram attached to this Joint Information Circular as Appendix "H" – "*Pro Forma Condensed Consolidated Financial Statements of Organigram Global* Inc." (the "**Organigram Pro Forma Financial Statements**") are presented for illustrative purposes only and are not necessarily indicative of either (a) the financial position or the results of operations that would have occurred as at such dates or for such periods had the Arrangement been effective as of June 30, 2026 (in the case of the pro forma statement of financial position) or October 1, 2025 and October 1, 2024 (in the case of the pro forma statements of operations for the nine months ended June 30, 2026 and the year ended September 30, 2025, respectively), as applicable, or (b) the financial position or results of operations for Organigram in future years if the Arrangement is completed. The actual adjustments will differ from those reflected in such unaudited pro forma consolidated financial statements and such differences may be material.

The Aurora financial information included in the Organigram Pro Forma Financial Statements has been derived from, among other things, the Aurora Interim Financial Statements, the unaudited condensed interim financial statements of Aurora for the three months ended June 30, 2026 and the six months ended September 30, 2025 and September 30, 2024, and the Aurora Annual Financial Statements, adjusted as necessary to conform to the periods presented for Organigram.

Unaudited Pro Forma Condensed Consolidated Financial Information as at and for the Nine Months Ended June 30, 2026

	Organigram Global Inc. for the nine months ended June 30, 2026	Aurora Cannabis Inc. for the nine months ended June 30, 2026	Pro forma adjustments	Pro forma combined	Note
REVENUE					
Gross revenue	$ 335,619	$ 247,939	$ -	$ 583,558	
Excise taxes	(106,505)	(12,677)	-	(119,182)	
Net revenue	**$ 229,114**	**$ 235,262**	**$ -**	**$ 464,376**	
Cost of sales	151,801	122,744	-	274,545	
Gross margin before fair value adjustments	**$ 77,313**	**$ 112,518**	**$ -**	**$ 189,831**	
Realized fair value on inventories and biological assets sold	(53,155)	(100,480)	-	(153,635)	
Unrealized gain on changes in fair value of biological assets	56,986	95,562	-	152,548	
Gross margin	**$ 81,144**	**$ 107,600**	**$ -**	**$ 188,744**	
OPERATING EXPENSES					
General and administrative	$ 50,488	$ 78,003	$ 2,605	$ 131,096	*3 (e)*
Sales and marketing	29,785	46,473	-	76,258	
Business development costs	-	2,882	-	2,882	
Research and development	6,324	3,230	-	9,554	
Depreciation and amortization	-	2,605	(2,605)	-	*3 (e)*
Share-based compensation	2,428	831	(500)	10,766	*3 (c)*
			8,007		*3 (c)*
Impairment of property, plant and equipment	-	-	2,250	2,250	*3 (e)*
Impairment of intangible assets and goodwill	5,800	-	-	5,800	
Total operating expenses	**$ 94,825**	**$ 134,024**	**$ 9,757**	**$ 238,606**	
Loss from operations	**$ (13,681)**	**$ (26,424)**	**$ (9,757)**	**$ (49,862)**	
OTHER (INCOME) EXPENSE					
Interest and investment (income) loss, net	$ (889)	$ (3,172)	$ -	$ (4,061)	
Finance and other costs	1,025	1,368	6,417	8,810	*3 (a)*
Acquisition and transaction costs	11,129	-	234	23,185	*3 (b)*
			11,822		*3 (c)*
Change in fair value of contingent consideration	(8,924)	-	-	(8,924)	
Change in fair value of derivative liabilities, preferred shares and other financial assets	(139,838)	-	-	(139,838)	
Foreign exchange gain	-	(553)	-	(553)	
Other non-operating (income) expense, net	820	(997)	-	(177)	
Impairment of property, plant and equipment	-	2,250	(2,250)	-	*3 (e)*
Impairment of intangible assets and goodwill	-	-	-	-	
Total other (income) expense	**$ (136,677)**	**$ (1,104)**	**$ 16,223**	**$ (121,558)**	
Income (loss) before income taxes	**$ 122,996**	**$ (25,320)**	**$ (25,980)**	**$ 71,696**	
INCOME TAX (RECOVERY) EXPENSE					
Current	$ (34)	$ 2,309	$ -	$ 2,275	*3 (d)*
Deferred, net	(1,556)	(2,345)	-	(3,901)	*3 (d)*
Total income tax (recovery) expense	**$ (1,590)**	**$ (36)**	**$ -**	**$ (1,626)**	
Net income (loss) from continuing operations	**$ 124,586**	**$ (25,284)**	**$ (25,980)**	**$ 73,322**	
Net loss from discontinued operations, net of tax	-	(41,799)	-	(41,799)	
NET INCOME (LOSS)	**$ 124,586**	**$ (67,083)**	**$ (25,980)**	**$ 31,523**	

	Organigram Global Inc. for the nine months ended June 30, 2026	Aurora Cannabis Inc. for the nine months ended June 30, 2026	Pro forma adjustments	Pro forma combined	Note
OTHER COMPREHENSIVE INCOME (LOSS)					
Change in fair value of investments at fair value through other comprehensive income (loss)	$ (1,238)	$ -	$ -	$ (1,238)	
Foreign currency transaction (loss) gain	(663)	2,273	-	1,610	
Cash flow hedge reserve	(198)	-	-	(198)	
Total other comprehensive income (loss)	**$ (2,099)**	**$ 2,273**	**$ -**	**$ 174**	
Comprehensive loss from continuing operations	$ 122,487	$ (23,011)	$ (25,980)	$ 73,496	
Comprehensive loss from discontinued operations	-	(41,799)	-	(41,799)	
COMPREHENSIVE INCOME (LOSS)	**$ 122,487**	**$ (64,810)**	**$ (25,980)**	**$ 31,697**	
Net income (loss) from continuing operations attributable to:					
Common shareholders	$ 124,586	$ (25,284)	$ (25,980)	$ 73,322	
Non-controlling interests	-	-	-	-	
	$ 124,586	**$ (25,284)**	**$ (25,980)**	**$ 73,322**	
Net income (loss) from discontinued operations attributable to:					
Common shareholders	$ -	$ (33,826)	$ -	$ (33,826)	
Non-controlling interests	-	(7,973)	-	(7,973)	
	$ -	**$ (41,799)**	**$ -**	**$ (41,799)**	
Comprehensive income (loss) attributable to:					
Common shareholders	$ 122,487	$ (56,837)	$ (25,980)	$ 39,670	
Non-controlling interests	-	(7,973)	-	(7,973)	
	$ 122,487	**$ (64,810)**	**$ (25,980)**	**$ 31,697**	
Net income (loss) per common share, basic					
Continuing operations				$ 0.17	
Discontinued operations				$ (0.08)	
Total operations				**$ 0.09**	
Net income (loss) per common share, diluted					
Continuing operations				$ 0.15	
Discontinued operations				$ (0.07)	
Total operations				**$ 0.08**	

Unaudited Pro Forma Condensed Consolidated Financial Information for the Year Ended September 30, 2025

	Organigram Global Inc. for the year ended September 30, 2025	Aurora Cannabis Inc. for the twelve months ended September 30, 2025	Pro forma adjustments	Pro forma combined	Note
REVENUE					
Gross revenue	$ 403,024	$ 335,845	$ -	$ 738,869	
Excise taxes	(143,841)	(26,891)	-	(170,732)	
Net revenue	**$ 259,183**	**$ 308,954**	**$ -**	**$ 568,137**	
Cost of sales	$ 174,850	$ 151,932	$ -	$ 326,782	
Gross margin before fair value adjustments	**$ 84,333**	**$ 157,022**	**$ -**	**$ 241,355**	
Realized fair value on inventories and biological assets sold and other inventory charges	$ (67,125)	$ (137,851)	$ -	$ (204,976)	
Unrealized gain on changes in fair value of biological assets	73,008	142,464	-	215,472	
Gross margin	**$ 90,216**	**$ 161,635**	**$ -**	**$ 251,851**	
OPERATING EXPENSES					
General and administrative	$ 59,499	$ 101,348	$ 3,165	$ 164,012	*3 (e)*
Sales and marketing	31,097	57,226	-	88,323	
Business development costs	-	2,125	-	2,125	
Research and development	10,945	3,447	-	14,392	
Depreciation and amortization	-	3,165	(3,165)	-	*3 (e)*
Share-based compensation	3,975	12,598	(5,900)	18,680	*3 (c)*
			8,007		*3 (c)*
Impairment of property, plant and equipment	-	-	1,092	1,092	*3 (e)*
Impairment of intangible assets and goodwill	-	-	13,186	13,186	*3 (e)*
Total operating expenses	**$ 105,516**	**$ 179,909**	**$ 16,385**	**$ 301,810**	
Loss from operations	**$ (15,300)**	**$ (18,274)**	**$ (16,385)**	**$ (49,959)**	
OTHER (INCOME) EXPENSE					
Interest and investment (income) loss, net	$ (1,747)	$ (8,454)	$ -	$ (10,201)	
Finance and other costs	597	2,661	8,356	11,614	*3 (a)*
Acquisition, transaction and business development costs	6,580	-	234	18,636	*3 (b)*
			11,822		*3 (c)*
Loss (gain) on disposal of property, plant and equipment and intangible assets	9	-	-	9	
Change in fair value of contingent consideration	(9,743)	-	-	(9,743)	
Change in fair value of derivative liabilities, preferred shares and other financial assets	27,505	-	-	27,505	
Foreign exchange gain	-	(11,178)	-	(11,178)	
Share issuance costs allocated to derivative liabilities and preferred shares	170	-	-	170	
Other non-operating (income) expense	(142)	302	-	160	
Impairment of property, plant and equipment	-	1,092	(1,092)	-	*3 (e)*
Impairment of intangible assets and goodwill	-	13,186	(13,186)	-	*3 (e)*
Total other (income) expense	**$ 23,229**	**$ (2,391)**	**$ 6,134**	**$ 26,972**	
Loss before income taxes	**$ (38,529)**	**$ (15,883)**	**$ (22,519)**	**$ (76,931)**	
INCOME TAX (RECOVERY) EXPENSE					
Current	$ -	$ 5,810	$ -	$ 5,810	*3 (d)*
Deferred, net	(13,770)	(370)	-	(14,140)	*3 (d)*
Total income tax (recovery) expense	**$ (13,770)**	**$ 5,440**	**$ -**	**$ (8,330)**	
Net loss from continuing operations	**$ (24,759)**	**$ (21,323)**	**$ (22,519)**	**$ (68,601)**	
Net loss from discontinued operations, net of tax	-	(41,059)	-	(41,059)	
Net loss	**$ (24,759)**	**$ (62,382)**	**$ (22,519)**	**$ (109,660)**	

	Organigram Global Inc. for the year ended September 30, 2025	Aurora Cannabis Inc. for the twelve months ended September 30, 2025	Pro forma adjustments	Pro forma combined	Note
OTHER COMPREHENSIVE INCOME (LOSS)					
Change in fair value of investments at fair value through other comprehensive income (loss)	$ 666	$ -	$ -	$ 666	
Foreign currency transaction (loss)	-	(1,701)	-	(1,701)	
Cash flow hedge reserve	-	-	-	-	
Total other comprehensive income (loss)	**$ 666**	**$ (1,701)**	**$ -**	**$ (1,035)**	
Comprehensive loss from continuing operations	$ (24,093)	$ (23,024)	$ (22,519)	$ (69,636)	
Comprehensive loss from discontinued operations	-	(41,059)	-	(41,059)	
COMPREHENSIVE LOSS	**$ (24,093)**	**$ (64,083)**	**$ (22,519)**	**$ (110,695)**	
Net loss from continuing operations attributable to:					
Common shareholders	$ (24,759)	$ (21,323)	$ (22,519)	$ (68,601)	
Non-controlling interests	-	-	-	-	
	$ (24,759)	**$ (21,323)**	**$ (22,519)**	**$ (68,601)**	
Net loss from discontinued operations attributable to:					
Common shareholders	$ -	$ (36,447)	$ -	$ (36,447)	
Non-controlling interests	-	(4,612)	-	(4,612)	
	$ -	**$ (41,059)**	**$ -**	**$ (41,059)**	
Comprehensive loss attributable to:					
Common shareholders	$ (24,093)	$ (59,471)	$ (22,519)	$ (106,083)	
Non-controlling interests	-	(4,612)	-	(4,612)	
	$ (24,093)	**$ (64,083)**	**$ (22,519)**	**$ (110,695)**	
Net loss per common share, basic					
Continuing operations				$ (0.17)	
Discontinued operations				$ (0.08)	
Total operations				**$ (0.25)**	
Net loss per common share, diluted					
Continuing operations				$ (0.17)	
Discontinued operations				$ (0.08)	
Total operations				**$ (0.25)**	

See Appendix "H" – "*Pro Forma Condensed Consolidated Financial Statements of Organigram Global* Inc.".

Pro Forma Consolidated Capitalization of Organigram

The following table summarizes Organigram's consolidated capitalization as at June 30, 2026, both before and after giving effect to the completion of the Arrangement and the BAT Private Placement, reflecting Aurora's consolidated capitalization as at June 30, 2026. For detailed information on the share and loan capital of Organigram and Aurora, see the Organigram Interim Financial Statements and Aurora Interim Financial Statements, each of which is incorporated by reference herein. See Appendix "J" – "*Information Concerning Organigram Global Inc.*" and Appendix "I" – "*Information Concerning Aurora Cannabis Inc.*".

The information below has been derived from, and should be read in conjunction with, the more detailed Organigram Pro Forma Financial Statements. Additionally, the Organigram Pro Forma Financial Statements are based on, and should be read in conjunction with, the Organigram Interim Financial Statements, Organigram Annual Financial

Statements, Aurora Interim Financial Statements and Aurora Annual Financial Statements, each of which is incorporated by reference herein.

	Organigram Global Inc. as at June 30, 2026	Aurora Cannabis Inc. as at June 30, 2026	Pro forma adjustments	Pro forma combined	Note
ASSETS					
Current assets					
Cash and cash equivalents	$ 10,851	$ 69,307	$ 131,609	$ 127,084	*3 (a)*
			186,912		*3 (b)*
			(259,773)		*3 (c)*
			(11,822)		*3 (c)*
Restricted cash	-	49,086	-	49,086	
Short-term investments	816	30,722	-	31,538	
Accounts and other receivables	88,605	41,091	-	129,696	
Biological assets	17,292	24,000	-	41,292	
Inventories	147,764	163,543	-	311,307	
Prepaid expenses, deposits and other current assets	14,758	12,564	-	27,322	
Assets held for sale	-	3,136	-	3,136	
Total current assets	**$ 280,086**	**$ 393,449**	**$ 46,926**	**$ 720,461**	
Non-current assets					
Property, plant and equipment	$ 121,148	$ 146,752	$ -	$ 267,900	
Intangible assets	203,506	32,731	(32,731)	203,506	*3 (c)*
Goodwill	194,717	27,342	(27,342)	287,433	*3 (c)*
			92,716		*3 (c)*
Long-term investments and other financial assets	19,831	12,533	-	32,364	
Deferred charges, deposits and other long-term assets	974	2,267	-	3,241	
Lease receivable	-	3,246	-	3,246	
Deferred tax assets	-	2,557	-	2,557	
Total non-current assets	**$ 540,176**	**$ 227,428**	**$ 32,643**	**$ 800,247**	
TOTAL ASSETS	**$ 820,262**	**$ 620,877**	**$ 79,569**	**$ 1,520,708**	
LIABILITIES					
Current liabilities					
Accounts payable and accrued liabilities	$ 99,933	$ 56,830	$ 26,038	$ 182,801	*3 (c)*
Income taxes payable	-	7,439	-	7,439	
Deferred revenue	-	799	(799)	-	*3 (e)*
Current portion of loans and borrowings	3,365	-	27,000	30,365	*3 (a)*
Lease liabilities – current portion	-	5,875	(5,875)	-	*3 (e)*
Derivative liabilities – current	1,637	-	-	1,637	
Provisions and other current liabilities	2,346	2,486	799	11,506	*3 (e)*
			5,875		*3 (e)*
Total current liabilities	**$ 107,281**	**$ 73,429**	**$ 53,038**	**$ 233,748**	
Non-current liabilities					
Loans and borrowings	17,608	-	$ 104,609	$ 122,217	*3 (a)*
Lease liabilities	-	16,809	(16,809)	-	*3 (e)*
Derivative liabilities	198	2,892	(1,300)	1,790	*3 (c)*
Preferred shares	71,057	-	73,276	144,333	*3 (b), 3 (f)*
Deferred income taxes	49,619	47	-	49,666	
Other long-term liabilities	89,037	569	16,809	106,415	*3 (e)*
Total non-current liabilities	**$ 227,519**	**$ 20,317**	**$ 176,585**	**$ 424,421**	
TOTAL LIABILITIES	**$ 334,800**	**$ 93,746**	**$ 229,623**	**$ 658,169**	
SHAREHOLDERS' EQUITY					
Share capital	$ 933,648	$ 7,027,979	$ (7,027,979)	$ 1,313,625	*3 (c)*
			266,107		*3 (c)*
			113,870		*3 (b)*
Equity reserves / contributed surplus	37,451	158,807	(158,807)	46,607	*3 (c)*
			9,156		*3 (c)*
Accumulated other comprehensive income (loss)	(1,496)	(213,714)	213,714	(1,496)	*3 (c)*
Accumulated deficit	(484,141)	(6,445,941)	6,445,941	(496,197)	*3 (c)*
			(234)		*3 (b)*
			(11,822)		*3 (c)*
Total shareholders' equity	**$ 485,462**	**$ 527,131**	**$ (150,054)**	**$ 862,539**	
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	**$ 820,262**	**$ 620,877**	**$ 79,569**	**$ 1,520,708**	

Description of Share Capital

The authorized share capital of Organigram will not be altered by the Arrangement. Following the completion of the Arrangement, the authorized capital of Organigram will continue to consist of an unlimited number of Organigram Common Shares and an unlimited number of preferred shares, issuable in series, of which the Organigram Preferred Shares are the only series designated.

Upon completion of the Arrangement and the BAT Private Placement, assuming there are no Dissenting Aurora Shareholders and that no Aurora Common Shares or Organigram Common Shares are issued between the date of the Arrangement Agreement and the Effective Date (other than pursuant to the BAT Private Placement), it is expected that there will be approximately 427,085,757 Organigram Common Shares issued and outstanding. Current Aurora Shareholders are expected to hold approximately 37% of the economic interest and 41% of the voting rights in Organigram, on a fully diluted basis, after completion of the Arrangement and the BAT Private Placement. The

Organigram Common Shares will continue to be listed and posted for trading on the TSX and Nasdaq under the symbol "OGI".

The following is a summary of the rights, privileges, restrictions and conditions attaching to the Organigram Common Shares and the Organigram Preferred Shares. For further information, see "*Capital Structure*" in the Organigram AIF, which is incorporated by reference in this Joint Information Circular.

Organigram Common Shares. Holders of Organigram Common Shares are entitled to receive notice of and to attend all meetings of Organigram Shareholders and to one vote at each such meeting for each Organigram Common Share held. The holders of Organigram Common Shares are, at the discretion of the Organigram Board and subject to applicable legal restrictions, entitled to receive any dividends declared by the Organigram Board on the Organigram Common Shares, and are entitled to share in the remaining property of Organigram upon liquidation, dissolution or winding-up, pari passu with the holders of the Organigram Preferred Shares on an as-converted basis.

Organigram Preferred Shares. The Organigram Preferred Shares, all of which are held by BAT, are non-voting except as required by law. They are convertible into Organigram Common Shares, initially on a one-for-one basis, with the conversion rate increasing at a rate of 7.5% per annum until such time as the holders would beneficially own 49.0% of the outstanding Organigram Common Shares. Holders participate pari passu with holders of Organigram Common Shares, on an as-converted basis, on liquidation, dissolution or winding-up, and dividends may not be declared on the Organigram Preferred Shares unless a corresponding dividend is declared on the Organigram Common Shares. The Organigram Preferred Shares are not listed on any stock exchange and, other than to affiliates, are not transferable. As of November 19, 2026, there were 49,204,021 Organigram Preferred Shares outstanding.

BAT Investor Rights. Pursuant to the Amended and Restated IRA, BAT has the right to designate up to 30% of the nominees to the Organigram Board, approval rights over certain fundamental actions of Organigram (including adverse amendments to its constating documents, the issuance of securities ranking senior to the Organigram Common Shares, share splits and consolidations, and capital expenditures and indebtedness above specified thresholds), and pre-emptive and top-up rights, in each case for so long as it maintains certain share ownership thresholds. BAT is also entitled to reasonable advance notice of any proposed dividend or other distribution.

Dividends

Dividends on the Organigram Common Shares are payable if, as and when determined by the Organigram Board. The amount and frequency of dividends declared and payable is at the discretion of the Organigram Board, which considers earnings, cash flow, capital requirements, the financial condition of Organigram and other relevant factors when making its dividend determinations.

Organigram has not declared or paid any dividends on the Organigram Common Shares and does not currently anticipate paying dividends in the foreseeable future.

Principal Holders of Organigram Common Shares

To the knowledge of the directors and executive officers of Organigram and Aurora, as at the date hereof, other than BAT, no person or company will beneficially own, or exercise control or direction over, directly or indirectly, Organigram Common Shares carrying 10% or more of the voting rights attached to the Organigram Common Shares following completion of the Arrangement. Following completion of the Arrangement and the BAT Private Placement, BAT is expected to beneficially own approximately 128,122,248 Organigram Common Shares, representing approximately 30% of the then outstanding Organigram Common Shares, and 104,299,117 Organigram Preferred Shares, representing an aggregate economic interest in Organigram of approximately 44%. The number of Organigram Common Shares that BAT will be issued pursuant to the BAT Private Placement will be limited such that its holdings will not exceed 30% of the then outstanding Organigram Common Shares; accordingly, the exact number of Organigram Common Shares to be issued to BAT is contingent upon the number of Organigram Common Shares outstanding following the completion of the Arrangement and therefore the foregoing numbers are estimates only.

Material Contracts

Except as otherwise disclosed in this Joint Information Circular or in the documents incorporated by reference herein with respect to Organigram and Aurora, there are no contracts that are expected to be material to Organigram or any of its Subsidiaries following completion of the Arrangement, other than contracts entered into by Organigram and Aurora in the ordinary course of business. For a description of the material contracts of Organigram and Aurora, see the Organigram AIF and the Aurora AIF, respectively, which are incorporated by reference in this Joint Information Circular. See Appendix "J" – "*Information Concerning Organigram Global Inc.*" and Appendix "I" – "*Information Concerning Aurora Cannabis Inc.*".

Auditors, Registrar and Transfer Agent

Following completion of the Arrangement, the auditors of Organigram will continue to be PricewaterhouseCoopers LLP.

Following completion of the Arrangement, the registrar and transfer agent for the Organigram Common Shares will continue to be TSX Trust Company, at its offices in Vancouver, British Columbia and Toronto, Ontario, Canada. The co-transfer agent for the Organigram Common Shares in the U.S. will continue to be VStock Transfer, LLC.

Risk Factors

An investment in the Organigram Common Shares is subject to certain risks. In addition to the risks set out in the documents incorporated by reference in this Joint Information Circular with respect to the businesses and operations of each of Organigram and Aurora, including the Organigram AIF and Aurora AIF, respectively, the proposed acquisition by Organigram of Aurora in connection with the Arrangement is subject to certain risks. See "*Risk Factors*". For additional information with respect to the risks of Organigram's business, see Appendix "J" – "*Information Concerning Organigram Global Inc.*", and for additional information with respect to the risks of Aurora's business, see Appendix "I" – "*Information Concerning Aurora Cannabis Inc.*". Aurora Shareholders and Organigram Shareholders should carefully consider such risk factors in evaluating whether to approve the Arrangement Resolution and the Organigram Share Issuance Resolution, as applicable.

TIMING

If the Meetings are held as scheduled and are not adjourned or postponed, and the necessary conditions for completion of the Arrangement are otherwise satisfied or waived, Aurora is expected to apply for the Final Order approving the Arrangement on or about December 30, 2026. If the Final Order is obtained in form and substance satisfactory to Aurora and Organigram and all other conditions set forth in the Arrangement Agreement are otherwise satisfied or waived, including with respect to Required Regulatory Approvals, Aurora and Organigram expect the Effective Date will occur in January 2027, and in any event not prior to the Inside Date of January 6, 2027. It is not possible, however, to state with certainty when the Effective Date will occur and it is possible that factors outside the control of Aurora and/or Organigram could result in the Arrangement being completed at a later date, or not at all. Subject to certain limitations, each Party may terminate the Arrangement Agreement if the Arrangement is not consummated by the Outside Date, being May 2, 2027, or such later date as may be agreed to in writing by the Parties, subject to the right of either Party to extend the Outside Date on no more than two occasions by 90 days each (not exceeding 180 days in the aggregate), by giving written notice to the other Party, if the Effective Date has not occurred as a result of the failure to obtain one or more Regulatory Approvals.

The Arrangement will become effective at the Effective Time specified in the Plan of Arrangement following the filing with the Registrar of the records and information required under section 292 of the BCBCA, including a copy of the entered Final Order.

The Effective Date could be delayed for a number of reasons, including an objection before the Court at the hearing of the application for the Final Order or the failure to receive any Required Regulatory Approvals in a timely manner.

RISK FACTORS

Aurora Shareholders voting in favour of the Arrangement Resolution and Organigram Shareholders voting in favour of the Organigram Share Issuance Resolution will be choosing to combine the businesses of Aurora and Organigram and, in the case of Aurora Shareholders, to acquire Organigram Common Shares. The completion of the Arrangement and the acquisition of Organigram Common Shares involves risks. In addition to the risk factors present in each of Aurora's and Organigram's businesses, described under "*Risk Factors*" in the Aurora AIF and the Organigram AIF, each of which is incorporated by reference herein, Aurora Shareholders and Organigram Shareholders should carefully consider the following risk factors in evaluating whether to approve the Arrangement Resolution and the Organigram Share Issuance Resolution, as applicable. Readers are cautioned that such risk factors are not exhaustive. These risk factors should be considered in conjunction with the other information included in this Joint Information Circular, including the documents incorporated by reference herein and the documents filed by Aurora and Organigram pursuant to applicable Laws from time to time.

Possible Failure to Realize Anticipated Benefits of the Arrangement

Aurora and Organigram are proposing to complete the Arrangement to create the opportunity to realize certain anticipated benefits including, among other things, those set forth in this Joint Information Circular under "*The Arrangement – Reasons for and Benefits of the Arrangement*", "*The Arrangement – Reasons for and Benefits of the Arrangement – Additional Reasons and Benefits for Aurora Shareholders*", "*The Arrangement – Reasons for and Benefits of the Arrangement – Additional Reasons and Benefits for Organigram Shareholders*" and "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement*". The Arrangement is subject to normal commercial risks that such transaction may not be completed on the terms negotiated or at all. Aurora and Organigram are proposing to complete the Arrangement to create a global cannabis leader with leading positions in Canada, Europe and Australia and realize certain benefits including, among other things, potential synergies, cost savings, innovation and enhanced capital markets profile. Achieving the benefits of the Arrangement depends in part on successfully consolidating functions and integrating operations, procedures and personnel in a timely and efficient manner, as well as Organigram's ability to realize the anticipated growth opportunities and synergies from integrating the respective businesses of Aurora and Organigram following completion of the Arrangement.

Achieving the benefits of the Arrangement also depends on the ability of Organigram to realize the anticipated capital and operating synergies and to maximize the potential of its improved growth opportunities and capital funding opportunities as a result of combining the businesses and operations of Aurora and Organigram.

The integration of the Aurora assets will require the dedication of substantial management effort, time and resources which may divert management's focus and resources from other strategic opportunities and operational matters. The integration process may result in the loss of key employees and the disruption of ongoing business and employee relationships that may adversely affect Organigram's ability to achieve the anticipated benefits of the Arrangement. A variety of factors, including the risk factors set forth in this Joint Information Circular and the documents incorporated by reference herein, may adversely affect the ability of Organigram to achieve the anticipated benefits of the Arrangement.

Satisfaction of Conditions Precedent

The completion of the Arrangement is subject to a number of conditions precedent, certain of which are outside the control of Aurora and Organigram. Among other things, completion of the Arrangement is subject to the approval of the Court, the approval of the Arrangement Resolution by the Aurora Shareholders, the approval of the Organigram Share Issuance Resolution by Organigram Shareholders and obtaining the Required Regulatory Approvals. Although completion of the Arrangement is not conditional on the completion of the BAT Private Placement, Organigram expects to fund a portion of the cash Consideration with the proceeds of the Organigram Financing, and any failure by BAT or the lenders to fund could adversely affect Organigram's ability to satisfy its obligations under the Arrangement Agreement. Aurora and Aurora Shareholders will have no rights or claims against ATB Financial, BAT or any other financing source, and Organigram's ability to enforce BAT's funding obligation is subject to conditions. A substantial delay in obtaining the Regulatory Approvals, including the Required Regulatory Approvals, or the imposition of unfavourable terms or conditions to the Regulatory Approvals, including the Required Regulatory Approvals, could delay the Effective Date and may adversely affect the business, financial condition and/or results of

Aurora, Organigram, or Organigram following completion of the Arrangement. There is no certainty, nor can Aurora or Organigram provide any assurance, that these conditions will be satisfied or, if satisfied, when they will be satisfied. If for any reason the Arrangement is not completed, or is materially delayed, the market price of the Aurora Common Shares and/or the Organigram Common Shares may be adversely affected. In addition, if the Arrangement is not completed, Aurora and/or Organigram could be subject to litigation related to the failure to complete the Arrangement or to require Aurora or Organigram to perform their respective obligations under the Arrangement Agreement.

In addition, the ATB Credit Facilities are conditional on, among other things, the receipt of cash proceeds under the BAT Equity Commitment, while BAT's funding obligation is conditional on the debt financing being funded, so a failure of either source could affect the other. Following completion of the Arrangement, Organigram will have increased secured indebtedness and will be subject to financial covenants, scheduled amortization and interest rate risk, and Organigram may be required to prepay a portion of the $115,000,000 acquisition term tranche after closing if the required appraisals of Aurora's assets are not delivered or do not support the required value. The terms of the ATB Credit Facilities may also change in connection with syndication, which could increase Organigram's borrowing costs or debt service obligations.

Governmental Entities or others could take action under antitrust or competition laws, including seeking to prevent the Arrangement from occurring, to rescind or dissolve the Arrangement or to conditionally approve the Arrangement upon the divestiture of certain assets of Aurora or Organigram or other remedies. There can be no assurance that a challenge to the Arrangement on antitrust or competition law grounds will not be made, or if a challenge is made, whether or not it will be successful. The requirement to take certain actions or to agree to certain conditions to satisfy such antitrust requirements or obtain any such antitrust approvals may have a material and adverse effect on the business and affairs of Organigram or the trading price of the Organigram Common Shares after completion of the Arrangement.

Even if all approvals, orders and consents are obtained and conditions precedent to the completion of the Arrangement are satisfied, no assurance can be made as to the terms, conditions and timing of such approvals, orders and consents. These approvals, orders and consents may impose conditions on or require divestitures relating to the divisions, operations or assets of Aurora and/or Organigram or may impose requirements, limitations or costs or place restrictions on the conduct of Organigram's or Aurora's respective businesses, and if such approvals, orders or consents require an extended period of time to be obtained, such extended period of time could increase the chance that an adverse event occurs with respect to Organigram or Aurora. Such extended period of time may also increase the chance that other adverse effects with respect to Organigram and/or Aurora could occur, such as the loss of key personnel. Each Party's obligation to complete the Arrangement is also subject to the accuracy of the representations and warranties of the other Party (subject to certain qualifications and exceptions) and the performance in all material respects of the other Party's covenants under the Arrangement Agreement. As a result of these conditions, the Parties cannot provide assurance that the Arrangement will be completed on the terms or timeline contemplated in the Arrangement Agreement, or at all.

Integration of Business Activities

Completion of the Arrangement will result in the integration of the current business activities currently carried on by Aurora into Organigram's business. The integration of these activities into Organigram's business may expose Aurora Shareholders and Organigram Shareholders to different business risks than those to which they were exposed prior to the Arrangement.

The integration of Aurora into the business of Organigram will require the dedication of substantial effort, time and resources on the part of management which may divert management's focus and resources from other strategic opportunities and from operational matters during this process. In addition, the integration process could result in disruption of existing relationships with suppliers, employees, customers and other constituencies of each company. There can be no assurance that management will be able to integrate the operations of each of the businesses successfully or achieve any of the synergies or other benefits that are anticipated to result from the Arrangement. Most operational and strategic decisions and certain staffing decisions with respect to integration have not yet been made. These decisions and the integration of the two companies will present challenges to management, including the integration of systems and personnel of the two companies which may be geographically separated, unanticipated liabilities and unanticipated costs. It is possible that the integration process could result in the loss of key employees,

the disruption of the respective ongoing businesses or inconsistencies in standards, controls, procedures and policies that adversely affect the ability of management to maintain relationships with customers, suppliers, employees or to achieve the anticipated benefits of the Arrangement. The performance of Organigram's operations following completion of the Arrangement could be adversely affected if Organigram cannot retain key employees to assist in the integration and operation of Aurora.

Any inability of management to successfully integrate the operations could have a material adverse effect on the business, financial condition and results of operations of Organigram following the Arrangement.

After the completion of the Arrangement, Organigram will face many of the same risks that each of Aurora and Organigram currently face, in addition to other risks.

Organigram Business Mix Following Completion of the Arrangement will be Different than that of Organigram and Aurora as Separate Entities

Organigram's business is focused on the production and sale of cannabis and cannabis-derived products, primarily for the Canadian adult-use recreational market, together with European medical commercial operations. Aurora's business is focused on the production, distribution and sale of medical cannabis products in Canada and internationally, together with consumer cannabis products in Canada. Organigram's business following completion of the Arrangement will be a combination of these businesses, which will result in a different business mix than the current businesses of Organigram and Aurora, respectively, and which may subject Organigram following completion of the Arrangement to different business risks than those which are currently applicable to Organigram and Aurora as separate entities.

Market Price of Shares

If, for any reason, the Arrangement is not completed or its completion is materially delayed and/or the Arrangement Agreement is terminated, the market price of the Aurora Common Shares and/or the Organigram Common Shares may be materially adversely affected. The trading prices of the Organigram Common Shares and the Aurora Common Shares may be subject to material fluctuations and may increase or decrease in response to a number of events and factors, including: (a) changes in the market price of cannabis products and the cannabis industry generally; (b) current events affecting the economic situation in Canada, the United States and internationally; (c) trends in the global cannabis industry; (d) regulatory and/or government actions, rulings or policies; (e) changes in financial estimates and recommendations by securities analysts or rating agencies; (f) acquisitions and financings; (g) the economics of current and future projects of Aurora, Organigram or, following completion of the Arrangement, Organigram; (h) quarterly variations in operating results; and (i) the operating and share price performance of other companies, including those that investors may consider to be comparable.

The Arrangement Agreement May Be Terminated

Each of Aurora and Organigram has the right to terminate the Arrangement Agreement in certain circumstances. Accordingly, there is no certainty, nor can either of Aurora or Organigram provide any assurance, that the Arrangement Agreement will not be terminated by either Aurora or Organigram before the completion of the Arrangement. For instance, Organigram may terminate the Arrangement Agreement upon an Aurora Change in Recommendation or if the Hostile Bid is consummated, Aurora may terminate the Arrangement Agreement upon an Organigram Change in Recommendation or, subject to Organigram's right to match and payment of the Aurora Termination Fee, to enter into a definitive agreement with respect to a Superior Proposal, and either Party may terminate the Arrangement Agreement if the Arrangement Resolution or the Organigram Share Issuance Resolution is not approved, if the Effective Time does not occur by the Outside Date or upon certain uncured breaches by the other Party.

In addition, certain costs related to the Arrangement, such as legal, accounting and certain financial advisor fees, must be paid by Aurora and Organigram even if the Arrangement is not completed.

Under the Arrangement Agreement, Aurora is required to pay to Organigram the Aurora Termination Fee, and Organigram is required to pay to Aurora the Organigram Termination Fee, in certain circumstances. In addition,

Organigram is required to pay Aurora the Expense Fee if the Arrangement Agreement is terminated because the Organigram Share Issuance Resolution is not approved, whether or not any Acquisition Proposal has been made in respect of Organigram. The Aurora Termination Fee may discourage other parties from attempting to enter into a business transaction with Aurora, even if those parties would otherwise be willing to enter into an agreement with Aurora for a transaction and would be prepared to pay consideration with a higher price per Aurora Common Share or cash market value than the market value per Aurora Common Share proposed to be received or realized in the Arrangement. Payment of the Organigram Termination Fee or the Expense Fee could have an adverse effect on Organigram's financial condition and cash resources.

If the Arrangement is not completed for any reason, including in the event the Aurora Shareholders or Organigram Shareholders, respectively, do not approve the matters required to be voted on thereby, the ongoing businesses of Organigram and Aurora may be adversely affected and, without realizing any of the anticipated benefits of having completed the Arrangement, Aurora and Organigram would be subject to a number of risks, including the following:

- Aurora and Organigram may experience negative reactions from the financial markets, including a decline of their respective share prices (which may reflect a market assumption that the Arrangement will be completed);

- Aurora and Organigram may experience negative reactions from the investment community, their respective customers, suppliers, regulators and employees and other partners in the business community;

- Aurora and Organigram may be required to pay certain costs relating to the Arrangement, whether or not the Arrangement is completed; and

- matters relating to the Arrangement will have required substantial commitments of time and other resources by Organigram's and Aurora's management, which may otherwise have been devoted to day-to-day operations and strategic opportunities that may have been beneficial to Aurora and Organigram had the Arrangement not been contemplated.

See "*Effect of the Arrangement – The Arrangement Agreement – Termination*", "*Effect of the Arrangement – The Arrangement Agreement – Termination Fees*", and "*Effect of the Arrangement – Aurora Support Agreements*".

While the Arrangement is Pending, Aurora and Organigram are Restricted from Taking Certain Actions

The Arrangement Agreement restricts Aurora and Organigram from taking specified actions until the Arrangement is completed, without the consent of the other Party. These restrictions may prevent Aurora and/or Organigram from pursuing attractive business opportunities that may arise prior to completion or termination of the Arrangement.

While the Arrangement is Pending, Aurora's and Organigram's Business Relationships May be Adversely Impacted

Because the Arrangement is dependent upon satisfaction of certain conditions, its completion is subject to uncertainty. In response to this uncertainty, Aurora's and Organigram's customers and suppliers may delay or defer decisions concerning Aurora and Organigram. Any delay or deferral of those decisions by customers and suppliers could have an adverse effect on the business and operations of Aurora and Organigram, regardless of whether the Arrangement is ultimately completed.

The Pending Arrangement May Divert the Attention of Aurora's and Organigram's Management

The Arrangement could cause the attention of Aurora's and Organigram's management to be diverted from the day-to-day operations and customers or suppliers may seek to modify or terminate their business relationships with Aurora or Organigram. These disruptions could be exacerbated by a delay in the completion of the Arrangement and could have an adverse effect on the business, operating results or prospects of Aurora and/or Organigram.

The Share Alternative and the Share Portion of the Combination Alternative Are Fixed and Will Not Be Adjusted in the Event of Any Change in Either Aurora's or Organigram's Respective Share Prices

Upon closing of the Arrangement, each Aurora Shareholder (other than a Dissenting Aurora Shareholder) who elects (or is deemed to elect) the Share Alternative or the Combination Alternative, or who receives Organigram Common Shares as a result of proration, will receive a fixed number of Organigram Common Shares in respect of each Aurora Common Share held by such Aurora Shareholder. The number of Organigram Common Shares comprising the Share Alternative and the Combination Alternative is fixed in the Plan of Arrangement (subject only to adjustment in the limited circumstances provided in the Arrangement Agreement) and will not be adjusted for changes in the market price of either the Aurora Common Shares or the Organigram Common Shares. Changes in the price of the Organigram Common Shares prior to the consummation of the Arrangement will affect the market value that such Aurora Shareholders will be entitled to receive upon closing, and the value of the Share Alternative or the Combination Alternative may be more or less than the $7.80 Cash Alternative. Neither Aurora nor Organigram is permitted to terminate the Arrangement Agreement or, in the case of Aurora, resolicit the vote of the Aurora Shareholders, solely because of changes in the market price of either Party's common shares. Share price changes may result from a variety of factors (many of which are beyond Organigram's or Aurora's control), including the risk factors identified in the Aurora AIF and the Organigram AIF, respectively.

Aurora Shareholders May Not Receive the Form of Consideration They Elect

The aggregate cash payable and the aggregate number of Organigram Common Shares issuable under the Arrangement are limited to the Maximum Cash Consideration and the Maximum Share Consideration, respectively. As a result, Aurora Shareholders who elect the Cash Alternative or the Share Alternative may have their consideration prorated and may receive a portion of their consideration in a form other than the form they elected, which may have a different value or tax consequences.

Risks Relating to the Combined Company's Cannabis Business

Following completion of the Arrangement, Organigram will be subject to extensive regulation of the cultivation, production, distribution and sale of cannabis, including under the *Cannabis Act* (Canada) and its regulations, Health Canada licensing requirements and, in Germany, Australia and other international markets, applicable medical cannabis, narcotics and EU-GMP and other quality Laws and standards. Changes to such Laws and standards, or the loss or non-renewal of licences or certifications, could adversely affect Organigram following completion of the Arrangement. See also the risk factors relating to the regulation of the cannabis industry in the Aurora AIF and the Organigram AIF, each of which is incorporated by reference in this Joint Information Circular.

Aurora Dissent Rights

Registered Aurora Shareholders have the right to exercise certain dissent and appraisal rights and demand payment of the fair value of their Aurora Common Shares in cash in connection with the Arrangement in accordance with the BCBCA and the Interim Order. If there are a significant number of Dissenting Aurora Shareholders, a substantial cash payment may be required to be made to such Aurora Shareholders that could have an adverse effect on Organigram's financial condition and cash resources if the Arrangement is completed. It is a condition to the completion of the Arrangement in favour of Organigram that Dissent Rights shall not have been validly exercised, and not withdrawn, with respect to more than 10% of the issued and outstanding Aurora Common Shares.

Potential Undisclosed Liabilities Associated with the Arrangement

In connection with the Arrangement, there may be liabilities that Organigram or Aurora failed to discover or were unable to quantify in their respective due diligence, which due diligence was conducted prior to the execution of the Arrangement Agreement. It is possible that Aurora or Organigram may not be indemnified for some or all of such undisclosed liabilities.

Trading Access

The Aurora Common Shares are currently listed on the TSX and Nasdaq and quoted on the open market of the Frankfurt Stock Exchange. Following completion of the Arrangement, it is anticipated that the Aurora Common Shares will be delisted from the TSX and Nasdaq as promptly as practicable following the Effective Date, and Aurora Shareholders who receive only cash will cease to have any trading access to an interest in the combined business.

Although the TSX has conditionally approved the listing of the Organigram Common Shares issuable pursuant to the Arrangement and Organigram will notify the Nasdaq of their listing, listing is subject to Organigram fulfilling all of the listing requirements of the TSX and there can be no assurance that such listing will occur in a timely manner or at all.

Pro Forma Financial and Operational Information may not be Indicative of Organigram's Financial Condition or Performance or Results of Operations following the Arrangement

The unaudited pro forma financial and operational information contained in this Joint Information Circular is presented for illustrative purposes only as of the dates or for the periods indicated therein and may not be indicative of the financial condition, performance or results of operations of Organigram following completion of the Arrangement for several reasons. The unaudited pro forma financial information has been derived from the respective historical financial statements of Organigram and Aurora, and certain adjustments and assumptions made as of the dates indicated therein have been made to give effect to the Arrangement. The information upon which these adjustments and assumptions have been made is preliminary and such adjustments and assumptions are difficult to make with complete accuracy. Moreover, the unaudited pro forma financial information does not include, among other things, estimated costs or synergies, adjustments related to restructuring or integration activities, future acquisitions or disposals not yet known or probable, or impacts of Arrangement-related change in control provisions that are currently not factually supportable and/or likely to occur. Therefore, the pro forma financial and operational information contained herein is presented for informational purposes only and is not necessarily indicative of what Organigram's actual financial condition, performance or results of operations would have been had the Arrangement been completed on the date indicated. Accordingly, Organigram's business, assets, results of operations and financial condition or performance following the Arrangement may differ significantly from those indicated in the unaudited pro forma financial information. See Appendix "H" – "*Pro Forma Condensed Consolidated Financial Statements of Organigram Global* Inc.".

Income Tax Laws

There can be no assurance that the CRA, the IRS or other applicable taxing authorities will agree with the Canadian and U.S. federal income tax consequences of the Arrangement, as applicable, as summarized in this Joint Information Circular. Furthermore, there can be no assurance that applicable Canadian and U.S. income tax Laws, regulations or tax treaties will not be changed or interpreted in a manner, or that applicable taxing authorities will not take administrative positions, that are adverse to Aurora Shareholders in respect of the Arrangement or to Organigram and its securityholders following completion of the Arrangement. Such taxation authorities may also disagree with how Organigram and/or Aurora calculate or have in the past calculated their income for income tax purposes. In addition, the Arrangement and related transactions may restrict the ability of Organigram following completion of the Arrangement to use certain pre-combination tax attributes of either or both of Organigram and Aurora. Any such events could adversely affect Organigram, its share price or the dividends or other payments to be paid to Organigram Shareholders following completion of the Arrangement.

Future Dividends on Organigram Common Shares

There can be no assurance as to future dividend payments by Organigram on the Organigram Common Shares or the level thereof, as Organigram's dividend policy and the funds available for the payment of dividends from time to time will be dependent upon, among other things, operating cash flow generated by Organigram and its Subsidiaries, financial requirements for Organigram's operations, the execution of its growth strategy, restrictions under the Organigram Credit Facilities and the satisfaction of solvency tests imposed by section 42 of the CBCA for the declaration and payment of dividends. Organigram has not declared or paid any dividends on the Organigram Common Shares and does not currently anticipate paying dividends in the foreseeable future.

Organigram and Aurora may be the Targets of Legal Claims, Securities Class Actions, Derivative Lawsuits and Other Claims

Organigram and Aurora may be the target of securities class actions and derivative lawsuits which could result in substantial costs and may delay or prevent the Arrangement from being completed. Securities class action lawsuits and derivative lawsuits are often brought against companies that have entered into an agreement to merge, to acquire a public company or to be acquired. Third parties may also attempt to bring claims against Organigram and Aurora seeking to restrain the Arrangement or seeking monetary compensation or other remedies. Even if the lawsuits are without merit, defending against these claims can result in substantial costs and divert the time and resources of management. Additionally, if a plaintiff is successful in obtaining an injunction prohibiting consummation of the Arrangement, that injunction may delay or prevent the Arrangement from being completed.

In addition, political and public attitudes towards the Arrangement could result in negative press coverage and other adverse public statements affecting Organigram and Aurora. Adverse press coverage and other adverse statements could lead to investigations by regulators, legislators and law enforcement officials or to legal claims or otherwise negatively impact the ability of Organigram, Aurora or Organigram following completion of the Arrangement to take advantage of various business and market opportunities. The direct and indirect effects of negative publicity, and the demands of responding to and addressing such negative publicity, may have a material adverse effect on Organigram, Aurora or Organigram following completion of the Arrangement.

Aurora directors and officers may have interests in the Arrangement different from the interests of Aurora Shareholders following completion of the Arrangement

Certain of the directors and executive officers of Aurora were involved with negotiating the terms of the Arrangement Agreement, and the Aurora Board has unanimously recommended that Aurora Shareholders vote in favour of the Arrangement Resolution. These directors and executive officers may have interests in the Arrangement that are different from, or in addition to, those of Aurora Shareholders generally. These interests include, but are not limited to, the employment status of certain executive officers of Aurora following the Arrangement and the continued service of certain directors of Aurora as directors of Organigram. Other than its agreement under the Arrangement Agreement to cause Aurora to continue to honour its existing written employment agreements and benefit plans following the Effective Time, Organigram has not made any commitments (in the Arrangement Agreement or otherwise) or determinations with respect to such matters as of the date of this Joint Information Circular. For further information, see "*Interests of Certain Persons or Companies in the Arrangement*". Aurora Shareholders should be aware of these interests when they consider the Aurora Board's recommendation. The Aurora Special Committee and Aurora Board were aware of, and considered, these interests when they declared the advisability of the Arrangement Agreement and when the Aurora Board unanimously recommended that Aurora Shareholders approve the Arrangement Resolution.

The Hostile Bid and Other Competing Proposals

Curaleaf has made the Hostile Bid for the Aurora Common Shares and may further amend it or make another Acquisition Proposal. Under the Arrangement Agreement, the Hostile Bid is deemed not to be, and may not constitute, a Superior Proposal. However, any change to the amount or form of consideration offered under it would constitute a new and distinct Acquisition Proposal (an Amended Bid), which may constitute a Superior Proposal. The Hostile Bid, any Amended Bid or any other competing proposal could result in Aurora Shareholders tendering their Aurora Common Shares, could lead to an Aurora Change in Recommendation or delay the Aurora Shareholders' Meeting, and may cause Organigram to consider amending the terms of the Arrangement. If the Hostile Bid is consummated, Organigram may terminate the Arrangement Agreement, but the Aurora Termination Fee would not be payable to Organigram solely as a result of such termination, and Organigram would not be compensated for the loss of the anticipated benefits of the Arrangement.

Aurora May Terminate the Arrangement Agreement to Accept a Superior Proposal

Subject to Organigram's right to match, Aurora may terminate the Arrangement Agreement to enter into a definitive agreement with respect to a Superior Proposal, provided that it concurrently pays the Aurora Termination Fee. The Aurora Termination Fee may not fully compensate Organigram for the loss of the anticipated benefits of the Arrangement.

The Aurora Termination Fee may Discourage Other Parties from Making an Acquisition Proposal

Under the terms of the Arrangement Agreement, Aurora is required to pay the Aurora Termination Fee in the event of an Aurora Termination Fee Event. The obligation to pay the Aurora Termination Fee may discourage other parties from making an Acquisition Proposal, which may or may not constitute a Superior Proposal, even if such transaction could provide better value to Aurora Shareholders than the Arrangement.

Financing and Increased Indebtedness

Organigram intends to fund the cash Consideration in part through the Organigram Financing, including the BAT Private Placement and the ATB Credit Facilities. Completion of the Arrangement is not subject to a financing condition, and Organigram will be obligated to complete the Arrangement even if all or any portion of the Organigram Financing is unavailable. Following completion of the Arrangement, Organigram will have increased indebtedness, which will require it to dedicate a portion of its cash flow to debt service, may limit its flexibility to pursue other opportunities, and will subject it to covenants that restrict its operations. A failure to comply with such covenants could result in a default under the ATB Credit Facilities.

THE HOSTILE BID

On August 18, 2026, Curaleaf commenced the Hostile Bid. On October 6, 2026, Curaleaf varied the Hostile Bid by the Curaleaf Notice of Variation to provide for consideration of US$1.00 in cash and 0.4013 of a Curaleaf Share per Aurora Common Share, subject to a maximum value of US$6.00 per Aurora Common Share, and extended the expiry time to 11:59 p.m. (Mountain Time) on December 4, 2026. The Aurora Board has unanimously recommended that Aurora Shareholders REJECT the Hostile Bid and not tender their Aurora Common Shares. See Aurora's directors' circular dated September 1, 2026, as supplemented by the notices of change dated October 14, 2026 and November 3, 2026.

Aurora Shareholders who have tendered their Aurora Common Shares to the Hostile Bid may withdraw them in accordance with its terms. Aurora Shareholders looking for assistance to withdraw their shares should consult their broker or contact Kingsdale Advisors by phone at 1-800-749-9052 (toll-free in North America) or 416-623-4172 (text or call), or by email at contactus@kingsdaleadvisors.com.

If the Hostile Bid is extended, varied or completed before the Meetings, Aurora will issue a news release and, as required, a notice of change to the Directors' Circular, and Aurora and Organigram will update Aurora Shareholders and Organigram Shareholders as required by applicable Law. Under the Arrangement Agreement, if Curaleaf amends the consideration under the Hostile Bid less than five business days before the Aurora Shareholders' Meeting, Organigram may adjourn or postpone the Meetings, and Organigram may terminate the Arrangement Agreement if the Hostile Bid is consummated. See "*Effect of the Arrangement – The Arrangement Agreement – Covenants Regarding Non-Solicitation*" and "*Effect of the Arrangement – The Arrangement Agreement – Termination*".

INFORMATION CONCERNING AURORA CANNABIS INC.

See Appendix "I" – "*Information Concerning Aurora Cannabis Inc.*" attached to this Joint Information Circular for detailed information concerning Aurora.

INFORMATION CONCERNING ORGANIGRAM GLOBAL INC.

See Appendix "J" – "*Information Concerning Organigram Global Inc.*" attached to this Joint Information Circular for detailed information concerning Organigram.

COMPARISON OF SHAREHOLDER RIGHTS

Aurora is governed by the BCBCA and Organigram is governed by the CBCA. Aurora Shareholders who receive Organigram Common Shares pursuant to the Arrangement will become shareholders of Organigram, and their rights will be governed by the CBCA and Organigram's articles and by-laws. The following is a summary of certain

differences between the rights of Aurora Shareholders under the BCBCA and Aurora's articles and the rights of Organigram Shareholders under the CBCA and Organigram's articles and by-laws. This summary is not exhaustive and is qualified in its entirety by reference to the BCBCA, the CBCA and the constating documents of Aurora and Organigram.

General

In general terms, the CBCA provides shareholders with substantively the same rights as are available to shareholders under the BCBCA, including rights of dissent and appraisal and rights to bring derivative actions and oppression actions. There are, however, important differences concerning, among other things, the qualifications of directors and certain shareholder remedies.

The following is a summary comparison of certain provisions of the CBCA and the BCBCA which pertain to the rights of shareholders and other corporate matters. This summary is not intended to be exhaustive and nothing that follows should be construed as legal advice to any particular Aurora Shareholder. Reference should be made to the full text of both statutes and the regulations thereunder, and Aurora Shareholders should consult their own legal advisors regarding the implications of the Arrangement which may be of particular importance to them.

Board of Directors

Both the BCBCA and the CBCA provide that a public company or distributing corporation, as applicable, must have a minimum of three directors. The BCBCA does not impose any residency requirements on the directors. Under the CBCA, at least one-quarter of the directors must be resident Canadians. However, if a corporation has fewer than four directors, at least one director must be a resident Canadian. Subject to certain exceptions, generally an individual has to be ordinarily resident in Canada to be considered a resident Canadian under the CBCA.

Constating Documents

Under the BCBCA, a corporation has as its constating documents a notice of articles and articles which contain the rules of conduct of the corporation. The notice of articles must set forth, among other things, the name of the corporation, the amount and type of authorized share structure and must indicate if there are any rights and restrictions attached to the shares. The notice of articles is filed with the Registrar of Companies (British Columbia), while the articles are maintained at the corporation's records office. Similarly, under the CBCA, the constating documents of a corporation consist of: (i) articles of incorporation which must set forth, among other things, the name of the corporation, the amount and type of authorized capital and any restriction on the business that the corporation may carry on; and (ii) by-laws that regulate the business or affairs of a corporation. The articles are filed with the Director appointed under the CBCA; the by-laws are not required to be filed.

Amendments to Constating Documents and Other Fundamental Changes

Under the BCBCA, any substantive change to the corporate charter of a corporation, such as an alteration of the restrictions, if any, on the business carried on by the corporation, a change in the name of the corporation or an increase or reduction of the authorized share structure of the corporation, requires a special resolution passed by the majority of such number of votes as specified in the articles of the corporation so long as the prescribed majority (the "special majority") is at least two-thirds and not more than three-quarters of the votes cast by shareholders on the resolution or, if the articles do not contain such a provision, a special resolution passed by at least two-thirds of the votes cast on the resolution. A proposed amalgamation requires a similar resolution passed by a special majority of all holders of shares of the corporation (or such higher threshold as may be provided in the corporation's articles), whether or not they are otherwise entitled to vote. In addition, a right or special right attached to a class or series of shares cannot be prejudiced or interfered with unless at least two-thirds (or such higher majority up to and including three-quarters as may be provided by the articles, as described above) of the votes cast by the shareholders holding such class or series of shares consent to such change.

Any substantive change to the articles of a corporation under the CBCA, such as an alteration of the restrictions, if any, on the business carried on by a corporation, a change in the name of the corporation, an increase or reduction of

the stated capital of the corporation, or an alteration of the special rights and restrictions attached to issued shares, requires a special resolution passed by not less than two-thirds of the votes cast by the shareholders voting on the resolution authorizing such change. In addition, the holders of a class or series of shares (if such class or series is affected by an amendment in a manner different from other shares of the same class or series) are entitled to vote separately as a class or series on a proposal to amend the articles to add, change or remove any provision that affects the rights, privileges, restrictions or conditions attached to that class or series, whether or not they are otherwise entitled to vote. Other fundamental changes, such as a proposed amalgamation or a continuation of a corporation out of the federal jurisdiction, will also require a special resolution passed by not less than two-thirds of the votes cast by shareholders voting on the resolution authorizing such change, whether or not they are otherwise entitled to vote.

Removal of Directors

Under the BCBCA, subject to certain exceptions, a director may be removed before the expiration of the director's term of office by a special resolution of the shareholders of the corporation or by such other resolution or method as may be set out in its articles. The CBCA provides that, subject to certain exceptions, the shareholders of a corporation may by ordinary resolution at a special meeting remove any director or directors from office and that the articles of a corporation may not require a higher threshold to remove a director. An ordinary resolution means a resolution passed by a majority (i.e., over 50%) of the votes cast by the shareholders who voted in respect of that resolution.

Sale of Undertaking

Under the BCBCA, a corporation may sell, lease or otherwise dispose of all or substantially all of the undertaking (as opposed to the "property") of the corporation if it does so in the ordinary course of its business or if it has been authorized to do so by a special resolution passed by a special majority (being at least two-thirds and not more than three-quarters of the votes cast on the resolution) or, if the articles do not contain such a provision, a special resolution passed by at least two-thirds of the votes cast on the resolution. The CBCA requires shareholder approval for any sale, lease or exchange of all or substantially all of the property (as opposed to the "undertaking") of the corporation, other than in the ordinary course of business of a corporation, in accordance with the following: (i) each share of a corporation carries the right to vote in respect of the approval of a sale, lease or exchange of all or substantially all of the property of the corporation whether or not it otherwise carries the right to vote; (ii) the sale, lease or exchange is adopted when the holders of each class or series of shares entitled to vote thereon have approved of the sale, lease or exchange by a special resolution; and (iii) holders of shares of a class or series are entitled to vote separately as a class or series only if that class or series is affected by the sale, lease or exchange in a manner different from the shares of another class or series. While the shareholder approval thresholds can be the same under the BCBCA and the CBCA, the BCBCA allows for a corporation to specify a different approval level in its articles (at least two-thirds and not more than three-quarters).

Rights of Dissent and Appraisal

The BCBCA provides that shareholders who dissent with respect to certain actions being taken by a corporation may exercise a right of dissent and require the corporation to purchase the shares held by such shareholder at the fair value. Under the BCBCA, a holder of shares of any class may dissent if a court order permits such dissent or if the corporation proposes:

- to alter the articles to alter restrictions on the powers of the corporation or on the business it is permitted to carry on;
- to adopt an amalgamation agreement;
- to approve an amalgamation into a foreign jurisdiction;
- to approve an arrangement, the terms of which arrangement permit dissent;
- to authorize the sale, lease or other disposition of all or substantially all of the undertaking of the corporation;
- to authorize the continuation of the corporation into a jurisdiction other than British Columbia; and
- to approve any other resolution, if dissent is authorized by the resolution.

The CBCA contains similar dissent provisions which apply if a corporation proposes:

- to amend its articles to add, change or remove any provisions restricting or constraining the issue, transfer or ownership of shares of that class;
- to amend its articles to add, change or remove any restriction on the business or businesses that the corporation may carry on;
- to amalgamate (other than an amalgamation between a corporation and its wholly-owned subsidiary, or between wholly-owned subsidiaries of the same corporation);
- to be continued under the laws of another jurisdiction;
- to sell, lease or exchange all or substantially all its property;
- to carry out a going-private transaction or a squeeze-out transaction; or
- to amend its articles to add, modify or remove any provision that affects the characteristics, rights, privileges, restrictions or conditions attached to the shares of a class.

Oppression Remedies

Under the BCBCA, a shareholder (including a beneficial shareholder) of a corporation has the right to apply to court on the grounds that:

(i) the affairs of the corporation are being or have been conducted, or that the powers of the directors are being or have been exercised, in a manner oppressive to one or more of the shareholders, including the applicant; or

(ii) some act of the corporation has been done or is threatened, or that some resolution of the shareholders or of the shareholders holding shares of a class or series of shares has been passed or is proposed, that is unfairly prejudicial to one or more of the shareholders, including the applicant.

An application can also be made by any other person whom the court considers to be an appropriate person to make the application. The court can grant a variety of remedies, ranging from an order restraining the conduct complained of to an order requiring the corporation to repurchase the shareholder's shares or an order liquidating the corporation.

The CBCA also includes an oppression remedy which is similar but broader. Under the CBCA, the scope of potential complainants includes current and former registered holders and beneficial owners of securities of the corporation or any of its affiliates, current and former directors and officers of the corporation or any of its affiliates, and any other person who, in the discretion of the court, is a proper person to make an application. Claims may be based on conduct of the corporation or any of its affiliates that is oppressive or unfairly prejudicial to, or that unfairly disregards the interests of, any securityholder, creditor, director or officer. Unlike the CBCA, the BCBCA does not refer to conduct that "unfairly disregards" interests.

Shareholder Derivative Actions

Under the BCBCA, a registered shareholder, beneficial shareholder or director of a company may, with leave of the court, bring an action in the name and on behalf of the corporation to enforce a right, duty or obligation owed to the corporation that could be enforced by the corporation itself or to obtain damages for any breach of such right, duty or obligation. There is a similar right of a shareholder or director, with leave of the court, and in the name and on behalf of the corporation, to defend an action brought against the corporation. The court will grant leave under the BCBCA for an application to commence a derivative action if:

(i) the complainant has made reasonable efforts to cause the directors of the corporation to prosecute or defend the legal proceeding;

(ii) notice of the application for leave has been given to the corporation and to any other person the court may order;

(iii) the complainant is acting in good faith; and

(iv) it appears to the court that it is in the best interests of the corporation for the legal proceeding to be prosecuted or defended.

The CBCA extends the right to a broader group of complainants as it affords the right to a registered shareholder, former registered shareholder, beneficial shareholder, former beneficial shareholder, director, former director, officer and a former officer of a corporation or any of its affiliates, and any person who, in the discretion of the court, is a proper person to make an application to court to bring a derivative action. In addition, the CBCA permits derivative actions to be commenced in the name and on behalf of not only the corporation, but also any of its subsidiaries. No leave may be granted under the CBCA unless the court is satisfied that:

(i) the complainant has given at least fourteen (14) days' notice to the directors of the corporation or its subsidiary of the complainant's intention to apply to the court if the directors of the corporation or its subsidiary do not bring, diligently prosecute, defend or discontinue the action;

(ii) the complainant is acting in good faith; and

(iii) it appears to be in the interests of the corporation or its subsidiary that the action be brought, prosecuted, defended or discontinued.

Requisition of Meetings

The BCBCA provides that one or more shareholders of a corporation holding in aggregate not less than five percent (5%) of the issued voting shares of the corporation may give notice to the directors requiring them to call and hold a general meeting within four (4) months, subject to certain exceptions. If the directors of the corporation do not send a notice of meeting within twenty-one (21) days of receiving the requisition, the requisitioning shareholders (or any one of them holding more than two and one-half percent (2.5%) of the issued voting shares) may do so.

The CBCA permits the holders of not less than five percent (5%) of the issued and outstanding shares of a corporation that carry the right to vote at a meeting to requisition the directors to call and hold a meeting of shareholders for the purposes stated in the requisition. If the directors do not call a meeting within twenty-one (21) days after receiving the requisition, any shareholder who signed the requisition may call the meeting.

Place of Meeting

The BCBCA provides that meetings of shareholders must be held in British Columbia, however they may be held at a place outside of British Columbia if such place is: (a) provided for in the articles; (b) approved in writing by the Registrar of Companies (British Columbia) before any such meeting is held; or (c) approved by an ordinary resolution or such other resolution of shareholders required by the articles (provided the articles do not restrict the corporation from approving a location outside of British Columbia).

The CBCA provides that meetings of shareholders must be held at the place within Canada provided for in a corporation's by-laws, or in the absence of such provision, at such place within Canada that the directors so determine. A meeting may be held outside Canada if the articles so provide or if all the shareholders entitled to vote at the meeting agree that such meeting is to be so held.

Share Capital Matters

The BCBCA allows par value shares (even in foreign currency) and expressly confirms, subject to the articles of the corporation, the ability of a corporation to hold shares in its parent or itself (subject to some exceptions). The CBCA prohibits the creation of par value shares and, subject to limited exceptions, prohibits a corporation from holding shares in itself or its parent. The BCBCA also provides for inter-jurisdictional amalgamations, a mechanism not contemplated in the CBCA.

Shareholder Proposals

The BCBCA includes a more detailed regime for shareholder proposals than the CBCA. Under the BCBCA, a shareholder submitting a proposal must have been a registered or beneficial owner of one or more voting shares for at least two (2) years before signing the proposal, and the proposal must be signed by shareholders who, together with the submitter, are registered or beneficial owners of at least 1% of the corporation's voting shares or of shares with a fair market value exceeding the amount prescribed by regulation (currently $2,000). The CBCA permits a registered holder or beneficial owner of shares entitled to vote at a meeting to submit a proposal, subject to the minimum ownership and holding period requirements prescribed by regulation.

Notice of Shareholder Meetings

Under the BCBCA, a public company must give notice of a meeting of shareholders not less than twenty-one (21) days and not more than two (2) months before the meeting. Under the CBCA, notice of a meeting of shareholders must be given not less than twenty-one (21) days and not more than sixty (60) days before the meeting. Reporting issuers governed by either statute are also subject to the requirements of National Instrument 54-101 – Communication with Beneficial Owners of Securities of a Reporting Issuer.

Stock Splits or Consolidations

Under the BCBCA, a corporation may subdivide or consolidate its shares by the type of resolution specified in its articles, which may be a resolution of the directors. Under the CBCA, a special resolution of shareholders is required to change the shares of a class into a different number of shares of the same class.

Financial Assistance

The BCBCA provides that a corporation may give financial assistance to any person for any purpose, subject to certain disclosure obligations. The CBCA does not impose such disclosure obligations.

Indemnification of Directors and Officers

The BCBCA includes detailed provisions for permitted and prohibited indemnification of directors and officers and, unlike the CBCA, gives the court discretion to order indemnification or make any other order it considers appropriate. The provisions of the CBCA for the permitted indemnification of directors and officers are substantially similar to, but less detailed than, those in the BCBCA.

MATTERS TO BE CONSIDERED AT THE AURORA SHAREHOLDERS' MEETING

At the Aurora Shareholders' Meeting, Aurora Shareholders will be asked to consider the Arrangement Resolution in the form set forth in Appendix "A" of this Joint Information Circular.

Pursuant to the Interim Order, the Arrangement Resolution must, subject to further order of the Court, be approved by: (a) not less than 66⅔% of the votes cast by Aurora Shareholders, present virtually or represented by proxy and entitled to vote at the Aurora Shareholders' Meeting, voting together as a single class; and (b) a simple majority of the votes cast by Aurora Shareholders present virtually or represented by proxy and entitled to vote at the Aurora Shareholders' Meeting, excluding the votes attached to Aurora Common Shares held by persons described in items (a) through (d) of section 8.1(2) of MI 61-101, being only Mr. Miguel Martin. It is a condition to the completion of the Arrangement that the Arrangement Resolution be approved at the Aurora Shareholders' Meeting in the manner required by the Interim Order. Accordingly, if the Arrangement Resolution is not approved by Aurora Shareholders, the Arrangement will not be completed. However, the Arrangement Resolution authorizes the Aurora Board, without further notice to or approval of Aurora Shareholders: (a) to amend the Arrangement Agreement or the Plan of Arrangement, to the extent permitted by the Arrangement Agreement and the Plan of Arrangement; and (b) subject to the terms of the Arrangement Agreement, to disregard the Aurora Shareholders' approval and not proceed with the Arrangement.

Aurora Shareholders are urged to carefully review this Joint Information Circular when considering the Arrangement Resolution. In particular, see "*The Arrangement*", "*Effect of the Arrangement*" and Appendix "J" – "*Information Concerning Organigram Global Inc.*". For information relating to the impact of the Arrangement on Aurora and Organigram, see "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement*".

The Aurora Board, on the unanimous recommendation of the Aurora Special Committee, unanimously recommends that Aurora Shareholders vote FOR the Arrangement Resolution. See "*The Arrangement – Recommendation of the Aurora Board*".

It is the intention of the persons named in the enclosed form of proxy, if not expressly directed to the contrary in such form of proxy, to vote such proxy in favour of the Arrangement Resolution.

MATTERS TO BE CONSIDERED AT THE ORGANIGRAM SHAREHOLDERS' MEETING

At the Organigram Shareholders' Meeting, Organigram Shareholders will be asked to consider the Organigram Share Issuance Resolution in the form set forth in Appendix "B" of this Joint Information Circular.

Among other things, the Organigram Share Issuance Resolution approves the issuance of up to 223,071,951 Organigram Common Shares pursuant to the Arrangement and 140,986,255 Organigram Common Shares and/or Organigram Preferred Shares pursuant to the BAT Private Placement, for an aggregate of 364,058,206 Organigram securities (being approximately 191.3% of the Organigram Common Shares and Organigram Preferred Shares outstanding as of November 19, 2026 on a non-diluted basis).

The Organigram Common Shares issued pursuant to the Arrangement will consist of: (a) Organigram Common Shares issuable pursuant to the Arrangement in consideration for Aurora Common Shares; (b) Organigram Common Shares issuable upon the exercise of Replacement Options; and (c) a 5% buffer of Organigram Common Shares to account for clerical and administrative matters or changes in the number of Aurora Common Shares outstanding between the date hereof and the closing of the Arrangement. Based on the 65,748,913 Aurora Common Shares and 2,214,519 Aurora Options outstanding as of November 19, 2026, 200,080,517 Organigram Common Shares would be issued in consideration for Aurora Common Shares, 12,987,407 Organigram Common Shares would be issuable upon the exercise of Replacement Options and the issuance of an additional 9,991,849 Organigram Common Shares would be approved to account for clerical and administrative matters or changes in the number of Aurora Common Shares outstanding between the date hereof and the closing of the Arrangement.

In accordance with the applicable rules of the TSX Company Manual and MI 61-101, the Organigram Share Issuance Resolution must be approved by greater than (i) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, and (ii) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, excluding the 42,231,089 votes attached to Organigram Common Shares held by BAT and its affiliates (representing approximately 30% of the Organigram Common Shares outstanding as of November 19, 2026 on a non-diluted basis) (and, for purposes of MI 61-101, their respective directors and officers and other persons required to be excluded). It is a condition to the completion of the Arrangement that the Organigram Share Issuance Resolution be approved at the Organigram Shareholders' Meeting. Accordingly, if the Organigram Share Issuance Resolution is not approved by Organigram Shareholders, the Arrangement will not be completed. However, the Organigram Share Issuance Resolution authorizes the Organigram Board, without further notice to or approval of Organigram Shareholders: (i) to amend the Arrangement Agreement or the Plan of Arrangement, to the extent permitted by the Arrangement Agreement and the Plan of Arrangement; and (ii) subject to the terms of the Arrangement Agreement, to not proceed with the Arrangement.

If the Organigram Share Issuance Resolution is approved, the TSX will generally not require further Organigram Shareholder approval for the issuance of up to an additional 55,767,987 Organigram Common Shares, being 25% of the number of Organigram Common Shares approved for issuance pursuant to the Arrangement (including upon the exercise of Replacement Options) by the Organigram Shareholders.

Organigram Shareholders are urged to carefully review this Joint Information Circular when considering the Organigram Share Issuance Resolution. In particular, see "*The Arrangement*", "*Effect of the Arrangement*" and Appendix "H" – "*Pro Forma Condensed Consolidated Financial Statements of Organigram Global* Inc.". For information relating to the impact of the Arrangement on Organigram, see "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement*".

The Organigram Board (with the representatives of BAT abstaining in respect of the BAT Private Placement) unanimously recommends that Organigram Shareholders vote FOR the Organigram Share Issuance Resolution. See "*The Arrangement – Recommendation of the Organigram Board*".

It is the intention of the persons named in the enclosed form of proxy, if not expressly directed to the contrary in such form of proxy, to vote such proxy in favour of the Organigram Share Issuance Resolution.

GENERAL PROXY MATTERS – AURORA

Solicitation of Proxies

This Joint Information Circular is delivered in connection with the solicitation by or on behalf of management of Aurora of proxies for use at the Aurora Shareholders' Meeting. The cost of soliciting proxies will be borne by Aurora. The solicitation of proxies will be done primarily by mail and electronic means, but may also be solicited personally (virtually), by telephone, facsimile or other similar means by directors, officers, employees or agents of Aurora.

Aurora has engaged Kingsdale Advisors as its strategic shareholder advisor and proxy solicitation agent to assist management of Aurora in the solicitation of proxies from Aurora Shareholders for the Aurora Shareholders' Meeting. Kingsdale has been retained to provide a broad array of strategic advisory, governance, strategic communications, digital and investor campaign services on a global retainer basis in addition to certain fees accrued during the life of the engagement upon the discretion and direction of Aurora. The costs of preparing and distributing this Joint Information Circular and the other Meeting Materials will be borne by Aurora and Organigram, as applicable.

The Aurora Shareholders' Meeting is being called pursuant to the Interim Order to seek the requisite approvals of Aurora Shareholders to the Arrangement in accordance with section 289 of the BCBCA. See "*The Arrangement*", "*Effect of the Arrangement*" and "*Matters to be Considered at the Aurora Shareholders' Meeting*".

The information set forth below generally applies to registered holders of Aurora Common Shares. If you are a Beneficial Holder of Aurora Common Shares (i.e., your Aurora Common Shares are held through a broker, investment dealer, bank, trust company, custodian, nominee or other intermediary), see "*Information for Beneficial Holders*" at the front of this Joint Information Circular.

Appointment and Revocation of Proxies

Accompanying this Joint Information Circular is a form of proxy for registered Aurora Shareholders. The persons named in the enclosed form of proxy are directors and/or officers of Aurora. **A registered Aurora Shareholder has a choice of voting by proxy on the internet, by phone, by mail or by fax, or by using the form of proxy provided by Aurora to appoint another person (who need not be an Aurora Shareholder) other than the persons designated in the form of proxy provided by Aurora to attend the Aurora Shareholders' Meeting virtually and act on behalf of such Aurora Shareholder, or voting virtually by attending the Aurora Shareholders' Meeting. If an Aurora Shareholder votes by proxy on the internet, by telephone, by mail or by facsimile in advance of the Aurora Shareholders' Meeting, such Aurora Shareholder's vote will be counted, whether or not such Aurora Shareholder attends the Aurora Shareholders' Meeting. Even if an Aurora Shareholder attends the Aurora Shareholders' Meeting, it may be more convenient to vote in advance.** To exercise this right to vote at the Aurora Shareholders' Meeting, the Aurora Shareholder should strike out the names of management designees in the enclosed form of proxy and insert the name of the desired representative in the blank space provided in the form of proxy or submit another appropriate form of proxy. Completed forms of proxy must be received by the transfer agent and registrar of Aurora, Computershare, no later than the Aurora Proxy Deadline.

A registered Aurora Shareholder may vote in one of the following ways: (a) by internet, at the website indicated on the proxy form, for which the control number which is noted on the proxy form will be required; (b) by telephone, at 1-866-732-8683 (toll-free in North America), for which the control number as noted on the proxy form will be required (if an Aurora Shareholder chooses to vote by telephone, such Aurora Shareholder cannot appoint anyone other than the appointees named on the form of proxy as proxyholder); (c) by mailing a completed, signed and dated form of proxy using the enclosed return envelope or an envelope addressed to the registrar and transfer agent of Aurora, Computershare, Attention: Proxy Department, 320 Bay Street, 14th Floor, Toronto, Ontario M5H 4A6; (d) by hand delivery to Computershare, 320 Bay Street, 14th Floor, Toronto, Ontario M5H 4A6; (e) by facsimile, by sending a completed, signed and dated form of proxy to 1-866-249-7775 (toll-free in North America); or (f) virtually at the Aurora Shareholders' Meeting wherein the form of proxy does not need to be completed or returned in advance of the Aurora Shareholders' Meeting.

If you are an Aurora Shareholder and have any questions, need assistance in voting your Aurora Common Shares, please contact your financial, legal or other professional advisors or Kingsdale Advisors for assistance. You can reach Kingsdale Advisors at 1-800-749-9052 (toll-free in North America) or 416-623-4172 (text and call enabled outside North America) or by e-mail at contactus@kingsdaleadvisors.com. For further information visit voteyesaurora.com.

The following applies to Aurora Shareholders who wish to appoint as their proxyholders individuals other than those named in the proxy.

Aurora Shareholders who wish to appoint as their proxyholders individuals other than those named in the proxy to attend and participate in the Aurora Shareholders' Meeting and vote their securities MUST submit their proxies appointing such individuals as proxyholders AND register such proxyholders online, as described below. Registering your proxyholder is an additional step to be completed AFTER you have submitted your proxy. Failure to register the proxyholder will result in the proxyholder not receiving an invite code that is required to vote at the Aurora Shareholders' Meeting.

Step 1: Submit your proxy: To appoint someone other than the individuals named in the proxy as proxyholder, insert that person's name in the blank space provided in the proxy and follow the instructions for submitting such proxy. This must be completed before registering such proxyholder, which is an additional step to be completed once you have submitted your proxy.

Step 2: Register your proxyholder: To register a third-party proxyholder, you must visit https://www.computershare.com/Aurora by the Aurora Proxy Deadline and provide Computershare with the required proxyholder contact information so that Computershare may provide the proxyholder with an invite code via email. **Without an invite code, proxyholders will not be able to vote at the Aurora Shareholders' Meeting but will be able to participate as guests.**

In addition to revocation in any other manner permitted by law, an Aurora Shareholder may revoke or change a previously made proxy vote: (a) by accessing the Aurora Shareholders' Meeting by following the instructions under the heading "*How to Participate at the Aurora Shareholders' Meeting*" in this Joint Information Circular and voting their Aurora Common Shares during the designated time; (b) by an instrument in writing executed by the Aurora Shareholder or such Aurora Shareholder's attorney authorized in writing or, if the Aurora Shareholder is a corporation, under its corporate seal or by an officer or attorney thereof, duly authorized, indicating the capacity under which such officer or attorney is signing and deposited with Computershare, the transfer agent of Aurora, at the office designated in the Notice of Special Meeting of Aurora Shareholders not later than the Aurora Proxy Deadline; or (c) by a duly executed and deposited proxy as provided herein bearing a later date or time than the date or time of the proxy being revoked.

Proxy Voting

The Aurora Common Shares represented by an effective form of proxy will be voted or withheld from voting in accordance with the instructions specified therein. **If an Aurora Shareholder returns the form of proxy but does not indicate how to vote its securities, and does not appoint a person other than the persons designated on the form of proxy, the Aurora Common Shares, as applicable, will be voted:**

- **FOR the approval of the Arrangement Resolution.**

The enclosed applicable form of proxy confers discretionary authority in respect of amendments or variations to matters identified in the Notice of Special Meeting of Aurora Shareholders and with respect to other matters which may properly come before the Aurora Shareholders' Meeting or any adjournment or postponement thereof. As of the date hereof, management of Aurora is not aware of any amendments, variations or other matters to come before the Aurora Shareholders' Meeting. If an Aurora Shareholder attends the Aurora Shareholders' Meeting virtually and is eligible to vote, such Aurora Shareholder can vote on such amendments, variations or other matters that properly come before the Aurora Shareholders' Meeting in accordance with the wishes of such Aurora Shareholder. If an Aurora Shareholder is voting by proxy, the persons named in the form of proxy will have discretionary authority to vote on any such amendments, variations or other matters that may properly come before the Aurora Shareholders' Meeting,

as he or she sees fit for each item of business at the Aurora Shareholders' Meeting. Aurora and Kingsdale Advisors may utilize the Broadridge QuickVote™ service to assist non-registered (beneficial) shareholders with voting their Aurora Common Shares over the telephone.

If you are an Aurora Shareholder and have any questions or need assistance in voting your Aurora Common Shares, please contact your financial, legal or other professional advisors or Kingsdale Advisors for assistance. You can reach Kingsdale Advisors at 1-800-749-9052 (toll-free in North America) or 416-623-4172 (text and call enabled outside North America) or by e-mail at contactus@kingsdaleadvisors.com. For further information visit voteyesaurora.com.

General

Aurora is not using the "**notice-and-access**" procedures under applicable Canadian Securities Laws to send its proxy-related materials to the Aurora Shareholders, and paper copies of such materials will be sent to all Aurora Shareholders. Aurora is sending proxy-related materials indirectly through intermediaries to non-objecting Beneficial Holders and intends to pay for intermediaries to deliver proxy-related materials to objecting Beneficial Holders.

Voting Securities of Aurora and Principal Holders thereof

As at November 18, 2026, there were 65,745,102 Aurora Common Shares issued and outstanding. Each Aurora Common Share entitles the holder thereof to one vote per Aurora Common Share on the Arrangement Resolution at the Aurora Shareholders' Meeting.

Aurora Shareholders are entitled to vote if they were a holder of Aurora Common Shares at the close of business on November 18, 2026, the record date for the Aurora Shareholders' Meeting. Aurora will prepare, as of the Aurora Record Date, a list of Aurora Shareholders entitled to receive the Notice of Special Meeting of Aurora Shareholders, showing the number of Aurora Common Shares held by each such Aurora Shareholder. Aurora Shareholders whose names have been entered in the register of holders of Aurora Common Shares by the close of business on the Aurora Record Date will be entitled to receive notice of and to vote the Aurora Common Shares shown opposite such Aurora Shareholder's name at the Aurora Shareholders' Meeting.

To the knowledge of the directors and executive officers of Aurora, as of November 18, 2026, no person or company beneficially owns, or exercises control or direction over, directly or indirectly, more than 10% of the voting rights attached to all of the outstanding Aurora Common Shares. Curaleaf disclosed in the Original Curaleaf Bid that, to its knowledge after reasonable enquiry, as of August 18, 2026, no Aurora Common Shares or other securities of Aurora were beneficially owned, or subject to control or direction, by Curaleaf, its directors or officers, its insiders or their associates or affiliates, or any person acting jointly or in concert with Curaleaf, and that none of them had purchased or sold any securities of Aurora during the six-month period preceding the Original Curaleaf Bid.

Procedure and Votes Required

Pursuant to the Interim Order:

- each Aurora Common Share entitled to vote at the Aurora Shareholders' Meeting will entitle the holder to one vote at the Aurora Shareholders' Meeting in respect of the Arrangement Resolution;

- the number of votes required to pass the Arrangement Resolution shall be not less than 66⅔% of the votes cast by the Aurora Shareholders, present virtually or represented by proxy and entitled to vote at the Aurora Shareholders' Meeting, voting together as a single class, and a simple majority of such votes cast, excluding the votes attached to Aurora Common Shares held by persons described in items (a) through (d) of section 8.1(2) of MI 61-101, being only Mr. Miguel Martin;

- the quorum required in respect of the Arrangement Resolution at the Aurora Shareholders' Meeting will be two Aurora Shareholders present virtually, or represented by proxy, at the opening of the Aurora Shareholders' Meeting, and holding or representing at least 25% of the Aurora Common Shares entitled to be voted at the Aurora Shareholders' Meeting; and

- subject to the terms of the Arrangement Agreement, Aurora is authorized to adjourn or postpone the Aurora Shareholders' Meeting on one of more occasions without the need for the approval of the Court.

Notwithstanding the foregoing, the Arrangement Resolution authorizes the Aurora Board, without further notice to or approval of the Aurora Shareholders, to the extent permitted by the Arrangement Agreement and the Interim Order, to amend the Arrangement Agreement or the Plan of Arrangement and to not proceed with the Arrangement. See Appendix "A" to this Joint Information Circular for the full text of the Arrangement Resolution.

How to Participate at the Aurora Shareholders' Meeting

The Aurora Shareholders' Meeting will only be hosted online by way of a live webcast. Aurora Shareholders will not be able to attend the Aurora Shareholders' Meeting in person. Registered Aurora Shareholders and duly appointed proxyholders may only attend and participate in the Aurora Shareholders' Meeting virtually via live webcast, including by asking questions and voting online, provided they follow the instructions herein.

- Registered Aurora Shareholders and duly appointed proxyholders who participate by attending online will be able to listen to the proceedings of the Aurora Shareholders' Meeting, ask questions and vote on the applicable resolution during the specified times, provided they remain connected to the internet.

- If you are a non-registered (beneficial) shareholder, and wish to vote your Aurora Common Shares online during the Aurora Shareholders' Meeting, you must follow the instructions under the heading "*Information for Beneficial Holders*" and appoint yourself as proxyholder. Non-registered (beneficial) shareholders who have not duly appointed themselves as proxyholders may still attend the Aurora Shareholders' Meeting as guests, but will not be able to vote.

- Guests, including non-registered (beneficial) shareholders who have not duly appointed themselves as proxyholder, will be able to log in and listen to the proceedings of the Aurora Shareholders' Meeting but will not be able to vote or submit questions.

- Attendees can log in to the Aurora Shareholders' Meeting by following the instructions below.

    - Log in online at: meetnow.global/MQAVTRW. The virtual meeting platform is fully supported across most commonly used web browsers (note: Internet Explorer is not a supported browser). Aurora encourages you to log in prior to the start of the Aurora Shareholders' Meeting. You should allow ample time to log in to the Aurora Shareholders' Meeting to check compatibility and complete the related procedures.

    - For registered Aurora Shareholders, click "Shareholder" and enter your 15-digit control number; for duly appointed proxyholders, click "Invitation" and enter your invite code.

      OR

    - Click "Guest" and then complete the online form to access the Aurora Shareholders' Meeting.

Aurora believes that the ability to participate in the Aurora Shareholders' Meeting in a meaningful way remains important despite the decision to hold the Aurora Shareholders' Meeting virtually. It is anticipated that registered Aurora Shareholders and duly appointed proxyholders will have substantially the same opportunity to ask questions on matters of business before the Aurora Shareholders' Meeting as if the Aurora Shareholders' Meeting was being held in person. Aurora Shareholders will have the opportunity to submit questions at the Aurora Shareholders' Meeting by submitting them in writing through the virtual meeting platform. Any Aurora Shareholder who wishes to pose questions in advance of the Aurora Shareholders' Meeting is invited to send them by email to ir@auroramj.com. Questions received from Aurora Shareholders which relate to the business of the Aurora Shareholders' Meeting are expected to be addressed at a specified time during the course of the Aurora Shareholders' Meeting. Such questions will be read by the Chair of the Aurora Shareholders' Meeting or a designee of the Chair of the Aurora Shareholders' Meeting and responded to by a representative of Aurora. To ensure fairness for all attendees, the Chair of the Aurora

Shareholders' Meeting will decide on the amount of time allocated to each question and will have the right to limit or consolidate questions and to reject questions that do not relate to the business of the Aurora Shareholders' Meeting or which are determined to be inappropriate or otherwise out of order.

For registered Aurora Shareholders: The 15-digit control number located on the form of proxy or in the email notification delivered for the Aurora Shareholders' Meeting is the control number to log in to the Aurora Shareholders' Meeting. For duly appointed proxyholders: Computershare will provide the proxyholder with an invite code by email after the Aurora Proxy Deadline has passed provided that the proxyholder has been duly appointed and registered at https://www.computershare.com/Aurora as described in this Joint Information Circular. United States beneficial Aurora Shareholders must first obtain a valid legal proxy from their broker, bank or other agent and then register in advance with Computershare to attend the Aurora Shareholders' Meeting.

If an Aurora Shareholder attends the Aurora Shareholders' Meeting online, it is important to remain connected to the internet at all times in order to vote when the applicable balloting commences. It is the responsibility of such Aurora Shareholder to ensure internet connectivity is maintained for the duration of the Aurora Shareholders' Meeting. If you lose connectivity once the Aurora Shareholders' Meeting has commenced, there may be insufficient time to resolve your issue before ballot voting is completed. If you have any doubt of your system's compatibility or encounter technical difficulties, please contact Computershare at 1-888-724-2416 or internationally at 1-781-575-2748.

GENERAL PROXY MATTERS – ORGANIGRAM

Solicitation of Proxies

This Joint Information Circular is delivered in connection with the solicitation by or on behalf of management of Organigram of proxies for use at the Organigram Shareholders' Meeting. The cost of soliciting proxies will be borne by Organigram. The solicitation of proxies will be done primarily by mail and electronic means, but may also be solicited personally (virtually), by telephone, facsimile or other similar means by directors, officers, employees or agents of Organigram.

Organigram has engaged Sodali & Co as its proxy solicitation and information agent to assist management of Organigram in the solicitation of proxies from Organigram Shareholders for the Organigram Shareholders' Meeting. Organigram has agreed to pay Sodali & Co a fee for proxy solicitation services of approximately $125,000, plus a fee for inbound and outbound calls with Organigram Shareholders and reimbursement of disbursements. Organigram will bear the costs of this solicitation. The costs of preparing and distributing this Joint Information Circular and the other Meeting Materials will be borne by Organigram and Aurora, as applicable.

The Organigram Shareholders' Meeting is being called to seek the requisite approval of Organigram Shareholders of the Organigram Share Issuance Resolution. See "*The Arrangement*", "*Effect of the Arrangement*" and "*Matters to be Considered at the Organigram Shareholders' Meeting*".

The information set forth below generally applies to registered holders of Organigram Common Shares. If you are a Beneficial Holder of Organigram Common Shares (i.e., your Organigram Common Shares are held through a broker, investment dealer, bank, trust company, custodian, nominee or other intermediary), see "*Information for Beneficial Holders*" at the front of this Joint Information Circular.

Appointment and Revocation of Proxies

Accompanying this Joint Information Circular is a form of proxy for registered holders of Organigram Common Shares. The persons named in the enclosed form of proxy are directors and/or officers of Organigram. **A registered Organigram Shareholder has a choice of voting by proxy on the internet, by mail or hand delivery or by fax or by using the form of proxy provided by Organigram to appoint another person (who need not be an Organigram Shareholder) other than the persons designated in the form of proxy provided by Organigram to attend the Organigram Shareholders' Meeting virtually and act on behalf of such Organigram Shareholder, or voting virtually by attending the Organigram Shareholders' Meeting. If an Organigram Shareholder votes by proxy on the internet, by mail or hand delivery or by facsimile in advance of the Organigram Shareholders' Meeting, such Organigram Shareholder's vote will be counted, whether or not such Organigram Shareholder attends the Organigram Shareholders' Meeting. Even if an Organigram Shareholder attends the Organigram Shareholders' Meeting, it may be more convenient to vote in advance.** To exercise this right to vote at the Organigram Shareholders' Meeting, the Organigram Shareholder should strike out the names of management designees in the enclosed form of proxy and insert the name of the desired representative in the blank space provided in the form of proxy or submit another appropriate form of proxy. Completed forms of proxy must be received by the transfer agent and registrar of Organigram, TSX Trust Company, no later than the Organigram Proxy Deadline.

A registered Organigram Shareholder may vote in one of the following ways: (a) by internet, at www.voteproxyonline.com, for which the 12-digit control number which is noted on the proxy form will be required; (b) by mailing a completed, signed and dated form of proxy using the enclosed return envelope or an envelope addressed to the registrar and transfer agent of Organigram, TSX Trust Company, 100 Adelaide Street West, Suite 301, Toronto, Ontario M5H 4H1; (c) by hand delivery to TSX Trust Company, 100 Adelaide Street West, Suite 301, Toronto, Ontario M5H 4H1; (d) by facsimile, by sending a completed, signed and dated form of proxy to 416-595-9593; or (e) virtually at the Organigram Shareholders' Meeting wherein the form of proxy does not need to be completed or returned in advance of the Organigram Shareholders' Meeting.

If you are an Organigram Shareholder and have any questions or need assistance in voting your Organigram Common Shares, please contact your financial, legal or other professional advisors or Sodali & Co for assistance. You can reach

Sodali & Co at 1-833-830-9806 (North America) (1-289-695-3075 for calls outside North America) or by e-mail at assistance@investor.sodali.com.

The following applies to Organigram Shareholders who wish to appoint as their proxyholders individuals other than those named in the proxy.

Organigram Shareholders who wish to appoint as their proxyholders individuals other than those named in the proxy to attend and participate in the Organigram Shareholders' Meeting and vote their securities MUST submit their proxies appointing such individuals as proxyholders AND register such proxyholders online, as described below. Registering your proxyholder is an additional step to be completed AFTER you have submitted your proxy. Failure to register the proxyholder will result in the proxyholder not receiving a Meeting Access Number that is required to vote at the Organigram Shareholders' Meeting.

Step 1: Submit your proxy: To appoint someone other than the individuals named in the proxy as proxyholder, insert that person's name in the blank space provided in the proxy and follow the instructions for submitting such proxy. This must be completed before registering such proxyholder, which is an additional step to be completed once you have submitted your proxy.

Step 2: Register your proxyholder: To register a third-party proxyholder, you must visit tsxtrust.com/ resource/en/75 by the Organigram Proxy Deadline and provide TSX Trust with the required proxyholder contact information so that TSX Trust may provide the proxyholder with a Meeting Access Number via email. **Without a Meeting Access Number, proxyholders will not be able to vote or ask questions at the Organigram Shareholders' Meeting but will be able to participate as guests.**

In addition to revocation in any other manner permitted by law, an Organigram Shareholder may revoke or change a previously made proxy vote: (a) by attending the Organigram Shareholders' Meeting by following the instructions under the heading "*General Proxy Matters – Organigram – How to Participate at the Organigram Shareholders' Meeting*" in this Joint Information Circular and voting their Organigram Common Shares during the designated time; (b) by an instrument in writing executed by the Organigram Shareholder or such Organigram Shareholder's attorney authorized in writing or if the Organigram Shareholder is a corporation, under its corporate seal or by an officer or attorney thereof, duly authorized, indicating the capacity under which such officer or attorney is signing and deposited with TSX Trust Company, the transfer agent of Organigram, at the office designated in the Notice of Special Meeting of Organigram Shareholders not later than the Organigram Proxy Deadline; or (c) by a duly executed and deposited proxy as provided herein bearing a later date or time than the date or time of the proxy being revoked.

Proxy Voting

The Organigram Common Shares represented by an effective form of proxy will be voted or withheld from voting in accordance with such Organigram Shareholder's instructions. If an Organigram Shareholder returns the form of proxy but does not indicate how to vote such Organigram Common Shares, and does not appoint a person other than the persons designated on the form of proxy, **such Organigram Common Shares will be voted FOR approval of the Organigram Share Issuance Resolution. In respect of any other matters other than those set forth above which are to be considered at the Organigram Shareholders' Meeting, where no choice is specified, the Organigram Common Shares will be voted in favour of each matter identified in the accompanying Notice of Special Meeting of Organigram Shareholders.** Organigram Shareholders have the right to appoint a person other than the persons designated in the enclosed form of proxy as proxyholder to vote the Organigram Common Shares on their behalf.

The enclosed applicable form of proxy confers discretionary authority in respect of amendments or variations to matters identified in the Notice of Special Meeting of Organigram Shareholders and with respect to other matters which may properly come before the Organigram Shareholders' Meeting or any adjournment or postponement thereof. As of the date hereof, management of Organigram is not aware of any amendments, variations or other matters to come before the Organigram Shareholders' Meeting. If an Organigram Shareholder attends the Organigram Shareholders' Meeting virtually and is eligible to vote, such Organigram Shareholder can vote on any amendments, variations or other matters that properly come before the Organigram Shareholders' Meeting in accordance with the wishes of such Organigram Shareholder. If an Organigram Shareholder is voting by proxy, the persons named in the form of proxy will have discretionary authority to vote on any such amendments, variations or other matters that may

properly come before the Organigram Shareholders' Meeting, as he or she sees fit for each item of business at the Organigram Shareholders' Meeting.

Organigram may utilize the Broadridge QuickVote™ system, which involves non-objecting Beneficial Holders being contacted by Sodali & Co to obtain voting instructions over the telephone and relaying them to Broadridge (on behalf of the non-objecting Beneficial Shareholder's intermediary). While representatives of Sodali & Co. are soliciting proxies on behalf of Organigram's management, Shareholders are not required to vote in the manner recommended by the Organigram Board. The QuickVote™ system is intended to assist non-objecting Beneficial Shareholder in placing their votes; however, there is no obligation for any Beneficial Holders to vote using the QuickVote™ system, and Beneficial Holders may vote (or change or revoke their votes) at any other time and in any other applicable manner described in this Joint Information Circular. Any voting instructions provided by a Beneficial Shareholder using the QuickVote™ system will be recorded and such Beneficial Shareholder will receive a letter from Broadridge (on behalf of the Beneficial Shareholder's Intermediary) as confirmation that their voting instructions have been accepted.

If you are an Organigram Shareholder and have any questions or need assistance in voting your Organigram Common Shares, please contact your financial, legal or other professional advisors or Sodali & Co for assistance. You can reach Sodali & Co at 1-833-830-9806 (North America) (1-289-695-3075 for calls outside North America) or by e-mail at assistance@investor.sodali.com.

General

Organigram is not using the "**notice-and-access**" procedures under applicable Canadian Securities Laws to send its proxy-related materials to the Organigram Shareholders, and paper copies of such materials will be sent to all Organigram Shareholders. Organigram is sending proxy-related materials indirectly through intermediaries to non-objecting Beneficial Holders and intends to pay for intermediaries to deliver proxy-related materials to objecting Beneficial Holders.

Voting Securities of Organigram and Principal Holders thereof

As at November 18, 2026, there were 141,114,081 Organigram Common Shares issued and outstanding, which are its only outstanding voting securities. Each Organigram Common Share entitles the holder thereof to one vote on a ballot at the Organigram Shareholders' Meeting. The Organigram Preferred Shares do not carry the right to vote at the Organigram Shareholders' Meeting.

Organigram Shareholders are entitled to vote if they were a holder of Organigram Common Shares at the close of business on November 18, 2026, the record date for the Organigram Shareholders' Meeting. Organigram will prepare, as of the Organigram Record Date, a list of Organigram Shareholders entitled to receive the Notice of Special Meeting of Organigram Shareholders and showing the number of Organigram Common Shares held by each such Organigram Shareholder. Organigram Shareholders whose names have been entered in the register of holders of Organigram Common Shares at the close of business on the Organigram Record Date will be entitled to receive notice of and to vote the Organigram Common Shares shown opposite such Organigram Shareholder's name at the Organigram Shareholders' Meeting.

To the knowledge of the directors and executive officers of Organigram, as of November 18, 2026, no person or company beneficially owns, or exercises control or direction over, directly or indirectly, more than 10% of the voting rights attached to all of the outstanding Organigram Common Shares, other than BAT, which beneficially owns 42,231,089 Organigram Common Shares, representing approximately 30% of the outstanding Organigram Common Shares, and all of the 49,204,021 outstanding Organigram Preferred Shares.

Procedure and Votes Required

The Organigram Share Issuance Resolution must be approved by greater than (i) 50% of the votes cast by Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting and (ii) 50% of the votes cast by the Organigram Shareholders present virtually or represented by proxy at the Organigram Shareholders' Meeting, excluding the votes attached to Organigram Common Shares held by BAT and its affiliates (and, for purposes

of MI 61-101, their respective directors and officers and other persons required to be excluded). To the knowledge of Organigram, 42,231,089 Organigram Common Shares, representing approximately 30% of the outstanding Organigram Common Shares, will be excluded from such vote. Under Organigram's by-laws, a quorum for the Organigram Shareholders' Meeting is at least two individuals present at the commencement of the Organigram Shareholders' Meeting holding, or representing by proxy the holder or holders of, Organigram Common Shares carrying in the aggregate not less than 10% of the votes eligible to be cast at the Organigram Shareholders' Meeting.

How to Participate at the Organigram Shareholders' Meeting

The Organigram Shareholders' Meeting will only be hosted online by way of a live audio webcast at virtual-meetings.tsxtrust.com/2000 using the meeting password "ogi2026" (case sensitive). Organigram Shareholders will not be able to attend the Organigram Shareholders' Meeting in person. Registered Organigram Shareholders and duly appointed proxyholders may only attend and participate in the Organigram Shareholders' Meeting virtually via live audio webcast, including by asking questions and voting online, provided they follow the instructions herein and in the TSX Trust virtual meeting guide accompanying the Meeting Materials. Whether or not Organigram Shareholders plan to attend the Organigram Shareholders' Meeting virtually, registered Organigram Shareholders and non-registered Organigram Shareholders are encouraged to vote in advance of the Organigram Shareholders' Meeting.

- Registered Organigram Shareholders and duly appointed proxyholders who participate by attending online will be able to listen to the proceedings of the Organigram Shareholders' Meeting, ask questions and vote on the Organigram Share Issuance Resolution during the specified times, provided they remain connected to the internet.

- If you are a non-registered (beneficial) shareholder and wish to vote your Organigram Common Shares online during the Organigram Shareholders' Meeting, you must contact your intermediary well in advance of the Organigram Shareholders' Meeting, follow the instructions under the heading "*Information for Beneficial Holders*", appoint yourself as proxyholder and register yourself with TSX Trust at tsxtrust.com/resource/en/75 by the Organigram Proxy Deadline. Non-registered (beneficial) shareholders who have not duly appointed themselves as proxyholders may still attend the Organigram Shareholders' Meeting as guests, but will not be able to vote or ask questions.

- To attend the Organigram Shareholders' Meeting, go to https://virtual-meetings.tsxtrust.com/2000 in your web browser on your smartphone, tablet or computer. Registered Organigram Shareholders and duly appointed proxyholders should select "I have a Control Number / Meeting Access Number" and enter their 12-digit control number (located on the form of proxy or in the email notification received from TSX Trust) or Meeting Access Number, as applicable, and the meeting password "ogi2026" (case sensitive). Guests should select "I am a Guest" and fill in the required information. You will need the latest version of Chrome, Safari, Edge or Firefox (Internet Explorer is not a supported browser). Organigram recommends that you log in at least fifteen (15) minutes before the Organigram Shareholders' Meeting starts. Once voting is announced, click the voting icon, select your voting direction and click "Submit". If you use your control number to log in and vote at the Organigram Shareholders' Meeting, any vote you cast will revoke any proxy you previously submitted.

- Registered Organigram Shareholders and duly appointed proxyholders are eligible to ask questions in writing through the virtual meeting platform during the Q&A portion of the Organigram Shareholders' Meeting by selecting the messaging icon, typing their question in the chat box and clicking "Ask Now", at any time until the Chair closes the Q&A session. Questions will be moderated before being sent to the Chair. Guests may not ask questions. If you experience technical difficulties during the registration process or while accessing and attending the Organigram Shareholders' Meeting, please contact TSX Trust, the provider of the virtual meeting interface, 1-866-600-5869 or tsxtis@tmx.com, or refer to TSX Trust's Virtual Meeting Frequently Asked Questions page at https://www.tsxtrust.com/vagm-faq.

Any questions pertinent to the Organigram Shareholders' Meeting that cannot be answered during the Organigram Shareholders' Meeting due to time constraints will be posted online and answered at https://investors.organigram.ca/. The questions and answers will be available on Organigram's investor page as soon as practicable after the Organigram

Shareholders' Meeting and will remain available until one week after posting. The Chair of the Organigram Shareholders' Meeting has broad authority in all matters pertaining to the Organigram Shareholders' Meeting. To ensure that the Organigram Shareholders' Meeting is conducted in a timely manner, the Chair may exercise broad discretion with respect to, for example and without limitation, the questions and topics that will be addressed at the Organigram Shareholders' Meeting and the amount of time devoted to any question or topic. If there are any matters of individual concern to an Organigram Shareholder and not of general concern to all Organigram Shareholders, or if a question posed was not otherwise answered, such matters may be raised separately after the Organigram Shareholders' Meeting by contacting Organigram's Director of Investor Relations by email at investors@organigram.ca.

EXPENSES OF THE ARRANGEMENT

The estimated costs to be incurred by Aurora and Organigram with respect to the Arrangement, including legal, financial advisory, accounting, filing, depositary, proxy solicitation and printing and mailing costs, are approximately $26.0 million and $15.2 million, respectively. Except as otherwise provided in the Arrangement Agreement (including with respect to the termination fees and the Expense Fee), each Party will pay its own expenses, and Organigram will pay all regulatory filing fees (including any applicable taxes).

DEPOSITARY

Computershare Investor Services Inc. has been appointed as Depositary under the Arrangement to receive Letters of Transmittal and Election Forms and deposited certificates and DRS Advices, and to deliver the Consideration. The Depositary will receive reasonable and customary compensation and be reimbursed for certain out-of-pocket expenses. Documents to be received by the Depositary can be sent either by hand or by courier to 320 Bay Street, 14th Floor, Toronto, Ontario M5H 4A6, or by mail to P.O. Box 7021, 31 Adelaide St E, Toronto, ON M5C 3H2.

LEGAL MATTERS AND INTERESTS OF EXPERTS

Certain legal matters in connection with the Arrangement will be passed upon by Stikeman, on behalf of Aurora, and Goodmans, on behalf of Organigram. As at the date hereof, the partners and associates of each of Stikeman and Goodmans, as a group, beneficially own, directly or indirectly, less than 1% of the outstanding securities of Aurora or Organigram. Fort Capital, Origin and BMO Capital Markets have prepared the fairness opinions attached as Appendices "F" and "G" and have consented to their inclusion in this Joint Information Circular. See "*Consents*". Aurora's auditor, Ernst & Young LLP, has advised that it is independent of Aurora, and Organigram's former auditor, PKF O'Connor Davies, LLP, has advised that it was independent of Organigram, in each case within the meaning of the applicable rules of professional conduct.

ADDITIONAL INFORMATION

Additional information relating to Aurora and Organigram is available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Financial information is provided in each company's comparative financial statements and management's discussion and analysis for its most recently completed financial year and subsequent interim period.

QUESTIONS AND OTHER ASSISTANCE

If you are an Organigram Shareholder or an Aurora Shareholder and you have any questions about the information contained in this Joint Information Circular or require assistance in completing your form of proxy, Voting Instruction Form or Letter of Transmittal and Election Form, please contact your financial, legal, tax or other professional advisors.

AURORA DIRECTORS' APPROVAL

The contents of this Joint Information Circular, insofar as it relates to Aurora, and the sending thereof to the Aurora Shareholders entitled to notice of the Aurora Shareholders' Meeting, have been approved by the Aurora Board. A copy of this Joint Information Circular has been sent to: (a) each director of Aurora; (b) each Aurora Shareholder entitled to notice of the Aurora Shareholders' Meeting; and (c) the auditor of Aurora.

DATED this 20th day of November, 2026.

BY ORDER OF THE BOARD OF DIRECTORS
OF AURORA CANNABIS INC.

(signed) "Miguel Martin"

Miguel Martin
Executive Chairman and Chief Executive Officer

ORGANIGRAM DIRECTORS' APPROVAL

The contents of this Joint Information Circular, insofar as it relates to Organigram, and the sending thereof to the Organigram Shareholders entitled to notice of the Organigram Shareholders' Meeting, have been approved by the Organigram Board. A copy of this Joint Information Circular has been sent to: (a) each director of Organigram; (b) each Organigram Shareholder entitled to notice of the Organigram Shareholders' Meeting; and (c) the auditor of Organigram.

DATED this 20th day of November, 2026.

BY ORDER OF THE BOARD OF DIRECTORS
OF ORGANIGRAM GLOBAL INC.

(signed) "James Yamanaka"

James Yamanaka
Chief Executive Officer

CONSENTS

Consent of Fort Capital Partners

To the Board of Directors of Aurora Cannabis Inc. (the "**Aurora Board**"):

We refer to the full text of the written fairness opinion dated November 2, 2026 (the "**Fort Capital Fairness Opinion**"), which we prepared solely for the benefit and use of the Aurora Board in connection with the arrangement involving Aurora Cannabis Inc. and Organigram Global Inc., as described in the joint management information circular of Aurora Cannabis Inc. and Organigram Global Inc. dated November 20, 2026 (the "**Circular**").

We consent to the inclusion of the full text of the Fort Capital Fairness Opinion as part of Appendix "F" – "*Aurora Fairness Opinions*" to the Circular and to the references to our firm name and to the Fort Capital Fairness Opinion in the Circular.

In providing such consent, we do not intend that any person other than the Aurora Board shall be entitled to rely upon the Fort Capital Fairness Opinion.

November 20, 2026

(signed) "*Fort Capital Partners*"

FORT CAPITAL PARTNERS

Consent of Origin Merchant Partners

To the Board of Directors (the "**Aurora Board**") of Aurora Cannabis Inc. and the Special Committee of the Aurora Board (the "**Aurora Special Committee**"):

We refer to the full text of the written fairness opinion dated November 2, 2026 (the "**Origin Fairness Opinion**"), which we prepared solely for the benefit and use of the Aurora Special Committee and the Aurora Board in connection with the arrangement involving Aurora Cannabis Inc. and Organigram Global Inc., as described in the joint management information circular of Aurora Cannabis Inc. and Organigram Global Inc. dated November 20, 2026 (the "**Circular**").

We consent to the inclusion of the full text of the Origin Fairness Opinion as part of Appendix "F" – "*Aurora Fairness Opinions*" to the Circular and to the references to our firm name and to the Origin Fairness Opinion in the Circular.

In providing such consent, we do not intend that any person other than the Aurora Special Committee and the Aurora Board shall be entitled to rely upon the Origin Fairness Opinion.

November 20, 2026

(signed) "*Origin Merchant Partners*"

ORIGIN MERCHANT PARTNERS

Consent of BMO Nesbitt Burns Inc.

To the Board of Directors of Organigram Global Inc. (the "**Organigram Board**"):

We refer to the full text of the written fairness opinion dated November 2, 2026 (the "**Organigram Fairness Opinion**"), which we prepared solely for the benefit and use of the Organigram Board in connection with the arrangement involving Organigram Global Inc. and Aurora Cannabis Inc., as described in the joint management information circular of Aurora Cannabis Inc. and Organigram Global Inc. dated November 20, 2026 (the "**Circular**").

We consent to the inclusion of the full text of the Organigram Fairness Opinion as Appendix "G" – "*Organigram Fairness Opinion*" to the Circular and to the references to our firm name and to the Organigram Fairness Opinion in the Circular.

In providing such consent, we do not intend that any person other than the Organigram Board shall be entitled to rely upon the Organigram Fairness Opinion.

November 20, 2026

(signed) "*BMO Nesbitt Burns Inc.*"

BMO NESBITT BURNS INC.

APPENDIX "A"
ARRANGEMENT RESOLUTION

"**BE IT RESOLVED, AS A SPECIAL RESOLUTION, THAT:**

1. **The arrangement (the** "**Arrangement**") under section 288 of the Business Corporations Act (British Columbia) (the "**BCBCA**") involving Aurora Cannabis Inc. (the "**Company**"), the holders of the common shares of the Company (the "**Shareholders**") and Organigram Global Inc. ("**Organigram**"), as more particularly described and set forth in the joint management information circular of Organigram and the Company dated November 20, 2026 accompanying the notice of this meeting, as the Arrangement may be modified or amended in accordance with its terms, and all transactions contemplated thereby, are hereby authorized, approved and adopted.

2. The plan of arrangement (the "**Plan of Arrangement**") involving the Company, the Shareholders and Organigram, the full text of which is set out as Schedule A to the arrangement agreement dated November 2, 2026 between Organigram and the Company (as supplemented, modified or amended, the "**Arrangement Agreement**"), as the Plan of Arrangement may be modified or amended in accordance with its terms, is hereby authorized, approved and adopted.

3. The Arrangement Agreement, and all transactions contemplated therein, the actions of the directors of the Company in approving the Arrangement and the Arrangement Agreement and the actions of the directors and officers of the Company in executing and delivering the Arrangement Agreement and any amendments thereto in accordance with its terms and causing the performance by the Company of its obligations thereunder are hereby confirmed, ratified, authorized and approved.

4. Notwithstanding that this resolution has been passed (and the Plan of Arrangement adopted) by the Shareholders or that the Arrangement has been approved by the Supreme Court of British Columbia, the directors of the Company are hereby authorized and empowered, without further notice to or approval of the Shareholders (a) to amend the Arrangement Agreement or the Plan of Arrangement, to the extent permitted by the Arrangement Agreement and the Plan of Arrangement, and (b) subject to the terms of the Arrangement Agreement, to disregard the Shareholders' approval and not proceed with the Arrangement and to revoke this resolution at any time prior to the Effective Time (as defined in the Arrangement Agreement).

5. The Company is hereby authorized to apply for a final order from the Supreme Court of British Columbia to approve the Arrangement on the terms set forth in the Arrangement Agreement and the Plan of Arrangement (as they may be amended, modified or supplemented).

6. Any one director or officer of the Company be and is hereby authorized and directed for and on behalf of the Company to execute, under the corporate seal of the Company or otherwise, and to deliver to the Registrar for filing the records and information required under section 292 of the BCBCA and such other documents as are necessary or desirable to give effect to the Arrangement and the Plan of Arrangement in accordance with the Arrangement Agreement.

7. Any one director or officer of the Company be and is hereby authorized and directed for and on behalf of the Company to execute or cause to be executed, under the corporate seal of the Company or otherwise, and to deliver or cause to be delivered, all such other documents and instruments and to perform or cause to be performed all such other acts and things as in such person's opinion may be necessary or desirable to give full effect to the foregoing resolutions and the matters authorized thereby, such determination to be conclusively evidenced by the execution and delivery of such document, agreement or instrument or the doing of any such act or thing."

APPENDIX "B"
ORGANIGRAM SHARE ISSUANCE RESOLUTION

"**BE IT RESOLVED, AS AN ORDINARY RESOLUTION THAT:**

1. The holders of common shares of Organigram Global Inc. ("**Organigram**") hereby authorize and approve the issuance of up to 223,071,951 common shares of Organigram (the "**Arrangement Consideration Shares**") in connection with the acquisition of all of the issued and outstanding common shares of Aurora Cannabis Inc. ("**Aurora**"), including those Arrangement Consideration Shares that are issuable upon the exercise of the Organigram replacement options, which figure includes a 5% buffer to account for clerical and administrative matters or changes in the number of common shares of Aurora outstanding between the date hereof and the closing of the Arrangement, all in accordance with the arrangement (the "**Arrangement**") described in the joint management information circular of Organigram and Aurora dated November 20, 2026 (the "**Circular**"), the arrangement agreement dated as of November 2, 2026 between Organigram and Aurora (as may be modified or amended, the "**Arrangement Agreement**"), and the related plan of arrangement (as may be modified or amended, the "**Plan of Arrangement**"), the full text of which is set out in Appendix "C" to the Circular.

2. The holders of common shares of Organigram hereby authorize and approve the issuance of up to 140,986,255 common shares of Organigram and/or Class A preferred shares of Organigram (the "**Private Placement Shares**") to BT DE Investments Inc. ("**BAT**") on a private placement basis (the "**BAT Private Placement**") in connection with the Arrangement and pursuant to the subscription agreement between Organigram and BAT dated November 2, 2026 (the "**BAT Equity Commitment**"), which approval, for greater certainty, includes any common shares of Organigram issued upon the conversion of Class A preferred shares of Organigram issued pursuant to the BAT Private Placement as described further in the Circular.

3. Notwithstanding that this resolution has been passed by the holders of common shares of Organigram, or that the Arrangement has been approved by the Supreme Court of British Columbia, the directors of Organigram are hereby authorized and empowered, without further notice to or approval of the holders of common shares of Organigram: (a) to amend the Arrangement Agreement or the Plan of Arrangement, to the extent permitted by the Arrangement Agreement or the Plan of Arrangement, as applicable, and to amend the BAT Equity Commitment, to the extent permitted thereby, including to increase the number of Arrangement Consideration Shares or Private Placement Shares issuable thereunder (subject to the limitations imposed by the Toronto Stock Exchange); and (b) subject to the terms of the Arrangement Agreement and the BAT Equity Commitment, as applicable, to disregard the approval of the holders of common shares of Organigram of this resolution and not proceed with the Arrangement and/or the BAT Private Placement.

4. Any one director or officer of Organigram be and is hereby authorized and directed, for and on behalf of Organigram, to execute or cause to be executed, under the corporate seal of Organigram or otherwise, and to deliver or cause to be delivered, all such other documents, agreements and instruments and to perform or cause to be performed all such other acts and things as in such person's opinion may be necessary or desirable to give full effect to the foregoing resolutions and the matters authorized thereby, such determination to be conclusively evidenced by the execution and delivery of such document, agreement or instrument or the doing of any such act or thing."

APPENDIX "C"
PLAN OF ARRANGEMENT

(See attached)

SCHEDULE A
PLAN OF ARRANGEMENT

UNDER SECTION 288 OF THE *BUSINESS CORPORATIONS ACT* (BRITISH COLUMBIA)

ARTICLE 1
INTERPRETATION

Section 1.1 Definitions.

Unless indicated otherwise, where used in this Plan of Arrangement, capitalized terms used but not defined shall have the meanings specified in the Arrangement Agreement and the following terms shall have the following meanings (and grammatical variations of such terms shall have corresponding meanings):

"**Arrangement**" means the arrangement pursuant to Section 288 of the BCBCA on the terms and subject to the conditions set out in this Plan of Arrangement, subject to any amendments or variations to this Plan of Arrangement made in accordance with the terms of the Arrangement Agreement and Section 7.1 or made at the direction of the Court in the Final Order with the prior written consent of the Parties, each acting reasonably.

"**Arrangement Agreement**" means the arrangement agreement, together with the Schedules attached thereto, the Aurora Disclosure Letter and the Purchaser Disclosure Letter, dated November 2, 2026, between the Purchaser and Aurora as the same may be amended, supplemented or otherwise modified from time to time in accordance with its terms.

"**Arrangement Filings**" means the records and information required under Section 292 of the BCBCA to be filed with the Registrar to give effect to the Arrangement after the Final Order is made, together with a copy of the entered Final Order, in a form and content satisfactory to the Parties, each acting reasonably.

"**Arrangement Resolution**" means the special resolution of the Shareholders approving the Arrangement to be considered at the Aurora Meeting, substantially in the form of Schedule B to the Arrangement Agreement.

"**Aurora**" means Aurora Cannabis Inc., a corporation existing under the laws of the Province of British Columbia.

"**Aurora Cash DSUs**" means the outstanding deferred share units issued under the Aurora DSU Cash Plan.

"**Aurora Cash RSUs**" means the outstanding restricted share units issued under the Aurora PRSU Cash Plan.

"**Aurora Cash PSUs**" means the outstanding performance share units issued under the Aurora PRSU Cash Plan.

"**Aurora DSU Cash Holders**" means holders of Aurora Cash DSUs.

"**Aurora DSU Cash Plan**" means the non-employee directors deferred share unit cash plan of Aurora effective June 8, 2023, as amended effective August 9, 2024.

"**Aurora DSU Holders**" means, collectively, the Aurora DSU Cash Holders and the Aurora DSU Share Holders.

"**Aurora DSU Share Holders**" means holders of Aurora Share DSUs.

"**Aurora DSU Share Plan**" means the non-employee directors deferred share unit plan of Aurora effective October 5, 2018, as amended, including as amended by the Aurora Shareholders on November 12, 2020, November 14, 2022 and August 9, 2024.

"**Aurora DSUs**" means, collectively, the Aurora Cash DSUs and the Aurora Share DSUs.

"**Aurora Meeting**" means the special meeting of Shareholders, including any adjournment or postponement of such special meeting in accordance with the terms of the Arrangement Agreement, to be called and held in accordance with the Interim Order to consider the Arrangement Resolution and for any other purpose as may be set out in the Joint Circular and agreed to in writing by the Parties.

"**Aurora Option Holders**" means holders of Aurora Options.

"**Aurora Options**" means the outstanding options to purchase Shares granted under or otherwise subject to the Aurora Stock Option Plan.

"**Aurora PSU Cash Holders**" means holders of Aurora Cash PSUs.

"**Aurora PSU Holders**" means, collectively, the Aurora PSU Cash Holders and the Aurora PSU Share Holders.

"**Aurora PSU Share Plan**" means the performance share unit plan of Aurora instituted effective as of August 8, 2025.

"**Aurora PSU Share Holders**" means the holders of Aurora Share PSUs.

"**Aurora PSUs**" means, collectively, the Aurora Cash PSUs and the Aurora Share PSUs.

"**Aurora PRSU Cash Plan**" means the performance share unit and restricted share unit long-term cash settled plan of Aurora effective June 8, 2023, as amended effective August 8, 2025.

"**Aurora RSU Cash Holders**" means holders of Aurora Cash RSUs.

"**Aurora RSU Holders**" means, collectively, the Aurora RSU Cash Holders and the Aurora RSU Share Holders.

"**Aurora RSU Share Holders**" means holders of Aurora Share RSUs.

"**Aurora RSU Share Plan**" means the restricted share unit plan of Aurora last approved by the Aurora Shareholders on August 8, 2025, as amended by the Aurora Board on June 10, 2026.

"**Aurora RSUs**" means, collectively, the Aurora Cash RSUs and the Aurora Share RSUs.

"**Aurora Share DSUs**" means the outstanding deferred share units issued under the Aurora DSU Share Plan.

"**Aurora Share PSUs**" means the outstanding performance share units issued under the Aurora PSU Share Plan.

"**Aurora Share RSUs**" means the outstanding restricted share units issued under the Aurora RSU Share Plan.

"**Aurora Shareholder Rights Plan**" means the Amended and Restated Shareholder Rights Plan Agreement dated as of October 4, 2018 between Aurora and Computershare Trust Company of Canada, as rights agent.

"**Aurora Stock Option Plan**" means the share option plan of Aurora dated August 8, 2025.

"**Available Cash Election Amount**" means, expressed in dollars, an amount equal to the greater of (A) zero; and (B) the Cash Maximum, less: (i) the aggregate amount of Cash Consideration payable to Combination Electing Shareholders and (ii) the aggregate amount of Cash Consideration that would be payable to Dissenting Shareholders if each Dissenting Shareholder were a Combination Electing Shareholder.

"**Available Share Election Number**" means the Share Maximum less: (i) the aggregate number of Consideration Shares deliverable to Combination Electing Shareholders and (ii) the aggregate number of Consideration Shares that would be payable to Dissenting Shareholders if each Dissenting Shareholder were a Combination Electing Shareholder.

"**BCBCA**" means the *Business Corporations Act* (British Columbia).

"**Business Day**" means any day, other than a Saturday, a Sunday or a statutory or civic holiday in Toronto, Ontario or Calgary, Alberta.

"**Cash Consideration**" means the consideration in the form of cash to be paid to Shareholders (other than to Dissenting Shareholders) pursuant to this Plan of Arrangement.

"**Cash Elected Consideration**" means an amount in cash equal to the Cash Value.

"**Cash Electing Shareholder**" means a Shareholder, other than a Dissenting Shareholder, who has duly and properly elected, in a Filed Letter of Transmittal and Election Form, to receive the Cash Elected Consideration in respect of their Shares.

"**Cash Election Amount**" means the aggregate amount of Cash Consideration that would be payable to Cash Electing Shareholders before giving effect to Section 2.4.

"**Cash Maximum**" means the aggregate amount in cash equal to the product obtained by multiplying the number of Shares issued and outstanding immediately prior to the Effective Time by $3.75.

"**Cash Value**" means $7.80.

"**Combination Elected Consideration**" means: (i) $3.75 in cash; and (ii) 3.0431 Consideration Shares.

"**Combination Electing Shareholder**" means each Shareholder, other than a Dissenting Shareholder, who has duly and properly elected in a Filed Letter of Transmittal and Election Form, or has been deemed to have so elected, to receive the Combination Elected Consideration in respect of their Shares.

"**Consideration**" means the aggregate consideration to be paid and received pursuant to this Plan of Arrangement in respect of each Share that is transferred to the Purchaser, consisting of (i) the Cash Consideration, and/or (ii) the Share Consideration, subject to the elections, maximum amounts and pro rationing as set forth in this Plan of Arrangement.

"**Consideration Election**" has the meaning specified in Section 3.1(1).

"**Consideration Shares**" means the Purchaser Shares to be issued as Share Consideration pursuant to this Plan of Arrangement.

"**Court**" means the Supreme Court of British Columbia.

"**Depositary**" means any trust company, bank or financial institution agreed to in writing by the Parties, each acting reasonably, for the purpose of, among other things, exchanging certificates representing Shares for the Consideration in connection with the Arrangement.

"**Dissent Rights**" has the meaning specified in Section 4.1.

"**Dissenting Shareholder**" means a registered holder of Shares as of the record date of the Aurora Meeting who: (i) has validly exercised its Dissent Rights in strict compliance with the Dissent Rights, (ii) has not withdrawn or been deemed to have withdrawn such exercise of Dissent Rights, and (iii) is ultimately entitled to be paid the fair value for their Shares, but only in respect of the Shares in respect of which Dissent Rights are validly exercised by such holder.

"**Effective Date**" means the date upon which the Arrangement becomes effective, as set out in Section 2.10(b) of the Arrangement Agreement.

"**Effective Time**" means 12:01 a.m. (Toronto time) on the Effective Date, or such other time as the Parties agree to in writing before the Effective Date.

"**Election Deadline**" means 5:00 p.m. (Toronto time) on the date that is (i) agreed by Aurora and the Purchaser, each acting reasonably, and (ii) announced by Aurora by means of a news release at least two (2) Business Days before such date.

"**Eligible Holder**" means a beneficial holder of Shares that is: (a) a resident of Canada for the purposes of the Tax Act (other than a partnership) and not exempt from tax under Part I of the Tax Act; or (b) a partnership any member of which is a resident of Canada for the purposes of the Tax Act (other than a partnership all members of which that are residents of Canada are exempt from tax under Part I of the Tax Act).

"**Entitlement Date**" means, in respect of an Aurora PSU, the "Entitlement Date" (as such term is defined in the applicable Incentive Plan) applicable to such Aurora PSU.

"**Exchange Ratio**" means 5.8626 of a Purchaser Share for each Aurora Share, subject to adjustment (if any) pursuant to Section 2.14 of the Arrangement Agreement.

"**Filed Letter of Transmittal and Election Form**" means a duly and properly completed Letter of Transmittal and Election Form deposited with the Depositary on or before the Election Deadline by a Shareholder, accompanied by the certificate(s) representing such holder's Shares.

"**Final Order**" means the final order of the Court pursuant to Section 291 of the BCBCA, in a form acceptable to the Parties, each acting reasonably, approving the Arrangement, as such

order may be amended by the Court (with the consent of both the Parties, each acting reasonably) at any time prior to the Effective Date or, if appealed, then, unless such appeal is withdrawn or denied, as affirmed or as amended (provided that any such amendment is acceptable to both the Parties, each acting reasonably) on appeal.

"**Governmental Entity**" means any applicable: (a) multinational, national, federal, provincial, state, regional, municipal, local or other government, governmental or public department, minister, central bank, court, tribunal, arbitral body, commission, board, bureau or agency, domestic or foreign; (b) subdivision, agent, commission, commissioner, board or authority of any of the foregoing; (c) quasi-governmental or private body, including any tribunal, commission, regulatory agency or self-regulatory organization, exercising any regulatory, expropriation or taxing authority under or for the account of any of the foregoing; or (d) stock exchange.

"**Incentive Plans**" means, collectively: (a) the Aurora Stock Option Plan; (b) the Aurora DSU Cash Plan; (c) the Aurora DSU Share Plan; (d) the Aurora PRSU Cash Plan; (e) the Aurora RSU Share Plan; and (f) the Aurora PSU Share Plan.

"**Interim Order**" means the interim order of the Court pursuant to Section 291 of the BCBCA, in a form acceptable to the Parties, each acting reasonably, made in connection with the Arrangement and providing for, among other things, the calling and holding of the Aurora Meeting, as the same may be amended, supplemented or varied by the Court (with the consent of the Parties, each acting reasonably).

"**In-The-Money Value**" means, in respect of an option at any time, the amount, if any, by which the aggregate fair market value at that time of the securities subject to such option exceeds the aggregate exercise price of such option.

"**Law**" or "**Laws**" means all laws (including common law), by-laws, statutes, rules, regulations, principles of law and equity, orders, rulings, ordinances, judgements, injunctions, determinations, awards, decrees or other requirements of any Governmental Entity having the force of law (including the rules of any stock exchange), whether domestic or foreign, and the terms and conditions of any grant of approval, permission, authority or license of any Governmental Entity, including any Cannabis Laws, and the term "**applicable**" with respect to such Laws and in a context that refers to one or more Persons, means such Laws as are applicable to such Person or its business, undertaking, assets, property or securities and emanate from a Person having jurisdiction over the Person or Persons or its or their business, undertaking, assets, property or securities.

"**Letter of Transmittal and Election Form**" means the letter of transmittal and election form sent by Aurora to Shareholders to surrender the certificates representing their Shares and to elect to receive, on completion of the Arrangement, the Cash Elected Consideration, Share Elected Consideration or Combination Elected Consideration, in exchange for their Shares.

"**Liens**" means any hypothecs, mortgages, pledges, assignments, liens, charges, claims against title, security interests, statutory or deemed trusts, encumbrances and adverse rights or claims, other third Person interest or encumbrance of any kind, whether contingent or absolute, including any instrument registered against title to real or immovable property, and any agreement, option, right or privilege (whether by Law, contract or otherwise) capable of becoming any of the foregoing.

"**Option Exchange Ratio**" means the quotient obtained by dividing (A) the Cash Value by (B) the Purchaser Share Price, subject to adjustment (if any) pursuant to Section 2.14 of the Arrangement Agreement.

"**Parties**" means the Purchaser and Aurora, and "**Party**" means any one of them.

"**Person**" includes an individual, partnership, association, company, corporation, body corporate, limited liability company, unincorporated association, unincorporated syndicate, unincorporated organization, trust, trustee, executor, administrator, legal representative, government (including any Governmental Entity) or any other entity, whether or not having legal status.

"**Plan of Arrangement**" means this plan of arrangement proposed under Section 288 of the BCBCA, and any amendments or variations made in accordance with the terms of the Arrangement Agreement and Section 7.1 or made at the direction of the Court in the Final Order with the prior written consent of the Parties, each acting reasonably.

"**Purchaser**" means Organigram Global Inc., a corporation existing under the laws of Canada.

"**Purchaser Shares**" means the common shares in the capital of the Purchaser as currently constituted.

"**Purchaser Share Price**" means the deemed price per Purchaser Share of $1.33.

"**Registrar**" means the Registrar of Companies appointed pursuant to Section 400 of the BCBCA.

"**Remaining Cash Amount**" means, expressed in dollars, the Available Cash Election Amount less the aggregate amount of Cash Consideration payable to Cash Electing Shareholders.

"**Remaining Share Number**" means the Available Share Election Number less the aggregate number of Consideration Shares deliverable to Share Electing Shareholders.

"**Replacement Option**" means an option to purchase Purchaser Shares granted by the Purchaser in exchange for an Aurora Option pursuant to Section 2.3(3).

"**Securities Authorities**" means the applicable securities commissions or other securities regulatory authorities in each of the provinces and territories of Canada.

"**Securityholders**" means, collectively, the Shareholders, the Aurora Option Holders, the Aurora DSU Holders, the Aurora RSU Holders and the Aurora PSU Holders.

"**Share Consideration**" means the consideration in the form of Consideration Shares to be issued to Shareholders (other than Dissenting Shareholders) pursuant to this Plan of Arrangement.

"**Share Elected Consideration**" means, in respect of each Share held by a Share Electing Shareholder, such number of Consideration Shares as is equal to the Exchange Ratio.

"**Share Electing Shareholder**" means a Shareholder, other than a Dissenting Shareholder, who has duly and properly elected, in a Filed Letter of Transmittal and Election Form, to receive the Share Elected Consideration in respect of their Shares.

"**Share Election Number**" means the aggregate number of Consideration Shares that would be deliverable to Share Electing Shareholders before giving effect to Section 2.4.

"**Share Maximum**" means such number of Consideration Shares as is equal to the product obtained by multiplying the number of Shares issued and outstanding immediately prior to the Effective Time by 3.0431.

"**Shareholders**" means the registered and/or beneficial holders of Shares, as the context requires.

"**Shares**" means the common shares in the capital of Aurora, as currently constituted.

"**Subsidiary**" means with respect to a Person, any entity, whether incorporated or unincorporated: (i) of which such Person or any other subsidiary of such Person is a general partner; or (ii) at least a majority of the securities or other interests of which having by their terms ordinary voting power to elect a majority of the board of directors or other Persons performing similar functions with respect to such corporation or other organization is directly or indirectly owned or controlled by such Person and/or by any one or more of its subsidiaries; and shall include any body corporate, partnership, joint venture or other entity over which it exercises direction or control. For purposes of this definition, "control" when used with respect to any Person means the power to direct the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise.

"**Tax Act**" means the *Income Tax Act* (Canada).

"**U.S. Securities Act**" means the United States *Securities Act of 1933*.

"**Unvested Aurora PSU**" means an Aurora PSU outstanding immediately prior to the Effective Time that is not a Vested Aurora PSU.

"**Vested Aurora PSU**" means an Aurora PSU outstanding immediately prior to the Effective Time that has vested in accordance with its terms, including any Aurora PSU that vests in accordance with the terms of the applicable Incentive Plan or any agreement or instrument evidencing the grant thereof, including any applicable employment agreement, as a result of the Arrangement.

Section 1.2 Certain Rules of Interpretation.

In this Plan of Arrangement, unless otherwise specified:

(1) **Headings, etc.** The division of this Plan of Arrangement into Articles and Sections and the insertion of headings are for convenient reference only and do not affect the construction or interpretation of this Plan of Arrangement. Unless the contrary intention appears, references in this Plan of Arrangement to an Article, Section, subsection or paragraph by number or letter or both refer to the Article, Section, subsection or paragraph, respectively, bearing that designation in this Plan of Arrangement.

(2) **Currency**. All references to dollars or to $ are references to Canadian dollars.

(3) **Gender and Number**. Any reference to gender includes all genders. Words importing the singular number also include the plural and vice versa.

(4) **Certain Phrases and References, etc.** The words "including," "includes" and "include" mean "including (or includes or include) without limitation," and "the aggregate of," "the total of," "the sum of," or a phrase of similar meaning means "the aggregate (or total or sum), without duplication, of." Unless stated otherwise, "Article" and "Section" followed by a number or letter mean and refer to the specified Article or Section of this Plan of Arrangement. The terms "Plan of Arrangement," "hereof," "herein" and similar expressions refer to this Plan of Arrangement (as it may be amended, modified or supplemented from time to time) and not to any particular article, section or other portion hereof and include any instrument supplementary or ancillary hereto.

(5) **Statutes**. Any reference to a statute refers to such statute and all rules and regulations made under it, as it or they may have been or may from time to time be amended or re-enacted, unless stated otherwise.

(6) **Computation of Time**. For purposes of this Plan of Arrangement, a period of time is to be computed as beginning on the day following the event that began the period and ending at 5:00 p.m. on the last day of the period, if the last day of the period is a Business Day, or at 5:00 p.m. on the next Business Day if the last day of the period is not a Business Day. If the date on which any action is required or permitted to be taken under this Plan of Arrangement by a Person is not a Business Day, such action shall be required or permitted to be taken on the next succeeding day which is a Business Day.

(7) **Time References**. References to time herein or in any Letter of Transmittal and Election Form are to local time, Vancouver, British Columbia.

ARTICLE 2
THE ARRANGEMENT

Section 2.1 Arrangement.

This Plan of Arrangement constitutes an arrangement under Section 288 of the BCBCA and is made pursuant to, and is subject to the provisions of, the Arrangement Agreement, except in respect of the sequence of the steps comprising the Arrangement, which shall occur in the order set forth herein. If there are any inconsistencies or conflict between this Plan of Arrangement and the Arrangement Agreement, the terms of this Plan of Arrangement shall govern.

Section 2.2 Binding Effect.

This Plan of Arrangement and the Arrangement will become effective, and be binding on Aurora, the Purchaser, all Securityholders (including Dissenting Shareholders), any agent or transfer agent therefor, the Depositary and all other Persons at and after the Effective Time, without any further act or formality required on the part of any Person, except as expressly provided in this Plan of Arrangement.

Section 2.3 Arrangement.

Commencing at the Effective Time, each of the events and transactions set out below shall occur and shall be deemed to occur consecutively in the following order without any further act or formality, in each case, unless stated otherwise, effective as at one (1) minute intervals starting at the Effective Time:

(1) the Aurora Shareholder Rights Plan shall be terminated without any further act required by Aurora or Computershare Trust Company of Canada, in its capacity as rights agent, all rights

issued pursuant to the Aurora Shareholder Rights Plan shall be cancelled without any payment in respect thereof, and the Aurora Shareholder Rights Plan shall be of no further force or effect;

(2) each Aurora DSU and Aurora RSU, whether vested or unvested, that is outstanding immediately prior to the Effective Time shall, in the case of an Aurora DSU, immediately following the holder thereof ceasing to hold office as a director of Aurora and, notwithstanding the terms of the Incentive Plans or any agreement or instrument evidencing the grant thereof, and without any further action by or on behalf of the holder thereof, be cancelled and terminated in exchange for, subject to Section 6.3, a cash payment (without interest) from Aurora equal to the Cash Value multiplied by the number of Shares subject to such Aurora DSU or Aurora RSU, and, with respect to each Aurora DSU and Aurora RSU so cancelled and terminated: (A) the holder thereof shall cease to be the holder of such Aurora DSU or Aurora RSU, (B) the holder thereof shall cease to have any rights as a holder in respect of such Aurora DSU or Aurora RSU, or under the Incentive Plans or any agreement or instrument evidencing the grant thereof, other than the right to receive the cash payment to which such holder is entitled pursuant to this Section 2.3(2), (C) such holder's name shall be removed from the applicable register, and (D) all agreements, grants and similar instruments relating thereto shall be cancelled and terminated;

(3) each Vested Aurora PSU outstanding immediately prior to the Effective Time shall, notwithstanding the terms of the Incentive Plans or any agreement or instrument evidencing the grant thereof, and without any further action by or on behalf of the holder thereof, be cancelled and terminated in exchange for, subject to Section 6.3, a cash payment (without interest) from Aurora equal to the Cash Value multiplied by the number of Shares underlying such Vested Aurora PSU, multiplied by 100%, and, with respect to each Vested Aurora PSU so cancelled: (A) the holder thereof shall cease to be the holder of such Vested Aurora PSU, (B) the holder thereof shall cease to have any rights as a holder in respect of such Vested Aurora PSU, or under the Incentive Plans or any agreement or instrument evidencing the grant thereof, other than the right to receive the cash payment to which such holder is entitled pursuant to this Section 2.3(3), (C) such holder's name shall be removed from the applicable register, and (D) all agreements, grants and similar instruments relating thereto shall be cancelled and terminated;

(4) each Unvested Aurora PSU outstanding immediately prior to the Effective Time shall, notwithstanding the terms of the Incentive Plans or any agreement or instrument evidencing the grant thereof, and without any further action by or on behalf of the holder thereof, remain outstanding and shall thereafter, for each Share underlying such Unvested Aurora PSU, entitle the holder thereof to receive, on the Entitlement Date and subject to satisfaction of the applicable vesting conditions, an amount in cash (without interest) from Aurora equal to the Cash Value multiplied by 100%, subject to Section 6.3, and shall be subject to the same terms and conditions applicable to such Unvested Aurora PSU set forth in the applicable Incentive Plan and/or any agreement or instrument relating thereto, including any applicable employment agreement, in effect immediately prior to the Effective Time, other than those terms and conditions that are rendered inoperative by the transactions contemplated hereby. For greater certainty, immediately following the Effective Time, the holder of an Unvested Aurora PSU subject to this Section 2.3(4) shall have no right to receive any Shares or Purchaser Shares based on or in respect of such Unvested Aurora PSU and shall not be eligible to receive any dividends or other distributions (whether in cash or otherwise) in respect thereof;

(5) simultaneously with Section 2.3(6), each outstanding Share held by a Dissenting Shareholder in respect of which Dissent Rights have been validly exercised shall be deemed to have been transferred without any further act or formality by the holder thereof to the Purchaser (free and

clear of all Liens) in consideration for a debt claim against the Purchaser for the amount determined under Article 4, and:

(a) such Dissenting Shareholder shall cease to have any rights as a Shareholder other than the right to be paid the fair value of its Shares by the Purchaser in accordance with Article 4;

(b) the name of such holder shall be removed from the register of holders of Shares maintained by or on behalf of Aurora; and

(c) the Purchaser shall be recorded on the register of holders of Shares maintained by or on behalf of Aurora as the holder of the Shares so transferred and shall be deemed to be the legal and beneficial owner thereof;

(6) simultaneously with Section 2.3(5), each outstanding Share (other than Shares held by any Dissenting Shareholder who has validly exercised such holder's Dissent Rights) shall be transferred without any further act or formality by the holder thereof to the Purchaser (free and clear of all Liens), subject to Section 6.3, Section 6.5 and Section 6.6 and:

(a) in exchange for the transfer of each such Share:

(i) each Combination Electing Shareholder shall receive the Combination Elected Consideration from the Purchaser;

(ii) subject to Section 2.4, each Cash Electing Shareholder shall receive the Cash Elected Consideration from the Purchaser; and

(iii) subject to Section 2.4, each Share Electing Shareholder shall receive the Share Elected Consideration from the Purchaser;

(b) the holder of such Share shall be deemed to have executed and delivered all consents, releases, assignments and waivers, statutory or otherwise, required to transfer and assign such Share to the Purchaser;

(c) the holder of such Share shall cease to have any rights as a holder of Shares other than the right to receive the Consideration in exchange for each such Share in accordance with this Plan of Arrangement;

(d) the name of such holder shall be removed from the register of holders of Shares maintained by or on behalf of Aurora;

(e) the Purchaser shall be recorded on the register of holders of Shares maintained by or on behalf of Aurora as the holder of the Shares so transferred and shall be deemed to be the legal and beneficial owner thereof (free and clear of all Liens); and

(f) where a Shareholder receives both Cash Consideration and Consideration Shares, whether pursuant to the elections (including deemed elections), maximum amounts or pro rationing as set forth in this Plan of Arrangement:

(i) the Shareholder shall be deemed to have solely exchanged for Consideration Shares that number of Shares (including any fraction thereof) equal to the Shares then held by the Shareholder multiplied by the proportion of the value of the Consideration Shares (calculated based on the Purchaser Share Price)

received by the Shareholder is of the Consideration received by the Shareholder, and to have exchanged such Shareholder's remaining number of Shares (including any fraction thereof) for the Cash Consideration received; except that

(ii) notwithstanding (i) hereof, if the Shareholder indicates in its Filed Letter of Transmittal and Election Form that it intends to make a joint election with the Purchaser in accordance with Section 2.6 to have the transfer of its Shares to the Purchaser under this Plan of Arrangement take place pursuant to the provisions of subsection 85(1) or (2) of the Tax Act (and the analogous provisions of any provincial tax laws), then such Shareholder shall be deemed to have transferred all of the Shareholder's Shares to the Purchaser as a single transaction for consideration consisting of the combination of Cash Consideration and Consideration Shares received under this Plan of Arrangement;

(7) each Aurora Option, whether vested or unvested, that is outstanding immediately prior to the Effective Time shall, notwithstanding the terms of the Aurora Stock Option Plan or any agreement or instrument evidencing the grant thereof, and without any further action by or on behalf of the holder thereof, be exchanged for a Replacement Option to purchase from the Purchaser the number of Purchaser Shares (rounded down to the nearest whole Purchaser Share) equal to the product of: (A) the number of Shares subject to such Aurora Option immediately prior to the Effective Time, multiplied by (B) the Option Exchange Ratio. Each such Replacement Option shall provide for an exercise price per Purchaser Share (rounded up to the nearest whole cent) equal to the quotient of: (X) the exercise price per Share of the exchanged Aurora Option immediately prior to the Effective Time, divided by (Y) the Option Exchange Ratio. It is intended that the provisions of subsection 7(1.4) of the Tax Act apply to such exchange of Aurora Options for Replacement Options. Accordingly, and notwithstanding the foregoing, if required, the exercise price per Purchaser Share of a Replacement Option shall be increased such that the In-The-Money Value of the Replacement Option immediately after the exchange does not exceed the In-The-Money Value of the Aurora Option for which it was exchanged immediately before the exchange. Except as set out in this Section 2.3(3), all terms and conditions of a Replacement Option, including the term to expiry, vesting conditions and conditions to and manner of exercising, shall be the same as the Aurora Option for which it was exchanged, and shall be governed by the terms of the Aurora Stock Option Plan (which shall be assumed by the Purchaser in respect of the Replacement Options) and/or any agreement or instrument relating to such Aurora Option, including any applicable employment agreement, and any agreement or instrument evidencing an Aurora Option shall thereafter evidence and be deemed to evidence such Replacement Option. With respect to each Aurora Option so exchanged: (A) the holder thereof shall cease to be the holder of such Aurora Option, (B) the holder thereof shall cease to have any rights as a holder in respect of such Aurora Option, other than the rights in respect of the Replacement Option to which such holder is entitled pursuant to this Section 2.3(3), and (C) such holder's name shall be removed from the register of Aurora Options and shall be entered on the register of Replacement Options maintained by or on behalf of the Purchaser.

Section 2.4 Arrangement Elections.

The Purchaser shall not be obligated to pay or cause the payment of more Cash Consideration than the Cash Maximum or more Share Consideration than the Share Maximum and, in this regard and notwithstanding any provision herein to the contrary, either:

(1) if, but for this Section 2.4, the Share Election Number exceeds the Available Share Election Number, then each Share Electing Shareholder will receive from the Purchaser, in aggregate:

(a) such number of Consideration Shares equal to the product obtained by multiplying the Available Share Election Number by a fraction the numerator of which is the number of Consideration Shares that would otherwise be deliverable to such Shareholder pursuant to Section 2.3(6)(a) and the denominator of which is the Share Election Number; and

(b) a cash amount equal to the product obtained by multiplying the Remaining Cash Amount by a fraction the numerator of which is the number of Consideration Shares that would otherwise be deliverable to such Shareholder pursuant to Section 2.3(6)(a) and the denominator of which is the Share Election Number; or

(2) if, but for this Section 2.4, the Cash Election Amount exceeds the Available Cash Election Amount, then each Cash Electing Shareholder will receive from the Purchaser, in aggregate:

(a) a cash amount equal to the product obtained by multiplying the Available Cash Election Amount by a fraction the numerator of which is the amount of cash that would otherwise be payable to such Shareholder pursuant to Section 2.3(6)(a) and the denominator of which is the Cash Election Amount; and

(b) such number of Consideration Shares equal to the product obtained by multiplying the Remaining Share Number by a fraction the numerator of which is the amount of cash that would otherwise be payable to such Shareholder pursuant to Section 2.3(6)(a) and the denominator of which is the Cash Election Amount; provided however, that if, as a result of this Section 2.4, a Cash Electing Shareholder would receive a cash amount equal to less than the amount such Cash Electing Shareholder would have received if such Cash Electing Shareholder was a Combination Electing Shareholder, such Cash Electing Shareholder shall be deemed to have been a Combination Electing Shareholder and elected to receive the Combination Elected Consideration pursuant to Section 2.3(6)(a)(i).

Section 2.5 Fully Paid and Non-Assessable Shares.

All Consideration Shares issued pursuant hereto, and all Purchaser Shares issued upon the exercise of Replacement Options in accordance with their terms, shall be validly issued and outstanding as fully paid and non-assessable shares.

Section 2.6 Tax Election.

An Eligible Holder who receives Consideration Shares pursuant to Section 2.3(6) shall be entitled to make an income Tax election, pursuant to subsection 85(1) of the Tax Act or subsection 85(2) of the Tax Act, as applicable (and in each case, where applicable, the analogous provision of provincial income Tax Law) (a "Section 85 Election"), by providing two duly completed and signed copies of the election form prescribed by the Tax Act (and, if applicable, any provincial Tax statute) (each, a "Section 85 Tax Election Form") to the Purchaser within 90 days following the Effective Date (the "Section 85 Election Period"). Provided such information is correct and complete and in compliance with the requirements imposed under the Tax Act (or applicable provincial income Tax Law), the Purchaser shall, within 60 days after the receipt thereof, return two signed copies of each Section 85 Tax Election Form so delivered to it to such Eligible Holder for filing with the applicable Governmental Entities by such Eligible Holder. The Purchaser will not be responsible for the proper or accurate completion of any Section 85 Tax Election Form or for checking or verifying the contents of any Section 85 Tax

Election Form and, except for the Purchaser's obligation to return, within 60 days of receipt, duly completed Section 85 Tax Election Forms received by it before the end of the Section 85 Election Period, none of the Purchaser, Aurora or any successor corporation will be responsible for any Taxes, interest or penalties or any other costs or damages resulting from the failure by an Eligible Holder to properly and accurately complete or file the Section 85 Tax Election Forms in the form and manner and within the time prescribed by the Tax Act (or any applicable provincial income tax Law).

ARTICLE 3
CONSIDERATION ELECTION

Section 3.1 Consideration Election.

(1) Subject to Section 3.1(4), each beneficial owner of Shares may elect, prior to the Election Deadline, with respect to any and all issued and outstanding Shares (other than Shares for which Dissent Rights have been validly exercised) held by such holder immediately before the Election Deadline to receive the Consideration to which he, she or it is entitled in the form of the Combination Elected Consideration, the Share Elected Consideration or the Cash Elected Consideration (the "**Consideration Election**").

(2) The Consideration Election shall be made by a Shareholder (or if applicable, by the registered Shareholder on such beneficial owner's behalf) by depositing with the Depositary, prior to the Election Deadline, a Filed Letter of Transmittal and Election Form indicating such Shareholder's election, together with certificates (if any) representing such Shareholder's Shares.

(3) Any Letter of Transmittal and Election Form, once deposited with the Depositary, shall be irrevocable and may not be withdrawn by a Shareholder except as may be expressly provided in the Letter of Transmittal and Election Form.

(4) Any Shareholder, other than a Dissenting Shareholder, who does not deposit with the Depositary a Filed Letter of Transmittal and Election Form, or otherwise fails to comply with the requirements of this Section 3.1 and the Letter of Transmittal and Election Form shall be deemed to have elected to receive the Combination Elected Consideration and shall be deemed, for all purposes of this Plan of Arrangement, to be a Combination Electing Shareholder.

ARTICLE 4
DISSENT RIGHTS

Section 4.1 Dissent Rights.

(1) Registered holders of Shares as of the record date of the Aurora Meeting may exercise dissent rights with respect to the Shares held by such Shareholder as of such date ("**Dissent Rights**") in connection with the Arrangement pursuant to and in the manner set forth in Division 2 of Part 8 of the BCBCA, as modified by the Interim Order, Final Order and this Section 4.1; provided that notwithstanding Section 242(1)(a) of the BCBCA, the written notice of dissent to the Arrangement Resolution referred to in Section 242(1)(a) of the BCBCA must be received by Aurora c/o Torys LLP, Suite 2800, 79 Wellington St. W., Toronto, Ontario M5K 1N2, Attention: Andrew Gray and Colette Koopman, by no later than 9:30 a.m. (Toronto time) two (2) Business Days immediately preceding the date of the Aurora Meeting (as it may be adjourned or postponed from time to time).

(2) Dissenting Shareholders who duly exercise their Dissent Rights shall be deemed to have transferred the Shares held by them and in respect of which Dissent Rights have been validly exercised to the Purchaser free and clear of all Liens, as provided in Section 2.3(5) and, if they:

(a) are ultimately entitled to be paid fair value for such Shares: (i) shall be deemed not to have participated in the transactions in Article 2 (other than Section 2.3(5)), (ii) shall be entitled to be paid the fair value of such Shares by the Purchaser (less any amounts withheld pursuant to Section 6.3), which fair value shall be determined as of the close of business on the last Business Day before the Arrangement Resolution was adopted, and (iii) will not be entitled to any other payment or consideration, including any payment that would be payable under the Arrangement had such holders not exercised their Dissent Rights in respect of such Shares; or

(b) are ultimately not entitled, for any reason, to be paid fair value for such Shares, shall be deemed to have participated in the Arrangement on the same basis as Shareholders who have not exercised Dissent Rights in respect of such Shares and be entitled to receive the Combination Elected Consideration.

Section 4.2 Recognition of Dissenting Shareholders.

(1) In no case shall Aurora, the Purchaser or any other Person be required to recognize a Person exercising Dissent Rights: (i) unless such Person is the registered holder of the Shares in respect of which such rights are sought to be exercised as of the record date for the Aurora Meeting, (ii) if such Person has voted or instructed a proxyholder to vote such Shares in favour of the Arrangement Resolution, or (iii) unless the Person has strictly complied with the procedures for exercising Dissent Rights and does not withdraw such dissent prior to the Effective Time.

(2) In no case shall Aurora, the Purchaser or any other Person be required to recognize any Shareholder who exercises Dissent Rights as a Shareholder after the Effective Time.

(3) Shareholders who withdraw, or are deemed to withdraw, their right to exercise Dissent Rights shall be deemed to have participated in the Arrangement, as of the Effective Time, and will be entitled to receive the Combination Elected Consideration.

(4) In addition to any other restrictions under Division 2 of Part 8 of the BCBCA, none of the following shall be entitled to Dissent Rights: (a) Aurora Option Holders, Aurora DSU Holders, Aurora RSU Holders and Aurora PSU Holders, in respect of their Aurora Options, Aurora DSUs, Aurora RSUs and Aurora PSUs, and (b) Shareholders who vote or have instructed a proxyholder to vote their Shares in favour of the Arrangement Resolution. A registered Shareholder may only exercise Dissent Rights in respect of all, and not less than all, of its Shares.

ARTICLE 5
U.S. SECURITIES LAWS

Section 5.1 U.S. Securities Laws.

The Purchaser and Aurora agree that this Plan of Arrangement will be carried out with the intention that the issuance of the securities under this Plan of Arrangement, including the Consideration Shares and Replacement Options, will be issued by the Purchaser in reliance on the exemption from the registration requirements of the U.S. Securities Act provided by Section 3(a)(10) thereof and pursuant

to exemptions from registration under any applicable U.S. state securities laws, and each of the Purchaser and Aurora shall take such reasonable actions as shall be required to facilitate reliance on such exemption in connection with the Arrangement.

ARTICLE 6
CERTIFICATES AND PAYMENTS

Section 6.1 Payment of Consideration.

(1) The Purchaser shall, following receipt of the Final Order and prior to the filing by Aurora of the Arrangement Filings with the Registrar in accordance with the Arrangement Agreement, deliver or cause to be delivered to the Depositary in escrow pending the Effective Time (the terms and conditions of such escrow to be satisfactory to the Parties, each acting reasonably): (i) sufficient funds to satisfy the aggregate Cash Consideration; and (ii) sufficient Purchaser Shares (and any irrevocable treasury directions addressed to the Purchaser's transfer agent as may be necessary) to satisfy the aggregate Share Consideration, in each case to be paid or issued to Shareholders in accordance with Section 2.3 and as provided for in this Plan of Arrangement, excluding any such payment in respect of Shares for which Dissent Rights have been validly exercised and not withdrawn.

(2) Following the Effective Time, upon delivery to the Depositary of a Filed Letter of Transmittal and Election Form in respect of any Shares to be exchanged for the applicable Consideration under the Arrangement and such other documents and instruments as the Depositary may reasonably require, upon surrender to the Depositary of any certificate(s) which immediately prior to the Effective Time represented such Shares, such Shareholders shall be entitled to receive in exchange therefor in respect of such Shares, and the Depositary shall promptly deliver to such former Shareholder (in each case without interest and as adjusted for any rounding or withholding pursuant to Section 6.3, Section 6.5 and Section 6.6), the relevant Consideration which such former Shareholder has the right to receive (together with any dividends or other distributions with respect thereto pursuant to Section 6.1(7)), and the certificate (if any) so surrendered shall forthwith be cancelled.

(3) The cash deposited with the Depositary by or on behalf of the Purchaser shall be held, unless determined otherwise by the Purchaser, in an interest-bearing account and any interest earned on such funds shall be for the account of the Purchaser.

(4) Until surrendered as contemplated by this Section 6.1, each certificate that immediately prior to the Effective Time represented Shares (other than Shares in respect of which Dissent Rights have been validly exercised and not withdrawn) shall be deemed at all times after the Effective Time to represent only the right to receive upon such surrender of the applicable certificate, the applicable Consideration (in each case without interest and as adjusted for any rounding or withholding pursuant to Section 6.3, Section 6.5 and Section 6.6) which such former Shareholder has the right to receive (together with any dividends or other distributions with respect thereto pursuant to Section 6.1(7)).

(5) To the extent that a former Shareholder shall not have complied with the provisions of Section 6.1 on or before the third (3rd) anniversary of the Effective Date, then the Consideration that such former Shareholder was entitled to receive shall be deemed to have been surrendered to the Purchaser for cancellation for no consideration and shall be delivered to the Purchaser by the Depositary and the interest of the former Shareholder in such Consideration (and any dividend or other distribution referred to in Section 6.1(7)) to which it was entitled shall be terminated as of such date, and the certificates formerly representing Shares, if any, shall cease to represent a right or claim of any kind or nature as of such date.

Any payment made by way of cheque by the Depositary (or Aurora, if applicable) in accordance with this Plan of Arrangement that has not been deposited or has been returned to the Depositary (or Aurora) or that otherwise remains unclaimed, in each case, on or before the third (3rd) anniversary of the Effective Date, and any right or claim to payment hereunder that remains outstanding on the third (3rd) anniversary of the Effective Date shall cease to represent a right or claim of any kind or nature and the right of the holder to receive the applicable Consideration in respect of Shares pursuant to this Plan of Arrangement shall be terminated and deemed to have been surrendered and forfeited to the Purchaser. For greater certainty, no former Shareholder shall have any right, claim or interest of any kind or nature whatsoever in respect of Shares from and after the third (3rd) anniversary of the Effective Date, including, any entitlement to receive any Consideration for any reason, or any entitlement to dividends or distributions, on or in respect of Shares or the Consideration, and in accordance with this Section 6.1(5) all such rights and interests of former Shareholders shall be deemed to have been surrendered to the Purchaser, and forfeited by such former Shareholders for no consideration as of such date.

(6) No Securityholder shall be entitled to receive any consideration with respect to such holder's Shares, Aurora Options, Aurora DSUs, Aurora RSUs or Aurora PSUs, except any payment or Replacement Option to which such holder is entitled to receive in accordance with Section 2.3 and this Section 6.1 (in each case without interest and as adjusted for any rounding or withholding pursuant to Section 6.3, Section 6.5 and Section 6.6).

(7) No dividend or other distribution declared or made after the Effective Time with respect to the Consideration Shares with a record date after the Effective Time shall be delivered to the holder of any unsurrendered certificate that, immediately prior to the Effective Time, represented outstanding Shares unless and until the holder of such certificate shall have complied with the provisions of Section 6.1. Subject to applicable Law, at the time of such compliance, there shall, in addition to the delivery of a certificate representing the Consideration Shares to which such holder is thereby entitled, be delivered to such holder, without interest, the amount of the dividend or distribution with a record date after the Effective Time theretofore paid with respect to such Consideration Shares. All dividends or other distributions payable on the Consideration Shares held by the Depositary with a record date after the Effective Time shall be paid by the Purchaser to the Depositary and shall be held by the Depositary in trust for the former holders of Shares entitled to receive such Consideration Shares pursuant to the Arrangement, in each case until delivery to the Depositary of a Filed Letter of Transmittal and Election Form in respect of such Shares and such other documents and instruments as the Depositary may reasonably require and the surrender of any certificate or certificates which, immediately prior to the Effective Time, represented such Shares in accordance with this Section 6.1. Subject to applicable Laws, following the delivery to the Depositary of a Filed Letter of Transmittal and Election Form in respect of such Shares and such other documents and instruments as the Depositary may reasonably require and the surrender of any certificate or certificates which, immediately prior to the Effective Time, represented such Shares in accordance with this Section 6.1, the Depositary shall pay to the applicable former holder of Shares, without interest, the amount of dividends or other distributions with a record date after the Effective Time theretofore paid with respect to such Consideration Shares to which such holder is entitled pursuant to the Arrangement.

(8) At, or as soon as reasonably practicable after, the Effective Time (and, in the case of Aurora DSUs, in no event before the holder has ceased to hold office as a director of Aurora), Aurora shall deliver to each former Aurora DSU Holder, Aurora RSU Holder and Aurora PSU Holder, as reflected on the applicable register maintained by or on behalf of Aurora, the cash payment (if any) which such holder has the right to receive pursuant to Section 2.3(2) or Section 2.3(3), less any amounts withheld pursuant to Section 6.3, and, within the time required by the

applicable Incentive Plan following the applicable Entitlement Date, Aurora shall deliver to each holder of an Unvested Aurora PSU the cash payment (if any) which such holder has the right to receive pursuant to Section 2.3(4), less any amounts withheld pursuant to Section 6.3. Such payments shall be made, to the extent practicable, through the payroll or equity plan administration systems of Aurora and its Subsidiaries and in a manner consistent with how such individuals otherwise receive payments from Aurora, or in such other manner as Aurora and the Purchaser may agree that is consistent with the Incentive Plans and applicable award agreements, but in any event in readily available funds. As soon as reasonably practicable after the Effective Time, the Purchaser shall deliver or cause to be delivered to each former Aurora Option Holder notice or other evidence of the Replacement Options to which such holder is entitled pursuant to Section 2.3(7).

Section 6.2 Lost Certificates.

In the event any certificate which immediately prior to the Effective Time represented one or more Shares that were transferred pursuant to Section 2.3 shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming such certificate to be lost, stolen or destroyed and who was listed immediately prior to the Effective Time as the registered holder thereof on the share register maintained by or on behalf of Aurora, the Depositary shall issue in exchange for such lost, stolen or destroyed certificate, the relevant Consideration to which such holder is entitled to receive for such Shares under this Plan of Arrangement in accordance with such holder's Letter of Transmittal and Election Form. When authorizing such payment in exchange for any lost, stolen or destroyed certificate, the Person to whom such Consideration is to be delivered shall, as a condition precedent to the delivery of such Consideration, give a bond satisfactory to the Purchaser and the Depositary (each acting reasonably) in such sum as the Purchaser may direct, or otherwise indemnify Aurora and the Purchaser in a manner satisfactory to Aurora and the Purchaser (each acting reasonably) against any claim that may be made against Aurora or the Purchaser with respect to the certificate alleged to have been lost, stolen or destroyed.

Section 6.3 Withholding Rights.

(1) Each of Aurora, the Purchaser, the Depositary and any Person that makes a payment in connection with this Plan of Arrangement (each a "**payor**"), as applicable, shall be entitled to deduct and withhold from any amount otherwise payable or deliverable to any Person in connection with this Plan of Arrangement, including any amounts paid to Shareholders exercising Dissent Rights and dividends and other amounts otherwise payable to any former Shareholders or holders of Aurora Options, Aurora DSUs, Aurora RSUs or Aurora PSUs, such amounts (whether in cash or Consideration Shares) as it is required to deduct and withhold with respect to such payment under the Tax Act or any provision of any other applicable Law in respect of Taxes and shall remit such withheld amount to the appropriate Governmental Entity. To the extent that amounts are so deducted, withheld and remitted to the appropriate Governmental Entity, such amounts shall be treated for all purposes hereof as having been paid to the Person in respect of which such deduction, withholding and remittance was made.

(2) To the extent that the amount required to be deducted or withheld from any consideration payable to a Person under this Plan of Arrangement exceeds the cash portion of the consideration otherwise payable to such Person, any payor under this Section 6.3 is hereby authorized to sell or otherwise dispose of, on behalf of such Person, such portion of the Consideration Shares otherwise deliverable to such Person as is necessary to provide sufficient funds (after deduction of all reasonable out-of-pocket expenses, Taxes and commissions incurred in connection with such sales) to the payor, as the case may be, to enable it to comply with all deduction or withholding requirements applicable to it, and no payor shall be liable to any Person for any deficiency in respect of any proceeds received (including

as a result of any loss relating to the manner or timing of such sales, the prices at which the Consideration Shares are sold or otherwise), and the payor, as applicable, shall notify the holder thereof and remit to the holder thereof any unapplied balance of the net proceeds of such sale.

Section 6.4 No Liens.

Any exchange or transfer of securities in accordance with this Plan of Arrangement shall be free and clear of any Liens or other claims of third parties of any kind.

Section 6.5 Rounding of Cash Consideration.

Notwithstanding anything contained herein, if the aggregate cash amount which a former Securityholder is entitled to receive pursuant to Section 2.3 would: (i) be less than $0.01 in the aggregate, such cash shall be rounded up to $0.01; or (ii) otherwise include a fraction of $0.01, then the aggregate cash amount to which such former Securityholder shall be entitled to receive shall be rounded down to the nearest whole $0.01.

Section 6.6 No Fractional Shares.

No fractional Consideration Shares shall be issued pursuant to this Plan of Arrangement. Where the aggregate number of Consideration Shares to be issued to a Shareholder pursuant to this Plan of Arrangement would result in a fraction of a Consideration Share being issuable, the number of Consideration Shares to be issued to such Shareholder shall be rounded down to the nearest whole Consideration Share and no consideration will be paid in lieu of the issuance of such fractional Consideration Share. In calculating such fractional interests, all Shares registered in the name of or beneficially held by a Shareholder or its nominee shall be aggregated.

Section 6.7 Book-Based Registrations.

For the purposes of this Plan of Arrangement, any reference to a “certificate” in respect of Shares or Consideration Shares shall include evidence of registered ownership of Shares or Consideration Shares, as the case may be, in an electronic book-based system maintained by the registrar and transfer agent of the Shares or Consideration Shares, and the provisions of this Plan of Arrangement shall be read and construed (and where applicable, modified) to give effect to such interpretation.

Section 6.8 Paramountcy.

From and after the Effective Time: (a) this Plan of Arrangement shall take precedence and priority over any and all Shares, Aurora Options, Aurora DSUs, Aurora RSUs and Aurora PSUs issued or outstanding prior to the Effective Time; (b) the rights and obligations of the Securityholders, Aurora, the Purchaser, the Depositary and any transfer agent or other depositary therefor in relation thereto, shall be solely as provided for in this Plan of Arrangement; and (c) all actions, causes of action, claims or proceedings (actual or contingent and whether or not previously asserted) based on or in any way relating to any Shares, Aurora Options, Aurora DSUs, Aurora RSUs or Aurora PSUs shall be deemed to have been settled, compromised, released and determined without liability except as set forth in this Plan of Arrangement.

ARTICLE 7
AMENDMENTS

Section 7.1 Amendments.

(1) Aurora and the Purchaser may amend, modify and/or supplement this Plan of Arrangement at any time and from time to time prior to the Effective Time, provided that each such amendment, modification and/or supplement must be: (i) set out in writing; (ii) approved by Aurora and the Purchaser, each acting reasonably; (iii) filed with the Court and, if made following the Aurora Meeting, approved by the Court subject to Section 7.1(4) and Section 7.1(5); and (iv) communicated to Shareholders if and as required by the Court.

(2) Any amendment, modification or supplement to this Plan of Arrangement may be proposed by Aurora or the Purchaser at any time prior to the Aurora Meeting (provided that Aurora or the Purchaser, as applicable, shall have consented thereto) with or without any other prior notice or communication, and if so proposed and accepted by the Persons voting at the Aurora Meeting (other than as may be required under the Interim Order), shall become part of this Plan of Arrangement for all purposes.

(3) Any amendment, modification or supplement to this Plan of Arrangement that is approved or directed by the Court following the Aurora Meeting shall be effective only if: (i) it is consented to in writing by each of Aurora and the Purchaser (in each case, acting reasonably); and (ii) if required by the Court, approved by the Shareholders in the manner directed by the Court.

(4) Any amendment, modification or supplement to this Plan of Arrangement may be made following the granting of the Final Order without filing such amendment, modification or supplement with the Court or seeking Court approval, provided that: (i) it concerns a matter which, in the reasonable opinion of the Parties, is of an administrative nature required to better give effect to the implementation of this Plan of Arrangement and is not adverse to the interest of any Securityholder; or (ii) it is an amendment contemplated in Section 7.1(5).

(5) Any amendment, modification or supplement to this Plan of Arrangement may be made following the Effective Date unilaterally by the Purchaser, provided that it concerns a matter which, in the reasonable opinion of the Purchaser, is of an administrative nature required to better give effect to the implementation of this Plan of Arrangement and is not adverse to the economic interest of any former Securityholder.

(6) This Plan of Arrangement may be withdrawn prior to the Effective Time in accordance with the terms of the Arrangement Agreement.

ARTICLE 8
FURTHER ASSURANCES

Section 8.1 Further Assurances.

Notwithstanding that the transactions and events set out in this Plan of Arrangement shall occur and shall be deemed to occur in the order set out in this Plan of Arrangement without any further act or formality, each of the parties to the Arrangement Agreement will, from time to time, do all acts and things and execute and deliver all such further documents and instruments, as the other Party may reasonably require to effectively carry out or better evidence or perfect the full intent and meaning of this Plan of Arrangement.

APPENDIX "D"
INTERIM ORDER

(See attached)

SUPREME COURT
OF BRITISH COLUMBIA
VANCOUVER REGISTRY
NOV 20 2026
ENTERED

No. VLC-S-S-268586
Vancouver Registry

IN THE SUPREME COURT OF BRITISH COLUMBIA

IN THE MATTER OF PART 9, DIVISION 5, SECTION 291 OF THE *BUSINESS CORPORATIONS ACT*, S.B.C. 2002, C. 57, AS AMENDED

AND

IN THE MATTER OF A PROPOSED PLAN OF ARRANGEMENT OF AURORA CANNABIS INC. INVOLVING ORGANIGRAM GLOBAL INC.

AURORA CANNABIS INC.

Petitioner

ORDER MADE AFTER APPLICATION (INTERIM ORDER)

BEFORE Associate Judge Vos

FRIDAY, THE 20TH DAY OF NOVEMBER 2026

ON THE APPLICATION OF the Petitioner, Aurora Cannabis Inc. ("**Aurora**"), without notice coming on for hearing at the Courthouse at 800 Smithe Street, Vancouver, British Columbia on November 20, 2026; AND ON HEARING Andrew Gray and Colette Koopman, counsel for the Petitioner and Tom Friedland, counsel for Organigram Global Inc. ("**Organigram**"); AND UPON READING the Notice of Application filed herein and Affidavit #1 of Miguel Martin made November 18, 2026 (the "**Martin Affidavit**"); AND UPON BEING ADVISED that it is the intention of Organigram to rely upon section 3(a)(10) of the United States *Securities Act of 1933*, as amended (the "**U.S. Securities Act**"), as a basis for an exemption from the registration requirements of the U.S. Securities Act with respect to the issuance of the securities under the Plan of Arrangement (as defined below), including the Consideration Shares and the Replacement Options (as such terms are defined in the Plan of Arrangement), based on the Court's approval of the Arrangement (as defined below), which approval through the issuance of the Final Order will constitute its determination of the fairness of the Arrangement;

THIS COURT ORDERS that:

DEFINITIONS

1. Unless otherwise defined, all capitalized terms used in this Interim Order shall have the meaning ascribed thereto in the joint management information circular of Aurora and Organigram (the "**Circular**") attached as Exhibit "A" to the Martin Affidavit.

SPECIAL MEETING

2. Aurora is authorized to call, hold, and conduct a special meeting (the "**Aurora Meeting**") of the holders of common shares in the capital of Aurora (the "**Aurora Shareholders**" who hold the "**Aurora Shares**"), on December 23, 2026 at 9:30 a.m., (Toronto time) in virtual or hybrid meeting format, or such other date as may result from postponement or adjournment in accordance with this Interim Order.

3. At the Aurora Meeting, the Aurora Shareholders will, *inter alia*, consider, and, if deemed advisable, approve an arrangement resolution (the "**Arrangement Resolution**"), in the form attached as Appendix "A" to the Circular, adopting, with or without amendment, the arrangement (the "**Arrangement**") involving Aurora as set forth in the plan of arrangement (the "**Plan of Arrangement**"), a copy of which is included in Appendix "C" to the Circular.

4. At the Aurora Meeting, Aurora will also seek to transact such other business as is contemplated by the Circular or as otherwise may be properly brought before the Aurora Meeting.

5. The Aurora Meeting will be called, held, and conducted in accordance with the Notice of Meeting (the "**Meeting Notice**") to be delivered in substantially the form attached to and forming part of the Circular, and in accordance with the applicable provisions of the British Columbia *Business Corporations Act*, S.B.C. 2002, c. 57, as amended (the "**BCBCA**"), the terms of this Interim Order, any further Order of this Court, the rulings and directions of the Chairperson of the Aurora Meeting, and in accordance with the terms, restrictions and conditions of the articles of Aurora, including quorum requirements and all other matters. To the extent of any inconsistency or discrepancy between this Interim Order and the terms of any of the foregoing, this Interim Order will govern.

RECORD DATE

6. The Record Date for determination of Aurora Shareholders entitled to vote and to receive the Meeting Notice, Circular and a form of voting proxy or voting instruction form, as applicable (together, the "**Meeting Materials**") is the close of business on November 18, 2026 (the "**Record Date**"), or such other date as the directors of Aurora may determine in accordance with the articles of Aurora, the BCBCA or as disclosed in the Meeting Materials.

NOTICE OF SPECIAL MEETING

7. The Meeting Materials will be provided substantially in accordance with the provisions of National Instrument 54-101 – *Communication with Beneficial Owners of Securities of a Reporting Issuer* ("**NI 54-101**"), as follows:

   (a) to the registered Aurora Shareholders at the close of business on the Record Date, at least twenty-one (21) days prior to the date of the Aurora Meeting, by mail to the addresses of the Aurora Shareholders as they appear on the books and records of Aurora, or of their registrars and transfer agents, at the close of business on the Record Date and if no address is shown therein, then the last address of the person known to Aurora;

   (b) to non-registered Aurora Shareholders at the close of business on the Record Date, by providing sufficient copies of the Meeting Materials to intermediaries and registered nominees in a timely manner, in accordance with NI 54-101.

8. The Meeting Materials will be sent by electronic transmission to each director and the auditor of Aurora at his, her, their or its email address as appearing in the records of Aurora.

9. The Meeting Materials will be sent by electronic transmission to holders of outstanding:

   (a) deferred share units issued under the Aurora DSU Plans;

   (b) restricted share units issued under the Aurora RSU Plan;

   (c) performance share units issued under the Aurora PSU Plan; and

   (d) options to purchase Aurora Shares granted under the Aurora Stock Option Plan (collectively, the "**Aurora Incentive Awards**").

10. Substantial compliance with paragraphs 7 to 9 above will constitute good and sufficient notice of the Aurora Meeting and delivery of the Meeting Materials.

11. The accidental failure or omission to give notice of the Aurora Meeting, or non-receipt of such notice, or any failure or omission to give such notice as a result of events beyond the reasonable control of Aurora (including, without limitation, any inability to use postal services), will not constitute a breach of the Interim Order or a defect in the calling of the Aurora Meeting and will not invalidate any resolution passed or taken at the Aurora Meeting, but if any such failure or omission is brought to the attention of Aurora, then Aurora will use reasonable efforts to rectify it by the method, and in the time, most reasonably practicable in the circumstances.

12. The Meeting Materials are hereby deemed to represent sufficient and adequate disclosure, including for the purpose of section 290(1)(a) of the BCBCA. Aurora will not be required to send Aurora Shareholders or holders of the Aurora Incentive Awards any other or additional information or statement pursuant to section 290(1)(a) of the BCBCA, unless this Court orders otherwise.

DEEMED RECEIPT OF THE MEETING MATERIALS

13. The Meeting Materials will be deemed, for the purposes of this Interim Order, to have been received on the date the Meeting Materials are mailed or delivered in accordance with paragraph 7.

14. Notice of any amendments, modifications, updates or supplements to any of the information provided in the Meeting Materials may be communicated at any time prior to the Aurora Meeting by press release, news release, or newspaper advertisement, in which case such notice will be deemed to have been received at the time of publication, or by notice sent by the most appropriate method of alternative communication as determined by Aurora.

PERMITTED ATTENDEES

15. The only persons entitled to attend the Aurora Meeting will be:

    (a) the Aurora Shareholders as of the Record Date or their respective proxyholders;

    (b) the officers, directors, secretary and assistant secretary of Aurora;

    (c) the auditor and advisors of Aurora;

    (d) representatives and advisors of Organigram; and

    (e) such other persons who receive the consent of the Chairperson of the Aurora Meeting.

QUORUM & VOTING AT THE AURORA MEETING

16. The quorum required for the Aurora Meeting will be two Aurora Shareholders present virtually, or represented by proxy, at the opening of the Aurora Meeting, and holding or representing at least 25% of the Aurora Shares entitled to be voted at the Aurora Meeting.

17. The only persons permitted to vote on the Arrangement Resolution at the Aurora Meeting will be Aurora Shareholders appearing on the records of Aurora as of the close of business on the Record Date and their valid proxyholders as described in the Circular and as determined by the Chairperson of the Aurora Meeting upon consultation with the Scrutineers (as hereinafter defined) and legal counsel to Aurora.

18. The required level of approval on the Arrangement Resolution taken at the Aurora Meeting shall be:

    (a) not less than two-thirds of the votes cast by Aurora Shareholders present in person or virtually, or represented by proxy and entitled to vote at the Aurora Meeting, voting together as a single class; and

    (b) not less than a majority of the votes cast by Aurora Shareholders present in person or virtually, or represented by proxy and entitled to vote at the Aurora Meeting, excluding for this purpose the votes attached to Aurora Shares held by persons described in items (a) through (d) of section 8.1(2) of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions of the Canadian Securities Regulatory Authorities.

19. Each Aurora Shareholder will be entitled to one vote for each Aurora Share held on the Record Date.

20. The terms, restrictions and conditions of the articles of Aurora, including quorum requirements and other matters, will apply in respect of the Aurora Meeting unless otherwise modified in this Interim Order.

ADJOURNMENT OF THE AURORA MEETING

21. If Aurora deems advisable, subject to the terms of the Arrangement Agreement, and notwithstanding the provisions of the BCBCA or the articles of Aurora, Aurora is specifically authorized to adjourn or postpone the Aurora Meeting on one or more occasions without the necessity of first convening the Aurora Meeting or first obtaining any vote of the Aurora Shareholders respecting the adjournment or postponement and without the need for approval of the Court. Notice of any such adjournments or postponements shall be provided by press release, news release, or newspaper advertisement, in which case such notice will be deemed to have been received at the time of publication, or by notice sent by the most appropriate method of alternative communication as determined by Aurora.

22. The Record Date for Aurora Shareholders entitled to notice of and to vote at the Aurora Meeting will not change as a result of adjournments or postponements of the Aurora Meeting without a further order of this Court.

AMENDMENTS

23. Aurora is authorized to make, subject to the Arrangement Agreement, such amendments, modifications or supplements to the Plan of Arrangement, the Arrangement Agreement, the Circular and the Meeting Notice as it may determine without any additional notice to or authorization of the Aurora Shareholders or further orders of this Court, and amendments, modifications or supplements to the Plan of Arrangement may be made only in accordance with the Arrangement Agreement. The Plan of Arrangement, the Arrangement Agreement, the Circular and the Meeting Notice as so amended, modified or supplemented, shall be the

Plan of Arrangement, the Arrangement Agreement, the Circular and the Meeting Notice to be submitted to Aurora Shareholders at the Aurora Meeting, as applicable, and the subject of the Arrangement Resolution.

SCRUTINEER

24. Representatives of the registrar and transfer agent (or any agent thereof) of Aurora, Computershare Investor Services Inc., are authorized to act as scrutineers for the Aurora Meeting (the "**Scrutineers**").

PROXY SOLICITATION

25. Aurora is authorized to permit Aurora Shareholders to vote by proxy using forms of proxy that comply with the articles of Aurora, the provisions of the BCBCA and the *Securities Act* (British Columbia) relating to the form and content of proxies, and Aurora may in its discretion extend or waive generally the time limits for deposit of proxies if Aurora deems it fair and reasonable to do so. Aurora is authorized to solicit proxies directly and through its officers, directors and employees, and through such agents or representatives as it may retain for that purpose and by mail, telephone or such other form of personal or electronic communication as it may determine.

26. The procedures for the form and use of proxies and the revocation of proxies will be as set out in the Meeting Materials.

DELIVERY OF COURT MATERIALS

27. Aurora will include in the Meeting Materials a copy of this Interim Order, a copy of the Petition and a Notice of Hearing of Petition for Final Order (the "**Court Materials**").

28. Delivery of the Court Materials with the Meeting Materials in accordance with this Interim Order will constitute good and sufficient service or delivery of such Court Materials upon all persons who are entitled to receive the Court Materials pursuant to this Interim Order and no other form of service or delivery need be made and no other materials need to be served on or delivered to such persons in respect of these proceedings, subject to the discretion of the Court.

DISSENT RIGHTS

29. Each registered Aurora Shareholder as of the Record Date will, as set out in the Plan of Arrangement, have the right to dissent in respect of the Arrangement Resolution in accordance with the dissent procedures set forth in sections 237 to 247 of the BCBCA, as modified by the terms of this Interim Order, the Plan of Arrangement, and any further order of this Court (the "**Dissent Rights**"), provided that the written notice of dissent (the "**Dissent Notice**") must be received from registered Aurora Shareholders who wish to dissent by Aurora c/o Torys LLP attn: Andrew Gray and Colette Koopman at Suite 2800, 79 Wellington Street West,

Toronto, Ontario, Canada M5K 1N2 (agray@torys.com; ckoopman@torys.com), not later than 9:30 a.m. (Toronto time) on the date that is two (2) Business Days (as defined in the Plan of Arrangement) immediately preceding the date of the Aurora Meeting (as it may be adjourned or postponed from time to time).

30. Notice to registered Aurora Shareholders of their right to dissent with respect to the Arrangement Resolution and to receive, subject to the provisions of the BCBCA and the Plan of Arrangement, the fair value of their Aurora Shares, will be given by including information with respect to this right in the Circular to be provided to Aurora Shareholders in accordance with this Interim Order.

31. A registered Aurora Shareholder who wishes to exercise Dissent Rights, notwithstanding anything in the BCBCA, must:

    (a) be an Aurora Shareholder as of the Record Date;

    (b) not have voted his/her/its Aurora Shares at the Aurora Meeting, either by proxy or in person, for the Arrangement Resolution, and a vote against the Arrangement Resolution or an abstention shall not constitute a Dissent Notice. Filing a Dissent Notice does not deprive a registered Aurora Shareholder of the right to vote at the Aurora Meeting, however, a registered Aurora Shareholder who has submitted a Dissent Notice and who votes or instructs a proxyholder to vote for the Arrangement Resolution will no longer be considered a Dissenting Shareholder (as defined in the Circular);

    (c) exercise Dissent Rights with respect to all of the Aurora Shares of which such registered Aurora Shareholder is both the registered and beneficial owner and in respect of which it has received instructions to dissent from the beneficial holder(s) thereof; and

    (d) otherwise strictly comply with the provisions of the BCBCA, as modified by the terms of this Interim Order, the Plan of Arrangement, and any further order of this Court.

32. A beneficial holder of Aurora Shares registered in the name of a broker, investment dealer or other intermediary, who wishes to dissent, must make arrangements for the registered Aurora Shareholder to dissent on behalf of the beneficial holder of Aurora Shares.

33. Registered Aurora Shareholders who exercise Dissent Rights in accordance with paragraphs 29 to 32 above and who:

    (a) are ultimately determined to be entitled to be paid fair value for their Aurora Shares shall be paid an amount equal to such fair value by Organigram determined in accordance with the procedures applicable to the payout value set out in sections 244 and 245 of the BCBCA and determined as of the close of business on the last business day before the Arrangement Resolution was adopted; or

(b) are ultimately determined not to be entitled, for any reason, to be paid fair value for their Aurora Shares shall be deemed to have participated in the Arrangement, as of the Effective Time (as defined in the Circular), on the same basis as a non-dissenting holder of Aurora Shares.

FINAL APPROVAL HEARING

34. Upon the approval, with or without variation, of the Arrangement Resolution in the manner set forth in this Interim Order, Aurora may set the Petition down for hearing and apply for an order of this Court: (i) approving the Plan of Arrangement; and (ii) determining that the Arrangement is procedurally and substantively fair and reasonable (collectively, the "**Final Order**"), at 9:45 a.m. (Vancouver time) on December 30, 2026, or such other date as counsel may be heard or the Court may direct.

35. Any Aurora Shareholder, Aurora optionholder or other Aurora securityholder has the right to appear (either in person or by counsel) and make submissions at the hearing of the Petition provided that such shareholder or interested party shall file with this Court a Response by no later than 4:00 p.m. (Vancouver time) on December 23, 2026 in the form prescribed by the Supreme Court Civil Rules and deliver a copy of the filed Response together with a copy of all materials on which such party intends to rely at the hearing of the Petition, including an outline of such party's proposed submissions to:

Aurora's counsel:

Torys LLP
Attn: Andrew Gray and Colette Koopman
Suite 2800, 79 Wellington Street West
Toronto, Ontario M5K 1N2
Tel: 416-865-7630
Email: agray@torys.com; ckoopman@torys.com

with a copy to Organigram's counsel at:

Goodmans LLP
Barristers & Solicitors
Attn: Tom Friedland
Bay Adelaide Centre – West Tower
333 Bay Street, Suite 3400
Toronto, Ontario M5H 2S7
Tel: 416-597-4218
Email: tfriedland@goodmans.ca

by no later than 4:00 p.m. (Vancouver time) on December 23, 2026 or as the Court may otherwise direct.

36. If the application for the Final Order is adjourned, only those persons who have filed and delivered a Response, in accordance with the preceding paragraph of this Interim Order, need to be served with notice of the adjourned date.

37. Aurora will not be required to comply with Rules 8-1 and 16-1 of the Supreme Court Civil Rules in relation to the hearing of the Petition for the Final Order approving the Plan of Arrangement, and any materials to be filed in support of the application for the Final Order may be filed prior to the hearing of the application for the Final Order without further order of this Court.

VARIANCE

38. Aurora is at liberty to apply to this Court to vary the Interim Order or for advice and direction with respect to the Arrangement or any of the matters related to the Interim Order and Aurora need not comply with Rule 8-1 of the Supreme Court Civil Rules in any application to do so.

39. The signature of counsel for Organigram is dispensed with.

THE FOLLOWING PARTIES APPROVE THE FORM OF THIS ORDER AND CONSENT TO EACH OF THE ORDERS, IF ANY, THAT ARE INDICATED ABOVE AS BEING BY CONSENT:

Signature of Lawyers for the Petitioner
Torys LLP
(Andrew Gray ~~and Colette Koopman~~)

BY THE COURT

REGISTRAR

No. VLC-S-S-268586
Vancouver Registry

IN THE SUPREME COURT OF BRITISH COLUMBIA

AURORA CANNABIS INC.

Petitioner

ORDER MADE AFTER APPLICATION

TORYS LLP
79 Wellington St. W., 28th Floor
Box 270, TD South Tower
Toronto, ON M5K 1N2

Andrew Gray (46626V)
agray@torys.com
Tel: 416.865.7630

Colette Koopman (81804R)
ckoopman@torys.com
Tel: 416.865.7393

Tel: 416.865.0040
Fax: 416.865.7380

Lawyers for the Petitioner

AGENT: HL LITIGATION

APPENDIX "E"
PETITION AND NOTICE OF HEARING OF PETITION

(See attached)

SUPREME COURT
OF
BRITISH COLUMBIA
SEAL
18-Nov-26
Vancouver
REGISTRY

Court File No. VLC-S-S-268586
No.
Vancouver Registry

IN THE SUPREME COURT OF BRITISH COLUMBIA

IN THE MATTER OF PART 9, DIVISION 5, SECTION 291 OF THE *BUSINESS CORPORATIONS ACT*, S.B.C. 2002, C. 57, AS AMENDED

AND

IN THE MATTER OF A PROPOSED PLAN OF ARRANGEMENT OF AURORA CANNABIS INC. INVOLVING ORGANIGRAM GLOBAL INC.

AURORA CANNABIS INC.

Petitioner

PETITION TO THE COURT

ON NOTICE TO: The holders of the common shares of Aurora Cannabis Inc.

AND ON NOTICE TO: The holders of deferred share units issued under the Aurora DSU Plans, restricted share units issued under the Aurora RSU Plan, performance share units issued under the Aurora PSU Plan and options to purchase Aurora Shares granted under the Aurora Stock Option Plan.

AND ON NOTICE TO: Organigram Global Inc.

The address of the registry is:
Vancouver Registry
800 Smithe Street
Vancouver, BC V6Z 2E1

The petitioner estimates that the hearing of the petition will take 15 minutes.

This matter is not an application for judicial review.

This proceeding is brought for the relief set out in Part 1 below by

☒ the person(s) named as petitioner(s) in the style of proceedings above.

If you intend to respond to this petition, you or your lawyer must

(a) file a Response to Petition in Form 67 in the above-named registry of this court within the time for Response to Petition described below, and

(b) serve on the petitioner

(i) 2 copies of the filed Response to Petition, and

(ii) 2 copies of each filed Affidavit on which you intend to rely at the hearing.

Orders, including orders granting the relief claimed, may be made against you, without any further notice to you, if you fail to file the Response to Petition within the time for response.

Time for Response to Petition

A Response to Petition must be filed and served on the petitioner,

(a) if you were served with the petition anywhere in Canada, within 21 days after that service,

(b) if you were served with the petition anywhere in the United States of America, within 35 days after that service,

(c) if you were served with the petition anywhere else, within 49 days after that service, or

(d) if the time for response has been set by order of the court, within that time.

(1)	The ADDRESS FOR SERVICE of the petitioner is: c/o Andrew Gray/Colette Koopman Torys LLP 79 Wellington St. W., 28th Floor Box 270, TD South Tower Toronto, ON M5K 1N2 Fax number address for service (if any) of the petitioner: 416.865.7380 E-mail address for service (if any) of the petitioner: agray@torys.com/ckoopman@torys.com
(2)	The names and office address of the petitioner's lawyers are: c/o Andrew Gray/Colette Koopman

	Torys LLP 79 Wellington St. W., 28th Floor Box 270, TD South Tower Toronto, ON M5K 1N2

CLAIM OF THE PETITIONER

Part 1: ORDERS SOUGHT

1. The Petitioner, Aurora Cannabis Inc. ("**Aurora**"), applies to the Court pursuant to section 291 of the British Columbia *Business Corporations Act*, S.B.C. 2002, c. 57, as amended (the "**BCBCA**"), Rules 4-4, 4-5, 8-1 and 16-1 of the *Supreme Court Civil Rules*, B.C. Reg. 168/2009, and the inherent jurisdiction of the court for:

   (a) an order (the "**Interim Order**") in the form attached as Schedule "A" to this Petition;

   (b) an order (the "**Final Order**") in the form attached as Schedule "B" to this Petition; and

   (c) such further and other relief as counsel for the Petitioner may advise and this honourable court may deem just.

Part 2: FACTUAL BASIS

Definitions

2. As used in this Petition, unless otherwise defined, capitalized terms have the meanings set out in the joint management information circular of Aurora and Organigram Global Inc. ("**Organigram**") (the "**Circular**"), a draft of which is attached as Exhibit "A" to Affidavit #1 of Miguel Martin, made November 18, 2026 (the "**Martin Affidavit**").

Overview of these Proceedings

3. The Petition concerns an arrangement agreement dated November 2, 2026 (as the same may be amended, the "**Arrangement Agreement**") between Aurora and Organigram pursuant to which Organigram agreed to acquire all of the issued and outstanding common shares of Aurora (the "**Aurora Shares**") for consideration having an implied value of C$7.80 per Aurora Share (the "**Transaction**"). Holders of Aurora Shares (the "**Aurora Shareholders**") will have the ability to elect to receive common shares of Organigram ("**Organigram Common Shares**"), cash or a combination of both, subject to proration. Aurora seeks to effect the Transaction by way of a court-approved plan of arrangement under section 291 of the BCBCA (the "**Plan of Arrangement**").

4. Aurora seeks an Interim Order for directions in connection with: (i) the calling and holding of a special meeting (the "**Aurora Meeting**") of the Aurora Shareholders on December 23, 2026 at 9:30 a.m., (Toronto time) in virtual or hybrid meeting format, or such other date as may result from any postponement or adjournment; and (ii) shareholder approval of the arrangement (the "**Arrangement**") and related matters at the Aurora Meeting.

5. At the Aurora Meeting, the Aurora Shareholders will, *inter alia*, consider, and, if deemed advisable, approve an arrangement resolution (the "**Arrangement Resolution**"), in the form attached as Appendix "A" to the Circular, adopting, with or without amendment, the Arrangement as set forth in the Plan of Arrangement, a copy of which is included in Appendix "C" to the Circular.

6. Following shareholder approval, the Petitioner will seek a Final Order approving the Arrangement on the basis*, inter alia*, that it is fair and reasonable to those securityholders the legal rights of which are affected by the Arrangement. The Petitioner intends to bring an application on December 30, 2026, or such other date as counsel may be heard or the Court may direct, for the Final Order.

7. The Court's approval of the Arrangement pursuant to the Final Order, if granted, which includes a finding of the procedural and substantive fairness of the terms and conditions of the Arrangement, will serve as the basis for an exemption from the registration requirements of the United States *Securities Act of 1933,* as amended, provided by Section 3(a)(10) thereof with respect to the issuance of securities pursuant to the Arrangement.

The Parties

8. Aurora is incorporated under the BCBCA and has its head office in Edmonton, Alberta. Aurora's principal strategic business lines are focused on the production, distribution and sale of cannabis products in Canada and internationally.

9. As at November 16, 2026, Aurora has 65,748,913 issued and outstanding Aurora Shares. The Aurora Shares trade on the TSX and Nasdaq under the symbol "ACB" and are quoted on the open market of the Frankfurt Stock Exchange under the symbol "21P." Aurora is authorized to issue an unlimited number of Aurora Shares, an unlimited number of Class A shares, issuable in series, and an unlimited number of Class B shares, issuable in series, of which only Aurora Shares are issued and outstanding.

10. In addition to the Aurora Shares, Aurora has outstanding:

    (a) deferred share units issued under the Aurora DSU Plans (the "**Aurora DSUs**");

    (b) restricted share units issued under the Aurora RSU Plan (the "**Aurora RSUs**");

(c) performance share units issued under the Aurora PSU Plan (the "**Aurora PSUs**"); and

(d) options to purchase Aurora Shares granted under the Aurora Stock Option Plan (the "**Aurora Options**").

11. Organigram is a corporation existing under the *Canada Business Corporations Act*, R.S.C., 1985, c. C-44 and its head office is in Toronto, Ontario. Organigram Inc., a wholly-owned subsidiary of Organigram, is a leading Canadian licensed producer of high quality cannabis and cannabis-derived products for consumers in Canada, and has various international business relationships that it continuously seeks to develop in order to expand its global footprint.

12. The Petitioner's address for service for the purpose of this proceeding is Torys LLP, Suite 2800, 79 Wellington Street West, Toronto, Ontario, M5K 1N2.

The Arrangement

13. The detailed steps in the Arrangement are set out in the Plan of Arrangement, a copy of which is set forth in Appendix "C" to the Circular. By way of general description, the steps of the Arrangement include, amongst other things:

(a) Organigram will acquire all issued and outstanding Aurora Shares. Aurora Shareholders, other than Aurora Shareholders who have validly exercised dissent rights (discussed further below), will be entitled to receive, at their election (subject, in the cases of (i) and (ii) below, to proration[1]), for each Aurora Share:

(i) $7.80 in cash (the "**Cash Alternative**");

(ii) 5.8626 Organigram Common Shares (the "**Share Alternative**"); or

(iii) a combination of $3.75 in cash and 3.0431 Organigram Common Shares (the "**Combination Alternative**");

(b) all outstanding Aurora DSUs, Aurora RSUs and Vested Aurora PSUs will be cancelled in exchange for cash payments from Aurora of $7.80 per underlying Aurora Share (multiplied by 100% in the case of Vested Aurora PSUs);

(c) all outstanding Aurora PSUs that are not Vested Aurora PSUs will remain outstanding and be settled in cash at $7.80 per underlying share (multiplied

[1] The aggregate share consideration will include no more than 3.0431 Organigram Common Shares multiplied by the number of Aurora Shares outstanding immediately prior to the Effective Time and the aggregate cash consideration will include no more than $3.75 in cash multiplied by the number of Aurora Shares outstanding immediately prior to the Effective Time.

by 100%) on their Entitlement Date as defined in the applicable Aurora PSU Plan, subject to vesting; and

(d) Aurora Options will be exchanged for an option to purchase Organigram Common Shares.

14. The Arrangement is contingent on, amongst other things, the holders of Organigram Common Shares approving the issuance of the Organigram Common Shares issuable pursuant to the Arrangement and the concurrent private placement of Organigram securities to BT DE Investments Inc. ("**BAT**") to fund a portion of the cash component of the consideration to be paid pursuant to the Arrangement.

Background to the Arrangement

15. The background to the Arrangement is described below and in the Circular.

16. The board of directors of Aurora (the "**Aurora Board**") and Aurora's management are executing a long-term international strategy to focus on prioritizing global medical cannabis growth. Through years of operating large-scale EU-GMP-certified facilities, Aurora has developed the scientific, cultivation, regulatory and operational capabilities that support its global medical cannabis strategy. Aurora has also completed acquisitions of businesses and significant investments in international assets to further support this strategic plan and facilitate market access. In particular, Aurora's recently completed acquisition of the Safari Flower Company builds on Aurora's global medical cannabis platform and leverages its diversified and scaled network and strong balance sheet to build sustainable, long-term shareholder value. As part of this strategic plan, Aurora has historically and continues to evaluate additional opportunities, including potential acquisitions, joint ventures, business combinations and other similar transactions, to expand this capacity and add shareholder value.

17. The offer made by Organigram was made against the backdrop of an unsolicited take-over bid (the "**Hostile Bid**") launched by Curaleaf Holdings, Inc. ("**Curaleaf**"). Based on the independent committee of the Aurora Board comprised of independent directors' (the "**Aurora Special Committee**") unanimous recommendation and receipt of legal and financial advice, the Aurora Board unanimously recommended to the Aurora Shareholders that they reject the Hostile Bid.

18. On August 23, 2026, Mr. James Yamanaka, Organigram's Chief Executive Officer, unsolicitedly contacted Mr. Miguel Martin, Aurora's Chief Executive Officer, by e-mail inviting a discussion to explore potential business opportunities. On August 24, 2026, Mr. Yamanaka called Mr. Martin to express that Organigram would potentially be interested in exploring a negotiated business combination with, or acquisition of, Aurora, and subsequently delivered a letter to Mr. Martin and Mr. Michael Singer, Aurora's Lead Independent Director, reinforcing that interest. The

letter did not include any indication of price or other terms, but expressed that Organigram viewed a transaction with Aurora as a compelling strategic alternative capable of delivering a significant premium to Aurora Shareholders. The letter also noted that any proposal would be dependent on customary due diligence and indicated Organigram's willingness to enter into a customary non-disclosure and standstill agreement to facilitate that work.

19. On September 22, 2026, the Aurora Special Committee met with management, Fort Capital Partners, Aurora's financial advisor ("**Fort Capital**"), Stikeman Elliott LLP, Aurora's legal counsel ("**Stikeman**"), and Torys LLP, independent legal counsel to the Aurora Special Committee ("**Torys**"). At the meeting, management and Fort Capital provided an update with respect to the process to solicit alternative acquisition proposals, noting that the parties that had entered into non-disclosure and standstill agreements with Aurora, including Organigram, had been granted access to certain confidential information concerning Aurora.

20. On September 23, 2026, management representatives from Aurora and Organigram met, together with their respective financial and legal advisors, for Aurora management to present on various aspects of Aurora's business.

21. At an Aurora Special Committee meeting held on September 29, 2026, at which Stikeman and Torys also attended, management and Fort Capital provided a further update on the process to solicit alternative acquisition proposals, noting that parties who had entered into non-disclosure and standstill agreements with Aurora continued to perform due diligence and providing an update from the management diligence session held with Organigram on September 23, 2026.

22. On October 9, 2026, Organigram delivered a non-binding letter of intent to Aurora (the "**First Organigram Proposal**") subject to due diligence and proposing an acquisition of all of the Aurora Shares for consideration, comprised of $3.10 in cash and 3.1633 Organigram Common Shares per Aurora Share on a fully prorated basis, representing a stated value of $7.75 per Aurora Share, and including the ability of Aurora Shareholders to elect the form of consideration they wished to receive subject to proration, maximum amounts and adjustments. Such price represented a 92% premium to the Unaffected Price and a 13% premium relative to the implied value of the Hostile Bid of $6.84 as of October 8, 2026. The First Organigram Proposal contemplated a 21-day exclusivity period in order for Organigram to conduct final confirmatory due diligence and for definitive transaction agreements to be negotiated, and described that those agreements would contemplate customary deal protection provisions, subject to a fiduciary out in favour of Aurora and a termination fee of 4.5% of the purchase price. On the same day, Business of Cannabis reported that Organigram and Aurora were in discussions regarding a potential transaction.

23. Between October 10 and 13, 2026, Fort Capital engaged in a number of discussions with BMO Capital Markets, Organigram's financial advisor, with respect to the price, exclusivity and other terms contemplated in the First

Organigram Proposal. On the morning of October 14, 2026, BMO Capital Markets communicated to Fort Capital Organigram's proposal to increase the price offered to $3.10 in cash and 3.2789 Organigram Common Shares per Aurora Share on a fully prorated basis, representing a stated value of $7.92 per Aurora Share, subject to all of the same terms contained in the First Organigram Proposal (the "**Second Organigram Proposal**") and reiterating Organigram's requirement that it would only continue discussions and work towards a potential transaction on an exclusive basis.

24. At an October 14, 2026 meeting of the Aurora Special Committee, at which management, Torys, Stikeman and Fort Capital also attended, Fort Capital provided a detailed presentation regarding its financial analysis of the Hostile Bid as well as its preliminary analysis of the Second Organigram Proposal. Fort Capital also noted that while multiple other parties had performed due diligence regarding Aurora and expressed different levels of interest in pursuing a potential transaction with Aurora, none of those parties had delivered an expression of interest in a particular transaction. Following discussion and an in-camera session during which only the Aurora Special Committee, Torys and Fort Capital were in attendance, it was determined that the price contemplated by the Second Organigram Proposal remained inadequate. In addition, the Aurora Special Committee objected to the duration and other terms of the exclusivity period, and the quantum of the proposed termination fee. The Aurora Special Committee therefore directed management and Fort Capital to undertake negotiations with Organigram and its representatives on each of those points.

25. As directed by the Aurora Special Committee, on October 15, 2026, Fort Capital delivered a counter-proposal to BMO Capital Markets contemplating an increase in the price to represent a stated value of $8.34, comprised of $3.10 in cash and 3.6162 Organigram Common Shares per Aurora Share, a shortened exclusivity period expiring on the earlier of November 2, 2026 or Curaleaf announcing an amendment to the Hostile Bid to change the amount or form of consideration offered, and a reduced termination fee of 3.25%. The counter-proposal also expressly permitted Aurora, the Aurora Board and the Aurora Special Committee to comply with applicable securities laws in respect of the Hostile Bid or any other take-over bid.

26. On October 16, 2026, Organigram responded by delivering a revised non-binding letter of intent to Aurora contemplating a consideration comprised of $3.45 in cash and 3.2501 Organigram Common Shares per Aurora Share on a fully prorated basis, representing a stated value of $8.16 per Aurora Share (the "**Third Organigram Proposal**"), representing a 103% premium to the Unaffected Price and a 32% premium relative to the implied value of the Hostile Bid of $6.19 as of October 15, 2026[2]. In addition, the Third Organigram Proposal contemplated a shorter exclusivity period through November 2, 2026, subject to extension to

[2] Based on the closing price of Curaleaf Shares on the TSX on October 15, 2026, and assuming a USD/CAD exchange rate of 1.4196.

November 9, 2026 if Organigram continued to diligently pursue the proposed transaction, but rejected the earlier termination trigger of the exclusivity period linked to Curaleaf announcing an amendment to the Hostile Bid to change the amount or form of consideration offered. The Third Organigram Proposal also contemplated a termination fee of 3.99% and accepted the ability of Aurora, the Aurora Board and the Aurora Special Committee to comply with applicable securities laws in respect of the Hostile Bid or any take-over bid.

27. Between October 16 and 17, 2026, representatives of Torys, Stikeman and Goodmans, counsel to Organigram, engaged in several discussions with respect to the terms of the exclusivity period. During those discussions, the Torys representatives communicated the Aurora Special Committee's view that an exclusivity period would only be acceptable if it permitted Aurora to engage with Curaleaf in the event it amended the Hostile Bid to a price higher than that contemplated in Organigram's proposal. Meanwhile, Fort Capital and BMO Capital Markets also met to discuss the price of Organigram's proposal and the quantum of the termination fee, with BMO Capital Markets stating that Organigram was not willing to increase its price above the amount offered in the Third Organigram Proposal.

28. Following those discussions and exchange of several revised drafts, on October 18, 2026, the non-binding letter of intent was settled (the "**LOI**"), contemplating the same consideration as the Third Organigram Proposal (and a stated value of $8.16 per Aurora Share). The LOI continued to contemplate an exclusivity period expiring on November 2, 2026, subject to extension to November 9, 2026 if Organigram continued to diligently pursue the proposed transaction, but contained an early termination of that period if (i) Curaleaf amended the Hostile Bid to increase the amount of consideration offered, (ii) the Aurora Board determined that the Hostile Bid, as amended, would if consummated reasonably be expected to lead to a transaction more favourable from a financial point of view to Aurora Shareholders than the transaction with Organigram contemplated by the LOI and (iii) Organigram did not increase the price contemplated under the LOI such that (ii) is no longer true within two business days. The LOI also contemplated a reduced termination fee of 3.9%. The LOI was signed by Aurora and Organigram on October 18, 2026. Despite the exclusivity provisions of the LOI, Curaleaf did not contact Aurora or propose an increased price to the Hostile Bid prior to announcement of the Arrangement.

29. On October 18, 2026, Stikeman and Torys shared an initial draft of the Arrangement Agreement with Goodmans. Shortly thereafter, representatives of Aurora were granted access to an electronic data room containing Organigram confidential information so that Aurora could complete its due diligence on Organigram's business.

30. On October 20, 2026, the Aurora Special Committee met to receive an update on the process from management, Fort Capital, Torys and Stikeman. In addition to receiving updates on negotiations and due diligence being conducted on

Organigram, the Aurora Special Committee discussed the financial advice and opinion from Fort Capital that would be received in connection with announcing a transaction with Organigram and decided to retain an additional and independent fairness opinion provider on a fixed fee basis.

31. Between October 20 and 23, 2026 the Aurora Special Committee reached out to, and received proposals from, several potential fairness opinion providers. On October 24, 2026, the Aurora Special Committee retained Origin Merchant Partners ("**Origin**") as its independent financial advisor based on its qualifications and experience in the industry and with similar mandates. Origin's mandate included providing the Aurora Special Committee with financial analysis and advice in respect of the Arrangement (or any alternative transaction) and, if requested, providing a fairness opinion in connection therewith. Pursuant to the terms of the engagement letter with Origin, Aurora would be obligated to pay a flat fee to Origin and no portion of the fees payable to Origin for its services would be contingent upon the value of any transaction, its completion or the conclusions reached in Origin's fairness opinion.

32. During the period between October 18 and November 2, 2026, the parties, with the assistance of their respective legal and financial advisors, negotiated the definitive terms of the Arrangement Agreement and the voting support agreements to be entered into with the respective party's directors and officers and BAT while due diligence continued (including reverse due diligence by Aurora which included meetings between Aurora and Organigram management, attended by each party's legal and financial advisors, that occurred on October 21 and 23 and a site visit by representatives of Aurora at Organigram's main Moncton facility that week). The Aurora Special Committee also met several times over that period to receive updates on and oversee that process. At such meetings, representatives of management, Torys and Stikeman provided updates to the Aurora Special Committee with respect to their discussions with Organigram's and BAT's respective counsel and reported to the Aurora Special Committee as to open issues with respect to the draft transaction agreements. The Aurora Special Committee then instructed Torys and Stikeman as to the terms and conditions of such agreements that would be acceptable to it, including provisions relating to deal certainty and closing risk allocation (such as regulatory approvals and other closing conditions, and the scope of Aurora's representations, warranties and interim operating covenants), the nature of the non-solicitation provisions, the circumstances in which each party would be permitted to terminate the Arrangement Agreement, and the voting support agreement to be entered into with BAT, the consequences of termination (including the remedies available to Aurora) and the instances in which a termination fee would be payable by Aurora and a reverse termination fee would be payable by Organigram. Those Aurora Special Committee meetings also included updates from Fort Capital and Origin on their respective financial analyses. The Aurora Special Committee also met separately with only Torys and Origin.

33. In particular, it was of critical importance to the Aurora Special Committee that the Aurora Board maintain the ability to change its recommendation to Aurora Shareholders or terminate the Arrangement Agreement in the event a Superior Proposal surfaced (including an Amended Bid by Curaleaf), subject to Organigram's right to match. This was in contrast to Organigram's desire to maximize deal certainty. Ultimately, following lengthy negotiations and discussions amongst the parties, the Aurora Special Committee agreed to an increased termination fee of 4.5% of the purchase price in exchange for maintaining Aurora's right to terminate the Arrangement Agreement in the event of a Superior Proposal that Organigram elects not to match.

34. On November 1, 2026, Organigram proposed to increase the amount of cash that would be available to Aurora Shareholders under the Arrangement and correspondingly reduce the number of Organigram Common Shares. Based on updated trading data as of November 2, 2026, the revised proposal represented a price of $7.80[3], comprised of $3.75 in cash and 3.0431 Organigram Common Shares per Aurora Share on a fully prorated basis. Aurora Shareholders would be able to elect to receive (i) $7.80 in cash, (ii) 5.8626 Organigram Common Shares or (iii) a combination of $3.75 in cash and 3.0431 Organigram Common Shares, in each case per Aurora Share and subject to proration. The Aurora Special Committee, with the advice of its and Aurora's financial and legal advisors, decided to accept the increased amount of cash being offered provided Aurora Shareholders with greater certainty in value and greater liquidity.

35. On the afternoon of November 2, 2026, the Aurora Special Committee met with Origin and Torys to review Origin's financial analysis of the Arrangement. Later that evening, the Aurora Special Committee reconvened. Following a briefing of the finalized key terms of the definitive transaction agreements, including the Arrangement Agreement, from Torys and Stikeman, Origin and Fort Capital rendered the oral Origin Fairness Opinion and oral Fort Capital Fairness Opinion, respectively, to the Aurora Special Committee and the Aurora Board. Based upon the Aurora Special Committee's consideration of, among other things, the Aurora Fairness Opinions and the advice of external legal and financial advisors, the Aurora Special Committee unanimously recommended to the Aurora Board, among other things, that the Aurora Board (i) determine that the Arrangement is in the best interests of Aurora; (ii) determine that the Arrangement is fair to the Aurora Shareholders; (iii) approve the entering into, execution, delivery and performance of Aurora's obligations under the definitive transaction agreements to which Aurora is a party, including the Arrangement Agreement; (iv) recommend that Aurora Shareholders vote in favour of the Arrangement Resolution; and (v) continue to reject the Hostile Bid and recommend that Aurora Shareholders not tender their Aurora Shares to the Hostile Bid. Based on the recommendation of the Aurora Special Committee and the Aurora Board's consideration of, among other things, the Aurora Fairness Opinions and the advice of external legal and financial

[3] Based on the 20-day volume-weighted average trading price of the Organigram Common Shares on the TSX of approximately $1.33 as of November 2, 2026.

advisors, the Aurora Board, among other things, unanimously (i) determined that the Arrangement is in the best interests of Aurora; (ii) determined that the Arrangement is fair to the Aurora Shareholders; (iii) approved the entering into, execution, delivery and performance of Aurora's obligations under the definitive transaction agreements to which Aurora is a party, including the Arrangement Agreement; (iv) recommended that Aurora Shareholders vote in favour of the Arrangement Resolution; and (v) determined to continue to reject the Hostile Bid and recommend that Aurora Shareholders not tender their Aurora Shares to the Hostile Bid.

36. The Arrangement Agreement and other transaction documents were finalized and executed on the evening of November 2, 2026, and a press release announcing the transaction was issued on November 3, 2026, prior to the opening of trading of Aurora Shares on the TSX or Nasdaq.

Reasons and Support for the Arrangement

37. The Board of Aurora and the Special Committee carefully evaluated the Arrangement and believe that the Arrangement is in the best interests of Aurora. The Board of Aurora and the Special Committee unanimously recommend that Aurora Shareholders vote in favour of the Arrangement Resolution. In their evaluations, the Board of Aurora and the Special Committee considered, among other things, the following factors:

    (a) *Creates a Global Cannabis Leader* with a scaled, Canadian-headquartered global cannabis platform with leading positions in five nationally legal cannabis markets – Canada, Germany, Poland, Australia and New Zealand – and meaningful operations in other key markets.

    (b) *Significant Premium and Choice of Consideration*. Aurora Shareholders may elect the Cash Alternative, the Share Alternative or the Combination Alternative, subject, in the case of the Cash Alternative and the Share Alternative, to proration, with an implied value of $7.80 per Aurora Share, representing a premium of approximately 93% to the Unaffected Price and approximately 21% to the implied value of the Hostile Bid as of November 2, 2026.

    (c) *Superior to the Hostile Bid*, which the Aurora Board and the Aurora Special Committee have twice unanimously determined to be financially inadequate, with the Arrangement offering a larger cash component at a fixed price.

    (d) *Attractive Valuation.* Approximately 9.4x LTM Adjusted EBITDA and 1.4x LTM Net Revenue for the twelve months ended June 30, 2026.

    (e) *Complementary Capabilities* across Organigram's Canadian adult-use leadership, diversified production and cultivation capabilities, research and

development platform and European medical market presence, and Aurora's global medical cannabis leadership, genetics expertise and EU-GMP certified manufacturing capacity.

(f) *Meaningful Synergies* of more than $50 million annually, with Aurora Shareholders who retain Organigram Common Shares participating in the value of such synergies to the extent realized.

(g) *Accelerates Product Innovation and Commercial Growth*, through the combined company's scale and cross-border infrastructure, which are expected to create a platform for shared innovation and brand building, supported by BAT's demonstrated expertise in research and development, innovative product development and global supply chain management.

(h) *Attractive Organigram Common Shares*, listed on the TSX and Nasdaq, with a single class of voting shares, no controlling shareholder and a supportive strategic shareholder in BAT.

(i) *Preferred Outcome of a Robust Competitive Strategic Process* following the unsolicited offer by Curaleaf, as amended, which the Aurora Special Committee and the Aurora Board have determined remains inadequate and significantly undervalues Aurora.

(j) *Role of the Special Committee.* The Arrangement is the result of a strategic process undertaken with the supervision and involvement of the Aurora Special Committee, advised by experienced and qualified external legal and financial advisors. The Arrangement was unanimously recommended to the Aurora Board by the Aurora Special Committee on the basis described herein and on the basis of the legal and financial advice that was received by the Aurora Special Committee.

(k) *High Likelihood of Completion.* The Arrangement is subject to only a limited number of customary conditions, and is not subject to any financing or due diligence condition. The only Required Regulatory Approvals are approval under the *Competition Act* (Canada) and clearance under German foreign direct investment laws, and Aurora and Organigram believe that meaningful regulatory challenges are unlikely given the complementary nature of their respective operations. Completion of the Arrangement is expected to occur in January 2027.

No Creditor Impact

38. The Arrangement does not contemplate a compromise of any debt or debt instrument of the Petitioner, and no creditor of the Petitioner will be materially affected by the Arrangement.

Dissent Rights

39. It is proposed by the Petitioner that registered Aurora Shareholders will have the right to dissent in respect of the Arrangement Resolution. The Dissent Rights are set out in the Interim Order and described in the Circular.

United States Securities Law

40. Section 3(a)(10) of the United States *Securities Act of 1933*, as amended (the "**U.S. Securities Act**") provides an exemption (the "**Section 3(a)(10) Exemption**") from the registration requirements of the U.S. Securities Act for securities issued in exchange for one or more bona fide outstanding securities, claims or property interests, or partly in such exchange and partly for cash, where the terms and conditions of such issuance and exchange are approved by a court of competent jurisdiction that is expressly authorized by law to grant such approval, after a hearing upon the procedural and substantive fairness of the terms and conditions of such issuance and exchange at which all persons whom it is proposed to issue such securities shall have the right to appear and receive the timely and adequate notice thereof.

41. Organigram intends to rely on the Section 3(a)(10) Exemption in completing the Arrangement. Securityholders to whom securities will be issued under the Arrangement shall receive such securities in reliance on the Section 3(a)(10) Exemption based on the Court's approval of the Arrangement.

The Meeting and Securityholder Approval

42. Aurora will call, hold, and conduct the Aurora Meeting on December 23, 2026 at 9:30 a.m. (Toronto time) in virtual or hybrid meeting format, or such other date as may result from postponement or adjournment in accordance with the Interim Order. At the Aurora Meeting, the Aurora Shareholders will, *inter alia*, consider, and, if deemed advisable, approve the Arrangement Resolution. The Aurora Meeting will be called, held, and conducted in accordance with the Notice of Meeting to be delivered in substantially the form attached to and forming part of the Circular, and in accordance with the applicable provisions of the BCBCA, the terms of the Interim Order, any further Order of the Court, the rulings and directions of the Chairperson of the Aurora Meeting, and in accordance with the terms, restrictions and conditions of the articles of Aurora, including quorum and voting requirements and all other matters.

Part 3: LEGAL BASIS

43. The Petitioner relies on:

    (a) sections 288 and 291 of the BCBCA;

    (b) Rules 4-4, 4-5, 8-1 and 16-1 of the *Supreme Court Civil Rules*;

(c) the Interim Order; and

(d) the equitable and inherent jurisdiction of the Court.

44. The test to be applied in considering an application for final court approval is set out in *BCE Inc. v. 1976 Debentureholders*, 2008 SCC 69 ("***BCE***"). In *BCE* the Court held at para. 137 that a corporation seeking approval of an arrangement pursuant to section 192 of the CBCA (and, by extension, section 291 of the BCBCA) bears the onus of satisfying the reviewing court that:

(a) the statutory procedures have been met;

(b) the application has been put forward in good faith; and

(c) the Arrangement is fair and reasonable.

45. The applicable statutory requirements under section 291 are that, pursuant to section 288 of the BCBCA, the proposed arrangement constitutes an "arrangement".

46. The application has been brought in good faith. As evidenced by the background and reasons set out in the Petition, the Arrangement is being put forward in good faith and for a good business purpose. The Arrangement is the result of arm's length negotiations between representatives of Aurora, including the Aurora Special Committee, and Organigram and their respective financial and legal advisors.

47. In determining whether an arrangement is fair and reasonable, the court must be satisfied that the arrangement serves a valid business purpose, and the objections of those whose legal rights are being arranged are being resolved in a fair and balanced way.

BCE at paras. 138 and 143

48. Whether these requirements are met is determined by taking into account a variety of relevant factors, including the approval, if any, of a majority of securityholders entitled to vote.

BCE at para. 154

Part 4: MATERIAL TO BE RELIED ON

1. Affidavit #1 of Miguel Martin, made November 18, 2026.

2. Affidavit #2 of Miguel Martin, to be affirmed.

3. Such further and other affidavits and other documents as counsel for the Petitioner may advise.

Date: November 18, 2026



Signature of ☐ Petitioner
☒ Lawyer for Petitioner

Andrew Gray/Colette Koopman

To be completed by the court only:

Order made

☐ in the terms requested in paragraphs _____ of Part 1 of this petition

☐ with the following variations and additional terms:

_____

_____

_____

Date: _____ _____

Signature of ☐ Judge ☐ Associate Judge

Schedule “A”
Interim Order

No.
Vancouver Registry

IN THE SUPREME COURT OF BRITISH COLUMBIA

IN THE MATTER OF PART 9, DIVISION 5, SECTION 291 OF THE *BUSINESS CORPORATIONS ACT*, S.B.C. 2002, C. 57, AS AMENDED

AND

IN THE MATTER OF A PROPOSED PLAN OF ARRANGEMENT OF AURORA CANNABIS INC. INVOLVING ORGANIGRAM GLOBAL INC.

AURORA CANNABIS INC.

Petitioner

ORDER MADE AFTER APPLICATION (INTERIM ORDER)

BEFORE	)))))))	FRIDAY, THE 20TH DAY OF NOVEMBER 2026

ON THE APPLICATION OF the Petitioner, Aurora Cannabis Inc. ("**Aurora**"), without notice coming on for hearing at the Courthouse at 800 Smithe Street, Vancouver, British Columbia on November 20, 2026; AND ON HEARING Andrew Gray and Colette Koopman, counsel for the Petitioner and Tom Friedland, counsel for Organigram Global Inc. ("**Organigram**"); AND UPON READING the Notice of Application filed herein and Affidavit #1 of Miguel Martin made November 18, 2026 (the "**Martin Affidavit**"); AND UPON BEING ADVISED that it is the intention of Organigram to rely upon section 3(a)(10) of the United States *Securities Act of 1933*, as amended (the "**U.S. Securities Act**"), as a basis for an exemption from the registration requirements of the U.S. Securities Act with respect to the issuance of the securities under the Plan of Arrangement (as defined below), including the Consideration Shares and the Replacement Options (as such terms are defined in the Plan of Arrangement), based on the Court's approval of the Arrangement (as defined below), which approval through the issuance of the Final Order will constitute its determination of the fairness of the Arrangement;

THIS COURT ORDERS that:

DEFINITIONS

1. Unless otherwise defined, all capitalized terms used in this Interim Order shall have the meaning ascribed thereto in the joint management information circular of Aurora and Organigram (the "**Circular**") attached as Exhibit "A" to the Martin Affidavit.

SPECIAL MEETING

2. Aurora is authorized to call, hold, and conduct a special meeting (the "**Aurora Meeting**") of the holders of common shares in the capital of Aurora (the "**Aurora Shareholders**" who hold the "**Aurora Shares**"), on December 23, 2026 at 9:30 a.m., (Toronto time) in virtual or hybrid meeting format, or such other date as may result from postponement or adjournment in accordance with this Interim Order.

3. At the Aurora Meeting, the Aurora Shareholders will, *inter alia*, consider, and, if deemed advisable, approve an arrangement resolution (the "**Arrangement Resolution**"), in the form attached as Appendix "A" to the Circular, adopting, with or without amendment, the arrangement (the "**Arrangement**") involving Aurora as set forth in the plan of arrangement (the "**Plan of Arrangement**"), a copy of which is included in Appendix "C" to the Circular.

4. At the Aurora Meeting, Aurora will also seek to transact such other business as is contemplated by the Circular or as otherwise may be properly brought before the Aurora Meeting.

5. The Aurora Meeting will be called, held, and conducted in accordance with the Notice of Meeting (the "**Meeting Notice**") to be delivered in substantially the form attached to and forming part of the Circular, and in accordance with the applicable provisions of the British Columbia *Business Corporations Act*, S.B.C. 2002, c. 57, as amended (the "**BCBCA**"), the terms of this Interim Order, any further Order of this Court, the rulings and directions of the Chairperson of the Aurora Meeting, and in accordance with the terms, restrictions and conditions of the articles of Aurora, including quorum requirements and all other matters. To the extent of any inconsistency or discrepancy between this Interim Order and the terms of any of the foregoing, this Interim Order will govern.

RECORD DATE

6. The Record Date for determination of Aurora Shareholders entitled to vote and to receive the Meeting Notice, Circular and a form of voting proxy or voting instruction form, as applicable (together, the "**Meeting Materials**") is the close of business on November 18, 2026 (the "**Record Date**"), or such other date as the directors of Aurora may determine in accordance with the articles of Aurora, the BCBCA or as disclosed in the Meeting Materials.

7. The Meeting Materials will be provided substantially in accordance with the provisions of National Instrument 54-101 – *Communication with Beneficial Owners of Securities of a Reporting Issuer* ("**NI 54-101**"), as follows:

   (a) to the registered Aurora Shareholders at the close of business on the Record Date, at least twenty-one (21) days prior to the date of the Aurora Meeting, by mail to the addresses of the Aurora Shareholders as they appear on the books and records of Aurora, or of their registrars and transfer agents, at the close of business on the Record Date and if no address is shown therein, then the last address of the person known to Aurora;

   (b) to non-registered Aurora Shareholders at the close of business on the Record Date, by providing sufficient copies of the Meeting Materials to intermediaries and registered nominees in a timely manner, in accordance with NI 54-101.

8. The Meeting Materials will be sent by electronic transmission to each director and the auditor of Aurora at his, her, their or its email address as appearing in the records of Aurora.

9. The Meeting Materials will be sent by electronic transmission to holders of outstanding:

   (a) deferred share units issued under the Aurora DSU Plans;

   (b) restricted share units issued under the Aurora RSU Plan;

   (c) performance share units issued under the Aurora PSU Plan; and

   (d) options to purchase Aurora Shares granted under the Aurora Stock Option Plan (collectively, the "**Aurora Incentive Awards**").

10. Substantial compliance with paragraphs 7 to 9 above will constitute good and sufficient notice of the Aurora Meeting and delivery of the Meeting Materials.

11. The accidental failure or omission to give notice of the Aurora Meeting, or non-receipt of such notice, or any failure or omission to give such notice as a result of events beyond the reasonable control of Aurora (including, without limitation, any inability to use postal services), will not constitute a breach of the Interim Order or a defect in the calling of the Aurora Meeting and will not invalidate any resolution passed or taken at the Aurora Meeting, but if any such failure or omission is brought to the attention of Aurora, then Aurora will use reasonable efforts to rectify it by the method, and in the time, most reasonably practicable in the circumstances.

12. The Meeting Materials are hereby deemed to represent sufficient and adequate disclosure, including for the purpose of section 290(1)(a) of the BCBCA. Aurora will not be required to send Aurora Shareholders or holders of the Aurora Incentive Awards any other or additional information or statement pursuant to section 290(1)(a) of the BCBCA, unless this Court orders otherwise.

DEEMED RECEIPT OF THE MEETING MATERIALS

13. The Meeting Materials will be deemed, for the purposes of this Interim Order, to have been received on the date the Meeting Materials are mailed or delivered in accordance with paragraph 7.

14. Notice of any amendments, modifications, updates or supplements to any of the information provided in the Meeting Materials may be communicated at any time prior to the Aurora Meeting by press release, news release, or newspaper advertisement, in which case such notice will be deemed to have been received at the time of publication, or by notice sent by the most appropriate method of alternative communication as determined by Aurora.

PERMITTED ATTENDEES

15. The only persons entitled to attend the Aurora Meeting will be:

    (a) the Aurora Shareholders as of the Record Date or their respective proxyholders;

    (b) the officers, directors, secretary and assistant secretary of Aurora;

    (c) the auditor and advisors of Aurora;

    (d) representatives and advisors of Organigram; and

    (e) such other persons who receive the consent of the Chairperson of the Aurora Meeting.

QUORUM & VOTING AT THE AURORA MEETING

16. The quorum required for the Aurora Meeting will be two Aurora Shareholders present virtually, or represented by proxy, at the opening of the Aurora Meeting, and holding or representing at least 25% of the Aurora Shares entitled to be voted at the Aurora Meeting.

17. The only persons permitted to vote on the Arrangement Resolution at the Aurora Meeting will be Aurora Shareholders appearing on the records of Aurora as of the close of business on the Record Date and their valid proxyholders as described in the Circular and as determined by the Chairperson of the Aurora Meeting upon consultation with the Scrutineers (as hereinafter defined) and legal counsel to Aurora.

18. The required level of approval on the Arrangement Resolution taken at the Aurora Meeting shall be:

    (a) not less than two-thirds of the votes cast by Aurora Shareholders present in person or virtually, or represented by proxy and entitled to vote at the Aurora Meeting, voting together as a single class; and

    (b) not less than a majority of the votes cast by Aurora Shareholders present in person or virtually, or represented by proxy and entitled to vote at the Aurora Meeting, excluding for this purpose the votes attached to Aurora Shares held by persons described in items (a) through (d) of section 8.1(2) of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions of the Canadian Securities Regulatory Authorities.

19. Each Aurora Shareholder will be entitled to one vote for each Aurora Share held on the Record Date.

20. The terms, restrictions and conditions of the articles of Aurora, including quorum requirements and other matters, will apply in respect of the Aurora Meeting unless otherwise modified in this Interim Order.

ADJOURNMENT OF THE AURORA MEETING

21. If Aurora deems advisable, subject to the terms of the Arrangement Agreement, and notwithstanding the provisions of the BCBCA or the articles of Aurora, Aurora is specifically authorized to adjourn or postpone the Aurora Meeting on one or more occasions without the necessity of first convening the Aurora Meeting or first obtaining any vote of the Aurora Shareholders respecting the adjournment or postponement and without the need for approval of the Court. Notice of any such adjournments or postponements shall be provided by press release, news release, or newspaper advertisement, in which case such notice will be deemed to have been received at the time of publication, or by notice sent by the most appropriate method of alternative communication as determined by Aurora.

22. The Record Date for Aurora Shareholders entitled to notice of and to vote at the Aurora Meeting will not change as a result of adjournments or postponements of the Aurora Meeting without a further order of this Court.

AMENDMENTS

23. Aurora is authorized to make, subject to the Arrangement Agreement, such amendments, modifications or supplements to the Plan of Arrangement, the Arrangement Agreement, the Circular and the Meeting Notice as it may determine without any additional notice to or authorization of the Aurora Shareholders or further orders of this Court, and amendments, modifications or supplements to the Plan of Arrangement may be made only in accordance with the Arrangement Agreement. The Plan of Arrangement, the Arrangement Agreement, the Circular and the Meeting Notice as so amended, modified or supplemented, shall be the

Plan of Arrangement, the Arrangement Agreement, the Circular and the Meeting Notice to be submitted to Aurora Shareholders at the Aurora Meeting, as applicable, and the subject of the Arrangement Resolution.

SCRUTINEER

24. Representatives of the registrar and transfer agent (or any agent thereof) of Aurora, Computershare Investor Services Inc., are authorized to act as scrutineers for the Aurora Meeting (the "**Scrutineers**").

PROXY SOLICITATION

25. Aurora is authorized to permit Aurora Shareholders to vote by proxy using forms of proxy that comply with the articles of Aurora, the provisions of the BCBCA and the *Securities Act* (British Columbia) relating to the form and content of proxies, and Aurora may in its discretion extend or waive generally the time limits for deposit of proxies if Aurora deems it fair and reasonable to do so. Aurora is authorized to solicit proxies directly and through its officers, directors and employees, and through such agents or representatives as it may retain for that purpose and by mail, telephone or such other form of personal or electronic communication as it may determine.

26. The procedures for the form and use of proxies and the revocation of proxies will be as set out in the Meeting Materials.

DELIVERY OF COURT MATERIALS

27. Aurora will include in the Meeting Materials a copy of this Interim Order, a copy of the Petition and a Notice of Hearing of Petition for Final Order (the "**Court Materials**").

28. Delivery of the Court Materials with the Meeting Materials in accordance with this Interim Order will constitute good and sufficient service or delivery of such Court Materials upon all persons who are entitled to receive the Court Materials pursuant to this Interim Order and no other form of service or delivery need be made and no other materials need to be served on or delivered to such persons in respect of these proceedings, subject to the discretion of the Court.

DISSENT RIGHTS

29. Each registered Aurora Shareholder as of the Record Date will, as set out in the Plan of Arrangement, have the right to dissent in respect of the Arrangement Resolution in accordance with the dissent procedures set forth in sections 237 to 247 of the BCBCA, as modified by the terms of this Interim Order, the Plan of Arrangement, and any further order of this Court (the "**Dissent Rights**"), provided that the written notice of dissent (the "**Dissent Notice**") must be received from registered Aurora Shareholders who wish to dissent by Aurora c/o Torys LLP attn: Andrew Gray and Colette Koopman at Suite 2800, 79 Wellington Street West,

Toronto, Ontario, Canada M5K 1N2 (agray@torys.com; ckoopman@torys.com), not later than 9:30 a.m. (Toronto time) on the date that is two (2) Business Days (as defined in the Plan of Arrangement) immediately preceding the date of the Aurora Meeting (as it may be adjourned or postponed from time to time).

30. Notice to registered Aurora Shareholders of their right to dissent with respect to the Arrangement Resolution and to receive, subject to the provisions of the BCBCA and the Plan of Arrangement, the fair value of their Aurora Shares, will be given by including information with respect to this right in the Circular to be provided to Aurora Shareholders in accordance with this Interim Order.

31. A registered Aurora Shareholder who wishes to exercise Dissent Rights, notwithstanding anything in the BCBCA, must:

    (a) be an Aurora Shareholder as of the Record Date;

    (b) not have voted his/her/its Aurora Shares at the Aurora Meeting, either by proxy or in person, for the Arrangement Resolution, and a vote against the Arrangement Resolution or an abstention shall not constitute a Dissent Notice. Filing a Dissent Notice does not deprive a registered Aurora Shareholder of the right to vote at the Aurora Meeting, however, a registered Aurora Shareholder who has submitted a Dissent Notice and who votes or instructs a proxyholder to vote for the Arrangement Resolution will no longer be considered a Dissenting Shareholder (as defined in the Circular);

    (c) exercise Dissent Rights with respect to all of the Aurora Shares of which such registered Aurora Shareholder is both the registered and beneficial owner and in respect of which it has received instructions to dissent from the beneficial holder(s) thereof; and

    (d) otherwise strictly comply with the provisions of the BCBCA, as modified by the terms of this Interim Order, the Plan of Arrangement, and any further order of this Court.

32. A beneficial holder of Aurora Shares registered in the name of a broker, investment dealer or other intermediary, who wishes to dissent, must make arrangements for the registered Aurora Shareholder to dissent on behalf of the beneficial holder of Aurora Shares.

33. Registered Aurora Shareholders who exercise Dissent Rights in accordance with paragraphs 29 to 32 above and who:

    (a) are ultimately determined to be entitled to be paid fair value for their Aurora Shares shall be paid an amount equal to such fair value by Organigram determined in accordance with the procedures applicable to the payout value set out in sections 244 and 245 of the BCBCA and determined as of the close of business on the last business day before the Arrangement Resolution was adopted; or

(b) are ultimately determined not to be entitled, for any reason, to be paid fair value for their Aurora Shares shall be deemed to have participated in the Arrangement, as of the Effective Time (as defined in the Circular), on the same basis as a non-dissenting holder of Aurora Shares.

FINAL APPROVAL HEARING

34. Upon the approval, with or without variation, of the Arrangement Resolution in the manner set forth in this Interim Order, Aurora may set the Petition down for hearing and apply for an order of this Court: (i) approving the Plan of Arrangement; and (ii) determining that the Arrangement is procedurally and substantively fair and reasonable (collectively, the "**Final Order**"), at 9:45 a.m. (Vancouver time) on December 30, 2026, or such other date as counsel may be heard or the Court may direct.

35. Any Aurora Shareholder, Aurora optionholder or other Aurora securityholder has the right to appear (either in person or by counsel) and make submissions at the hearing of the Petition provided that such shareholder or interested party shall file with this Court a Response by no later than 4:00 p.m. (Vancouver time) on December 23, 2026 in the form prescribed by the Supreme Court Civil Rules and deliver a copy of the filed Response together with a copy of all materials on which such party intends to rely at the hearing of the Petition, including an outline of such party's proposed submissions to:

Aurora's counsel:

Torys LLP
Attn: Andrew Gray and Colette Koopman
Suite 2800, 79 Wellington Street West
Toronto, Ontario M5K 1N2
Tel: 416-865-7630
Email: agray@torys.com; ckoopman@torys.com

with a copy to Organigram's counsel at:

Goodmans LLP
Barristers & Solicitors
Attn: Tom Friedland
Bay Adelaide Centre – West Tower
333 Bay Street, Suite 3400
Toronto, Ontario M5H 2S7
Tel: 416-597-4218
Email: tfriedland@goodmans.ca

by no later than 4:00 p.m. (Vancouver time) on December 23, 2026 or as the Court may otherwise direct.

36. If the application for the Final Order is adjourned, only those persons who have filed and delivered a Response, in accordance with the preceding paragraph of this Interim Order, need to be served with notice of the adjourned date.

37. Aurora will not be required to comply with Rules 8-1 and 16-1 of the Supreme Court Civil Rules in relation to the hearing of the Petition for the Final Order approving the Plan of Arrangement, and any materials to be filed in support of the application for the Final Order may be filed prior to the hearing of the application for the Final Order without further order of this Court.

VARIANCE

38. Aurora is at liberty to apply to this Court to vary the Interim Order or for advice and direction with respect to the Arrangement or any of the matters related to the Interim Order and Aurora need not comply with Rule 8-1 of the Supreme Court Civil Rules in any application to do so.

39. The signature of counsel for Organigram is dispensed with.

THE FOLLOWING PARTIES APPROVE THE FORM OF THIS ORDER AND CONSENT TO EACH OF THE ORDERS, IF ANY, THAT ARE INDICATED ABOVE AS BEING BY CONSENT:

_____

Signature of Lawyers for the Petitioner
Torys LLP
(Andrew Gray and Colette Koopman)

BY THE COURT

_____

REGISTRAR

No.
Vancouver Registry

IN THE SUPREME COURT OF BRITISH COLUMBIA

AURORA CANNABIS INC.

Petitioner

ORDER MADE AFTER APPLICATION

TORYS LLP
79 Wellington St. W., 28th Floor
Box 270, TD South Tower
Toronto, ON M5K 1N2

Andrew Gray (46626V)
agray@torys.com
Tel: 416.865.7630

Colette Koopman (81804R)
ckoopman@torys.com
Tel: 416.865.7393

Tel: 416.865.0040
Fax: 416.865.7380

Lawyers for the Petitioner

AGENT: HL LITIGATION

Schedule “B”
Final Order

No.
Vancouver Registry

IN THE SUPREME COURT OF BRITISH COLUMBIA

IN THE MATTER OF PART 9, DIVISION 5, SECTION 291 OF THE *BUSINESS CORPORATIONS ACT*, S.B.C. 2002, C. 57, AS AMENDED

AND

IN THE MATTER OF A PROPOSED PLAN OF ARRANGEMENT OF AURORA CANNABIS INC. INVOLVING ORGANIGRAM GLOBAL INC.

AURORA CANNABIS INC.

Petitioner

ORDER MADE AFTER APPLICATION (FINAL ORDER)

BEFORE THE HONOURABLE JUSTICE	)	WEDNESDAY, THE 30TH DAY OF DECEMBER 2026

ON THE APPLICATION of the Petitioner, Aurora Cannabis Inc. ("**Aurora**"), coming on for hearing at 800 Smithe Street, Vancouver, British Columbia, at 9:45 a.m. on December 30, 2026;

AND UPON HEARING Andrew Gray and Colette Koopman, counsel to the Petitioner, counsel to Organigram Global Inc. ("**Organigram**") and no one appearing on behalf of any holders of common shares in the capital of Aurora ("**Aurora Shares**");

AND UPON reading the Petition herein, the Order Made After Application of Associate Judge _____ made November _____, 2026, the Affidavit #1 of Miguel Martin, made November 18, 2026 and the Affidavit #2 of Miguel Martin, made December ____, 2026;

AND UPON BEING ADVISED that it is the intention of Organigram to rely upon section 3(a)(10) of the United States *Securities Act of 1933* (the "**U.S. Securities Act**") and that the declaration of the fairness of and the approval of the arrangement (the

"**Arrangement**") contemplated in the plan of arrangement (the "**Plan of Arrangement**") attached hereto as Schedule "A" by this Honourable Court will serve as the basis for reliance on the exemption provided by Section 3(a)(10) of the U.S. Securities Act, from the registration requirements otherwise imposed by the U.S. Securities Act, regarding the issuance of the securities pursuant to the Arrangement;

THIS COURT ORDERS and DECLARES that:

1. Pursuant to the provisions of section 291 of the *Business Corporations Act*, S.B.C. 2002, c. 57, as amended (the "**BCBCA**"), the Arrangement as provided for in the Plan of Arrangement, including the terms and conditions thereof and the issuances and exchanges of securities contemplated therein, is procedurally and substantively fair and reasonable to all Persons (as defined in the Plan of Arrangement) entitled to receive Consideration Shares or Replacement Options pursuant to the Arrangement;

2. The Arrangement, as provided for in the Plan of Arrangement, be and hereby is approved pursuant to the provisions of section 291 of the BCBCA;

3. This Order shall serve as the basis for reliance on the exemption provided by Section 3(a)(10) of the U.S. Securities Act, as amended, from the registration requirements otherwise imposed by the U.S. Securities Act, regarding the issuance of common shares of Organigram and options to purchase common shares of Organigram pursuant to the Plan of Arrangement;

4. Aurora shall be entitled at any time to seek leave to vary this Order, to seek direction of this Court as to the implementation of this Order or to apply for such further order or orders as may be appropriate; and

5. The signature of counsel for Organigram is dispensed with.

THE FOLLOWING PARTIES APPROVE THE FORM OF THIS ORDER AND CONSENT TO EACH OF THE ORDERS, IF ANY, THAT ARE INDICATED ABOVE AS BEING BY CONSENT:

Signature of Lawyers for the Petitioner
Torys LLP
(Andrew Gray and Colette Koopman)

BY THE COURT

REGISTRAR

Schedule “A”
Plan of Arrangement

[To be added once finalized]

No.
Vancouver Registry

IN THE SUPREME COURT OF BRITISH COLUMBIA

AURORA CANNABIS INC.

Petitioner

ORDER MADE AFTER APPLICATION

TORYS LLP
79 Wellington St. W., 28th Floor
Box 270, TD South Tower
Toronto, ON M5K 1N2

Andrew Gray (46626V)
agray@torys.com
Tel: 416.865.7630

Colette Koopman (81804R)
ckoopman@torys.com
Tel: 416.865.7393

Tel: 416.865.0040
Fax: 416.865.7380

Lawyers for the Petitioner

AGENT: HL LITIGATION

No. VLC-S-S-268586
Vancouver Registry

IN THE SUPREME COURT OF BRITISH COLUMBIA

IN THE MATTER OF PART 9, DIVISION 5, SECTION 291 OF THE *BUSINESS CORPORATIONS ACT*, S.B.C. 2002, C. 57, AS AMENDED

AND

IN THE MATTER OF A PROPOSED PLAN OF ARRANGEMENT OF AURORA CANNABIS INC. INVOLVING ORGANIGRAM GLOBAL INC.

AURORA CANNABIS INC.

Petitioner

NOTICE OF HEARING OF PETITION

TO: The holders of common shares in the capital of Aurora Cannabis Inc.

AND TO: The holders of deferred share units issued under the Aurora DSU Plans, restricted share units issued under the Aurora RSU Plan, performance share units issued under the Aurora PSU Plan, and options to purchase Aurora Shares granted under the Aurora Stock Option Plan

AND TO: Organigram Global Inc.

NOTICE IS HEREBY GIVEN that a Petition to the Court has been filed by Aurora Cannabis Inc. ("**Aurora**") in the Supreme Court of British Columbia for approval, pursuant to section 291 of the *Business Corporations Act*, S.B.C. 2002, c. 57, as amended, of an arrangement of Aurora involving Organigram Global Inc. ("**Organigram**").

NOTICE IS FURTHER GIVEN that by Order of Associate Judge Vos of the Supreme Court of British Columbia, pronounced November 20, 2026, the Court has given directions by means of an interim order (the "**Interim Order**") on the calling of a special meeting of holders of the common shares in the capital of Aurora Cannabis Inc. (the "**Aurora Shares**" held by the "**Aurora Shareholders**") to consider, among other things, and, if deemed advisable, approve, with or without variation, a special resolution to approve the Arrangement (the "**Arrangement Resolution**").

NOTICE IS FURTHER GIVEN that if the Arrangement Resolution is approved by the requisite majorities of Aurora Shareholders and the Organigram Common Share Issuance Resolution is approved by the requisite majority of Organigram Shareholders,

the Petitioner intends to apply to the Supreme Court of British Columbia for a final order (the "**Final Order**") approving the Arrangement and declaring that the Arrangement is procedurally and substantively fair and reasonable to the Aurora Shareholders, which application is expected to be heard at the courthouse at 800 Smithe Street, in the City of Vancouver, in the Province of British Columbia or as the Court may direct on December 30, 2026 at 9:45 a.m. (Pacific time), or as soon thereafter as counsel may be heard or at such other date and time as the Board of Aurora, or the Court may direct.

NOTICE IS FURTHER GIVEN that the Final Order approving the Arrangement will, if made, serve as the basis of an exemption from the registration requirements of the United States *Securities Act of 1933*, as amended, pursuant to section 3(a)(10) thereof with respect to the issuance of securities pursuant to the Arrangement.

IF YOU WISH TO BE HEARD AT THE HEARING OF THE APPLICATION FOR THE FINAL ORDER OR WISH TO BE NOTIFIED OF ANY FURTHER PROCEEDINGS, YOU MUST GIVE NOTICE OF YOUR INTENTION by filing a form entitled "Response to Petition" together with any evidence or materials which you intend to present to the Court at the Vancouver Registry of the Supreme Court of British Columbia or as the Court may direct and YOU MUST ALSO DELIVER a copy of the Response to Petition and any other evidence or materials to the Petitioner's address for delivery with a copy to Organigram's counsel, at the addresses set out below, on or before December 23, 2026 at 4:00 p.m. (Vancouver time).

YOU OR YOUR SOLICITOR may file the Response to Petition. You may obtain a form of Response to Petition at the Registry or online from the BC Supreme Court website. The address of the Registry is 800 Smithe Street, Vancouver, British Columbia, V6Z 2E1.

IF YOU DO NOT FILE A RESPONSE TO PETITION AND ATTEND EITHER IN PERSON (OR AS DIRECTED BY THE COURT) OR BY COUNSEL at the time of the hearing of the application for the Final Order, the Court may approve the Arrangement, as presented, or may approve it subject to such terms and conditions as the Court deems fit, all without further notice to you. If the Arrangement is approved, it will affect the rights of the Aurora Shareholders.

A copy of the Petition to the Court and the other documents that were filed in support of the Interim Order and will be filed in support of the Final Order will be delivered to any Aurora Shareholder who makes a request in writing addressed to the solicitors of the Petitioner at the address for delivery set out below.

The Petitioner's address for delivery is:

Torys LLP
Attn: Andrew Gray and Colette Koopman
Suite 2800, 79 Wellington Street West
Toronto, Ontario M5K 1N2
Tel: 416-865-7630

Email: agray@torys.com; ckoopman@torys.com

Organigram's counsel's address for delivery:

Goodmans LLP
Barristers & Solicitors
Attn: Tom Friedland
Bay Adelaide Centre – West Tower
333 Bay Street, Suite 3400
Toronto, Ontario M5H 2S7
Tel: 416-597-4218
Email: tfriedland@goodmans.ca

DATED this 20th day of November 2026.



Counsel for the Petitioner,
Aurora Cannabis Inc.

Andrew Gray/Colette Koopman

APPENDIX "F"
AURORA FAIRNESS OPINIONS

(See attached)

Fort Capital

Fort Capital Partners
1010 – 510 Burrard Street
Vancouver, BC V6C 3A8

November 2, 2026

The Special Committee of the Board of Directors and the Board of Directors
Aurora Cannabis Inc.
2207-90b Street SW
Edmonton, Alberta
T6X 1V8
Canada

To the Members of the Special Committee and the Board of Directors of Aurora Cannabis Inc.:

Fort Advisory Partners ("**Fort Capital**", "**we**" or "**us**") understands that Aurora Cannabis Inc. ("**Aurora**" or the "**Company**") and Organigram Global Inc. ("**Organigram**" or the "**Purchaser**") have entered into an arrangement agreement dated November 2, 2026 (the "**Arrangement Agreement**"), pursuant to which the Purchaser will acquire all of the issued and outstanding common shares of the Company (the "**Aurora Shares**") by way of a plan of arrangement under the *Business Corporations Act* (British Columbia) (the "**Plan of Arrangement**", and the arrangement contemplated thereby, the "**Arrangement**").

Under the Arrangement, each holder of Aurora Shares (each, an "**Aurora Shareholder**") will be entitled to elect to receive, for each Aurora Share, $7.80 in cash (the "**Cash Elected Consideration**"), 5.8626 common shares of the Purchaser (the "**Organigram Shares**") (the "**Share Elected Consideration**") or $3.75 in cash and 3.0431 Organigram Shares (the "**Combination Elected Consideration**"). An Aurora Shareholder who does not make a valid election prior to the election deadline will be deemed to have elected to receive the Combination Elected Consideration. The elections are subject to aggregate maximum amounts of cash and Organigram Shares specified in the Plan of Arrangement, and the consideration payable to Aurora Shareholders electing the Cash Elected Consideration or the Share Elected Consideration is subject to pro rating to the extent those maximum amounts would otherwise be exceeded (the cash so payable and the Organigram Shares so issuable, collectively, the "**Consideration**"). The exchange ratio under the Arrangement is fixed and is not subject to adjustment by reference to the trading price of the Organigram Shares. The terms and conditions of the Arrangement are set out in the Arrangement Agreement and the Plan of Arrangement, and will be described in the joint management information circular of the Company and the Purchaser to be prepared in connection with the Arrangement (the "**Joint Circular**").

Fort Capital has been retained to provide financial advice to the Company, including our opinion (this "**Opinion**") to the special committee of independent directors of the board of directors of the Company (the "**Special Committee**") and to the board of directors of the Company (the "**Board**") as to whether the Consideration to be received under the Arrangement is fair, from a financial point of view, to the Aurora Shareholders.

Engagement of Fort Capital

On July 7, 2026, Curaleaf Holdings, Inc. ("**Curaleaf**") delivered to the Company a letter of intent in respect of a proposed acquisition of all of the Aurora Shares, following earlier unsolicited contact from Curaleaf. Fort Capital was engaged by the Company pursuant to an agreement effective July 7, 2026 (the "**Engagement Agreement**") to act as financial advisor in connection with the Company's response to Curaleaf, including the unsolicited take-over bid subsequently made by Curaleaf on August 18, 2026, (the "**Take-Over Bid**"), and the consideration of any alternative transaction. Fort Capital delivered opinions to the Special Committee and the Board dated September 1, 2026 (in respect to the consideration offered under the Take-Over Bid) and October 14, 2026 (in respect of the consideration offered under a revised take-over bid made by Curaleaf on October 6, 2026 (the "**Revised Take-Over Bid**"). Under the terms of the Engagement Agreement, Fort Capital has agreed to provide the Company, the Special Committee and the Board with various advisory services, including, among other things, the provision of this Opinion.

Fort Capital will receive a fee for rendering this Opinion, which fee is payable without regard to the conclusion reached in this Opinion. Under the Engagement Agreement, we will also receive fees for advisory services provided to the Company, which may be contingent upon the completion of the Arrangement, the Revised Take-Over Bid, alternative transactions, or circumstances where no transaction is completed at all. In addition, the Company has also agreed to reimburse us for our reasonable out-of-pocket expenses and to indemnify us against certain liabilities that might arise out of our engagement.

Credentials of Fort Capital

Fort Capital is an independent investment banking firm which provides financial advisory services to corporations, business owners, and investors. Members of Fort Capital are professionals that have been financial advisors in a significant number of transactions involving public and private companies in North America and have experience in preparing fairness opinions and valuations.

This Opinion represents the opinion of Fort Capital, the form and content of which have been approved for release by Fort Capital. While this Opinion has been prepared in accordance with the Disclosure Standards for Formal Valuations and Fairness Opinions of the Canadian Investment Regulatory Organization ("**CIRO**"), Fort Capital is not a member of CIRO and CIRO has not been involved in the preparation or review of this Opinion.

Independence of Fort Capital

Neither Fort Capital, nor any of our affiliates, is an insider, associate or affiliate (as those terms are defined in the *Securities Act* (Ontario) or the rules made thereunder) of the Company, Organigram, or any of their respective associates or affiliates (collectively, the "**Interested Parties**").

Neither Fort Capital, nor any of our affiliates, has been engaged to provide any financial advisory services, nor has it participated in any financing, involving Organigram or any of its associates or affiliates within the past two years. Fort Capital is and has been engaged by the Company from time to time to provide financial advisory services in the ordinary course of our business, including within the past two years and including in respect of matters other than the Arrangement, for which we have received or expect to receive customary fees. Fort Capital most

recently received fees for opinions delivered with respect to the Take-Over Bid and the Revised Take-Over Bid, and for advisory work in connection with the acquisition of Safari Flower Company in April 2026. Other than pursuant to our engagements with the Company, there are no understandings, agreements or commitments between Fort Capital and any of the Interested Parties with respect to future business dealings. Fort Capital may, in the future, in the ordinary course of business, provide financial advisory, investment banking, or other financial services to one or more of the Interested Parties from time to time.

The Company has represented to Fort Capital that, to the best of its knowledge, there have been no prior valuations (as that term is used in Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions* ("**MI 61-101**")) of the Company or any material property of the Company made in the preceding twenty-four months.

Scope of Review

In preparing this Opinion, Fort Capital has, among other things, reviewed, considered, and relied upon, without attempting to verify independently the completeness or accuracy thereof, the following:

(a) a draft of the Arrangement Agreement dated November 2, 2026, including the draft Plan of Arrangement attached as Schedule A thereto;

(b) the letter of intent between the Company and the Purchaser dated October 18, 2026;

(c) the offer to purchase and take-over bid circular of Curaleaf Holdings, Inc. dated August 18, 2026, and the notice of variation, change and extension dated October 6, 2026;

(d) the Company's directors' circular dated September 1, 2026, and the notices of change thereto dated October 14, 2026 and November 2, 2026;

(e) certain internal financial, operating, corporate and other information with respect to the business, operations and prospects of the Company furnished to, or discussed with, us by management of the Company;

(f) the financial model and the financial forecasts, projections, estimates and budgets relating to the Company prepared by management of the Company;

(g) the financial forecasts, projections and estimates relating to Organigram prepared by management of Organigram;

(h) a summary prepared by management of the Company of the issued and outstanding Aurora Shares as at October 31, 2026 and of the dilutive securities of the Company as at October 28, 2026;

(i) a summary prepared by management of Organigram of the issued and outstanding Organigram Shares as at September 30, 2026;

(j) annual financial statements and management's discussion and analysis of the Company for the years ended March 31, 2026, 2025, 2024 and 2023;

(k) annual financial statements and management's discussion and analysis of Organigram for the years ended September 30, 2025, 2024, and 2023;

(l) interim financial statements and management's discussion and analysis of each of the Company and Organigram for the most recently completed interim periods;

(m) the commitment letter dated November 2, 2026 between the Purchaser and ATB Financial in respect of the Purchaser's credit facilities, and the related term sheet (the "**Commitment Letter**");

(n) the subscription agreement dated November 2, 2026 between the Purchaser and BT DE Investments Inc., a subsidiary of British American Tobacco p.l.c., in respect of its subscription for Organigram Shares and/or preferred shares of the Purchaser (the "**Subscription Agreement**");

(o) certain publicly available information relating to the business, operations, financial condition and trading history of the Company, Organigram and other selected public companies we considered relevant;

(p) public information with respect to selected precedent transactions involving Canadian and United States cannabis targets we considered relevant, and premiums paid in selected precedent transactions involving public company targets;

(q) various reports published by equity research analysts and industry sources we considered relevant;

(r) discussions with senior management of the Company relating to the Company's current business, plans, financial condition and prospects;

(s) discussions with senior management of Organigram relating to Organigram's current business, plans, financial condition and prospects;

(t) discussions with legal counsel to the Company and to the Special Committee;

(u) a letter of representation as to certain factual matters and the completeness and accuracy of certain information upon which this Opinion is based, addressed to us and dated as of the date hereof, provided by senior officers of the Company; and

(v) such other information, investigations, analyses and discussions as we considered necessary or appropriate in the circumstances.

Fort Capital has not, to the best of our knowledge, been denied access by the Company to any information under the Company's control requested by Fort Capital.

Assumptions and Limitations

Fort Capital has, subject to the exercise of our professional judgement, relied, without independent verification, upon the completeness, accuracy and fair presentation of all financial and other information, data, advice, opinions, representations and other material obtained by us from public sources or provided to us by or on behalf of the Company or Organigram or otherwise obtained by us in connection with our engagement (the "**Information**"). This Opinion is conditional upon such completeness, accuracy and fair presentation. We have assumed that the forecasts, projections, estimates and budgets relating to each of the Company and Organigram provided to us and used in our analyses were reasonably prepared on bases reflecting the best currently available assumptions, estimates and judgements of the management of the Company and of Organigram, respectively.

Fort Capital expresses no view as to the achievability of, or the assumptions underlying, any such forecast, projection, estimate or budget. Fort Capital has also had regard to estimates published by equity research analysts, which in some cases differed from those of management. These estimates are the work of third parties and have not been independently verified by Fort Capital and with respect to which Fort Capital expresses no view. This Opinion does not constitute, and should not be construed as, any assurance that any forecast, projection, estimate or budget will be realized or that actual results will not differ materially therefrom.

Senior officers of the Company have represented to Fort Capital in a letter of representation delivered on November 2, 2026, among other things, that: (i) the Information in respect of the Company or any of its subsidiaries provided to Fort Capital orally by, or in the presence of, an officer or employee of the Company, or in writing by the Company or any of its subsidiaries or any of its or their representatives in connection with our engagement was, at the date the Information was provided to Fort Capital, and is, as of the date hereof, complete, true and correct in all material respects, and did not and does not contain a misrepresentation (as defined in the *Securities Act* (Ontario)); and (ii) since the dates on which the Information was provided to Fort Capital, except as disclosed in writing to Fort Capital, there has been no material change, financial or otherwise, in the financial condition, assets, liabilities (contingent or otherwise), business, operations or prospects of the Company or any of its subsidiaries, and no change has occurred in the Information or any part thereof which would have or which could reasonably be expected to have a material effect on this Opinion.

In preparing this Opinion, we have made several assumptions, including that the disclosure provided or incorporated by reference in the Joint Circular with respect to the Company, the Purchaser and the Arrangement will be true, complete and correct in all material respects, and that the Arrangement will be completed substantially in accordance with the terms of the Arrangement Agreement and the Plan of Arrangement and in compliance with applicable laws. Fort Capital expresses no view as to whether the conditions to the completion of the Arrangement are, or are capable of being, satisfied or waived, or as to the likelihood that the Arrangement will be completed.

We have further assumed that the financing required to fund the cash component of the Consideration will be available on the terms contemplated by the Commitment Letter and the Subscription Agreement, and Fort Capital expresses no view as to whether such financing will be available or as to the terms on which it may be obtained.

This Opinion is rendered on the basis of securities markets, economic, financial and general business conditions prevailing as of the date hereof and the condition and prospects, financial and otherwise, of the Company and Organigram as they are reflected in the Information and as they have been represented to Fort Capital in discussions with the management of the Company and of Organigram and their respective representatives. In our analyses and in preparing this Opinion, Fort Capital made numerous assumptions with respect to industry performance, general business and economic conditions and other matters which we believe to be reasonable and appropriate in the exercise of our professional judgement, many of which are beyond the control of Fort Capital or any party involved in the Arrangement.

We have not been asked to prepare and have not prepared a formal valuation or appraisal of the securities or assets of the Company, Organigram, or of any of their affiliates, and this Opinion should not be construed as such. This Opinion is not, and should not be construed as, advice as to

the price at which the securities of the Company or Organigram may trade at any time. Fort Capital was not engaged to review any legal, tax or regulatory aspects of the Arrangement and this Opinion does not address any such matters. We have relied upon, without independent verification, the assessment by the Company and its legal and tax advisors with respect to such matters. This Opinion addresses only the fairness of the Consideration, from a financial point of view, to the Aurora Shareholders, and does not address the fairness or adequacy of any other term or aspect of the Arrangement. This Opinion does not address the relative merits of the Arrangement as compared to any other transaction or strategic alternative that may be available to the Company. This Opinion is not addressed to, and Fort Capital expresses no view as to the fairness of the Consideration to, holders of securities of the Company other than Aurora Shares. This Opinion is not addressed to the shareholders of the Purchaser.

This Opinion is provided to the Special Committee and the Board for their exclusive use only in considering the Arrangement and may not be used or relied upon by any other person or for any other purpose without our prior written consent. This Opinion does not constitute a recommendation as to how any Aurora Shareholder should vote or act on any matter relating to the Arrangement. Except for the inclusion of this Opinion in its entirety and a summary thereof, in a form acceptable to us, in the Joint Circular, this Opinion is not to be reproduced, disseminated, quoted from or referred to, in whole or in part, without our prior written consent.

Fort Capital believes that our analyses must be considered as a whole and that selecting portions of the analyses or the factors considered by us, without considering all factors and analyses together, could create a misleading view of the process underlying this Opinion. The preparation of an opinion of this nature is a complex process and is not necessarily susceptible to partial analysis or summary description. Any attempt to do so could lead to undue emphasis on any particular factor or analysis.

This Opinion is rendered as of the date hereof and Fort Capital disclaims any undertaking or obligation to advise any person of any change in any fact or matter affecting this Opinion which may come or be brought to the attention of Fort Capital after the date hereof. Without limiting the foregoing, in the event that there is any material change in any fact or matter affecting this Opinion after the date hereof, Fort Capital reserves the right to change, modify or withdraw this Opinion.

Consideration Analysis

In accordance with the Arrangement Agreement, the Consideration is payable in a combination of cash and Organigram Shares, subject to the elections and proration described above. As the value of the Consideration ultimately received by Aurora Shareholders will depend in part on the trading price of the Organigram Shares, Fort Capital conducted such analyses with respect to Organigram as we considered necessary in the circumstances. In doing so, Fort Capital reviewed certain financial forecasts relating to Organigram prepared by management of Organigram, held discussions with senior management of Organigram, and considered the form of the Consideration being paid, the ongoing financial strength of the pro forma entity, and the ability of Aurora Shareholders to realize upon the value implied by the Consideration. In this regard, Fort Capital considered the criteria for a “liquid market” under MI 61-101 and is of the view that such criteria are met in respect of the Organigram Shares, such that the trading price of the Organigram Shares can reasonably be regarded as a proxy for their underlying value. With respect to the cash component

of the Consideration, the Purchaser has obtained the Commitment Letter and entered into the Subscription Agreement in respect of the funding thereof.

Considerations in Arriving at this Opinion

In considering the fairness, from a financial point of view, of the Consideration to be received by the Aurora Shareholders pursuant to the Arrangement, Fort Capital took into account that the Consideration comprises a combination of cash and Organigram Shares, that the exchange ratio is fixed and is not subject to adjustment by reference to the trading price of the Organigram Shares, and that the elections available to Aurora Shareholders are subject to proration. The value of the Consideration ultimately received by Aurora Shareholders will accordingly depend in part on the trading price of the Organigram Shares. Fort Capital has assessed the Consideration by reference to the 20-day volume weighted average trading price of the Organigram Shares, which implied a value of $7.80 per Aurora Share as at November 2, 2026.

In arriving at this Opinion, Fort Capital reviewed, analyzed and considered ranges of implied value for the Aurora Shares derived on a standalone basis using comparable company trading multiples, including on the application of a change of control premium, precedent transaction multiples and a discounted cash flow analysis of the Company. In applying comparable company trading multiples and in preparing the discounted cash flow analysis, Fort Capital used and relied upon forecasts, projections and estimates prepared by management of the Company, which Fort Capital reviewed and discussed with management and which have not been publicly disclosed by the Company. Fort Capital placed primary reliance on comparable company trading multiples, and the ranges of implied value indicated by the discounted cash flow analysis were consistent with that approach.

Fort Capital had further regard, as points of reference, to target prices and estimates published by equity research analysts covering each of the Company and Organigram, the historical trading range of the Aurora Shares, the implied exchange ratio between the Aurora Shares and the Organigram Shares, the premiums implied by the Consideration relative to the trading price of the Aurora Shares on the last trading day prior to the announcement by Curaleaf of its intention to make the Take-Over Bid (being August 10, 2026), the pro forma ownership of Organigram that Aurora Shareholders would hold upon completion of the Arrangement, and the results of the market canvass conducted on behalf of the Company. Fort Capital also took into account the Company's cash position and the absence of funded indebtedness, and the value inherent in the execution of management's business plan.

Conclusion

Based upon and subject to the foregoing and such other matters as we considered relevant, Fort Capital is of the opinion that, as of the date hereof, the Consideration to be received by the

Aurora Shareholders pursuant to the Arrangement is fair, from a financial point of view, to the Aurora Shareholders.

Yours very truly,



FORT ADVISORY PARTNERS

ORIGIN
MERCHANT PARTNERS

199 Bay Street, Suite 4610
Commerce Court West, PO Box 172
Toronto, Ontario M5L 1E7

416-800-0850
www.originmerchant.com

November 2, 2026

The Special Committee of the Board of Directors and the Board of Directors
Aurora Cannabis Inc.
1500 - 1199 West Hastings Street
Vancouver, BC, V6E 3T5

The Members of the Special Committee and the Board of Directors of Aurora Cannabis Inc.:

Origin Merchant Partners ("**Origin**", "**we**" or "**us**"), understands that Aurora Cannabis Inc. (the "**Company**" or "**Aurora**") proposes to enter into a definitive arrangement agreement (the "**Arrangement Agreement**") with Organigram Global Inc. ("**Organigram**" or the "**Acquirer**") pursuant to which, among other things, the Acquirer will acquire all of the outstanding common shares of the Company (the "**Aurora Shares**") at a price of C$7.80 per Aurora Share (the "**Transaction**").

We also understand that, on the terms and subject to the conditions of the Arrangement Agreement, holders of the Aurora Shares ("**Aurora Shareholders**") will have the option to elect to receive, as consideration (the "**Consideration**") for each Aurora Share:

(a) C$7.80 in cash (the "**Cash Consideration**"); or
(b) 5.8626 common shares of Organigram (the "**Share Consideration**"); or
(c) C$3.75 in cash plus 3.0431 common shares of Organigram (the "**Combined Consideration**"),

provided that Aurora Shareholders electing to receive the Cash Consideration or the Share Consideration will be subject to proration as set out in the Arrangement Agreement such that the maximum amounts of cash and common shares of Organigram (the "**Organigram Shares**") will not exceed the maximum amounts specified in the plan of arrangement attached to the Arrangement Agreement.

Further, we understand that the Arrangement Agreement contemplates that the Transaction will be effected by way of a plan of arrangement under the *Business Corporations Act* (British Columbia) and will be subject to the approvals by:

(a) at least two-thirds of the votes cast by Aurora Shareholders present in person or represented by proxy at a special meeting of Aurora Shareholders (the "**Aurora Meeting**");
(b) a simple majority of the votes cast by Aurora Shareholders present in person or represented by proxy at the Aurora Meeting, excluding votes from certain shareholders, as required under Multilateral Instrument 61-101 - *Protection of Minority Security Holders in Special Transactions* ("**MI 61-101**"); and
(c) the Supreme Court of British Columbia.

In addition, we understand that the terms of the Arrangement Agreement and the Transaction and certain related matters will be more fully described in a joint management information circular (the "**Circular**")

which will be sent to the Aurora Shareholders and other securityholders in connection with the Aurora Meeting to be held to consider and, if deemed advisable, approve the Transaction.

Engagement

Origin was initially contacted by a special committee of independent directors (the "**Special Committee**") of Aurora's board of directors (the "**Board**") on October 23, 2026 and engaged by letter agreement dated October 24, 2026 (the "**Engagement Agreement**"). Pursuant to the Engagement Agreement, the Special Committee engaged Origin to provide an opinion (this "**Opinion**") to the Special Committee and the Board as to the fairness, from a financial point of view, of the Consideration to be received by Aurora Shareholders pursuant to the Transaction. The Engagement Agreement provides that Origin Merchant would not be required to prepare a "formal valuation" (as such term is defined in, and for the purposes of, MI 61-101) as part of our engagement, and this Opinion should not be construed as such. In addition, Origin was not engaged to review or advise on any legal, tax or regulatory aspects of the Transaction and this Opinion does not address any such matters. Origin has, however, conducted such analyses as it considered necessary in the circumstances to prepare and deliver this Opinion.

Pursuant to the Engagement Agreement, Origin Merchant was paid a fixed fee upon entering into the Engagement Agreement and will be paid an additional fixed fee for the preparation and delivery of this Opinion to the Special Committee. Origin Merchant will also be reimbursed for its reasonable out-of-pocket expenses in carrying out its obligations hereunder, including for the fees and taxes of Origin Merchant's legal counsel, McCarthy Tétrault LLP. In addition, the Company has agreed to indemnify Origin Merchant, its subsidiaries and affiliates and their respective partners, employees, directors and officers against certain losses, claims, damages and liabilities which may arise out of its engagement. None of the fees payable to Origin Merchant under the Engagement Agreement are contingent in whole or in part upon the completion of the Transaction or on the conclusion reached in the Opinion.

Credentials of Origin Merchant Partners

Origin is an independent Canadian advisory firm providing a full range of advisory services including mergers and acquisitions, valuations, fairness opinions, restructurings, recapitalizations and private placement financings. Origin was founded in 2011 and its affiliate, Origin Merchant Securities Inc., is registered with the Ontario Securities Commission as an Exempt Market Dealer. Origin and its principals have extensive experience in the Canadian capital markets and have advised and participated in many advisory transactions involving both public and private companies.

This Opinion represents the opinion of Origin Merchant and the form and content thereof have been approved for release by a committee of partners, directors and other professionals of Origin Merchant, each of whom is experienced in mergers, business combinations, divestitures, valuation and fairness opinion matters.

Independence of Origin Merchant Partners

Neither Origin nor any of its affiliates is an insider, associate or affiliate (as those terms are defined in the *Securities Act* (British Columbia) or the rules made thereunder) of the Company, the Acquirer nor any of their respective associates or affiliates (collectively, the "**Interested Parties**"). Origin is not acting as an

advisor to the Company or any other Interested Party, in connection with the Transaction, other than to provide the Opinion to the Special Committee and the Board under the Engagement Agreement.

Origin has not participated in any offering of securities of or had a material financial interest in any transaction involving the Company, the Acquirer or any other Interested Party during the 24-month period preceding the date Origin was first contacted in respect of this Opinion. Further, other than to provide the Opinion to the Special Committee and the Board under the Engagement Agreement, and Origin has not been engaged to provide any financial advisory services involving the Company, the Acquirer or any other Interested Party during such 24-month period.

Although Origin and its affiliates may in the future and in the ordinary course of its business, provide financial advisory or investment banking services to any of the Interested Parties, there are no understandings, agreements or commitments between Origin and any of the Interested Parties regarding any future advisory or investment banking business. Origin does not provide research reports concerning securities or engage in the business of securities trading or lending.

Scope of Review

In arriving at its Opinion, Origin has reviewed, analyzed, considered and relied upon or carried out, among other things, the following:

(a) the Company's audited annual consolidated financial statements and management's discussion and analysis ("**MD&A**") as at and for the years ended March 31, 2026 and March 31, 2025;
(b) the Company's unaudited condensed interim consolidated financial statements and MD&A for the three months ended June 30, 2026;
(c) the Company's annual information form ("**AIF**") dated June 10, 2026 for the financial year ended March 31, 2026;
(d) certain unaudited financial information of the Company as at September 30, 2026, as provided by the Company's management ("**Management**");
(e) selected public filings of Organigram from the fiscal years ended September 30, 2025 up to the date hereof, to the extent deemed relevant by Origin, in the exercise of our professional judgement;
(f) participation in a due diligence meeting on October 26, 2026 with Organigram's and Aurora's respective management teams, legal counsel and financial advisors;
(g) certain financial forecasts, projections and estimates relating to Organigram prepared by management of Organigram;
(h) the non-binding letter of intent dated October 18, 2026 between Organigram and the Company;
(i) a draft dated November 2, 2026 of the Arrangement Agreement, including the form of the plan of arrangement attached as an exhibit thereto;
(j) drafts of the voting and support agreements for execution by the Company's directors and officers;
(k) drafts of the subscription agreement between Organigram and BAT in respect of the Private Placement and the commitment letter of ATB Financial in respect of the amended and restated credit facilities of Organigram

(l) the take-over bid circular of Curaleaf Holdings, Inc. ("**Curaleaf**") dated August 18, 2026, as amended by the notice of variation dated October 6, 2026, and the Company's directors' circular dated September 1, 2026, as amended by the notice of change dated October 14, 2026;
(m) discussions with the Special Committee and its legal counsel, Torys LLP, Management, the Company's financial advisor, Fort Capital Partners, and Organigram's management;
(n) an internal five-year financial forecast (FY2027E – FY2031E) prepared by Management (the "**Management Forecast**") and the related forecast narrative prepared by Fort Capital Partners;
(o) a management presentation (September 2026) prepared by Management and supplementary materials regarding the Company's facilities, cultivation and production assets, breeding and genetics program and European operations;
(p) selected corporate information, including the organizational chart, executive change of control arrangements, share count and equity award summary as at October 7, 2026, and a summary of tax loss attributes;
(q) selected reports published by equity research analysts at various firms and industry sources regarding the Company, Organigram, the industry and other public entities, to the extent deemed relevant by Origin, in the exercise of our professional judgement;
(r) selected public market trading statistics, financial information and selected financial metrics of the Company and Organigram, comparable publicly traded entities and precedent transactions deemed relevant by Origin, in exercise of our professional judgement;
(s) selected other public disclosure documents (e.g., management's discussion and analysis, financial statements, annual information form, material change reports and press releases) filed by the Company and the Acquirer on the *System for Electronic Data Analysis and Retrieval+* ("**SEDAR+**") as of November 2, 2026;
(t) certain internal financial, operating, corporate and other information prepared or provided by or on behalf of the Company concerning the business operations, assets, liabilities and prospects of the Company;
(u) a certificate dated the date hereof (the "**Management Representation Letter**"), addressed to Origin from certain officers of the Company, regarding the completeness and accuracy of certain information upon which this Opinion is based, including the information referred to in sub-paragraphs (a) through (t) above; and
(v) such other corporate, industry and financial market information, investigations and analyses as considered by Origin to be relevant in the circumstances.

Origin has not, to the best of its knowledge, been denied access by the Company to any information requested by us. Origin did not meet with the auditors of the Company or Organigram and has assumed the accuracy and fair presentation of, and has relied upon, the audited consolidated financial statements of each of the Company and Organigram the reports of the auditor thereon.

Prior Valuations

The Company has represented to Origin that, among other things, it has no knowledge of any prior valuations (as defined in MI 61-101) of the Company in the past 24 months.

Assumptions and Limitations

This Opinion is subject to the assumptions, explanations, and limitations set forth below. Origin has relied upon, and has assumed without independent verification the completeness, accuracy and fair presentation of all financial and other information, data, advice, opinions and representations obtained by us from public sources, or provided to us by the Company, Organigram or their respective affiliates or management, or otherwise obtained by us pursuant to the Engagement Agreement, and our Opinion is conditional upon such completeness, accuracy and fair presentation.

Without limiting the generality of the foregoing, we have assumed that, the final, signed Arrangement Agreement will be in substantially the form of the draft provided to us, the parties' respective representations and warranties contained in the Arrangement Agreement are true and correct in all material respects as of the dates provided therein, the Transaction will be completed in accordance with the terms of the Arrangement Agreement and all applicable laws, each of the Company and Organigram has complied with its disclosure obligations under applicable securities laws, the Circular will satisfy all applicable legal requirements, no unanticipated tax or regulatory consequences will result from the announcement or completion of the Transaction and all required consents and regulatory approvals will be obtained on terms not adverse to the Company, the Aurora Shareholders or Organigram.

Certain officers of the Company have represented to us in the Management Representation Letter, among other things, that the information, data and other materials provided to us by or on behalf of the Company, including the written information and discussions concerning the Company referred to above under the heading "Scope of Review" (collectively, "**Information**"), were complete, correct and true in all material respects as at the date the Information was provided to us and that, since the date the Information was provided to us, there has been no material change, financial or otherwise, in the financial condition, assets, liabilities (contingent or otherwise), business, operations or prospects of the Company or any of its affiliates and no material change has occurred in Information or any part thereof which would have, or would reasonably be expected to have, a material effect on this Opinion.

With respect to the Management Forecast and any other financial forecasts, projections or estimates provided to Origin by Management and used in the analysis supporting this Opinion, we have assumed that they have been reasonably prepared on bases reflecting the best currently available estimates and judgments as to the matters covered thereby and which, in the opinion of Management, are (or were at the time of preparation and continue to be) reasonable in the circumstances. By rendering this Opinion, we express no view as to the reasonableness of any such forecasts, projections or estimates or the assumptions on which they are based.

We are not legal, tax or accounting experts and we express no opinion concerning any legal, tax or accounting matters with respect to the Transaction. This Opinion is rendered on the basis of securities markets, economic, financial and general business conditions prevailing as at the date hereof and the condition and prospects, financial and otherwise, of the Company and its subsidiaries and affiliates, as they were reflected in the Information and as they have been represented to Origin in discussions with Management and with Organigram's management. In our analyses and in preparing this Opinion, Origin made numerous assumptions with respect to industry performance, current market conditions, general business and economic conditions, and other matters, many of which are beyond the control of Origin or any party involved in the Transaction.

In providing this Opinion, Origin expresses no opinion as to the trading price or value of the Aurora Shares or Organigram Shares following the announcement or completion of the Transaction. This Opinion has been prepared at the request of the Special Committee and for the exclusive use of the Special Committee and the Board and, except as contemplated in the Engagement Agreement, may not be disclosed, used, relied upon, reproduced, disseminated, quoted from or referred to, in whole or in part, for any other purpose without our prior written consent.

We understand that the Opinion will be one factor, among several others, that the Company's directors will consider in their evaluation of the Transaction. This Opinion does not constitute a recommendation to the Board as to whether they should approve the Arrangement Agreement or recommend that Aurora Shareholders vote in favour of the Transaction, nor as a recommendation to any Aurora shareholder as to whether or how to vote their Aurora Shares at the Aurora Meeting. This Opinion does not address the relative merits of the Transaction as compared to other transactions or business strategies that might be available to the Company. In assessing the fairness, from a financial point of view, of the Consideration, Origin considered the Transaction from the perspective of the Aurora Shareholders generally and did not consider the specific circumstances of any particular Aurora Shareholder; each Aurora Shareholder will have its own financial objectives, investment horizon, cost base, liquidity needs, risk appetite and other relevant considerations.

This Opinion is given as of the date hereof and Origin disclaims any undertaking or obligation to advise any person of any change in any fact or matter affecting this Opinion which may come, or be brought, to the attention of Origin after the date hereof. Without limiting the foregoing, in the event that there is any material change in any fact or matter affecting this Opinion after the date hereof, including, without limitation, the terms and conditions of the Transaction, or if Origin learns that the Information relied upon in rendering this Opinion was inaccurate, incomplete or misleading in any material respect, Origin reserves the right to amend, supplement or withdraw this Opinion.

Origin believes that its analyses must be considered as a whole and that selecting portions of the analyses or the factors considered by it, without considering all factors and analyses together, could create a misleading view of the process underlying this Opinion. The preparation of an Opinion is a complex process and is not necessarily susceptible to partial analysis or summary description. Any attempt to do the latter could lead to undue emphasis on any particular factor or analysis. This Opinion should be read in its entirety.

Overview of Aurora

Aurora is a Canadian cannabis company focused on medical cannabis markets in Canada, Europe, Australia and New Zealand. The Company cultivates, processes and distributes cannabis products under brands including Aurora, MedReleaf, Pedanios, IndiMed, San Raf and Whistler Medical Marijuana Corporation, and operates EU-GMP certified production facilities in Canada and Germany. In recent periods, the Company has shifted its focus toward higher-margin international medical cannabis markets, including Germany, Poland and the United Kingdom, and has wound down its Canadian consumer cannabis operations. Aurora Shares trade on the Toronto Stock Exchange (the "**TSX**") and the Nasdaq Stock Market ("**Nasdaq**") under the symbol "ACB".

Overview of Organigram

Organigram is a Canadian licensed producer of cannabis and Canada's largest licensed producer by market share, with a leading position in the Canadian adult-use market. Organigram operates facilities in Moncton, New Brunswick; Lac-Supérieur, Quebec; Winnipeg, Manitoba; and Aylmer and London, Ontario, and its brand portfolio includes Edison, Big Bag O' Buds, SHRED, Monjour, Tremblant, Collective Project, Trailblazer, BOXHOT and DEBUNK. Through its April 2026 acquisition of Sanity Group GmbH, Organigram participates in the German medical cannabis market and other European markets. BAT is Organigram's largest shareholder. Organigram Shares trade on the TSX and Nasdaq under the symbol "OGI". Although we understand that the Transaction is exempt from the formal valuation and minority approval requirements prescribed by MI 61-101, we note that the Organigram Shares satisfy the criteria of a "liquid market" for purposes of section 1.2 of MI 61-101 and, accordingly, in preparing this Opinion, we have assumed that the fair value of the Organigram Shares is reflected in their recent trading prices on the TSX and Nasdaq.

Fairness Considerations

Pursuant to the Arrangement Agreement, the Combined Consideration to be received by Aurora Shareholders who elect to receive Combined Consideration will be comprised of C$3.75 in cash plus 3.0431 Organigram Shares (such number of Organigram Shares being the "**Exchange Ratio**"), which represents an implied value of C$7.80 per Aurora Share[1] based on the Organigram Share 20-day VWAP as of November 2, 2026, of approximately C$1.33 (the "**Notional Offer Price**"). The Exchange Ratio is fixed and, as such, Aurora Shareholders are anticipated to own approximately 35% of the *pro forma* combined company on an economic basis (based on fully diluted shares outstanding) and approximately 42% on a voting basis, with existing shareholders of Organigram, including BAT following completion of the Private Placement, owning the remainder. In considering the fairness, from a financial point of view, of the Consideration to be received by the Aurora Shareholders pursuant to the Transaction, Origin relied upon the methodologies presented herein, as well as the assumptions, explanations and limitations set forth herein, to determine a range of values for the Aurora Shares. Given the proration provisions described above, Origin has used the Combined Consideration as representative of the Consideration to be received by Aurora Shareholders. Origin compared the range of values of the Aurora Shares with the Notional Offer Price.

As part of the analyses and investigations carried out in the preparation of the Opinion, Origin reviewed and considered the items outlined under "Scope of Review". In the context of the Opinion, Origin has considered the following principal methodologies (as each such term is defined below):

a) Discounted Cash Flow Analysis
b) Precedent Transactions Analysis
c) Comparable Trading with Control Premium Analysis

[1] Calculated by multiplying Organigram Shares' 20-day VWAP on November 2, 2026 by the Exchange Ratio (3.0431) and adding the cash component of C$3.75.

Discounted Cash Flow Analysis

Origin performed a discounted cash flow ("**DCF**") analysis of the Company. This intrinsic valuation analysis considers the amount, timing and relative certainty of projected, unlevered, after-tax free cash flows expected to be generated by Aurora. Origin used the Management Forecast for the fiscal years ending March 31, 2027 through March 31, 2031 to project the Company's unlevered, after-tax free cash flows, and added the present value of the terminal value, the present value of the Company's Canadian tax loss carry-forwards remaining after FY2031E and the Company's cash as at September 30, 2026 to calculate the Company's *en bloc* equity value per fully diluted Aurora Share. The analysis was performed on a stand-alone basis as at November 2, 2026 and does not reflect any synergies that may be realized by Organigram. In performing its analysis, Origin relied on the Management Forecast, with certain adjustments made by Origin, including the presentation of EBITDA on a pre-IFRS 16 basis by deducting approximately C$5 million of annual lease payments and the projection of the utilization of the Company's remaining tax loss carry-forwards beyond FY2031E. The Management Forecast included estimates regarding future market demand, market share, pricing, production volumes, operating costs, capital expenditures and working capital.

Origin performed a weighted average cost of capital ("**WACC**") build-up to assess an appropriate discount rate for the Company, taking into account market-based inputs including the risk-free rate, equity risk premium, beta assumptions and size premium reflective of the Company's scale. Based on this analysis, which incorporated a risk-free rate of 3.8%, an unlevered beta of 1.17 (being the median of selected comparable Canadian licensed producers), an equity risk premium of 4.2% and a size premium of 4.1%, Origin determined a discount rate range of 12.0% – 13.0% to apply to the projected, unlevered, after-tax free cash flows, with a selected discount rate of 12.5%. We believe this range reflects (i) the risk inherent in Aurora based on current market conditions and the cannabis market environment and (ii) discount rates utilized by equity research analysts and other financial and industry participants in evaluating companies of a similar nature. In assessing the terminal value of the Company's projected, unlevered, after-tax free cash flows, Origin selected a terminal growth rate of 2.0% - 4.0% to apply to the Company's projected, unlevered, after-tax free cash flows beyond the Management Forecast. We believe this range is consistent with terminal growth rates utilized by equity research analysts and other financial and industry participants in evaluating companies of a similar nature.

Table 1: Key Assumptions for Aurora DCF Analysis

<table>
<tr><td rowspan="3">Market Demand & Flower Pricing[2]</td><td>FYE March 31 FY2027E FY2028E FY2029E FY2030E FY2031E</td></tr>
<tr><td>Europe (Germany, Poland, United Kingdom)
Market Demand (kg) 198,526 260,191 323,889 386,416 452,136
Pricing based on Management Forecast in the respective markets</td></tr>
<tr><td>Canada
Canadian Medical revenue decline of 23% in FY2027E, growth of 4% per annum thereafter</td></tr>
</table>

[2] Based on the Management Forecast

	Australia & New Zealand Australia and New Zealand growth of 10% per annum
Discount Rate[3]	12.5%
Terminal Growth Rate[4]	2.0% - 4.0%

Summary of Aurora DCF Analysis

To determine the value range for an Aurora Share, calculated on a fully diluted basis, Origin relied on the Management Forecast. Projected unlevered, after-tax free cash flows were based on Management's assumptions regarding market demand, flower pricing, production volumes, operating costs and capital costs, with certain adjustments made by Origin. Projected cash flows were discounted using a discount rate of 12.5%, with terminal growth rates ranging from 2.0% to 4.0%.

Based on the analysis described above, Origin determined a value range of C$7.56 to C$8.14 per Aurora Share under the Management Forecast.

Precedent Transactions Analysis

Origin reviewed publicly available information on select acquisition transactions involving cannabis cultivators, processors and operators in Canada, the United States and Europe. Origin reviewed the total enterprise value to EBITDA ("**TEV/EBITDA**") multiples based on last-twelve-month ("**LTM**") or the publicly available EBITDA metric of the target at the time of each transaction, among other metrics and multiples, observable in previous transactions involving cannabis companies in North America and other geographies, since 2020. As no acquisition transaction can be identical to the Transaction, Origin Merchant selected precedent transactions that were, in the exercise of our professional judgment, deemed relevant for purposes of our financial analyses and the preparation of this Opinion.

Origin considered each of these transactions and the merits of the targets relative to Aurora including:

a) The business model of the target;
b) The size of the transaction;
c) Forecast operating and financial performance; and
d) Geographic diversification and exposure to various regulatory regimes.

Table 2: Aurora Set of Precedent Transactions

Date Announced	Target	Acquirer
Jul 2026	Planet 13	Vireo Growth Inc.
Jun 2026	C21 Investments Inc.	Vireo Growth Inc.
Feb 2026	Sanity Group	Organigram
Dec 2025	MTL Cannabis Corp.	Canopy Growth Corporation

[3] Consistent with the discount rates used by equity research analysts when valuing cannabis companies
[4] Consistent with equity research analysts' terminal growth rates when valuing cannabis companies

Date Announced	Target	Acquirer
Dec 2025	CanAdelaar B.V.	Cronos Group Inc.
Aug 2023	VidaCann	Planet 13
Apr 2023	HEXO Corp.	Tilray Brands
Dec 2021	Bloom Dispensaries	Curaleaf Holdings, Inc.
Dec 2021	Laurentian Organic Inc.	Organigram
Dec 2021	Next Green Wave	Planet 13
Sept 2020	Pure Sunfarms Corp	Village Farms International

The following table outlines the range of observed transaction multiples for the set of precedent transactions selected by Origin:

Table 3: Precedent Transactions Multiple Summary

Precedent Transactions	Multiple Observed
Average TEV / EBITDA	8.5x
Median TEV / EBITDA	8.0x
High	16.2x
Low	2.9x

Summary of Precedent Transactions Analysis

Based on the analysis described above, Origin applied a range of TEV/EBITDA multiples of 6.7x to 9.4x to Aurora's LTM EBITDA as at June 30, 2026 of approximately C$41.4 million, presented on a pre-IFRS 16 basis. The selected range reflects the interquartile range of observed TEV/EBITDA multiples for the selected precedent transactions, excluding transactions for which EBITDA was not available or not meaningful. This methodology resulted in the following implied value ranges for the Aurora Shares:

Table 4: Precedent Transactions Implied Share Price Summary

Metric	Aurora
TEV / EBITDA (LTM)	C$5.84 - C$7.42

Comparable Trading with Control Premium Analysis

Aurora

Origin reviewed publicly available information regarding comparable Canadian licensed producer cannabis companies ("**Canadian LPs**") to determine TEV/EBITDA multiples on a calendar year 2027 ("**CY2027**") basis as at November 2, 2026.

Origin also reviewed the trading metrics of U.S. multi-state operators ("**U.S. MSOs**") but did not rely on them for valuation purposes given differences in regulatory environments and market dynamics. None of the companies in the comparable company set are identical to Aurora. Accordingly, an analysis derived from the multiples of TEV/EBITDA requires complex considerations and judgements concerning the

similarities between the set of comparable companies and Aurora as well as other qualitative and quantitative factors that may affect such multiples.

Table 5: Aurora Set of Comparable Companies

No.	Canadian LPs
1	Auxly Cannabis Group Inc.
2	Cannara Biotech Inc.
3	Canopy Growth Corporation
4	Cronos Group Inc.
5	Organigram Global Inc.
6	Tilray Brands, Inc.
7	Village Farms International, Inc.

TEV/EBITDA is the most commonly used valuation methodology employed by equity research analysts and other financial and industry participants in evaluating assets of this nature and in determining the value per share of cannabis companies. Using the TEV/EBITDA approach, Origin applied a range of TEV/EBITDA multiples to (i) Aurora's estimated CY2027 EBITDA of approximately C$38.8 million as implied by the Management Forecast, and (ii) the average of equity research analysts' estimates ("**Consensus Estimates**") of Aurora's CY2027 EBITDA of approximately C$26.2 million, in each case presented on a pre-IFRS 16 basis by deducting approximately C$5 million of annual lease payments.

The following table outlines the range of observed trading multiples for the set of comparable companies selected for Aurora:

Table 6: Aurora Comparable Companies Multiple Summary

Comparable Companies	TEV / CY2027E EBITDA
Average	6.1x
Median	5.7x
High	8.0x
Low	4.8x

Summary of Aurora Comparable Companies Analysis

Based on the observed TEV/EBITDA trading multiples for the comparable companies, Origin applied an interquartile range of 5.3x to 7.0x adjusted for the average 20-day VWAP premium of 27.0% observed in cannabis change of control transactions announced since 2020, implying a range of 6.7x to 8.9x to Aurora's CY2027 EBITDA derived from the Management Forecast and to Consensus Estimates of Aurora's CY2027 EBITDA as at November 2, 2026. This methodology resulted in the following implied value ranges for the Aurora Shares:

Table 7: Aurora Implied Share Price Summary

Metric	Aurora
CY2027 EBITDA (Management Forecast)	C$5.61 - C$6.80
CY2027 EBITDA (Consensus)	C$4.40 - C$5.21

Valuation of the Combined Consideration

As noted above, Origin has not independently valued the Organigram Shares, which satisfy the "liquid market" test for purposes of MI 61-101. Instead, in assessing the value of the Share Consideration and the share component of the Combined Consideration, Origin has relied on the 20-day VWAP of the Organigram Shares on the TSX, having considered that: (a) Organigram is a reporting issuer in each of the provinces and territories of Canada and the Organigram Shares are listed on the TSX and Nasdaq; (b) the Organigram Shares have traded with meaningful liquidity, with average daily trading volume of approximately 1.0 million shares since January 2023, representing approximately 10 times the public float over that period; (c) the Company has advised Origin that, other than in respect of the Transaction and related transactions, it has no knowledge of any material information concerning Organigram or the Organigram Shares that has not been generally disclosed; and (d) the Organigram Shares issuable under the Transaction are expected to be freely tradeable upon issuance, subject to customary exceptions. Origin notes that the number of Organigram Shares issuable pursuant to the Transaction and the Private Placement is significant relative to the number of Organigram Shares currently outstanding, and that the market price of the Organigram Shares could be affected by the announcement and completion of the Transaction.

Opinion

Based upon and subject to the foregoing and such other matters as we considered relevant, Origin is of the opinion that, as at the date hereof, the Consideration to be received by Aurora Shareholders pursuant to the Transaction is fair, from a financial point of view, to Aurora Shareholders.

Yours very truly,

Origin Merchant Partners

ORIGIN MERCHANT PARTNERS

APPENDIX "G"
ORGANIGRAM FAIRNESS OPINION

(See attached)

BMO Capital Markets

November 2, 2026

The Board of Directors
Organigram Global Inc.
1400-145 King Street West
Toronto, ON, M5H 1J8

To the Board of Directors:

BMO Nesbitt Burns Inc. ("BMO Capital Markets" or "we" or "us") understands that Organigram Global Inc. (the "Company") and Aurora Cannabis Inc. (the "Acquisition Candidate") propose to enter into an arrangement agreement to be dated November 2, 2026 (the "Arrangement Agreement") pursuant to which, among other things, the Company will acquire all of the outstanding shares (the "Aurora Shares") of the Acquisition Candidate and pursuant to which each holder of the Aurora Shares (the "Aurora Shareholders") will be entitled to elect to receive C$7.80 in total consideration per Aurora Share, consisting of, at the election of the Aurora Shareholder, (i) C$7.80 in cash; (ii) 5.8626 common shares of the Company (the "Organigram Shares") or (iii) a combined consideration of C$3.75 in cash plus 3.043 Organigram Shares (collectively, the "Consideration"). Aurora Shareholders electing to receive the Consideration set out in (i) or (ii) will be subject to proration (as provided for in the Arrangement Agreement) so that that the maximum amount of cash consideration available will be C$253,638,772 and the maximum number of Organigram Shares available will be 205,826,172. We are expressing no opinion as to the proration procedures and limitations provided for in the Arrangement Agreement. We also understand that the acquisition contemplated by the Arrangement Agreement is proposed to be effected by way of a plan of arrangement (the "Arrangement") under the *Business Corporations Act* (British Columbia).

The terms and conditions of the Arrangement Agreement will be summarized in the joint management information circular (the "Joint Circular") of the Company and the Acquisition Candidate to be mailed to holders of Organigram Shares (the "Organigram Shareholders") and the Aurora Shareholders in connection with the special meetings of the Organigram Shareholders and the Aurora Shareholders, each to be held to consider and, if deemed advisable, to provide the requisite approval of the Arrangement.

We have been retained to provide financial advice to the Company, including our opinion (the "Opinion") to the board of directors of the Company (the "Board of Directors") as to the fairness, from a financial point of view, to the Company of the Consideration to be paid by the Company pursuant to the Arrangement.

This Opinion has been prepared in accordance with the Disclosure Standards for Formal Valuations and Fairness Opinions of the Canadian Investment Regulatory Organization ("CIRO"), but CIRO has not been involved in the preparation and review of this Opinion.

Engagement of BMO Capital Markets

The Company initially contacted BMO Capital Markets regarding a potential advisory assignment on August 12, 2026. BMO Capital Markets was formally engaged by the Company pursuant to an agreement dated September 16, 2026 (the "Engagement Agreement"). Under the terms of the Engagement Agreement, BMO Capital Markets has agreed to provide the Company and the Board of Directors with various advisory services in connection with the Arrangement including, among other things, the provision of the Opinion.

BMO Capital Markets will receive a fee for rendering the Opinion, no part of which is contingent on the conclusion of the Opinion or the successful completion of the Arrangement. We will also receive certain fees for our advisory services under the Engagement Agreement, a substantial portion of which is contingent upon the successful completion of the Arrangement. The Company has also agreed to reimburse us for our reasonable out-of-pocket expenses and to indemnify us against certain liabilities that might arise out of our engagement.

Credentials of BMO Capital Markets

BMO Capital Markets is one of North America's largest investment banking firms, with operations in all facets of corporate and government finance, mergers and acquisitions, equity and fixed income sales and trading, investment research and investment management. BMO Capital Markets has been a financial advisor in a significant number of transactions throughout North America involving public and private companies in various industry sectors and has extensive experience in preparing fairness opinions.

The Opinion represents the opinion of BMO Capital Markets, the form and content of which have been approved for release by a committee of our officers who are collectively experienced in merger and acquisition, divestiture, restructuring, valuation, fairness opinion and capital markets matters.

Independence of BMO Capital Markets

Neither BMO Capital Markets, nor any of our affiliates, is an insider or affiliate (as those terms are defined in the *Securities Act* (Ontario) (the "Act") or the rules made thereunder) of the Company, the Acquisition Candidate or any of their respective affiliates (collectively, the "Interested Parties").

BMO Capital Markets has not been engaged to provide any financial advisory services nor has it participated in any financings involving the Interested Parties within the past two years, other than: (i) acting as financial advisor to the Company pursuant to the Engagement Agreement; (ii) acting as financial advisor to the Company and the investment committee of the Board of Directors in connection with providing an opinion with respect to the acquisition of Sanity Group GmbH ("Sanity Group"); and (iii) acting as financial advisor to the Company in connection with the acquisition of Motif Labs Ltd. in 2024. In addition, BMO Capital Markets may provide currency hedging arrangements in connection with the Arrangement.

Other than as may be disclosed herein, BMO Capital Markets has not been engaged to provide any financial advisory services to the Acquisition Candidate or any of its affiliates within the past two years.

Other than as set forth above, there are no understandings, agreements or commitments between BMO Capital Markets and any of the Interested Parties with respect to future business dealings. BMO Capital Markets may, in the future, in the ordinary course of business, provide financial advisory, investment banking, or other financial services to one or more of the Interested Parties from time to time.

BMO Capital Markets and certain of our affiliates act as traders and dealers, both as principal and agent, in major financial markets and, as such, may have or have had and may in the future have positions in the securities of one or more of the Interested Parties and, from time to time, may have executed or may execute transactions on behalf of one or more Interested Parties for which BMO Capital Markets or such affiliates received or may receive compensation. As investment dealers, BMO Capital Markets and certain of our affiliates conduct research on securities and may, in the ordinary course of business, provide research reports and investment advice to clients on investment matters, including with respect to one or more of the Interested Parties or the Arrangement. In addition, Bank of Montreal ("BMO"), of which BMO Capital Markets is a wholly-owned subsidiary, or one or more affiliates of BMO, may provide banking or other financial services to one or more of the Interested Parties in the ordinary course of business.

Overview of the Company and the Acquisition Candidate

The Company is listed on the NASDAQ Global Select Market and Toronto Stock Exchange. The Company's wholly-owned subsidiary, Organigram Inc., is a licensed cultivator and processor. Through its acquisition of Sanity Group, the Company participates in the German medical cannabis market and other emerging markets within Europe. The Company is focused on producing high-quality cannabis for adult consumers, as well as extending the Company's global footprint. The Company has also developed and acquired a portfolio of cannabis brands and operates facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and infused pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by Health Canada under the *Cannabis Act* and its regulations.

The Acquisition Candidate is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. The Acquisition Candidate serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, the Acquisition Candidate continues to expand its global footprint and deliver consistent, high-quality cannabis products.

Scope of Review

In connection with rendering the Opinion, we have reviewed and relied upon, or carried out, among other things, the following:

1. a draft of the Arrangement Agreement dated November 2, 2026;

2. a draft of the investor presentation on the Arrangement prepared by the Company dated November 2, 2026;

3. a draft of the voting support agreement dated October 22, 2026 between the Acquisition Candidate and BT DE Investment Inc.;

4. an equity financing subscription agreement dated October 31, 2026 between the Company and BT DE Investment Inc. (the "Subscription Agreement");

5. certain publicly available information relating to the business, operations, financial condition and trading history of the Company and the Acquisition Candidate, as applicable, and other selected public companies we considered relevant;

6. certain internal financial, operating, corporate and other information prepared or provided by or on behalf of the Company or the Acquisition Candidate relating to the respective business, operations and financial condition of the Company or the Acquisition Candidate;

7. internal management forecasts, projections, estimates and budgets prepared or provided by or on behalf of management of the Company for each of the Company and the Acquisition Candidate;

8. a draft financial due diligence report on the Acquisition Candidate dated October 27, 2026 prepared by a third-party advisor to the Company;

9. discussions with management of the Company relating to the Company's and the Acquisition Candidate's respective current business, plan, financial condition and prospects;

10. public information with respect to selected precedent transactions we considered relevant;

11. various reports published by equity research analysts and industry sources we considered relevant;

12. a letter of representation as to certain factual matters and the completeness and accuracy of certain information upon which the Opinion is based, addressed to us and dated as of the date hereof, provided by senior officers of the Company (the "Management Representation Letter"); and

13. such other information, investigations, analyses and discussions as we considered necessary or appropriate in the circumstances.

BMO Capital Markets has not, to the best of its knowledge, been denied access by the Company or the Acquisition Candidate to any information under the Company's or the Acquisition Candidate's control, as applicable, requested by BMO Capital Markets.

Assumptions and Limitations

We have relied upon and assumed the completeness, accuracy and fair presentation of all financial and other information, data, advice, opinions, representations and other material obtained by us from public sources or provided to us by or on behalf of the Company or otherwise obtained by us in connection with our engagement. The Opinion is conditional upon such completeness, accuracy and fair presentation. We have not been requested to, and have not assumed any obligation to, independently verify the completeness, accuracy or fair presentation of any such information. We have assumed that forecasts, projections, estimates and budgets provided to us and used in our analyses were reasonably prepared on bases reflecting the best currently available assumptions, estimates and judgments of management of the Company and the Acquisition Candidate, having regard to the business, plans, financial condition and prospects of the Company, the Acquisition Candidate and their respective subsidiaries.

Senior officers of the Company have represented to BMO Capital Markets in the Management Representation Letter, among other things, that: (i) the information provided to BMO Capital Markets orally by an officer or employee of the Company or any of its subsidiaries (as defined in National Instrument 45-106 – *Prospectus Exemptions*), or in writing by the Company or any of its subsidiaries or in any manner by any of its or their representatives in connection with our engagement (collectively, the "Information"), in respect of the Company, was at the date the Information was provided to BMO Capital Markets, and (except to the extent superseded by more current Information provided) is, as of the date hereof, complete, true and correct in all material respects, and did not and does not contain a misrepresentation (as defined in the Act) and, in respect of the Acquisition Candidate or any of its subsidiaries, to the best of their knowledge, information and belief, was at the date the Information was provided to BMO Capital Markets, and (except to the extent superseded by more current Information provided) is, as of the date hereof, complete, true and correct in all material respects, and did not and does not contain a misrepresentation; and (ii) since the dates on which the Information was provided to BMO Capital Markets, except as disclosed to BMO Capital Markets, there has been no material change, financial or otherwise, in the financial condition, assets, liabilities (contingent or otherwise), business, operations or prospects of the Company or any of its subsidiaries or, to the best of their knowledge, information and belief, the Acquisition Candidate or any of its subsidiaries and no change has occurred in the Information or any part thereof which would have or which could reasonably be expected to have a material effect on the Opinion.

In preparing the Opinion, we have assumed that the executed Arrangement Agreement and the Subscription Agreement will not differ in any material respect from the draft that we reviewed, and that the Arrangement will be consummated in accordance with the terms and conditions of the Arrangement Agreement without waiver of, or amendment to, any term or condition that is in any way material to our analyses.

The Opinion is rendered on the basis of securities markets, economic, financial and general business conditions prevailing as of the date hereof and the condition and prospects, financial and otherwise, of the Company and the Acquisition Candidate as they are reflected in the Information and as they have been represented to BMO Capital Markets in discussions with management of the Company and its representatives. In our analyses and in preparing the Opinion, BMO Capital

Markets made numerous judgments and assumptions with respect to industry performance, general business, market and economic conditions and other matters, many of which are beyond our control or that of any party involved in the Arrangement.

The Opinion is provided to the Board of Directors for their exclusive use only in considering the Arrangement and may not be used or relied upon by any other person or for any other purpose without our prior written consent. The Opinion does not constitute a recommendation as to how any shareholder or other persons should vote or act on any matter relating to the Arrangement. Except for the inclusion of the Opinion in its entirety and a summary thereof (in a form acceptable to us) in the Joint Circular, the Opinion is not to be reproduced, disseminated, quoted from or referred to (in whole or in part) without our prior written consent.

We have not been asked to prepare and have not prepared a formal valuation or appraisal of the securities or assets of the Company, the Acquisition Candidate or of any of their respective subsidiaries, and the Opinion should not be construed as such. The Opinion is not, and should not be construed as, advice as to the price at which the securities of the Company may trade at any time. BMO Capital Markets was not engaged to review any legal, tax or regulatory aspects of the Arrangement and the Opinion does not address any such matters. We have relied upon, without independent verification, the assessment by the Company and its legal and tax advisors with respect to such matters. In addition, the Opinion does not address the relative merits of the Arrangement as compared to any strategic alternatives that may be available to the Company.

The preparation of the Opinion is a complex process and is not necessarily amenable to being partially analyzed or summarized. Any attempt to do so could lead to undue emphasis on any particular factor or analysis. BMO Capital Markets believes that our analyses must be considered as a whole and that selecting portions of the analyses or the factors considered by us, without considering all factors and analyses together, could create an incomplete or misleading view of the process underlying the Opinion. This opinion letter should be read in its entirety.

The Opinion is rendered as of the date hereof and BMO Capital Markets disclaims any undertaking or obligation to advise any person of any change in any fact or matter affecting the Opinion which may come or be brought to the attention of BMO Capital Markets after the date hereof. Without limiting the foregoing, if we learn that any of the Information we relied upon in preparing the Opinion was inaccurate, incomplete or misleading in any material respect, BMO Capital Markets reserves the right to change or withdraw the Opinion.

The Opinion does not address the solvency, creditworthiness or fair value of the Company or the Acquisition Candidate under any applicable laws relating to bankruptcy, insolvency or similar matters. The Opinion does not constitute an opinion or representation that any specific amount of consideration is the only appropriate consideration for the Arrangement.

Approach to Fairness and Analysis

In considering the fairness of the Consideration from a financial point of view to the Company, BMO Capital Markets principally considered and relied upon, among other things, the following: (i) a comparison of the multiples implied by the Consideration to an analysis of selected publicly traded companies, (ii) a comparison of the multiples implied by the Consideration to an analysis

of selected publicly traded companies after applying a control premium, (iii) a comparison of the multiples implied by the Consideration to an analysis of selected precedent transactions and (iv) a comparison of the Consideration to a discounted cash flow analysis. In arriving at the Opinion, BMO Capital Markets considered the results of each of the foregoing analyses together with the other factors described herein. No single methodology or factor was determinative of the Opinion and each methodology has inherent strengths and weaknesses. The relative significance of each was a matter of judgment for BMO Capital Markets. In performing its analyses, BMO Capital Markets also considered certain potential benefits to the Company that could result from the successful completion of the Arrangement, including potential synergies and cost savings.

Conclusion

Based upon and subject to the foregoing, BMO Capital Markets is of the opinion that, as of the date hereof, the Consideration to be paid by the Company pursuant to the Arrangement Agreement is fair, from a financial point of view, to the Company.

Yours truly,

BMO Nesbitt Burns Inc.

BMO Nesbitt Burns Inc.

APPENDIX "H"
PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF ORGANIGRAM GLOBAL INC.

(See attached)

Unaudited Pro Forma Condensed Consolidated Financial Statements of

ORGANIGRAM GLOBAL INC.

AS AT JUNE 30, 2026
FOR THE YEAR ENDED SEPTEMBER 30, 2025
FOR THE NINE-MONTHS ENDED JUNE 30, 2026

ORGANIGRAM GLOBAL INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at June 30, 2026

(Expressed in CDN $000's except share and per share amounts)

	Organigram Global Inc. as at June 30, 2026	Aurora Cannabis Inc. as at June 30, 2026	Pro forma adjustments	Pro forma combined	Note
ASSETS					
Current assets					
Cash and cash equivalents	$ 10,851	$ 69,307	$ 131,609	$ 127,084	3 (a)
			186,912		3 (b)
			(259,773)		3 (c)
			(11,822)		3 (c)
Restricted cash	-	49,086	-	49,086	
Short-term investments	816	30,722	-	31,538	
Accounts and other receivables	88,605	41,091	-	129,696	
Biological assets	17,292	24,000	-	41,292	
Inventories	147,764	163,543	-	311,307	
Prepaid expenses, deposits and other current assets	14,758	12,564	-	27,322	
Assets held for sale	-	3,136	-	3,136	
Total current assets	**$ 280,086**	**$ 393,449**	**$ 46,926**	**$ 720,461**	
Non-current assets					
Property, plant and equipment	$ 121,148	$ 146,752	$ -	$ 267,900	
Intangible assets	203,506	32,731	(32,731)	203,506	3 (c)
Goodwill	194,717	27,342	(27,342)	287,433	3 (c)
			92,716		3 (c)
Long-term investments and other financial assets	19,831	12,533	-	32,364	
Deferred charges, deposits and other long-term assets	974	2,267	-	3,241	
Lease receivable	-	3,246	-	3,246	
Deferred tax assets	-	2,557	-	2,557	
Total non-current assets	**$ 540,176**	**$ 227,428**	**$ 32,643**	**$ 800,247**	
TOTAL ASSETS	**$ 820,262**	**$ 620,877**	**$ 79,569**	**$ 1,520,708**	
LIABILITIES					
Current liabilities					
Accounts payable and accrued liabilities	$ 99,933	$ 56,830	$ 26,038	$ 182,801	3 (c)
Income taxes payable	-	7,439	-	7,439	
Deferred revenue	-	799	(799)	-	3 (e)
Current portion of loans and borrowings	3,365	-	27,000	30,365	3 (a)
Lease liabilities – current portion	-	5,875	(5,875)	-	3 (e)
Derivative liabilities – current	1,637	-	-	1,637	
Provisions and other current liabilities	2,346	2,486	799	11,506	3 (e)
			5,875		3 (e)
Total current liabilities	**$ 107,281**	**$ 73,429**	**$ 53,038**	**$ 233,748**	
Non-current liabilities					
Loans and borrowings	17,608	-	$ 104,609	$ 122,217	3 (a)
Lease liabilities	-	16,809	(16,809)	-	3 (e)
Derivative liabilities	198	2,892	(1,300)	1,790	3 (c)
Preferred shares	71,057	-	73,276	144,333	3 (b), 3 (f)
Deferred income taxes	49,619	47	-	49,666	
Other long-term liabilities	89,037	569	16,809	106,415	3 (e)
Total non-current liabilities	**$ 227,519**	**$ 20,317**	**$ 176,585**	**$ 424,421**	
TOTAL LIABILITIES	**$ 334,800**	**$ 93,746**	**$ 229,623**	**$ 658,169**	
SHAREHOLDERS' EQUITY					
Share capital	$ 933,648	$ 7,027,979	$ (7,027,979)	$ 1,313,625	3 (c)
			266,107		3 (c)
			113,870		3 (b)
Equity reserves / contributed surplus	37,451	158,807	(158,807)	46,607	3 (c)
			9,156		3 (c)
Accumulated other comprehensive income (loss)	(1,496)	(213,714)	213,714	(1,496)	3 (c)
Accumulated deficit	(484,141)	(6,445,941)	6,445,941	(496,197)	3 (c)
			(234)		3 (b)
			(11,822)		3 (c)
Total shareholders' equity	**$ 485,462**	**$ 527,131**	**$ (150,054)**	**$ 862,539**	
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	**$ 820,262**	**$ 620,877**	**$ 79,569**	**$ 1,520,708**	

See accompanying notes to unaudited Pro Forma Condensed Consolidated Financial Statements

ORGANIGRAM GLOBAL INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND OTHER COMPREHENSIVE (LOSS) INCOME

For the year ended September 30, 2025

(Expressed in CDN $000's except share and per share amounts)

	Organigram Global Inc. for the year ended September 30, 2025	Aurora Cannabis Inc. for the twelve months ended September 30, 2025	Pro forma adjustments	Pro forma combined	Note
REVENUE					
Gross revenue	$ 403,024	$ 335,845	$ -	$ 738,869	
Excise taxes	(143,841)	(26,891)	-	(170,732)	
Net revenue	**$ 259,183**	**$ 308,954**	**$ -**	**$ 568,137**	
Cost of sales	$ 174,850	$ 151,932	$ -	$ 326,782	
Gross margin before fair value adjustments	**$ 84,333**	**$ 157,022**	**$ -**	**$ 241,355**	
Realized fair value on inventories and biological assets sold and other inventory charges	$ (67,125)	$ (137,851)	$ -	$ (204,976)	
Unrealized gain on changes in fair value of biological assets	73,008	142,464	-	215,472	
Gross margin	**$ 90,216**	**$ 161,635**	**$ -**	**$ 251,851**	
OPERATING EXPENSES					
General and administrative	$ 59,499	$ 101,348	$ 3,165	$ 164,012	*3 (e)*
Sales and marketing	31,097	57,226	-	88,323	
Business development costs	-	2,125	-	2,125	
Research and development	10,945	3,447	-	14,392	
Depreciation and amortization	-	3,165	(3,165)	-	*3 (e)*
Share-based compensation	3,975	12,598	(5,900)	18,680	*3 (c)*
			8,007		*3 (c)*
Impairment of property, plant and equipment	-	-	1,092	1,092	*3 (e)*
Impairment of intangible assets and goodwill	-	-	13,186	13,186	*3 (e)*
Total operating expenses	**$ 105,516**	**$ 179,909**	**$ 16,385**	**$ 301,810**	
Loss from operations	**$ (15,300)**	**$ (18,274)**	**$ (16,385)**	**$ (49,959)**	
OTHER (INCOME) EXPENSE					
Interest and investment (income) loss, net	$ (1,747)	$ (8,454)	$ -	$ (10,201)	
Finance and other costs	597	2,661	8,356	11,614	*3 (a)*
Acquisition, transaction and business development costs	6,580	-	234	18,636	*3 (b)*
			11,822		*3 (c)*
Loss (gain) on disposal of property, plant and equipment and intangible assets	9	-	-	9	
Change in fair value of contingent consideration	(9,743)	-	-	(9,743)	
Change in fair value of derivative liabilities, preferred shares and other financial assets	27,505	-	-	27,505	
Foreign exchange gain	-	(11,178)	-	(11,178)	
Share issuance costs allocated to derivative liabilities and preferred shares	170	-	-	170	
Other non-operating (income) expense	(142)	302	-	160	
Impairment of property, plant and equipment	-	1,092	(1,092)	-	*3 (e)*
Impairment of intangible assets and goodwill	-	13,186	(13,186)	-	*3 (e)*
Total other (income) expense	**$ 23,229**	**$ (2,391)**	**$ 6,134**	**$ 26,972**	
Loss before income taxes	**$ (38,529)**	**$ (15,883)**	**$ (22,519)**	**$ (76,931)**	
INCOME TAX (RECOVERY) EXPENSE					
Current	$ -	$ 5,810	$ -	$ 5,810	*3 (d)*
Deferred, net	(13,770)	(370)	-	(14,140)	*3 (d)*
Total income tax (recovery) expense	**$ (13,770)**	**$ 5,440**	**$ -**	**$ (8,330)**	
Net loss from continuing operations	**$ (24,759)**	**$ (21,323)**	**$ (22,519)**	**$ (68,601)**	
Net loss from discontinued operations, net of tax	-	(41,059)	-	(41,059)	
Net loss	**$ (24,759)**	**$ (62,382)**	**$ (22,519)**	**$ (109,660)**	

See accompanying notes to unaudited Pro Forma Condensed Consolidated Financial Statements

ORGANIGRAM GLOBAL INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND OTHER COMPREHENSIVE (LOSS) INCOME

For the year ended September 30, 2025

(Expressed in CDN $000's except share and per share amounts)

	Organigram Global Inc. for the year ended September 30, 2025	Aurora Cannabis Inc. for the twelve months ended September 30, 2025	Pro forma adjustments	Pro forma combined	Note
OTHER COMPREHENSIVE INCOME (LOSS)					
Change in fair value of investments at fair value through other comprehensive income (loss)	$ 666	$ -	$ -	$ 666	
Foreign currency transaction (loss)	-	(1,701)	-	(1,701)	
Cash flow hedge reserve	-	-	-	-	
Total other comprehensive income (loss)	**$ 666**	**$ (1,701)**	**$ -**	**$ (1,035)**	
Comprehensive loss from continuing operations	$ (24,093)	$ (23,024)	$ (22,519)	$ (69,636)	
Comprehensive loss from discontinued operations	-	(41,059)	-	(41,059)	
COMPREHENSIVE LOSS	**$ (24,093)**	**$ (64,083)**	**$ (22,519)**	**$ (110,695)**	
Net loss from continuing operations attributable to:					
Common shareholders	$ (24,759)	$ (21,323)	$ (22,519)	$ (68,601)	
Non-controlling interests	-	-	-	-	
	$ (24,759)	**$ (21,323)**	**$ (22,519)**	**$ (68,601)**	
Net loss from discontinued operations attributable to:					
Common shareholders	$ -	$ (36,447)	$ -	$ (36,447)	
Non-controlling interests	-	(4,612)	-	(4,612)	
	$ -	**$ (41,059)**	**$ -**	**$ (41,059)**	
Comprehensive loss attributable to:					
Common shareholders	$ (24,093)	$ (59,471)	$ (22,519)	$ (106,083)	
Non-controlling interests	-	(4,612)	-	(4,612)	
	$ (24,093)	**$ (64,083)**	**$ (22,519)**	**$ (110,695)**	
Net loss per common share, basic					
Continuing operations				$ (0.17)	
Discontinued operations				$ (0.08)	
Total operations				**$ (0.25)**	
Net loss per common share, diluted					
Continuing operations				$ (0.17)	
Discontinued operations				$ (0.08)	
Total operations				**$ (0.25)**	

See accompanying notes to unaudited Pro Forma Condensed Consolidated Financial Statements

ORGANIGRAM GLOBAL INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND OTHER COMPREHENSIVE (LOSS) INCOME

For the nine months ended June 30, 2026

(Expressed in CDN $000's except share and per share amounts)

	Organigram Global Inc. for the nine months ended June 30, 2026	Aurora Cannabis Inc. for the nine months ended June 30, 2026	Pro forma adjustments	Pro forma combined	Note
REVENUE					
Gross revenue	$ 335,619	$ 247,939	$ -	$ 583,558	
Excise taxes	(106,505)	(12,677)	-	(119,182)	
Net revenue	**$ 229,114**	**$ 235,262**	**$ -**	**$ 464,376**	
Cost of sales	151,801	122,744	-	274,545	
Gross margin before fair value adjustments	**$ 77,313**	**$ 112,518**	**$ -**	**$ 189,831**	
Realized fair value on inventories and biological assets sold	(53,155)	(100,480)	-	(153,635)	
Unrealized gain on changes in fair value of biological assets	56,986	95,562	-	152,548	
Gross margin	**$ 81,144**	**$ 107,600**	**$ -**	**$ 188,744**	
OPERATING EXPENSES					
General and administrative	$ 50,488	$ 78,003	$ 2,605	$ 131,096	*3 (e)*
Sales and marketing	29,785	46,473	-	76,258	
Business development costs	-	2,882	-	2,882	
Research and development	6,324	3,230	-	9,554	
Depreciation and amortization	-	2,605	(2,605)	-	*3 (e)*
Share-based compensation	2,428	831	(500)	10,766	*3 (c)*
			8,007		*3 (c)*
Impairment of property, plant and equipment	-	-	2,250	2,250	*3 (e)*
Impairment of intangible assets and goodwill	5,800	-	-	5,800	
Total operating expenses	**$ 94,825**	**$ 134,024**	**$ 9,757**	**$ 238,606**	
Loss from operations	**$ (13,681)**	**$ (26,424)**	**$ (9,757)**	**$ (49,862)**	
OTHER (INCOME) EXPENSE					
Interest and investment (income) loss, net	$ (889)	$ (3,172)	$ -	$ (4,061)	
Finance and other costs	1,025	1,368	6,417	8,810	*3 (a)*
Acquisition and transaction costs	11,129	-	234	23,185	*3 (b)*
			11,822		*3 (c)*
Change in fair value of contingent consideration	(8,924)	-	-	(8,924)	
Change in fair value of derivative liabilities, preferred shares and other financial assets	(139,838)	-	-	(139,838)	
Foreign exchange gain	-	(553)	-	(553)	
Other non-operating (income) expense, net	820	(997)	-	(177)	
Impairment of property, plant and equipment	-	2,250	(2,250)	-	*3 (e)*
Impairment of intangible assets and goodwill	-	-	-	-	
Total other (income) expense	**$ (136,677)**	**$ (1,104)**	**$ 16,223**	**$ (121,558)**	
Income (loss) before income taxes	**$ 122,996**	**$ (25,320)**	**$ (25,980)**	**$ 71,696**	
INCOME TAX (RECOVERY) EXPENSE					
Current	$ (34)	$ 2,309	$ -	$ 2,275	*3 (d)*
Deferred, net	(1,556)	(2,345)	-	(3,901)	*3 (d)*
Total income tax (recovery) expense	**$ (1,590)**	**$ (36)**	**$ -**	**$ (1,626)**	
Net income (loss) from continuing operations	**$ 124,586**	**$ (25,284)**	**$ (25,980)**	**$ 73,322**	
Net loss from discontinued operations, net of tax	-	(41,799)	-	(41,799)	
NET INCOME (LOSS)	**$ 124,586**	**$ (67,083)**	**$ (25,980)**	**$ 31,523**	

See accompanying notes to unaudited Pro Forma Condensed Consolidated Financial Statements

ORGANIGRAM GLOBAL INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS AND OTHER COMPREHENSIVE (LOSS) INCOME

For the nine months ended June 30, 2026

(Expressed in CDN $000's except share and per share amounts)

	Organigram Global Inc. for the nine months ended June 30, 2026	Aurora Cannabis Inc. for the nine months ended June 30, 2026	Pro forma adjustments	Pro forma combined	Note
OTHER COMPREHENSIVE INCOME (LOSS)					
Change in fair value of investments at fair value through other comprehensive income (loss)	$ (1,238)	$ -	$ -	$ (1,238)	
Foreign currency transaction (loss) gain	(663)	2,273	-	1,610	
Cash flow hedge reserve	(198)	-	-	(198)	
Total other comprehensive income (loss)	**$ (2,099)**	**$ 2,273**	**$ -**	**$ 174**	
Comprehensive loss from continuing operations	$ 122,487	$ (23,011)	$ (25,980)	$ 73,496	
Comprehensive loss from discontinued operations	-	(41,799)	-	(41,799)	
COMPREHENSIVE INCOME (LOSS)	**$ 122,487**	**$ (64,810)**	**$ (25,980)**	**$ 31,697**	
Net income (loss) from continuing operations attributable to:					
Common shareholders	$ 124,586	$ (25,284)	$ (25,980)	$ 73,322	
Non-controlling interests	-	-	-	-	
	$ 124,586	**$ (25,284)**	**$ (25,980)**	**$ 73,322**	
Net income (loss) from discontinued operations attributable to:					
Common shareholders	$ -	$ (33,826)	$ -	$ (33,826)	
Non-controlling interests	-	(7,973)	-	(7,973)	
	$ -	**$ (41,799)**	**$ -**	**$ (41,799)**	
Comprehensive income (loss) attributable to:					
Common shareholders	$ 122,487	$ (56,837)	$ (25,980)	$ 39,670	
Non-controlling interests	-	(7,973)	-	(7,973)	
	$ 122,487	**$ (64,810)**	**$ (25,980)**	**$ 31,697**	
Net income (loss) per common share, basic					
Continuing operations				$ 0.17	
Discontinued operations				$ (0.08)	
Total operations				**$ 0.09**	
Net income (loss) per common share, diluted					
Continuing operations				$ 0.15	
Discontinued operations				$ (0.07)	
Total operations				**$ 0.08**	

See accompanying notes to unaudited Pro Forma Condensed Consolidated Financial Statements

1. DESCRIPTION OF THE ARRANGEMENT

These Pro Forma Financial Statements (as defined below) of Organigram Global Inc. (the "Company" or "Organigram") have been prepared by management of the Company for the purpose of inclusion in a joint management information circular of the Company and Aurora Cannabis Inc. ("Aurora") dated November 20, 2026 (the "Circular") in connection with the Arrangement (as defined below).

On November 2, 2026, the Company entered into an arrangement agreement (the "Arrangement Agreement") with Aurora, pursuant to which the Company agreed to acquire all of the issued and outstanding common shares of Aurora (each, an "Aurora Share") for a combination of cash and common shares of the Company (the "Arrangement").

Under the terms of the Arrangement Agreement, Aurora shareholders will have the option to elect to receive:
i) C$7.80 per Aurora Share in cash (the "Cash Alternative");
ii) 5.8626 common shares in the capital of Organigram (the "Organigram Shares") per Aurora Share (the "Share Alternative"); or
iii) a combination of C$3.75 in cash plus 3.0431 Organigram Shares (the "Combination Alternative"), in each case per Aurora Share (collectively, the "Consideration").

Aurora shareholders electing to receive the Cash Alternative or the Share Alternative will be subject to proration as set out in the Arrangement Agreement so that the aggregate consideration will not exceed C$3.75 in cash and 3.0431 Organigram Shares multiplied by the number of Aurora Shares outstanding immediately prior to Closing.

The date on which the Arrangement is completed is referred to herein as the "Closing Date" or "Closing".

Completion of the Arrangement is subject to the requisite approvals of Aurora shareholders and Organigram shareholders, court and regulatory approvals, including approval of the Toronto Stock Exchange (the "TSX"), and the satisfaction of certain other customary closing conditions.

Sources of Cash

Cash consideration payable to Aurora shareholders will be funded through a combination of cash on hand, a drawdown of $20,000 under the existing revolving facility with ATB Financial and a drawdown of $115,000 under the expanded Term Facility (as defined below) with ATB Financial (collectively, the "Concurrent Debt Financing").

In addition, the Company will receive proceeds of GBP 99,999,999.82 ($187,512 based on the GBP/CAD exchange rate on November 2, 2026) from the private placement investment by BT DE Investments Inc. ("BAT") (the "BAT Financing") in the form of common shares and/or Non-Voting Class A Convertible Preferred Shares (the "Preferred Shares") as described in Note 3(b).

The Arrangement will be accounted for as a business combination in accordance with IFRS 3, *Business Combinations*, with Organigram identified as the accounting acquirer and Aurora as the accounting acquiree. Accordingly, the identifiable assets acquired and liabilities assumed of Aurora have been preliminarily measured at their estimated acquisition-date fair values for purposes of these Pro Forma Financial Statements. There will be adjustments to the estimated fair values as the purchase price allocation is finalized. These differences may be material.

2. BASIS OF PREPARATION

The unaudited Pro Forma Condensed Consolidated Statement of Financial Position as of June 30, 2026, and the unaudited Pro Forma Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the nine-month period ended June 30, 2026, and year ended September 30, 2025 (collectively, the "Pro Forma Financial Statements") have been prepared by the management of the Company to illustrate the pro forma impact of the Arrangement.

The Pro Forma Financial Statements are based on the historical consolidated financial statements of Organigram and the historical financial statements of Aurora. The pro forma adjustments are limited to the Arrangement reflecting Organigram's acquisition of Aurora, and adjustments related to the Concurrent Debt Financing and the BAT Financing.

The Pro Forma Financial Statements have been prepared in accordance with Canadian securities legislation and based on the principles of IFRS® Accounting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). The Pro Forma Financial Statements are presented in Canadian Dollars ("CAD"), the presentation currency of Organigram.

The unaudited Pro Forma Condensed Consolidated Statement of Financial Position gives effect to the Arrangement, Concurrent Debt Financing and BAT Financing as if they had occurred on June 30, 2026, as described in Note 3. The unaudited Pro Forma Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the nine months ended June 30, 2026, and year ended September 30, 2025, give effect to the Arrangement, Concurrent Debt Financing, BAT Financing and related activities as if they had occurred on October 1, 2025 and October 1, 2024, respectively.

These Pro Forma Financial Statements have been prepared from information derived from, and should be read in conjunction with, the following financial statements:

i) the unaudited interim consolidated financial statements of Organigram Global Inc. for the nine months ended June 30, 2026, and audited consolidated financial statements for the year ended September 30, 2025.
ii) the unaudited condensed interim financial statements of Aurora Cannabis Inc. for the three months ended June 30, 2026, and six months ended September 30, 2025 and September 30, 2024, and the audited financial statements for the years ended March 31, 2026 and March 31, 2025.

As Organigram's financial year-end and Aurora's financial year-end differ by more than 93 days, the historical financial information of Aurora has been adjusted in accordance with National Instrument 51-102 to conform to Organigram's reporting periods. For the twelve months ended September 30, 2025, the Pro Forma Financial Statements add the six-month period ended September 30, 2025 to, and subtract the six-month period ended September 30, 2024 from, the March 2025 fiscal year-end financial statements of Aurora. For the nine months ended June 30, 2026, the Pro Forma Financial Statements subtract the six-month period ended September 30, 2025 from, and add the three-month period ended June 30, 2026 to, the March 2026 fiscal year-end financial statements of Aurora.

The pro forma financial information was prepared for the purpose of the Pro Forma Financial Statements and does not conform to the financial statements for the business included elsewhere in the Circular.

The assumptions and estimates underlying the adjustments to the Pro Forma Financial Statements are described in the accompanying notes.

The adjustments to the Pro Forma Financial Statements are estimates and have been made solely for the purpose of presenting the Pro Forma Financial Statements, which are necessary to comply with applicable securities and reporting requirements.

The pro forma financial information may not reflect the financial condition or operating results of the consolidated Company or may not be useful in predicting the future condition and operating results of the Company. The Pro Forma

Financial Statements do not necessarily reflect what the consolidated Company's financial condition or results of operations would have been had the Arrangement, Concurrent Debt Financing and BAT Financing occurred on the dates indicated. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. It is management's opinion that the Pro Forma Financial Statements contain all adjustments necessary for the fair presentation of the Arrangement, Concurrent Debt Financing and BAT Financing in all material respects.

3. PRO FORMA ASSUMPTIONS AND FINANCIAL STATEMENT ADJUSTMENTS

The pro forma adjustments to the Pro Forma Financial Statements have been prepared based on the following assumptions:

a) Concurrent Debt Financing

In connection with the Arrangement, the Company entered into a commitment letter with ATB Financial ("ATB"). ATB has committed to increase its senior secured credit facilities from $70,000 to $210,000. The revolving facility will increase from $40,000 to $65,000 and the non-revolving term facility (the "Term Facility") from $20,000 to $135,000. The existing $10,000 revolving operating facility remains unchanged.

ATB's obligation to fund on Closing is subject only to a limited set of conditions, including: execution of the amended and restated credit agreement and delivery of the required security, in some cases in escrow pending completion of the Arrangement; receipt of the Final Order (as defined in the Circular); and evidence that cash proceeds of not less than the Canadian dollar equivalent of GBP 100,000,000 under the BAT Financing have been or will be received substantially concurrently with Closing.

New ATB Term Facility

The additional $115,000 available under the Term Facility is expected to be fully drawn on Closing to fund the Arrangement. The Term Facility will bear interest at the Canadian Overnight Repo Rate Average ("CORRA") plus an applicable margin of 2.75% to 3.75%, based on the Company's net funded debt to earnings before interest, taxes, depreciation and amortization ("EBITDA") ratio, plus a credit spread adjustment of 0.29547% for 1-month CORRA loans and 0.32138% for 3-month CORRA loans. The rate increases by 2.00% upon an event of default. For the Pro Forma Financial Statements, interest has been calculated at 5.56% per annum. The Term Facility will mature three years from Closing. Quarterly principal instalments of $6,750 are expected from the end of the first full fiscal quarter following Closing, with a bullet payment at maturity. The Company expects to incur directly attributable transaction costs of $2,888, consisting primarily of advisory and underwriting fees, lender commitment fees, legal fees and property appraisal fees. These amounts have been treated as debt issuance costs and will be amortized using the effective interest method.

Existing ATB Revolving Facility

In addition, the Company expects to draw up to $20,000 under the revolving facility, which may, subject to certain conditions, be used to partially finance the Arrangement. For pro forma purposes, interest has been calculated at 5.56% per annum, and the drawdown has a term of three years. The revolving facility has no scheduled amortization and is not repayable on demand; any amounts outstanding under this facility are due in full at the maturity date. The Company expects to incur directly attributable transaction costs of $503, consisting of advisory fees, lender commitment fees, legal fees and property appraisal fees, which are treated as debt issuance costs and amortized using the effective interest method. The amendment to the existing ATB revolving credit facility was accounted for as a non-substantial modification, with no gain or loss recognized on modification.

Estimated net proceeds	New ATB Term Facility (000s)	Existing ATB Revolving Facility (000s)	Total (000s)
Estimated debt issuance	$115,000	$20,000	$135,000
Estimated transaction expenses	$(2,888)	$(503)	$(3,391)
Estimated net proceeds	$112,112	$19,497	$131,609

The unaudited Pro Forma Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income are adjusted to increase interest expense for the Concurrent Debt Financing. The following table summarizes the changes in interest expense on the unaudited Pro Forma Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income.

	New ATB Term Facility (000s)	Existing ATB Revolving Facility (000s)	Pro Forma Adjustment (000s)
For the nine months ended June 30, 2026	$5,469	$948	$6,417
For the year ended September 30, 2025	$7,087	$1,269	$8,356

b) BAT Financing

In connection with the Arrangement, BAT, a wholly owned indirect subsidiary of British American Tabacco plc, has agreed to subscribe for an aggregate of 140,986,255 shares of the Company at a price of GBP 0.709289 (C$1.33 based on the GBP/CAD exchange rate on November 2, 2026) per share by way of the BAT Financing, for aggregate gross proceeds of GBP 99,999,999.82 ($187,512 based on the GBP/CAD exchange rate on November 2, 2026). To the extent the issuance of common shares would result in BAT's ownership exceeding 30% of the issued and outstanding common shares of the Company, BAT will receive Preferred Shares in lieu of common shares.

For the purposes of the Pro Forma Financial Statements, the Company is assumed to issue 85,891,159 common shares and 55,095,096 Non-Voting Class A Convertible Preferred Shares, each at $1.33 per share (being the CAD equivalent of GBP 0.709289 per share based on the GBP/CAD exchange rate on November 2, 2026, the fixed price under the subscription agreement dated November 2, 2026). The subscription proceeds are denominated in British pounds sterling and are GBP 99,999,999.82 ($187,512), which has been translated into Canadian dollars at a GBP/CAD exchange rate of 1:1.87512, being the exchange rate on November 2, 2026, which subscription proceeds are fixed under the subscription agreement.

The Preferred Shares are eligible for conversion into Organigram Shares at BAT's option, provided that such conversion would not result in BAT's voting interest in the Company exceeding 30%. Each Preferred Share is economically equivalent to an Organigram Share and is convertible into Organigram Shares without payment of any additional consideration. The initial conversion ratio is one-for-one, and this ratio increases at a rate of 7.5% per annum, compounded annually, until such time as the Preferred Shares are converted into Organigram Shares or the aggregate equity interest of BAT in the Company (inclusive of both the Organigram Shares and Preferred Shares as if converted into Organigram Shares) reaches 49%. The Preferred Shares are not entitled to vote until they are converted into Organigram Shares. BAT is required to periodically convert Preferred Shares to the extent that its holding of the Organigram Shares falls below 30%. As the number of Organigram Shares to be issued upon conversion is not fixed, the Preferred Shares are classified as financial liabilities under IFRS 9, *Financial Instruments* and are measured at Fair Value Through Profit or Loss ("FVTPL"). Although the conversion feature represents an embedded derivative that would qualify for bifurcation, the Company has elected to measure the entire instrument at FVTPL as permitted by IFRS 9.

The net proceeds will partially fund the cash consideration payable to Aurora shareholders and certain transaction expenses. Estimated transaction costs of $366 directly attributable to the BAT Financing have been recorded as a reduction of share capital.

The estimated transaction costs of $234 allocated to the Preferred Shares have been expensed in the unaudited Pro Forma Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the nine months ended June 30, 2026 and the year ended September 30, 2025.

The net proceeds expected to be received after transaction costs are estimated to be $186,912.

c) Arrangement Agreement

Under the Arrangement Agreement, the Company will acquire 100% of the issued and outstanding common shares of Aurora. For purposes of the Pro Forma Financial Statements, Aurora's 65,748,913 common shares issued and outstanding as of November 19, 2026, were used to estimate the number of shares acquired. Accordingly, the number of Aurora Shares, Organigram Shares issuable, Aurora incentive awards and replacement options used in these Pro Forma Financial Statements may differ from the current figures presented elsewhere in the Circular.

For purposes of these Pro Forma Financial Statements, the Company has assumed that Aurora shareholders will receive 3.0431 common shares of the Company for each Aurora Share held, resulting in the issuance of an aggregate of 200,080,517 common shares of the Company. For purposes of these Pro Forma Financial Statements, the fair value of the Organigram Shares expected to be issued has been estimated based on the 20-day volume-weighted average trading price of Organigram Shares on the TSX of approximately C$1.33 on November 2, 2026, the day on which the Arrangement Agreement was executed, resulting in estimated share consideration of $266,107. As the Arrangement will occur on the Closing Date, the quoted market price of the shares on the Closing Date may differ materially from the amount used in these Pro Forma Financial Statements.

For purposes of these Pro Forma Financial Statements, the Company has also assumed that Aurora shareholders will receive cash consideration of C$3.75 for each Aurora Share held, resulting in an estimated aggregate cash consideration of $246,558.

Aurora RSUs, DSUs and PSUs

Under the Arrangement, each Aurora RSU and Aurora DSU (whether vested or unvested) outstanding immediately prior to the Closing will be cancelled in exchange for a cash payment from Aurora of C$7.80 per underlying Aurora Share (in the case of Aurora DSUs, immediately after the holder ceases to be a director of Aurora). Each vested Aurora PSU will be cancelled in exchange for a cash payment of C$7.80 per underlying Aurora Share, assuming a performance multiplier of 100%. Each unvested Aurora PSU will remain outstanding and entitle the holder to the same cash payment on its entitlement date, subject to the applicable vesting conditions.

The cash settlement of Aurora RSUs, DSUs and PSUs at C$7.80 per underlying share has been allocated between amounts attributable to pre-combination and post-combination service. The portion attributable to pre-combination service has been included in consideration transferred, while the portion attributable to post-combination service will be recognized as share-based compensation expense. As the unvested RSUs will be cash-settled at Closing pursuant to the Plan of Arrangement (as defined in the Circular), the related post-combination compensation expense of $8,007 has been reflected in the unaudited Pro Forma Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the nine months ended June 30, 2026 and the year ended September 30, 2025. The portion attributable to post-combination service for PSUs will be recognized as share-based compensation expense over the remaining vesting period. The number of awards outstanding is based on the Circular dated November 20, 2026.

The following table summarizes the estimated cash settlement of Aurora's outstanding awards and the allocation between consideration transferred and post-combination compensation expense.

	Number of awards	Total Cash settlement (000s)	Estimated Post-Combination Services (000s)	Consideration (000s)
Aurora RSUs	1,552,145	12,107	8,007	4,100
Aurora DSUs	358,867	2,799	-	2,799
Aurora PSUs	2,277,672	17,766	11,450	6,316
Total awards	**4,188,684**	**32,672**	**19,457**	**13,215**

Aurora Stock Options:

Under the Arrangement, each Aurora stock option outstanding immediately prior to Closing will be exchanged for a replacement stock option to acquire Organigram Shares, based on the Option Exchange Ratio (as defined in the Circular) of C$7.80 divided by C$1.33 (5.8647). The exercise price is adjusted by the same ratio, and the expiry and vesting terms are unchanged.

The fair value of the estimated 12,987,407 replacement options expected to be issued was estimated using the Black-Scholes option pricing model in accordance with IFRS 2, *Share-based Payment*. Key valuation assumptions included a share price of C$1.33, expected volatility of 85.53% and a risk-free interest rate of 2.86%. The resulting fair value was allocated between pre-combination and post-combination service. The portion attributable to pre-combination service of $9,156 has been included in consideration transferred, with a corresponding increase to contributed surplus. The portion attributable to post-combination service will be recognized as share-based compensation expense over the remaining vesting period.

Consideration consists of the following components:

	Amount (000s)
Cash consideration to shareholders	$246,558
Fair value of shares issued	$266,107
Cash settlement of RSUs, DSUs and PSUs	$13,215
Fair value of replacement stock options attributable to pre-combination services	$9,156
Fair value of consideration	**$535,036**
Estimated value of identifiable net assets	$(442,320)
Intangible assets and Goodwill	**$92,716**

This Purchase Price Allocation (“PPA”) is preliminary and will be finalized when the valuation analysis is complete.

The following pro forma adjustments reflect the adjustments related to the Arrangement:

Cash and cash equivalents

The unaudited Pro Forma Condensed Consolidated Statement of Financial Position reflects the use of cash of $259,773 to complete the acquisition, comprising cash consideration payable to Aurora shareholders and the cash settlement of Aurora’s awards. The unaudited Pro Forma Condensed Consolidated Statement of Financial Position also reflects the use of cash relating to $11,822 of transaction costs relating to the Arrangement.

Intangible assets and Goodwill

The unaudited Pro Forma Condensed Consolidated Statement of Financial Position reflects the pro forma adjustment eliminating the historical intangible assets and goodwill of Aurora of $32,731 and $27,342, respectively. It also reflects an increase of $92,716 in intangible assets and goodwill arising from the preliminary purchase price allocation.

Total shareholders’ equity

The unaudited Pro Forma Condensed Consolidated Statement of Financial Position reflects changes in equity to eliminate historical share capital, contributed surplus, accumulated other comprehensive loss and accumulated deficit of Aurora. Total new share capital of $266,107 has been adjusted to record the additional 200,080,517 common shares issued.

Additionally, contributed surplus includes the fair value of replacement stock options attributable to pre-combination services amounting to $9,156.

Derivative liability

Aurora's existing derivative liability of $1,300 related to cash-settled DSUs has been reversed in the unaudited Pro Forma Condensed Consolidated Statement of Financial Position because the DSUs are settled through the pro forma adjustments described above.

Transaction costs

The estimated Organigram transaction costs for the Arrangement of $11,822 have been expensed in the unaudited Pro Forma Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the nine months ended June 30, 2026 and the year ended September 30, 2025.

The estimated Aurora transaction costs for the Arrangement of $26,038 are added as a pro forma adjustment to accounts payable and accrued liabilities and the corresponding impact is reflected in goodwill and intangible assets in the unaudited Pro Forma Condensed Consolidated Statement of Financial Position.

Share-based compensation costs

The historical share-based compensation expense related to Aurora RSUs and DSUs of $500 and $5,900 has been removed from the unaudited Pro Forma Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the nine months ended June 30, 2026, and the year ended September 30, 2025, respectively. As the Arrangement is assumed to have occurred at the beginning of each period presented, the historical RSUs and DSUs are assumed to have been cash settled at that time and, accordingly, the related historical share-based compensation expense would not have been incurred.

As the unvested RSUs will be cash settled at Closing pursuant to the Plan of Arrangement, the related post-combination compensation expense of $8,007 has been included in the unaudited Pro Forma Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the nine months ended June 30, 2026, and the year ended September 30, 2025.

d) Tax effect on pro forma adjustments

The pro forma adjustments are not expected to change the taxable income positions of the respective entities and, accordingly, no income tax adjustment has been reflected in the Pro Forma Financial Statements.

e) Reclassification

Certain accounts in Aurora's financial statements were reclassified or combined in these Pro Forma Financial Statements to conform with Organigram's financial statement presentation as follows:

i) Deferred revenue and lease liabilities – current portion in the amounts of $799 and $5,875, respectively, were reclassified to Provisions and other current liabilities.

ii) Lease liabilities (long-term) in the amount of $16,809 was reclassified to Other long-term liabilities.

iii) Depreciation and amortization in the amounts of $3,165 and $2,605 for the year ended September 30, 2025, and for the nine months ended June 30, 2026, respectively, were reclassified to General and administrative expenses.

iv) Impairment of property, plant and equipment in the amounts of $1,092 and $2,250 for the year ended September 30, 2025, and for the nine months ended June 30, 2026, respectively, were reclassified from Other (income) expense to Operating expenses.

v) Impairment of intangible assets and goodwill in the amount of $13,186 for the year ended September 30, 2025, was reclassified from Other (income) expense to Operating expenses.

f) Classification of Preferred Shares

The Pro Forma Statement of Financial Position presents the Preferred Shares as a non-current liability, consistent with the Company's June 30, 2026, interim financial statements. The Company has since determined that, under IAS 1, the Preferred Shares should be classified as current, as it did not have the right, as of September 30, 2025, to defer settlement through conversion for at least twelve months. The Company has concluded that this classification change is not material to previously issued financial statements. In its audited financial statements for the year ended September 30, 2026, the Company will present the Preferred Shares as current and revise the September 30, 2025, comparative to reclassify $68.7 million from non-current to current liabilities. The reclassification does not affect the carrying amount of the Preferred Shares, total liabilities, equity, net income (loss) or cash flows.

4. Share Capital

The following table presents the number of Company shares used in calculating pro forma basic and diluted earnings per share for the nine months period ended June 30, 2026:

	Number of shares (Basic)	Number of shares (Diluted)
Organigram's weighted average shares as of June 30, 2026	136,890,284	138,563,856
Shares issued to Aurora shareholders on acquisition as described in Note 3 (c)	200,080,517	200,080,517
Common shares issued pursuant to the BAT Financing	85,891,159	85,891,159
Preferred shares converted to common shares	-	55,095,096
Common shares issuable upon exercise of replacement options	-	12,987,407
	422,861,960	**492,618,035**

The following table presents the number of Company shares used in calculating pro forma basic and diluted earnings per share for the year ended September 30, 2025. As the Company is in a net loss position for the pro forma year ended September 30, 2025, potential common shares are anti-dilutive and, accordingly, basic and diluted earnings per share are the same.

	Number of shares (Basic and Diluted)
Organigram's weighted average shares as of September 30, 2025	127,674,167
Shares issued to Aurora shareholders on acquisition as described in Note 3 (c)	200,080,517
Common shares issued pursuant to the BAT Financing	85,891,159
Preferred shares converted to common shares	-
Common shares issuable upon exercise of replacement options	-
	413,645,843

APPENDIX "I"
INFORMATION CONCERNING AURORA CANNABIS INC.

Notice to Reader

Unless the context indicates otherwise, capitalized terms which are used in this Appendix "I" – "*Information Concerning Aurora Cannabis Inc.*" and not otherwise defined in this Appendix "I" have the respective meanings given to such terms under the heading "*Glossary of Terms*" in this Joint Information Circular.

In Appendix "I" – "*Information Concerning Aurora Cannabis Inc.*", references to "we", "our" or "us" refer to Aurora; and, unless otherwise indicated, references to officer titles or board positions and roles are only intended to refer to the officers of Aurora holding such offices and the roles and positions of the members of the Aurora Board.

Forward-Looking Statements

Certain statements contained in this Appendix "I", and in certain documents incorporated by reference in this Appendix "I", constitute forward-looking statements or information (collectively, "**forward-looking statements**") within the meaning of applicable Canadian Securities Laws. Such forward-looking statements relate to future events or Aurora's future performance. See "*Forward-Looking Statements and Information*" in this Joint Information Circular. Readers should also carefully consider the matters and cautionary statements discussed under the heading "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement*" in the Joint Information Circular and under the heading "*Risk Factors*" in this Appendix "I", the Aurora AIF and the Aurora Annual MD&A.

Documents Incorporated by Reference

Information has been incorporated by reference in this Joint Information Circular, including this Appendix "I", from documents filed with securities commissions or similar authorities in Canada. Copies of the documents incorporated in this Joint Information Circular by reference may be obtained on request without charge from Aurora by mail at 2207-90B Street SW, Edmonton, Alberta T6X 0J9 or by email at ir@auroramj.com, and are also available electronically on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

The following documents of Aurora have been filed with the various securities commissions or similar authorities in each of the provinces of Canada and are specifically incorporated by reference in and form an integral part of this Joint Information Circular:

(a) the Aurora AIF;

(b) the Aurora Annual Financial Statements;

(c) the Aurora Annual MD&A;

(d) the Aurora Interim Financial Statements;

(e) the Aurora Interim MD&A;

(f) the material change report of Aurora dated April 16, 2026 relating to the indirect acquisition by a wholly owned subsidiary of Aurora of all of the shares of 9869247 Canada Limited (Safari Flower Company);

(g) the material change report of Aurora dated November 3, 2026 relating to the execution of the Arrangement Agreement;

(h) the Arrangement Agreement;

(i) the management information circular of Aurora dated June 24, 2026 relating to the annual general meeting of Aurora Shareholders held on August 7, 2026 (the "**Aurora AGM Circular**"); and

(j) the directors' circular of Aurora dated September 1, 2026 in response to the Original Curaleaf Bid, as supplemented by the notices of change to directors' circular of Aurora dated October 14, 2026 and November 3, 2026.

Any documents of the type required by National Instrument 44-101 – *Short Form Prospectus Distributions* to be incorporated by reference in a short form prospectus, including any material change reports (excluding confidential reports), comparative interim financial statements, comparative annual financial statements and the auditor's report thereon, managements discussion and analysis of financial condition and results of operations, information circulars, annual information forms, marketing materials and business acquisition reports filed by Aurora with the securities commissions or similar authorities in Canada subsequent to the date of this Joint Information Circular and before the Effective Date, are deemed to be incorporated by reference in this Joint Information Circular including this Appendix "I".

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Joint Information Circular to the extent that a statement contained herein or in any other subsequently filed document which also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. The modifying or superseding statement need not state that it has modified or superseded a prior statement or include any other information set forth in the document that it modifies or supersedes. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation, an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Joint Information Circular.

General

Aurora was incorporated under the BCBCA on December 21, 2006 under the name "Milk Capital Corp." and changed its name to "Aurora Cannabis Inc." effective October 2, 2014.

Aurora's principal strategic business lines are focused on the production, distribution and sale of cannabis products in Canada and internationally. Aurora currently conducts the following key business activities: (a) the production, distribution and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; (b) the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and (c) the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Aurora's current principal medical markets are Canada, Germany, the United Kingdom, Poland and Australia. For a description of the business and operations of Aurora, see "*Description of the Business*" in the Aurora AIF, which is incorporated by reference herein.

The Aurora Common Shares are listed on the TSX and Nasdaq under the symbol "ACB" and are quoted on the open market of the Frankfurt Stock Exchange under the symbol "21P". Aurora is a reporting issuer in each of the provinces of Canada.

The head office of Aurora is located at 2207-90B Street SW, Edmonton, Alberta T6X 0J9 and its registered office is located at Suite 1700, 666 Burrard Street, Vancouver, British Columbia V6C 2X8.

Intercorporate Relationships

For a description of the intercorporate relationships of Aurora, including its material subsidiaries, see "*Corporate Structure – Intercorporate Relationships*" in the Aurora AIF, which is incorporated by reference in this Joint Information Circular.

Directors, Executive Officers, Compensation and Corporate Governance

Information regarding the directors and executive officers of Aurora, executive and director compensation, indebtedness of directors and executive officers, the audit committee of the Aurora Board and Aurora's corporate governance practices is contained under the headings "*Directors and Officers*" and "*Audit Committee*" in the Aurora AIF and under the headings "*Compensation Discussion & Analysis*", "*Statement of Executive Compensation*", "*Director Compensation – Non-Executive Directors*", "*Statement of Corporate Governance*" and "*General Matters – Indebtedness of Directors and Officers*" in the Aurora AGM Circular, each of which is incorporated by reference in this Joint Information Circular.

Consolidated Capitalization

There have been no material changes in the share and loan capital of Aurora on a consolidated basis since September 30, 2026. As at September 30, 2026, Aurora had no loans or borrowings outstanding, its lease liabilities totalled approximately $21.4 million (of which approximately $6.1 million was the current portion) and its total shareholders' equity was approximately $518.4 million. See the Aurora Interim Financial Statements and the Aurora Interim MD&A incorporated by reference in this Joint Information Circular for additional information with respect to Aurora's consolidated capitalization.

Description of Share Capital

Aurora is authorized to issue an unlimited number of Aurora Common Shares without par value, an unlimited number of Class A shares with a par value of $1.00 each, and an unlimited number of Class B shares with a par value of $5.00 each. As of November 19, 2026, there were 65,748,913 Aurora Common Shares issued and outstanding and no Class A shares or Class B shares issued and outstanding. As of such date, there were outstanding 2,214,519 Aurora Options, 1,537,786 Aurora RSUs, 28,555 Aurora DSUs and 494,897 Aurora PSUs, in each case settled in Aurora Common Shares, as well as 14,359 cash-settled restricted share units, 1,782,775 cash-settled performance share units and 330,312 cash-settled deferred share units of Aurora. Aurora has no outstanding share purchase warrants. As at the Aurora Record Date, there were 65,748,913 Aurora Common Shares issued and outstanding.

For a description of the Aurora Common Shares, the Class A shares and the Class B shares, see "*Description of Capital Structure*" in the Aurora AIF, which is incorporated by reference in this Joint Information Circular.

Dividends and Distributions

Aurora has not declared or paid any cash dividends on any of its issued shares since its inception. Other than requirements imposed under applicable corporate law, there are no restrictions on Aurora's ability to pay dividends under its constating documents. Aurora does not currently have a dividend or distribution policy and does not anticipate paying dividends on the Aurora Common Shares for the foreseeable future. Pursuant to the Arrangement Agreement, Aurora has agreed not to declare, set aside or pay any dividend or other distribution (whether in cash, stock or property or any combination thereof) prior to the earlier of the Effective Time and the termination of the Arrangement Agreement without the prior written consent of Organigram (such consent not to be unreasonably withheld, conditioned or delayed).

Prior Sales

During the 12-month period prior to the date of this Joint Information Circular, Aurora has issued the following Aurora Common Shares and securities convertible into Aurora Common Shares:

Date of Distribution	Type of Security / Nature of Issuance	Number of Securities Issued	Price per Security ($)	Aggregate Proceeds ($)
February 10, 2026 – August 18, 2026	Aurora Common Shares – issued under the ATM Program[(1)]	6,140,309	4.52 (weighted average)[(2)]	27,871,000 (gross)
April 14, 2026	Aurora Common Shares – issued as partial consideration for the acquisition of Safari Flower Company[(3)]	2,417,180	4.81 (deemed)	11,627,000 (deemed, non-cash proceeds)
November 19, 2025 – November 19, 2026	Aurora Common Shares – issued on settlement of vested Aurora RSUs, Aurora PSUs and Aurora DSUs[(5)]	484,583	Nil	Nil
June 18, 2026	Aurora Options[(6)]	369,370	4.22 (exercise price)	N/A
June 18, 2026	Aurora RSUs[(7)]	1,043,203	—	N/A
June 18, 2026	Aurora PSUs[(7)]	313,963	—	N/A

Notes:

(1) Issued under the ATM Program at prevailing market prices on the TSX and Nasdaq. The price shown is the weighted average price at which the Aurora Common Shares were sold and the aggregate proceeds are gross proceeds before commissions and expenses. The last sale under the ATM Program settled on August 18, 2026 and no further Aurora Common Shares have been issued under the ATM Program since that date.

(2) The average U.S. dollar to Canadian dollar exchange rate for the period from February 10, 2026 to August 18, 2026 of $1.39, as published by the Bank of Canada, was applied to convert the applicable amounts from U.S. dollars to Canadian dollars.

(3) Issued on April 14, 2026 as partial consideration for the acquisition of 9869247 Canada Limited (Safari Flower Company) at a deemed price of $4.81 per Aurora Common Share.

(4) Issued on the exercise of Aurora Options granted under the Aurora Stock Option Plan. The price shown is the weighted average exercise price of the Aurora Options exercised.

(5) Issued on the settlement of vested Aurora RSUs, Aurora PSUs and Aurora DSUs that were settleable in Aurora Common Shares under the Aurora RSU Share Plan, the Aurora PSU Share Plan and the Aurora DSU Share Plan. No amount is payable to Aurora on the settlement of such awards. Awards that are settleable only in cash under the Aurora DSU Cash Plan and the Aurora PRSU Cash Plan are not securities convertible into Aurora Common Shares and are not included in the table.

(6) Granted under the Aurora Stock Option Plan. Each Aurora Option is exercisable for one Aurora Common Share at the exercise price shown.

(7) Granted under the Aurora RSU Share Plan and the Aurora PSU Share Plan, respectively. Each Aurora RSU and Aurora PSU entitles the holder, on vesting, to one Aurora Common Share (or, in the case of Aurora PSUs, the number of Aurora Common Shares determined by the applicable performance multiplier) or, at Aurora's election, a cash payment in lieu, in accordance with the terms of the applicable plan. No amount is payable to Aurora on the settlement of Aurora RSUs or Aurora PSUs.

Price Range and Trading Volumes

The Aurora Common Shares are listed and trade on the TSX and Nasdaq under the symbol "ACB". The following tables set forth the price range and trading volume of the Aurora Common Shares on the TSX and Nasdaq for the periods indicated.

TSX

Period	High Trading Price ($)	Low Trading Price ($)	Volume (#)
November 1 – 19, 2026	$7.50	$5.715	10,738,815
October 2026	$6.65	$5.37	6,726,319
September 2026	$6.055	$5.095	6,386,710
August 2026	$5.66	$3.79	12,954,283
July 2026	$4.22	$3.59	6,490,134
June 2026	$5.04	$3.77	10,119,313
May 2026	$5.105	$4.46	6,158,966
April 2026	$5.65	$4.44	10,782,911
March 2026	$5.15	$4.285	5,664,790
February 2026	$5.58	$4.50	8,703,667
January 2026	$6.15	$5.50	9,947,184
December 2025	$8.75	$5.73	16,123,025
November 2025	$7.05	$5.64	8,642,676

Nasdaq

Period	High Trading Price (US$)	Low Trading Price (US$)	Volume (#)
November 1 – 19, 2026	US$5.30	US$4.09	34,417,243
October 2026	US$4.67	US$3.84	22,720,938
September 2026	US$4.30	US$3.68	17,916,283
August 2026	US$4.10	US$2.69	40,059,070
July 2026	US$2.98	US$2.56	25,942,867
June 2026	US$3.65	US$2.73	24,060,131
May 2026	US$3.70	US$3.23	13,464,673
April 2026	US$4.13	US$3.25	32,165,484
March 2026	US$3.77	US$3.07	13,059,279
February 2026	US$4.09	US$3.28	20,215,049
January 2026	US$4.49	US$4.03	21,373,630
December 2025	US$6.36	US$4.17	59,321,009
November 2025	US$5.02	US$3.99	19,605,888

On November 2, 2026, the last trading day prior to the announcement of the Arrangement, the closing price of the Aurora Common Shares on the TSX was $5.89 and on Nasdaq was US$4.22. On November 19, 2026, the last trading day prior to the date of this Joint Information Circular, the closing price of the Aurora Common Shares on the TSX and Nasdaq was $6.14 and US$4.26, respectively.

Risk Factors

An investment in the securities of Aurora is subject to certain risks. Aurora Shareholders should carefully review and consider all other information contained in this Joint Information Circular, including the risk factors described under the heading "*Risk Factors*". In addition, Aurora Shareholders should carefully consider the risk factors and cautionary statements contained in the Aurora AIF and the Aurora Annual MD&A, each of which is incorporated by reference herein. If any of the identified risks were to materialize, Aurora's business, financial position, results and/or future operations may be materially affected.

Legal Proceedings and Regulatory Actions

Aurora is, from time to time, subject to legal proceedings and regulatory actions arising in the ordinary course of its business. For a description of the legal proceedings to which Aurora is a party, see "*Legal Proceedings and Regulatory Actions*" in the Aurora AIF, which is incorporated by reference in this Joint Information Circular. Since the date of the Aurora AIF, on September 14, 2026, Curaleaf applied to the Alberta Securities Commission for an order halting further sales under the ATM Program while the Curaleaf offer remained outstanding; the application was dismissed on October 26, 2026.

Principal Shareholders

To the knowledge of the directors and executive officers of Aurora, as of November 19, 2026, no person or company beneficially owned, or controlled or directed, directly or indirectly, voting securities carrying 10% or more of the voting rights attached to any class of voting securities of Aurora.

Material Contracts

Except for contracts entered into in the ordinary course of business, the only material contracts entered into by Aurora within the most recently completed financial year, or before the most recently completed financial year which are still in effect, are described under "*Material Contracts*" in the Aurora AIF, which is incorporated by reference in this Joint Information Circular.

Since the date of the Aurora AIF, Aurora has entered into the Arrangement Agreement and the Organigram Support Agreements. See "*The Arrangement Agreement*" and "*Effect of the Arrangement – Organigram Support Agreements*".

Auditors, Transfer Agent and Registrar

Ernst & Young LLP are the external auditors of Aurora and have confirmed that they are independent of Aurora within the meaning of the relevant rules and related interpretations prescribed by the relevant professional bodies in Canada and any applicable legislation or regulations, and that they are independent accountants with respect to Aurora under all relevant U.S. professional and regulatory standards.

Computershare Investor Services Inc., at its offices at 510 Burrard Street, 3rd Floor, Vancouver, British Columbia V6C 3B9, is the transfer agent and registrar of the Aurora Common Shares.

Interest of Informed Persons in Material Transactions

Except as otherwise disclosed in this Joint Information Circular, there were no material interests, direct or indirect, of Aurora directors or executive officers, or any person who beneficially owns, directly or indirectly, or exercises control or direction over, more than 10% of the voting rights attached to the Aurora Common Shares, or any other Informed Person (as defined in National Instrument 51-102 – *Continuous Disclosure Obligations*) or any known associate or affiliate of such persons, in any transaction since April 1, 2025, or in any proposed transaction, which has materially affected or would materially affect Aurora or any of its Subsidiaries. See "*Interests of Certain Persons or Companies in the Arrangement – Aurora*" in this Joint Information Circular.

Interest of Experts

Certain Canadian legal matters relating to the Arrangement are to be passed upon by Stikeman Elliott LLP on behalf of Aurora and certain United States legal matters relating to the Arrangement are to be passed upon by Paul, Weiss, Rifkind, Wharton & Garrison LLP on behalf of Aurora. As at the date hereof, the partners and associates of Stikeman Elliott LLP beneficially own, directly or indirectly, less than 1% of the outstanding Aurora Common Shares and less than 1% of the outstanding Organigram Common Shares. Fort Capital and Origin have prepared the Fort Capital Fairness Opinion and the Origin Fairness Opinion, respectively. To the knowledge of Aurora, each of Fort Capital and Origin and their respective designated professionals beneficially own, directly or indirectly, less than 1% of the outstanding securities of each class of Aurora and Organigram.

Additional Information

Additional information relating to Aurora can be found on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Additional financial information is provided in the Aurora Annual Financial Statements, the Aurora Annual MD&A, the Aurora Interim Financial Statements and the Aurora Interim MD&A, which are incorporated by

reference in this Joint Information Circular, including this Appendix "I". See "*Documents Incorporated by Reference*" in this Appendix "I".

Information contained in or otherwise accessible through Aurora's website does not form a part of this Joint Information Circular and is not incorporated by reference in this Joint Information Circular.

APPENDIX "J"
INFORMATION CONCERNING ORGANIGRAM GLOBAL INC.

Notice to Reader

Unless the context indicates otherwise, capitalized terms which are used in this Appendix "J" and not otherwise defined in this Appendix "J" have the meanings given to such terms under the heading "*Glossary of Terms*" in this Joint Information Circular.

Forward-Looking Statements and Information

Certain statements contained in this Appendix "J", and in the documents incorporated by reference in this Appendix "J", constitute forward-looking statements and forward-looking information (collectively, "**forward-looking statements**") within the meaning of applicable securities laws. Such forward-looking statements relate to future events or Organigram's future performance. See "*Forward-Looking Statements and Information*" in this Joint Information Circular. Readers should also carefully consider the matters and cautionary statements discussed under the heading "*Risk Factors*" in this Joint Information Circular, as well as those discussed under the heading "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement*" in the Joint Information Circular and under the heading "*Risk Factors*" in this Appendix "J", the Organigram AIF, the Organigram Annual MD&A and the Organigram Interim MD&A.

Documents Incorporated by Reference

Information in respect of Organigram has been incorporated by reference in this Joint Information Circular, including this Appendix "J", from documents filed with securities commissions or similar authorities in each of the provinces of Canada. Copies of the documents incorporated herein by reference may be obtained on request without charge from the Corporate Secretary of Organigram at 1400-145 King Street West, Toronto, Ontario M5H 1J8, Telephone: 1 (844) 644-4726. In addition, copies of the documents incorporated herein by reference may be obtained by accessing the disclosure documents available under Organigram's profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

The following documents filed by Organigram with the securities commissions or similar authorities in each of the provinces of Canada are specifically incorporated by reference in, and form an integral part of, this Joint Information Circular:

(a) the Organigram AIF;

(b) the Organigram Annual Financial Statements;

(c) the Organigram Annual MD&A;

(d) the Organigram Interim Financial Statements;

(e) the Organigram Interim MD&A;

(f) the Organigram AGM Circular;

(g) the material change report of Organigram dated December 4, 2025 relating to the appointment of James Yamanaka as Chief Executive Officer and the interim appointment of Peter Amirault as Executive Chair;

(h) the material change report of Organigram dated March 2, 2026 relating to the share purchase agreement dated February 18, 2026 to indirectly acquire all of the issued and outstanding shares of Sanity Group GmbH not already owned by Organigram, the related ATB Credit Facilities commitment and the related private placement with BAT;

(i) the material change report of Organigram dated August 31, 2026 relating to the accelerated integration of Sanity Group, the amendment to the Sanity Group share purchase agreement and the appointments of Finn Age Hänsel and Adrian Frenzel;

(j) the material change report of Organigram dated November 12, 2026 relating to the entering into of the Arrangement Agreement, the BAT Equity Commitment and the ATB Commitment Letter;

(k) the Arrangement Agreement; and

(l) the BAT Equity Commitment.

Any documents of the type required by National Instrument 44-101 – *Short Form Prospectus Distributions* to be incorporated by reference in a short form prospectus, including any material change reports (excluding material change reports filed on a confidential basis), interim financial reports, annual financial statements and the auditors' reports thereon, management's discussion and analysis of financial condition and results of operations, information circulars, annual information forms and business acquisition reports filed by Organigram with the securities commissions or similar authorities in each of the provinces of Canada subsequent to the date of this Joint Information Circular and prior to the Effective Time, shall be deemed to be incorporated by reference in this Joint Information Circular. A reference made in the Joint Information Circular, including this Appendix "J", to other documents or to information or documents available on a website, including Organigram's website, does not constitute the incorporation by reference into the Joint Information Circular, including this Appendix "J", of such other documents or such other information or documents available on such website, unless otherwise stated.

Any statement contained in this Joint Information Circular or in a document (or part thereof) incorporated, or deemed to be incorporated, by reference herein, shall be deemed to be modified or superseded, for the purposes of this Joint Information Circular, to the extent that a statement contained herein or in any subsequently filed document (or part thereof) which also is, or is deemed to be, incorporated by reference herein, modifies or supersedes such statement. The modifying or superseding statement need not state that it has modified or superseded a prior statement or include any other information set forth in the document that it modifies or supersedes. The making of a modifying or superseding statement shall not be deemed an admission, for any purposes, that the modified or superseded statement, when made, constituted a misrepresentation, an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make a statement not misleading in light of the circumstances in which it was made. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Joint Information Circular.

General

Organigram was incorporated under the BCBCA on July 5, 2010 as "Inform Resources Corp." and was continued under the *Canada Business Corporations Act* on April 6, 2016. On March 24, 2025, Organigram changed its name from "Organigram Holdings Inc." to "Organigram Global Inc.". Organigram Inc. is a licensed producer of cannabis that operates in the Canadian adult-use and medical cannabis markets and internationally through its international business unit. Organigram's core operations are based in Moncton, New Brunswick, with four additional cannabis facilities in Winnipeg, Manitoba, Lac-Supérieur, Québec, London, Ontario and Aylmer, Ontario. Through its recent acquisition of Sanity Group GmbH, Organigram also participates in the German medical cannabis market and other emerging markets within Europe. The Organigram Common Shares are listed on the TSX and Nasdaq under the symbol "OGI". For a description of the business and operations of Organigram, see "*Description of the Business*" in the Organigram AIF, which is incorporated by reference herein.

Organigram's head office is located at 1400-145 King Street West, Toronto, Ontario M5H 1J8 and its registered office is located at 35 English Drive, Moncton, New Brunswick.

Intercorporate Relationships

Organigram carries on its business principally through its wholly owned subsidiary Organigram Inc., a corporation governed by the *Canada Business Corporations Act* that holds Organigram's Health Canada licences and is the successor to the amalgamations of Organigram Inc. with The Edibles and Infusions Corporation, Laurentian Organic Inc., Motif Labs Ltd. and Collective Project Limited. Organigram Inc. holds all of the shares of Organigram USA Inc., a Delaware corporation. Following completion of the acquisition of Sanity Group, Organigram indirectly owns all of the issued and outstanding shares of Sanity Group GmbH, which in turn owns all of the issued and outstanding shares of Vayamed GmbH.

BAT Private Placement

Concurrently with the execution of the Arrangement Agreement, Organigram entered into a subscription agreement with BAT pursuant to which BAT has agreed to subscribe for Organigram Common Shares and/or Organigram Preferred Shares for aggregate proceeds of £99,999,999.82 (approximately $187.5 million based on the GBP/CAD exchange rate on November 2, 2026), through the issuance of 140,986,255 Organigram Common Shares and/or Organigram Preferred Shares at a price of £0.709289 (approximately $1.33) per share, concurrently with the completion of the Arrangement. See "*Effect of the Arrangement – BAT Equity Commitment*".

Organigram Financing

In connection with the Arrangement, Organigram has obtained a commitment from ATB Financial to amend and restate its existing credit agreement dated April 14, 2026 to provide up to $210,000,000 of senior secured credit facilities, consisting of a $10,000,000 operating facility, a $65,000,000 revolving facility and a $135,000,000 term facility (including a $20,000,000 term tranche previously drawn to fund the acquisition of Sanity Group and a $115,000,000 term tranche to be drawn on closing), with up to $35,000,000 under the revolving facility also available to fund a portion of the cash Consideration once the second term tranche has been drawn in full. "*Effect of the Arrangement – BAT Equity Commitment – ATB Debt Financing*".

Acquisition of Sanity Group

On February 18, 2026, Organigram entered into a share purchase agreement to indirectly acquire all of the issued and outstanding shares of Sanity Group GmbH ("**Sanity Group**") not already owned by Organigram. Organigram completed the acquisition on April 15, 2026 for an upfront purchase price of €107.3 million, consisting of €78.0 million in cash and €29.3 million satisfied through the issuance of 3,146,195 Organigram Common Shares and 12,638,228 Organigram Preferred Shares (the latter issued to BAT). Concurrently with closing, Organigram: (a) completed a private placement with BAT for gross proceeds of $65.2 million through the issuance of 1,152,800 Organigram Common Shares and 22,771,630 Organigram Preferred Shares, including 9,897,356 Organigram Preferred Shares issued on the exercise of BAT's existing top-up rights; (b) entered into a credit agreement with ATB Financial, as administrative agent, and the lenders party thereto providing for $60 million of senior secured credit facilities, consisting of a $10 million operating facility, a $30 million revolving facility and a $20 million term facility (drawn in full on closing to partially fund the acquisition), each maturing on April 15, 2029; (c) entered into a second amended and restated investor rights agreement with BAT; and (d) appointed Max Konrad Narr, a representative of the former Sanity Group shareholders, to the Organigram Board for the earnout period. On August 20, 2026, Organigram announced the accelerated integration of Sanity Group, appointed Finn Age Hänsel as President, Rest of World & Chief Strategy Officer and Adrian Frenzel as Global Chief Operating Officer, and amended the share purchase agreement to replace the performance-based earnout with a fixed earnout equal to 85% of the maximum earnout value, consisting of €20 million in cash and approximately €76.2 million in Organigram Common Shares (priced at the 20-day VWAP on the TSX, subject to a $3.00 floor and $4.00 cap), payable as of April 1, 2027 and to be paid or issued no later than May 1, 2027.

The Arrangement

On November 2, 2026, Organigram entered into the Arrangement Agreement with Aurora, pursuant to which Organigram proposes to acquire all of the issued and outstanding Aurora Common Shares by way of a plan of

arrangement under the BCBCA. For a full description of the Arrangement and the Arrangement Agreement, see "*The Arrangement*" and "*Effect of the Arrangement*" in this Joint Information Circular. Also see "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement*" in this Joint Information Circular and Appendix "I" – "*Information Concerning Aurora Cannabis Inc.*".

Directors, Executive Officers, Compensation and Corporate Governance

Information regarding the directors and executive officers of Organigram, executive and director compensation, indebtedness of directors and executive officers, the audit committee of the Organigram Board and Organigram's corporate governance practices is contained under the headings "*Directors and Executive Officers*" and "*Audit Committee Information*" in the Organigram AIF and under the headings "*Corporate Governance Disclosure*", "*Compensation of Executive Officers*", "*Director Compensation*" and "*Indebtedness of Directors and Executive Officers*" in the Organigram AGM Circular, each of which is incorporated by reference in this Joint Information Circular.

Consolidated Capitalization

There has been no material change in the share and loan capital of Organigram, on a consolidated basis, since June 30, 2026. Between June 30, 2026 and November 2, 2026, the number of outstanding Organigram Common Shares increased from 140,975,357 to 141,114,081, the number of outstanding Organigram Options increased from 2,685,508 to 5,874,925, the number of outstanding Organigram RSUs increased from 3,201,500 to 3,239,623 and the number of outstanding Organigram PSUs decreased from 1,911,107 to 1,829,499, in each case as a result of grants, exercises, settlements and forfeitures under the Organigram Equity Incentive Plan. As at June 30, 2026, Organigram had drawn the $20 million term facility and approximately $2.6 million under the operating facility of its credit facilities with ATB Financial, with approximately $37.4 million remaining undrawn and available. Organigram is also obligated to pay the fixed Sanity Group earnout described under "*Acquisition of Sanity Group*" by May 1, 2027. See the Organigram Interim Financial Statements and Organigram Interim MD&A, which are incorporated by reference in this Joint Information Circular, for more information about Organigram's consolidated capitalization. Also see the table under the heading "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement – Pro Forma Consolidated Capitalization of Organigram*" in this Joint Information Circular for more information about Organigram's consolidated capitalization both before and after giving effect to the Arrangement.

Description of Share Capital

The authorized capital of Organigram consists of an unlimited number of Organigram Common Shares and an unlimited number of preferred shares, issuable in series. As of November 19, 2026, there were 141,114,081 Organigram Common Shares and 49,204,021 Organigram Preferred Shares (all of which are held by BAT) outstanding. As of November 19, 2026, the Organigram Preferred Shares were convertible, in certain circumstances, into 52,773,948 Organigram Common Shares, reflecting accretion at a rate of 7.5% per annum until such time as the holders would beneficially own 49.0% of the outstanding Organigram Common Shares. In addition, as of November 19, 2026, there were outstanding 5,874,925 Organigram Options, 3,239,623 Organigram RSUs, 1,829,499 Organigram PSUs, and 4,450,500 warrants exercisable at an exercise price of $3.65. Under the Amended and Restated IRA, BAT also has a top-up right to subscribe for additional Organigram securities in connection with certain issuances by Organigram that are not subject to BAT's pre-emptive right (including issuances under Organigram's equity incentive plans), exercisable within 30 business days after Organigram delivers a notice following the end of each calendar quarter (or earlier in certain circumstances). Organigram Preferred Shares are issued in place of Organigram Common Shares to the extent required for BAT's holdings not to exceed the 30% threshold set out in the Amended and Restated IRA. As of November 19, 2026, no top-up rights were exercisable by BAT.

The following is a summary of the rights, privileges, restrictions and conditions attaching to the Organigram Common Shares. For a description of the Organigram Preferred Shares, see "*Pro Forma Information Concerning Organigram After Giving Effect to the Arrangement – Description of Share Capital*" in this Joint Information Circular and "*Capital Structure*" in the Organigram AIF, which is incorporated by reference in this Joint Information Circular.

Holders of Organigram Common Shares are entitled to receive notice of and to attend all meetings of Organigram Shareholders and to one vote at each such meeting for each Organigram Common Share held. The holders of

Organigram Common Shares are, at the discretion of the Organigram Board and subject to applicable legal restrictions, entitled to receive any dividends declared by the Organigram Board on the Organigram Common Shares, and are entitled to share in the remaining property of Organigram upon liquidation, dissolution or winding-up, pari passu with the holders of the Organigram Preferred Shares on an as-converted basis.

Dividends

Organigram has no dividend record and has no current intention to declare dividends on the Organigram Common Shares in the foreseeable future. Any decision to pay dividends on the Organigram Common Shares in the future will be at the discretion of the Organigram Board and will depend on, among other things, Organigram's results of operations, current and anticipated cash requirements and surplus, financial condition, contractual restrictions and financing agreement covenants (including under the Organigram Credit Facilities), solvency tests imposed by corporate law and other factors that the Organigram Board may deem relevant. Under the Amended and Restated IRA, Organigram is required to provide BAT with reasonable advance notice of any proposed dividend or other distribution, and the proceeds of the BAT Private Placement may not be used to pay dividends.

Securities Authorized for Issuance under Equity Compensation Plans

The following table sets forth details of Organigram's compensation plans under which equity securities of Organigram are authorized for issuance as at the end of Organigram's most recently completed financial year, being September 30, 2026.

Plan Category	Number of securities to be issued upon exercise or settlement of outstanding Organigram Options, Organigram RSUs, Organigram PSUs and Organigram DSUs	Weighted-average exercise price of outstanding Organigram Options, Organigram RSUs, Organigram PSUs and Organigram DSUs	Number of securities remaining available for future issuance under equity compensation plans[(1)(2)]
Equity compensation plans approved by securityholders	10,929,351	$2.32	3,763,470
Equity compensation plans not approved by securityholders	Nil	Nil	Nil
Total	10,929,351	$2.32	3,763,470

Notes:

(1) Assumes all Organigram Options, Organigram RSUs, Organigram PSUs and Organigram DSUs available for future grants are to be settled for Organigram Common Shares issued from treasury.

(2) Excludes securities reflected in the first column. The 2020 long-term omnibus equity incentive plan forming part of the Organigram Equity Incentive Plan is a rolling "evergreen" plan under which the aggregate number of Organigram Common Shares issuable upon the exercise or settlement of awards may not exceed 10% of the issued and outstanding Organigram Common Shares from time to time, and Organigram Common Shares covered by awards that have been exercised, settled or terminated become available for subsequent grants. No further awards may be granted under the 2017 equity incentive plan or 2011 stock option plan forming part of the Organigram Equity Incentive Plan.

For a description of the material terms of Organigram's equity compensation plans, see "*Equity Incentive Plans*" in the Organigram AGM Circular, which is incorporated by reference in this Joint Information Circular.

Prior Sales

During the 12-month period prior to the date of this Joint Information Circular, Organigram has issued the following Organigram Common Shares and securities convertible into Organigram Common Shares:

Date of Distribution	Type of Security / Nature of Issuance	Number of Securities Issued	Price per Security ($)	Aggregate Proceeds ($)
November 19, 2025, to November 19, 2026	Common Shares – issued on settlement of vested RSUs	523,653	-	-
November 19, 2025, to November 19, 2026	Common Shares – issued on settlement of vested RSUs	87,934	-	-
December 19, 2025	PSUs	728,261	-	-
December 22, 2025	Common Shares – exercise of options	3,350	1.90	6,365.00
January 7, 2026	RSUs	28,542	-	-
January 7, 2027	PSUs	883	-	-
February 23, 2026	Common Shares – Collective Project Limited earnout (first milestone)	1,195,397	1.93	2,307,116.21 (deemed, non-cash proceeds)
April 15, 2026	Common Shares – BAT private placement	1,152,800	3.00	3,458,400
April 15, 2026	Common Shares – consideration for the acquisition of Sanity Group	3,146,195	3.00 (€1.8547)	9,438,585 (deemed, non-cash proceeds)
April 15, 2026	Organigram Preferred Shares – BAT private placement	12,874,274	3.00	38,622,822
April 15, 2026	Organigram Preferred Shares – exercise of BAT top-up rights	9,897,356	2.335854	23,118,778
April 15, 2026	Organigram Preferred Shares – consideration for the acquisition of Sanity Group (issued to BAT)	12,638,229	3.00 (€1.8547)	37,914,687 (deemed, non-cash proceeds)

Date of Distribution	Type of Security / Nature of Issuance	Number of Securities Issued	Price per Security ($)	Aggregate Proceeds ($)
April 7, 2026	Options	750,000	$1.88	-
April 7, 2026	RSUs	304,253	-	-
April 7, 2026	PSUs	66,489	-	-
August 30, 2026	RSUs	233,938	-	-
August 31, 2026	Options	3,500,000	$1.71	-

Price Range and Trading Volumes

The Organigram Common Shares are listed and posted for trading on the TSX and Nasdaq under the symbol "OGI". The following tables set forth the price ranges for and trading volumes of the Organigram Common Shares on the TSX and Nasdaq for the twelve months prior to the date of this Joint Information Circular.

TSX

Period	High Trading Price ($)	Low Trading Price ($)	Volume (#)
November 1 – 19, 2026	$1.365	$0.90	6,425,879
October 2026	$1.45	$1.28	1,409,375
September 2026	$1.68	$1.42	2,104,774
August 2026	$1.84	$1.325	4,987,049
July 2026	$1.50	$1.195	5,080,570
June 2026	$1.60	$1.325	3,076,771
May 2026	$1.955	$1.435	4,352,112
April 2026	$2.30	$1.81	3,943,664
March 2026	$2.07	$1.73	4,056,788
February 2026	$2.24	$1.73	5,635,696
January 2026	$2.45	$2.03	4,986,614
December 2025	$3.09	$2.20	11,686,338
November 2025	$2.46	$2.05	3,599,136

Nasdaq

Period	High Trading Price (US$)	Low Trading Price (US$)	Volume (#)
November 1 – 19, 2026	US$0.98	US$0.63	13,657,018
October 2026	US$1.02	US$0.90	7,369,834
September 2026	US$1.21	US$0.99	11,352,322
August 2026	US$1.32	US$0.93	36,629,579
July 2026	US$1.07	US$0.85	7,615,307
June 2026	US$1.15	US$0.92	11,893,414
May 2026	US$1.45	US$1.04	15,633,542
April 2026	US$1.67	US$1.30	16,833,117
March 2026	US$1.52	US$1.24	11,540,535
February 2026	US$1.64	US$1.27	15,067,405
January 2026	US$1.77	US$1.28	17,388,239
December 2025	US$2.24	US$1.49	37,024,009
November 2025	US$1.75	US$1.45	10,199,121

On November 2, 2026, the last trading day prior to the announcement of the Arrangement, the closing price of the Organigram Common Shares on the TSX and Nasdaq was $1.36 and US$0.9651, respectively. On November 19, 2026, the last trading day prior to the date of this Joint Information Circular, the closing price of the Organigram Common Shares on the TSX and Nasdaq was $0.90 and US$0.6296, respectively.

Risk Factors

An investment in the Organigram Common Shares is subject to certain risks. Readers should carefully review and consider all other information contained in this Joint Information Circular, including the matters and cautionary statements discussed under the heading "*Risk Factors*" in this Joint Information Circular, as well as those discussed under "*Risk Factors*" in the Organigram AIF, the Organigram Annual MD&A and the Organigram Interim MD&A, which are incorporated by reference in this Joint Information Circular.

All statements regarding Organigram's business should be viewed in light of these risk factors. Readers should consider carefully whether an investment in Organigram Common Shares is suitable for them in light of the information set forth in this Joint Information Circular and in the documents incorporated by reference in this Joint Information Circular. Such information does not purport to be an exhaustive list. If any of the identified risks were to materialize, Organigram's current or future business, financial results and/or operations may be materially adversely affected.

Additional risks and uncertainties not presently known to Organigram, or which Organigram currently deems immaterial, may also have an adverse effect upon Organigram.

Readers should also carefully review and consider all other information contained in this Joint Information Circular and in the documents incorporated by reference in this Appendix "J" before making an investment decision and consult their own professional advisors.

Legal Proceedings and Regulatory Actions

To the knowledge of Organigram, there are no material legal proceedings to which Organigram is a party or to which its property is subject, and no such proceedings are known to be contemplated. To the knowledge of Organigram, there have been no material penalties or sanctions imposed by a court or regulatory body against Organigram, and Organigram has not entered into any settlement agreements with a court or securities regulatory authority relating to securities legislation, during the financial year ended September 30, 2025 or since that date. See "*Legal Proceedings and Regulatory Actions*" in the Organigram AIF, which is incorporated by reference herein.

Principal Shareholders

To the knowledge of the directors and executive officers of Organigram, as of November 18, 2026, the only person or company that beneficially owned, or controlled or directed, directly or indirectly, voting securities carrying 10% or more of the voting rights attached to any class of voting securities of Organigram was BAT, which held 42,231,089 Organigram Common Shares, representing approximately 30% of the outstanding Organigram Common Shares, and all 49,204,021 of the outstanding Organigram Preferred Shares. See "*Effect of the Arrangement – BAT Equity Commitment*" for BAT's expected interest following completion of the Arrangement and the BAT Private Placement.

Material Contracts

Except for contracts entered into in the ordinary course of business, the only contracts that are material to Organigram and that were entered into within the most recently completed financial year, or before the most recently completed financial year but are still in effect, are: (a) the warrant indenture dated April 2, 2024 between Organigram and TSX Trust Company; (b) the second amended and restated investor rights agreement dated April 15, 2026 between Organigram and BAT; (c) the product development collaboration agreement with BAT; (d) the share purchase agreement dated December 6, 2024 among Organigram, the shareholders of Motif Labs Ltd. and the vendors' representative party thereto in respect of the acquisition of Motif Labs Ltd.; (e) the share sale and purchase agreement dated February 18, 2026 among Organigram, Blitz 25-645 GmbH, Blitz 25-646 GmbH, Sanity Group GmbH and the sellers and other parties thereto, as amended on April 8, 2026 and August 20, 2026, in respect of the acquisition of Sanity Group; (f) the subscription agreement dated February 18, 2026 between Organigram and BAT; (g) the credit agreement dated April 14, 2026 among Organigram, ATB Financial and the lenders party thereto; (h) the Arrangement Agreement; and (i) the BAT Equity Commitment. See "*Material Contracts*" in the Organigram AIF, which is incorporated by reference in this Joint Information Circular.

Auditors, Registrar and Transfer Agent

PricewaterhouseCoopers LLP are the auditors of Organigram, having been appointed in February 2026. PKF O'Connor Davies, LLP, Organigram's former auditors, audited Organigram's consolidated financial statements as at and for the year ended September 30, 2025, which are incorporated by reference herein, and have confirmed that they were independent with respect to Organigram within the meaning of the relevant rules and related interpretations prescribed by the relevant professional bodies in Canada and any applicable legislation or regulations and also that they were independent accountants with respect to Organigram under all relevant U.S. professional and regulatory standards.

The transfer agent and registrar for the Organigram Common Shares is TSX Trust Company, at its offices in Vancouver, British Columbia and Toronto, Ontario. VStock Transfer, LLC is Organigram's co-transfer agent in the United States.

Interest of Experts

The following persons, firms and companies are named as having prepared or certified a report, valuation, statement or opinion described or included herein, either directly or in a document incorporated by reference herein, and whose profession or business gives authority to the report, valuation, statement or opinion, in each case with respect to Organigram:

(a) PKF O'Connor Davies, LLP; and

(b) BMO Nesbitt Burns Inc.

To the knowledge of Organigram, as of the date of this Joint Information Circular, BMO Nesbitt Burns Inc. and its "designated professionals" (as defined in Form 51-102F2 – *Annual Information Form*), in aggregate, beneficially own, directly or indirectly, less than 1% of the outstanding securities of each class of securities of Organigram, Aurora or any associate or affiliate of Organigram or Aurora, as applicable.

Interest of Informed Persons in Material Transactions

Except as otherwise disclosed in this Joint Information Circular, including in respect of BAT and the BAT Private Placement, to the knowledge of Organigram, there were no material interests, direct or indirect, of Organigram's directors or executive officers, any director or executive officer of a subsidiary of Organigram, any person who beneficially owns, or controls or directs, directly or indirectly, more than 10% of the outstanding Organigram Common Shares, or any other "informed person" (as defined in National Instrument 51-102 – *Continuous Disclosure Obligations*) or any associate or affiliate of such persons, in any transaction since the commencement of Organigram's most recently completed financial year or in any proposed transaction which has materially affected or would materially affect Organigram or any of its Subsidiaries.

Additional Information

Additional information relating to Organigram is available under its profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Financial information concerning Organigram is provided in the Organigram Annual Financial Statements, the Organigram Interim Financial Statements, the Organigram Annual MD&A and the Organigram Interim MD&A, which are incorporated by reference herein. See "*Documents Incorporated by Reference*" above.

APPENDIX "K"
DIVISION 2 OF PART 8 OF THE *BUSINESS CORPORATIONS ACT* (BRITISH COLUMBIA)

Definitions and application

237 (1) In this Division:

"**dissenter**" means a shareholder who, being entitled to do so, sends written notice of dissent when and as required by section 242;

"**notice shares**" means, in relation to a notice of dissent, the shares in respect of which dissent is being exercised under the notice of dissent;

"**payout value**" means,

(a) in the case of a dissent in respect of a resolution, the fair value that the notice shares had immediately before the passing of the resolution,

(b) in the case of a dissent in respect of an arrangement approved by a court order made under section 291 (2) (c) that permits dissent, the fair value that the notice shares had immediately before the passing of the resolution adopting the arrangement,

(c) in the case of a dissent in respect of a matter approved or authorized by any other court order that permits dissent, the fair value that the notice shares had at the time specified by the court order, or

(d) in the case of a dissent in respect of a community contribution company, the value of the notice shares set out in the regulations, excluding any appreciation or depreciation in anticipation of the corporate action approved or authorized by the resolution or court order unless exclusion would be inequitable.

(2) This Division applies to any right of dissent exercisable by a shareholder except to the extent that

(a) the court orders otherwise, or

(b) in the case of a right of dissent authorized by a resolution referred to in section 238 (1) (g), the court orders otherwise or the resolution provides otherwise.

Right to dissent

238 (1) A shareholder of a company, whether or not the shareholder's shares carry the right to vote, is entitled to dissent as follows:

(a) under section 260, in respect of a resolution to alter the articles

(i) to alter restrictions on the powers of the company or on the business the company is permitted to carry on,

(ii) without limiting subparagraph (i), in the case of a community contribution company, to alter any of the company's community purposes within the meaning of section 51.91, or

(iii) without limiting subparagraph (i), in the case of a benefit company, to alter the company's benefit provision;

(b) under section 272, in respect of a resolution to adopt an amalgamation agreement;

(c) under section 287, in respect of a resolution to approve an amalgamation under Division 4 of Part 9;

(d) in respect of a resolution to approve an arrangement, the terms of which arrangement permit dissent;

(e) under section 301 (5), in respect of a resolution to authorize or ratify the sale, lease or other disposition of all or substantially all of the company's undertaking;

(f) under section 309, in respect of a resolution to authorize the continuation of the company into a jurisdiction other than British Columbia;

(g) in respect of any other resolution, if dissent is authorized by the resolution;

(h) in respect of any court order that permits dissent.

(1.1) A shareholder of a company, whether or not the shareholder's shares carry the right to vote, is entitled to dissent under section 51.995 (5) in respect of a resolution to alter its notice of articles to include or to delete the benefit statement.

(2) A shareholder wishing to dissent must

(a) prepare a separate notice of dissent under section 242 for

(i) the shareholder, if the shareholder is dissenting on the shareholder's own behalf, and

(ii) each other person who beneficially owns shares registered in the shareholder's name and on whose behalf the shareholder is dissenting,

(b) identify in each notice of dissent, in accordance with section 242 (4), the person on whose behalf dissent is being exercised in that notice of dissent, and

(c) dissent with respect to all of the shares, registered in the shareholder's name, of which the person identified under paragraph (b) of this subsection is the beneficial owner.

(3) Without limiting subsection (2), a person who wishes to have dissent exercised with respect to shares of which the person is the beneficial owner must

(a) dissent with respect to all of the shares, if any, of which the person is both the registered owner and the beneficial owner, and

(b) cause each shareholder who is a registered owner of any other shares of which the person is the beneficial owner to dissent with respect to all of those shares.

Waiver of right to dissent

239 (1) A shareholder may not waive generally a right to dissent but may, in writing, waive the right to dissent with respect to a particular corporate action.

(2) A shareholder wishing to waive a right of dissent with respect to a particular corporate action must

(a) provide to the company a separate waiver for

(i) the shareholder, if the shareholder is providing a waiver on the shareholder's own behalf, and

(ii) each other person who beneficially owns shares registered in the shareholder's name and on whose behalf the shareholder is providing a waiver, and

(b) identify in each waiver the person on whose behalf the waiver is made.

(3) If a shareholder waives a right of dissent with respect to a particular corporate action and indicates in the waiver that the right to dissent is being waived on the shareholder's own behalf, the shareholder's right to dissent with respect to the particular corporate action terminates in respect of the shares of which the shareholder is both the registered owner and the beneficial owner, and this Division ceases to apply to

(a) the shareholder in respect of the shares of which the shareholder is both the registered owner and the beneficial owner, and

(b) any other shareholders, who are registered owners of shares beneficially owned by the first mentioned shareholder, in respect of the shares that are beneficially owned by the first mentioned shareholder.

(4) If a shareholder waives a right of dissent with respect to a particular corporate action and indicates in the waiver that the right to dissent is being waived on behalf of a specified person who beneficially owns shares registered in the name of the shareholder, the right of shareholders who are registered owners of shares beneficially owned by that specified person to dissent on behalf of that specified person with respect to the particular corporate action terminates and this Division ceases to apply to those shareholders in respect of the shares that are beneficially owned by that specified person.

Notice of resolution

240 (1) If a resolution in respect of which a shareholder is entitled to dissent is to be considered at a meeting of shareholders, the company must, at least the prescribed number of days before the date of the proposed meeting, send to each of its shareholders, whether or not their shares carry the right to vote,

(a) a copy of the proposed resolution, and

(b) a notice of the meeting that specifies the date of the meeting, and contains a statement advising of the right to send a notice of dissent.

(2) If a resolution in respect of which a shareholder is entitled to dissent is to be passed as a consent resolution of shareholders or as a resolution of directors and the earliest date on which that resolution can be passed is specified in the resolution or in the statement referred to in paragraph (b), the company may, at least 21 days before that specified date, send to each of its shareholders, whether or not their shares carry the right to vote,

(a) a copy of the proposed resolution, and

(b) a statement advising of the right to send a notice of dissent.

(3) If a resolution in respect of which a shareholder is entitled to dissent was or is to be passed as a resolution of shareholders without the company complying with subsection (1) or (2), or was or is to be passed as a directors' resolution without the company complying with subsection (2), the company must, before or within 14 days after the passing of the resolution, send to each of its shareholders who has not, on behalf of every person who beneficially owns shares registered in the name of the shareholder, consented to the resolution or voted in favour of the resolution, whether or not their shares carry the right to vote,

(a) a copy of the resolution,

(b) a statement advising of the right to send a notice of dissent, and

(c) if the resolution has passed, notification of that fact and the date on which it was passed.

(4) Nothing in subsection (1), (2) or (3) gives a shareholder a right to vote in a meeting at which, or on a resolution on which, the shareholder would not otherwise be entitled to vote.

Notice of court orders

241 If a court order provides for a right of dissent, the company must, not later than 14 days after the date on which the company receives a copy of the entered order, send to each shareholder who is entitled to exercise that right of dissent

(a) a copy of the entered order, and

(b) a statement advising of the right to send a notice of dissent.

Notice of dissent

242 (1) A shareholder intending to dissent in respect of a resolution referred to in section 238 (1) (a), (b), (c), (d), (e), (f) or (1.1) must,

(a) if the company has complied with section 240 (1) or (2), send written notice of dissent to the company at least 2 days before the date on which the resolution is to be passed or can be passed, as the case may be,

(b) if the company has complied with section 240 (3), send written notice of dissent to the company not more than 14 days after receiving the records referred to in that section, or

(c) if the company has not complied with section 240 (1), (2) or (3), send written notice of dissent to the company not more than 14 days after the later of

(i) the date on which the shareholder learns that the resolution was passed, and

(ii) the date on which the shareholder learns that the shareholder is entitled to dissent.

(2) A shareholder intending to dissent in respect of a resolution referred to in section 238 (1)(g) must send written notice of dissent to the company

(a) on or before the date specified by the resolution or in the statement referred to in section 240(2) (b) or (3)(b) as the last date by which notice of dissent must be sent, or

(b) if the resolution or statement does not specify a date, in accordance with subsection (1) of this section.

(3) A shareholder intending to dissent under section 238(1)(h) in respect of a court order that permits dissent must send written notice of dissent to the company

(a) within the number of days, specified by the court order, after the shareholder receives the records referred to in section 241, or

(b) if the court order does not specify the number of days referred to in paragraph (a) of this subsection, within 14 days after the shareholder receives the records referred to in section 241.

(4) A notice of dissent sent under this section must set out the number, and the class and series, if applicable, of the notice shares, and must set out whichever of the following is applicable:

(a) if the notice shares constitute all of the shares of which the shareholder is both the registered owner and beneficial owner and the shareholder owns no other shares of the company as beneficial owner, a statement to that effect;

(b) if the notice shares constitute all of the shares of which the shareholder is both the registered owner and beneficial owner but the shareholder owns other shares of the company as beneficial owner, a statement to that effect and

(i) the names of the registered owners of those other shares,

(ii) the number, and the class and series, if applicable, of those other shares that are held by each of those registered owners, and

(iii) a statement that notices of dissent are being, or have been, sent in respect of all of those other shares;

(c) if dissent is being exercised by the shareholder on behalf of a beneficial owner who is not the dissenting shareholder, a statement to that effect and

(i) the name and address of the beneficial owner, and

(ii) a statement that the shareholder is dissenting in relation to all of the shares beneficially owned by the beneficial owner that are registered in the shareholder's name.

(5) The right of a shareholder to dissent on behalf of a beneficial owner of shares, including the shareholder, terminates and this Division ceases to apply to the shareholder in respect of that beneficial owner if subsections (1) to (4) of this section, as those subsections pertain to that beneficial owner, are not complied with.

Notice of intention to proceed

243 (1) A company that receives a notice of dissent under section 242 from a dissenter must,

(a) if the company intends to act on the authority of the resolution or court order in respect of which the notice of dissent was sent, send a notice to the dissenter promptly after the later of

(i) the date on which the company forms the intention to proceed, and

(ii) the date on which the notice of dissent was received, or

(b) if the company has acted on the authority of that resolution or court order, promptly send a notice to the dissenter.

(2) A notice sent under subsection (1)(a) or (b) of this section must

(a) be dated not earlier than the date on which the notice is sent,

(b) state that the company intends to act, or has acted, as the case may be, on the authority of the resolution or court order, and

(c) advise the dissenter of the manner in which dissent is to be completed under section 244.

Completion of dissent

244 (1) A dissenter who receives a notice under section 243 must, if the dissenter wishes to proceed with the dissent, send to the company or its transfer agent for the notice shares, within one month after the date of the notice,

(a) a written statement that the dissenter requires the company to purchase all of the notice shares,

(b) the certificates, if any, representing the notice shares, and

(c) if section 242(4)(c) applies, a written statement that complies with subsection (2) of this section.

(2) The written statement referred to in subsection (1)(c) must

(a) be signed by the beneficial owner on whose behalf dissent is being exercised, and

(b) set out whether or not the beneficial owner is the beneficial owner of other shares of the company and, if so, set out

(i) the names of the registered owners of those other shares,

(ii) the number, and the class and series, if applicable, of those other shares that are held by each of those registered owners, and

(iii) that dissent is being exercised in respect of all of those other shares.

(3) After the dissenter has complied with subsection (1),

(a) the dissenter is deemed to have sold to the company the notice shares, and

(b) the company is deemed to have purchased those shares, and must comply with section 245, whether or not it is authorized to do so by, and despite any restriction in, its memorandum or articles.

(4) Unless the court orders otherwise, if the dissenter fails to comply with subsection (1) of this section in relation to notice shares, the right of the dissenter to dissent with respect to those notice shares terminates and this Division, other than section 247, ceases to apply to the dissenter with respect to those notice shares.

(5) Unless the court orders otherwise, if a person on whose behalf dissent is being exercised in relation to a particular corporate action fails to ensure that every shareholder who is a registered owner of any of the shares beneficially owned by that person complies with subsection (1) of this section, the right of shareholders who are registered owners of shares beneficially owned by that person to dissent on behalf of that person with respect to that corporate action terminates and this Division, other than section 247, ceases to apply to those shareholders in respect of the shares that are beneficially owned by that person.

(6) A dissenter who has complied with subsection (1) of this section may not vote, or exercise or assert any rights of a shareholder, in respect of the notice shares, other than under this Division.

Payment for notice shares

245 (1) A company and a dissenter who has complied with section 244 (1) may agree on the amount of the payout value of the notice shares and, in that event, the company must

(a) promptly pay that amount to the dissenter, or

(b) if subsection (5) of this section applies, promptly send a notice to the dissenter that the company is unable lawfully to pay dissenters for their shares.

(2) A dissenter who has not entered into an agreement with the company under subsection (1) or the company may apply to the court and the court may

(a) determine the payout value of the notice shares of those dissenters who have not entered into an agreement with the company under subsection (1), or order that the payout value of those notice shares be established by arbitration or by reference to the registrar, or a referee, of the court,

(b) join in the application each dissenter, other than a dissenter who has entered into an agreement with the company under subsection (1), who has complied with section 244(1), and

(c) make consequential orders and give directions it considers appropriate.

(3) Promptly after a determination of the payout value for notice shares has been made under subsection (2)(a) of this section, the company must

(a) pay to each dissenter who has complied with section 244(1) in relation to those notice shares, other than a dissenter who has entered into an agreement with the company under subsection (1) of this section, the payout value applicable to that dissenter's notice shares, or

(b) if subsection (5) applies, promptly send a notice to the dissenter that the company is unable lawfully to pay dissenters for their shares.

(4) If a dissenter receives a notice under subsection (1)(b) or (3)(b),

(a) the dissenter may, within 30 days after receipt, withdraw the dissenter's notice of dissent, in which case the company is deemed to consent to the withdrawal and this Division, other than section 247, ceases to apply to the dissenter with respect to the notice shares, or

(b) if the dissenter does not withdraw the notice of dissent in accordance with paragraph (a) of this subsection, the dissenter retains a status as a claimant against the company, to be paid as soon as the company is lawfully able to do so or, in a liquidation, to be ranked subordinate to the rights of creditors of the company but in priority to its shareholders.

(5) A company must not make a payment to a dissenter under this section if there are reasonable grounds for believing that

(a) the company is insolvent, or

(b) the payment would render the company insolvent.

Loss of right to dissent

246 The right of a dissenter to dissent with respect to notice shares terminates and this Division, other than section 247, ceases to apply to the dissenter with respect to those notice shares, if, before payment is made to the dissenter of the full amount of money to which the dissenter is entitled under section 245 in relation to those notice shares, any of the following events occur:

(a) the corporate action approved or authorized, or to be approved or authorized, by the resolution or court order in respect of which the notice of dissent was sent is abandoned;

(b) the resolution in respect of which the notice of dissent was sent does not pass;

(c) the resolution in respect of which the notice of dissent was sent is revoked before the corporate action approved or authorized by that resolution is taken;

(d) the notice of dissent was sent in respect of a resolution adopting an amalgamation agreement and the amalgamation is abandoned or, by the terms of the agreement, will not proceed;

(e) the arrangement in respect of which the notice of dissent was sent is abandoned or by its terms will not proceed;

(f) a court permanently enjoins or sets aside the corporate action approved or authorized by the resolution or court order in respect of which the notice of dissent was sent;

(g) with respect to the notice shares, the dissenter consents to, or votes in favour of, the resolution in respect of which the notice of dissent was sent;

(h) the notice of dissent is withdrawn with the written consent of the company;

(i) the court determines that the dissenter is not entitled to dissent under this Division or that the dissenter is not entitled to dissent with respect to the notice shares under this Division.

Shareholders entitled to return of shares and rights

247 If, under section 244(4) or (5), 245(4)(a) or 246, this Division, other than this section, ceases to apply to a dissenter with respect to notice shares,

(a) the company must return to the dissenter each of the applicable share certificates, if any, sent under section 244(1)(b) or, if those share certificates are unavailable, replacements for those share certificates,

(b) the dissenter regains any ability lost under section 244(6) to vote, or exercise or assert any rights of a shareholder, in respect of the notice shares, and

(c) the dissenter must return any money that the company paid to the dissenter in respect of the notice shares under, or in purported compliance with, this Division.

ORGANIGRAM SHAREHOLDERS



If you have any questions or require any assistance in
executing your proxy or voting instruction form,
please call Sodali & Co at:

North American Toll-Free Number: 1-833-830-8205
Outside North America, Banks, Brokers and Collect Calls: 1-289-695-3075
Email: assistance@investor.sodali.com
North American Toll-Free Facsimile: 1-877-218-5372

ORGANIGRAM GLOBAL INC.
145 King Street West #1400
Toronto, ON, M5H 1J8, Canada
E: info@organigram.ca

Download the latest about Organigram Global Inc. at:
www.OrganigramXAurora.com and www.VoteYesAurora.com
Organigram Global Inc. is traded on the TSX and Nasdaq under “OGI”

AURORA SHAREHOLDERS

QUESTIONS? NEED HELP VOTING?

CONTACT US

KINGSDALE Advisors

North American Toll Free Phone
(Aurora Shareholders)
1-800-749-9052

E-mail: contactus@kingsdaleadvisors.com
Fax: 1-416-867-2339
Toll Free Facsimile: 1-866-545-5580
For more information visit voteyesaurora.com

Outside North America, Banks and Brokers
Call Collect: 1-416-623-4172